cluster,concept,cuis
6147,acute medication intake ( days / month ),C0013227;C0205178;C0556971;C1512806;C3244316;C4284232
6147,acute ( < $nmbr$ hr ),C0205178
6146,acute reaction,C0205178;C0443286
6146,acute and delayed reaction,C0205178
6145,study drug loading days ( actual ) : $nmbr$ ( n = $nmbr$ ),C0013175;C0237400;C0439228;C1708715
6145,actual or estimated weight  kg,C0237400
6145,actual ( l ),C0237400
6144,biventricular pacemaker,C1719274
6143,cardiac pacemaker — no . ( % ),C0030163;C0037189
6142,prior pacemaker  n ( % ),C0030163;C0332152;C0810633;C1546728;C2826257;C3275122;C3853703
6142,pacemaker — no . ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
6142,pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703
6142,pacemaker  n ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
6142,pacemaker  ( % ),C0030163;C0810633;C1546728;C3275122;C3853703
6142,pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
6141,paracetamol,C0000970
6141,acetaminophen,C0000970;C2917659
6140,avr,C0449217
6139,< $nmbr$ vr — no . ( % ),C3476815
6139,$nmbr$ - $nmbr$ vr — no . ( % ),C3476815
6138,avm ( n = $nmbr$ ),C0003857;C0279476
6138,avm % △ ( se ),C0003857;C0036919;C0279476
6137,arr ( % ),C2170357;C4084934
6137,arr ( $nmbr$ % cl ),C0596019;C2170357;C4084934
6137,arr ( $nmbr$ % ci ),C0008107;C2170357;C3259781;C4084934
6137,arr,C2170357;C4084934
6136,ez / simva n = $nmbr$ n ( % ),C0206578
6136,ez / simva < % >,C0206578
6136,ez / simva $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
6136,ez / simva $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0206578;C0439269;C1960952;C2346927;C4321396;C4521761
6136,ez / simva,C0206578
6136,all ez / simva,C0206578
6135,a $nmbr$ + ez n = $nmbr$ a $nmbr$ n = $nmbr$,C0206578
6135,a $nmbr$ + ez n = $nmbr$,C0206578
6135,a $nmbr$ + ez $nmbr$ a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0206578
6135,a $nmbr$ + ez $nmbr$,C0206578
6134,ldl - cz,C0206578
6134,czech republic,C0206578
6133,h pylori serology *,C0036745;C0079488;C0220911;C0455278
6132,hder *,C3898895
6131,$nmbr$ hr prandial glucose ' * ’,C0017725;C1998602;C4553624
6130,nx *,C0445085
6129,antibodies to infliximab  n ( % ) * *,C3533054
6128,antibiotics * *,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
6127,old stroke *,C1536121
6126,score on asthma control questionnaire * *,C4706265
6125,congestion *,C0700148;C2826600
6124,ldlc : hdlc,C1416822;C1704429
6123,ldlc,C1416822
6123,baseline ldlc level ( n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
6122,fdc $nmbr$ / $nmbr$   μ g ( n   =   $nmbr$ ),C0340427;C0439267;C1413520;C3539652
6122,fdc $nmbr$ / $nmbr$ pg vs placebo,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
6122,fdc $nmbr$ / $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
6122,fdc $nmbr$ / $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
6122,fdc $nmbr$ / $nmbr$ pg,C0030827;C0072225;C0340427;C1266240;C1413520;C3539652
6121,fluticasone propionate / salmeterol fdc,C0340427;C1413520;C1622832;C3539652
6121,budesonide / formoterol fdc,C0340427;C1276807;C1413520;C3539652
6120,gaviscon da ( n = $nmbr$ ),C0011318;C0061146;C3668815
6119,> $nmbr$ da of capillary nonperfusion in the eyec,C0006901;C0011318;C0935624;C3668815
6118,dd ( n = $nmbr$ ),C3538867;C3814791
6118,dd,C3538867;C3814791
6117,gp mdi,C0993596;C1705010;C1839839;C3811116;C4049613
6116,mdi / hfa  n,C0015458;C0993596;C1839839;C4049613
6116,mdi,C0993596;C1839839;C4049613
6116,gff mdi,C0993596;C1839839;C4049613
6116,ff mdi,C0993596;C1839839;C4049613;C4554348
6115,sdai < $nmbr$ t,C3871128
6115,sdai < $nmbr$ . $nmbr$ *,C3871128
6115,sdai ( $nmbr$ - $nmbr$ ),C3871128
6115,sdai  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3871128
6115,sdai,C3871128
6114,cdai score < $nmbr$,C0683448;C1413248;C3273706
6114,cdai score  median ( min  max ),C0683448;C1413248;C3273706
6114,cdai score  mean ( s . d . ),C0683448;C1413248;C3273706
6114,cdai > $nmbr$  n [ % ],C0683448;C1413248;C3273706
6114,cdai < $nmbr$ t,C0683448;C1413248;C3273706
6114,cdai < $nmbr$ . $nmbr$ *,C0683448;C1413248;C3273706
6114,cdai ( $nmbr$ - $nmbr$ ),C0683448;C1413248;C3273706
6114,cdai  mean ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
6113,cdai score  mean ± sda,C0683448;C1413248;C3273706
6113,cdai,C0683448;C1413248;C3273706
6113,baseline cdai score  mean ( sd ),C0168634;C0683448;C1413248;C1442488;C3273706
6113,baseline cdai score  mean ( s . d . ),C0168634;C0683448;C1413248;C1442488;C3273706
6113,baseline cdai  mean ( sd ),C0168634;C0444504;C0683448;C1413248;C1442488;C2347634;C2348143;C2699239;C3273706
6113,baseline cdai,C0168634;C0683448;C1413248;C1442488;C3273706
6112,mean cdai score ( sd ),C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
6112,mean cdai score,C0444504;C0683448;C1413248;C2347634;C2348143;C3273706
6112,cdai §,C0683448;C1413248;C3273706
6112,cdai score §,C0683448;C1413248;C3273706
6112,cdai score,C0683448;C1413248;C3273706
6111,rosiglitazone ( n = $nmbr$ ),C0289313
6111,rosiglitazone $nmbr$ mg daily,C0024671;C0026410;C0289313;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
6111,rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0289313;C0439269;C1960952;C2346927;C4321396;C4521761
6111,rosiglitazone,C0289313
6110,rosiglitazone versus metformin,C0289313
6110,rosiglitazone versus glyburide,C0289313
6110,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0019409;C0242960;C0289313;C1709380
6109,timi major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
6109,major bleeding $nmbr$ to $nmbr$,C0019080;C0205082;C0205164;C4318856;C4521762
6109,history of major bleeding,C0019080;C0019664;C0019665;C0205082;C0205164;C0262512;C0262926;C1705255;C2004062;C4318856;C4521762
6109,bleeding,C0019080
6108,bleeding outcomes,C0019080;C1274040
6108,any gusto bleeding,C0019080
6107,gusto severe bleed,C0019080;C0205082;C4050465;C4050466
6107,any overt bleed,C0019080
6106,glycemic indexes,C1136206
6105,glycemic status f,C0016327;C1320980
6105,glycemic status,C1320980
6104,no dysglycaemia or mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C1960636
6104,no dysglycaemia or mets,C1960636
6104,dysglycemic categories  n ( % ),C0683312;C1960636
6104,dysglycaemia or mets,C1960636
6103,normoglycemic $nmbr$,C0580545
6103,normoglycemic,C0580545
6103,normoglycaemic individuals  n ( % ),C0027361;C0237401;C0580545
6103,individuals with normoglycaemia,C0027361;C0237401;C0580545
6102,normoglycemic {,C0580545
6102,normoglycemic ^,C0580545
6102,normoglycemia ^,C0580545
6102,normoglycemia,C0580545
6102,baseline normoglycemia,C0168634;C0580545;C1442488
6101,hypovolaemia,C0546884
6100,hyponatremia,C0020625;C4553967
6099,severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
6099,nonsevere hypoglycemia,C0020615;C4553659
6099,non - severe hypoglycaemia,C0020615;C0205082;C1518422;C4050465;C4050466;C4553659
6099,no severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
6099,no nonsevere hypoglycemia,C0020615;C4553659
6099,b nonsevere hypoglycemia,C0020615;C4553659
6099,a severe hypoglycemia,C0020615;C0205082;C4050465;C4050466;C4553659
6098,major hypoglycemia,C0020615;C0205082;C0205164;C4318856;C4521762;C4553659
6098,hypoglycemia ^,C0020615;C4553659
6098,hypoglycemia,C0020615;C4553659
6097,other hypoglycemic agent  n ( % ),C0020616
6097,other antihyperglycemic agents  not listed,C0020616
6097,naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C0450442;C1254351;C1363945;C1521826
6097,hypoglycemic agent,C0020616
6097,hypoglycaemic therapy,C0020616;C0039798;C0087111;C1363945
6097,hypoglycaemic agents,C0020616
6097,antihyperglycemic oral agent therapy,C0020616;C0039798;C0087111;C0442027;C0450442;C1254351;C1363945;C1521826;C4521986
6097,antihyperglycemic,C0020616
6096,glycohemoglobin  %  mean ( sd ),C0202054;C0444504;C0696092;C2347634;C2348143;C2699239
6096,glycohemoglobin  %,C0202054;C0696092
6096,glycated hemoglobin level,C0202054
6096,glycated hemoglobin  nonstandardized level — %,C0202054
6095,hemoglobin a ^ c  %,C0019020;C3889898
6095,hemoglobin a $nmbr$ c ( % ),C0019020;C3889898
6095,hemoglobin a $nmbr$ c  %,C0019020;C3889898
6095,hemoglobin a $nmbr$ c,C0019020;C3889898
6095,hemoglobin - a $nmbr$ c ( % ) ' • ■ * *,C0019020;C3889898
6094,mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent,C0017853;C0439165;C0444504;C0520870;C0589120;C1521970;C1522577;C1704685;C2347634;C2348143;C3274571
6094,glycated hemoglobin | |,C0017853
6094,glycated hemoglobin ( % ),C0017853
6094,glycated hemoglobin  mean ( sd )  %,C0017853;C0444504;C2347634;C2348143;C2699239
6094,glycated hemoglobin  %  mean ( sd ),C0017853;C0444504;C2347634;C2348143;C2699239
6094,glycated hemoglobin  %,C0017853
6094,glycated hemoglobin,C0017853
6094,glycated haemoglobin ( % ),C0017853
6093,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *,C0017853;C0030705
6093,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode of severe hypoglycemia *,C0017853;C0030705
6093,patients with glycated hemoglobin < $nmbr$ . $nmbr$ % and no severe hypoglycemia or diabetic ketoacidosis,C0017853;C0030705
6093,glycosylated hemoglobin  %,C0017853
6093,glycated hemoglobin — % -,C0017853
6093,glycated hemoglobin — %,C0017853
6093,glycated hemoglobin - % ’,C0017853
6093,glycated hemoglobin  standardized level — %,C0017853
6093,glycated haemoglobin  %,C0017853
6092,hemoglobin 一 g / dl,C0019046;C0439267;C1319312;C3642216
6092,hemoglobin — g / dl,C0019046;C0439267;C1319312;C3642216
6092,hemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
6092,hemoglobin  g / dlf,C1319312
6092,hemoglobin  g / dl,C0019046;C0439267;C1319312;C3642216
6092,hemoglobin  g $nmbr$ $nmbr$,C1319312
6092,haemoglobin ( g / dl )  mean + sd  available for $nmbr$ patients,C0019046;C0439267;C0444504;C1319312;C2347634;C2348143;C2699239;C3642216
6092,haemoglobin ( g / dl ),C0019046;C0439267;C1319312;C3642216
6092,baseline hemoglobin  median ( iqr  g / dl ),C0019046;C0168634;C0439267;C0549183;C0876920;C1319312;C1442488;C2347635;C2348144;C2939193;C3642216
6091,hemoglobin ( g r $nmbr$ ),C0205090;C0684010;C1319312;C2603358
6091,hemoglobin ( g $nmbr$ ! ),C1319312
6090,hemoglobin level  %,C0019029;C1314664
6090,hemoglobin concentration — g / liter,C0019029;C0086045;C0439267;C0475211;C1314664;C1318517;C1319312;C1446561;C3827302
6089,for combined hemoglobin groups,C0019046;C0205195
6088,hemoglobin category,C0019046;C0683312;C3889287
6088,hemoglobin,C0019046
6088,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  hr  hazard ratio  k ( rate )  # of events per $nmbr$ patient - years of follow - up  yr  year . multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates .,C0009667;C0019046;C0022661;C0030705;C0168634;C0201976;C0439234;C0441471;C0589120;C0596019;C0597277;C0600061;C0683312;C0871208;C1442488;C1521828;C1522577;C1549954;C1565830;C1704685;C1708601;C2985465;C3161035;C3274571;C3274659;C3541888;C3714583;C3853906;C3889287
6087,hemoglobin aj ^ ( % ),C0004486;C0019046;C0230613
6087,baseline hemoglobin aj ^ values,C0004486;C0019046;C0042295;C0168634;C0230613;C1442488
6086,bsl hb  gl - $nmbr$,C0018229;C0019046;C1423073;C1427674;C1549954
6085,hemoglobin ( gl ' ),C0018229;C0019046;C1423073;C1427674
6085,glyeated haemoglobin,C0019046
6084,laparoscopic cholecystectomy,C0162522
6083,colonoscopy,C0009378;C1548837
6082,patients with evaluable endoscopy,C0014245;C2986511
6081,endoscopy subscore  n ( % ),C0014245
6081,endoscopy subscore,C0014245
6081,endoscopic disease severity,C0014245;C0442418;C0521117
6080,semaglutide exposure  nmol / l,C0274281;C0332157;C0439282;C3885068
6079,pollen exposure,C0032385;C0274281;C0332157;C0795585;C1320238
6078,prior immunosuppressive exposure  n ( % ),C0021081;C0274281;C0332152;C0332157;C2826257
6078,prior anti - tnf exposure,C0274281;C0332152;C0332157;C1448177;C2826257
6078,exposed ( n = $nmbr$ ),C0332157
6078,exposed,C0332157
6077,exposure to study drug — days,C0013175;C0332157;C0439228
6076,mean ( sd ) extent of exposure  days,C0274281;C0332157;C0439228;C0439792;C0444504;C2347634;C2348143;C2699239
6076,exposure,C0274281;C0332157
6075,one vessel,C0005847;C0205447
6075,one or more exacerbations,C0205447
6075,one or more copd exacerbations ( n / n [ % ] ),C0205447
6075,one of the above,C0205447
6074,patients with at least one concomitant disease | |,C0030705;C0205447;C0243087
6074,patients with at least one concomitant disease *,C0030705;C0205447;C0243087
6073,one tnfi and,C0205447
6073,one tnfi *,C0205447
6073,one antihypertensive medication,C0003364;C0205447
6072,one or more requiring hospitalization in $nmbr$ mo before screening — no . ( % ) $nmbr$,C0205447
6072,one or more medications,C0205447
6072,one or more blood pressure medications  n ( % ),C0205447
6072,one lesion,C0205447;C0221198;C1546698
6071,spine *,C0037949;C2752558
6071,spine,C0037949;C2752558
6071,post erior - anterior spine,C0037949;C0205094;C0687676;C1704687;C2752558;C3469826
6070,ocn,C1412791;C2347392
6069,absolute time spent “ on ” without troublesome dyskinesia  h / day,C0439546
6069,absolute time spent “ on ” with troublesome dyskinesia  h / day,C0439546
6069,absolute time spent “ on ”  h / day,C0439546
6068,“ on ” without troublesome dyskinesia,C0013384
6068,“ on ” with troublesome dyskinesia,C0013384
6067,somnolence,C0013144;C2830004;C4553740
6066,in emergency department before ambulance transfer,C0002422;C0040671;C0562508;C1705822;C3846685;C4319192
6066,in ambulance,C0002422;C3846685
6065,ambulance ( % ),C0002422;C3846685
6065,ambulance  n ( % ),C0002422;C3846685
6065,ambulance,C0002422;C3846685
6064,no aminosalicylates  n,C0368663
6064,aminosalicylates  n,C0368663
6064,aminosalicylate,C0368663;C2825094
6064,$nmbr$ - aminosalicylates | | | |,C0368663
6064,$nmbr$ - aminosalicylates {,C0368663
6063,oral aminosalicylates,C0368663;C0442027;C4521986
6063,aminosalicylates * *,C0368663
6063,aminosalicylates,C0368663
6062,subdural / epidural,C0038541;C0228134;C0812144
6061,sacral and / or lumbar,C0036037
6060,lumbar epidural,C0581283
6059,pnd,C1417807;C1956415;C4552608
6059,paroxysmal nocturnal dyspnea,C1956415
6058,spinal,C0521329
6057,final analysis ( all patients ),C0002778;C0205088;C0936012;C1524024;C1546485;C3853528
6057,final a $nmbr$ c ( % ),C0205088;C1546485;C3853528
6056,final timi flow grade post - ppci,C0205088;C0441800;C0687676;C0919553;C1546485;C1704687;C3244287;C3272266;C3469826;C3853528
6056,final timi flow grade < $nmbr$,C0205088;C0441800;C0919553;C1546485;C3244287;C3272266;C3853528
6056,final timi flow,C0205088;C1546485;C3272266;C3853528
6055,final mean  mg / dl,C0205088;C0439269;C0444504;C1546485;C2347634;C2348143;C3853528
6055,final mean,C0205088;C0444504;C1546485;C2347634;C2348143;C3853528
6055,final,C0205088;C1546485;C3853528
6054,pravastatin sodium,C0700474
6053,sodium - glucose cotransporter $nmbr$ inhibitor,C0017725;C0037473;C0597484;C1999216;C3541959;C3714642
6053,sodium  meq / l,C0037473;C0439375;C0597484;C3541959;C3714642
6053,sodium,C0037473;C0597484;C3541959;C3714642
6052,serum albumin concentration  g / l,C0001924;C0036773;C0086045;C0229671;C0439294;C0456615;C0486291;C0683149;C0728877;C1446561;C1546774;C1550100;C3827302
6052,serum albumin - adjusted calcium ( mg / dl ),C0036773;C0728877
6052,serum albumin  g / l,C0036773;C0439294;C0456615;C0728877
6052,serum albumin  g / dl,C0036773;C0439267;C0728877
6052,serum albumin  g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
6051,ileum ses - cd score  mean ( sd ),C0007928;C0020885;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4552032
6051,ileum or colon,C0020885
6051,ileum and colon  n ( % ),C0020885
6051,ileum and colon  ' n ( % ),C0020885
6051,ileum and colon,C0020885
6051,ileum,C0020885
6050,caffeine consumption *,C0948365
6049,caffeine,C0006644;C0236734
6048,caffeine users  n ( % ),C3532939
6048,caffeine user  n ( % ),C3532939
6048,caffeine user,C3532939
6047,sufficient,C0205410
6046,j $nmbr$ coefficient,C1707429
6046,coefficient,C1707429
6046,basal insulin analogue dose * ( coefficient,C0178602;C0205112;C0243071;C0366513;C0650607;C0869039;C1114758;C1707429;C2825028
6045,supplementary oxygen,C0030054
6044,supplemental oxygen,C4534306
6043,use of supplemental oxygen  n ( % ),C4067893;C4554557
6042,open — no . ( % ),C0175566
6042,open triple ( n = $nmbr$ ),C0175566
6042,open,C0175566
6041,estrogens,C0014939;C3537250;C3541386;C3714615
6040,no estrogen,C0014939;C2936882;C4542544
6040,estrogen supplementation -,C0014939;C0242297;C2936882;C4542544
6040,estrogen supplementation,C0014939;C0242297;C2936882;C4542544
6040,estrogen ( ' % ? ),C0014939;C2936882;C4542544
6040,estrogen,C0014939;C2936882;C4542544
6039,primary enrollment diagnoses  n ( % ),C0332137;C0801658;C1516879;C1696073;C3888021
6038,pre - enrollment antihyperglycemic therapy,C0020616;C1516879;C1696073;C1882440;C3888021
6037,us site of enrollment,C1516879;C1696073;C2945843;C3888021
6036,enrollment to randomization,C0034656;C1516879;C1696073;C3888021
6035,hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
6035,enrollment strata : prior hospitalization,C0019993;C0332152;C1516879;C1696073;C2826257;C3888021
6034,thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
6034,statin at enrollment,C0360714;C1516879;C1696073;C3888021
6034,beta - blocker at enrollment,C0001645;C1516879;C1696073;C3888021
6034,aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
6033,medications at enrolment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
6033,medications at enrollment  n ( % ) :,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
6033,medication at enrollment — no . ( % ),C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
6033,medication after enrolment,C0013227;C1516879;C1696073;C3244316;C3888021;C4284232
6032,enrollment in lmwh substudy,C0019139;C1516879;C1696073;C3536766;C3888021
6032,enrollment in lmwh,C0019139;C1516879;C1696073;C3536766;C3888021
6031,reason for enrollment in active a — no . ( % ),C0392360;C1516879;C1696073;C3888021
6031,reason for enrollment in active a,C0392360;C1516879;C1696073;C3888021
6030,enrolled into osler,C4684790
6030,enrolled in the americas,C0002454;C0596070;C4684790
6030,enrolled from re - cover study — no . ( % ),C4684790
6030,enrolled from re - cover ii study — no . ( % ),C4684790
6029,sustained mucosal healingc n / n ( % ),C0026724;C0443318
6029,sustained mucosal healingc,C0026724;C0443318
6029,mucosal healingf,C0026724
6029,mucosal healingc n / n ( % ),C0026724
6028,musculoskeletal stiffness,C0427008;C0497254;C2707260
6028,musculoskeletal,C0497254;C2707260
6027,significant worsening in kccq clinical score ( ≥ $nmbr$ ) at $nmbr$ mo †,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
6027,significant worsening in kccq clinical score ( > $nmbr$ ) at $nmbr$ months $nmbr$,C0332271;C0449820;C1457868;C1546960;C2826293;C3476798;C4050231
6027,significant worsening in kccq clinical,C0237881;C0332271;C0750502;C1457868;C1546944;C1546960;C3476798
6027,kccq score,C3476798
6026,diclofenac ( n = $nmbr$ ),C0012091
6026,diclofenac ( n = $nmbr$  $nmbr$ ),C0012091
6026,diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
6026,diclofenac $nmbr$ mg  n = $nmbr$  n ( % ),C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
6026,diclofenac,C0012091
6025,diclofenac group ( n = $nmbr$ $nmbr$ ),C0012091;C0441848
6025,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091
6024,included in analysis,C0002778;C0332257;C0936012;C1524024
6024,( including hypertension ),C0332257
6023,cyclosporine ( n = $nmbr$ ),C0010592;C0010594
6023,cyclosporin,C0010592;C0010594
6022,ticlopidine ( n = $nmbr$ ),C0040207
6022,ticlopidine,C0040207
6021,dulaglutide $nmbr$ . $nmbr$ mgf,C1366394;C3179549;C3712803;C3887684
6020,table $nmbr$ . selected baseline characteristics of the study patients . *,C0039224;C1706074
6020,table $nmbr$ . characteristics of the patients at baseline . *,C0039224;C0815172;C1706074
6020,table $nmbr$ . characteristics of patients treated with losartan and atenolol *,C0039224;C0815172;C1706074
6019,si . gni . fi . canr ecg changes  positive biomarkers  and age < $nmbr$ vrs,C1623258;C4050619
6019,$nmbr$ . $nmbr$ ( fi . $nmbr$ ),C4050619
6018,height in meters .,C0441074;C0489786
6017,> = $nmbr$ meters,C0441074
6017,< $nmbr$ meters,C0441074
6016,relative risk ( $nmbr$ % confidence interval ),C0009667;C0242492
6015,risk ratio [ $nmbr$ % cl ],C0028873;C0242492;C0596019
6015,relative risk ® ( $nmbr$ % cl ),C0242492;C0596019
6015,relative risk ® ' ( $nmbr$ % cl ),C0242492;C0596019
6015,relative risk vs . placebo ( $nmbr$ % cl ),C0242492
6015,relative risk * ( $nmbr$ % cl ),C0242492;C0596019
6015,relative risk ( $nmbr$ % cl ),C0242492;C0596019
6014,risk reduction ( $nmbr$ % cl ),C0596019;C1137094
6014,risk reduction  %,C1137094
6014,relative risk reduction ( $nmbr$ % cl ) percent,C0080103;C0205345;C0242492;C0301630;C0392756;C0439165;C0596019;C1137094;C1293152;C1547039;C4551656
6014,relative risk reduction ( $nmbr$ % cl ),C0080103;C0205345;C0242492;C0301630;C0392756;C0596019;C1137094;C1293152;C1547039;C4551656
6014,% risk reduction ( $nmbr$ % cl ),C0596019;C1137094
6013,risk model endpoint,C0035647;C2349179;C2826544;C3161035;C3274659;C3714583;C3853906;C4552904
6013,model $nmbr$ §,C3161035;C3274659;C3714583;C3853906
6013,model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
6013,model $nmbr$ +,C3161035;C3274659;C3714583;C3853906
6013,model $nmbr$,C3161035;C3274659;C3714583;C3853906
6013,model  n,C3161035;C3274659;C3714583;C3853906
6013,crude model hr ( $nmbr$ % ci ),C0008107;C3161035;C3259781;C3274659;C3714583;C3853906
6012,other countries,C0454664
6012,hba $nmbr$ c ( % ) all countries,C0019016;C0454664;C1825777;C3538758
6012,all countries,C0454664
6011,country  n ( % ),C0454664;C1511538
6011,country,C0454664;C1511538
6010,contrast volume > $nmbr$ ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
6010,contrast volume ( ml ),C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
6010,contrast volume,C0009924;C0449468;C1690016;C1705102;C1979874;C2700258
6010,contrast used ( ml ) *,C0009924;C1979874
6009,microalbuminuria — no . / total no . ( % ),C0730345
6009,microalbuminuria — no . ( % ),C0730345
6009,microalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C0730345;C1442488
6009,microalbuminuria  n ( % ),C0730345
6009,microalbuminuria,C0730345
6008,microalbuminuria or proteinuria,C0730345
6008,microalbuminuria or macroalbuminuria §,C0730345
6008,microalbuminuria or macroalbuminuria,C0730345
6008,microalbuminuria ( uacr $nmbr$ – $nmbr$ ),C0730345
6008,high microalbuminuria to macroalbuminuria ( n = $nmbr$ ),C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
6007,worsened,C1457868;C4084902
6006,tanezumab ( all doses combined ) + nsaida,C2346819
6006,tanezumab ( all doses combined ),C2346819
6005,combined therapy vsta msu iosin,C0024776;C0033972;C1412759
6005,combined therapy vsdutasteride,C0033972
6005,combined therapy ( / v = $nmbr$ )  $nmbr$ / $nmbr$,C0033972
6004,source,C0449416;C1705919;C4521696
6003,third heart sound  n ( % ),C0232237;C0232278
6003,third heart sound,C0232237;C0232278
6002,continued treatment study,C0549178;C3161471
6001,continuous variables  mean ( sd ) ^,C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
6001,continuous variables  mean ( sd ),C0439828;C0444504;C0549178;C2347634;C2348143;C2699239
6001,continuous,C0549178
6001,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
6001,$nmbr$ ( $nmbr$ . $nmbr$ ) ( continued ),C0549178
6000,ongoing atopic or allergic condition — no . { % ),C0392707;C0549178
5999,continued thienopyridine n ( % ),C0549178;C1120149
5999,continued thienopyridine %,C0549178;C1120149
5999,continue thienopyridine n = $nmbr$,C0549178
5998,testing order,C0039593;C0392366;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
5997,ppg post - meal test  mmol / l,C0022885;C0039593;C0376674;C0392366;C0456984;C1418888;C1515976;C1532563;C3831328;C4318744
5997,positive orthostatic test },C0022885;C0039593;C0231472;C0392366;C0439178;C0456984;C1446409;C1514241;C1515976;C2825490;C3812269;C3831328;C4318744
5997,orthostatic test *,C0022885;C0039593;C0231472;C0392366;C0456984;C1515976;C3831328;C4318744
5997,likelihood test,C0022885;C0033204;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
5997,laboratory tests,C0022885
5997,laboratory testing,C0022885
5997,heterogeneity test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C3831328;C4318744
5997,heterogeneity / trend test,C0019409;C0022885;C0039593;C0242960;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
5997,dfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
5997,cfisher ' s exact test .,C0022885;C0039593;C0392366;C0456984;C1515976;C2828393;C3831328;C4050514;C4318744
5996,$nmbr$ st : $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0036056;C0439284;C3272372
5995,st - $nmbr$ ( ng / ml ),C0036056;C0439275;C3272372
5995,st +,C0036056;C3272372
5994,st,C0036056;C3272372
5994,> $nmbr$ st and < $nmbr$ nd quartile,C0036056;C3272372
5994,< $nmbr$ st quartile,C0036056;C2828255;C3272372
5994,$nmbr$ st tertile ( < = $nmbr$ mg / dl [ < = $nmbr$ . $nmbr$ mmol / l ] ) b,C0036056;C0439269;C1532563;C3272372
5994,$nmbr$ st < $nmbr$ . $nmbr$,C0036056;C3272372
5993,st / t wave,C0036056;C0429103;C3272372
5993,st - t wave changes,C0036056;C0429103;C3272372
5993,st - t wave  no . ( % ),C0036056;C0429103;C3272372
5993,st - t wave  n ( % ),C0036056;C0429103;C3272372
5993,st - t wave,C0036056;C0429103;C3272372
5993,st -,C0036056;C3272372
5992,st - t wavett,C0036056;C3272372
5992,st - t waveft,C0036056;C3272372
5992,st - t wave abnormality d,C0036056;C1839341;C3272372
5991,stemi,C1536220;C3538872
5991,st - segment — elevation myocardial infarction,C1536220
5991,st - segment elevation myocardial infarction,C1536220
5991,st - segment - elevation myocardial infarction — no . ( % ),C1536220
5991,st - elevation myocardial infarction,C1536220;C3538872
5991,prior stemi,C0332152;C1536220;C2826257;C3538872
5991,no prior stemi,C0332152;C1536220;C2826257;C3538872
5991,myocardial infarction without st - segment elevation — no . ( % ),C1536220
5990,stemi ( % ),C1536220;C3538872
5990,qualifying mi : stemi,C1514624;C1536220;C3538872;C3810814
5989,obesity *,C0028754;C1963185
5989,obesity ( bmi > $nmbr$ kg / m $nmbr$ )  %,C0028754;C0578022;C1532718;C1963185
5989,obesity ( % ) §,C0028754;C1963185
5989,obesity  % *,C0028754;C1963185
5989,obesity,C0028754;C1963185
5988,obesity t,C0028754;C1963185
5988,> $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
5988,$nmbr$ - $nmbr$ - $nmbr$  obesity class $nmbr$,C0028754;C0456387;C1518526;C1705943;C1963185
5987,obese ( bmi £ $nmbr$ ),C0028754;C0578022
5986,obese ( bmi > $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718
5986,obese ( > $nmbr$ kg / m $nmbr$ ) b,C0028754;C1532718
5986,obese ( > $nmbr$ kg / m $nmbr$ ),C0028754;C1532718
5986,obese,C0028754
5985,abdominal obesity *,C0311277
5985,abdominal obesity,C0311277
5984,tjc ( / $nmbr$ joints ),C0022417;C0392905
5984,tjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
5984,tjc ( $nmbr$ joints ),C0022417;C0392905
5984,sjc ( / $nmbr$ joints ),C0022417;C0392905
5984,sjc ( $nmbr$ joints )  mean ( sd ),C0022417;C0392905;C0444504;C2347634;C2348143;C2699239
5984,sjc ( $nmbr$ joints ),C0022417;C0392905
5983,locf ),C2825507
5983,$nmbr$ locf ),C2825507
5982,low renin ( pra < $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0633231;C0855389;C1141951;C1419788;C1533072;C3274822;C3669212;C4050009;C4283900
5981,irr = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,C4082285
5980,li $nmbr$ ( $nmbr$ . $nmbr$ ),C0023617;C3495095
5979,initiation of dialysis  renal transplantation  or creatinine . $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mmol / l ),C0011945;C0011946;C0019004;C0022671;C0040732;C0040733;C0589507;C1059964;C1158830;C1704686;C4551529
5978,europa ( n = $nmbr$ l $nmbr$ ),C0242751
5977,nebivolol ( n = $nmbr$ ),C0068475
5976,metoprolol group ( n = $nmbr$ ),C0025859;C0441848
5976,metoprolol ( n = $nmbr$ $nmbr$ ),C0025859
5975,$nmbr$ early intervention ( n = $nmbr$ ),C0242687;C1964029
5974,fluvastatin ( n = $nmbr$ ),C0082608
5973,semuloparin ( n = $nmbr$ ),C2700104
5972,dalteparin ( n = $nmbr$ ),C0206461
5971,tirofiban ( n = $nmbr$ ),C0247025
5971,heparin ± tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
5971,heparin plus tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0332287;C0770546
5971,heparin + tirofiban ( n = $nmbr$ ),C0019134;C0247025;C0770546
5970,£ $nmbr$ yo ( n = $nmbr$ ),C1413296
5970,< $nmbr$ yo ( n = $nmbr$ ),C1413296
5969,solifenacin ( n = $nmbr$ ),C1099677
5968,sildenafil ( n = $nmbr$ ),C0529793
5967,nintedanib ( n   =   $nmbr$ ),C2930789
5967,nintedanib ( n = $nmbr$ ),C2930789
5966,normotensive ( n = $nmbr$ ),C2712122
5965,rerapamil - sr strategy ( n = $nmbr$ ),C0679199;C0753208;C1709991;C3813610;C3890900;C3891546
5965,conservative strategy ( n = $nmbr$  $nmbr$ ),C0679199
5964,r $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0687673;C1960952;C2346927;C4321396;C4521761
5964,r $nmbr$ + ezio ( n = $nmbr$ ),C0687673
5964,r $nmbr$ ( n = $nmbr$ ),C0687673
5963,air + ig ( n = $nmbr$ ),C0001861;C0021027;C0305052;C0360506;C3536832
5963,air ( n = $nmbr$ ),C0001861;C3536832
5962,hypertrophy per ecg ( n = $nmbr$ $nmbr$ ),C0020564;C1623258
5962,hypertrophy  n ( % ),C0020564
5961,ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
5961,ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C2699257;C3891295;C4551874
5960,aggressive ( n = $nmbr$ ),C0001807;C0580822
5960,aggressive ( $nmbr$ ),C0001807;C0580822
5959,t ( n = $nmbr$  $nmbr$ ),C2986835
5958,> $nmbr$ days to $nmbr$ year ( n = $nmbr$ ),C0556972
5957,roflumilast ( n = $nmbr$  $nmbr$ ),C0965618
5956,cr imputation ( random . ) ( n = $nmbr$ ),C0034656;C0201975;C0439605;C2699638;C3539604;C3711669;C4084730;C4553336;C4553337
5956,bocf - iike imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C2984917
5955,dmab ( n = $nmbr$ ),C0012411
5954,mar imputation ( random . ) ( n = $nmbr$ ),C0034656;C0439605;C2699638;C3829202;C4255469
5954,mar ( itt ) ( n = $nmbr$ ),C3829202;C4255469
5953,tah ( n = $nmbr$ ),C0404079
5952,sal ( n   = $nmbr$  $nmbr$ ),C0036140;C0037494;C0206136
5952,sal ( n = $nmbr$ ),C0036140;C0037494;C0206136
5952,sal $nmbr$ pg ( n = $nmbr$ ),C0030827;C0036140;C0037494;C0072225;C0206136;C1266240
5951,ibs ( $nmbr$ . $nmbr$ ),C0022104;C0432306
5950,nfs > $nmbr$ . $nmbr$ ( high ),C1555018
5950,nfs < - $nmbr$ . $nmbr$ ( low ),C1555018
5950,low nafld fibrosis score ( nfs < - $nmbr$ . $nmbr$ ),C0205251;C0400966;C1550472;C1555018;C1954436;C1954437;C3890211;C4048187;C4321351;C4522223
5950,high nafld fibrosis score ( nfs > $nmbr$ . $nmbr$ ),C0205250;C0400966;C1299351;C1555018;C1954436;C1954437;C2700149;C3887512;C3889660;C4321237;C4522209
5949,s $nmbr$ years ( n = $nmbr$ ),C0439234;C2986823
5949,s $nmbr$ gallop  n ( % ),C2986823
5949,s $nmbr$ ( n = $nmbr$ ),C2986823
5949,$nmbr$ < $nmbr$ s ) n $nmbr$ ( $nmbr$ . $nmbr$ ),C2986823
5948,- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$  - c ) . $nmbr$ r,C0722969
5947,wc ( cm ),C0013123;C2825512
5946,prostate volume ( ml ),C0439526;C1441416;C1705224;C3887665
5946,prostate volume ( cm $nmbr$ ),C1441416
5945,normal weight ( bmi < $nmbr$ ),C0005910;C0043100;C0578022;C1305866;C1705104;C2712185;C4229017
5945,normal ( bmi < $nmbr$ ),C4229017
5944,vas ( $nmbr$ - $nmbr$ ),C0042815;C3536884;C3827561
5944,ptga ( $nmbr$ - $nmbr$ cm vas ),C0042815;C3536884;C3827561
5944,physician global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4050369
5944,physician ' s assessment of disease activity ( vas )  mm,C0031831;C0042815;C0456681;C0804815;C1261322;C1292728;C1516048;C3536884;C3827561
5944,patient global assessment of disease activity ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C3536884;C3827561;C4054228
5944,activity ( $nmbr$ - $nmbr$ vas ),C0042815;C0205177;C0439167;C0441655;C1561536;C3536884;C3668946;C3827561;C4049938;C4049939
5944,( $nmbr$ - $nmbr$ - cm vas ),C0042815;C3536884;C3827561
5943,patient assessment of pain ( $nmbr$ - $nmbr$ cm  vas ),C0042815;C0679830
5943,patient ' s assessment of pain ( $nmbr$ - $nmbr$ vas ),C0042815;C0679830
5942,pain vas ( range $nmbr$ - $nmbr$ )  mean ± sd,C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
5942,pain ( vas ),C0042815
5942,baseline skin pain vas  mean ( sd ),C0042815;C0168634;C0241136;C0444099;C0444504;C1123023;C1442488;C1963195;C2347634;C2348143;C2699239;C3536884;C3827561;C4520765
5941,atopy ( specific ige ) c  n ( % ),C0205369;C0392707;C1552740;C3539705
5940,no atopy ( n = $nmbr$ ),C0392707;C3539705
5940,met atopy and ige $nmbr$ - $nmbr$ ku / l criteria  ( n = $nmbr$ ),C0392707;C0428210;C1550543;C3539705;C4317104
5940,atopy ( n = $nmbr$  $nmbr$ ),C0392707;C3539705
5939,atopy by phadiatop test  n ( % ),C0022885;C0039593;C0392366;C0392707;C0456984;C1441070;C1515976;C3539705;C3831328;C4318744
5939,atopic ( based on phadiatop test ),C0392707
5938,freedom from gtc seizures  n ( % ),C1299590
5937,previous coronary angioplasty  n ( % ),C2114427
5936,scalp psoriasis  n ( % ),C0406326
5935,facial psoriasis  n ( % ),C1276112
5934,prior analgesic products  n ( % ),C0002771;C0332152;C2826257
5934,analgesic medication  n ( % ),C0002771
5933,racec  n ( % ),C4287599
5932,history of osteoporotic fracture  n ( % ) a,C4075937
5931,paternal history  n ( % ),C0424909
5930,maternal history  n ( % ),C0559473
5929,el  n ( % ),C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
5928,history of elms  n ( % ),C0019664;C0019665;C0262512;C0262926;C0330531;C1705255;C2004062;C2980688
5928,elms  n ( % ),C0330531;C2980688
5927,dose adjustment n ( % ),C2826232
5926,bowel stricturing  ' n ( % ),C0267465
5925,digital clubbing  n ( % ),C0009080;C0149651
5924,smoking habit  n ( % ),C4505437
5923,draining cutaneous fistula at baseline  n ( % ),C0013103;C0180499;C4265177
5922,atv n ( % ),C0210243;C0674679;C1145759;C1334862
5921,abdominal or perianal fistula at baseline  n ( % ),C0000726
5920,intravenous vasodilators ( % ),C0443081
5919,strain ( % ),C0080194;C0456178;C1518614;C2987481
5918,pr / virgin islands  n ( % ),C0042752;C0279759;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
5917,riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ ),C0683610;C4553947
5916,angioedema present  n ( % ) {,C0002994;C0150312;C0449450
5916,angioedema present  n ( % ) $nmbr$,C0002994;C0150312;C0449450
5916,angioedema ( adjudicated )  n ( % ),C0002994
5915,ca - channel blockers  n ( % ),C0870261;C3887642
5914,infected  n ( % ) a,C0439663
5913,clean  n ( % ) a,C1947930
5912,kl $nmbr$ ( % ),C1366480;C1416656;C1704887
5911,hla - b $nmbr$  n ( % ) ⁎ ⁎,C1426226
5910,triple - vessel disease  n ( % ),C0856738
5909,$nmbr$ % ( ito $nmbr$ ),C0022283
5909,$nmbr$ % ( - ito $nmbr$ ),C0022283
5908,low - trauma fracture since age $nmbr$  n ( % ),C0521170
5907,fraction ( % ),C1264633;C1554103
5906,risedronate n / n ( % ),C0246719
5906,risedronate ( n   =   $nmbr$ ),C0246719
5906,risedronate ( n = $nmbr$ ),C0246719
5905,teriparatide n / n ( % ),C0070093
5905,teriparatide ( n   =   $nmbr$ ),C0070093
5904,injectable anti ‐ hyperglycaemic  n ( % ),C0432633;C1272883
5903,anti ‐ hyperglycaemic agent  n ( % ),C0432633;C1321567
5902,ularitide n / n ( % ),C0077910
5902,ularitide ( n = $nmbr$ ),C0077910
5901,nutraceuticals  n ( % ),C1518478
5901,any llt other than nutraceuticals  n ( % ),C1518478;C2347090
5900,glycated hemoglobin  n ( % ),C0062408;C3666909
5899,$nmbr$ ( mono ),C1551432;C1551969
5898,bone erosion ( judged by physician )  n ( % ),C0587240
5897,geographical location  n ( % ),C4545686
5896,plaque ( n  % ),C0011389;C0241148;C0332461;C0333463;C4316797
5895,planned treatment duration  n ( % ),C4528394
5894,tachyarrhythmias  n ( % ),C0080203
5893,type of treatment  n ( % ),C0455708
5892,number of medications  n ( % ),C1718138
5892,number of antihypertensive medications used  n ( % ) no antihypertensive therapy,C0003364;C1718138
5892,number of antihypertensive medications  n ( % ),C0003364;C1718138
5891,metabolizer phenotype ( % ) §,C0031437;C1285572
5890,method of identification ofstenosis ( % ),C1301921
5889,distal anastomosis ( % ),C0448964
5888,prothrombin mutation ( % ),C1610621
5887,respiratory medication taken at baseline  n ( % ),C0418986
5887,respiratory medication ( % ),C0418986
5887,( b ) concomitant respiratory medications [ n ( % ) ],C0418986;C0521115
5886,mycophenolate ( any derivative ),C0883242
5885,negative for helicobacter pylori — no . / total no . ( % ),C4688581
5885,helicobacter pylori - negative  n ( % ),C4688581
5884,nonsustained ventricular tachycardia — no . ( % ) - j -,C0750194;C2919575
5883,electrophysiological study — no . ( % ) weight — ibj,C0850293
5882,history of asthma - related intubation — no . ( % ),C0455544
5881,geographic distribution - no . ( % ),C0681686
5880,exercise category ( % ),C3669314
5879,coronary risk factors — no . ( % ),C2024776
5878,( fxs ),C0016667
5877,traditional chinese medicine for respiratory disease — no . ( % ),C0025124;C0035204;C0035242;C1515884
5876,chronic cardiovascular disease  no . ( % ),C1290380
5875,glatiramer acetate  no . ( % ),C0289884
5874,attack ( % ),C0277793;C1261512;C1304680
5873,adults ( aged   ≥ $nmbr$ y )  no . ( % ),C0001675
5872,adolescents ( aged $nmbr$ - $nmbr$ y )  no . ( % ),C0205653
5871,aicd  ( % ),C0972395;C2611803;C3537205;C3546309
5870,systemic corticosteroids — no . ( % ),C4053960
5870,systemic corticosteroids  n ( % ) a,C4053960
5870,systemic corticosteroids  n ( % ),C4053960
5869,body height ( cm ),C0005890;C0487985
5868,waist ( cm ),C0230097
5867,tdi e ' ( septal ) ( cm / sec ),C0205976;C0439392;C0442004;C2674784;C3714807
5866,ae ' ( per cm / s ),C0439392;C3887670
5865,lathosterol / total c ( | imol / mmol ),C0064673;C0439175;C0439190;C0439810
5865,lathosterol ( jimol / l ),C0064673
5864,inspiratory capacity ( l ),C0021610;C0802663
5863,apo a - l ( g / l ),C0628062
5862,testosterone level ( nmol / l ),C0428412;C0439282;C0523912
5861,unbound pcsk $nmbr$ ( nmol / l ),C0439282
5861,cholesterol ( nmol / l ),C0008377;C0439282
5860,testosterone ( tt ) ( nmol / l ),C0039601;C0439282;C1452561;C4554543
5860,testosterone ( nmol / l ),C0039601;C0439282
5859,hscrp ( nmol / l ),C0439282
5859,crp  nmol / l  median ( range ),C0439282;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
5858,titre ( u / ml ) t,C0439340;C0475208;C1880521;C2945590
5858,fpi  m - u / ml ( pmol / l ),C0369637;C0439192;C0439284;C0439340;C0441923;C0456616;C1880521;C2945590
5857,igelow ( < i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
5857,igelow ( < $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0439340
5857,igehigh ( > i $nmbr$ ku / l  n = i  $nmbr$ ),C0021966;C0221138;C0439340
5856,imt ( $nmbr$ ),C0334121;C1704614;C4318736
5855,tnf - r $nmbr$ a ( ng / ml ),C1363984;C1706001
5854,dietary epa - dha intake ( mg / day ) *,C0142831;C0439422;C1286104;C2348308
5854,dha ( n = $nmbr$ ),C0142831;C2348308
5853,subarachnoid hemorrhage,C0038525
5852,non ‐ haemorrhagic stroke — no . ( % ),C0333275;C1518422
5852,haemorrhagic,C0333275
5851,ischemic stroke without hemorrhagic conversior,C0333275;C0475224;C0553692;C0948008
5851,hemorrhagic,C0333275
5850,• hemorrhagic stroke,C0553692
5850,hemorrhagic stroke ( n = $nmbr$ ),C0553692
5850,hemorrhagic stroke,C0553692
5850,haemorrhagic stroke — no . ( % ),C0553692
5850,haemorrhagic stroke,C0553692
5849,thyroid hormone,C0040135;C4522017
5848,hormone - refractory prostate carcinoma,C1328504
5847,hormones,C0019932
5847,estrogen - containing hormones,C0014939;C0019932;C0332256;C2700400;C2936882;C4542544
5846,use of hormone replacement therapy ( a ),C0282402;C1524063
5846,hormone replacement therapy use,C0042153;C0282402;C0457083;C1947944
5846,hormone replacement therapy,C0282402
5846,hormone replacement ! !,C0282402
5846,hormone replacement,C0282402
5845,hrt use,C0042153;C0282402;C0457083;C1947944
5845,hrt,C0282402
5844,pre - menopausal without hormone replacement,C0206158;C0282402
5844,pre - menopausal with hormone replacement,C0206158;C0282402
5843,stroke / se,C0036919;C0038454;C4554100
5843,stroke / non -,C0038454;C4554100
5843,cvd / stroke / see,C0007222;C0038454;C4554100
5842,stroke / embolism,C0013922;C0038454;C1704212;C4554100
5842,stroke,C0038454;C4554100
5841,stroke ( fatal / nonfatal ),C0038454;C4554100
5841,nonfatal stroke ®,C0038454;C4554100
5841,nonfatal stroke,C0038454;C4554100
5841,fatal stroke,C0038454;C1302234;C1705232;C4554100
5841,fatal / nonfatal stroke  n ( % ),C0038454;C1302234;C1705232;C4554100
5841,fatal / nonfatal stroke,C0038454;C1302234;C1705232;C4554100
5840,time from qualifying stroke to randomization,C0038454;C0040223;C1514624;C3541383;C4554100
5840,time from onset of qualifying stroke to randomization,C0038454;C0449244;C1514624;C4554100
5839,qualifying stroke,C0038454;C1514624;C4554100
5839,months from qualifying stroke *   ( % ),C0038454;C0439231;C1514624;C4554100
5838,stroke thought due to atherothrombotic disease,C0038454;C4554100
5838,sensorimotor stroke,C0038454;C4554100
5838,pure sensory stroke,C0038454;C0445254;C2247561;C4554100
5837,stroke at entry ( vs transient ischemic attack ),C0038454;C1705654;C4554100
5837,stroke at entry,C0038454;C1705654;C4554100
5836,early ichaem ic stroke,C0020750;C0038454;C1279919;C4554100;C4554818
5836,all stroke,C0038454;C4554100
5835,stroke — no . / total no . ( % ),C0038454;C4554100
5835,stroke — no . ( % ),C0038454;C4554100
5835,stroke or tia — no . ( % ),C0038454;C4554100
5835,stroke or tia,C0038454;C4554100
5835,stroke or se ( s / se ),C0038454;C4554100
5835,stroke or,C0038454;C4554100
5835,stroke n ( % ),C0038454;C4554100
5835,stroke and tia  n ( % ),C0038454;C4554100
5835,stroke  n ( % ),C0038454;C4554100
5835,no . of strokes / no . of patients in category ( and % ),C0038454
5835,no . of strokes ( % ),C0038454
5835,history of stroke or tia — no . ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
5835,history of stroke or tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
5835,history of stroke / see / tia  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
5835,atherothrombotic stroke  n ( % ),C0038454;C4554100
5834,stroke non - fatal,C0038454;C4554100
5834,history of non - hemor - rhagic stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1518422;C1705255;C2004062;C4554100
5833,• any stroke,C0038454;C4554100
5833,stroke of any etiology,C0015127;C0038454;C1314792;C1524003;C4554100
5833,stroke any,C0038454;C4554100
5833,any stroke ( n = $nmbr$ ),C0038454;C4554100
5833,any stroke,C0038454;C4554100
5832,new stroke *,C0038454;C0205314;C4554100
5831,prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
5831,nonfatal stroke ( n = $nmbr$ ),C0038454;C4554100
5831,no prior stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C4554100
5831,hemispheric stroke n = $nmbr$,C0038454;C0205139;C4554100
5830,stroke subtype  n ( % ),C0038454;C0449560;C4554100
5830,stroke subtype,C0038454;C0449560;C4554100
5829,stroke or systemic embolism,C0038454;C4554100
5829,stroke or systemic,C0038454;C4554100
5829,stroke or see,C0038454;C4554100
5829,stroke or cerebrovascular disease,C0038454;C4554100
5829,stroke  see  or death,C0038454;C4554100
5829,stroke  see  or cv death,C0038454;C4554100
5829,prior stroke or tza,C0038454;C0332152;C2826257;C4554100
5829,prior stroke or transient ischemic attack,C0038454;C0332152;C2826257;C4554100
5829,prior stroke or tia  %,C0038454;C0332152;C2826257;C4554100
5829,prior stroke or tia,C0038454;C0332152;C2826257;C4554100
5828,stroke  total,C0038454;C4554100
5828,stroke  fatal and nonfatal,C0038454;C4554100
5828,nondisabling  nonfatal stroke,C0038454;C4554100
5828,life - threatening bleeding  disabling stroke  and death,C0019080;C0038454;C1546953;C2826244;C3537125;C4554100
5828,disabling stroke,C0038454;C4554100
5827,stroke ortiab,C0038454;C4554100
5827,stroke ortia,C0038454;C4554100
5827,stroke or transient ischemic attack,C0038454;C4554100
5827,stroke or pvd  ( % ),C0038454;C4554100
5827,stroke / transient ischemic attack,C0038454;C4554100
5827,stroke ( vs tia ),C0038454;C4554100
5827,previous stroke ortransient ischaemic attack ( % ),C0038454;C0205156;C0745413;C1552607;C4554100
5827,previous stroke ortia $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
5827,previous stroke ortia,C0038454;C0205156;C1552607;C4554100
5827,previous stroke or transient ischemic attack — no . / total,C0038454;C0205156;C1552607;C4554100
5827,previous stroke or transient ischemic attack  no . / total no . ( % ),C0038454;C0205156;C1552607;C4554100
5827,previous stroke or tl a $nmbr$ - $nmbr$,C0038454;C0205156;C1552607;C4554100
5827,previous stroke or tl a,C0038454;C0205156;C1552607;C4554100
5827,previous stroke or tia ( % ),C0038454;C0205156;C1552607;C4554100
5827,previous stroke or tia  n ( % ),C0038454;C0205156;C1552607;C4554100
5827,previous stroke or tia,C0038454;C0205156;C1552607;C4554100
5827,previous stroke *,C0038454;C0205156;C1552607;C4554100
5827,previous stroke  n ( % ),C0038454;C0205156;C1552607;C4554100
5827,previous stroke,C0038454;C0205156;C1552607;C4554100
5827,previous clinical stroke or transient ischemic attack ( % ),C0038454;C0205156;C0205210;C1552607;C4554100
5827,previous clinical stroke or tia,C0038454;C0205156;C0205210;C1552607;C4554100
5827,no previous stroke ortia,C0038454;C0205156;C1552607;C4554100
5827,a stroke,C0038454;C4554100
5826,stroke n = $nmbr$,C0038454;C4554100
5826,previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
5826,no stroke n = $nmbr$ $nmbr$,C0038454;C4554100
5826,no stroke ( n = $nmbr$ ),C0038454;C4554100
5826,no previous stroke or tia ( n = $nmbr$ ),C0038454;C0205156;C1552607;C4554100
5825,stroke deaths,C0011065;C0038454;C1306577;C4554100
5825,stroke / see,C0038454;C4554100
5825,net clinical benefit : cv death  mi  stroke  gusto moderate / severe bleeding,C0011065;C0038454;C1306577;C1456447;C3538987;C3810814;C3853572;C3887809;C3890893;C4048877;C4082313;C4318503;C4552775;C4554100;C4684590
5825,macce ( death  mi  stroke ),C0011065;C0038454;C1306577;C3810814;C4082313;C4552775;C4554100
5825,cv death / mi / stroke / ucr,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
5825,cv death / mi / stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
5825,cv death  mi  stroke  or urgent coronary revascularization,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
5825,all - cause death / stroke / see,C0011065;C0015127;C0038454;C1306577;C1524003;C4082313;C4552775;C4554100
5824,cerebrovascular accident / tia,C0007787;C0038454;C0917805;C1054154
5824,cerebrovascular accident,C0038454
5823,median duration of study - drug administration ( iqr ) — days,C0013175;C0439228;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
5823,median duration of study - drug administration,C0013175;C0549183;C0876920;C2347635;C2348144;C2348354;C2939193
5823,duration of study - drug administration — hr,C0013175;C2348354
5822,temporary discontinuation of study drug,C0013175;C0205374;C0457454;C1444662;C1548539;C3245481;C4552847
5822,study drug,C0013175
5821,time from study drug administration to coronary revascularization  median ( iqr )  h,C0013175;C0040227;C0150270;C0206209;C2349982;C3469597
5821,time from randomization to study - drug initiation — hr,C0013175;C0013227;C0034656;C0040223;C0040227;C0589507;C1158830;C1254351;C1704686;C2349982;C3541383
5821,time from randomization to study - drug administration — hr,C0013175;C0034656;C0040227;C0150270;C0206209;C2349982;C3469597
5820,study population,C2348561
5820,overall study population,C0282416;C1561607;C2348561
5819,six - study placebo - controlled set,C0036849;C0205452;C0557651;C1442518;C1705195;C1706408;C2603343
5818,in extension study,C0231448;C0557651;C1880641;C2603343
5817,this study,C0557651;C2603343
5817,included in this study ( n = $nmbr$ ),C0332257;C0557651;C2603343
5816,study $nmbr$ . $nmbr$,C0557651;C2603343
5816,p < $nmbr$ . $nmbr$ ) between the study groups in any of the baseline characteristics . ace,C0369773;C0441849;C0557651;C0681848;C1959644;C2603343;C2603361
5815,study druga,C0557651;C2603343
5815,permanently stopped study drug because of adverse events,C0041755;C0557651;C1272691;C2603343
5814,induction study treatment,C0205263;C0557651;C0857127;C1521826;C2603343;C4049995
5813,duration of study - drug infusion,C0392877;C0449238;C0557651;C2603343;C2926735
5812,study,C0557651;C2603343
5812,duration antiplatelet use as % of study duration ( sd ),C0557651;C1881378;C2603343;C2699239;C2826775
5811,intravenous study drug administered — no . ( % ),C0013175;C0348016;C0557651;C0683092;C2603343
5810,study $nmbr$,C0557651;C2603343
5810,other lipid - modifying drug use at study entry  n ( % ),C0013175;C0013227;C0023779;C0042153;C0242510;C0392747;C0457083;C0557651;C0869040;C1254351;C1705654;C1947944;C2603343
5810,administration of study drug ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1254351;C1533734;C2603343;C3161471;C3469597
5810,administration of study - drug bolus — no . / total no . ( % ),C0001554;C0013175;C0013227;C0150270;C0262754;C0557651;C1186706;C1254351;C1511237;C1533734;C1705509;C2603343;C3161471;C3469597;C3812160
5809,puva,C0853073;C1704892
5808,uvb,C0454530;C0564461
5807,pvd,C0085096;C4521226
5806,history of pvd  no . ( % ),C4534349
5806,history of pvd  n ( % ),C4534349
5806,history of pvd,C4534349
5805,pump,C0182537
5805,off pump,C0182537;C1518543
5805,off - pump,C0182537;C1518543
5804,on pump,C3842462
5804,on - pump,C3842462
5803,orthopaedic,C0029355
5802,orthostatic hypotension,C0020651
5801,not hispanic or latino ( n — $nmbr$ ),C1518424
5801,not hispanic or latino ( n = $nmbr$ ),C1518424
5801,not hispanic or latino,C1518424
5801,not hispanic / latino ( n = $nmbr$  $nmbr$ ),C0086528;C1518424
5801,not hispanic / latino,C0086528;C1518424
5801,not hispanic,C1518424
5801,non - hispanic or latino,C1518424
5801,non - hispanic and latino,C1518424
5801,non - hispanic  non - latino,C0086528;C1518424
5800,non - hispanic black,C0005680;C0027567;C0085756;C0439541;C1518424
5800,non - hispanic,C1518424
5800,black non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
5800,black  non - hispanic,C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
5799,cryptogenic localization - related,C0332240;C0475264;C1744691
5799,cryptogenic,C0332240
5798,idiopathic / familial,C0015576;C0241888;C0332240
5798,idiopathic,C0332240
5797,epistaxis,C0014591;C4554627
5796,metastatic,C0036525;C1522484;C4085632
5795,metastatic disease,C0027627;C2939419;C2939420
5794,hispanic — no . ( % ),C0086409
5794,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409
5794,hispanic ethnic group — no . ( % ) f,C0015031;C0086409;C1879937
5794,hispanic ethnic group  n ( % ),C0015031;C0086409;C0441848;C0680174
5794,hispanic  n ( % ),C0086409
5793,hispanic or latino ( n = $nmbr$ ),C0086409
5793,hispanic ( n = $nmbr$ l $nmbr$ ),C0086409
5793,hispanic ( n = $nmbr$ ),C0086409
5793,biack hispanic,C0086409
5793,american hispanic ( n   = $nmbr$ ),C0086409;C0596070
5792,hispanic or latino ( n — $nmbr$ ),C0086409
5792,hispanic or latino,C0086409
5792,hispanic / latino ( n = $nmbr$ ),C0086409;C0086528
5792,hispanic / latino,C0086409;C0086528
5791,hispanic or latino ethnic groupf,C0086409
5791,hispanic or latino ethnic groupb,C0086409
5791,hispanic or latino ethnic group *,C0086409
5791,hispanic or latino ethnic group !,C0086409
5791,ethnicitya hispanic or latino,C0086409
5791,ethnicity - - hispanic or latino,C0015031;C0086409;C0243103
5790,hispanic / non - hispanic,C0086409;C1518422
5790,hispanic,C0086409
5789,psycholeptics,C3653516
5788,psychogenic,C0458006
5787,ischaemic skin lesions,C0037284;C0475224
5786,ischemic tvr,C0475224
5786,ischemic outcomes,C0475224;C1274040
5786,ischaemic or unknown stroke,C0475224
5785,non - ischaemic cause,C0015127;C0475224;C1518422;C1524003
5785,ischemic cause,C0015127;C0475224;C1524003
5785,ischaemic cause,C0015127;C0475224;C1524003
5784,non - ischemic,C0475224;C1518422
5784,non - ischaemic ( n = $nmbr$ o $nmbr$ ),C0475224;C1518422
5784,non - ischaemic ( n = $nmbr$ ),C0475224;C1518422
5784,non - ischaemic,C0475224;C1518422
5784,ischemic,C0475224
5783,ischemic hf  % ( n ),C0018488;C0475224;C1313497;C1538440;C3273279
5783,ischaemic ( n = $nmbr$ l $nmbr$ ),C0475224
5783,ischaemic ( n = $nmbr$ ),C0475224
5783,ischaemic  n ( % ),C0475224
5783,ischaemic,C0475224
5782,primary ischemic stroke,C0205225;C0439612;C0439631;C0948008
5782,ischemic stroke ( vs . tia ),C0948008
5782,ischemic stroke ( incl . uncertain ),C0948008
5781,ischemic stroke with hemnrrhnaic cnnversinn,C0948008
5781,ischemic stroke subtype,C0449560;C0948008
5780,prior ischemic stroke,C0332152;C0948008;C2826257
5780,ischemic stroke or see,C0948008
5779,• ischemic stroke,C0948008
5779,minor ischaemic stroke,C0026193;C0205165;C0948008
5778,previous ischemic stroke ortia,C0205156;C0948008;C1552607
5778,previous ischemic stroke / tia ( n = $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
5778,previous ischemic stroke  n ( % ),C0205156;C0948008;C1552607
5778,nonfatal ischemic stroke,C0948008
5778,ischemic stroke ( % ),C0948008
5778,ischemic stroke,C0948008
5778,ischaemic stroke  n ( % ),C0948008
5778,ischaemic stroke,C0948008
5777,post - acute ischemic stroke,C0205178;C0475224;C0687676;C0751956;C0948008;C1704687;C3469826
5777,all ischemic stroke,C0948008
5776,austria,C0004348
5775,the netherlands  australia  new zealand  and south africa,C0027778;C4289954
5774,australia / new zealand / south africa,C0037712;C4289954
5773,australia / new zealand,C4289954
5773,asia / australia / new zealand,C0003980;C4289954
5772,australasia,C0282279;C1257882
5771,north america plus australia and new zealand,C0004340;C0028405;C0332287
5771,north america ( plus australia and new zealand ),C0004340;C0028405;C0332287
5771,australia and new zealand,C0004340
5770,australia / nz,C0004340;C0027978
5769,western europe / australia / israel,C0004340;C0015176;C0022271;C0043128;C0043129
5769,western europe / australia,C0004340;C0015176;C0043128;C0043129
5769,australia,C0004340
5768,asthma population ( n = $nmbr$ ),C0004096;C0032659;C1257890;C2984299
5767,newly diagnosed asthma ( n ),C0004096;C0011900;C0750546;C2984299
5767,asthma - related health -,C0004096;C2984299
5766,total asthma symptom score :,C0004096;C2984299;C3533163
5766,total asthma symptom score  mean ± sdz,C0004096;C0444504;C2347634;C2348143;C2984299;C3533163
5766,total asthma symptom score  mean ± sd ‡,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
5766,total asthma symptom score,C0004096;C2984299;C3533163
5766,mean ( sd ) total asthma symptom scores,C0004096;C0444504;C2347634;C2348143;C2699239;C2984299;C3533163
5766,asthma,C0004096;C2984299
5765,cardiac rhythm,C0232187
5764,cardiac rhythm disorders,C0264886
5764,cardiac rhythm disorder at baseline yes,C0168634;C0264886;C1442488;C1549445;C1705108;C1710701
5764,cardiac rhythm disorder at baseline no,C0168634;C0264886;C1442488
5763,sinus rhythm at baseline,C0168634;C0232201;C1442488
5763,sinus rhythm,C0232201
5762,cardiac arrhythmia  n ( % ),C0003811;C0264886;C1560249
5762,cardiac arrhythmia,C0003811;C0264886;C1560249
5762,arrhythmia !,C0003811
5762,arrhythmia,C0003811
5761,prior arrhythmias  n ( % ),C0003811;C0332152;C2826257
5761,arrhythmias,C0003811
5760,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195;C0231174;C0301380;C0680095
5760,antiarrhythmic drugs    n   ( % ),C0003195
5760,antiarrhythmic drug,C0003195;C0301380
5759,use of antiarrhythmic agent,C0003195;C0301380;C1524063
5759,antiarrhythmic agent,C0003195;C0301380
5758,other antiarrhythmics ^,C0003195
5758,antiarrhythmics,C0003195
5758,antiarrhythmic therapy,C0003195;C0039798;C0087111;C1363945;C3537142
5758,antiarrhythmic,C0003195;C3537142
5758,anti arrhythmic,C0003195;C3537142
5757,computed tomographic angiography,C1536105
5756,normal coronary angiography,C0853522
5755,medications at coronary angiography,C0013227;C0085532;C0802604;C1548829;C2598133;C4284232
5755,coronary angiography — no . ( % ),C0085532;C1548829
5755,coronary angiography and intervention,C0085532;C1548829
5755,coronary angiography,C0085532;C1548829
5754,angiography and revascularization,C0002978
5754,additional angiography,C0002978;C1524062
5753,prior angiography showing stenosis ≥ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0002978;C0332152;C2826257
5753,prior angiography showing stenosis > $nmbr$ %  n = $nmbr$ °,C0002978;C0332152;C2826257
5753,diagnostic angiography,C0002978
5752,contrast angiography,C0002978;C0009924;C1979874
5752,angiography — no . ( % ),C0002978
5752,angiography,C0002978
5751,radionuclide ventriculography,C0017200;C0034610
5750,duplex ultrasonography,C3825392
5749,coronary angioplasty or stenting,C0002997;C0190211
5748,balloon angioplasty plus abciximab,C0002996;C0002997;C0288672;C0332287
5747,previous balloon angioplasty  n ( % ),C0002996;C0002997;C0205156;C1552607
5747,previous balloon angioplasty,C0002996;C0002997;C0205156;C1552607
5747,balloon angioplasty — no . ( % ),C0002996;C0002997
5747,balloon angioplasty,C0002996;C0002997
5746,peripheral angioplasty,C0162577;C0205100;C1548817
5745,prior angioplasty,C0162577;C0332152;C1548817;C2826257
5745,angioplasty,C0162577;C1548817
5744,inappropriate,C1548788;C3537135;C3542467
5743,no nadroparin ( n = $nmbr$ ),C0206232
5743,nadroparin vs control,C0206232
5743,nadroparin ( n = $nmbr$ ),C0206232
5743,nadroparin,C0206232
5742,myopathy,C0026848
5741,autonomic neuropathy,C0259749
5740,neuropathy — no . ( % ),C0442874
5740,neuropathy,C0442874
5739,peripheral sensory neuropathy,C0151313;C4554142
5738,peripheral neuropathy,C0031117
5737,component . for all instruments  higher scores indicate more severe disease . ara denotes american rheumatism association ( now called,C0205250;C0449432;C0449820;C1705248;C4551823
5736,mental component summary,C0229992;C0449432;C1552616;C1705248;C1706244
5736,mental component score ( mcs ),C0229992;C0449432;C0449820;C1705248;C4050231
5736,mental component,C0229992;C0449432;C1705248
5735,components,C0449432
5735,chads $nmbr$ components  n ( % ),C0007928;C0449432;C1413373
5734,poor compliance / noncompliance,C0032646;C0376405;C0457432
5734,noncompliant,C0457432
5734,non - compliance,C0376405;C0457432
5733,fondaparinux — no . ( % ),C1098510
5733,fondaparinux ( n = $nmbr$ ),C1098510
5733,fondaparinux ( n = $nmbr$  $nmbr$ ),C1098510
5733,commercially available fondaparinux,C0470187;C1098510
5732,total time of fondaparinux treatment before,C0039798;C0040223;C0087111;C0439175;C0439810;C1098510;C1522326;C1533734;C1705169;C3538994;C3541383;C3887704
5732,fondaparinux,C1098510
5731,hong kong,C0019907;C2987742
5730,long term *,C0443252
5730,long term ( n = $nmbr$ ) +,C0443252
5730,long - term aspirin,C0004057;C0443252
5729,short term ^,C0443303
5729,short term ( n = $nmbr$ ) +,C0443303
5728,serum mg > $nmbr$ . $nmbr$ mmol / l ( normal mg / hvpermagnesemia ),C0205307;C0229671;C0231683;C0439166;C0439190;C1546774;C1550100;C2347086;C2827881;C4553972
5728,renal function  normal - mild,C0205307;C0231683;C0232804;C0439166;C2347086;C2945599;C4553972
5728,normal or mild ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal or increased gfr ( > $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal hba $nmbr$ c  n = $nmbr$,C0019016;C0205307;C0231683;C0439166;C1825777;C2347086;C3538758;C4553972
5728,normal fasting glucose level ( n = $nmbr$ ),C0015663;C0202045;C0205307;C0231683;C0439166;C0522082;C2347086;C4553972
5728,normal acr ( < $nmbr$ mg / mg ) at baseline to albuminuria ( acr > $nmbr$ mg / g ),C0168634;C0205307;C0231683;C0439166;C1319635;C1412134;C1442488;C1515941;C2347086;C4553972
5728,normal > $nmbr$ - $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal - high renin ( pra > $nmbr$ . $nmbr$ ng / ml / h ) ( n = $nmbr$ ),C0205307;C0231683;C0439166;C0633231;C0855390;C1141951;C1419788;C1533072;C2347086;C3274822;C3669212;C4050009;C4283900;C4553972
5728,normal ( ≤   uln ) n   =   $nmbr$,C0205307;C0231683;C0439166;C1519815;C2347086;C4553972
5728,normal ( > $nmbr$ mlvmin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0441923;C2347086;C4553972
5728,normal ( > $nmbr$ ml / min ),C0205307;C0231683;C0439166;C0439445;C2347086;C4553972
5728,normal ( > $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
5728,normal ( < $nmbr$ . $nmbr$ u / ml ),C0205307;C0231683;C0439166;C0439340;C1880521;C2347086;C2945590;C4553972
5728,normal  < $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
5727,predicted normal ) t,C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
5727,predicted normal ( % ),C0205307;C0231683;C0439166;C0681842;C1882327;C2347086;C4553972
5727,normal troponin,C0041199;C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal study termination,C0205307;C0231683;C0439166;C0557651;C1549081;C1692758;C2347086;C2603343;C4553972
5727,normal responders ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal responder ( n = $nmbr$ ),C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
5727,normal crp and,C0205307;C0231683;C0439166;C2347086;C3890735;C4048285;C4553972
5727,normal baseline crp,C0168634;C0205307;C0231683;C0439166;C1442488;C2347086;C3890735;C4048285;C4553972
5727,normal ( ≥ $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C2347086;C4553972
5727,normal ( egfr ≥ $nmbr$ )  n ( % ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
5727,normal,C0205307;C0231683;C0439166;C2347086;C4553972
5727,mean ( sd ) % of predicted normal fevi,C0205307;C0231683;C0429706;C0439166;C0444504;C0681842;C0849974;C1561566;C1882327;C2347086;C2347634;C2348143;C2699239;C4528367;C4553972
5727,mean ( sd ) % of predicted normal eevi,C0205307;C0231683;C0439166;C0444504;C0681842;C1882327;C2347086;C2347634;C2348143;C2699239;C4553972
5726,colectomy ( partial or total ),C0009274
5725,total bleeds,C0232100
5725,total bleeding,C0232100
5724,total body ( without head ),C0018670;C0229960;C1706305
5724,total body,C0229960
5723,femoral neckc,C0015811
5723,femoral access — no . / total no . ( % ),C0015811
5723,femoral access,C0015811;C0444454;C1554204
5723,femoral,C0015811
5722,rate of oral or systemic corticosteroid,C0442027;C0871208;C1521828;C4521986
5722,oral or other systemic corticosteroid,C0442027;C4521986
5721,oral,C0442027;C4521986
5721,duration of oral antidiabetic treatment  y  mean ( sd ),C0442027;C0444504;C0444921;C0935929;C2347634;C2348143;C2699239;C4521986
5720,oral corticosteroid use at enrolmentt,C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
5720,oral corticosteroid dose ( mg / day ),C0001617;C0178602;C0439422;C0442027;C0869039;C1114758;C3536709;C4521986
5720,oral corticosteroid,C0001617;C0442027;C3536709;C4521986
5720,current oral corticosteroid use,C0001617;C0239126;C0442027;C0521116;C1527415;C1705970;C3536709;C4521986
5719,oral study drug administered — no . / total no . ( % ),C0013175;C0442027;C4521986
5718,oral treprostinil ( n = $nmbr$ ),C0442027;C1145760;C4521986
5717,oral antidiabetes monotherapya  n ( % ),C0442027;C4521986
5717,oral antidiabetes combination therapy without insulina  n ( % ),C0009429;C0442027;C0556895;C4521986
5716,oral fi - blockers,C0442027;C4050619;C4521986
5715,oral β - adrenergics  n ( % ),C0001637;C0442027;C4521986
5714,oral ( % ),C0442027;C4521986
5714,concomitant oral glucose - lowering agents  zz ( % ),C0017725;C0441994;C0442027;C2003888;C2347310;C2347852;C4521986
5713,oral medications,C0304289
5713,oral antidiabetic drugs / insulin ( % / % ),C0021641;C0029167;C0175795;C0304289;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
5713,oral antidiabetic drugs,C0029167;C0175795;C0304289;C0442027;C0935929;C4521986
5712,total included in combined analysis,C0439175;C0439810
5712,total cohort,C0009247;C0439175;C0439810;C0599755
5711,total no . $nmbr$,C0439175;C0439810
5711,total no .,C0439175;C0439810
5711,total gadolinium - enhancing lesion count . no . ( % ),C0439175;C0439810;C1333400
5711,total gadolinium - enhancing lesion count  no . ( % ),C0439175;C0439810;C1333400
5710,total randomized,C0439175;C0439810
5710,o total randomized,C0439175;C0439810;C0483204
5709,total invasive cancer,C0439175;C0439810;C0677898
5709,total,C0439175;C0439810
5708,total hipc,C0439175;C0439810
5708,total hip or knee replacement,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
5707,total resolution of nail psoriasisd,C0027342;C0439175;C0439810;C1432728;C1514893;C1706463;C2699488;C3538766
5707,total resolution of enthesitisc,C0439175;C0439810;C1514893;C1706463;C2699488
5707,total resolution of dactylitisb,C0439175;C0439810;C1514893;C1706463;C2699488
5706,total sgrq score,C0439175;C0439810
5706,mean aqlq total score t,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236;C4055434
5705,total !,C0439175;C0439810
5705,st george ' s respiratory questionnaire total score !,C0439175;C0439810;C3472502
5704,total no . of patients,C0439175;C0439810
5704,total no . of events / total no . of participants,C0439175;C0439810
5704,total no . of events / participants,C0439175;C0439810
5704,total no . of events ( % of participants ) / total no . of participants,C0439175;C0439810
5704,no . with event / total no . { % ),C0439175;C0439810;C0441471;C4019010
5704,no . / total no . ( % ) t,C0439175;C0439810
5704,no . / total no . ( % ),C0439175;C0439810
5704,no . / total 	 no . ( % ),C0439175;C0439810
5704,no . / total,C0439175;C0439810
5704,event / total,C0439175;C0439810;C0441471;C4019010
5704,clopidogrel / total no . of patients % %,C0070166;C0439175;C0439810
5704,$nmbr$ — no . / total no . ( % ),C0439175;C0439810
5704,$nmbr$ - $nmbr$ — no . / total no . ( % ),C0439175;C0439810
5704,$nmbr$  no . / total no . ( % ),C0439175;C0439810
5703,total randomised ( n ),C0439175;C0439810
5703,total events  n,C0439175;C0439810;C0441471;C3541888
5703,no of events / total n ( % ),C0439175;C0439810;C0441471;C3541888
5702,total ige — lu / ml,C0439175;C0439810;C2697941
5701,total glucose mg / dl,C0017725;C0439175;C0439269;C0439810
5701,total chol  mg / dl,C0201950;C0439175;C0439269;C0439810
5701,total c ( mg / dl ) *,C0439175;C0439269;C0439810
5701,total *,C0439175;C0439810
5700,total ldl - c *,C0439175;C0439810
5700,total cholesterol : hdl - c ratio,C0439175;C0439810;C0523558
5700,total c / hdl - c ratio * *,C0439175;C0439810;C0456603;C1547037;C3715113
5700,total - c,C0439175;C0439810
5699,total c,C0439175;C0439810
5699,sgrq - c total scoreb,C0439175;C0439810;C3826872
5698,duration of total exposure to study treatment  weeks,C0439175;C0439810;C2826870
5697,total ige  geometric,C0439175;C0439810
5697,cvd  total,C0007222;C0439175;C0439810
5697,chd  total,C0280604;C0439175;C0439810;C3542407
5696,total patients n = $nmbr$,C0030705;C0439175;C0439810
5696,total patients  n,C0030705;C0439175;C0439810
5696,total patients,C0030705;C0439175;C0439810
5696,total n   =   $nmbr$,C0439175;C0439810
5696,total n = $nmbr$,C0439175;C0439810
5696,total n,C0439175;C0439810
5696,total comparators  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C1707454;C3541888;C4553389;C4553390
5696,total > atients,C0439175;C0439810
5695,total haq  $nmbr$ - $nmbr$,C0102923;C0439175;C0439810;C0451208
5694,total updrs score ( baseline )  mean ( sd ),C0439175;C0439810;C3639721
5694,total $nmbr$,C0439175;C0439810
5694,second primary ( estimated change in total updrs score from baseline to wk $nmbr$ ),C0205225;C0205436;C0392747;C0439175;C0439612;C0439631;C0439810;C0443172;C0457385;C0565930;C0750572;C1561503;C1705190;C1705241;C3639721;C4319952
5693,v total ( n = $nmbr$ ),C0439175;C0439810
5693,total n = $nmbr$ n ( % ),C0439175;C0439810
5693,total n $nmbr$,C0439175;C0439810
5693,total group ( n = $nmbr$ ),C0439175;C0439810;C0441848
5693,total comparators ( n = $nmbr$ ),C0439175;C0439810;C1707454;C4553389;C4553390
5693,total ( n   = $nmbr$ ),C0439175;C0439810
5693,total ( n = $nmbr$  $nmbr$ ) - -,C0439175;C0439810
5693,total ( n = $nmbr$  $nmbr$ ),C0439175;C0439810
5693,total  n = $nmbr$ $nmbr$,C0439175;C0439810
5693,total  n = $nmbr$,C0439175;C0439810
5692,total study population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
5692,total study population ( n = $nmbr$  $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
5692,total ( n ),C0439175;C0439810
5692,total ( n $nmbr$ $nmbr$ ),C0439175;C0439810
5691,total ( n   =   $nmbr$ ),C0439175;C0439810
5691,total ( n = $nmbr$ ),C0439175;C0439810
5691,total ( n = $nmbr$ $nmbr$ ),C0439175;C0439810
5691,men  total ( n = $nmbr$ ),C0025266;C0439175;C0439810
5691,asian itt population total ( n = $nmbr$ ),C0032659;C0078988;C0439175;C0439810;C1257890
5690,total phase $nmbr$ pooled ( n = $nmbr$ ),C0205390;C0439175;C0439810;C1710475
5690,total ( v = $nmbr$  $nmbr$ ),C0439175;C0439810
5689,total occlusion  n ( % ),C0001168;C0011382;C0028778;C0439175;C0439810;C0441597;C1110554;C1947917
5689,total ( n [ $nmbr$ ),C0439175;C0439810
5688,total deaths  n,C0011065;C0439175;C0439810;C1306577
5688,total deaths,C0011065;C0439175;C0439810;C1306577
5688,total death,C0011065;C0439175;C0439810;C1306577;C4082313;C4552775
5687,distal forearm,C0588203
5686,forearm,C0016536
5685,forearm fracture,C1305215
5684,focal,C0205234
5684,> $nmbr$ % focal seizure frequency responders,C0149775;C0205234;C0376249;C0439603;C0751495;C0871396;C1561548;C1705502;C3898838;C4321352
5683,normal cognitive,C2712133
5682,normal function or mild impairment,C4296962
5681,mild dysfunction or normal,C3274775
5680,abnormal angiogram,C0002978;C0205161;C1548816;C2347472;C2699333;C3891555;C4255126
5680,abnormal,C0205161;C2347472;C2699333
5679,alanine aminotransferase or aspartate aminotransferase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0001899;C0057041;C1415274;C3887708
5679,alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708
5679,alanine aminotransferase  u / l,C0001899;C0057041;C0439339;C1415274;C3887708
5678,aspartate aminotransferase increased,C0004002
5678,aspartate aminotransferase  u / l,C0004002;C0439339
5677,involved gl areas,C0018229;C1423073;C1427674;C1879646
5676,involved intestinal area  n ( % ),C0021853;C1879646
5675,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0015733;C0205146;C0439272;C0549183;C0876920;C0950624;C1335798;C1366582;C1708130;C2347635;C2348144;C2939193;C3539617;C4050121;C4319729
5675,areas,C0205146;C4319729
5674,cardiac procedure :,C1279986
5673,renal fmclicn : creatntoe clearance,C0232813;C0699829
5672,notes :,C1317574
5671,copd exacerbation : yes,C0740304;C1549445;C1705108;C1710701
5671,copd exacerbation : no,C0740304
5670,heritable,C0439660
5669,probable stent thrombosis,C0033204;C0332148;C3897493
5669,probable,C0033204;C0332148
5669,definite / probable stent thrombosis,C0033204;C0332148;C0439544;C1704787;C3897493
5668,chloroquine,C0008269
5667,no methotrexate  hydroxychloroquine  or sulfasalazine treatment,C0020336;C0025677
5666,hydroxychloroquine treatment §,C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
5666,hydroxychloroquine,C0020336
5665,hydralazine,C0020223
5664,ranolazine  n   =   $nmbr$,C0073633
5664,ranolazine  n = i $nmbr$ i $nmbr$,C0021966;C0073633;C0221138
5663,ranolazine n = $nmbr$,C0073633
5663,ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ ),C0032042;C0073633;C1696465;C1706408
5663,ranolazine ( n = $nmbr$ ),C0073633
5663,ranolazine ( n = $nmbr$  $nmbr$ ),C0073633
5663,ranolazine ( n $nmbr$ $nmbr$ ),C0073633
5663,ranolazine,C0073633
5662,ranolazine vs . placebo km failure rate,C0073633
5662,effect of ranolazine compared with placebo on angina and recurrent ischemia,C0073633;C1280500;C1518681;C2348382
5661,cognitive functioning,C0392334;C0392335
5660,impaired cognitive,C0338656
5659,cognitive subscale on alzheimer ' s disease assessment scale  mean ( sd ) e,C0444504;C0450989;C1516691;C2347634;C2348143;C2699239
5659,cognitive,C1516691
5658,connective tissue disease,C0009782
5658,connective - tissue disease,C0009782
5658,associated with connective tissue disease,C0009782;C0332281
5658,assoc  with connective tissue disease,C0009782
5657,drug discontinuation not due to death,C0013227;C0457454;C1254351;C1444662;C4552847
5657,discontinuations teaes,C0457454
5657,discontinuations,C0457454
5656,premature treatment discontinuation,C0039798;C0087111;C0151526;C0205252;C0457454;C1444662;C1522326;C1533734;C1705169;C3538994;C3887704;C4018905;C4552847
5656,premature discontinuation,C0151526;C0205252;C0457454;C1444662;C4018905;C4552847
5655,discontinued,C1444662
5655,discontinuation of lama prior to baseline  n ( % ),C0457454;C0999593;C1416775;C1444662;C4552847
5655,discontinuation of ics / laba prior to baseline  n ( % ),C0457454;C0815320;C1444662;C4551720;C4552847
5654,concordant stress test abnormalities,C0000768;C0000769;C0015260;C3494508;C4553529
5653,notable abnormalities,C0000768;C0000769;C4288581
5652,normalized womac score,C0449820;C1882115;C4050231
5652,normalized,C1882115
5651,coumadin,C0699129
5650,iief - ef domain score  visit $nmbr$ y,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
5650,iief - ef domain score  visit $nmbr$ * *,C0449820;C0545082;C1512346;C1880389;C1883221;C2826704;C3541951;C3641331;C4050231
5650,ef domain,C1880389;C1883221;C3541951
5649,sf - $nmbr$ v $nmbr$ domain scores  mean [ sd ],C0037712;C1880389;C1883221;C3541951
5649,ibdq domain scores  mean [ sd ],C1880389;C1883221;C3541951
5648,native latin,C0302891
5648,native coronary - artery lesions,C0205042;C0221198;C0302891
5647,treated vessel - native coronary,C0005847;C0018787;C0302891;C1522326
5647,native coronary,C0018787;C0302891
5646,pharmaco - invasive n = $nmbr$,C0205281;C1334278
5646,pharmaco - invasive ( n = $nmbr$ ),C0205281;C1334278
5646,invasive,C0205281;C1334278
5646,intent of early invasive strategy  %,C0162425;C0205281;C0679199;C1279919;C1283828;C1334278;C1550453
5646,early invasive strategy ( n = $nmbr$  $nmbr$ ),C0205281;C0679199;C1279919;C1334278
5646,early invasive *,C0205281;C1279919;C1334278
5646,early invasive $nmbr$,C0205281;C1279919;C1334278
5645,troponin negative ( n = $nmbr$ ),C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
5645,rf negative and acpa positive  n ( % ),C0035448;C0201660;C0205160;C0748398;C1513916;C1547111;C2825415;C2825491;C3853545
5645,patients with negative anti - dsdna,C0030705;C0205160;C0741099;C1513916;C2825415;C2825491;C3853545
5645,negative ctnl ( n = $nmbr$  $nmbr$ ),C0205160;C1513916;C2825415;C2825491;C3853545
5645,negative ( < $nmbr$ . $nmbr$ )  n ( % ),C0205160;C1513916;C2825415;C2825491;C3853545
5645,negative,C0205160;C1513916;C2825415;C2825491;C3853545
5645,anti - gad negative ( n = $nmbr$ ),C0205160;C0270549;C0432633;C1414925;C1513916;C2825415;C2825491;C3853545
5645,anti - gad negative,C0205160;C0270549;C1414925;C1513916;C2825415;C2825491;C3853545
5644,pre - bronchodilation fvc,C0439566;C3714541
5644,pre - bronchodilation fev $nmbr$,C0439566;C3714541
5643,pre - bronchodilator fev $nmbr$  l *,C2599602;C3714541
5643,baseline pre - bronchodilator fev $nmbr$  l,C0168634;C1442488;C2599602;C3714541
5642,post - bronchodilation fvc,C0439576;C3714541
5642,post - bronchodilation fev $nmbr$,C0439576;C3714541
5641,post - bronchodilator fev $nmbr$ / fvc ratio  mean ( sd ),C0444504;C0456603;C1547037;C2347634;C2348143;C2599594;C2699239;C3714541
5641,post - bronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
5641,post - bronchodilator fev  / fvc,C2599594;C3714541
5641,fvc post - bronchodilator,C3714541
5640,postbronchodilator fev $nmbr$  l,C2599594;C3714541
5640,postbronchodilator fev $nmbr$  % predicted,C2599594;C3714541
5640,post - bronchodilator fev $nmbr$ / fvc ( % ) a,C2599594;C3714541
5640,post - bronchodilator fev $nmbr$ ( % predicted normal ) a,C2599594;C3714541
5640,post - bronchodilator fev $nmbr$  % predicted of normal value,C2599594;C3714541
5640,mean ( sd ) postbronchodilator fev $nmbr$ % predicted,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
5640,mean ( sd ) fev $nmbr$ postbronchodilator  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
5640,fev $nmbr$ post - bronchodilator  % predicted normal,C3714541
5640,fev $nmbr$ / fvc  post - albuterol  %,C3714541
5640,fev $nmbr$ / fvc  % a,C3714541
5640,fev $nmbr$ / fvc  % *,C3714541
5640,fev $nmbr$ % predicted normal,C3714541
5640,fev $nmbr$ % predicted  post - albuterol  %,C3714541
5640,fev $nmbr$  % predicteda,C3714541
5640,fev $nmbr$  % predicted,C3714541
5639,post - bronchodilator fvc ( l ) a,C2599594;C3714541
5639,fvc ( l ),C3714541
5639,fev_ ( l ) :,C3714541
5638,post - salbutamol fev $nmbr$ ( l ) b  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
5638,post - bronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
5638,mean postbronchodilatora fev $nmbr$  % predicted ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
5638,mean fev $nmbr$  l ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
5638,mean change in fev $nmbr$,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3714541;C4319952
5638,mean - sd change in pre - bronchodilator fev $nmbr$  l,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2599602;C2699239;C3714541;C4319952
5638,mean ( sd ) fev $nmbr$ ( l ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
5638,mean ( sd ) fev $nmbr$ ( l ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239;C3714541
5638,mean ( sd ) fev $nmbr$  l,C0444504;C2347634;C2348143;C2699239;C3714541
5638,fvc  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
5638,fvc  l,C3714541
5638,fev $nmbr$ post - bronchodilator,C3714541
5638,fev $nmbr$ / fvc,C3714541
5638,fev $nmbr$ ( l )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
5638,fev $nmbr$ ( l ),C3714541
5638,fev $nmbr$ ( % predicted ),C3714541
5638,fev $nmbr$ % predicted,C3714541
5638,fev $nmbr$  mean ( sd ) pre - bd fev $nmbr$ / fvc,C0005126;C0332152;C0444504;C0740175;C2257086;C2344255;C2347634;C2348143;C2699239;C3669034;C3714541;C4050145
5638,fev $nmbr$  mean  l,C0444504;C2347634;C2348143;C3714541
5638,fev $nmbr$  mean  % predicted,C0444504;C2347634;C2348143;C3714541
5638,fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
5638,fev $nmbr$  l,C3714541
5638,fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
5638,fev  % predicted,C3714541
5638,fev,C3714541
5638,baseline mean fev $nmbr$ ( sd )  ml,C0168634;C0439526;C0444504;C1442488;C1705224;C2347634;C2348143;C2699239;C3714541;C3887665
5638,% predicted prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C0681842;C1882327;C2347634;C2348143;C2599602;C2699239;C3714541
5637,prebronchodilator fev $nmbr$ / fvc,C2599602;C3714541
5637,prebronchodilator fev $nmbr$ ( % predicted normal ) t,C2599602;C3714541
5637,prebronchodilator fev $nmbr$ ( %,C2599602;C3714541
5637,prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
5637,prebronchodilator fev $nmbr$,C2599602;C3714541
5637,pre - bronchodilator fev $nmbr$ / fvc ( % ),C2599602;C3714541
5637,pre - bronchodilator fev $nmbr$ ( % predicted normal ),C2599602;C3714541
5637,fev $nmbr$ prebronchodilator [ % pn ]  mean ± sd,C0219433;C0444504;C1549735;C2347634;C2348143;C2599602;C2699239;C3541307;C3714541;C4049640;C4049767
5637,fev $nmbr$ pre - bronchodilator ( % predicted normal )  mean ( sd ) c  d,C2599602;C3714541
5637,fev $nmbr$ / fvc prebronchodilatort,C3714541
5637,fev $nmbr$ / fvc %,C3714541
5637,fev $nmbr$ ( % predicted normal ),C3714541
5637,fev $nmbr$  l prebronchodilator fev $nmbr$  % predicted,C2599602;C3714541
5636,fev $nmbr$  l *,C3714541
5636,baseline fvc  l,C0168634;C1442488;C3714541
5636,baseline fev $nmbr$  median ( range )  l,C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3714541
5636,baseline fev $nmbr$  l *,C0168634;C1442488;C3714541
5636,baseline fev  ( l ),C0168634;C1442488;C3714541
5635,fvc ∗,C3714541
5635,fev $nmbr$ / fvc at baseline ( randomization ) ( % ) ∗,C0034656;C0168634;C1442488;C3714541
5634,fev $nmbr$ at baseline,C0168634;C1442488;C3714541
5634,fev $nmbr$ % predicted at baseline,C3714541
5634,fev  at baseline,C0168634;C1442488;C3714541
5634,% predicted ” fev  at baseline  % *,C0168634;C0681842;C1442488;C1882327;C3714541
5633,fev $nmbr$ percent predicted ( sd ),C0439165;C3714541
5632,post - bronchodilator percent of predicted fev $nmbr$  % ( sd ),C1882327;C2599594;C2699239;C3714541
5632,percent of predicted fev $nmbr$,C1882327;C3714541
5631,post - bronchodilator fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C2599594;C3714541
5631,fev $nmbr$ — % of predicted value,C0681842;C1522609;C1882327;C3714541
5631,fev $nmbr$ ( % of predicted value ),C0681842;C1522609;C1882327;C3714541
5631,fev $nmbr$ % predicted ≥ $nmbr$ %,C3714541
5631,fev $nmbr$ % predicted ( post salbutamol ),C3714541
5631,% predicted fev ^,C0681842;C1882327;C3714541
5631,% predicted fev $nmbr$,C0681842;C1882327;C3714541
5631,% predicted fev,C0681842;C1882327;C3714541
5630,iv : fev $nmbr$ < $nmbr$ % predicted,C0022326;C3714541;C4265176
5630,fev  < $nmbr$ % predicted,C3714541
5629,iii : fev $nmbr$ > $nmbr$ % - < $nmbr$ % predicted,C0439070;C1705160;C3714541
5629,fev $nmbr$ % predicted < $nmbr$ %,C3714541
5628,fvc > $nmbr$ % predicted,C3714541
5628,fvc ( % predicted ),C3714541
5628,fvc % predicted !  t,C3714541
5628,fvc  % predicted  mean ( sd ),C3714541
5628,fvc  % predicted,C3714541
5628,absolute decline in fvc > $nmbr$ % predicted or death  n ( % ),C0205344;C3714541
5628,absolute decline in fvc > $nmbr$ % predicted,C0205344;C3714541
5627,i & ii : fev $nmbr$ > $nmbr$ % predicted,C0021966;C0221138;C1710602;C3714541;C4082587
5627,fev  > $nmbr$ % predicted,C3714541
5626,trough fev $nmbr$,C0444506;C3714541
5626,trough fev  response ( l ) i,C0021966;C0221138;C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
5625,fev auc i $nmbr$ h,C0021966;C0033727;C0221138;C0369286;C0376690;C0441932;C0564385;C3714541;C4528284
5625,fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0376690;C3714541
5624,pre fev $nmbr$   % pred,C0332152;C0740175;C2257086;C3669034;C3714541
5624,pre fev $nmbr$,C0332152;C0740175;C2257086;C3669034;C3714541
5624,pre - bd fvc < $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
5624,fvc < $nmbr$ % predicted,C3714541
5624,fev $nmbr$ reversibilityz ( pre / post ipratropium )  %,C0027235;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
5624,fev $nmbr$ ( pre - albuterol )  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
5624,fev $nmbr$ % pred,C3714541
5624,fev $nmbr$  pre - albuterol  l,C0001927;C0332152;C0740175;C2257086;C3669034;C3714541
5624,fev $nmbr$  litres ( pre salbutamol )  mean ( sd ),C0001927;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
5624,fev $nmbr$  litres ( pre ipratropium )  mean ( sd ),C0027235;C0332152;C0444504;C0475211;C0740175;C2257086;C2347634;C2348143;C2699239;C3669034;C3714541
5624,fev $nmbr$,C3714541
5624,$nmbr$ ( fev $nmbr$ < $nmbr$ % pred ),C3714541
5623,predose fvc ( l ) *,C0439565;C3714541;C3812758
5623,predose fvc ( l ),C0439565;C3714541;C3812758
5623,predose fev $nmbr$ ( l ) *,C0439565;C3714541;C3812758
5623,fvc ( l ) *,C3714541
5622,post fvc % pred,C0687676;C1704687;C3469826;C3714541
5622,post fvc,C0687676;C1704687;C3469826;C3714541
5622,post fev $nmbr$   % pred,C0687676;C1704687;C3469826;C3714541
5622,post fev $nmbr$,C0687676;C1704687;C3469826;C3714541
5622,fvc,C3714541
5622,fev $nmbr$ / fvc ( post salbutamol ),C0001927;C0687676;C1704687;C3469826;C3714541
5622,fev $nmbr$ / fvc ( post - albuterol ),C3714541
5622,fev $nmbr$  litres ( post ipratropium )  mean ( sd ),C0027235;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
5622,fev $nmbr$  litres ( post - salbutamol )  mean ( sd ),C0001927;C0444504;C0475211;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
5621,local eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205276;C0750879;C3897966;C4049765
5621,eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0750879;C3897966;C4049765
5621,eos count ( cells / pl ),C0007584;C0007634;C0750480;C1623465;C1705566;C1861303;C3897966;C4049765
5621,( cells per pl ) t,C0007584;C0007634;C3897966;C4049765
5620,eosinophil count ( cells / pl )  median ( range ) c,C0007584;C0007634;C0200638;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3897966;C4049765
5620,> $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
5620,< $nmbr$ cells / pl,C0007584;C0007634;C3897966;C4049765
5620,/ pl $nmbr$ $nmbr$,C3897966;C4049765
5619,eosinophils ( cells / ll ) inclusion criteria  n ( % ),C0682547
5619,eosinophil counf cells pl ',C0682547;C3897966;C4049765
5619,baseline eosinophil < $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
5619,baseline eosinophil $nmbr$ cells / pl,C0168634;C0682547;C1442488;C3897966;C4049765
5618,lymphocytes  $nmbr$ / + il,C0020898;C0021764;C0022271;C0024264;C4018897
5617,treatment group  on - treatment il - $nmbr$ threshold,C0020898;C0021764;C0022271;C0039798;C0087111;C0441833;C0449864;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
5617,il - $nmbr$,C0020898;C0021764;C0022271
5616,western european includinq australia  israel  and south africa,C0004340;C0022271;C0043128;C0239307;C0239312;C1535514
5616,israel,C0022271
5615,serum creatinine  弘 mol 儿 | |,C0027960;C0201976;C0324740;C0439189;C0600061;C1456781;C1824986;C3665593
5615,epa  mol %,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
5615,aa  mol %,C0027960;C0282379;C0324740;C0439189;C1235746;C1456781;C1824986;C1882141;C3665593;C4554792
5614,trigl yeerides * ( m mol / l ),C0027960;C0324740;C0347982;C0369637;C0439189;C0441923;C0456616;C1456781;C1824986;C3665593
5614,epa ( mol % ),C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
5613,role physical,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
5613,role emotional,C0013987;C0035820;C0849912;C1705810;C3871154
5613,physical role,C0031809;C0035820;C0205485;C1509143;C1705810;C3871154
5613,emotional role,C0013987;C0035820;C0849912;C1705810;C3871154
5612,previous ml or abnormal angiogram,C0205156;C0439526;C1552607;C1705224;C3887665
5612,previous ml ( interaction : p = $nmbr$ . $nmbr$ ),C0205156;C0439526;C1552607;C1704675;C1705224;C3887665
5612,previous ml ( before index acs ),C0205156;C0439526;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C1705224;C2986546;C3887665;C4318612
5612,previous ml,C0205156;C0439526;C1552607;C1705224;C3887665
5611,prior ml or stroke at baseline,C0332152;C0439526;C1705224;C2826257;C3887665
5611,prior ml or abnormal angiogram,C0332152;C0439526;C1705224;C2826257;C3887665
5611,prior ml ( before index acs ),C0332152;C0439526;C0600653;C0742343;C0918012;C1552854;C1637833;C1705224;C2826257;C2986546;C3887665;C4318612
5611,prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
5611,no prior ml or stroke,C0332152;C0439526;C1705224;C2826257;C3887665
5611,no prior ml,C0332152;C0439526;C1705224;C2826257;C3887665
5611,ml,C0439526;C1705224;C3887665
5610,lvesv ( ml ),C0439526;C1705224;C3887665
5610,lvedv ( ml ),C0439526;C1705224;C3887665
5610,lav ( ml ),C0019682;C0439526;C1705224;C3887665
5610,fpi  gu / ml ( pmol / l ),C0120446;C0439192;C0439284;C0439526;C1635169;C1705224;C3887515;C3887665
5610,alvesv ( per ml ),C0439526;C1705224;C3887665
5610,alvedv ( per ml ),C0439526;C1705224;C3887665
5610,alav ( per ml ),C0439526;C1705224;C3887665
5609,ml ),C0439526;C1705224;C3887665
5609,mean ( sd ) fevi  ml,C0429706;C0439526;C0444504;C0849974;C1561566;C1705224;C2347634;C2348143;C2699239;C3887665;C4528367
5609,mean ( sd ) eevi  ml,C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
5609,adjusted ∗   mean of difference ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C1705241;C1705242;C2347634;C2348143;C3887665
5609,adjusted ∗   mean ( se ) ( ml ),C0036919;C0439526;C0444504;C0456081;C1705224;C2347634;C2348143;C3887665
5609,adjusted mean ( se ) fevi auco_ $nmbr$  ml,C0036919;C0429706;C0439526;C0444504;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
5608,decline #   ml · yr − $nmbr$,C0439234;C0439526;C1705224;C3887665
5607,cvdeath  ml  or ischemic stroke,C0439526;C1705224;C3887665
5607,cv death  ml or ischemic stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
5607,cv death  ml  ischemic stroke,C0011065;C0439526;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
5606,post - bronchodilator fev $nmbr$ ml,C0439526;C1705224;C2599594;C3714541;C3887665
5606,ml c,C0439526;C1705224;C3887665
5606,fvc  ml,C0439526;C1705224;C3714541;C3887665
5606,c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0439526;C0444506;C0547047;C1705224;C3714541;C3887665
5606,baseline post - bronchodilator fev $nmbr$   ( sd )  ml,C0168634;C0439526;C1442488;C1705224;C2599594;C2699239;C3714541;C3887665
5605,< $nmbr$ ml,C0439526;C1705224;C3887665
5605,$nmbr$ to < $nmbr$ ml per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1705224;C3887665
5604,patients with prior ml hr ( $nmbr$ % cl ),C0030705;C0332152;C0439526;C0596019;C1705224;C2826257;C3887665
5604,patients with > $nmbr$ % ■ $nmbr$ ml increase in fev $nmbr$ post - bronchodilator ( % ),C0030705;C0439526;C0442805;C1705224;C3887665
5604,> $nmbr$ ml,C0439526;C1705224;C3887665
5604,> $nmbr$ ( ml ) additional angiography,C0002978;C0439526;C1524062;C1705224;C3887665
5603,type of ml  no . ( % ),C0332307;C0439526;C1547052;C1705224;C3887665
5603,nontatal ml,C0439526;C1705224;C3887665
5603,nonfatal ml,C0439526;C1705224;C3887665
5603,* nonfatal ml,C0439526;C1705224;C3887665
5602,pvr volume  ml  mean ( sd ),C0242852;C0439526;C0444504;C0449468;C0456261;C1419141;C1690016;C1705102;C1705224;C2347634;C2348143;C2699239;C2700258;C3887665
5602,pvr  ml,C0242852;C0439526;C0456261;C1419141;C1705224;C3887665
5602,pv  ml,C0030840;C0032463;C0439526;C1705224;C3887665
5601,> = $nmbr$ ml / mln,C0439526;C1417190;C1705224;C3815103;C3887665
5600,quartiles of fgf - $nmbr$ ( ru / ml ),C0016026;C0035970;C0439526;C0919505;C1425796;C1705224;C2828255;C3887665
5600,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ) §,C0439526;C1705224;C3887665
5600,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n = $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
5600,$nmbr$ ml ( $nmbr$ to $nmbr$ ) ( n - $nmbr$ / $nmbr$ ),C0439526;C1705224;C3887665
5600,$nmbr$ - $nmbr$ ml / rain,C0034640;C0439526;C1705224;C3887665
5599,non - hdl - c ( mmol / l ),C1518422;C1532563;C3715113
5599,ldl - c / hdl - cx,C3715113
5599,ldl - c / hdl - c,C3715113
5599,hdl - c ( mmol / l ),C1532563;C3715113
5599,hdl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143;C3715113
5599,hdl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239;C3715113
5599,hdl - c  mmol / l,C1532563;C3715113
5599,hdl ( mmol / l ),C1532563;C3715113
5598,hdl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5598,hdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3715113
5598,hdl,C3715113
5597,non - hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
5597,mean sd hdl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5597,hdl - c ( mg / dl ) - mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5597,hdl - c ( mg / dl ),C0439269;C3715113
5597,hdl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5597,hdl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5597,hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5597,hdl - c  mg / dl,C0439269;C3715113
5597,hdl - c,C3715113
5597,hdl $nmbr$ - c,C3715113
5596,hdl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3715113
5596,hdl ( mg / dl ),C0439269;C3715113
5596,hdl  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3715113
5595,non - hdl - c ( mg / dl ) * *,C0439269;C1518422;C3715113
5595,hdl - c ( mg / dl ) *,C0439269;C3715113
5595,hdl *,C3715113
5594,hdl - c level  < $nmbr$ mg / dld,C0024671;C0026410;C0439269;C0441889;C0456079;C1414063;C1547707;C1960952;C2346927;C2826331;C2946261;C3715113;C4321396;C4521761
5594,hdl - c < $nmbr$ mg / dl_,C0439269;C3715113
5594,hdl - c < $nmbr$ mg / dl  no . ( % ),C0439269;C3715113
5594,hdl - c < $nmbr$ mg / dl,C0439269;C3715113
5594,hdl $nmbr$,C3715113
5593,hdl - cy,C0010622;C0332298;C2239193;C3715113
5592,total cholesterol / hdl - c,C0023822;C0201950;C0439175;C0439810;C0543421;C3715113
5592,total - c : hdl - c,C0439175;C0439810;C3715113
5592,ldl - c : hdl - c,C3715113
5591,tolal choleslerol - lo - hdl choleslerol ralio,C0206579;C1232424;C3715113
5591,hdl choleslerol,C3715113
5590,reduced hdl cholesterol,C0151691
5590,low hdl cholesterol * |,C0151691
5590,low hdl cholesterol,C0151691
5590,low hdl - c,C0151691
5589,blisibimod ( n = $nmbr$ ),C3713826
5588,aliskiren / valsartan ( n = $nmbr$ ),C2733073
5587,simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /,C0033228;C0074554;C0332287;C1319635
5587,fenofibrate ( n = $nmbr$ ),C0033228
5586,entocort ec ( n = $nmbr$ ),C1170256
5585,rotigotine n = $nmbr$,C1700683;C4318637
5585,rotigotine ( n = $nmbr$ ),C1700683;C4318637
5584,ixekizumab every $nmbr$ weeks ( n = $nmbr$ ),C3489764
5583,montelukast ( n = $nmbr$ ),C0298130
5582,levosimendan ( n   = $nmbr$ ),C0246904
5581,eplerenone ( n   = $nmbr$ ),C0961485
5580,subcutaneous ( n = $nmbr$ ),C0443315
5579,anacetrapib ( n = $nmbr$ ),C2604745
5579,anacetrapib ( n = $nmbr$  $nmbr$ ),C2604745
5579,anacetrapib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
5578,lebrikizumab ( n = $nmbr$ ),C2981360
5578,lebrikizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
5578,lebrikizumab $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
5577,mmf ( n = $nmbr$ ),C0083765;C0209368;C3848524
5576,$nmbr$ mg / $nmbr$ wk ( n = $nmbr$ ),C1881833
5575,rate - control group ( n = $nmbr$ ),C0441848;C0489879
5574,indacaterol group ( n = $nmbr$ ),C0441848;C1722260
5574,indacaterol - glycopyrronium group ( n = $nmbr$ ),C0441848;C1722260;C3814772
5573,colesevelam hydrochloride group ( n = $nmbr$ ),C0441848;C0541154
5572,device group ( n = $nmbr$ ),C0025080;C0441848;C0699733
5571,pioglitazone group ( n = $nmbr$ ),C0071097;C0441848
5570,no epa group n = $nmbr$,C0441848
5570,epa group n = $nmbr$,C0441848
5570,benazepril - hydrochlorothiazide group ( n = $nmbr$ ),C0441848;C0717481
5569,tiotropium group ( n = $nmbr$ ),C0213771;C0441848
5569,group a ( n = $nmbr$ ),C0441848
5568,antiplatelet - only group ( n = $nmbr$ ),C0205171;C0441848;C1720467
5568,antiplatelet - onl group ( n = $nmbr$ ),C0441848
5567,group c ( n = $nmbr$ ),C0441848
5567,fatty acid group ( n = $nmbr$ ),C0015684;C0441848
5567,c group ( n = $nmbr$ ),C0441848
5566,etoricoxib group ( n = $nmbr$ $nmbr$ ),C0441848;C0972314
5565,group b ( n = $nmbr$ ),C0441848
5565,certolizumab group ( n = $nmbr$ ),C0441848;C1872109
5564,lower - target group ( n = $nmbr$ ),C0441848;C0441994;C1521840;C1548802;C2003888;C2986546
5564,higher - target group ( n = $nmbr$ ),C0205250;C0441848;C1521840;C2986546
5563,vilanterol  n = $nmbr$,C2935023
5562,ticagrelor pre ‐ hosp ( n = $nmbr$ ),C0332152;C0740175;C1999375;C2257086;C3669034
5562,ticagrelor in ‐ hosp ( n = $nmbr$ ),C1999375
5562,prehospital ticagrelor ( n = $nmbr$ ),C1999375
5561,oxypurinol ( n = $nmbr$ ),C0030086
5560,monitoring group ( n = $nmbr$ ),C0150369;C0441848;C1283169
5560,monitoring ( n = $nmbr$ ),C0150369;C1283169
5559,colesevelam ( n = $nmbr$ ),C0541155
5558,cholecystectomy ( n = $nmbr$ ),C0008320
5557,no colchicine ( n = $nmbr$ ),C0009262
5557,colchicine ( n = $nmbr$ ),C0009262
5556,readmission ( n = $nmbr$ ),C1548168;C4489276
5556,no readmission ( n = $nmbr$ ),C1548168;C4489276
5555,non - carrier ( n = $nmbr$ ),C2986416
5554,ivc ( n = $nmbr$ ),C4085887
5553,ifx ( n = $nmbr$ ),C0020823
5552,igl ( n = $nmbr$ ),C0021037;C0314619;C2247518
5551,igm ( n = $nmbr$ ),C1706005
5550,lansoprazole ( n = $nmbr$ ),C0050940
5549,pctindopnl - indapamide ( n = $nmbr$ ),C0021186
5548,albiglutide ( n = $nmbr$ ),C2607479
5547,post - fibrinolysis angioplasty ( n = $nmbr$ ),C0016017;C0162577;C0687676;C1305868;C1548817;C1704687;C3469826
5547,fibrinolysis ( n = $nmbr$ ),C0016017;C1305868
5546,lce  n = $nmbr$,C1423759;C3273355
5545,aortic valve disease ( n = $nmbr$ $nmbr$ ),C1260873;C4553103
5544,alive ( n = $nmbr$ ),C2584946;C4551704
5543,mitral valve disease ( n = $nmbr$ $nmbr$ ),C0026265;C4553832
5542,peace ( n = $nmbr$ ),C0680443
5541,hope patients with coronary - artery disease ( n = $nmbr$ ),C0010054;C0010068;C0030705;C0392347;C1956346
5541,hope ( n = $nmbr$ ),C0392347
5540,fluticasone furoate and vilanterol ( n = $nmbr$ ),C1948374
5540,fluticasone furoate  n = $nmbr$,C1948374
5539,umec $nmbr$ . $nmbr$ mcg ( n = $nmbr$ ),C0439211;C3463985
5539,tio i $nmbr$ mcg ( n = $nmbr$ ),C0021966;C0221138;C0439211;C3463985
5538,feno  $nmbr$ mg dn = $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
5538,feno  $nmbr$ dn = $nmbr$ ),C1333964;C1707618
5537,= sia,C1225105;C1551538
5536,without psoriasis ( zi = $nmbr$ ),C0033860;C0043476
5536,without psoriasis ( zi = $nmbr$  $nmbr$ ),C0033860;C0043476
5536,with psoriasis ( zi = $nmbr$ ),C0033860;C0043476
5536,[ zi = $nmbr$ ] $nmbr$ ( $nmbr$ . $nmbr$ ),C0043476
5535,ind / glyb n = $nmbr$,C1415124;C4049864
5534,ind $nmbr$ mg q . d . n = $nmbr$,C0439422;C4049864
5533,sfc $nmbr$ / $nmbr$ | ig bid n = $nmbr$,C0021027;C0305052;C0360506;C4521536
5533,qva $nmbr$ $nmbr$ / $nmbr$ | ig od n = $nmbr$,C0021027;C0229089;C0305052;C0360506;C0439164;C1512019;C3273373;C3665488
5533,olodaterol $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
5533,olodaterol $nmbr$ $nmbr$ | ig tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0021027;C0305052;C0360506;C1518422;C4032878
5532,umec $nmbr$ . $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
5532,tio $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
5532,ig ( n = $nmbr$ ),C0021027;C0305052;C0360506
5532,ff / vi $nmbr$ / $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0205999;C0305052;C0360506;C4554348
5532,ff $nmbr$ | ig ( n = $nmbr$ ),C0021027;C0305052;C0360506;C4554348
5531,watchman ( n = $nmbr$ ),C0335390
5531,device = watchman filter,C0180860;C0335390
5530,non cns embolism,C0013922;C1518422;C1704212;C3714787
5529,systemic embolism,C0013922;C0205373;C1704212
5529,cns systemic embolism,C0013922;C0205373;C1704212;C3714787
5528,peripheral embolism,C0013922;C0205100;C1704212
5528,embolism,C0013922;C1704212
5527,pulmonary embolism ± deep vein thrombosis,C0034065;C0149871;C0226514;C0852030
5527,pulmonary embolism,C0034065
5526,c $nmbr$ e $nmbr$ fab bolus ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
5526,c $nmbr$ e $nmbr$ fab bolus,C1186706;C1511237;C1705509;C3812160
5526,bolus of heparin given,C0019134;C0770546;C1186706;C1511237;C1705509;C3812160
5525,c $nmbr$ e $nmbr$ fab bolus and infusion ( n = $nmbr$ ),C1186706;C1511237;C1705509;C3812160
5525,bolus insulin doseh,C0021641;C1186706;C1511237;C1533581;C1579433;C1705509;C3714501;C3812160
5525,bolus and infusion,C1186706;C1511237;C1705509;C3812160
5525,bolus and corrections,C1186706;C1511237;C1705509;C3812160
5525,bolus alone,C1186706;C1511237;C1705509;C3812160
5525,bolus administered — no . ( % ),C1186706;C1511237;C1705509;C3812160
5525,bolus,C1186706;C1511237;C1705509;C3812160
5524,> $nmbr$ yr from the united states,C0041703;C0439234
5523,united states ( n   = $nmbr$  $nmbr$ ),C0041703
5523,united states,C0041703
5523,region united states,C0017446;C0041703;C0205147
5522,non - united states,C0041703;C1518422
5521,usa ( n = $nmbr$ ),C0041703
5521,usa ( n = $nmbr$  $nmbr$ ),C0041703
5521,usa,C0041703
5521,non usa,C0041703;C1518422
5520,usa and canada,C0041703
5520,usa / canada,C0006823;C0041703
5520,united states or canada,C0041703
5520,united states and canada,C0041703
5520,united states  canada,C0006823;C0041703
5519,upper limb fracture,C0178316
5518,upper limbs,C1140618
5518,upper limb fractures,C1140618
5518,upper limb,C1140618
5517,upper gastrointestinal tract,C3203348
5517,upper gastrointestinal,C3203348
5517,history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C0441471;C1705255;C2004062;C3203348;C4019010
5516,† includes patients originally randomized to placebo who were switched to secukinumab per the study designs .   ‡ aes that occurred in at least $nmbr$ . $nmbr$ % of the patients in the any secukinumab group during the $nmbr$ ‐ week placebo ‐ controlled period and events with an eair of at least $nmbr$ . $nmbr$ cases per $nmbr$ patient ‐ years in the any secukinumab group during the entire treatment period . events listed according to preferred term in the medical dictionary for regulatory activities ( meddra version $nmbr$ . $nmbr$ )  sorted in descending order of eair in the any secukinumab group for the entire treatment period . the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies . ae  adverse event  as  ankylosing spondylitis  eair  exposure adjusted incidence rates    n  number of randomized patients  sae  serious adverse event  urti  upper respiratory tract infection .,C0012113;C0030705;C0034656;C0035171;C0036043;C0038013;C0039798;C0041912;C0087111;C0274281;C0332157;C0332174;C0332257;C0333052;C0374505;C0439230;C0439531;C0439751;C0441471;C0441655;C0444667;C0680240;C0868928;C0871208;C0877248;C1140263;C1412268;C1511726;C1512346;C1519255;C1521828;C1522326;C1533148;C1533734;C1552866;C1622657;C1705169;C1705187;C1706408;C1709637;C1948053;C2347664;C2360800;C2607870;C2699274;C2700399;C2983265;C2986888;C3179547;C3245479;C3538994;C3541888;C3714741;C3815594;C3887670;C3887704;C4553214
5516,number of treated patients,C1522326;C2360800
5516,number of patients with fractures,C2360800
5516,number of patients with events,C2360800
5516,number of patients with dose available,C2360800
5516,number of patients with available data,C2360800
5516,number of patients with,C2360800
5516,number of patients randomized,C2360800
5516,number of patients ( % ) or mean 士 sd,C2360800
5516,number of patients ( % ) or mean ± sd,C2360800
5516,number ( % ) of patients with event,C2360800
5515,total number of patients,C0439175;C0439810;C2360800
5515,number of patients with exacerbations in the previous $nmbr$ months  n ( % ),C2360800
5515,number of patients,C2360800
5515,number ( % ) of patients,C2360800
5514,number of treated lesions ( per patient ),C0449791;C1522326
5514,number of treated lesions,C0449791;C1522326
5514,number of lesions  n ( % ) a,C0449791
5513,operative procedure,C0543467;C0677612
5512,without previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
5512,with previous surgery,C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
5512,valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1704414;C3888056
5512,type of surgery cabg only,C0010055;C0038894;C0038895;C0205171;C0332307;C0543467;C1274039;C1547052;C1720467
5512,type of surgery cabg,C0010055;C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
5512,type of surgery,C0038894;C0038895;C0332307;C0543467;C1274039;C1547052
5512,surgery,C0038894;C0038895;C0543467;C1274039
5512,previous cabg surgery,C0010055;C0038894;C0038895;C0205156;C0543467;C1274039;C1552607
5512,planned valve surgery  n ( % ),C0038894;C0038895;C0184252;C0543467;C1186983;C1274039;C1301732;C1704414;C3888056
5512,cardiac valve surgery : no ( n = $nmbr$ ),C0018821;C0018826;C0038894;C0038895;C0184252;C0524727;C0543467;C1186983;C1274039;C1704414;C3888056
5512,cabg surgery,C0010055;C0038894;C0038895;C0543467;C1274039
5511,cigarette users,C0677453;C1704760;C1706077;C3890423
5510,statin users,C0360714;C1706077
5510,bivariate frailty model ( statin users vs non - users ),C0360714;C0424594;C1706077;C3161035;C3274659;C3714583;C3853906
5509,statin users ( n = $nmbr$ ),C0360714;C1706077
5509,statin non - users ( n = $nmbr$ ),C0360714;C1518422;C1706077
5508,biologics user,C0005515;C0005522;C1548600;C1706077;C4553887
5507,user,C1548600;C1706077
5507,methotrexate user,C0025677;C1548600;C1706077
5506,non - user $nmbr$,C1518422;C1548600;C1706077
5506,laba users,C1706077
5506,laba non - users,C1518422;C1706077
5505,ulcers / gangrene,C0017086;C0041582
5504,ulcer  n ( % ) a,C0041582;C3887532
5504,ulcer,C0041582;C3887532
5503,left main coronary artery bifurcation,C3898614
5502,lad artery,C0003842;C0226004
5502,imaged artery,C0003842;C0226004;C1704254;C1704922;C3542466
5501,left circumflex coronary artery,C0226037
5501,left circumflex artery  n ( % ),C0226037
5501,left circumflex artery,C0226037
5500,ischemic coronary artery disease,C0852149
5499,history of coronary artery disease — no . { % ),C1881055
5499,history of coronary artery disease - n ( % ),C1881055
5499,history of coronary artery disease,C1881055
5498,peripheral artery diseasef,C0489868
5498,peripheral artery diseaseb,C0489868
5498,peripheral artery,C0489868
5498,history of peripheral artery disease — no . { % ),C0489868;C0683519;C0730226;C0850708;C0944983
5498,history of peripheral artery disease,C0489868;C0683519;C0730226;C0850708;C0944983
5497,duration of coronary artery disease — yr,C0018787;C0439234;C0449238;C0852949;C2926735
5497,coronar y artery disease,C0852949
5497,coronaiy artery disease,C0852949
5496,urgent surgery,C2188405
5496,emergent / urgent surgery,C0750573;C2188405
5495,previous bypass surgery  n ( % ),C0205156;C1536078;C1552607
5495,bypass surgery,C1536078
5494,lower - limb angioplasty or bypass surgery,C0745788
5493,minor surgery,C0038904
5492,major surgery,C0679637
5491,elective surgery,C0206058
5490,hungary,C0020174
5489,prior oabg surgery,C0455610
5489,prior cabg surgery,C0010055;C0455610
5489,prior aortocoronary bypass surgery 一 no . ( % ),C0010055;C0455610
5489,prior aortocoronary bypass surgery — no . ( % ),C0010055;C0455610
5489,prior aortocoronary bypass surgery,C0010055;C0455610
5489,history of cabg surgery,C0010055;C0455610
5488,prior surgery for cd  n [ % ],C0007928;C0034283;C0455610;C4552032
5488,prior surgery for cd  n ( % ),C0007928;C0034283;C0455610;C4552032
5488,prior surgery : no,C0455610
5487,cuban,C1553379
5486,mean lumbar spine t score,C0024091;C3533236;C3887615
5486,lumbar spine bmd t - score,C0024091;C0449820;C3887615;C4050231
5486,lumbar spine bmd t -,C0024091;C3887615
5486,lumbar spine,C0024091;C3887615
5486,flex baseline bmd t - score at lumbar spine ( meanisd ),C0024091;C0168634;C0449820;C1442488;C3887615;C4050231
5485,t - score categories lumbar spineb,C0024090;C0683312;C3854607
5485,lumbar,C0024090
5484,luts = lower urinary tract symptoms  is =,C0574785
5484,luts / bph characteristics,C0005001;C0574785;C1521970;C1704272
5483,utis,C0042029
5483,uti,C0042029;C0077906;C1412376
5482,adjusted or ( $nmbr$ % ci ) c,C0456081
5482,adjusted or ( $nmbr$ % ci ) b,C0456081
5482,adjusted mean ± se ( $nmbr$ % ci ),C0008107;C0036919;C0444504;C0456081;C2347634;C2348143;C3259781
5482,adjusted mean difference ( $nmbr$ % ci ),C0008107;C0444504;C0456081;C1705241;C1705242;C2347634;C2348143;C3259781
5482,adjusted mean ( se ),C0036919;C0444504;C0456081;C2347634;C2348143
5482,adjusted * or ( $nmbr$ % ci ) p value,C0456081
5482,adjusted,C0456081
5481,adjusted or ( $nmbr$ % cl ),C0456081
5481,adjusted hr ( enl vs lcz ) ( $nmbr$ % cl ),C0456081
5481,adjusted hr ( $nmbr$ % cl ),C0456081;C0596019
5481,adjusted $nmbr$ or ( $nmbr$ % cl ),C0456081
5480,adjusted hr losartan vs atenolol *,C0126174;C0456081
5480,adjusted *   hr,C0456081
5480,adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl ),C0126174;C0456081;C1137094
5479,unadjusted irr,C1439367;C4082285
5479,unadjusted hr .,C1439367
5479,unadjusted hr,C1439367
5478,unadjusted or ( $nmbr$ % ci ) p value,C1439367
5478,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ standard deviation increment,C0008107;C0871420;C1439367;C1705117;C3259781
5478,unadjusted hr ( $nmbr$ % ci ) for $nmbr$ sd increment,C0008107;C1439367;C1705117;C2699239;C3259781
5478,unadjusted hr ( $nmbr$ % ci ) a,C0008107;C1439367;C3259781
5478,unadjusted,C1439367
5477,rofecoxib,C0762662
5476,etoricoxib ( n = $nmbr$ ),C0972314
5476,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314
5476,etoricoxib ( n = $nmbr$  $nmbr$ ),C0972314
5476,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
5476,etoricoxib $nmbr$ mg  n = $nmbr$  n ( % ),C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
5476,etoricoxib,C0972314
5475,valdecoxib,C0913246
5474,celecoxib ( n = $nmbr$ ),C0538927
5474,celecoxib,C0538927
5473,cough ( leading to study drug discontinuation ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
5473,cough ( investigator reported ),C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727
5473,cough  n ( % ),C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
5473,cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
5473,any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
5472,lacunar infarction  n ( % ),C0333559
5471,lacunar,C0241970;C1459585
5470,endovascular — no . ( % ),C0524425
5470,endovascular,C0524425
5469,adalimumab croup  n / n ( % ),C0010380;C1122087
5468,both adalimumab groups ( n = $nmbr$ ) no baseline cd - related antibiotic use,C1122087
5468,both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use,C1122087
5468,both adalimumab groups ( n = $nmbr$ ) baseline cd - related antibiotic use,C1122087
5468,both adalimumab groups ( n = $nmbr$ ),C1122087
5468,adalimumab group ( n = $nmbr$ ) t,C0036669;C1122087
5468,adalimumab ( n = $nmbr$ ),C1122087
5468,adalimumab,C1122087
5467,golimumab $nmbr$ mg ( n = $nmbr$ ) †,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
5467,golimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
5467,golimumab,C2353893
5466,omalizumab ( lsm ),C0966225
5466,omalizumab $nmbr$ mg ( n [ $nmbr$ ),C0024671;C0026410;C0439269;C0966225;C1960952;C2346927;C4321396;C4521761
5466,omalizumab,C0966225
5465,evolocumab + soc ( n = $nmbr$ ),C3529352
5465,evolocumab ( n = $nmbr$ ),C3529352
5465,evolocumab ( $nmbr$ mg ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
5465,evolocumab $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
5465,evolocumab,C3529352
5464,adhere,C3714578
5463,fixed triple ( n = $nmbr$ ),C0205174;C0443218;C2827483;C3714578
5462,diet controlled or no,C0743195
5462,diet - controlled ( % ),C0743195
5461,anterior { % ),C0205094
5461,anterior circulation,C0005775;C0205094;C1516559
5461,anterior ( n  % ),C0205094
5460,not anterior,C0205094;C1518422
5460,non - anterior,C0205094;C1518422
5460,anterior or non - anterior ml,C0205094
5460,anterior,C0205094
5459,intermediate ( $nmbr$ - $nmbr$ ),C0205103;C1550465;C2827755;C3889971
5459,intermediate ( $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205103;C1550465;C2827755;C3889971
5459,intermediate ( $nmbr$ )  %,C0205103;C1550465;C2827755;C3889971
5459,intermediate,C0205103;C1550465;C2827755;C3889971
5458,long - acting  intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
5458,intermediate / long - acting + fast - acting,C0015663;C0079613;C0205103;C0205166;C0456962;C1550465;C1704930;C1706317;C1869853;C2827755;C2985769;C3889971;C3890007;C4048375
5458,intermediate - acting,C0205103;C1550465;C2827755;C3889971
5457,inter p - value,C0205103;C1548610
5457,inter . p - value,C0205103;C1548610
5457,inter .,C0205103;C1548610
5456,preamendment,C1548596
5455,before amendment ( % ),C0680532;C2346732
5455,before amendment,C0680532;C2346732
5455,after amendment ( % ),C0680532;C2346732
5455,after amendment,C0680532;C2346732
5454,increased risk for thrombotic cardiovascular event ^  n ( % ),C0087086;C0205217;C0442805;C1273410
5454,augment copd,C0205217
5453,cangrelor n / n ( % ),C1121991
5453,cangrelor clopidogrel no . of events / total no . ( % ),C0070166;C1121991
5453,cangrelor ( n = $nmbr$ ) n / n ( % ),C1121991
5453,cangrelor ( n = $nmbr$ ),C1121991
5453,cangrelor  %,C1121991
5453,cangrelor,C1121991
5452,carvedilol  % ( n ),C0054836
5452,carvedilol,C0054836
5451,category $nmbr$,C0683312;C3889287
5451,age category ( years )  n ( % ),C0683312;C1510829;C3889287
5451,age category ( % ),C0001779;C0683312;C3889287
5451,age category  n ( % ) :,C0001779;C0683312;C3889287
5451,age category  n ( % ),C0001779;C0683312;C3889287
5451,age category,C0001779;C0683312;C3889287
5450,qmax category  n ( % ) :,C0683312;C3889287
5450,mace category  n ( % ) [ ir ],C0022065;C0022071;C0349381;C0683312;C0949745;C1445339;C1448132;C3889287
5450,glycatedhemoglobin category  %,C0683312;C3889287
5449,categorical variables . no . ( % ) * ’,C0439828;C0683312;C3889287
5449,categorical variables,C0439828;C0683312;C3889287
5448,cardiovascular disease risk category,C0683312;C1113685;C3889287
5447,background csdmard category,C0683312;C1706907;C3889287
5446,category $nmbr$ and $nmbr$,C0683312;C3889287
5446,body mass index category  no . ( % ) l,C0005893;C0578022;C0683312;C1305855;C3889287
5445,p value within category,C0683312;C1709380;C3889287
5444,ejection fraction category,C0489482;C0683312;C2700378;C3889287
5444,category,C0683312;C3889287
5443,category — no . / total no . ( % ),C0683312;C3889287
5443,/ \ge category,C0683312;C1292300;C3538705;C3889287
5442,calcium level,C0201925;C0428302
5441,doubling of creatinine level,C0205173;C0428279;C1705764
5441,creatinine level,C0428279
5440,triglyceride level,C0428475
5440,< $nmbr$ . $nmbr$ mmol / liter triglyceride level,C0428475;C0439190;C0475211
5439,never nsaid,C0003211;C2003901;C3536840
5439,never been on a vka,C2003901
5438,never / rarely,C0522498;C2003901
5438,never,C2003901
5437,postmenopausal  never or past hormone therapy use,C0232970;C2003901
5437,never or past,C2003901
5436,never took alendronate,C2003901
5436,never smoking,C2003901
5436,never smoked — no . ( % ),C2003901
5436,never smoked  n ( % ),C0037366;C0439994;C1881674;C2003901
5436,never smoked,C2003901
5436,never drink,C2003901
5435,fasting plasma insulin — mu / liter,C0015663;C0028971;C0347978;C0475211;C0857690;C3714918
5434,serum sodium — mmol / liter,C0439190;C0475211;C0523891
5434,serum sodium — meq / liter,C0439152;C0475211;C0523891
5433,triglycerides — mmol / liter,C0041004;C0439190;C0475211
5433,serum triglycerides — mmol / liter,C0439190;C0475211;C0542495
5433,serum cholesterol — mmol / liter,C0439190;C0475211;C0587184
5433,free fatty acids — mmol / liter,C0015688;C0439190;C0475211
5433,cholesterol — mmol / liter,C0008377;C0439190;C0475211
5433,> $nmbr$ / tmol / liter — no . ( % ),C0475211
5433,> $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
5433,< $nmbr$ . $nmbr$ mmol / liter estimated gfr,C0439190;C0475211
5433,< $nmbr$ . $nmbr$ mmol / liter,C0439190;C0475211
5432,glucose — mmol / liter,C0017725;C0439190;C0475211
5432,fasting blood glucose — mmol / liter,C0428568;C0439190;C0475211;C1261430
5431,plasma glucose — mmol per liter,C0202042;C0439190;C0455280;C0475211
5431,plasma glucose $nmbr$ hr after glucose load — mmol / liter,C0202042;C0439190;C0455280;C0475211;C1550025;C1704782;C1708715
5431,fasting plasma glucose — mmol / liter,C0015663;C0202042;C0439190;C0455280;C0475211
5430,serum potassium 一 mmol / liter,C0302353;C0439190;C0475211;C0543465
5430,serum potassium — mmol / liter,C0302353;C0439190;C0475211;C0543465
5429,serum triglycerides — pmol / liter,C0439192;C0475211;C0542495
5428,> $nmbr$ . $nmbr$ pmol / liter hscrp level,C0439192;C0441889;C0456079;C0475211;C1547707;C2946261
5428,> $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
5428,< $nmbr$ . $nmbr$ pmol / liter,C0439192;C0475211
5427,post - bronchodilator fev $nmbr$ — liters,C0475211;C2599594;C3714541
5427,fvc — liters,C0475211;C3714541
5427,fvc ( liters ),C0475211;C3714541
5427,fev $nmbr$ — liters,C0475211;C3714541
5427,fev $nmbr$ ( liters ),C0475211;C3714541
5426,troponin level,C0041199;C0441889;C0456079;C1547707;C2946261
5426,level $nmbr$ immobility § | |,C0231441;C0441889;C0456079;C1547707;C2946261
5426,level $nmbr$ immobility ^,C0231441;C0441889;C0456079;C1547707;C2946261
5426,ldl cholesterol level,C0023824;C0201950;C0202117;C0428466;C0441889;C0456079;C1547707;C2946261
5426,hscrp level,C0441889;C0456079;C1547707;C2946261
5426,hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
5426,cardiac troponin t level > $nmbr$ . $nmbr$ pg / l,C0439278;C0441889;C0456079;C1547707;C2946261;C3538889
5426,baseline total pcsk $nmbr$ level by median,C0168634;C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C2347635;C2348144;C2939193;C2946261
5426,baseline total pcsk $nmbr$ level,C0168634;C0439175;C0439810;C0441889;C0456079;C1442488;C1547707;C2946261
5426,baseline free pcsk $nmbr$ level by median,C0168634;C0332296;C0441889;C0456079;C0549183;C0876920;C1442488;C1547707;C1880497;C1996904;C2347635;C2348144;C2939193;C2946261
5426,baseline free pcsk $nmbr$ level,C0168634;C0332296;C0441889;C0456079;C1442488;C1547707;C1880497;C1996904;C2946261
5426,atrial fibrillation ldl cholesterol level,C0004238;C0023824;C0202117;C0344434;C0441889;C0456079;C1547707;C1963067;C2946261
5426,> $nmbr$ . $nmbr$ hdl cholesterol level,C0023822;C0201950;C0392885;C0428466;C0441889;C0456079;C1547707;C2946261;C3715113
5425,serum k + level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261
5425,no active cancer center - level inr percent time,C0040223;C0205177;C0439165;C0441889;C0456079;C0525032;C1513817;C1547707;C1704538;C2946261;C3541383;C3853793;C3888249
5425,level of thyroperoxidase antibody at baseline,C0021965;C0428536;C0441889;C0456079;C0487652;C1318460;C1364508;C1429427;C1547707;C2946261;C3272921
5425,geometric anti - dsdna antibody binding level,C0441889;C0449829;C0456079;C1145667;C1167622;C1547707;C2355607;C2746079;C2946261
5425,center - level ihr percent time in therapeutic range for warfarin subjects,C0040223;C0087111;C0205099;C0302350;C0439165;C0441889;C0456079;C0460097;C1547707;C1554109;C2946261;C3541383;C3810851
5425,antibody binding level at baseline,C0168634;C0428536;C0441889;C0456079;C1145667;C1149306;C1167622;C1442488;C1547707;C2946261
5424,variable_level,C0439828;C0441889;C0456079;C1547707;C2946261;C4553760
5424,level — no . ( % ),C0441889;C0456079;C1547707;C2946261
5424,level $nmbr$,C0441889;C0456079;C1547707;C2946261
5424,elevated natriuretic peptide level ( n = $nmbr$ ),C0205250;C0441889;C0456079;C1144709;C1547707;C2709270;C2946261;C3163633;C3537020
5424,baseline tg level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
5424,baseline ldlc level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
5424,baseline ldlc level ( n = $nmbr$  $nmbr$ ) ^ $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
5423,killip class > ii ( % ),C2697845
5422,hi ) ah ( % ),C0018619;C0239849;C1412082;C1412316;C1431594;C1836672;C4552857
5421,> $nmbr$ y pathogenesis  n ( % ),C0543483;C0699748
5420,teaes ( > $nmbr$ % in any treatment group ) *,C0374505
5420,teaes ( > $nmbr$ % in any treatment group ),C0374505
5419,ors ( $nmbr$ % cis ) :,C0069590;C1963718
5418,$nmbr$ % cit,C0008864;C0523573;C1427027;C4553421
5417,pm  n ( % ),C0030266;C4049155
5417,lta ( max response to $nmbr$ pm adp ) defined hpr ( % patients ),C0030266;C0523452;C2611142;C4049155
5416,vasp pri - defined hpr ( % patients ),C0034044;C0255567;C1421428;C1826843;C3539761;C3539762
5415,intermediate risk ( ri = $nmbr$ ),C0035487;C1826843;C3640764
5415,( ri = $nmbr$ ),C0035487;C1826843
5414,leeds enthesitis index ^ score > $nmbr$ — no . { % ),C0451148
5413,$nmbr$ % c . i .,C1547546
5412,killip class i — no . ( % ),C2697844
5412,killip class > i  %,C2697844
5411,ankle edema,C0235439
5410,eczema,C0013595;C4553957
5409,peripheral edema,C0085649
5408,physical exam oedema,C0013604;C0031809;C1717255
5408,edema peripheral,C0013604;C1717255
5408,edema  peripheral,C0013604;C1717255
5408,edema  n ( % ),C0013604;C1717255
5408,edema  ( % ),C0013604;C1717255
5408,edema  % z,C0013604;C1717255
5407,extreme tortuosity,C0205403;C0333076;C3641272;C4085555
5406,very severe n z $nmbr$,C3641272;C4050419
5406,very severe copd,C0024117;C1412502;C3641272;C3714496;C4050419
5405,very severe ( itt ) ( n = $nmbr$ ),C3641272;C4050419
5405,very severe ( gold $nmbr$ ),C0018026;C1304897;C3641272;C4050419
5405,very severe  gold $nmbr$,C0018026;C1304897;C3641272;C4050419
5405,very severe,C3641272;C4050419
5405,$nmbr$ - $nmbr$ ( very severe ),C3641272;C4050419
5404,ebria,C1917247
5403,era monotherapy,C1521863;C3495919
5403,era and pde - $nmbr$ i,C1521863;C3495919
5403,era and pde $nmbr$ inhibitors,C1521863;C3495919
5403,era,C1521863;C3495919
5402,korean,C1556095
5401,korea,C0022771
5400,korea  republic of,C0022773
5399,osteoprotegerin decreased,C0538161;C1308614;C1336645
5398,decreased appetite,C0232462
5397,% with haq - di decrease > $nmbr$ . $nmbr$,C0392756;C0547047;C3826998;C4321476
5396,sustained decrease of > $nmbr$ % in egfr ®,C0392756;C0443318;C0547047
5396,relative decrease > $nmbr$ %,C0080103;C0205345;C0392756;C0547047;C1547039
5395,absolute fvc decrease > $nmbr$ %,C0205344;C0392756;C0547047;C3714541
5395,absolute decrease > $nmbr$ %,C0205344;C0392756;C0547047
5394,a decrease of > $nmbr$ points in the cdai score,C0392756;C0547047;C2924612
5393,$nmbr$ mwd decrease > $nmbr$ m,C0369637;C0392756;C0441923;C0547047
5392,transaminases increased,C0002594;C0919834
5391,pancreas,C0030274
5390,leflunomide,C0063041
5389,digoxin / digitalis glycoside,C0012253;C0012265
5389,digitalis glycoside,C0012253
5388,torsemide,C0076840
5387,furosemide equivalent  mg / kg,C0016860;C0205163;C0439185;C0439272
5387,furosemide,C0016860
5386,viidagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
5386,glimepiride,C0061323
5385,vitamin k antagonists,C3653316
5384,vitamin k antagonist naive,C1096489;C2267235
5384,vitamin k antagonist ( e . g . warfarin / coumarol ),C1096489;C2267235
5384,long - term vitamin k antagonist,C0443252;C1096489;C2267235
5383,vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ ),C1096489;C2267235
5383,vitamin k antagonist experienced  n ( % ),C1096489;C2267235
5383,vitamin k antagonist,C1096489;C2267235
5383,previous use of vitamin k antagonist for > $nmbr$ days — no . ( % ),C0205156;C1096489;C1524063;C1552607;C2267235
5382,vitamins,C0042890;C3540032;C3714649
5382,other plain vitamin preparations,C0042890
5381,diltiazem or verapamil,C0012373
5380,verapamil sr strategy ( n = $nmbr$  $nmbr$ ),C0679199;C1527129
5380,verapamil sr n = $nmbr$ no . ( % ),C1527129
5380,verapamil sr n = $nmbr$,C1527129
5380,verapamil sr ( no . = $nmbr$ ),C1527129
5380,verapamil sr,C1527129
5380,verapamil - sr strategy,C0679199;C1527129
5380,verapamil - sr ( « = $nmbr$ $nmbr$ ),C1527129
5379,verapamil ( n  % ),C0042523
5378,use of verapamil or quinidine,C0042523;C1524063
5377,thienopyridine + dipyridamole,C0012582;C1120149
5377,dipyridamole alone,C0012582
5377,dipyridamole,C0012582
5376,aspirin + dipyridamole ( n = $nmbr$ ),C0732279
5376,aspirin + dipyridamole,C0732279
5375,very good or excellent,C3641222
5374,no incident dm or change in fg > $nmbr$,C0011816;C1551358;C3250443
5374,incident or worsening nephropathy,C1551358
5374,incident dm or change in,C0011816;C1551358;C3250443
5373,three or more lesions,C0205449
5373,three or more drugs,C0205449
5373,three or more agents,C0205449
5373,multivessel ( two vessel  three vessel  or left main ),C0205449;C4012475;C4037954
5372,benzodiazepine or bzra ‡,C0005064;C3536850;C4048284
5371,oxcarbazepine,C0069751
5370,oral anticoagulants,C0354604
5370,oral anticoagulant — no . / total no . ( % ),C0354604
5370,oral anticoagulant n ( % ),C0354604
5370,oral anticoagulant drugs  n ( % ),C0354604
5370,oral anticoagulant drugs,C0354604
5370,oral anticoagulant agent,C0354604
5370,oral anticoagulant  n ( % ),C0354604
5370,oral anticoagulant,C0354604
5369,oral contraceptives,C0009905
5369,oral contraceptive pills — no . / total no . ( % ),C0009905;C0009906;C0029151
5368,ovary,C0029939;C0227898
5367,patent foramen ovale,C0016522;C0344724
5366,other oral hypoglycemic drug ( s ),C0359086
5366,oral hypoglycemics hormone replacement,C0282402;C0359086
5366,oral hypoglycemics,C0359086
5366,oral hypoglycemic drug,C0359086
5366,oral hypoglycemic agentsj,C0359086
5366,oral hypoglycemic agents,C0359086
5366,oral hypoglycemic agent,C0359086
5366,oral hypoglycemic,C0359086
5366,oral antihyperglycaemic  n ( % ),C0359086
5366,any oral hypoglycemic drug 一 no . ( % ),C0359086
5365,cd duration  y,C0007928;C0034283;C0449238;C2926735;C4552032
5365,cd complications,C0007928;C0009566;C0034283;C1171258;C4552032
5365,cd [ gemini $nmbr$ ] * ’,C0007928;C0034283;C4552032
5364,previous cd related surgery ( ref ) a,C0007928;C0034283;C0205156;C1552607;C4552032
5364,no previous cd related surgery $nmbr$,C0007928;C0034283;C0205156;C1552607;C4552032
5363,patients with eligible ses - cd score,C0007928;C0030705;C0034283;C0449820;C1548635;C4050231;C4552032
5363,hdl - cd,C0007928;C0034283;C3715113;C4552032
5362,vldl cholesterol,C0023826;C0523560
5362,vldl - c,C0523560
5362,vldl,C0523560
5361,relative risk comparing icd therapy and placebo,C0021122;C0039798;C0087111;C0242492;C1363945;C1707455
5361,icd vs . placebo,C0021122
5361,icd therapy vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0021122;C0039798;C0087111;C1363945
5361,icd or crt - d,C0021122
5360,relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0021122;C0039798;C0087111;C0242492;C0596019;C1363945;C1707455
5360,icd therapy ( n =,C0021122;C0039798;C0087111;C1363945
5360,icd / crt - d  n ( % ),C0021122
5360,icd  n ( % ),C0021122
5360,icd  %,C0021122
5360,icd,C0021122
5359,group d,C0441838
5358,d - dimer levelsatinclusion,C0060323
5358,d - dimer ( ng / ml ),C0060323;C0439275
5357,vitamin d §,C0014695;C0042866;C2936842;C3537249;C3714503
5357,serum vitamin d ( nmol / l ),C0014695;C0042866;C0229671;C0439282;C1546774;C1550100;C2936842;C3537249;C3714503
5357,daily dose of vitamin d ( iu / day ),C0014695;C0042866;C0439465;C2348070;C2936842;C3537249;C3714503
5357,baseline vitamin - d,C0014695;C0042866;C0168634;C1442488;C2936842;C3537249;C3714503
5357,$nmbr$ ( oh ) vitamin d ( ng / ml ),C0014695;C0042866;C0220853;C0439275;C2936842;C3537249;C3714503
5356,symptomatic pad of lower extremities *,C0023216;C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
5356,risk factors for pad,C0035648;C0182158;C0332568;C1553898;C3540603;C3669270;C3814046;C4319657
5356,prior pad,C0182158;C0332152;C0332568;C2826257;C3540603;C3669270;C3814046;C4319657
5356,pad lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
5356,pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
5356,no pad baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
5355,pad symptoms ( % ),C0182158;C0332568;C0683368;C1457887;C3540603;C3669270;C3814046;C4319657
5355,pad details  n ( % ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
5355,pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
5355,no pad ( n - $nmbr$  $nmbr$ ),C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
5354,d population,C0032659;C0073187;C0332173;C1257890;C4484261
5354,d includes cardiac glycosides  antiarrhythmics classes i and iii  vasodilators used in cardiac disease and other cardiac preparations .,C0073187;C0332173;C4484261
5354,d $nmbr$ vs warfarin,C0073187;C0332173;C4484261
5353,d / mi / idr / st,C0036056;C0073187;C0332173;C3272372;C3810814;C4484261
5353,d / mi / idfvst,C0073187;C0332173;C3810814;C4484261
5352,d ( $nmbr$ % ci ),C0008107;C0073187;C0332173;C3259781;C4484261
5352,d $nmbr$ vs warfarin rr ( $nmbr$ % ci  p value ),C0073187;C0332173;C4484261
5352,d $nmbr$ % ( n / n ),C0073187;C0332173;C4484261
5352,d  mitral stenosis vhd ( n = $nmbr$ ),C0026269;C0073187;C0264766;C0332173;C4484261
5352,d,C0073187;C0332173;C4484261
5351,use of low - dose aspirin ( < $nmbr$ mg daily ),C0024671;C0026410;C0332173;C0439269;C1524063;C1960952;C2346927;C2608320;C4321396;C4521761
5351,mg daily ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
5351,mean ( sd ) calcium intake in mg daily,C0024671;C0026410;C0332173;C0439269;C0444504;C0489458;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
5351,daily exercise ( % ),C0332173
5351,daily,C0332173
5351,baricitinib  $nmbr$ mg daily ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
5350,upa $nmbr$ mg qd,C0024671;C0026410;C0042071;C0332173;C0439269;C1706177;C1960952;C2346927;C4321396;C4521761
5350,qd,C0332173
5350,lansoprazole $nmbr$ mg qd,C0024671;C0026410;C0050940;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
5350,dexlansoprazole mr $nmbr$ mg qd,C0024485;C0024671;C0026410;C0332173;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
5350,baricitinib $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
5350,$nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
5349,cg / ld,C0043444;C0694649;C1567075;C3540479
5348,ld,C0694649
5348,< $nmbr$ . $nmbr$ ld,C0694649
5348,$nmbr$ mg ld,C0024671;C0026410;C0439269;C0694649;C1960952;C2346927;C4321396;C4521761
5347,gold group d — no . ( % ) | |,C0018026;C0441838;C1304897
5347,gold group d,C0018026;C0441838;C1304897
5347,gold d,C0018026;C1304897
5346,gold group b,C0018026;C1304897;C4522078
5346,gold b,C0018026;C1304897
5345,gold group  n ( % ),C0018026;C0441848;C1304897
5345,gold group,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1705428;C1705429
5345,gold grades $nmbr$ - $nmbr$ ( percent - predicted fev ( )  n,C0018026;C1304897
5345,gold $nmbr$ groups  n ( % ),C0018026;C1304897
5345,gold $nmbr$ groups,C0018026;C0441833;C0687744;C1257890;C1304897;C1519504;C1552839;C1705428;C1705429
5345,gold $nmbr$ - $nmbr$ ( n = $nmbr$ ),C0018026;C1304897
5345,gold $nmbr$ - $nmbr$,C0018026;C1304897
5344,severity ofcopd ( gold $nmbr$ )  n ( % ),C0018026;C0439793;C0522510;C1304897
5344,severity of the disease ( gold $nmbr$ )  n ( % ),C0018026;C0521117;C1304897
5344,severity of airflow limitation ( gold $nmbr$ - $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
5344,severity of airflow limitation ( gold $nmbr$ )  n ( % ),C0018026;C0231999;C0439793;C0443288;C0449295;C0522510;C1304897
5344,gold $nmbr$ - $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
5344,gold $nmbr$ ( « = $nmbr$ ),C0018026;C1304897
5344,gold  n ( % ),C0018026;C1304897
5343,gold grade $nmbr$ and ics users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
5343,gold grade $nmbr$ and ics non - users at screening,C0018026;C0441800;C0919553;C1304897;C3244287
5343,gold grade $nmbr$,C0018026;C0441800;C0919553;C1304897;C3244287
5343,gold $nmbr$,C0018026;C1304897
5342,gold stage — no . ( % ) * *,C0018026;C1304897
5342,gold stage [ n ( % ) ],C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage ( % ) f,C0016327;C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage #,C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage  nf * ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage  n ( % ),C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage  %,C0018026;C0205390;C1300072;C1304897;C1306673
5342,gold stage,C0018026;C0205390;C1300072;C1304897;C1306673
5341,gold stage ( % ) : c,C0018026;C0441785;C1304897
5341,gold c,C0018026;C1304897
5340,gold groups a - d using mmrcb,C0018026;C1304897
5340,gold classification,C0008902;C0008903;C0018026;C0678229;C1304897
5340,gold a,C0018026;C1304897
5339,gained bmd,C1517378
5338,volumetric bmd by qct,C0412669;C0445383
5337,lost bmd,C0745777;C3815882
5336,form / bud,C0348078;C0376315;C1522492;C2700462;C2945744;C4255237
5335,bud / fm $nmbr$ / $nmbr$ atg n = ^ $nmbr$,C2700462;C2945744;C3540627;C3815109
5334,bud $nmbr$ ptg n = $nmbr$,C0039512;C1418830;C2700462;C2945744
5333,subpopulation analyses according to bmi,C0578022;C0680240;C1514228
5332,overweight ( bmi £ $nmbr$ to < $nmbr$ ),C0497406;C0578022
5332,overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ ),C0497406;C0578022
5332,bmi $nmbr$ – $nmbr$ overweight,C0497406;C0578022
5332,bmi $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,C0578022
5332,bmi $nmbr$ - $nmbr$ - $nmbr$ $nmbr$,C0578022
5332,bmi $nmbr$ $nmbr$ - $nmbr$ $nmbr$,C0578022
5331,mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C3533236
5331,mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0578022;C1880389;C1883221;C3533236;C3541951;C3641331
5330,bmi   kg · m − $nmbr$,C0578022;C1532718
5330,bmi kg · m − $nmbr$,C0578022;C1532718
5330,bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5330,bmi > $nmbr$ kg / m $nmbr$ *,C0578022;C1532718
5330,bmi > $nmbr$ kg / m $nmbr$,C0578022;C1532718
5330,bmi  kg per m $nmbr$,C0578022;C1532718
5330,bmi  kg / m ^ *,C0578022;C1532718
5330,bmi  kg / m $nmbr$ cholesterol  mg / dl,C0008377;C0439269;C0578022;C1532718
5329,bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ ),C0032659;C0578022;C1257890;C1532718
5329,bmi > = $nmbr$ kg / m $nmbr$,C0578022;C1532718
5329,bmi > = $nmbr$,C0578022
5329,bmi > $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5329,bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5329,bmi > $nmbr$,C0578022
5328,low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
5328,bmi < = $nmbr$,C0578022
5328,bmi < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5328,bmi < $nmbr$ kg / m $nmbr$,C0578022;C1532718
5328,bmi < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5328,bmi < $nmbr$,C0578022
5328,bmi ( kg / m $nmbr$ ) < $nmbr$,C0578022;C1532718
5328,bmi $nmbr$ - < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5328,bmi $nmbr$ - < $nmbr$ kg / m - ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5328,bmi $nmbr$ - < $nmbr$ kg / m  ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5328,baseline bmi < $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
5328,$nmbr$ < bmi < $nmbr$,C0578022
5327,bmi kg - m - $nmbr$,C0578022;C1532718
5327,bmi ^,C0578022
5327,bmi - kg / m $nmbr$,C0578022;C1532718
5327,bmi ( kg / m ^ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5327,bmi ( kg / m ^ ),C0578022;C1532718
5327,bmi ( kg / m $nmbr$ ) [ mean - sd ],C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5327,bmi ( . kg / m - ) *,C0578022;C1532718
5326,screening bmi ( kg / m $nmbr$ ),C0220908;C0220909;C0578022;C1532718;C1698960;C1710031;C1710032;C1710477;C2348164
5326,bmi > $nmbr$ kg / m $nmbr$ ( % ),C0578022;C1532718
5326,bmi > $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
5326,bmi > $nmbr$ ( % ),C0578022
5326,bmi < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5326,bmi ( kg = m $nmbr$ ),C0578022;C1532718
5326,bmi ( kg / m $nmbr$ ) *,C0578022;C1532718
5326,bmi $nmbr$ - < $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
5326,bmi  no . ( % ),C0578022
5326,bmi  kg / m $nmbr$ uac  no . ( % ),C0578022;C1532718
5325,( a ) bmi subgroups,C0578022;C1079230
5324,bmi indicates body mass index  sbp  systolic blood pressure  dbp  lipoprotein ( a ) . ldl - c was calculated with the friedewald formula . ' hypertension and diabetes were based on physician diagnosis . ! smoker includes current and past smokers .,C0020538;C0065058;C0125953;C0521116;C0578022;C1096202;C1439335;C1705970;C1963138
5324,bmi a $nmbr$,C0578022
5323,bmi distribution  n ( % ),C0520511;C0578022;C1704711
5323,bmi > $nmbr$  n ( % ),C0578022
5323,bmi  n ( % ),C0578022
5322,bmi category ( % ),C0578022;C0683312;C3889287
5322,bmi category  no . ( % ),C0578022;C0683312;C3889287
5322,bmi category,C0578022;C0683312;C3889287
5322,bmi categories  n ( % ),C0578022;C0683312
5321,risk factors bmi ( kg / m $nmbr$ )  mean + sd,C0035648;C0444504;C0578022;C1532718;C1553898;C2347634;C2348143;C2699239
5321,mean ± s . d . bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
5321,mean bmi ± s . d .  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
5321,mean bmi ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,mean bmi ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
5321,mean bmi ( kg / m $nmbr$ ) ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,mean bmi ( $nmbr$ % ci ),C0008107;C0444504;C0578022;C2347634;C2348143;C3259781
5321,mean bmi  kg / m $nmbr$ ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,mean bmi  kg / m $nmbr$ ( s . d . ),C0022718;C0439209;C0444504;C0578022;C1512018;C2347634;C2348143;C4054209
5321,mean bmi,C0444504;C0578022;C2347634;C2348143
5321,mean ( sd ) bmi ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,mean ( sd ) bmi,C0444504;C0578022;C2347634;C2348143;C2699239
5321,mean ( s . d . ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
5321,bmi — mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,bmi ( kg / m ^ )  mean ± s . d .,C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C0578022;C1275571;C1513009;C2347634;C2348143;C4054209
5321,bmi ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0578022
5321,bmi $nmbr$,C0578022
5321,bmi  mean ( sd ) b,C0444504;C0578022;C2347634;C2348143;C2699239
5321,bmi  mean ( sd )  kg / rn $nmbr$,C0022718;C0439209;C0444504;C0578022;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
5321,bmi  mean ( sd )  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,bmi  mean ( sd ),C0444504;C0578022;C2347634;C2348143;C2699239
5321,bmi  kg / m $nmbr$ ( mean $nmbr$ sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,bmi  kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
5321,bmi  kg / m $nmbr$  mean,C0444504;C0578022;C1532718;C2347634;C2348143
5321,bmi,C0578022
5320,body mass index > $nmbr$ — no . ( % ) f,C0005893;C0578022;C1305855
5320,bmi > $nmbr$ — no . { % ) $,C0578022
5320,bmi > $nmbr$ — no . ( % ) f,C0578022
5320,bmi > $nmbr$ obese,C0578022
5319,mean body mass index ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5319,body mass index mean kg / m $nmbr$ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5319,body mass index / mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
5319,body mass index - mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
5319,body mass index $nmbr$,C0005893;C0578022;C1305855
5319,body mass index  mean ± sd ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5319,body mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
5319,body mass index  kg / rn \ mean ( sd ),C0005893;C0022718;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239;C2827110;C3540639;C4054209;C4281819
5319,body mass index  kg / m $nmbr$ ( mean ± sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5319,body mass index,C0005893;C0578022;C1305855
5319,body - mass index ),C0005893;C0578022;C1305855
5319,body - mass index  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
5319,body - mass index,C0005893;C0578022;C1305855
5318,mean body - mass index ( = sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5318,mean body - mass index  kg / m $nmbr$   ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5318,body mass index subgroups,C0005893;C0578022;C1079230;C1305855
5318,body mass index > $nmbr$ t,C0005893;C0578022;C1305855
5318,body mass index > $nmbr$ kg / m $nmbr$  n ( % ),C0005893;C0578022;C1305855;C1532718
5318,body mass index > $nmbr$ kg / m  n ( % ),C0005893;C0578022;C1305855;C1532718
5318,body mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
5318,body mass index ( kgm _ $nmbr$ ),C0005893;C0578022;C1305855
5318,body mass index ( kg / m $nmbr$ ) baseline systolic blood,C0005767;C0005768;C0005893;C0039155;C0168634;C0229664;C0578022;C1305855;C1442488;C1532718
5318,body mass index  %,C0005893;C0578022;C1305855
5318,body - mass index — no . ( % ) $,C0005893;C0578022;C1305855
5318,body - mass index §,C0005893;C0578022;C1305855
5318,body - mass index > $nmbr$ kg / nrn,C0005893;C0022718;C0439209;C0578022;C1305855;C1425210;C4054209
5318,body - mass index > $nmbr$  n ( % ),C0005893;C0578022;C1305855
5318,body - mass index > $nmbr$,C0005893;C0578022;C1305855
5318,body - mass index - ! ',C0005893;C0578022;C1305855
5318,body - mass index ) -,C0005893;C0578022;C1305855
5318,body - mass index ) ',C0005893;C0578022;C1305855
5318,body - mass index ( kg / m ’ ),C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / m   $nmbr$ ),C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / m - ) !,C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / m - ),C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / m ' ),C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
5318,body - mass index ( kg / cm $nmbr$ ),C0005893;C0578022;C1305855;C4054689
5318,body - mass index $,C0005893;C0578022;C1305855
5318,body - mass index  kq / nrn,C0005893;C0578022;C1305855;C1425210
5318,baseline body mass index,C0005893;C0168634;C0578022;C1305855;C1442488
5317,mean body mass index ( kg / m $nmbr$ ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
5317,mean body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
5317,mean body - mass index  kg / m $nmbr$ ( sd ) *,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,mean body - mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
5317,body mass index ^,C0005893;C0578022;C1305855
5317,body mass index [ kg / m $nmbr$ ]  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,body mass index < $nmbr$ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
5317,body mass index - kg / m $nmbr$ t,C0005893;C0578022;C1305855;C1532718
5317,body mass index +,C0005893;C0578022;C1305855
5317,body mass index *,C0005893;C0578022;C1305855
5317,body mass index ( kg / m “ ) ^,C0005893;C0578022;C1305855;C1532718
5317,body mass index ( kg / m ’ ) ^,C0005893;C0578022;C1305855;C1532718
5317,body mass index ( kg / m ^ ) ^,C0005893;C0578022;C1305855;C1532718
5317,body mass index ( kg / m ^ ),C0005893;C0578022;C1305855;C1532718
5317,body mass index ( kg / m $nmbr$ ) * ',C0005893;C0578022;C1305855;C1532718
5317,body mass index  mean kg / m ^ ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,body mass index  kg / m ^ mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,body mass index  kg / m ^ ^,C0005893;C0578022;C1305855;C1532718
5317,body mass index  kg / m ^ ( meanisd ),C0005893;C0578022;C1305855;C1532718
5317,body mass index  kg / m ^,C0005893;C0578022;C1305855;C1532718
5317,body mass index  kg / m $nmbr$  mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,body mass index  kg / m $nmbr$  mean + sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
5317,body mass index  * kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
5317,body - mass index \ kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
5317,body - mass index *,C0005893;C0578022;C1305855
5317,body - mass index ( kg / m $nmbr$ ) t,C0005893;C0578022;C1305855;C1532718
5317,body - mass index ( kg / m $nmbr$ ) *,C0005893;C0578022;C1305855;C1532718
5317,body - mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
5316,body mass index :,C0005893;C0578022;C1305855
5316,body - mass index — no . ( % ) : i :,C0005893;C0578022;C1305855
5316,body - mass index categories — no . ( % ) : c,C0005893;C0578022;C0683312;C1305855
5316,body - mass index ^ :,C0005893;C0578022;C1305855
5316,body - mass index ^,C0005893;C0578022;C1305855
5316,body - mass index : ! : blood pressure — mm hg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
5316,body - mass index : ! :,C0005893;C0578022;C1305855
5315,body - mass index ”,C0005893;C0578022;C1305855
5315,body - mass index  !  waist - to - hip ratio,C0005893;C0205682;C0578022;C1305855
5315,body - mass index  !,C0005893;C0578022;C1305855
5314,improved,C0184511;C0332272;C1561611;C4084203
5313,impaired fasting glucose §,C1272092
5313,impaired fasting glucose ( > $nmbr$ mg / dl ) ( % ),C0439269;C1272092
5312,who / idf impaired fasting glucose,C1272092
5312,ada impaired fasting glucose,C1060325;C1272092;C3811629
5311,impaired fasting glucose level ( n = $nmbr$ ),C0202045;C0221099;C0441889;C0456079;C1272092;C1547707;C2946261
5311,impaired fasting glucose,C1272092
5310,hospitalized without airway compromise,C0701159;C4055482
5310,airway compromise,C4055482
5309,a compared wi,C0043193;C1520135;C1707455
5309,a compared w,C1707455
5308,comparison with baseline ( mean,C0168634;C0444504;C1442488;C1707455;C2347634;C2348143
5308,comparison with baseline,C0168634;C1442488;C1707455
5308,comparison,C1707455
5307,pairwise comparison,C1707455
5307,between - treatment comparison of percentage change from baseline in total hip bmd,C0439165;C1299575;C1549488;C1561533;C1707455
5306,married,C0024841;C0555047
5305,marital status  married,C0024819;C1716536;C3172566
5304,other / mixed ( n = $nmbr$ ),C0205430;C3160715
5304,mixed hispanic,C0086409;C0205430;C3160715
5304,mixed ( n = $nmbr$ ),C0205430;C3160715
5304,mixed ( itt ) ( n = $nmbr$ ),C0205430;C3160715
5304,mixed,C0205430;C3160715
5303,losmapimod ( n = $nmbr$ ),C3272847
5303,losmapimod,C3272847
5302,week $nmbr$ crp,C0332174;C0439230;C3890735;C4048285
5301,clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
5301,cfb at week $nmbr$,C0009002;C0332174;C0439230;C1824728
5300,week $nmbr$ czp dose combined ( n   =   $nmbr$ ),C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
5300,week $nmbr$ czp dose combined,C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
5300,week $nmbr$ *,C0332174;C0439230
5300,week $nmbr$  % ( n ) * *,C0332174;C0439230
5300,pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C0178602;C0332174;C0439230;C0869039;C1114758;C1861828;C1872109
5300,dose ratio at week $nmbr$ ( $nmbr$ % cl ),C0178602;C0332174;C0439230;C0456603;C0596019;C0869039;C1114758;C1547037
5299,week $nmbr$ mean ± sem,C0332174;C0439230;C0444504;C2347634;C2348143
5299,nighttime mean dbp ( abpm ) at week $nmbr$  mmhg,C0240526;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
5299,mean treatment exposure  wk,C0039798;C0087111;C0274281;C0332157;C0332174;C0439230;C0444504;C1522326;C1533734;C1705169;C2347634;C2348143;C3538994;C3887704
5299,mean change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
5299,in ibdq total score at week $nmbr$  mean [ se ],C0036919;C0332174;C0439175;C0439230;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
5299,daytime mean dbp ( abpm ) at week $nmbr$  mmhg,C0332169;C0332174;C0439230;C0439475;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
5299,at week $nmbr$,C0332174;C0439230
5299,$nmbr$ wk,C0332174;C0439230
5299,$nmbr$ week,C0332174;C0439230
5298,week $nmbr$ fpg  mean ( s . e . ),C0332174;C0439230;C0444504;C2347634;C2348143
5298,week,C0332174;C0439230
5298,nighttime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0240526;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
5298,( week ),C0332174;C0439230
5297,week   $nmbr$,C0332174;C0439230
5297,week $nmbr$ * ’ ’,C0332174;C0439230
5297,change to   week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
5297,change to week $nmbr$ * ’ ’,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
5296,night - time awakenings / week,C0332174;C0439230;C0860510
5295,week $nmbr$ — mg / liter ^,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
5295,week $nmbr$ — mg / liter,C0024671;C0026410;C0332174;C0439230;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
5295,week $nmbr$ / et,C0332174;C0439230
5295,mtx ≥ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
5295,mtx £ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
5295,mtx dose > $nmbr$ mg / week  %,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
5295,mtx > $nmbr$ – $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
5295,mtx < $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
5295,mean ( median ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C0549183;C0876920;C1960952;C2346927;C2347634;C2347635;C2348143;C2348144;C2939193;C4321396;C4521761
5295,> $nmbr$ weeks,C0439230
5295,> $nmbr$ to < $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
5295,> $nmbr$ / week,C0332174;C0439230
5295,> $nmbr$ - $nmbr$ mg / week,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4321396;C4521761
5295,$nmbr$ / week,C0332174;C0439230
5294,week $nmbr$  % ( n ) j,C0332174;C0439230
5294,week $nmbr$  % ( n ) ^,C0332174;C0439230
5294,week $nmbr$  % ( n ),C0332174;C0439230
5294,beam   <   $nmbr$   mg / dl at week $nmbr$  n ( % ),C0332174;C0338248;C0439230;C0439269;C2347880;C4521565
5293,tdi total score ( week $nmbr$,C0205976;C0332174;C0439230;C2674784;C2964552;C3714807
5293,sgrq total score ( week,C0332174;C0439230;C2964552
5292,week $nmbr$ outcomes,C0332174;C0439230;C1274040
5292,week $nmbr$ outcome,C0332174;C0439230;C1274040
5292,disease activity outcomes ( itt population ) week $nmbr$,C0032659;C0205177;C0332174;C0439167;C0439230;C0441655;C0679250;C1257890;C1274040;C1292728;C1561536;C3542417;C3668946;C4049938;C4049939
5291,endpoint week $nmbr$,C0332174;C0439230;C2349179;C2826544
5290,week $nmbr$ - baseline,C0168634;C0332174;C0439230;C1442488
5290,week $nmbr$,C0332174;C0439230
5290,open - label phase ( baseline = week $nmbr$ ),C0168634;C0205390;C0332174;C0439230;C1442488;C1709323;C1710475
5290,db baseline ( week $nmbr$ ),C0168634;C0332174;C0439230;C1418892;C1442488
5289,week - $nmbr$ changea,C0332174;C0439230;C4349366
5289,non - hdl cholesterol ( week $nmbr$ ),C0332174;C0439230;C0729627;C1535899
5288,week and,C0332174;C0439230
5288,hdl cholesterol ( week $nmbr$ ) a,C0023822;C0332174;C0392885;C0439230
5287,ldl particle size ( week $nmbr$ ),C0332174;C0439230;C3641256
5287,ldl particle numbers ( week $nmbr$ ),C0237753;C0332174;C0439230;C0449788;C2612459
5286,calculated ldl cholesterol ( week $nmbr$ ),C0023824;C0202117;C0332174;C0439230;C0444686;C1441506
5285,week $nmbr$ ( non - ee responders ),C0332174;C0439230;C1518422
5285,atv  atorvastatin  ldl - c  low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment   [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline  ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .,C0018017;C0023824;C0039798;C0087111;C0210243;C0237455;C0286651;C0332174;C0439230;C0674679;C0680230;C1079230;C1145759;C1334862;C1515021;C1518422;C1522326;C1533734;C1571704;C1704675;C1705169;C1709380;C2360800;C3538994;C3887704
5285,- - week $nmbr$ - -,C0332174;C0439230
5285,$nmbr$ - $nmbr$ / week,C0332174;C0439230
5284,week $nmbr$ ( mmol / l ),C0332174;C0439230;C1532563
5284,week $nmbr$ ( before ee ),C0332174;C0439230
5284,week $nmbr$  % ( n ) §,C0332174;C0439230
5284,week $nmbr$  % ( n ) | | or for cana vs pbo ( $nmbr$ % ci ) §,C0332174;C0439230
5284,week $nmbr$  % ( n ) $nmbr$ or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
5284,week $nmbr$  % ( n ) # or for cana vs pbo ( $nmbr$ % ci ) | |,C0332174;C0439230
5284,week $nmbr$  % ( n ) #,C0332174;C0439230
5284,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) at week $nmbr$,C0332174;C0439230;C3829066
5284,apob ( week $nmbr$ ),C0003593;C0332174;C0439230;C3252643
5284,< $nmbr$ weeks,C0439230
5284,< $nmbr$ week,C0332174;C0439230
5283,week $nmbr$ a,C0332174;C0439230
5283,triglycerides ( week $nmbr$ ) a,C0041004;C0332174;C0439230
5283,lp ( a ) ( week $nmbr$ ),C0065058;C0332174;C0439230;C1439335;C4553379
5283,$nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
5283,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ) $nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
5283,$nmbr$ - $nmbr$ / week ( n = $nmbr$ ),C0332174;C0439230
5282,week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230
5282,week $nmbr$  % ( n ) $nmbr$,C0332174;C0439230
5282,acr $nmbr$ week $nmbr$ responders  ( n = $nmbr$ ),C0332174;C0439230;C1412134;C1515941
5282,acr $nmbr$ response at week $nmbr$  n ( % ),C0332174;C0439230;C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
5281,habitual fish intake : < $nmbr$ servings / wk ( n = $nmbr$ ),C0205353;C0332174;C0439230;C0556216;C1519269
5281,> $nmbr$ servings / wk ( n = $nmbr$ ),C0332174;C0439230;C1519269
5280,weeks_measured,C0439230
5280,at six weeks,C0205452;C0439230
5279,weeks,C0439230
5279,bw at $nmbr$ weeks  kg +,C0005910;C0006041;C0022718;C0439209;C0439230;C2986891;C4054209
5279,at weeks $nmbr$ and $nmbr$,C0439230
5278,weekly iss {,C0332174;C1740819;C1845118
5278,weekly iss $nmbr$,C0332174;C1740819;C1845118
5278,weekly,C0332174
5278,patients with weekly iss mid response  n ( % ) v,C0030705;C0332174;C0871261;C1704632;C1706817;C1740819;C1845118;C2911692
5278,median ( $nmbr$ % ci ) time to weekly iss mid response up to week $nmbr$ ( wk ) f,C0008107;C0034746;C0332174;C0549183;C0876920;C1740819;C1845118;C2347635;C2348144;C2939193;C3259781
5278,baseline weekly iss,C0168634;C0332174;C1442488;C1740819;C1845118
5277,device group,C1706365
5276,panel b,C0441833;C1706365;C1999270
5276,panel a,C0441833;C1706365;C1999270
5275,warfarin group,C0043031;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,treatment group,C0039798;C0087111;C0441833;C0687744;C1257890;C1519504;C1522326;C1533734;C1705169;C1705428;C1705429;C3538994;C3887704
5275,total group,C0439175;C0439810;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,table_group,C0039224;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1706074
5275,subject group,C0441833;C0681850;C0687744;C1257890;C1519504;C1550501;C1705428;C1705429;C1706203;C2349001;C2697811
5275,statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,salmeterol - fluticasone group,C0441833;C0687744;C0939232;C1257890;C1519504;C1705428;C1705429
5275,randomized group by subgroup interaction,C0034656;C0441833;C0687744;C1079230;C1257890;C1515021;C1519504;C1704675;C1705428;C1705429;C3815594
5275,randomization groups $nmbr$ and $nmbr$,C0034656;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
5275,randomization group,C0034656;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
5275,patients in the placebo group  nt - probnp values were reported for $nmbr$ patients,C0030705;C0032042;C0042295;C0441833;C0669479;C0687744;C0754710;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408
5275,mepolizumab group,C0441833;C0687744;C0969324;C1257890;C1519504;C1705428;C1705429
5275,low - dose rivaroxaban + aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1739768;C2608320
5275,indacaterol - glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1722260;C3814772
5275,in the spironolactone group and $nmbr$ patients in the placebo group .,C0037982;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
5275,group difference,C0441833;C0687744;C1257890;C1519504;C1705241;C1705242;C1705428;C1705429
5275,group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,ezetimibe / simvastatin group,C0441833;C0687744;C1257890;C1519504;C1532737;C1705428;C1705429
5275,experimental treatment group,C0441833;C0687744;C0949266;C1257890;C1519504;C1705428;C1705429;C2585119
5275,events / statin group,C0360714;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C3541888
5275,diet group,C0012155;C0012159;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
5275,diet + pravastatin group,C0012155;C0012159;C0085542;C0441833;C0687744;C1257890;C1519433;C1519504;C1705428;C1705429;C2983588;C3668949
5275,dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2348066
5275,certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1872109
5275,bp : blood pressure  ci : confidence interval  esrd : end - stage renal disease  hr  hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd  rate : event rate per $nmbr$ years of follow - up  pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata  adjusted : a multivariate cox model with treatment group  time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp,C0005823;C0008107;C0009667;C0012634;C0017446;C0022661;C0030705;C0034510;C0035078;C0039155;C0039798;C0040223;C0087111;C0205088;C0205147;C0441471;C0441833;C0687744;C0871208;C1257890;C1319635;C1519504;C1521828;C1522326;C1533734;C1705169;C1705428;C1705429;C1706779;C2316810;C2826245;C2985465;C3259781;C3538994;C3541383;C3853635;C3887704;C4019010
5275,aspirin group,C0004057;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5275,* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme  cabg coronary - artery bypass grafting  nt - probnp n - terminal pro - b – type natriuretic peptide  nyha new york heart association  and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past  with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$  with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors  including age  sex  body - mass index  and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .,C0001779;C0002871;C0004083;C0005893;C0005910;C0009253;C0010055;C0018787;C0025266;C0027976;C0030705;C0032042;C0034510;C0036864;C0040223;C0040363;C0041260;C0042295;C0043100;C0079399;C0086715;C0184661;C0205088;C0205447;C0332288;C0332307;C0332490;C0376558;C0439175;C0439209;C0439810;C0439849;C0441074;C0441833;C0441889;C0441994;C0445022;C0449820;C0475211;C0522523;C0578022;C0596306;C0596672;C0687744;C0699792;C0804628;C0886296;C1000483;C1144709;C1257890;C1273869;C1275491;C1281911;C1292769;C1305855;C1305866;C1314687;C1317554;C1444637;C1452534;C1519504;C1522384;C1547052;C1548802;C1696465;C1705104;C1705314;C1705315;C1705428;C1705429;C1706408;C1706779;C1719797;C1882084;C1883351;C2003888;C2709270;C2825907;C2911648;C3537020;C3541383;C3827682;C3853635;C4284014;C4284038;C4284302;C4554633
5274,weight group  no . ( % ),C0005910;C0043100;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
5274,vascular disease ( % of group ),C0042373;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,previous coronary procedure ( % of group ),C0018787;C0018821;C0205156;C0441833;C0687744;C1257890;C1279986;C1519504;C1552607;C1705428;C1705429;C2986530
5274,no epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,no . of diseased vessels ( % of group ),C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,hbaic group ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,group — no . ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,group dif . ( $nmbr$ ),C0441833;C0687744;C0812246;C1257890;C1519504;C1705428;C1705429;C1710304
5274,epa group no . of events ( % ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5274,coronary procedure ( % of group ),C0018787;C0018821;C0441833;C0687744;C1257890;C1279986;C1519504;C1705428;C1705429;C2986530
5274,bmi group — no . ( % ),C0441833;C0578022;C0687744;C1257890;C1519504;C1705428;C1705429
5274,alc group ( % ),C0441833;C0687744;C1257890;C1424945;C1519504;C1705428;C1705429;C3811058
5274,( % of group ),C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
5273,ind $nmbr$ gg q . d . n / n ( % ),C0017454;C0018370;C4049864
5273,gly $nmbr$ . $nmbr$ gg b . i . d n / n ( % ),C0017454;C0018370;C0152277;C1415124
5273,gg,C0017454;C0018370
5272,formoterol $nmbr$ gg bid,C0017454;C0018370;C0060657
5272,formoterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C0060657
5271,ff / vi $nmbr$ / $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C0205999;C4554348
5271,ff $nmbr$ gg ( n = $nmbr$  $nmbr$ ),C0017454;C0018370;C4554348
5270,tiotropium $nmbr$ gg qd,C0017454;C0018370;C0213771;C0332173
5270,indacaterol $nmbr$ gg qd,C0017454;C0018370;C0332173;C1722260
5269,ag + gg,C0002037;C0017454;C0018370;C0051080;C0152305;C3888235
5269,ag,C0002037;C0051080;C0152305;C3888235
5268,salmeterol / fluticasone $nmbr$ / $nmbr$ pg twice daily,C0030827;C0072225;C0585361;C0939232;C1266240
5267,indacaterol $nmbr$ pg,C0030827;C0072225;C1266240;C1722260
5267,formoterol $nmbr$ pg vs placebo,C0030827;C0060657;C0072225;C1266240
5267,formoterol $nmbr$ pg,C0030827;C0060657;C0072225;C1266240
5267,aclidinium / formoterol $nmbr$ / $nmbr$ pg twice daily,C0030827;C0060657;C0072225;C0585361;C1266240;C2699757
5267,aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C2699757
5267,aclidinium $nmbr$ pg,C0030827;C0072225;C1266240;C2699757
5266,tiotropium $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
5266,tiotropium $nmbr$ . $nmbr$ pg,C0030827;C0072225;C0213771;C1266240
5266,sfc $nmbr$ / $nmbr$ pg b . i . d . n = $nmbr$,C0021966;C0030827;C0072225;C0152277;C0221138;C1266240;C2827928;C4521536
5266,gly ( $nmbr$ . $nmbr$ pg b . i . d . ) n = $nmbr$,C0030827;C0072225;C0152277;C1266240;C1415124
5265,qva $nmbr$ / $nmbr$ pg once daily ( n = $nmbr$ ),C0030827;C0072225;C0332173;C1266240
5265,ff $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
5265,ab / ff $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240;C4554348
5265,ab $nmbr$ pg ( n = $nmbr$ ),C0030827;C0072225;C1266240
5264,nt - probnp pg / mla ( iqr ),C0030827;C0072225;C0599973;C0669479;C0754710;C1266240
5264,nt - probnp  pg / mlt,C0030827;C0072225;C0669479;C0754710;C1266240;C4553833
5263,vi $nmbr$   µ g,C0205999;C0439267
5262,femoral neck bmd ( g / cm $nmbr$ ),C0015815;C0439267
5262,femoral neck ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0015815;C0439267;C2699239
5261,nos $nmbr$ glu $nmbr$ asp g . t  n ( % ),C0125690;C0326287;C0439267;C1518425
5261,glu $nmbr$ asp g . t,C0125690;C0439267
5261,$nmbr$ a . g,C0439267
5260,w eight ( k g ),C0205454;C0439267;C0597277;C1708601
5259,formoterol $nmbr$   μ g ( n   =   $nmbr$ ),C0060657;C0439267
5258,aclidinium $nmbr$   μ g bid ( n   =   $nmbr$ ),C0439267;C2699757
5258,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) b,C0439267;C2699757
5258,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ) a,C0439267;C2699757
5258,aclidinium $nmbr$   μ g ( n   =   $nmbr$ ),C0439267;C2699757
5258,$nmbr$ μ g bid ( n = $nmbr$ ),C0439267
5258,$nmbr$ μ g ( n = $nmbr$ ),C0439267
5257,u » c » ( mg / g ),C0024671;C0026410;C0439148;C0439267;C0439269;C1300563;C1532633;C1638407;C1960952;C2346927;C2608091;C4321396;C4521761
5257,g + c,C0439267
5256,g - blockers,C0439267
5256,creatinine clearance by c - g ( ml / min ),C0151280;C0439267
5255,bdp / ff / g ( n = $nmbr$ ),C0004906;C0439267;C1422585;C1538710;C4554348
5254,ff / vi $nmbr$ / $nmbr$   µ g,C0205999;C0439267;C4554348
5254,ff $nmbr$   µ g,C0439267;C4554348
5253,mean — g / dl,C0439267;C0444504;C2347634;C2348143
5253,mean bmd ( = sd )  g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
5253,mean ( sd ) bmd in g / cm $nmbr$,C0439267;C0444504;C2347634;C2348143;C2699239
5253,g,C0439267
5253,flex baseline bmd  mean ( sd )  g / cm $nmbr$,C0168634;C0439267;C0444504;C1442488;C2347634;C2348143;C2699239
5253,bone mineral density ( g / cm $nmbr$ )  mean ( sd ),C0005938;C0177804;C0439267;C0444504;C2347634;C2348143;C2699239
5252,albumin  g / dl,C0001924;C0439267
5251,hgb  g / dl < $nmbr$ men  < $nmbr$ women,C0019029;C0019046;C0025266;C0043210;C0439267;C0518015;C1424337
5251,hgb  g / dl,C0019029;C0019046;C0439267;C0518015;C1424337
5250,hb decrease ≥ $nmbr$ g / dl,C0019046;C0392756;C0439267;C0547047;C3642216;C3843510
5250,hb  g / dl,C0019046;C0439267;C3642216;C3843510
5249,lrg,C1428862
5248,ltg subgroup  n = $nmbr$,C1079230;C1420817;C1515021;C4521367;C4521846
5248,ltg - naive,C1420817;C4521367;C4521846
5248,ltg - exposed,C1420817;C4521367;C4521846
5247,tg > $nmbr$ . $nmbr$,C0337445
5247,tg < = $nmbr$ . $nmbr$,C0337445
5247,tg,C0337445
5247,baseline tg level ( n = $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
5247,baseline tg > $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
5247,baseline tg,C0168634;C0337445;C1442488
5246,tg §,C0337445
5246,tg ( mmol / l ) c,C0337445;C1532563
5246,tg ( mmol / l ),C0337445;C1532563
5245,tg < $nmbr$  hdl > $nmbr$ ( n = $nmbr$ ),C0337445;C3715113
5245,tg +,C0337445
5244,lowest tg tertile,C0337445;C1708760
5243,tg *,C0337445
5243,highest tg tertile,C0337445;C1522410
5242,tg ’,C0337445
5242,hdl - c   high - density lipoprotein cholesterol    ldl - c   low - density lipoprotein cholesterol    sestandard error    tg   triglycerides .,C0023822;C0337445;C0743559;C0858892;C1608199
5241,q $nmbr$ : < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
5241,q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
5241,bm $nmbr$  kg / m $nmbr$ ( mean ± s . d . ),C0006416;C0022718;C0369637;C0439209;C0439493;C0441923;C0444504;C1275571;C1513009;C2347634;C2348143;C4054209
5241,< = € $nmbr$ kg,C0022718;C0439209;C4054209
5241,< = $nmbr$ kg,C0022718;C0439209;C4054209
5241,< $nmbr$ kg  mj ( reference ),C0022718;C0439209;C0439254;C4054209;C4284025
5241,< $nmbr$ kg,C0022718;C0439209;C4054209
5241,. $nmbr$ kg,C0022718;C0439209;C4054209
5240,weight at randomization ( kg ),C0022718;C0439209;C2985844;C4054209
5240,weight ( range ) ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1514721;C1705104;C2348147;C3542016;C4054209
5240,mean body weight  kg ( range ),C0005910;C0022718;C0439209;C0444504;C1305866;C1514721;C2347634;C2348143;C2348147;C3542016;C4054209
5240,data are number of patients ( % ) or mean ( sd )  unless otherwise indicated . cabg = coronary - artery bypass grafting . ptca = percutaneous transluminal coronary angioplasty  ldl = low - density lipoprotein . hdl = high - density lipoprotein . iqr = i nterquarti le range  hmg coa ri = $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a reductase inhibitor . bmi = body - mass index  which is weight in kg divided by the square of height in metres  * median ( iqr ) .,C0009235;C0010055;C0021966;C0022718;C0023190;C0023821;C0023823;C0035487;C0047420;C0162577;C0189695;C0221138;C0439090;C0439209;C0522520;C0522523;C0545743;C0549183;C0597153;C0700307;C0876920;C1305855;C1423767;C1444656;C1511726;C1514721;C1522231;C1548817;C1655741;C1826843;C2347635;C2348144;C2348147;C2697858;C2936173;C2939193;C3245479;C3542016;C3714741;C4054209
5239,mean body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0444504;C0578022;C1305855;C2347634;C2348143;C4054209
5239,body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0578022;C0687744;C1257890;C1305855;C1519504;C1705428;C1705429;C1709500;C4054209
5239,body mass index ( kg / nr ),C0005893;C0022718;C0027496;C0439209;C0578022;C1305855;C3844738;C4054209
5239,body mass index ( kg / ma ),C0005893;C0022718;C0024443;C0439209;C0578022;C1305855;C3887485;C4054209
5239,body - mass index ( kg / mq,C0005893;C0022718;C0024853;C0439209;C0578022;C1305855;C4054209
5239,bmi group ( kg / m ^ ),C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1519504;C1532718;C1705428;C1705429;C4054209
5239,bmi ( kg / rrr ),C0022718;C0439209;C0578022;C4054209
5238,dose adjustment reason < $nmbr$ kg,C0022718;C0439209;C2826286;C4054209
5237,£ $nmbr$ kg,C0022718;C0439209;C4054209
5237,body mass index ( bmi  kg / m $nmbr$ )  n ( % ) < $nmbr$ kg / m $nmbr$,C0005893;C0022718;C0439209;C0578022;C1305855;C1709500;C4054209
5237,body mass  kg,C0022718;C0439209;C0518010;C4054209
5237,< $nmbr$ kg  n ( % ),C0022718;C0439209;C4054209
5236,low body weight ( < $nmbr$ kg ),C0022718;C0041667;C0439209;C4054209
5236,baseline weight  kg,C0022718;C0439209;C1303013;C4054209
5236,$nmbr$ to < $nmbr$ kg,C0022718;C0439209;C4054209
5235,nonobese ( < $nmbr$ kg / nr ),C0022718;C0027496;C0439209;C3844738;C4054209
5235,> $nmbr$ kg nr,C0022718;C0027496;C0439209;C3844738;C4054209
5235,> $nmbr$ kg / nr,C0022718;C0027496;C0439209;C3844738;C4054209
5234,bmi : < $nmbr$ kg / nr,C0022718;C0027496;C0439209;C0578022;C3844738;C4054209
5234,bmi $nmbr$ - < $nmbr$ kg / ni - ( n = $nmbr$ / $nmbr$ ),C0022718;C0028075;C0439209;C0578022;C2348274;C3869926;C3869927;C4054209
5234,$nmbr$ - < $nmbr$ kg,C0022718;C0439209;C4054209
5233,« $nmbr$ kg,C0022718;C0439209;C4054209
5233,weight > $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5233,weight > $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5233,weight < $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5233,weight # $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5233,weight  mean ± sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5233,weight  kg  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5233,weight  kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5233,q $nmbr$ : > $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),C0022718;C0439209;C4054209
5233,mean ± s . d . weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
5233,mean weight  kg  mean = sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5233,bw  mean ( sd )  kg,C0005910;C0006041;C0022718;C0439209;C0444504;C2347634;C2348143;C2699239;C2986891;C4054209
5233,bw  kg,C0005910;C0006041;C0022718;C0439209;C2986891;C4054209
5233,bodyweight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
5233,body weight  mean = sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
5233,> = $nmbr$ kg,C0022718;C0439209;C4054209
5233,> $nmbr$ kg — no . ( % ),C0022718;C0439209;C4054209
5233,> $nmbr$ kg,C0022718;C0439209;C4054209
5233,> $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
5233,> $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
5233,> $nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
5233,> $nmbr$ ( n  % ) weight  kg,C0005910;C0022718;C0043100;C0369718;C0439209;C0441922;C1305866;C1705104;C4054209
5233,< $nmbr$ . $nmbr$ kg,C0022718;C0439209;C4054209
5233,$nmbr$ kg,C0022718;C0439209;C4054209
5233,$nmbr$ - $nmbr$ kg,C0022718;C0439209;C4054209
5233,# $nmbr$ kg,C0022718;C0439209;C4054209
5232,weight 一 kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight — kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight in kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight [ kg ],C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight - kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
5232,weight - kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight ( kg ) a,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight ( kg ) *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight ( kg ) ( mean ± sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight ( kg )  mean   ±   sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight ( kg )  mean ± sd,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight  mean ± sd ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight  kg mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight  kg : mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,weight  kg $nmbr$,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
5232,weight  kg  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,median body weight — kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
5232,mean weight ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,mean ( sd ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
5232,kg,C0022718;C0439209;C4054209
5232,bodyweight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
5232,body weight — kg,C0005910;C0022718;C0439209;C1305866;C4054209
5232,body weight ( kg ) *,C0005910;C0022718;C0439209;C1305866;C4054209
5232,body weight ( kg )  mean ± sd,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
5232,body weight ( kg )  mean ( sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
5232,body weight ( kg ),C0005910;C0022718;C0439209;C1305866;C4054209
5232,body weight  kg ( sd ),C0005910;C0022718;C0439209;C1305866;C2699239;C4054209
5231,nocturnal symptoms in past week,C0240526;C0683368;C1457887;C2987125
5230,days with asthma symptoms / week,C0004096;C0677547;C0683368;C1457887;C2984299
5230,asthma symptoms in the past $nmbr$ weeks,C0004096;C0683368;C1457887;C2984299;C2987125
5229,daytime symptoms more than twice per week,C0332169;C0683368;C1457887;C1720725;C1948050
5228,systemic symptoms,C0205373;C0683368;C1457887
5228,symptoms and feelings,C0683368;C1457887
5227,who fc ii symptoms at baselinef,C0683368;C1457887;C1710602;C2983605;C4082587
5227,who fc ii symptoms at baseline $nmbr$,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
5227,who fc ii symptoms at baseline,C0168634;C0683368;C1442488;C1457887;C1710602;C2983605;C4082587
5227,symptoms,C0683368;C1457887
5226,$nmbr$ = minor symptoms  no limitations,C0026193;C0205165;C0683368;C1457887
5225,* determined by investigator to be possibly  probably or definitely related to study drug tmyopathy defined as cpk > $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^ consecutive defined as two or more measurements at least one week apart or one measurement < $nmbr$ days after the last dose of study drug ( presumed consecutive ) § two patients had incomplete data to assess chd status simva = simvastatin  eze = ezetimibe  ae = adverse event  alt = alanine aminotransferase  ast = aspartate aminotransferase  cpk = creatine phosphokinase  uln = upper limit of normal,C0010287;C0013175;C0026845;C0035173;C0205448;C0332281;C0439849;C0445223;C0521095;C0683368;C0805162;C1266129;C1415181;C1457887;C1516048;C1519815;C1704788;C3539106;C3891303;C4083049;C4553172
5225,$nmbr$ = no symptoms,C0683368;C1457887
5224,symptoms of atrial fibrillation in the $nmbr$ months before randomization — no . ( % ),C0004238;C0344434;C0683368;C1457887;C1963067
5224,symptoms of atrial fibrillation in the $nmbr$ months before randomiza -,C0004238;C0344434;C0683368;C1457887;C1963067
5224,no symptoms,C0683368;C1457887
5223,symptom bother,C1457887;C3854129
5223,> lto £ $nmbr$ symptom days per week,C0677547;C1457887;C3854129
5223,> $nmbr$ symptom days per week,C0677547;C1457887;C3854129
5223,$nmbr$ to $nmbr$ symptom days per week,C0677547;C1457887;C3854129
5222,symptom duration  months,C0439231;C0449238;C1457887;C2926735;C3854129
5222,symptom duration,C0449238;C1457887;C2926735;C3854129
5222,ra symptom duration < $nmbr$ months — number ( % ),C0237753;C0439231;C0449238;C0449788;C1457887;C2926735;C3538806;C3854129;C4048756
5221,atwo ‐ sample t ‐ test .,C0370003;C0871472;C2347026
5220,total sample = $nmbr$ ( % ),C0370003;C0439175;C0439810;C2347026
5220,sample sizea,C0370003;C2347026
5219,subgoup_name,C0027365;C1547383;C4522128
5218,the plot shows hazard ratios and $nmbr$ % confidence intervals for the primary outcome  with patients stratified according to eight sub - groups prespecified in the statistical analysis plan . no heterogeneity was observed for these subgroups .,C0205225;C0439612;C0439631;C0871424;C1079230;C1547647
5218,prespecified subgroups,C1079230
5217,subgroups,C1079230
5217,renal function subgroups,C0232804;C1079230
5216,subgroup analyses,C2986480
5216,prespecified subgroup analyses,C2986480
5216,additional subgroup analyses,C1524062;C2986480
5215,serious teaes,C0205404
5215,serious ae,C0205404;C3887670
5215,any serious teaes,C0205404
5215,any serious ae  n ( % ),C0205404;C3887670
5214,serious decline in kidney function *,C0205404;C0232804
5214,serious decline in kidney function $nmbr$,C0205404;C0232804
5214,serious,C0205404
5213,serum bone - specific alkaline,C0205369;C0229671;C0262950;C1546774;C1550100;C1552740;C1979842
5212,serum n - propeptide of type $nmbr$ collagen,C0009325;C0229671;C0332307;C1546774;C1547052;C1550100;C1709708;C1875696
5212,serum c - terminal telopeptide of,C0229671;C1546774;C1550100;C1707271
5211,serum values ^,C0042295;C0229671;C1546774;C1550100
5211,serum values,C0042295;C0229671;C1546774;C1550100
5210,serum urea nitrogen  mg / dl,C0028158;C0229671;C0439269;C0600137;C0856666;C1291218;C1546774;C1550100;C1550581;C3683557
5210,serum gastrint  pg / ml,C0229671;C0439297;C1546774;C1550100
5210,serum fg  mg / dl,C0016703;C0229671;C0439214;C0439269;C1546774;C1550100;C1638318;C2348814;C3642216
5210,serum,C0229671;C1546774;C1550100
5210,fasting serum glucose level  mean ( sd )  mg / dl,C0015663;C0202045;C0229671;C0439269;C0444504;C0583332;C1546774;C1550100;C2347634;C2348143;C2699239
5209,serum ctx i ( ng / ml ),C0229671;C0439275;C0631180;C1546774;C1550100
5209,serum ctx - $nmbr$  ng / ml  median ( iqr ),C0010377;C0229671;C0439275;C0549183;C0631180;C0876920;C1546774;C1550100;C2347635;C2348144;C2939193;C3539598
5209,serum ctx ( ng / ml ),C0010377;C0229671;C0439275;C0631180;C1546774;C1550100;C3539598
5209,serum $nmbr$ - hydroxyvitamin d  ng / ml,C0020337;C0229671;C0439275;C1546774;C1550100
5208,serum pepsinogen i / iit,C0077923;C0229671;C0523816;C1546774;C1550100
5207,serum trap - $nmbr$ b ( u / liter ),C0184047;C0229671;C0439148;C0475211;C1336677;C1546774;C1550100;C1566918;C1706005;C1710330;C3887583
5207,serum p $nmbr$ np ( ^ g / liter ),C0065827;C0229671;C0439267;C0475211;C1546774;C1550100;C1706141;C3887659
5206,concomitant therapy  n [ % ],C1707479
5206,concomitant therapies at hospital discharge,C0586003;C1707479
5205,concomitant therapy  no . ( % ),C1707479
5205,concomitant therapies n ( % ),C1707479
5205,concomitant cardiovascular therapy ( taken > $nmbr$ days ),C0007226;C0521115;C0587038;C1707479;C3887460
5205,concomitant cardiovascular therapies — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
5204,use of concomitant lipid - modifying therapy,C0023779;C0392747;C1524063;C1707479
5204,concomitant therapy,C1707479
5204,concomitant lipid - modifying therapy — no . { % ),C0023779;C0392747;C1707479
5203,concomitant drug therapies  n ( % ),C0013216;C0521115
5202,concomitant methotrexate use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1947944
5202,concomitant methotrexate  n ( % ),C0025677;C0521115
5202,concomitant csdmards other than methotrexate  n ( % ),C0025677;C0521115
5201,number of concomitant aeds  n ( % ),C0180309;C0237753;C0449788;C0521115
5201,concomitant aedsb    n   ( % ),C0521115
5201,concomitant aedsb  n ( % ),C0521115
5201,concomitant aedsa,C0521115
5201,concomitant aeds  n ( % ),C0180309;C0521115
5200,most common concomitant aeds  n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
5200,most common concomitant aeds  d n ( % ),C0180309;C0205214;C0205393;C0521115;C1522138;C3245511
5200,concomitant oads  n ( % ),C0521115
5199,no concomitant antiplatelet,C0521115
5199,main concomitant treatments  no . ( % ),C0087111;C0205225;C0521115;C1542147
5199,concomitant antiplatelet,C0521115
5198,concomitant use of mtx to week $nmbr$,C0025677;C0521115;C1417487;C1524063
5198,concomitant mtx —,C0025677;C0521115;C1417487
5198,concomitant,C0521115
5197,chest discomfort,C0235710
5196,left circumflex  n ( % ),C0205091;C0443246;C1552822;C1880089
5196,left circumflex,C0205091;C0443246;C1552822;C1880089
5196,circumflex,C1880089
5195,hip circumference — cm,C0562350
5194,waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women ),C0025266;C0455829
5194,waist circumference .,C0455829
5194,waist circumference  ( cm ),C0455829
5193,waist circumference — cmj,C0455829
5193,waist circumference — cm,C0455829
5193,increased waist circumference,C0205217;C0442805;C0455829
5192,waist circumference ( cm ) : mean ± sd,C0444504;C0455829;C2347634;C2348143;C2699239
5192,waist circumference ( cm ),C0455829
5192,waist circumference  mean ( sd )  cm,C0444504;C0455829;C2347634;C2348143;C2699239
5192,waist circumference  cm mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
5192,waist circumference  cm ( sd ),C0455829;C2699239
5192,waist circumference  cm  mean ( sd ),C0444504;C0455829;C2347634;C2348143;C2699239
5192,waist circumference  cm,C0455829
5192,waist circumference,C0455829
5192,mean ± sd waist circumference  cm,C0444504;C0455829;C2347634;C2348143;C2699239
5191,time point,C2348792
5190,pint,C0560012;C3811619;C3890014;C3890556
5189,tender joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451530;C2347634;C2348143;C2699239
5189,tender joint count ( n / $nmbr$ ),C0451530
5189,tender joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
5189,tender joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451530;C2347634;C2348143;C2699239
5189,tender joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
5189,tender joint count ( $nmbr$ joints ),C0451530
5189,tender joint count ( $nmbr$ - $nmbr$ ),C0451530
5189,tender joint count ( $nmbr$ - $nmbr$  per tender joint ),C0451530
5189,tender joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451530;C2347634;C2348143;C2699239
5189,tender joint count,C0451530
5188,tender joint count of $nmbr$ joints,C0451530
5188,tender joint count ( range $nmbr$ - $nmbr$ joints ),C0451530;C1514721;C2348147;C3542016
5188,tender joint count ( $nmbr$ - $nmbr$ joints ),C0451530
5188,tender joint count  of $nmbr$,C0451530
5188,tender - joint count ( of $nmbr$ joints ),C0451530
5188,tender - joint count  of $nmbr$ joints examined,C0451530
5187,enthesitis count,C0750480;C1282952;C1705566
5186,dactylitis count ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0750480;C1705566;C2347634;C2348143;C2699239
5186,dactylitis count,C0239161;C0750480;C1705566
5185,red blood cell counting  $nmbr$ / l,C0005767;C0005768;C0022827;C0229664;C0332575;C0750480;C1260956;C1705566;C4049926
5185,pre - bronchodilator fef $nmbr$ . $nmbr$ ( ml / s ) baseline blood eosinophil count,C0005767;C0005768;C0014467;C0168634;C0200638;C0229664;C0439390;C0750480;C0750879;C1442488;C1705566;C2599602
5185,eosinoohil count,C0750480;C1705566
5184,< $nmbr$ with no historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
5184,< $nmbr$ with historical count > $nmbr$,C0750480;C1552658;C1552723;C1705566;C2004062
5184,< $nmbr$ regardless of historical count,C0750480;C1552658;C1552723;C1705566;C2004062
5183,full cohort,C0009247;C0443225;C0599755
5182,itt cohort  overall study period,C0009247;C0599755
5182,cohort,C0009247;C0599755
5182,$nmbr$ mg cohort,C0009247;C0024671;C0026410;C0439269;C0599755;C1960952;C2346927;C4321396;C4521761
5181,cohort $nmbr$ ( n = $nmbr$ ) f,C0009247;C0016327;C0599755
5181,cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755
5180,secondary - prevention cohort,C0009247;C0599755;C0679699
5180,primary - prevention cohort,C0009247;C0033144;C0599755
5179,whole cohort,C0009247;C0444667;C0599755
5179,entire evaluable cohort,C0009247;C0439751;C0444667;C0599755;C1516986
5179,entire cohort gender,C0009247;C0079399;C0439751;C0444667;C0599755;C1522384
5179,entire cohort,C0009247;C0439751;C0444667;C0599755
5179,* p < $nmbr$ . $nmbr$ for between - treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean ± standard error simva = simvastatin  eze = ezetimibe  chd = coronary heart disease,C0009247;C0012634;C0018787;C0074554;C0280604;C0369773;C0439751;C0444504;C0444667;C0599755;C1142985;C1511726;C1710181;C2347634;C2348143;C2603361;C3245479;C3542407;C3714741
5178,elevated biomarkers and st - segment changes,C0005516;C0205250;C3163633
5177,elevated cardiac markers — no . ( % ) : t,C0205250;C1271630;C3163633
5177,elevated cardiac markers,C0205250;C1271630;C3163633
5176,elevated tg,C0205250;C0337445;C3163633
5176,elevated fasting glucose,C0205250;C3163633
5175,elevated hscrp > $nmbr$ mg / l  n ( % ),C0205250;C0439268;C3163633
5175,elevated hscrp,C0205250;C3163633
5174,elevated vs normalb,C0205250;C3163633
5174,elevated vs . normalc,C0205250;C3163633
5174,elevated vs . normalb,C0205250;C3163633
5174,elevated at wk $nmbr$ — no . ( % ) $nmbr$,C0205250;C0332174;C0439230;C3163633
5174,elevated at wk $nmbr$ — no . ( % ) !,C0205250;C0332174;C0439230;C3163633
5173,total aim ‐ high study,C0205250;C0439175;C0439810;C0557651;C1299351;C1947946;C2603343;C2700149;C2744535;C2948600;C3540471;C3540472;C3887512;C3889660;C3890193;C4321237;C4522209
5173,high vs . normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5173,high vs . normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5173,high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5173,high on - treatment platelet reactivity *,C0005821;C0039798;C0087111;C0205250;C0443286;C1299351;C1522326;C1533734;C1705169;C2700149;C3538994;C3887512;C3887704;C3889660;C4321237;C4522209
5173,high crp or esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
5173,high crp and esr,C0205250;C1299351;C2700149;C3887512;C3889660;C3890735;C4048285;C4321237;C4522209
5173,high *,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5172,fgf - $nmbr$ high / egfr > $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
5172,fgf - $nmbr$ high / egfr < $nmbr$,C0016026;C0205250;C0919505;C1299351;C1739039;C2700149;C3811844;C3812682;C3887512;C3889660;C4321237;C4522209
5172,fgf - $nmbr$ high / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
5172,fgf - $nmbr$ high / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0919505;C1299351;C2700149;C3163633;C3887512;C3889660;C4321237;C4522209
5171,ige high ( > $nmbr$ ku / l  n = $nmbr$  $nmbr$ ),C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high tt > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1452561;C2700149;C3887512;C3889660;C4321237;C4522209;C4554543
5171,high trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high subgroup,C0205250;C1079230;C1299351;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high periostin subgroup ( > $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205250;C0219433;C0439275;C1079230;C1299351;C1424662;C1515021;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
5171,high normal ( n = $nmbr$ ),C0205250;C0205307;C0231683;C0439166;C1299351;C2347086;C2700149;C3887512;C3889660;C4321237;C4522209;C4553972
5171,high nfs nfs > $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205250;C1299351;C1513839;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high - dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
5171,high - dosage ics plus laba with baseline blood eosinophils > $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
5171,high - dosage ics plus laba with baseline blood eosinophils < $nmbr$ cells per pl ( n = $nmbr$ ),C0178602;C0205250;C0815320;C1299351;C2700149;C2986497;C3887512;C3889660;C4321237;C4522209;C4551720
5171,high ( n = $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( >   uln and   ≤   $nmbr$ xuln ) ( n   =   $nmbr$ ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > uln ),C0205250;C1299351;C1519815;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205250;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ . $nmbr$ u / ml ),C0205250;C0439340;C1299351;C1880521;C2700149;C2945590;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ )  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ % ) baseline hbalc,C0168634;C0205250;C1299351;C1442488;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( > $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( $nmbr$ - $nmbr$ ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high ( $nmbr$ % ),C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high  %,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
5171,hazard ratio with high ( $nmbr$ % cl ),C0205250;C0596019;C1299351;C2700149;C2985465;C3887512;C3889660;C4321237;C4522209
5170,persistent or permanent immobilization,C0205322;C0332996
5170,persistent or paroxysmal,C0205322;C0332996
5170,persistent *,C0205322;C0332996
5170,long - standing persistent,C0205166;C0205322;C0231472;C0332996;C1706317
5169,persistent wrf ( n = $nmbr$ ),C0205322;C0332996
5169,persistent faol ( n [ $nmbr$ ),C0205322;C0332996
5169,persistent faod ( n [ $nmbr$ ),C0205322;C0332996
5169,persistent / permanent,C0205322;C0205355;C0332996
5169,persistent ( n  % ),C0205322;C0332996
5169,persistent  n ( % ),C0205322;C0332996
5169,persistent,C0205322;C0332996
5169,no persistent wrf ( n = $nmbr$  $nmbr$ ),C0205322;C0332996
5168,periostin low,C0219433;C1424662;C3812270
5168,periostin,C0219433;C1424662;C3812270
5168,median serum periostin ( ng / ml ) t,C0219433;C0229671;C0439275;C0549183;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
5168,median serum periostin  ng / mla,C0017887;C0028074;C0219433;C0229671;C0549183;C0599973;C0876920;C1424662;C1546774;C1550100;C2347635;C2348144;C2939193;C3812270
5167,periostin high,C0219433;C1424662;C3812270
5167,periostin ( ng / ml ),C0219433;C0439275;C1424662;C3812270
5167,mean ( sd ) periostin  ng / ml,C0219433;C0439275;C0444504;C1424662;C2347634;C2348143;C2699239;C3812270
5167,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
5166,sertraline,C0074393;C0524265
5165,penetrating no . of resections  n ( % ),C0205321
5165,penetrating disease  %,C0012634;C0205321
5165,penetrating,C0205321
5164,permanent users  n,C0205355;C1706077
5164,permanent users,C0205355;C1706077
5164,permanent ( n  % ),C0205355
5164,permanent  n ( % ),C0205355
5164,permanent,C0205355
5163,symptomatic hypotension,C0020649;C0231220;C3163620
5163,hypotension  n ( % ),C0020649;C3163620
5163,hypotension,C0020649;C3163620
5163,elevated symptomatic serum creatinine  hypotension > $nmbr$ . $nmbr$ mg / dl,C0020649;C0231220;C0439269;C0700225;C3163620
5162,patients with radiographic erosion  n / n ( % ),C0030705;C0333307;C0444708;C1880549;C1959609;C3887524
5162,erosion score ( $nmbr$ - $nmbr$ ),C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
5162,erosion score  median ( min  max ),C0333307;C0449820;C0549183;C0702093;C0876920;C1524029;C1880549;C1959609;C2347635;C2348144;C2939193;C3813700;C3887524;C4050231
5162,erosion score  mean ± sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
5162,erosion score  mean $nmbr$ sd,C0333307;C0444504;C0449820;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524;C4050231
5162,erosion score,C0333307;C0449820;C1880549;C1959609;C3887524;C4050231
5162,erosion,C0333307;C1880549;C1959609;C3887524
5162,> $nmbr$ erosion  n ( % ),C0333307;C1880549;C1959609;C3887524
5161,antidepressant,C0003289
5160,st depression ( without st elevation ),C0011570;C0011581;C0344315;C0439775;C0460137;C0520886;C0520887;C0702240;C4049644;C4084909;C4085311;C4553827
5160,no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
5160,depression ®,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
5160,depression ^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
5160,depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
5159,depressed only,C0344315;C0549249
5159,depressed and low perceived social support,C0344315;C0549249
5158,number of antihypertensive medications at study entry,C0003364;C1718138
5158,mean number of antihypertensive medications at $nmbr$ year   *,C0003364;C0444504;C1718138;C2347634;C2348143
5158,any antihypertensive drug,C0003364
5158,any antihypertensive agent,C0003364
5158,antihypertensives ' *,C0003364
5158,antihypertensive agents *,C0003364
5157,mean number of antihypertensive medication at last visit   ‡,C0003364;C0237753;C0444504;C0449788;C2347634;C2348143
5157,antihypertensive medication,C0003364
5156,other anti - hypertensives,C0003364
5156,other anti - hypertensive,C0003364
5156,on antihypertensive medication at baseline  n ( % ) ‡,C0003364;C0168634;C1442488
5156,baseline anti - hypertensive usea,C0003364;C0168634;C1442488
5156,any anti - hypertensive agent,C0003364
5156,anti - hypertensives,C0003364
5156,anti - hypertensive,C0003364
5156,$nmbr$ antihypertensive medication,C0003364
5155,use of antihypertensive drugs,C0003364;C1524063
5155,other blood pressure - lowering drugs,C0003364
5155,other blood - pressure drug,C0003364
5155,any blood - pressure - lowering drug 一 no . ( % ),C0003364
5155,antihypertensive drugs,C0003364
5154,type of antihypertensive medication use among patients using antihypertensive medications  n ( % ),C0003364;C0332307;C1524063;C1547052
5154,antihypertensives  n ( % ),C0003364
5154,antihypertensives,C0003364
5153,other antihypertensive medications,C0003364
5153,other antihypertensive drug,C0003364
5153,other antihypertensive agents,C0003364
5153,other antihypertensive,C0003364
5153,antihypertensive  antianginal  and other cardiovascular medications,C0003364;C1874267;C3537168
5152,prior antihypertensive medication  n ( % ),C0003364;C0332152;C2826257
5152,antihypertensive medication $nmbr$ ',C0003364
5152,antihypertensive,C0003364
5152,> $nmbr$ antihypertensive medications,C0003364
5152,> $nmbr$ antihypertensive medication  no . ( % ),C0003364
5151,no antihypertensive medication,C0003364
5151,antihypertensive randomization  no . ( % ) a,C0003364;C0034656
5151,antihypertensive medication  open - label  no . ( % ),C0003364
5150,antihypertensive medication use  n ( % ),C0003364;C0042153;C0457083;C1947944
5150,antihypertensive medication ),C0003364
5149,received antihypertensive within last $nmbr$ days  n ( % ),C0003364;C0439228;C1514756
5149,antihypertensive drug  %,C0003364
5148,patients on antihypertensive medications  n ( % ) | |,C0003364;C0030705
5148,antihypertensive agents ( n per patient ),C0003364;C0030705
5148,antihypertensive agents  n ( % ),C0003364
5148,antihypertensive agents,C0003364
5147,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease  abdom - inal aortic aneurysm  symptomatic carotid artery disease  transient isch - emic attack  and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg  on antihypertensive medication  or diagnosis of hypertension based on medical history . n number of randomly assigned patients  ncep atp national cholesterol education program adult treatment panel .,C0001675;C0001779;C0001792;C0003364;C0003850;C0004153;C0005823;C0007273;C0008377;C0011198;C0017480;C0019664;C0019665;C0020538;C0030688;C0040704;C0042295;C0080103;C0151526;C0205252;C0205345;C0205374;C0262512;C0262926;C0277793;C0280604;C0439234;C0439475;C0441833;C0441889;C0449286;C0542560;C0679841;C1261512;C1271104;C1272641;C1304680;C1425219;C1516050;C1518340;C1547039;C1552601;C1705255;C1706365;C1706450;C1963138;C1999167;C1999270;C2004062;C2348088;C2744579;C3245503;C3541240;C3542407;C4018905;C4552600
5147,antihypertensive medication or,C0003364
5146,ras agents,C0034678;C0450442;C0525678;C1254351;C1521826
5146,oral diabetic agent,C0241863;C0442027;C0450442;C1254351;C1521826;C4521986
5146,oral agents use,C0442027;C0450442;C1254351;C1521826;C4521986
5146,oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
5146,oral agent and / or insulin therapy,C0442027;C0450442;C1254351;C1521826;C4521986
5146,oral agent,C0442027;C0450442;C1254351;C1521826;C4521986
5146,> $nmbr$ oral agents,C0442027;C0450442;C1254351;C1521826;C4521986
5145,number of agents,C0237753;C0449788;C0450442;C1254351;C1521826
5145,no . of agents,C0450442;C1254351;C1521826
5144,conventional agents *,C0439858;C0450442;C1254351;C1521826
5143,other blood glucose - lowering agents,C0005802;C0441994;C0450442;C1254351;C1521826;C2003888
5143,any bp - lowering agents ^,C0037623;C0441994;C0450442;C1254351;C1415692;C1521826;C1708288;C2003888;C4318478
5143,antialdosterone agents,C0450442;C1254351;C1521826
5142,anyantianginal agent,C0450442;C1254351;C1521826
5142,anti - tnf agent ( s ),C0221141;C0313162;C0450442;C1254351;C1448177;C1521826
5141,use of anti - hypertensive agents  n ( % ) *,C0432633;C0450442;C0857121;C1254351;C1521826;C1524063
5141,anti ‐ platelet agents  n ( % ),C0005821;C0432633;C0450442;C1254351;C1521826
5140,diuretic agents ( excluding antialdosterone ),C0012798;C0450442;C1254351;C1521826
5140,diuretic agents,C0012798;C0450442;C1254351;C1521826
5140,diuretic agent,C0012798;C0450442;C1254351;C1521826
5139,treatment throughout study,C1521826;C3161471
5139,study treatment — no . / total no . ( % ),C1521826
5139,study treatment,C1521826
5139,previous treatment in the healing study  n ( % ),C0043240;C0205156;C0205249;C1521826;C1552607;C3161471
5138,unacceptable side effects,C0001688;C0877248;C0879626;C1883420
5137,gall bladder adverse event ( n = $nmbr$ ),C0016976;C0877248
5136,any early adverse event,C0877248;C1279919
5135,any adverse event leading to study drug discontinuation  n ( % ),C0877248
5135,any adverse event ( ae ),C0877248;C3887670
5135,adverse event,C0877248
5134,unacceptable adverse events,C0877248;C1705413;C1883420
5134,adverse events leading to premature treatment discontinuation,C0877248;C1705413
5134,adverse events ( any grade ),C0877248;C1705413
5133,juvenile myoclonic epilepsy,C0270853
5132,epilepsy with grand mal seizures on awakening,C0014549;C0494475
5131,evening mealb,C0587117
5131,evening,C0587117
5130,venous,C0042449;C0348013
5130,history of venous,C0019664;C0019665;C0042449;C0262512;C0262926;C0348013;C1705255;C2004062
5130,history of recurrent venous thromboembolism,C0042449;C0348013;C0455533;C1455761;C2945760
5129,total number of events / participants,C0439175;C0439810;C0679646;C4330837
5129,numbers of events ( % ) :,C4330837
5129,number of events ( annualised rate [ % ] ),C4330837
5129,number of events  event per $nmbr$ person - years,C4330837
5129,number of events,C4330837
5128,mestizos,C0682082
5127,in - stent restenosis of des,C0011702;C3272317;C4551552
5127,in - stent restenosis,C3272317
5126,venous insufficiency,C0042485
5125,jugular venous distention > $nmbr$ cm,C0425687
5125,jugular venous distension  n ( % ),C0425687
5124,vein bypass stented,C0042449;C0741847
5123,vein bypass graft stented,C0398147
5122,saphenous vein graft,C0729538
5122,saphenous - vein graft,C0729538
5121,without stent,C0038257
5121,with stent ^ l,C0038257
5121,with stent,C0038257
5121,with any stent,C0038257
5121,prior stent,C0038257;C0332152;C2826257
5120,stent group ( n = $nmbr$ ),C0038257;C0441848
5120,stent ( n = $nmbr$ ),C0038257
5119,other stent,C0038257
5119,number stent > $nmbr$,C0038257;C0237753;C0449788
5119,number of stents implanted,C0038257;C0237753;C0449788
5119,number of stents ( per patient ),C0038257;C0237753;C0449788
5119,number of stents,C0038257;C0237753;C0449788
5119,number of stent = l or $nmbr$ or $nmbr$,C0038257;C0237753;C0449788
5119,number of stent = $nmbr$,C0038257;C0237753;C0449788
5119,no . of stents,C0038257
5118,minimum stent diameter,C0038257;C4054490
5117,total stent length - mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
5117,total stent length ( mm )  mean ± sd,C0038257;C0439175;C0439810;C0444504;C1444754;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
5117,total stent length  mm,C0038257;C0439175;C0439810;C1444754;C1706316;C4330985;C4554674
5117,total stent length,C0038257;C0439175;C0439810;C1444754;C1706316
5117,stent,C0038257
5116,multivessel stenting,C0038257;C2348535
5116,direct stenting per lesion ‡,C0038257;C0221198;C0439851;C1546698;C1947931;C2348535
5115,lvh by ecg or echocardiographyd,C0232306
5115,lvh by ecg or echocardiography  no ( % ),C0232306
5115,lvh by ecg or echo . n ( % ),C0232306
5115,lvh by ecg ( minnesota code ),C0009219;C0026183;C0232306;C0805701;C3889831
5115,lvh by ecg,C0232306
5115,lv hypertrophy per ecg,C0232306
5114,lvh on ecg,C0232306
5114,ecg - lvh ( sokolow - lyon ),C0232306
5114,ecg - lvh ( cornell ),C0232306
5114,baseline ecg with lvh  n ( % ),C0168634;C0232306;C1442488
5113,lvh by echo or ecg,C0058928;C0149721;C1655045
5113,lvh by ecg / echo,C0058928;C0232306;C1655045
5112,lvh by echocardiography,C0013516;C0149721
5112,lvh by echocardiogram,C0013516;C0149721;C2243117
5112,lvh ( from echocardiogram ),C0013516;C0149721;C2243117
5112,lv hypertrophy  n ( % ),C0149721
5111,lvh by minnesota code  no . ( % ),C0009219;C0026183;C0149721;C0805701;C3889831
5111,lvh by minnesota code,C0009219;C0026183;C0149721;C0805701;C3889831
5110,lvh by ecgt blood pressure  mm hg,C0005823;C0149721;C0439475;C1271104;C1272641
5110,lvh - n = $nmbr$,C0149721
5110,lvh + n = $nmbr$,C0149721
5110,lvh,C0149721
5109,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ a,C0428772;C0488728
5109,lvef ≤ $nmbr$ %  n   =   $nmbr$   $nmbr$ ) a,C0428772;C0488728
5109,lvef — no . ( % )  i,C0428772;C0488728
5109,lvef within $nmbr$ months  %,C0428772;C0439231;C0488728
5109,lvef within $nmbr$ mo  %,C0026544;C0332177;C0428772;C0488728
5109,lvef > $nmbr$ %,C0428772;C0488728
5109,lvef < $nmbr$ %  n = $nmbr$ $nmbr$ ) “,C0428772;C0488728
5109,lvef < $nmbr$ %,C0428772;C0488728
5109,lvef  %,C0428772;C0488728
5108,left ventricular ejection fraction — no . / total no . ( % ),C0428772;C0488728
5108,left ventricular ejection fraction — % §,C0428772;C0488728
5108,left ventricular ejection fraction — %,C0428772;C0488728
5108,left ventricular ejection fraction within previous $nmbr$ mo — no . / total no . ( % ) $nmbr$,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
5107,left ventricular ejection fraction < $nmbr$ %,C0428772;C0488728
5107,left ventricular ejection fraction  % af history,C0019664;C0019665;C0262512;C0262926;C0344434;C0428772;C0488728;C1705255;C2004062;C4049859
5107,left ventricular ejection fraction  % *,C0428772;C0488728
5107,left ventricular ejection fraction  %,C0428772;C0488728
5107,left ventricular ejection fraction,C0428772;C0488728
5106,lvef ^ $nmbr$ . $nmbr$ and nyha class ii  iii at baseline,C0428772;C0488728
5106,lvef < $nmbr$ . $nmbr$,C0428772;C0488728
5106,baseline lvef  %,C0168634;C0428772;C0488728;C1442488
5106,baseline lvef,C0168634;C0428772;C0488728;C1442488
5105,lvef ( u ),C0428772;C0439148;C0488728
5104,lvef ( % ),C0428772;C0488728
5104,lvef  %  median ( iqr ),C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
5104,left ventricular ejection fraction ( % ),C0428772;C0488728
5104,left ventricular ejection fraction  median ( iqr )  %,C0428772;C0488728;C0549183;C0876920;C2347635;C2348144;C2939193
5103,mean lvef,C0428772;C0444504;C0488728;C2347634;C2348143
5103,lvef ( mean ± sd ),C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
5103,lvef ( % )  mean ± sd,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
5103,lvef,C0428772;C0488728
5102,nontraumatic leg or foot amputation,C0023216;C1140621
5101,lower limbs,C0023216
5101,lower limb fractures,C0023216
5101,lower limb fracture,C0016658;C0023216;C0441994;C0596838;C1548802;C2003888
5101,lower - limb arterial — no . ( % ),C0023216
5100,low molecular weight ( lmw ) heparin before randomisation,C0019139;C0034656;C3536766
5099,lmwh within $nmbr$ days before randomization — no . / total no . ( % ),C0019139;C0439228;C3536766
5099,lmwh,C0019139;C3536766
5098,low molecular weight heparin,C0019139;C3536766
5098,low - molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766
5098,low - molecular - weight heparin — no . ( % ),C0019139;C3536766
5098,low - molecular - weight heparin only,C0019139;C0205171;C1720467;C3536766
5098,low - molecular - weight heparin,C0019139;C3536766
5097,total intravenous loop diuretics  mg,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C1960952;C2346927;C4321396;C4521761
5097,loop diuretics,C0354100
5097,intravenous loop diuretics !,C0348016;C0354100
5096,total intravenous loop diuretic ( mg ) median,C0024671;C0026410;C0348016;C0354100;C0439175;C0439269;C0439810;C0549183;C0876920;C1960952;C2346927;C2347635;C2348144;C2939193;C3536704;C4321396;C4521761
5096,loop diuretic,C0354100;C3536704
5095,loop diuretic use,C0042153;C0354100;C0457083;C1947944;C3536704
5094,use of loop diuretics  n ( % ),C0354100;C1524063
5094,use of loop diuretics,C0354100;C1524063
5093,loop or thiazide diuretic ^,C0445022
5093,loop or thiazide diuretic : ! :,C0445022
5093,loop or thiazide diuretic #,C0445022
5093,loop or thiazide diuretic,C0445022
5093,loop diureties,C0445022
5093,loop at enrollment,C0445022;C1516879;C1696073;C3888021
5093,loop,C0445022
5092,lowest activated clotting,C0005778;C1328723;C1708760;C1879547
5091,with lowest hba $nmbr$ cd,C0007928;C0019016;C0034283;C1708760;C1825777;C3538758;C4552032
5091,with lowest bwb,C1708760
5090,lowest normal ( n = $nmbr$ ),C0205307;C0231683;C0439166;C1708760;C2347086;C4553972
5090,lowest,C1708760
5089,use of concomitant lipid - lowering treatment,C0023779;C0039798;C0087111;C0441994;C0521115;C1522326;C1524063;C1533734;C1705169;C2003888;C3538994;C3887704
5089,type of lipid - lowering regimen,C0023779;C0040808;C0332307;C0441994;C1547052;C2003888;C2945654
5089,lipid lowering medication use,C0023779;C0240320;C0441994;C2003888
5089,lipid lowering,C0023779;C0441994;C2003888
5089,lipid - lowering,C0023779;C0441994;C2003888
5088,other glucose - lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
5088,no . of background glucose - lowering therapies  no . ( % ),C0017725;C0087111;C0441994;C1706907;C2003888
5088,glucose - lowering therapy - no . ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
5088,glucose - lowering therapy  n ( % ),C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
5088,glucose - lowering therapy,C0017725;C0039798;C0087111;C0441994;C1363945;C2003888
5088,glucose - lowering therapies — no . { % ),C0017725;C0087111;C0441994;C2003888
5088,glucose - lowering therapies,C0017725;C0087111;C0441994;C2003888
5088,glucose - lowering medications,C0013227;C0017725;C0441994;C0802604;C2003888;C2598133;C4284232
5088,glucose - lowering medication,C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
5088,glucose - lowering drug,C0013227;C0017725;C0441994;C1254351;C2003888
5088,> $nmbr$ glucose - lowering medication . no . ( % ),C0013227;C0017725;C0441994;C2003888;C3244316;C4284232
5087,lower tertile : b $nmbr$ . $nmbr$,C0441994;C1548802;C2003888
5087,lower dose edoxaban regimen,C0441994;C1548802;C2003888;C2348331;C2975435
5086,lower than normal range — % ^,C0086715;C0441994;C1548802;C2003888
5086,lower,C0441994;C1548802;C2003888
5085,lipc,C1416867
5084,lipid disorder,C0154251
5083,background lipid - lowering therapy,C0585943;C1706907
5082,use of concomitant lipid - lowering therapy - no . ( % ),C0521115;C0585943;C1524063
5082,lipid ‐ lowering therapies  n ( % ),C0585943
5082,lipid lowering therapy,C0585943
5082,lipid - lowering therapy — no . ( % ),C0585943
5082,lipid - lowering therapy - no . ( % ),C0585943
5082,lipid - lowering therapy,C0585943
5082,concomitant lipid - lowering therapy ( any ),C0521115;C0585943
5082,concomitant lipid - lowering therapy  n ( % ),C0521115;C0585943
5081,prior lipid - lowering agent use,C0042153;C0086440;C0332152;C0457083;C1947944;C2826257
5081,other lipid lowering drugs,C0086440
5081,lipid lowering drugs,C0086440
5081,lipid lowering agent n ( % ),C0086440
5081,lipid - lowering drugs  n ( % ),C0086440
5081,lipid - lowering drugs,C0086440
5081,lipid - lowering drug * *,C0086440
5081,lipid - lowering drug,C0086440
5081,lipid - lowering agents ( % ),C0086440
5081,lipid - lowering agents,C0086440
5081,lipid - lowering agent §,C0086440
5081,lipid - lowering agent,C0086440
5081,any lipid - lowering agent use,C0042153;C0086440;C0457083;C1947944
5081,any lipid - lowering agent,C0086440
5080,without lipid - lowering agents,C0086440
5080,with lipid - lowering agents,C0086440
5080,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440;C0581603
5080,lipid lowering agents,C0086440
5079,mean lipid difference ( mg / dl ) hdl - c,C0023779;C0439269;C0444504;C1705241;C1705242;C2347634;C2348143;C3715113
5079,lipids — mg / dl,C0023779;C0439269
5079,lipid measures at baseline — mg / dl,C0023779
5079,lipid difference ( mg / dl ),C0023779;C0439269;C1705241;C1705242
5078,lipid profile,C0023779;C1979963;C2003903
5078,lipid,C0023779
5078,dbp $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C0536221;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239;C3813197;C4281799
5078,baseline lipid profile  mg / dl  mean ( sd ),C0023779;C0168634;C0439269;C0444504;C1442488;C1979963;C2003903;C2347634;C2348143;C2699239
5077,lipid concentrations total cholesterol ( mmol / l ),C0023779;C0086045;C0201950;C0543421;C1532563
5077,lipid concentrations,C0023779;C0086045
5076,mean lipid values  mg / dl,C0023779;C0042295;C0439269;C0444504;C2347634;C2348143
5076,lipid values  mmol / l,C0023779;C0042295;C1532563
5076,lipid values,C0023779;C0042295
5075,other lipid parameters,C0023779;C0449381
5075,lipid parameters  mg / dl  mean ( sd ),C0023779;C0439269;C0444504;C0449381;C2347634;C2348143;C2699239
5075,lipid parameters,C0023779;C0449381
5074,lipids  mean ( sd )  mg / dlt,C0023779;C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
5074,lipids  mean ( sd )  mg / dlf,C0023779;C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
5074,lipids,C0023779
5074,lipid values  mean ( sd ),C0023779;C0042295;C0444504;C2347634;C2348143;C2699239
5073,lipid and lipoprotein values ( mg / dl ),C0023779
5073,baseline lipids  mg / dl,C0023779;C0168634;C0439269;C1442488
5073,baseline lipids,C0023779;C0168634;C1442488
5073,baseline lipid parameters  mg / dl  mmol / l or g / l,C0023779;C0168634;C0439269;C0449381;C1442488;C1532563
5073,baseline lipid and lipoprotein values,C0023779;C0168634;C1442488
5073,baseline lipid / lipoprotem values,C0023779;C0042295;C0168634;C1442488
5072,receptor blockers  n ( % ) baseline lipid and apolipoprotein levels,C0023779;C0168634;C0597357;C1442488
5072,baseline lipid and apolipoprotein levels,C0023779;C0168634;C1442488
5071,lipid modifiers,C0023779;C4284280
5070,prior lipid - modifying therapy,C0023779;C0392747;C1514463
5069,other lipid - modifying drug 一 no . ( % ),C0013227;C0023779;C0392747;C1254351
5069,lipid - lowerinq druq,C0023779
5068,waist - to - hip  male,C0019552;C0022122;C0086582;C0230097;C1505163;C1706180;C1706428;C1706429;C3538851;C4284725
5068,waist - to - hip  female,C0019552;C0022122;C0043210;C0086287;C0230097;C1505163;C1705497;C1705498;C3538851;C4284725
5068,total hip bmi ) t - score,C0019552;C0022122;C0578022;C1505163;C2964552;C3538851;C4284725
5068,total hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
5068,total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
5068,total hip ( n = $nmbr$  $nmbr$ ) bmd ( g / cm $nmbr$ ) ( sd ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C2699239;C3538851;C4284725
5068,total hip,C0019552;C0022122;C0439175;C0439810;C1505163;C3538851;C4284725
5068,total - hip bmd t - score,C0019552;C0022122;C1505163;C2964552;C3538851;C4284725
5068,standardized total hip bmd ( g / cm $nmbr$ ),C0019552;C0022122;C0439175;C0439267;C0439810;C1505163;C3538851;C4284725
5068,hip + $nmbr$ vertebral fractures,C0019552;C0019557;C0022122;C0080179;C0549207;C1505163;C3538851;C4284725
5068,hip  femur,C0015811;C0019552;C0022122;C1505163;C3538851;C4284725
5068,hip,C0019552;C0022122;C1505163;C3538851;C4284725
5067,hip + other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725
5067,hip + nonvertebral + vertebral,C0019552;C0022122;C0549207;C1505163;C3538851;C4284725
5066,iv inotropic drug,C1971835
5065,ipah  hpah  hiv  drug or toxin induced,C0013227;C0019682;C0019699;C0152171;C0340543;C0637939;C1150929;C1254351
5065,hiv,C0019682;C0019699
5064,pool of fh i and ii studies,C0337051;C1260386;C1509144;C2349200
5063,fh ii,C1854107
5062,class iii / iii - v,C0439070;C0457166;C1705160;C1880098
5061,iii and iv ejection fraction,C0439070;C1705160
5061,iii and iv,C0439070;C1705160
5061,iii / iv,C0022326;C0439070;C1705160;C4265176
5061,iii - iv,C0022326;C0439070;C1705160;C4265176
5061,iii & iv,C0022326;C0439070;C1705160;C4265176
5061,gold iii - iv,C0018026;C0022326;C0439070;C1304897;C1705160;C4265176
5060,nyha iii or iv § ( n = $nmbr$ $nmbr$ ),C0439070;C1275491;C1705160
5060,nyha iii or iv,C0439070;C1275491;C1705160
5060,nyha iii  n ( % ),C0439070;C1275491;C1705160
5060,iii ( n z $nmbr$ ),C0439070;C1705160
5060,iii ( $nmbr$ ),C0439070;C1705160
5060,heart failure ( nyha ii ‐ iii )  n ( % ),C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
5059,who functional class ii / iii,C0205245;C0439070;C0441886;C0441887;C0542341;C1705160;C1710602;C2698968;C2698969;C2700217;C4082587
5059,killip class ii  iii  or iv — %,C0439070;C1705160;C1710602;C2697845;C2697846;C4082587
5059,iii or iv,C0439070;C1705160
5059,ii / iii,C0439070;C1705160;C1710602;C4082587
5058,who fc iii symptoms at baseline,C0168634;C0439070;C0683368;C1442488;C1457887;C1705160;C2983605
5058,iii,C0439070;C1705160
5057,belgium,C0004950
5056,dihydropyridine calcium - channel blocker,C2945601
5055,calcium channel,C0006685
5055,calcium - channel inhibitor,C0006685;C1999216
5055,calcium - channel blockersubgroup,C0006685
5055,calcium - channel blockerf,C0006685
5054,taking calcium supplements at baseline  n ( % ),C0006675;C0006726;C1515187;C2936886;C3540037;C3714611
5054,dense calcium  mm ’,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611;C4330985;C4554674
5054,dense calcium,C0006675;C0006726;C0439794;C2936886;C3540037;C3714611
5054,calcium supplements,C0006675;C0006726;C2936886;C3540037;C3714611
5054,calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
5054,calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
5054,calcium ( mmol / l ),C0006675;C0006726;C1532563;C2936886;C3540037;C3714611
5054,calcium  mmol $nmbr$ $nmbr$,C0006675;C0006726;C0439190;C2936886;C3540037;C3714611
5053,potassium — mmol / liter,C0032821;C0202194;C0304475;C0439190;C0475211;C0597277;C3714637
5053,potassium — mg / dl,C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
5053,potassium supplement,C0304475
5053,potassium at admission  mmol / l - $nmbr$,C0032821;C0184666;C0202194;C0304475;C0597277;C0809949;C1532563;C3714637
5053,potassium - sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C1516879;C1696073;C3714637;C3888021
5053,potassium ( mmol / l ),C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
5053,potassium ( mg / dl ),C0032821;C0202194;C0304475;C0439269;C0597277;C3714637
5053,potassium ( meql )  mean + sd  available for $nmbr$ patients,C0032821;C0202194;C0304475;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
5053,potassium ( meq / l ),C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
5053,potassium  mmol / l,C0032821;C0202194;C0304475;C0597277;C1532563;C3714637
5053,potassium  meq / l,C0032821;C0202194;C0304475;C0439375;C0597277;C3714637
5053,potassium  meq / dl  mean,C0032821;C0202194;C0304475;C0444504;C0597277;C1532568;C2347634;C2348143;C3714637
5053,potassium  mean ( sd )  meq / l,C0032821;C0202194;C0304475;C0439375;C0444504;C0597277;C2347634;C2348143;C2699239;C3714637
5053,potassium,C0032821;C0202194;C0304475;C0597277;C3714637
5053,hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l ),C0020621;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4553966
5053,hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l ),C0020461;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637;C4552983
5052,minimum — maxim um,C0024968;C1524031;C1552614;C2826545
5051,minimum — maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
5051,minimum : maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
5051,minimum / maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
5051,minimum - maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
5051,minimum  maximum,C0806909;C1524031;C1552614;C1552615;C2826545;C2826546
5051,minimum,C1524031;C1552614;C2826545
5051,hscrp ( mg / l )  median ( minimum ‒ maximum ),C0439268;C0549183;C0806909;C0876920;C1524031;C1552614;C1552615;C2347635;C2348144;C2826545;C2826546;C2939193
5051,( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline,C0168634;C0439228;C0751495;C0806909;C1414819;C1442488;C1524031;C1552614;C1552615;C2826545;C2826546
5050,mean of maximum cimt  mean ( sd )  mm,C0444504;C0806909;C1552615;C2347634;C2348143;C2699239;C2826546;C4330985;C4554674
5050,maximum cimt a med an,C0806909;C1552615;C2826546
5050,maximum,C0806909;C1552615;C2826546
5050,average of maximum far wall cimt ( mm ),C0205108;C0677535;C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
5050,average of maximum common carotid cimt ( mm ),C0205214;C0741968;C0806909;C1510992;C1522138;C1552615;C2825518;C2826546;C3245511;C4330985;C4554674
5050,average maximum common and bifurcation cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546
5050,average maximum cimt ( mm ),C0806909;C1510992;C1552615;C2825518;C2826546;C4330985;C4554674
5049,statin potency medium ( n = $nmbr$ ),C0009458;C0360714;C0439536;C1705217;C3244283;C3245505;C4085196;C4522282;C4522283
5049,small / medium,C0009458;C0439536;C0700321;C1705217;C3244283;C4085196;C4522282;C4522283
5049,medium normal ( n = $nmbr$ ),C0009458;C0205307;C0231683;C0439166;C0439536;C1705217;C2347086;C3244283;C4085196;C4522282;C4522283;C4553972
5049,medium - or low - intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
5049,medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
5049,low to medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
5048,pci for index mi ( % ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814;C4049621
5048,mi — no . ( % ),C3810814
5047,nonfatal mi ( n = $nmbr$ ),C3810814
5047,no history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
5047,mi  n ( % ),C3810814
5047,history of mi ( n = $nmbr$  $nmbr$ ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
5047,history of mi  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
5046,prior mi diagnosis :,C0332132;C3810814
5045,with prior mi / stroke ( n = $nmbr$ ),C0038454;C0332152;C2826257;C3810814;C4554100
5045,prior stroke / mi  n ( % ),C0038454;C0332152;C2826257;C3810814;C4554100
5045,prior mi within $nmbr$ y  no . ( % ),C0332152;C2826257;C3810814
5045,prior mi n = $nmbr$,C0332152;C2826257;C3810814
5045,prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
5045,prior mi ( n - $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
5045,prior mi  n / n ( % ),C0332152;C2826257;C3810814
5045,prior mi  %,C0332152;C2826257;C3810814
5045,no prior mi n = $nmbr$,C0332152;C2826257;C3810814
5045,no prior mi ( n = $nmbr$  $nmbr$ ),C0332152;C2826257;C3810814
5045,no prior mi,C0332152;C2826257;C3810814
5045,no mi ( n - $nmbr$  $nmbr$ ),C3810814
5045,no mi,C3810814
5045,mi,C3810814
5044,second prior mi,C0205436;C0332152;C0457385;C0565930;C1561503;C1705190;C2826257;C3810814
5044,prior mi,C0332152;C2826257;C3810814
5044,history of second prior mi  n ( % ),C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
5044,history of second prior mi,C0019664;C0019665;C0205436;C0262512;C0262926;C0332152;C0457385;C0565930;C1561503;C1705190;C1705255;C2004062;C2826257;C3810814
5043,primary ep ( cvd / mi / ri ),C0007222;C0035487;C0205225;C0439612;C0439631;C1826843;C1880476;C3810814;C4321526
5043,mi or cad,C3810814
5043,cvd without mi or stroke ( n = $nmbr$ ),C0007222;C3810814
5042,nocad / mi,C3810814
5042,no cad / mi,C1504769;C2239547;C3810814;C3813548;C4284121
5041,$nmbr$ days new mi or definite acute st,C0205314;C0439228;C3810814
5041,$nmbr$ days new mi,C0205314;C0439228;C3810814
5040,large mi,C0549177;C3810814
5040,death  large mi,C0011065;C0549177;C1306577;C3810814;C4082313;C4552775
5039,• any mi,C3810814
5039,documented mi,C1301725;C1609436;C3810814
5039,any mi ( n - $nmbr$  $nmbr$ ),C3810814
5039,any mi,C3810814
5038,mi > $nmbr$ months *,C0439231;C3810814
5038,mi < $nmbr$ months *,C0439231;C3810814
5038,mi *,C3810814
5037,type of myocardial infarction — no . ( % ),C0027051;C0332307;C0428953;C1547052;C2926063;C3810814;C4552959
5037,suspected myocardial infarction,C0027051;C0332147;C0428953;C0750491;C2926063;C3810814;C4552959
5037,previous stroke yes ( n  % ) previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C3841753;C4552959
5037,previous myocardial infarction  no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
5037,previous myocardial infarction  n ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
5037,nonfatal myocardial infarction ®,C0027051;C0428953;C2926063;C3810814;C4552959
5037,nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
5037,no previous myocardial infarction $nmbr$ / $nmbr$,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
5037,no previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
5037,no myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
5037,myocardial infarction — no . ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction §,C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction within the previous $nmbr$ yr,C0027051;C0205156;C0428953;C0439234;C1552607;C2926063;C3810814;C4552959
5037,myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction at presentation ( n = $nmbr$ ),C0027051;C0428953;C0449450;C2926063;C3810814;C4552959
5037,myocardial infarction :,C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction / cabg / pci < $nmbr$ years,C0010055;C0027051;C0428953;C0439234;C2926063;C3810814;C4049621;C4552959
5037,myocardial infarction / cabg / pci,C0010055;C0027051;C0428953;C2926063;C3810814;C4049621;C4552959
5037,myocardial infarction ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction  n ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction  ( % ),C0027051;C0428953;C2926063;C3810814;C4552959
5037,myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
5037,histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
5037,cardiovasculardeath / myocardial infarction / stroke,C0027051;C0038454;C0428953;C2926063;C3810814;C4552959;C4554100
5037,cardiovascular death / myocardial infarction / stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
5037,cardiovascular death  nonfatal myocardial infarction  nonfatal stroke,C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C4082313;C4552775;C4552959
5037,b . myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
5036,pcr after acs,C0032520;C0742343;C3853643;C4050242;C4318612
5035,days from acs to randomization,C0439228;C0742343;C4318612
5035,days between acs and rand,C0439228;C0742343;C4318612
5034,nste acs,C0742343;C4318612
5034,nste - acs,C0742343;C4318612
5034,acs type,C0332307;C0742343;C1547052;C4318612
5033,acs management  no . ( % ),C0001554;C0376636;C0742343;C1273870;C3273539;C4318612
5033,acs ( n = $nmbr$  $nmbr$ ),C0742343;C4318612
5033,acs ( n - $nmbr$  $nmbr$ ),C0742343;C4318612
5033,acs,C0742343;C4318612
5032,time between index acs and randomization — days,C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
5032,time between index acs and randomization ( days ),C0040223;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4318612
5032,no acs,C0742343;C4318612
5032,myocardial infarction before index acs — no . ( % ),C0027051;C0428953;C0600653;C0742343;C0918012;C1552854;C1637833;C2926063;C2986546;C3810814;C4318612;C4552959
5031,time from index acs event to randomisation ( days ),C0040223;C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C3541383;C4019010;C4318612
5031,labs at the index acs event,C0441471;C0587081;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
5031,at index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
5031,acs event,C0441471;C0742343;C4019010;C4318612
5030,no cs and is,C0010182;C0271160;C3540510;C4085345
5030,no cs and imm,C0010182;C0271160;C3540510;C4085345
5030,neither cs nor imm,C0010182;C0271160;C3540510;C4085345
5030,glycopyrrolate / glycopyrrolate / eflow cs $nmbr$ meg eflow cs $nmbr$ meg ( n = $nmbr$ ) ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
5030,glycopyrrolate / eflow cs $nmbr$ meg ( n = $nmbr$ ),C0010182;C0017970;C0024489;C0025175;C0072225;C0271160;C3540510;C4085345
5030,cs use : no,C0010182;C0271160;C3540510;C4085345
5030,cs only,C0010182;C0205171;C0271160;C1720467;C3540510;C4085345
5030,cs and is,C0010182;C0271160;C3540510;C4085345
5030,cs and imm,C0010182;C0271160;C3540510;C4085345
5030,cs and im,C0010182;C0271160;C3540510;C4085345
5030,cs,C0010182;C0271160;C3540510;C4085345
5029,with ics  n ( % ),C0815320;C4551720
5029,laba / ics use at screening  n ( % ),C0815320;C4551720
5029,ics users at screening,C0220908;C0220909;C0815320;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
5029,ics users at baseline  n ( % ),C0168634;C0815320;C1442488;C1706077;C4551720
5029,ics users at baseline  %,C0168634;C0815320;C1442488;C1706077;C4551720
5029,ics users  n ( % ),C0815320;C1706077;C4551720
5029,ics users,C0815320;C1706077;C4551720
5029,ics use at screeningg  n ( % ),C0815320;C4551720
5029,ics use at screening  n ( % ),C0815320;C4551720
5029,ics use at screening,C0815320;C4551720
5029,ics use,C0815320;C4551720
5029,ics nonusers  n ( % ),C0815320;C4551720
5029,ics  n ( % ),C0815320;C4551720
5028,non - ics +,C0815320;C1518422;C4551720
5028,ics non - users at screening,C0220908;C0220909;C0815320;C1518422;C1698960;C1706077;C1710031;C1710032;C1710477;C2348164;C4551720
5028,ics non - users,C0815320;C1518422;C1706077;C4551720
5027,ics use at baseline : yes,C0815320;C4551720
5027,ics : yes,C0815320;C1549445;C1705108;C1710701;C4551720
5026,no ics,C0815320;C4551720
5026,neither ics nor laba,C0815320;C4551720
5026,ics use yes,C0815320;C4551720
5026,ics use no,C0815320;C4551720
5026,ics use at baseline : no,C0815320;C4551720
5026,ics use at baseline  n ( % ),C0815320;C4551720
5026,ics use  %,C0815320;C4551720
5026,ics ? laba ( free or fdc ),C0815320;C4551720
5026,ics : no,C0815320;C4551720
5026,ics,C0815320;C4551720
5026,baseline ics use : yes,C0168634;C0815320;C1442488;C4551720
5026,baseline ics use : no,C0168634;C0815320;C1442488;C4551720
5026,baseline ics use  n ( % ),C0168634;C0815320;C1442488;C4551720
5026,baseline ics > $nmbr$ pg per day ( fluticasone propionate dpi or equivalent ) and laba,C0117996;C0168634;C0815320;C1442488;C2827928;C4551720
5025,use of ics at baseline  %,C0815320;C1524063;C4551720
5025,use of ics,C0815320;C1524063;C4551720
5025,ics use at baseline,C0815320;C4551720
5024,previous ics alone,C0205156;C0815320;C1552607;C4551720
5024,ics alone,C0815320;C4551720
5023,total ics dose at entry  / xg / d,C0017209;C0815320;C1292284;C1421532;C1705654;C2986497;C4551720
5023,ics use at enrollment  mean  mg / d,C0815320;C4551720
5023,ics  mg / day,C0439422;C0815320;C4551720
5022,laba / ics #,C0815320;C4551720
5022,ics use yes / no  %,C0815320;C4551720
5022,ics use  yes / no %,C0815320;C4551720
5022,ics use  yes / no  %,C0815320;C4551720
5022,ics usage,C0457083;C0815320;C4551720
5022,ics no laba,C0815320;C4551720
5022,ics # #,C0815320;C4551720
5022,ics  no laba  n ( % ),C0815320;C4551720
5022,calima overalldhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ),C0178602;C0815320;C2986497;C4551720
5022,calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y,C0178602;C0815320;C2986497;C4551720
5021,other ics versus no ics,C0815320;C4551720
5021,other ics,C0815320;C4551720
5021,ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0815320;C1696465;C1706408;C4551720
5021,ics  no laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0815320;C4551720
5020,without concomitant ics,C0521115;C0815320;C4551720
5020,with concomitant ics,C0521115;C0815320;C4551720
5019,laba + ics n = $nmbr$,C0815320;C4551720
5019,ics / lama,C0815320;C0999593;C1416775;C4551720
5019,- ics / + laba n z $nmbr$,C0815320;C4551720
5019,+ ics / + laba nz $nmbr$,C0027978;C0815320;C4551720
5019,+ ics / + laba n z $nmbr$,C0815320;C4551720
5018,previous ics / labd,C0205156;C0396059;C0815320;C1552607;C4551720
5018,ics / labd,C0396059;C0815320;C4551720
5017,laba   +   ics,C0815320;C4551720
5017,laba + ics ( free or fixed - dose combination ),C0815320;C4551720
5017,ics subset,C0815320;C1515021;C4551720
5017,ics / laba subset,C0815320;C1515021;C4551720
5017,ics + laba,C0815320;C4551720
5016,laba plus ics  n ( % ),C0332287;C0815320;C4551720
5016,laba + ics versus indzgly lsm difference ( $nmbr$ % cl ),C0815320;C4551720
5016,laba + ics,C0815320;C4551720
5016,ics plus laba,C0815320;C4551720
5016,ics / laba therapy  n ( % ),C0039798;C0087111;C0815320;C1363945;C4551720
5016,ics / laba,C0815320;C4551720
5015,s wave in v $nmbr$ ( mm ),C0456681;C4301968
5014,e $nmbr$ / s $nmbr$ vs s $nmbr$,C3846405
5014,e $nmbr$ / s $nmbr$ vs e $nmbr$,C3846405
5014,e $nmbr$ / s $nmbr$ ( n = $nmbr$ ),C3846405
5013,ssed as ls means,C0023668;C1704970
5012,ls / ul $nmbr$ $nmbr$,C0023668;C1300557
5011,csf lathosterol ( | jlg / cll ),C0023434;C0064673;C3540512;C3889436
5011,csf cholesterol,C0008377;C3540512;C3889436
5011,csf a ( $nmbr$ ( pm ),C3540512;C3889436
5011,csf,C3540512;C3889436
5010,density lipoprotein  csf =,C0023820;C0178587;C3540512;C3889436
5010,csf $nmbr$ s - hydroxy -,C3540512;C3889436
5009,uacr  mgg $nmbr$ ( gm ),C0017480;C3854019
5009,baseline upgr > $nmbr$ gm / gm ( $nmbr$ mg / mmole ),C0017480;C0168634;C0567349;C1442488;C2348885;C3854019
5008,hemoglobin ( gm / dl ),C0017480;C0019046;C3642216;C3854019
5008,gm,C0017480;C3854019
5007,germany,C0017480
5007,bmi : body mass index  dbp : diastolic blood pressure  gm : geometric mean  sbp : systolic blood pressure . the analysis was based on observed data without imputation on missing values . asubgroup of patients in whom $nmbr$ h urine was collected ( see materials and methods section ) .,C0017480;C0033727;C0039155;C0042036;C0042037;C0085805;C0152060;C0369286;C0428883;C0428886;C0441932;C0444504;C0488053;C0488055;C0564385;C0700320;C0871470;C1305855;C1306620;C1441672;C1511726;C1522472;C1552923;C1705191;C2347634;C2348143;C2699638;C2963137;C3245479;C3714523;C3714741;C3854019;C4528284
5007,( gm ),C0017480;C3854019
5006,de ( n = $nmbr$ ),C0011198;C0017480;C3541240
5006,de $nmbr$ n = $nmbr$,C0011198;C0017480;C3541240
5006,de,C0011198;C0017480;C3541240
5005,placebo ( dm - vs . dm + ),C0011816;C0032042;C1696465;C1706408;C3250443
5005,dm - ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
5005,dm + ( aliskiren vs . placebo ),C0011816;C1120110;C3250443
5005,aliskiren ( dm - vs . dm + ),C0011816;C1120110;C3250443
5004,oral anti - dm drug status  no . ( % ),C0011816;C0029167;C0175795;C0304289;C0449438;C3250443
5004,no dm,C0011816;C3250443
5004,concomitant oral anti - dm drugs  no . ( % ) a,C0011816;C0029167;C0175795;C0304289;C0521115;C3250443
5003,with dm,C0011816;C3250443
5003,patients with dm vs . patients without dm,C0011816;C0030705;C3250443
5003,patients with dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
5003,dm absent,C0011816;C3250443
5002,patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
5002,patients with possible new dm at randomization ( fpg > $nmbr$ - $nmbr$ ),C0011816;C0030705;C0205314;C0332149;C1705910;C2362652;C3250443
5002,new dm,C0011816;C0205314;C3250443
5001,previous dm,C0011816;C0205156;C1552607;C3250443
5001,dm or diabetic complications,C0011816;C3250443
5001,dm or ckd *,C0011816;C3250443
5000,without dm ( n = $nmbr$ i $nmbr$ * ),C0011816;C3250443
5000,previous dm  n ( % ),C0011816;C0205156;C1552607;C3250443
5000,no dm ( n = $nmbr$ ),C0011816;C3250443
5000,no dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
5000,dm ( n = $nmbr$ ),C0011816;C3250443
5000,dm ( n = $nmbr$  $nmbr$ ),C0011816;C3250443
5000,dm  n ( % ),C0011816;C3250443
4999,prior dm,C0011816;C0332152;C2826257;C3250443
4999,no prior dm,C0011816;C0332152;C2826257;C3250443
4999,dm,C0011816;C3250443
4998,without t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
4998,without dm,C0011816;C3250443
4998,with t $nmbr$ dm n = $nmbr$,C0011816;C2986835;C3250443
4997,enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C1120110;C3250443
4997,aliskiren dm = $nmbr$ non - dm = $nmbr$,C0011816;C1120110;C3250443
4996,non - insulin treated dm,C0011816;C0021641;C1518422;C1522326;C1533581;C1579433;C3250443;C3714501
4996,non - dm,C0011816;C1518422;C3250443
4995,sudden death,C0011071;C1964022;C4554103
4994,time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931
4994,time to all - cause death up to end of the study,C0007465;C0015127;C0040223;C1301931;C1524003;C3541383
4993,cause of death unknown,C0007465;C4050444
4993,by cause of death,C0007465;C4050444
4992,• death from any cause,C0007465
4992,death from cardiovascular causes,C0007226;C0007465;C3887460
4992,death from any cause,C0007465
4991,early death,C1836407
4990,sudden cardiac death §,C0085298
4989,cardiac death,C0376297
4988,temporal data and management strategy,C0442043;C1511726;C2362314;C3245479;C3714741
4987,no ef data | |,C1511726;C3245479;C3714741
4987,angiographic data and treatment :,C0002978;C1511726;C3245479;C3714741
4987,angiographic data,C0002978;C1511726;C3245479;C3714741
4986,data missing,C1511726;C3245479;C3714741
4986,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation,C0439453;C0439836;C1511726;C1719797;C2911648;C3245479;C3714741
4986,baseline data,C0168634;C1442488;C1511726;C3245479;C3714741
4986,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$  to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval  ldl low - density lipoprotein  and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition  we performed tests for interaction between treatment and the following continuous base - line variables : age  total  ldl  and hdl cholesterol  and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients  two in the placebo group and one in the pravastatin group .,C0008107;C0008377;C0019409;C0023820;C0034656;C0042295;C0231290;C0242960;C0332282;C0332287;C0441833;C0475211;C0687744;C1079230;C1257890;C1511726;C1518681;C1519504;C1705428;C1705429;C1719797;C1883712;C2911648;C3245479;C3259781;C3714741
4986,* data reported as n ( % ) or median ( quartiles $nmbr$  $nmbr$ ) .,C1511726;C3245479;C3714741
4986,* data are expressed as median ± sd  except,C1511726;C3245479;C3714741
4986,* data are expr,C1511726;C3245479;C3714741
4985,fpg data ',C1511726;C3245479;C3714741
4985,data presented as mean   ±   sd  unless otherwise specified    acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ]  gold $nmbr$ [ $nmbr$ ]    bon a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status  the mcid is a change of $nmbr$   units  on a scale of $nmbr$ – $nmbr$  with higher scores indicating more severe dyspnea  on a scale of $nmbr$ – $nmbr$  with higher scores indicating worse health status,C0205250;C0449820;C1511726;C3245479;C3714741
4985,data are mean ± standard deviation for continuous variables and number ( % ) for categoric variables . p,C1511726;C3245479;C3714741
4985,data  ' ' n,C1511726;C3245479;C3714741
4985,available data,C0470187;C1511726;C3245479;C3714741
4985,at c data,C1511726;C3245479;C3714741
4984,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871;C0521115;C2926618;C3899446
4984,concomitant dvt  n ( % ),C0149871;C0521115;C2926618;C3899446
4983,causes of dvt or pe — no . ( % ) ^ |,C0015127;C0149871;C1314792;C2926618;C3899446
4983,causes of dvt or pe  n ( % ),C0015127;C0149871;C1314792;C2926618;C3899446
4983,cause of dvt or pe — no . ( % ),C0015127;C0149871;C1524003;C2926618;C3899446
4982,treatment period index dvt : event,C0039798;C0087111;C0149871;C0439531;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1948053;C2926618;C2986546;C3538994;C3887704;C3899446;C4019010
4982,locafon of index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
4982,kheeatne index dvt,C0149871;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
4982,extent of index dvt ' ( n  % of dvt patients ' ),C0030705;C0149871;C0439792;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3899446
4982,dvt,C0149871;C2926618;C3899446
4981,acute dvt study,C0149871;C0205178;C0557651;C2603343;C2926618;C3899446
4980,without dvt dvt alone,C0149871;C2926618;C3899446
4980,secondary dvt . ' fe,C0027627;C0149871;C0175668;C0205436;C2926618;C3848561;C3899446
4980,sco . ’ ita ' rojs dvt . ' pe,C0022277;C0070939;C0149871;C1880476;C2926618;C2986561;C3899446;C4284304
4979,p value by gt,C1435727;C1704693;C1709380;C2697657
4978,gt + tt,C1435727;C1452561;C1704693;C2697657;C4554543
4978,gt,C1435727;C1704693;C2697657
4977,ct ratio > $nmbr$ . $nmbr$,C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
4977,ct ratio ( % ),C0007673;C0456603;C1547037;C3540513;C3813556;C3888140
4977,ct + tt,C0007673;C1452561;C3540513;C3813556;C3888140;C4554543
4977,ct,C0007673;C3540513;C3813556;C3888140
4976,ct or mr scan of the brain *,C0007673;C3540513;C3813556;C3888140
4976,ct findings,C0007673;C2607943;C2926606;C3539655;C3540513;C3813556;C3888140
4975,multivitamins,C0301532;C3714835
4974,multivitamin use yes,C0042153;C0301532;C0457083;C1549445;C1705108;C1710701;C1947944
4974,multivitamin use ( current ),C0042153;C0301532;C0457083;C0521116;C1705970;C1947944
4974,multivitamin use,C0042153;C0301532;C0457083;C1947944
4973,vitamin e,C0042874;C3714803
4973,i vitamin e ( n = $nmbr$ ),C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
4973,i vitamin e,C0021966;C0042874;C0042890;C0221138;C0683454;C3714803
4973,$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ ),C0042874;C3714803
4973,$nmbr$ vitamin e,C0042874;C3714803
4972,cholesterol absorption inhibitor ( ezetimibe ),C0000854;C0003277;C1142985;C1999216;C2347023;C2347080;C2698776;C2825050;C2945742
4971,statin + ezetimibe  n ( % ),C0360714;C1142985
4971,ezetimibe  n ( % ),C1142985
4970,ezetimibe $nmbr$ mg ( n — $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
4970,ezetimibe $nmbr$ mg ( n = $nmbr$ * ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
4970,ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
4970,ezetimibe,C1142985
4970,* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index  e ezetimibe $nmbr$ mg  hdl - c hdl cholesterol  ldl - c ldl cholesterol  tg triglycerides,C0005918;C0006413;C0023822;C0023824;C0024671;C0025266;C0026410;C0168634;C0202117;C0337445;C0368910;C0392885;C0439269;C1142985;C1305855;C1442160;C1442488;C1552663;C1960952;C2346927;C2360800;C2827109;C3642216;C3715113;C4321396;C4521761
4969,ezetimibe / simvastatin,C1532737
4969,ezetimibe + simvastatin ( n = $nmbr$ * ),C1532737
4969,ezetimibe + simvastatin ( n = $nmbr$  $nmbr$ * ),C1532737
4969,eze = ezetimibe $nmbr$ mg  pooled sinva = simvastatin pooled across doses  pooled eze / sinva = ezetimibe / simvastatin tablet pooled across doses  bni = body mass index  ldl - c = low - density lipoprotein cholesterol  t g = triglycerides  t c = total cholesterol  hdl - c = high - density lipoprotein cholesterol  apo — apolipoprotein  c rp — c - neactive protein  rlp - c = remnant - like particle - cholesterol .,C0003591;C0003594;C0008377;C0023821;C0023824;C0024671;C0026410;C0031529;C0033684;C0039225;C0041004;C0201950;C0439267;C0439269;C0543421;C0577559;C0577573;C0600653;C0674390;C0918012;C1096155;C1142985;C1306372;C1532737;C1538326;C1552854;C1637833;C1705223;C1960952;C2346927;C2986546;C3152252;C3539882;C3541325;C3891451;C4054077;C4283905;C4319774;C4321396;C4521761
4968,nste - mi,C3537184;C4255010
4968,non — st - segment — elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
4968,non - stemi,C3537184
4968,non - st - segment elevation myocardial infarction,C0441635;C1518422;C1536220;C1536221;C1536222;C3537184;C4255010
4968,non - st - elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
4967,qualifying nstemi  n ( % ),C1514624;C3537184;C4255010
4967,nstemi ( n = $nmbr$  $nmbr$ ),C3537184;C4255010
4967,nstemi ( % ),C3537184;C4255010
4967,nstemi,C3537184;C4255010
4966,bacterial pneumonia,C0004626
4965,pneumonia events  n,C0032285;C0441471;C3541888
4965,pneumonia,C0032285
4965,patients with pneumonia events  n ( % ) #,C0030705;C0032285;C0441471;C3541888
4964,necrosis  n ( % ) a,C0027540;C1334928
4963,necrotic core  mm ^,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653;C4330985;C4554674
4963,necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
4962,enthesitis  % §,C1282952
4962,current enthesitis  n ( % ) ’,C0521116;C1282952;C1705970
4961,presence of enthesitis  n ( % ),C0150312;C0392148;C1282952;C3854307
4961,enthesitis  n ( % ),C1282952
4960,enthesitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1282952;C1442488;C2347635;C2348144;C2939193;C4050231
4960,enthesitis score *,C0449820;C1282952;C4050231
4960,enthesitis,C1282952
4960,% improvement in enthesitis score at week $nmbr$  n,C0449820;C1282952;C2986411;C4050231
4959,hypersensitivity  n ( % ),C0020517;C0520946
4958,allergic disease by historyb  n ( % ),C0020517;C0851444
4957,sensitive responders ( n = $nmbr$ ),C0020517;C0332324;C1522640
4957,sensitive responder ( n = $nmbr$ ),C0020517;C0332324;C1522640
4957,sensitive,C0020517;C0332324;C1522640
4956,highly sensitive responders ( n = $nmbr$ ),C0439822
4956,highly sensitive responder ( n = $nmbr$ ),C0439822
4956,highly sensitive,C0439822
4955,non - extensive,C0205231;C1518422
4955,extensive  n ( % ),C0205231
4955,extensive,C0205231
4954,no extensive colitis  n,C0009319;C0205231;C1963084
4954,extensive colitisy,C0205231
4954,extensive colitis or pancolitis,C0009319;C0205231;C1963084
4954,extensive colitis  n,C0009319;C0205231;C1963084
4954,extensive colitis,C0009319;C0205231;C1963084
4953,distribution — no . { % ),C0520511;C1704711
4953,distribution — no . ( % ),C0520511;C1704711
4952,score distribution : < $nmbr$,C0449820;C0520511;C1704711;C4050231
4952,score distribution :,C0449820;C0520511;C1704711;C4050231
4951,hba $nmbr$ c distribution at baseline  n ( % ),C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
4951,hba $nmbr$ c distribution at baseline,C0019016;C0168634;C0520511;C1442488;C1704711;C1825777;C3538758
4951,hba $nmbr$ c distribution,C0019016;C0520511;C1704711;C1825777;C3538758
4951,a $nmbr$ c distribution ( % ),C0520511;C1704711
4950,remission  n ( % ),C0544452;C0687702
4950,asdas inactive disease  %,C0544452
4949,remission by : baseline steroid doses,C0038317;C0168634;C0178602;C0544452;C0687702;C1442488
4949,remission,C0544452;C0687702
4948,high blood pressure,C0020538;C2926615
4947,elevated blood pressure,C0020538;C0497247
4946,previous htn  n ( % ),C0020538;C0205156;C1552607
4946,htn,C0020538
4945,resistant htn n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
4945,resistant htn : spiro n = $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
4945,resistant htn : placebo n = $nmbr$,C0020538;C0032042;C0332325;C1514892;C1550464;C1696465;C1706408;C2827757
4945,no resistant htn n = $nmbr$  $nmbr$,C0020538;C0332325;C1514892;C1550464;C2827757
4945,no htn,C0020538
4944,treated hypertension :,C0020538;C1522326;C1963138
4944,treated for hypertension  %,C0020538;C1522326;C1963138
4944,hypertension ( % ) : t,C0020538;C1963138
4944,hypertension  treated,C0020538;C1963138
4944,hypertension  no . / total no . ( % ) medications in use at baseline  no . / total no . ( % ),C0020538;C1963138
4944,hypertension  %,C0020538;C1963138
4943,hypertension history,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C1963138;C2004062
4943,hypertension and left ventricular hypertrophy,C0020538;C1963138
4943,hypertension !,C0020538;C1963138
4942,systemic hypertension,C0020538
4942,reported hypertension *,C0020538;C0684224;C0700287;C1963138;C4319718
4942,isoiated systoiic hypertension *,C0020538;C1963138
4942,hypertension *,C0020538;C1963138
4942,arterial hypertension *,C0020538
4941,hypertension 本,C0020538;C1963138
4941,hypertension serum lipid values,C0020538;C0042295;C0428462;C1963138
4940,prior hypertension yes,C0020538;C0332152;C1549445;C1705108;C1710701;C1963138;C2826257
4940,prior hypertension,C0020538;C0332152;C1963138;C2826257
4940,hypertension requiring medical treatment,C0020538;C1963138
4940,hypertension absent,C0020538;C1963138
4940,hyper - tension,C0020538;C1963138
4939,systemic arterial hypertension  n ( % ),C0020538
4939,no hypertension ( n = $nmbr$ ),C0020538;C1963138
4939,no hypertension,C0020538;C1963138
4939,hypertension 一 no . ( % ),C0020538;C1963138
4939,hypertension — no . / total no . ( % ),C0020538;C1963138
4939,hypertension — no . ( % ) |,C0020538;C1963138
4939,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),C0020538;C1963138
4939,hypertension — no . ( % ),C0020538;C1963138
4939,hypertension § yes,C0020538;C1549445;C1705108;C1710701;C1963138
4939,hypertension §,C0020538;C1963138
4939,hypertension n ( % ),C0020538;C1963138
4939,hypertension ^,C0020538;C1963138
4939,hypertension : no ( n = $nmbr$ ),C0020538;C1963138
4939,hypertension ( n 二 $nmbr$ ),C0020538;C1963138
4939,hypertension ( % ),C0020538;C1963138
4939,hypertension $nmbr$ ( % ),C0020538;C1963138
4939,hypertension    n   ( % ),C0020538;C1963138
4939,hypertension  n / n ( % ),C0020538;C1963138
4939,hypertension  n ( % ) yes,C0020538;C1549445;C1705108;C1710701;C1963138
4939,hypertension  n ( % ),C0020538;C1963138
4939,hypertension  * n ( % ),C0020538;C1963138
4939,hypertension  ( % ),C0020538;C1963138
4939,arterial hypertension — no . ( % ),C0020538
4939,arterial hypertension  no . ( % ),C0020538
4939,arterial hypertension  n ( % ),C0020538
4939,arterial hypertension,C0020538
4938,without hypertension at baseline to hypertension,C0020538;C0168634;C1442488;C1963138
4938,hypertension at baseline,C0020538;C0168634;C1442488;C1963138
4938,hypertension,C0020538;C1963138
4937,mras,C1335594;C1367476
4936,body mass indext,C0518010
4936,body mass indexf  < $nmbr$,C0518010
4936,body mass indexf,C0518010
4936,body mass indexc,C0518010
4936,body mass indexb,C0518010
4936,body mass indexa < median,C0518010;C0549183;C0876920;C2347635;C2348144;C2939193
4936,body mass indexa,C0518010
4935,mean body - mass indexj,C0444504;C0518010;C2347634;C2348143
4935,body - mass indexj,C0518010
4935,body - mass indexf,C0518010
4934,lv mass index ( mg / m $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C0455825;C0600653;C0918012;C1552854;C1637833;C1960952;C2346927;C2986546;C4321396;C4521761
4934,lv mass,C0455825
4933,mtss cfb mean ± sd,C0009002;C0444504;C1824728;C2347634;C2348143;C2699239
4933,mtss cfb,C0009002;C1824728
4932,mmse ( points ),C0451306
4932,mean mmse score,C0451306;C3533236
4931,mmse > $nmbr$,C0451306
4931,mmse < $nmbr$,C0451306
4931,mmse $nmbr$ - $nmbr$,C0451306
4931,> < $nmbr$ . $nmbr$  < $nmbr$ . $nmbr$  r < mmse = mini - mental,C0205090;C0451306;C0684010;C2603358
4930,mini - mental state examination  mean ( sd ) d,C0444504;C0451306;C2347634;C2348143;C2699239
4930,mini - mental state examination,C0451306
4929,czp baseline,C0054841;C0168634;C1442488;C1861828;C1872109
4928,certolizumab pegol ( n = $nmbr$ ),C1872109
4927,czp + mtx to mtx,C0025677;C0054841;C1417487;C1861828;C1872109
4927,czp + mtx n = $nmbr$,C0025677;C0054841;C1417487;C1861828;C1872109
4927,czp + mtx ^ mtx,C0025677;C0054841;C1417487;C1861828;C1872109
4927,czp + mtx,C0025677;C0054841;C1417487;C1861828;C1872109
4926,mets w / o t $nmbr$ dm,C0011816;C0812270;C1705694;C2939420;C3250443
4925,non - mets,C0812270;C1518422;C1705694;C2939420
4925,mets,C0812270;C1705694;C2939420
4924,without mets,C0812270;C1705694;C2939420
4924,with mets,C0812270;C1705694;C2939420
4924,mets  n ( % ),C0812270;C1705694;C2939420
4924,i without mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
4924,i with mets ( n = $nmbr$ ),C0021966;C0221138;C0812270;C1705694;C2939420
4923,pts,C1419129;C2698747
4923,pioglitazone pts / n ( % ),C0071097;C1419129;C2698747
4923,no . pts,C1419129;C2698747
4923,# pts,C1419129;C2698747
4922,ms & ng,C0017887;C0028074;C2349943;C3539704;C3713294
4921,prior ms treatment with ifn - beta or glatiramer acetate . no . ( % ),C0015980;C1514463;C2349943;C3539704;C3713294
4921,prior ms treatment with ifn - beta or,C0015980;C1514463;C2349943;C3539704;C3713294
4921,no prior ms therapies,C1514463;C2349943;C3539704;C3713294
4920,qrs width  ms,C0487742;C2349943;C3539704;C3713294
4920,qrs duration > $nmbr$ ms  n ( % ),C0429025;C0488377;C2349943;C3539704;C3713294
4920,qrs duration  ms,C0429025;C0488377;C2349943;C3539704;C3713294
4920,qrs > $nmbr$ ms *,C2349943;C3539704;C3713294
4920,qrs > $nmbr$ ms  n ( % )  available for $nmbr$ patients,C2349943;C3539704;C3713294
4920,qrs > $nmbr$ ms  % ( n ),C2349943;C3539704;C3713294
4920,qrs < $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$  $nmbr$ ),C0596019;C2349943;C3539704;C3713294
4920,qrs $ $nmbr$ ms ( $nmbr$ % cl ) ( n - $nmbr$ ),C0596019;C2349943;C3539704;C3713294
4920,ms < $nmbr$  n [ % ],C2349943;C3539704;C3713294
4920,ms $nmbr$ - $nmbr$  n [ % ],C2349943;C3539704;C3713294
4919,ramus,C3538818
4918,rales  n ( % ),C0034642;C0240859
4918,rales  ( % ),C0034642;C0240859
4918,rales,C0034642;C0240859
4918,pulmonary rales  n ( % ),C0034642
4918,pulmonary rales,C0034642
4917,icsa plus laba  n ( % ),C0332287
4917,basal plus bolus,C0205112;C0332287;C1186706;C1511237;C1705509;C3812160
4916,psoriasis body surface area > $nmbr$ %,C0005902;C0033860
4916,psoriasis > $nmbr$ % of bsa,C0033860
4916,patients with psoriasis > $nmbr$ % of body surface area,C0017446;C0030705;C0033860;C0205146;C0489451
4915,without psoriasis ( n = $nmbr$ ),C0033860
4915,without psoriasis ( n = $nmbr$  $nmbr$ ),C0033860
4915,with psoriasis ( n = $nmbr$ ),C0033860
4915,psoriasis ( n =,C0033860
4915,patients without psoriasis ( n = $nmbr$ ),C0030705;C0033860
4915,patients with psoriasis ( n = $nmbr$ ),C0030705;C0033860
4915,patients with psoriasis ( bsa ≥   $nmbr$ % ),C0030705;C0033860
4915,dlqi ( patients with £ $nmbr$ % bsa psoriasis ),C0030705;C0033860;C3899393
4914,£ $nmbr$ % bsa psoriasis  no . ( % ),C0033860
4914,psoriasis covering > $nmbr$ % bsa  n ( % ) §,C0033860;C0180153;C0439844
4914,psoriasis bsa > $nmbr$ %  n ( % ),C0033860
4913,psoriasis,C0033860
4913,previous exposure to systemic psoriasis therapyb ( yes )  n ( % ),C0033860;C0205156;C0205373;C0332157;C1549445;C1552607;C1705108;C1710701
4913,previous exposure to non - biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1518422;C1549445;C1552607;C1705108;C1710701
4913,previous exposure to biologic systemic psoriasis therapyb ( yes )  n ( % ),C0005515;C0033860;C0205156;C0205373;C0205460;C0332157;C1549445;C1552607;C1705108;C1710701
4912,patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +,C0005910;C0006041;C0030705;C0392756;C0547047;C2986891
4911,patients with improvement $ $nmbr$ . $nmbr$,C0030705;C2986411
4910,patients with measurement,C0030705;C0242485
4910,patients treated with insulin,C0030705
4909,patients with dactylitisa,C0030705
4909,patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C3863761
4908,patients with perianal fistulae  n [ % ],C0030705;C0267561
4907,patient - reported hypertension — no . { % ),C0030705
4907,% patients with no progression,C0030705;C0242656;C0449258
4906,patients with dactylitis at baseline  no .,C0030705;C0239161
4906,patients with dactylitis  no . ( % ),C0030705;C0239161
4906,patients with $ $nmbr$ % bsa at baseline  no .,C0030705
4906,patients total no .,C0030705
4906,patients taking mtx  no . ( % ),C0030705
4906,patients receiving lcz  no . ( % ),C0030705
4906,patients receiving immunotherapy  no . ( % ),C0030705
4906,patients receiving enl  no . ( % ),C0030705
4906,patients randomized  no .,C0030705
4906,patients  no . / total no . ( % ),C0030705
4906,patients  no .,C0030705
4906,of patients,C0030705
4906,no . patients ( % ),C0030705
4906,no . of patients with events ( % ),C0030705
4906,no . of patients / total no . ( % ),C0030705
4906,no . of patients / no . of events ( % ) $nmbr$ / $nmbr$ ( $nmbr$ ) $nmbr$ / $nmbr$ ( $nmbr$ ),C0030705
4906,no . of patients / no . of events,C0030705
4906,no . of patients ( % ),C0030705
4906,no . of patients,C0030705
4906,no . ( % ) of patients with ≥ $nmbr$ % bsa affected,C0030705
4905,randomised patients with dactylitis at baseline,C0030705;C0239161
4905,patients with dactylitis at week $nmbr$  n ( % ),C0030705;C0239161
4905,patients with dactylitis,C0030705;C0239161
4904,patients without diabetesb,C0030705
4904,patients with diabetic nephropathy,C0011881;C0030705;C1442864
4904,patients who received positive results on test for antibodies to infliximabt,C0030705
4904,patients who received negative results on test for antibodies to infliximabt,C0030705
4904,patients who received indeterminate results on test for antibodies to infliximabt,C0030705
4904,no . patients with,C0030705
4904,no . of patients with ra,C0030705
4904,no . of patients with psa,C0030705
4904,no . of patients with as,C0030705
4904,no . ( % ) of patients with stroke,C0030705
4904,no . ( % ) of patients with atrial tachyarrhythmia,C0030705
4904,diabetic patients,C0030705;C0241863
4903,patients with pulmonary embolism,C0030705;C0034065
4902,patients with diabetesb,C0030705
4902,laboratory values in patients with history of diabetes,C0022877;C0030705;C0042295;C3244292;C4283904
4901,all patients with opg n - $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
4900,tcomparison of proportion of patients with nyha class lll / iv heart failure .,C0030705;C1709707
4900,proportion of patients who achieved acr $nmbr$ n / n ( % ),C0030705;C1709707
4900,proportion of patients in corticosteroid - free clinical remission at week $nmbr$,C0030705;C1709707
4900,patients who received $nmbr$ or $nmbr$ drugs,C0030705
4900,patients who received $nmbr$ drug,C0030705
4900,patients included in analysis,C0030705
4900,patients  n,C0030705
4900,of patients meeting criterion / total no . of patients,C0030705
4900,no . of hospitalised patients,C0030705
4899,proportion of patients with trough fevi > $nmbr$ ml above baseline  n ( % ),C0030705;C1709707
4899,patients with endpoin t  n ( % ),C0030705
4899,patients ( n ),C0030705
4899,itt patients  n ( % ),C0030705
4898,randomised patients with spondylitis at baseline  n,C0030705;C0038012
4898,patients randomly assigned,C0030705
4898,patients randomized  n,C0030705
4898,patients randomised  n,C0030705
4898,patients assessed,C0030705
4897,patients with normoalbuminuria at baseline,C0030705
4897,patients with microalbuminuria at baseline,C0030705;C0730345
4897,patients with macroalbuminuria at baseline,C0030705
4896,no new jsn among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314
4896,no new erosions among patients with ≥ $nmbr$ uninvolved joint at baseline ¶,C0030705;C0205314;C0333307;C1959609
4895,patients without syndesmophytes at baseline,C0030705;C0221690
4895,patients with syndesmophytes at baseline,C0030705;C0221690
4894,patients with nail psoriasis ( mnapsi > $nmbr$ ),C0030705;C0406322
4893,patients aged > $nmbr$ y  no  ( ss ),C0030705
4893,older patients ( aged > $nmbr$ years ),C0030705;C0580836
4892,patients with serum $nmbr$ ( oh ) d ≥   $nmbr$ . $nmbr$ and <   $nmbr$   ng / ml    n / n   ( % ),C0030705;C0220853;C0229671;C1546774;C1550100
4892,patients  n / n ( % ) a,C0030705
4891,patients treated with statins ( n = $nmbr$ ),C0030705
4891,patients treated with losartan ( n = $nmbr$ ),C0030705
4891,patients treated with atenoloi ( n = $nmbr$ ),C0030705
4891,patients not treated with statins ( n = $nmbr$ ),C0030705
4891,patients ( treated set * )  n,C0030705
4891,aii patients ( n = $nmbr$ ),C0030705;C1424250;C2698414
4890,all patients with fistulas ( n = $nmbr$ ),C0016169;C0030705
4890,all patients n = $nmbr$ $nmbr$,C0030705
4890,all patients n = $nmbr$,C0030705
4890,all patients ( « = $nmbr$ $nmbr$ ),C0030705
4890,all patients ( n   =   $nmbr$ ) b,C0030705
4890,all patients ( n = $nmbr$ ),C0030705
4890,all patients ( n = $nmbr$  $nmbr$ ),C0030705
4890,all patients ( n $nmbr$ $nmbr$ ),C0030705
4890,all patients  n =,C0030705
4890,all patients,C0030705
4889,patients without dm ( n = $nmbr$ ),C0011816;C0030705;C3250443
4889,patients without dm ( n = $nmbr$  $nmbr$ ),C0011816;C0030705;C3250443
4889,patients without,C0030705
4888,patients without draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
4888,patients with draining fistulae at baseline [ n = $nmbr$ ],C0030705;C0544791
4888,patients entering pt period n = $nmbr$,C0030705
4887,remaining patients,C0030705;C1527428
4887,patients receiving immunosuppressive agents at baseline,C0030705
4887,patients receiving corticosteroids at baseline,C0030705
4887,patients not receiving immunosuppressive agents at baseline,C0030705
4887,patients not receiving corticosteroids at baseline,C0030705
4886,patients in analysis  n,C0002778;C0030705;C0936012;C1524024
4886,patients analyzed  n,C0030705
4885,patients treated and operated  n ( % ),C0030705
4885,patients taking oral corticosteroids at baseline  n ( % ),C0030705
4885,patients taking mtx  n ( % ),C0030705
4885,patients > $nmbr$ %,C0030705
4885,n ( % of patients ),C0030705;C0369718;C0441922
4885,n ( % ) patients with risk faetors for cv disease aged > $nmbr$,C0030705;C0035647;C0369718;C0441922;C4552904
4885,> $nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
4885,$nmbr$ %  n ( % of patients ),C0030705;C0369718;C0441922
4884,treated patients with baseline and $nmbr$ post - baseline ef ﬁ cacy measurement  bp value for treatment group comparison ( proactive intervention vs usual care ) was calculated based on a $nmbr$ - sample t test for continuous variables and chi - square test for categorical variables  cbp values were measured at baseline ( week $nmbr$ )  whereas information on all of the other variables listed was collected during screening . abbreviations : bmi  body mass index  bp  blood pressure  chd  coronary heart disease  crucial  cluster randomized usual care vs caduet investigation assessing long - term - risk  dbp  diastolic blood pressure  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  sd  standard deviation  sbp  systolic blood pressure  tc  total cholesterol  tg  triglyceride .,C0005823;C0011849;C0012641;C0018787;C0023822;C0030705;C0035647;C0037623;C0039411;C0039798;C0040642;C0041004;C0041405;C0041698;C0042295;C0065055;C0085805;C0087111;C0168634;C0184661;C0201950;C0205251;C0237403;C0280604;C0332293;C0374505;C0428883;C0439828;C0441833;C0443252;C0488055;C0543421;C0549178;C0687744;C0871420;C0871470;C0886296;C1257890;C1273869;C1305855;C1306620;C1415692;C1442488;C1519504;C1522326;C1522609;C1533734;C1550472;C1705169;C1705428;C1705429;C1707455;C1708288;C1824670;C1947933;C2699239;C2986530;C3272447;C3538994;C3542407;C3887704;C3890211;C4048187;C4318478;C4321351;C4522122;C4522223;C4552904
4884,randomised patients ( n ),C0030705
4884,patients treated,C0030705
4884,patients randomized,C0030705
4884,normoalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
4884,macroalbuminuria at baseline ( $nmbr$ % of patients treated ),C0030705;C0168634;C1442488
4884,( $nmbr$ patients ),C0030705
4883,randomised patients with > $nmbr$ % bsa psoriasis skin involvement at baseline,C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
4883,patients with fingernail involvement,C0030705;C0222001;C1314939
4883,patients with > $nmbr$ % bsa psoriasis skin involvement  n ( % ),C0030705;C0033860;C0444099;C1123023;C1314939;C4520765
4883,patients with > $nmbr$ % bsa,C0030705
4883,no . ( % ) of patients with fingernail involvement,C0030705
4882,randomised patients with enthesitis at baselinet,C0030705;C1282952
4882,patients with enthesitis at week $nmbr$ radiographic progression § change from baseline to week $nmbr$ in psa - modified total shs score,C0030705;C1282952
4882,patients with enthesitis at week $nmbr$  n ( % ),C0030705;C1282952
4882,patients with enthesitis at baseline  no .,C0030705;C1282952
4882,patients with enthesitis ( lei > $nmbr$ ),C0023401;C0030705;C0428209;C1282952
4882,patients with enthesitis  no . ( % ),C0030705;C1282952
4882,patients with enthesitis  n ( % ),C0030705;C1282952
4882,patients with enthesitis,C0030705;C1282952
4882,patients receiving $nmbr$ mg of edoxaban at randomization — no . ( % ) f,C0030705
4882,all patients ( p = $nmbr$ . $nmbr$ ),C0030705
4882,all patients ( p < $nmbr$ . $nmbr$ ),C0030705
4882,% of patients $nmbr$ . $nmbr$ $nmbr$ . $nmbr$,C0030705
4881,patients > $nmbr$ y *,C0030705
4881,patients > $nmbr$ y,C0030705
4881,patients < $nmbr$ y *,C0030705
4881,patients < $nmbr$ y,C0030705
4881,laba use  % patients,C0030705;C0042153;C0457083;C1947944
4880,patients < $nmbr$ %,C0030705
4880,hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % ),C0019016;C0030705;C1825777;C3538758
4879,obese patients  ! n ( % ),C0028754;C0030705
4878,patients with supplemental vitamin d dose of $nmbr$ iu / day starting at screeningc    n   ( % ),C0030705;C0178602;C0420176;C0439465;C0439659;C0869039;C1114758;C3541352
4878,patients    n   ( % ),C0030705
4878,patients  n ( % ),C0030705
4877,week $nmbr$ % of patients,C0030705;C0332174;C0439230
4877,patients meeting the criteria to receive $nmbr$ mg of,C0030705
4876,score > $nmbr$ %  % of patients,C0030705;C0449820;C4050231
4876,patients treated for > $nmbr$ weeks ( % ),C0030705
4875,patients with pneumonia resulting in death  n ( % ),C0030705;C0032285
4874,patients with digits with dactylitis  n ( % ),C0030705;C0582802
4873,patients receiving any uc medication  n ( % ),C0030705
4873,medications  n ( % of patients ),C0013227;C0030705;C0802604;C2598133;C4284232
4872,vents / patients,C0030705
4872,placebo patients / events n,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
4872,patients n,C0030705
4872,patient,C0030705
4872,events / patient - year ( n ),C0030705;C0439234;C0439508;C0441471;C3541888
4872,albiglutide events / patients ( %,C0030705;C0441471;C2607479;C3541888
4872,% patients,C0030705
4871,patients with uncomplicated events ( p = o - $nmbr$ 十 ),C0030705;C0441471;C0443334;C3541888
4871,patients with uncomplicated events,C0030705;C0441471;C0443334;C3541888
4871,patients with complicated events ( p = $nmbr$ - $nmbr$ 十 ),C0030705;C0231242;C0441471;C3541888
4871,patients with complicated events,C0030705;C0231242;C0441471;C3541888
4870,patients ( ft ),C0030705
4870,event / patients ( $nmbr$ / pt - y ),C0030705;C0032743;C0441471;C0699718;C4019010
4870,diet diet + pravastatin event / patients ( $nmbr$ ooo / pt - y ),C0012155;C0012159;C0030705;C0032743;C0085542;C0441471;C0699718;C1519433;C2983588;C3668949;C4019010
4869,all patients on maximally tolerated statin ± other llt,C0030705;C0360714
4868,patients who used insulin pump,C0030705
4868,patients who had ulcerations at,C0030705
4868,patients who did not use insulin pump,C0030705
4868,patient classification,C0008902;C0008903;C0030705;C0678229
4867,patients receiving statin,C0030705
4867,patients receiving mtx  n =,C0030705
4867,patients receiving mtx,C0030705
4867,patients not receiving statin,C0030705
4867,patients not receiving mtx  n =,C0030705
4867,patient presentation,C0030705;C0449450
4866,patients with > $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268
4866,patients having exacerbation,C0030705
4866,patient characteristic,C0030705
4866,adjusted exacerbation rate { per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
4866,adjusted exacerbation rate ( per patient peryear ),C0030705;C0456081;C0871208;C1521828;C4086268
4865,patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
4865,patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C3810814
4865,patients using concurrent tiotropium,C0030705
4865,for patients using personal cgm,C0030705
4865,for patients not using personal cgm,C0030705
4864,patients with prior copd - related,C0024117;C0030705;C0332152;C0439849;C0445223;C1412502;C2826257;C3714496
4864,patients,C0030705
4863,paroxysmal atrial fibrillation — no . ( % ),C0235480;C4050122
4862,paroxysmal af,C0235480
4862,history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
4861,paroxysmal ( n  % ),C0205311
4861,paroxysmal !,C0205311
4861,paroxysmal  n ( % ),C0205311
4861,paroxysmal,C0205311
4860,pyrexia,C0015967
4859,proximal gi tract,C0017189;C0205107;C4489236
4859,proximal gastrointestinal tract,C0017189;C0205107;C0521362;C4489236
4858,proximal gl tract  n ( % ),C0018229;C0205107;C1185740;C1423073;C1427674;C4489236
4858,proximal,C0205107;C4489236
4857,proximal to the splenic flexure,C0205107;C0227387;C4489236
4857,proximal - mainleft,C0205107;C4489236
4856,all participants ^ ^ ( n = $nmbr$ / $nmbr$ ),C0679646
4856,aii participants ( n = $nmbr$ ),C0679646;C1424250;C2698414
4855,n participants,C0369718;C0441922;C0679646
4855,all participants * ( n = $nmbr$ / $nmbr$ ),C0679646
4855,all participants ( n = $nmbr$ ),C0679646
4854,participants at baseline  n,C0168634;C0679646;C1442488
4854,participants  n,C0679646
4853,all participants  mm hg : sbp  mean ( sd ),C0085805;C0439475;C0444504;C0679646;C2347634;C2348143;C2699239
4853,all participants,C0679646
4852,participants with an event per $nmbr$ patient - years,C0441471;C0679646;C4019010
4852,participants taking insulin,C0679646
4851,participants n,C0679646
4851,participants  no . ( % ),C0679646
4851,normal cognitive function ( spmsq < $nmbr$ ) . n - $nmbr$ . $nmbr$ n ( % ) participants with the event of interest,C0009240;C0392335;C0441471;C0679646;C1276356;C4019010;C4050130
4851,no . of participants with events ( % ),C0679646
4851,no . of participants ( % ),C0679646
4851,no . ( % ) of participants,C0679646
4851,impaired cognitive function ( spmsq > $nmbr$ ) . n - $nmbr$ n ( % ) participants with the event of interest,C0009240;C0221099;C0392335;C0441471;C0543488;C0679646;C4019010;C4050130
4851,$nmbr$ % participants,C0679646
4850,nondiabetic participants !,C0679646
4850,diabetic participants !,C0241863;C0679646
4850,diabetic participants,C0241863;C0679646
4850,by gfr stratum tor diabetic participants  ml / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0076836;C0241863;C0369637;C0439445;C0441923;C0679646;C1199517;C1419603;C1424601;C3539732
4850,by gfr stratum for diabetic participants  mt / min per $nmbr$ . $nmbr$ m ’ §,C0017654;C0241863;C0679646;C0702093;C1424601;C1524029;C3813700
4849,participants,C0679646
4849,no . of participants per $nmbr$ patient - yr,C0679646
4849,no . of participants,C0679646
4849,by gfr stratum for all participants  ml / min per $nmbr$ . $nmbr$ m ’ !,C0017654;C0439445;C0679646;C1424601
4848,participants randomized,C0679646
4848,participant - reported hypertension — no . { % ),C0679646;C2698741;C4554048
4847,nonblack participants,C0679646
4847,non - black participants,C0005680;C0027567;C0085756;C0439541;C0679646;C1518422
4847,black participants,C0005680;C0027567;C0085756;C0439541;C0679646
4846,ecg changes ( % ) t,C1623258
4846,ecg abnormality ( resting )  %,C1623258;C1704258
4845,ecg,C1623258
4845,af on baseline ecg  n ( % ),C0168634;C0344434;C1442488;C1623258;C4049859
4844,time of qualifying ecg to balloon inflation ( hrs ),C0040223;C1514624;C1623258;C3541383
4844,time from qualifying ecg to balloon inflation,C0040223;C1514624;C1623258;C3541383
4844,ecg left ventricular,C1623258
4844,ecg at time of qualifying symptoms,C0040223;C0683368;C1457887;C1514624;C1623258;C3541383
4844,ecg and imaging data,C1623258
4843,rec . ischemia due to ecg changes,C0022116;C0678226;C1424025;C1623258;C2606415;C4321499
4843,due to ecg changes,C1623258
4842,lvh by electrocardiogram  n ( % ),C0013798;C0149721;C1547122;C1623258
4842,lvh by electrocardiogram,C0013798;C0149721;C1547122;C1623258
4842,lvh ( from electrocardiogram ),C0013798;C0149721;C1547122;C1623258
4842,electrocardiogram,C0013798;C1547122;C1623258
4841,electrocardiography,C0013798;C1623258
4841,electrocardiograph results  no . ( % ),C0013798;C0180600;C1623258
4840,exercise status,C0015259;C0449438;C1522704
4840,exercise at least weekly ( a ),C0015259;C1522704
4840,exercise > once weekly ?,C0015259;C1522704
4840,exercise > once weekly,C0015259;C1522704
4839,exercise times per week  ( minimum,C0015259;C0456698;C1522704;C1524031;C1552614;C2826545
4839,exercise ( % ),C0015259;C1522704
4839,exercise  n ( % ),C0015259;C1522704
4839,exercise,C0015259;C1522704
4838,walk for exercise ( % ),C0015259;C0080331;C1522704
4838,walk for exercise,C0015259;C0080331;C1522704
4837,physical activity §,C0015259;C0026606
4837,physical activity  kcal / wk < $nmbr$,C0015259;C0026606;C0332174;C0439230;C0439259
4837,physical activity  kcal / wk *,C0015259;C0026606;C0332174;C0439230;C0439259
4837,physical activity  kcal / wk,C0015259;C0026606;C0332174;C0439230;C0439259
4836,some physical activity,C0015259;C0026606
4836,physical activity ( hours walking / wk ),C0015259;C0026606;C0439227
4835,reteplase,C0256103
4834,tenecteplase and pci ( n = $nmbr$ ),C0872913
4834,tenecteplase,C0872913
4833,hazard ratio ( $nmbr$ % confidence interval ) *,C0009667;C2985465
4833,hazard ratio ( $nmbr$ % confidence interval ),C0009667;C2985465
4833,coronary syndrome . ci = confidence interval  hr = hazard ratio .,C0008107;C0009667;C0018787;C0039082;C2985465;C3259781
4833,$nmbr$ % confidence interval,C0009667
4832,adherence to study regimen — no . ( % ) ff,C1510802
4832,adherence to study regimen — no . ( % ),C1510802
4832,adherence > $nmbr$ %,C1510802
4831,hypertensive  n ( % ),C0857121
4831,hypertensive,C0857121
4831,anti - hypertensive treatment history  n ( % ),C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0432633;C0857121;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
4830,personal relationships,C1552027
4829,perianal or anus,C0442158
4829,perianal gi tract,C0017189;C0442158
4829,perianal  n ( % ),C0442158
4828,> $nmbr$ yr warfarin experience,C0043031;C0237607;C0439234;C0596545
4827,experienced,C0237607;C0596545
4827,experience ( n  % ),C0237607;C0596545
4827,clinic research experience  n ( % ),C0008972;C0237607;C0596545
4827,cdmard experience  n ( % ),C0237607;C0596545
4826,prior vka experience,C0237607;C0332152;C0596545;C2826257
4826,experience,C0237607;C0596545
4825,region  latin america,C0017446;C0023122;C0205147
4825,latin america or south africa,C0023122
4825,latin america ( n = $nmbr$ ),C0023122
4825,latin america,C0023122
4824,latin american subgroup,C1079230;C1515021;C1553378
4824,latin american,C1553378
4823,mexican,C0240339
4822,hispanic american,C0019576
4822,hispanic / latin american,C0019576
4821,mexico  central / south america,C0007674;C0025885;C0037713;C0205099;C1710133;C1879652
4821,mexico,C0025885
4820,americas * *,C0002454;C0596070
4820,americas ( n = $nmbr$ ),C0002454;C0596070
4820,americas  excluding us,C0002454;C0596070
4820,americas,C0002454;C0596070
4819,n america,C0002454;C0369718;C0441922
4819,america,C0002454
4818,the american college of rheumatology ) .,C0035452;C0557806;C0596070
4817,indian ( american ) or alaskan native,C0596070;C1524069
4817,american,C0596070
4816,africa ! near east,C0001737;C1707877
4815,middle east  africa  or asia - pacific,C0001737;C0001741;C0026068;C0444598;C0549183;C1552826
4815,africa or near east,C0001737
4814,south africa / south america,C0001737;C0002454;C0037712;C0037713
4814,africa *,C0001737
4814,africa,C0001737
4813,reversibility : > $nmbr$ - < $nmbr$ %,C0449261
4813,reversibility : > $nmbr$ %,C0449261
4813,reversibility : < $nmbr$ %,C0449261
4813,airway reversibility  mean  %,C0178987;C0444504;C0449261;C0458827;C2347634;C2348143
4813,airway reversibility  %,C0178987;C0449261;C0458827
4812,reversibility [ % ]  median ( range ),C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4812,reversibility ( % )  median ( range ) c,C0449261;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4812,reversibility  %,C0449261
4812,reversibility,C0449261
4811,reversibility to salbutamolc  d  mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2699239
4811,reversibility to,C0449261
4811,reversibility ( b $nmbr$ - agonist )  %  mean ( sd ) $nmbr$,C0444504;C0449261;C2347634;C2348143;C2699239;C2987634
4811,mean reversibility ( % ),C0444504;C0449261;C2347634;C2348143
4811,% reversibility,C0449261
4810,reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
4810,reversibility > $nmbr$ % ( n = $nmbr$ ),C0449261
4810,reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
4810,reversibility < $nmbr$ % ( n = $nmbr$ ),C0449261
4810,reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261
4810,reversibility ( % ) t,C0449261
4810,bronchial reversibility %,C0205039;C0449261;C1442216
4810,% bronchial reversibility ( sd ),C0205039;C0449261;C1442216;C2699239
4809,reversibility — %,C0449261
4809,airflow reversibility — no . ( % ) |,C0231999;C0449261
4808,saba reversibility,C0449261
4808,reversibility ’ ' %,C0449261
4808,post - bronchodilator fev i reversibility  % b,C0021966;C0221138;C0449261;C2599594;C3714541
4808,fev $nmbr$ reversibility  % b,C0449261;C3714541
4808,% reversibility in fev ^ at,C0449261;C3714541
4807,postbronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
4807,post - bronchodilator reversibility fev $nmbr$ ( % ) mean ( sd ),C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
4807,post - bronchodilator fev $nmbr$ reversibility  % a,C0449261;C2599594;C3714541
4807,post - bronchodilator fev $nmbr$ reversibility  %,C0449261;C2599594;C3714541
4807,post - bronchodilator fev  reversibility,C0449261;C2599594;C3714541
4807,mean ( sd ) post - bronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
4807,fev $nmbr$ % reversibility,C0449261;C3714541
4806,reversibility stratum *,C0449261
4806,reversibility *,C0449261
4806,absolute reversibility in fev $nmbr$  ml *,C0205344;C0439526;C0449261;C1705224;C3714541;C3887665
4805,screening % reversibility fev $nmbr$,C0220908;C0220909;C0449261;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
4805,reversibility ( % predicted fev $nmbr$ ) *,C0449261
4805,fev $nmbr$ reversibility  % *,C0449261;C3714541
4804,reversibility of fev $nmbr$ ( % ),C0449261;C3714541
4804,reversibility ( % ),C0449261
4804,reversibility %,C0449261
4804,mean ( sd ) postbronchodilator fev $nmbr$ reversibility  %,C0444504;C0449261;C2347634;C2348143;C2599594;C2699239;C3714541
4804,mean ( sd ) % reversibility fev $nmbr$ at,C0444504;C0449261;C2347634;C2348143;C2699239;C3714541
4804,fev $nmbr$ % reversibility ( sd ),C0449261;C2699239;C3714541
4803,women ethnic origin,C0015031;C0043210
4803,ethnic origin *,C0015031
4803,ethnic origin  n ( % ),C0015031
4803,ethnic origin,C0015031
4802,hispanic ethnic group — no . { % ) ’ i ',C0015031;C0086409;C1879937
4802,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0015031;C0086409;C1879937
4802,hispanic ethnic group — no . ( % ) : t,C0015031;C0086409;C1879937
4802,ethnic group — no . ( % ) ',C0015031;C1879937
4802,ethnic group ( % ),C0015031;C1879937
4802,ethnic group,C0015031;C1879937
4802,ethnic background,C0015031
4801,othery ethnicity  n ( % ) *,C0015031;C0243103
4801,othery ethnicity  n ( % ),C0015031;C0243103
4801,hispanic ethnicity  n ( % ),C0015031;C0086409;C0243103
4801,hispanic ethnicity,C0015031;C0086409;C0243103
4801,hispanic / latino ethnicity  n ( % ),C0015031;C0086409;C0086528;C0243103
4801,hispanic / latino ethnicity,C0015031;C0086409;C0086528;C0243103
4801,ethnicity  not hispanic / latino    n   ( % ),C0015031;C0243103
4801,ethnicity  n ( % ) b,C0015031;C0243103
4801,ethnicity  n ( % ) :,C0015031;C0243103
4801,ethnicity  n ( % ) *,C0015031;C0243103
4801,ethnicity  n ( % ),C0015031;C0243103
4801,ethnicity  hispanic / latino  n ( % ),C0015031;C0086409;C0086528;C0243103
4801,ethnicity  %,C0015031;C0243103
4801,ethnicity,C0015031;C0243103
4800,race / ethnicity  no . ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
4800,race / ethnicity  % white non - hispanic,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1518422;C1518424;C1533020;C1533021;C1706779;C3853635
4800,race / ethnicity  %,C0015031;C0034510;C0243103;C1706779;C3853635
4800,ethnicity - no . ( % ),C0015031;C0243103
4800,ethnicity $nmbr$ ',C0015031;C0243103
4800,ethnicity  no . ( % ),C0015031;C0243103
4799,ethnicity t,C0015031;C0243103
4799,ethnicity ( % ),C0015031;C0243103
4799,age  mean ( sd )  y ethnicity  no . ( % ),C0001779;C0015031;C0243103;C0444504;C2347634;C2348143;C2699239
4798,estimated creatinine clearance < $nmbr$ rmb ' mint,C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C3890003
4798,estimated creatinine clearance < $nmbr$ ml / mint,C0439526;C0452249;C0522467;C0750572;C0812399;C1337213;C1576800;C1705224;C3887665;C3890003
4798,estimated creatinine clearance  !,C0750572;C0812399
4798,estimated * creatinine clearance < $nmbr$ mlvmin  %,C0750572;C0812399
4797,creatinine clearance  an   ( % ),C0812399
4797,baseline creatinine clearance,C0168634;C0812399;C1442488
4796,creatinine clearance — no . ( % ),C0812399
4796,creatinine clearance category  ml / min  no . ( % ) b,C0439445;C0683312;C0812399;C3889287
4796,creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % ),C0439445;C0812399
4796,creatinine clearance  no . ( % ),C0812399
4796,creatinine clearance  n ( % ),C0812399
4795,creatinine clearance ( ml / min )  mean ± sd,C0439445;C0444504;C0812399;C2347634;C2348143;C2699239
4795,creatinine clearance,C0812399
4794,statin intolerance $nmbr$  n ( % ),C0231199;C0360714;C1744706;C2355652
4794,intolerance ®,C0231199;C1744706;C2355652
4794,intolerance ',C0231199;C1744706;C2355652
4794,intolerance,C0231199;C1744706;C2355652
4793,incidence rate per $nmbr$ person years,C0027361;C0439234;C1708485;C2347489
4793,incidence rate per $nmbr$ person - years,C0027361;C0439234;C1708485;C2347489
4793,incidence rate no . ( / $nmbr$ person - years ),C1708485
4793,incidence rate ( per $nmbr$ person - yr ),C0027361;C0439234;C1708485;C2347489
4793,incidence rate ( n ) a,C1708485
4793,incidence rate ( n ),C1708485
4793,incidence [ n / n ( rate per $nmbr$ person - years ) ],C0027361;C0439234;C1708485;C2347489
4792,incidence rate *,C1708485
4792,$nmbr$ - y incidence rate ( se ) per $nmbr$ participants,C0036919;C0679646;C1708485
4791,incidence rate difference  linagliptin - placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408;C1708485;C2746078
4791,incidence rate,C1708485
4790,incidence of each outcome,C0021149;C0220856;C1274040
4789,incidence  %,C0021149;C0220856
4789,cumulative incidence lyear,C0021149;C0220856;C1511559
4789,cumulative incidence $nmbr$ years,C0021149;C0220856;C0439234;C1511559
4789,$nmbr$ - year cumulative incidence  % ( ci ),C0008107;C0021149;C0220856;C0439234;C0439508;C1511559;C3259781
4788,incidence ^,C0021149;C0220856
4788,^ ≥ $nmbr$ % incidence in any treatment group in the overall safety population .,C0021149;C0220856;C0374505
4787,incidence  ° / o ( $nmbr$ / $nmbr$ cl ),C0021149;C0220856;C0596019
4786,wafarin event incidence / n,C0021149;C0220856;C0441471;C4019010
4786,incidence *,C0021149;C0220856
4786,event incidence / n,C0021149;C0220856;C0441471;C4019010
4785,standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
4785,mean difference = seb,C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
4785,difference vs . pbof mean ( s . e . ) t,C1705241;C1705242
4784,lsm difference,C1705241;C1705242
4784,difference ( glargine - standard care ) lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0907402;C1442989;C1705241;C1705242;C1947933;C2828392;C4330985;C4554674
4783,difference vs placebo * *,C1705241;C1705242
4783,difference from placeboa,C1705241;C1705242
4783,difference from placebo ¥,C0032042;C1696465;C1705241;C1705242;C1706408
4783,difference from placebo,C0032042;C1696465;C1705241;C1705242;C1706408
4782,mean arterial pressure  difference,C0428886;C1705241;C1705242
4781,triglycerides tx difference vs pbo  ls mean % change from baseline ( se ),C0041004;C0041403;C1705241;C1705242
4781,insulin tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0021641;C0041403;C1533581;C1579433;C1705241;C1705242;C3714501
4781,homa_ % b tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
4781,high - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023822;C0041403;C1705241;C1705242
4781,fpg tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
4781,difference vs placebo ',C1705241;C1705242
4781,difference vs placebo  % [ $nmbr$ % cl ]  p,C1705241;C1705242
4781,difference vs placebo,C1705241;C1705242
4781,difference vs pbo,C1705241;C1705242
4781,difference vs . placebo  kg ( $nmbr$ % cl ),C1705241;C1705242
4781,difference vs . placebo  % ( $nmbr$ % cl ),C1705241;C1705242
4781,difference vs . placebo,C1705241;C1705242
4781,difference from baselinea,C1705241;C1705242
4780,difference in means,C1704970;C1705241;C1705242
4780,difference in ls means ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4779,ls mean difference vs placebo ( $nmbr$ % ci ),C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
4779,ls mean difference ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
4779,difference vs placebo ( $nmbr$ % ci ),C1705241;C1705242
4779,difference vs pbo ( $nmbr$ % ci ),C1705241;C1705242
4779,difference in ls mean vs placebo ( $nmbr$ % ci )  %,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
4779,difference ( a ) vs placebo ( $nmbr$ % cl ),C1705241;C1705242
4779,difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
4778,treatment difference ( $nmbr$ % ci ),C0008107;C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3259781;C3538994;C3887704
4778,ls means difference ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4778,ls means difference ( $nmbr$ % ci ) $nmbr$,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4778,least squares mean between - treatment difference ( $nmbr$ % ci ),C0008107;C0023189;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
4778,least - squares mean difference ( $nmbr$ % ci ) *,C0008107;C0023189;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
4778,difference vs ff $nmbr$ pg ( $nmbr$ % ci ),C1705241;C1705242
4778,difference in ls means ( $nmbr$ % ci ) versus placebo,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4778,difference in ls means ( $nmbr$ % ci ),C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4778,difference ( % ),C1705241;C1705242
4778,difference $nmbr$,C1705241;C1705242
4778,% difference  $nmbr$ % ci ),C0008107;C1705241;C1705242;C3259781
4778,$nmbr$ % ci for difference,C0008107;C1705241;C1705242;C3259781
4777,estimated difference ( $nmbr$ % ci ),C0008107;C0750572;C1705241;C1705242;C3259781
4777,estimated difference %,C0750572;C1705241;C1705242
4777,estimated difference,C0750572;C1705241;C1705242
4777,difference,C1705241;C1705242
4776,sex  men ( % ),C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
4776,men ( n  % ),C0025266
4776,men ( % ),C0025266
4776,men    n   ( % ),C0025266
4776,men  n ( % ) *,C0025266
4776,men  n ( % ),C0025266
4776,men  %,C0025266
4776,gender    n   ( % men ),C0025266;C0079399;C1522384
4775,low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl ),C0025266;C0151691;C0439269
4775,$nmbr$ - $nmbr$ ( men ),C0025266
4774,no . men,C0025266
4774,men ( n 二 $nmbr$ ),C0025266
4774,men  total ( n 二 $nmbr$ ),C0025266;C0439175;C0439810
4774,men  no . ( % ),C0025266
4773,men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
4773,men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0025266;C3538926
4773,men ( n = $nmbr$ vs $nmbr$ ),C0025266
4773,men ( n = $nmbr$ )  n / n ( % ),C0025266
4773,men ( n = $nmbr$ ),C0025266
4773,men ( n = $nmbr$ $nmbr$ ),C0025266
4772,£ $nmbr$ ( men ) / £ $nmbr$ ( women ),C0025266;C0043210
4772,women / men  %,C0025266;C0043210
4772,sex ( men / women ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
4772,sex  men / women  %,C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
4772,men : women ( % ),C0025266;C0043210
4772,gmi ( men ),C0025266
4771,waist circumference women : > $nmbr$ in ( $nmbr$ cm ) men : > $nmbr$ in ( $nmbr$ cm ) tc $nmbr$ c $nmbr$ mg / dl,C0025266;C0043210;C0455829
4771,men  > $nmbr$ cm,C0025266
4770,women men,C0025266;C0043210
4770,women / men [ % ],C0025266;C0043210
4770,men / women,C0025266;C0043210
4770,men ( n [ % ] ),C0025266
4770,hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women,C0025266;C0043210;C3642216;C3715113;C3898312
4770,< $nmbr$ ( men ) / < $nmbr$ ( women ),C0025266;C0043210
4770,( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl,C0025266;C0043210;C3539687;C3715113;C3898312
4769,men  < $nmbr$ cm,C0025266
4769,men,C0025266
4769,hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women ),C0023822;C0025266;C0392885
4769,hdl cholesterol  mmol / l  men  mean ± sd,C0023822;C0025266;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
4769,all men,C0025266
4768,women  > $nmbr$ cm,C0043210
4768,woman,C0043210;C4281745
4767,women,C0043210
4767,hdl cholesterol  mmol / l  women  mean ± sd,C0023822;C0043210;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
4766,women  no . ( % ),C0043210
4766,no . women,C0043210
4766,all women,C0043210
4766,all randomized women,C0034656;C0043210;C3815594
4765,women taking estrogen,C0043210
4765,women t,C0043210
4765,ratio of women to men — %,C0043210;C0456603;C1547037
4764,women  n ( % ) *,C0043210
4764,women  n ( % ),C0043210
4764,women  %,C0043210
4764,sex ( women  men ),C0009253;C0025266;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
4764,gender  women n  % ),C0043210;C0079399;C1522384
4764,$nmbr$ - $nmbr$ ( women ),C0043210
4763,women  < $nmbr$ cm,C0043210
4763,hemoglobin ( < $nmbr$ men  ， : : $nmbr$ women ),C0019046;C0025266;C0043210
4762,women — no . ( % ),C0043210
4762,women - no . ( % ),C0043210
4762,women ( n = $nmbr$ )  n / n ( % ),C0043210
4762,women ( n ( % ) ),C0043210
4762,women ( % ),C0043210
4762,( women only ),C0043210;C0205171;C1720467
4761,women ( n = $nmbr$ vs $nmbr$ ),C0043210
4761,women ( n = $nmbr$ ) events,C0043210;C0441471;C3541888
4761,women ( n = $nmbr$ ),C0043210
4761,gmi ( women ),C0043210
4760,philippines,C0031529
4759,transient monocular blindness,C0149793
4758,dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
4757,relative wall thickness,C0080103;C0205345;C0677535;C1280412;C1547039
4756,mean wall thickness ( cm ),C0677535;C4054557
4755,niacin ( n = $nmbr$ ),C0027996;C1142562
4755,niacin  n ( % ),C0027996;C1142562
4755,niacin,C0027996;C1142562
4755,extended - release niacin plus statin ( n = $nmbr$ ),C0027996;C0332287;C0360714;C1142562;C1707968
4754,spain ( n = $nmbr$ ),C0037747
4754,spain,C0037747
4753,question $nmbr$ ( neck / back / hip pain ),C0004600;C0004604;C0007859;C0019552;C0019559;C0022122;C0027530;C0205095;C0460009;C1505163;C1522634;C1963071;C1963180;C1995000;C3159206;C3538851;C4284725;C4551516;C4553909;C4553945
4753,neck pain,C0007859;C1963180;C4553909
4752,total back pain score ( $nmbr$ – $nmbr$   mm scale )  mean   ±   sd,C0004604;C0175659;C0349674;C0444504;C1947916;C1963071;C2347634;C2348143;C2699239;C2964552;C4330985;C4553945;C4554674
4752,total back pain  mean ( sd ),C0004604;C0439175;C0439810;C0444504;C1963071;C2347634;C2348143;C2699239;C4553945
4752,back pain,C0004604;C1963071;C4553945
4751,not - japan n = $nmbr$  $nmbr$,C0022341;C1518422
4751,not - japan,C0022341;C1518422
4751,japan n = $nmbr$,C0022341
4751,japan and south korea,C0022341
4751,japan,C0022341
4750,calima japan ( n = $nmbr$ ),C0022341
4750,asia ( excluding japan ),C0003980;C0022341;C0332196;C2828389
4749,japanese subgroup ( n = $nmbr$ ),C0376247;C1079230;C1515021;C1556094
4748,no . japanese,C0376247;C1556094
4748,japanese subpopulation,C0376247;C1257890;C1556094
4747,japanese,C0376247;C1556094
4747,aes in ≥ $nmbr$ japanese patients in a study arm  n ( % ) §,C0030705;C0376247;C1412268;C1556094;C2699274
4746,unknown — no . { % ),C0439673;C3541433;C4050014
4746,unknown type,C0332307;C0439673;C1547052;C3541433;C4050014
4746,unknown ( none of the above ),C0439673;C3541433;C4050014
4746,unknown ( % ),C0439673;C3541433;C4050014
4745,unknown or missing,C0439673;C3541433;C4050014
4745,unknown / missing,C0439673;C3541433;C4050014
4745,unknown,C0439673;C3541433;C4050014
4745,non - detectable / unknown  n ( % ),C0439673;C1518422;C3541433;C3830527;C4050014
4745,non - detectable / unknown,C0439673;C1518422;C3541433;C3830527;C4050014
4745,no / unknown,C0439673;C3541433;C4050014
4744,sfc ( n   = $nmbr$  $nmbr$ ),C4521536
4744,sfc ( n [ $nmbr$ ),C4521536
4744,sfc ( n = $nmbr$ ),C4521536
4744,sfc $nmbr$ / $nmbr$ pg twice daily ( n = $nmbr$ ),C0030827;C0072225;C0585361;C1266240;C4521536
4743,sfc,C4521536
4743,no . of patients ind / gly sfc,C0017890;C0030705;C0523677;C4049864;C4521536
4742,women  qva $nmbr$ - sfc,C0043210;C4521536
4741,severe cord * : qvai $nmbr$ - sfc,C0205082;C1550235;C1706500;C3489532;C4050465;C4050466;C4521536
4741,moderate cord * : qva $nmbr$ - sfc,C0205081;C1550235;C1706500;C1881878;C3489532;C4049705;C4049706;C4085643;C4321335;C4521536
4740,men : qvai $nmbr$ - sfc,C0025266;C4521536
4739,ics users : qvai $nmbr$ - sfc,C0815320;C1706077;C4521536;C4551720
4739,ics non - users : qvai $nmbr$ - sfc,C0815320;C1518422;C1706077;C4521536;C4551720
4738,ratio fp / sal : sal ( $nmbr$ % ci ),C0008107;C0016704;C0036140;C0037494;C0206136;C0456603;C1419068;C1419906;C1547037;C3259781;C3541238;C3541412
4738,fp / sal $nmbr$ / $nmbr$ pg ( n = $nmbr$ ),C0016704;C0030827;C0036140;C0037494;C0072225;C0206136;C1266240;C1419068;C1419906;C3541238;C3541412
4738,fp ( n   = $nmbr$  $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
4738,fp ( n [ $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
4738,fp ( n = $nmbr$ ),C0016704;C1419068;C1419906;C3541238;C3541412
4738,fp,C0016704;C1419068;C1419906;C3541238;C3541412
4737,fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412
4737,fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412
4736,age distribution  years  n ( % ),C0001782;C0439234;C0520511;C1510829;C1704711
4736,age distribution  n ( % ),C0001782
4736,age distribution,C0001782
4735,age categories ( y )  n ( % ),C2916832
4735,age categories  n ( % ),C2916832
4735,age categories,C2916832
4734,either ocs use  nasal polyps  pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years,C3844638
4733,age at diagnosis of ln  years,C0439234;C0861352;C1428884;C1828181;C3173302;C3714709
4733,age at diagnosis < $nmbr$ years,C0439234;C1828181;C3173302
4733,age at diagnosis  y,C1828181;C3173302
4733,age at asthma diagnosis years,C0004096;C0439234;C1828181;C2984299;C3173302
4732,inotropic agent,C0304509
4731,antithrombotic agents  n ( % ),C1704311
4731,antithrombotic agents,C1704311
4730,age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
4730,age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
4730,age years geographic region,C0017446;C1510829
4730,age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829
4730,age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829
4729,age  years geographical distribution of patients,C0030705;C0681686;C1510829
4729,age  years $nmbr$ ',C1510829
4728,age ≥ $nmbr$ years  n ( % ),C1510829
4728,age ≥ $nmbr$ years,C1510829
4728,age £ $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
4728,age s $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
4728,age at enrolment  years,C1510829;C1516879;C1696073;C3888021
4728,age at enrollment ( years )  mean ( sd ),C0444504;C1510829;C1516879;C1696073;C2347634;C2348143;C2699239;C3888021
4728,age at enrollment ( years ),C1510829;C1516879;C1696073;C3888021
4728,age ( years ) +,C1510829
4728,age ( per $nmbr$ years ),C1510829
4728,age $nmbr$ years ( n = $nmbr$ ),C1510829
4728,age $nmbr$ - $nmbr$ years ( n = $nmbr$ ),C1510829
4728,age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
4728,age  years ^,C1510829
4727,age at entry ( years ),C1510829;C1705654
4726,age at randomization ( years ),C0034656;C1510829
4726,age ( years ) a,C1510829
4725,demographics age ( years ),C0011298;C1510829;C1704791
4725,age > $nmbr$ years ( median ),C1510829
4725,age > $nmbr$ ( years ) t,C1510829
4724,age > = $nmbr$ years old,C1510829
4724,age > = $nmbr$ years,C1510829
4724,age > $nmbr$ years ( n = $nmbr$ ),C1510829
4724,age > $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
4724,age > $nmbr$ years,C1510829
4724,age : > $nmbr$ years,C1510829
4724,age ( years ) : > $nmbr$,C1510829
4724,age ( years ) - > = median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4724,> $nmbr$ years of age,C1510829
4723,age groiro : < $nmbr$ years,C1510829
4723,age category  n ( % ) < $nmbr$ years,C0683312;C1510829;C3889287
4723,age < $nmbr$ years old,C1510829
4723,age < $nmbr$ years ( n = $nmbr$ ),C1510829
4723,age < $nmbr$ years ( n = $nmbr$  $nmbr$ ),C1510829
4723,age < $nmbr$ years ( n =,C1510829
4723,age < $nmbr$ years ( median ),C1510829
4723,age < $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829
4723,age < $nmbr$ years $nmbr$,C1510829
4723,age < $nmbr$ years  n ( % ),C1510829
4723,age < $nmbr$ years,C1510829
4723,age : < $nmbr$ years ( n = $nmbr$ ),C1510829
4723,age : < $nmbr$ years,C1510829
4723,age ( years ) : < $nmbr$,C1510829
4723,age ( years ) : $nmbr$ - < $nmbr$,C1510829
4723,< $nmbr$ years of age,C1510829
4722,mean age  years ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
4722,age range ( years ),C1510829;C1514721;C2348147;C3542016
4722,age range  years,C1510829;C1514721;C2348147;C3542016
4722,age [ years ]  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4722,age < $nmbr$ years — no . ( % ),C1510829
4722,age ( years )  median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4722,age ( range ) ( years ),C1510829;C1514721;C2348147;C3542016
4722,age $nmbr$ years or more,C1510829
4722,age $ $nmbr$ years § *,C1510829
4722,age  years “,C1510829
4722,age  years *,C1510829
4722,age  years  mean ( range ),C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
4722,age  mean ( range ) years,C0444504;C1510829;C1514721;C2347634;C2348143;C2348147;C3542016
4721,age [ years ] ( interaction : p = $nmbr$ . $nmbr$ ),C1510829;C1704675
4721,age ( years ) *,C1510829
4720,mean ± s . d . age  years,C0444504;C1510829;C2347634;C2348143
4720,mean age ± s . d .  years,C0444504;C1510829;C2347634;C2348143
4720,mean age ( years ) race,C0444504;C1510829;C2347634;C2348143
4720,mean age ( years ) ( s . d . ),C0444504;C1510829;C2347634;C2348143
4720,mean age ( years ),C0444504;C1510829;C2347634;C2348143
4720,mean age  years ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4720,mean age  years ( $nmbr$ % ci ),C0008107;C0444504;C1510829;C2347634;C2348143;C3259781
4720,mean age  years,C0444504;C1510829;C2347634;C2348143
4720,mean ( sd ) age in years,C0444504;C1510829;C2347634;C2348143;C2699239
4720,mean ( sd ) age ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,mean ( s . d . ) age  years,C0444504;C1510829;C2347634;C2348143
4720,age — mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age in years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age in years  mean,C0444504;C1510829;C2347634;C2348143
4720,age in years,C1510829
4720,age [ years ],C1510829
4720,age > $nmbr$ years $nmbr$,C1510829
4720,age > $nmbr$ years  n ( % ),C1510829
4720,age > $nmbr$ years  %,C1510829
4720,age . years,C1510829
4720,age - years,C1510829
4720,age - mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age ( years ) mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age ( years ) : mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age ( years ) :,C1510829
4720,age ( years ) - mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age ( years )  mean _ sd,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age ( years )  mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
4720,age ( years ),C1510829
4720,age ( years ( s . d . ) ),C1510829
4720,age $nmbr$ years,C1510829
4720,age $nmbr$ + years,C1510829
4720,age  years mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  years mean ( s . d . ),C0444504;C1510829;C2347634;C2348143
4720,age  years ( mean = sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  years  mean + sd,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  years,C1510829
4720,age  mean years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  mean years  [ sd ],C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  mean = sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
4720,age  ( years ),C1510829
4720,age  $nmbr$ years,C1510829
4720,> $nmbr$ years of age  n ( % ),C1510829
4719,mean age ( years  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,mean age  years ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age years,C1510829
4719,age ( years ) ( mean  sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age ( years  sd ),C1510829;C2699239
4719,age  years ( sd ),C1510829;C2699239
4719,age  years ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  years ( mean $nmbr$ sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  years  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  mean ( sd ) years  n ( % ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  mean ( sd ) years,C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  mean ( sd ) ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
4719,age  mean $nmbr$ sd years,C0444504;C1510829;C2347634;C2348143;C2699239
4718,stage iii,C0441771
4718,gold stage iii,C0018026;C0441771;C1304897
4717,stage ii,C0441767
4717,gold stage ii,C0018026;C0441767;C1304897
4716,edge ii,C0205154;C1710602;C2697523;C4082587
4716,edge,C0205154;C2697523
4715,age — yr age group — no . ( % ),C0027362;C0439234;C2348001
4715,age group 一 ％,C0027362;C2348001
4715,age group — no . ( % ),C0027362;C2348001
4715,age group ( ≥ $nmbr$ years ) — no . ( % ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
4715,age group ( ≥ $nmbr$ ) — no . ( % ),C0027362;C2348001
4715,age group ( years ),C0027362;C0439234;C0441833;C0687744;C1257890;C1510829;C1519504;C1705428;C1705429;C2348001
4715,age group $nmbr$,C0027362;C2348001
4715,age group  no . ( % )  y,C0027362;C2348001
4715,age group  no . ( % ),C0027362;C2348001
4715,age group,C0027362;C2348001
4715,age cohort  no . ( % ),C2348001
4714,age > : $nmbr$,C0001779
4714,age > $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
4714,age < $nmbr$ : qvai $nmbr$ - sfc,C0001779;C4521536
4713,age subgroups,C0001779;C1079230
4713,- [ the null hypothesis is that there are no differences among subgroups  for age and time since randomization  the inter -,C0001779;C1079230;C4684719
4712,median age ( $nmbr$ %  $nmbr$ % )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4712,age   ≥ $nmbr$   y  n ( % ),C0001779
4712,age . y,C0001779
4712,age . . . . . . . . y ( n = $nmbr$ ),C0001779
4712,age  y . o .,C0001779
4711,age b $nmbr$ y ( n = $nmbr$ ),C0001779
4711,age < $nmbr$ yrs,C0001779
4711,age < $nmbr$ y ( n = $nmbr$ ),C0001779
4711,age < $nmbr$ y,C0001779
4711,age < $nmbr$,C0001779
4711,age ( yrs ) < $nmbr$,C0001779
4711,age ' $nmbr$ y ( n $nmbr$ ),C0001779
4711,age  yt,C0001779;C1412122
4711,age  y < $nmbr$,C0001779
4711,< $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
4710,mean age — yr ( range ),C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
4710,mean age — yr,C0001779;C0439234;C0444504;C2347634;C2348143
4710,mean age ( range ) — yr,C0001779;C0439234;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
4710,age — yrf,C0001779
4710,age — yr race — no . ( % ) f,C0001779;C0439234
4710,age — yr,C0001779;C0439234
4710,age *,C0001779
4710,age ( yr ) *,C0001779;C0439234
4710,age ( yr )  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4710,age ( yr ),C0001779;C0439234
4710,age  yr mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4710,age  yr  mean ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4710,age  yr,C0001779;C0439234
4710,age  mean yr ( sd ),C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4710,age  mean ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4709,characteristic age — yr,C0001779;C0439234;C1521970
4709,characteristic age,C0001779;C1521970
4709,age — y £,C0001779
4709,age — y  meantsd,C0001779
4709,age when diabetes first diagnosed — yr,C0001779
4708,age\\yr,C0001779;C0439234
4708,age ^ $nmbr$ yrs  n ( % ),C0001779
4708,age > $nmbr$ yrs  n ( % ),C0001779
4708,age > $nmbr$ yrs  %,C0001779
4708,age > $nmbr$ yrs,C0001779
4708,age > $nmbr$ yr 十,C0001779;C0439234
4708,age > $nmbr$ yr and st - segment changes,C0001779;C0439234
4708,age > $nmbr$ yr and elevated biomarkers,C0001779;C0439234
4708,age > $nmbr$ yr ( % ),C0001779;C0439234
4708,age > $nmbr$ yr  elevated biomarkers  and st - segment changes,C0001779;C0005516;C0205250;C0439234;C3163633
4708,age > $nmbr$ yr,C0001779;C0439234
4708,age > $nmbr$ y  n / n ( % ),C0001779
4708,age > $nmbr$ y  n ( % ),C0001779
4708,age > $nmbr$ y  %,C0001779
4708,age > $nmbr$  %,C0001779
4708,age > $nmbr$,C0001779
4708,age >,C0001779
4708,age < $nmbr$ yr or > $nmbr$ yr,C0001779;C0439234
4708,age < $nmbr$ yr,C0001779;C0439234
4708,age & $nmbr$,C0001779
4708,age $nmbr$ - $nmbr$ yr  elevated biomarkers  and previous vascular,C0001779;C0005516;C0205250;C0439234;C3163633
4708,age $nmbr$ + yrs,C0001779
4708,age $nmbr$ + y,C0001779
4708,age $nmbr$ +,C0001779
4708,age  yr  n ( % ),C0001779;C0439234
4708,age  n ( % ),C0001779
4707,age at completion of highest level of,C0001779;C0205197;C1554962;C4321237
4706,age category >,C0001779;C0683312;C3889287
4706,age > $nmbr$ yrs *,C0001779
4706,age > $nmbr$ y * *,C0001779
4706,age > $nmbr$ y *,C0001779
4706,age > $nmbr$ y ( n = $nmbr$ ),C0001779
4706,age > $nmbr$ y ( % ),C0001779
4706,age > $nmbr$ y,C0001779
4706,age > $nmbr$  y,C0001779
4705,aged a $nmbr$ years,C0001779;C0001792;C1999167
4705,aged ^ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
4705,aged < $nmbr$ years,C0001779;C0001792;C0439234;C1999167
4705,aged $nmbr$ y or older  n ( % ),C0001779;C0001792;C1999167
4705,age ^ $nmbr$,C0001779
4705,age < $nmbr$ vears n = $nmbr$,C0001779
4705,age ' ^ $nmbr$ yrs,C0001779
4704,x cr $nmbr$ . $nmbr$ x age,C0001779;C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
4704,age  x,C0001779
4703,baseline age,C0001779;C0168634;C1442488
4703,age ≥ $nmbr$ yearsa,C0001779
4703,age is > $nmbr$ vrs  significant ecg changes  and positive biomarkers,C0001779
4703,age is > $nmbr$ vrs  significant ecg changes  and no positive bi . omark . ers,C0001779
4703,age is > $nmbr$ vrs  positive biomarkers  and no si . gni . fi . canr ecg changes,C0001779
4703,age at baseline in years  mean ( sd ),C0001779;C0168634;C1442488
4703,age > = $nmbr$ yrs,C0001779
4703,age > = $nmbr$,C0001779
4703,age > $nmbr$ vears n = $nmbr$,C0001779
4703,age $nmbr$,C0001779
4703,age,C0001779
4703,> $nmbr$ yrs of age ( n = $nmbr$  $nmbr$ ),C0001779
4702,infarction before age $nmbr$ ( a ),C0001779;C0021308
4702,age a $nmbr$,C0001779
4702,age ( yrs ) $nmbr$ - $nmbr$,C0001779
4702,age ( p = o - $nmbr$ ),C0001779
4702,age $nmbr$ - $nmbr$ y ( n = $nmbr$ ),C0001779
4702,age $nmbr$ - $nmbr$,C0001779
4702,age  yf $nmbr$ - $nmbr$,C0001779
4701,( b ) age subgroups,C0001779;C1304659
4700,age group ( y ),C0001779;C0441858
4699,age £ $nmbr$,C0001779
4699,age groups  n ( % ),C0001779;C0441848
4699,age group  n ( % ),C0001779;C0441848
4698,mean ± sd age ( y ) mean bmi category ( % ),C0001779;C0444504;C0578022;C0683312;C2347634;C2348143;C2699239;C3889287
4698,mean age ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
4698,mean age  y ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4698,mean ( sd ) age  y,C0001779;C0444504;C2347634;C2348143;C2699239
4698,age ± sd ( yrs ),C0001779;C2699239
4698,age when diabetes first diagnosed ( years )  mean ( sd ),C0001779
4698,age ( y )  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4698,age ( y ),C0001779
4698,age ( sd )  y,C0001779;C2699239
4698,age  yrs,C0001779
4698,age  y mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4698,age  y ( sd ),C0001779;C2699239
4698,age  y ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4698,age  y  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4698,age  mean ( sd )  y,C0001779;C0444504;C2347634;C2348143;C2699239
4698,age  mean  yrs ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4697,mean age 士 s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
4697,mean age ± s . d .  year,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143
4697,mean age ( sd )  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4697,mean age  yrs,C0001779;C0444504;C2347634;C2348143
4697,mean age  y : ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
4697,mean age  y  mean = sd,C0001779;C0444504;C2347634;C2348143;C2699239
4697,mean age  y,C0001779;C0444504;C2347634;C2348143
4697,mean ( sd ) age  yr,C0001779;C0439234;C0444504;C2347634;C2348143;C2699239
4697,age s $nmbr$,C0001779
4697,age :,C0001779
4697,age ( yrs )  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
4697,age ( yrs )  mean *,C0001779;C0444504;C2347634;C2348143
4697,age $nmbr$ y,C0001779
4697,age $nmbr$ $nmbr$ y,C0001779
4697,age $ $nmbr$ yrs,C0001779
4697,age # $nmbr$ yrs,C0001779
4697,age  yrs *,C0001779
4697,age  ya,C0001779
4697,age  y ( mean ± s . d . ),C0001779;C0444504;C2347634;C2348143
4697,age  y  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
4697,age  y,C0001779
4697,age  mean ± sd  y,C0001779;C0444504;C2347634;C2348143;C2699239
4697,age  mean yr,C0001779;C0439234;C0444504;C2347634;C2348143
4697,age  mean ( s . e . ),C0001779;C0444504;C2347634;C2348143
4697,age  mean,C0001779;C0444504;C2347634;C2348143
4696,mean age ( yrs ),C0001779;C0444504;C2347634;C2348143
4696,mean age ( y ) ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4696,mean age ( y ),C0001779;C0444504;C2347634;C2348143
4696,age yrs,C0001779
4696,age ( yrs ),C0001779
4696,age ( yij,C0001779
4696,age ( y ) ∗,C0001779
4696,age ( y ) [ mean - sd ],C0001779;C0444504;C2347634;C2348143;C2699239
4696,age  yrs ( mean ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4696,age  yrs  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4696,age  mean ( sd ) [ range ]  y,C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
4696,age  mean ( sd )  yrs,C0001779;C0444504;C2347634;C2348143;C2699239
4696,age  mean ( min - max ) ( yrs ),C0001779;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
4695,p between age groups,C0001779;C0027362;C0369773;C0441849;C1959644;C2603361
4695,age groups,C0027362
4694,$nmbr$ to < $nmbr$ cel,C0208736;C0346421;C0439237;C1413336
4693,conversion to sinus rhythm in < $nmbr$ days,C1321500
4692,so $nmbr$ %,C0037640
4692,so,C0037640
4691,enox,C3147679
4690,cox bsl onlyc,C1549954;C1565830
4690,cox bsl + yr $nmbr$ hbd,C0439234;C1549954;C1565830
4689,row §,C1552840;C1552846
4689,row * n = $nmbr$,C1552840;C1552846
4689,row,C1552840;C1552846
4688,low ’,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4688,low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4688,low perceived social support only,C0030971;C0037438;C0205171;C0205251;C0748877;C1540833;C1550472;C1720467;C3669642;C3890211;C4048187;C4321351;C4522223
4688,low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4688,low c $nmbr$ / c $nmbr$ and anti - dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4688,low - molecular - weight only,C0026385;C0041667;C0205171;C0205251;C1521991;C1550472;C1720467;C3890211;C4048187;C4321351;C4522223
4688,low - molecular - weight,C0026385;C0041667;C0205251;C1521991;C1550472;C3890211;C4048187;C4321351;C4522223
4688,low - ceiling diuretic,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4688,fgf - $nmbr$ low / egfr > $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
4688,fgf - $nmbr$ low / egfr < $nmbr$,C0016026;C0205251;C0919505;C1550472;C1739039;C3811844;C3812682;C3890211;C4048187;C4321351;C4522223
4688,fgf - $nmbr$ low / > $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
4688,fgf - $nmbr$ low / < $nmbr$ elevated biomarkers,C0005516;C0016026;C0205250;C0205251;C0919505;C1550472;C3163633;C3890211;C4048187;C4321351;C4522223
4687,patients with low ( < $nmbr$ mg / dl ) c $nmbr$,C0030705;C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low { < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low tt < $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1452561;C1550472;C3890211;C4048187;C4321351;C4522223;C4554543
4687,low trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low subgroup,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low periostin subgroup (  $nmbr$ ng / ml ) ( n = $nmbr$ ),C0205251;C0219433;C0439275;C1079230;C1424662;C1515021;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
4687,low normal ( n = $nmbr$ ),C0205251;C0205307;C0231683;C0439166;C1550472;C2347086;C3890211;C4048187;C4321351;C4522223;C4553972
4687,low nfs nfs < - $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0205251;C1513839;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low feno subgroup (  $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205251;C1079230;C1415800;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low c $nmbr$ ( < $nmbr$ mg / dl )  %,C0205251;C0439269;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low c $nmbr$ ( < $nmbr$ . $nmbr$ g / l ),C0205251;C0439294;C0456615;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low - medium microalbuminuria ( n = $nmbr$ ),C0009458;C0205251;C0439536;C0730345;C1550472;C1705217;C3244283;C3890211;C4048187;C4085196;C4321351;C4522223;C4522282;C4522283
4687,low ( no risk factor ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( > $nmbr$ . $nmbr$ and < $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( < $nmbr$ kg / m ^ ) baseline bmi,C0168634;C0205251;C0578022;C1442488;C1532718;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( < $nmbr$ % ) baseline hbalc,C0168634;C0205251;C1442488;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( < $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0168634;C0205251;C1442488;C1550472;C1825777;C3538758;C3890211;C4048187;C4321351;C4522223
4687,low ( < $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( $nmbr$ - $nmbr$ ) ( n = $nmbr$  $nmbr$  $nmbr$ % ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( $nmbr$ - $nmbr$ )  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low ( $nmbr$ - $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low  %,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4687,$nmbr$ low ( n = $nmbr$ ),C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
4686,timi flow ‡,C3272266
4686,timi flow grade $nmbr$ of mi culprit vessel pre ‐ pci,C0005847;C0441800;C0919553;C3244287;C3272266;C3810814
4685,xho  p = o - $nmbr$,C4050013
4684,no . copies gly $nmbr$ - glu $nmbr$ - $nmbr$ c,C0068000;C1948062
4683,- o . os,C2673162
4682,> o - $nmbr$ - ii,C0483204;C1710602;C4082587
4682,$nmbr$ o / $nmbr$ o $nmbr$ ( $nmbr$ - $nmbr$ % ),C0483204
4682,$nmbr$ . $nmbr$ ( $nmbr$ . o - $nmbr$ . o ),C0483204
4682,$nmbr$ ( o - o $nmbr$ - o - $nmbr$ ),C0483204
4682,$nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
4681,o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
4681,o - oi $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0029118;C0029434;C0483204
4681,o $nmbr$ o ( oo $nmbr$ - o - $nmbr$ o ),C0483204
4681,- o - oo $nmbr$ ( - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0483204
4681,- o $nmbr$ o ( - $nmbr$ - loto - $nmbr$ - $nmbr$ ),C0483204
4681,$nmbr$ - $nmbr$ { o - $nmbr$ - $nmbr$ - o $nmbr$ ),C0483204
4681,$nmbr$ - $nmbr$ ( o - $nmbr$ s - o - $nmbr$ ),C0483204
4681,$nmbr$ - $nmbr$ ( o - $nmbr$ o - o - $nmbr$ ),C0483204
4681,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ o ),C0483204
4681,$nmbr$ - $nmbr$ ( o - $nmbr$ - o - $nmbr$ ),C0483204
4681,$nmbr$ - $nmbr$ ( o - $nmbr$ - $nmbr$ - oo ),C0483204
4681,$nmbr$ - $nmbr$ ( o $nmbr$ - o - $nmbr$ ),C0483204
4680,o $nmbr$,C0483204
4680,$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0483204
4679,o $nmbr$ kg  n ( % ),C0022718;C0439209;C0483204;C4054209
4679,o,C0483204
4678,lo ( lo - lo ),C0206579;C1232424
4678,$nmbr$ . $nmbr$ ( lo . i ),C0021966;C0206579;C0221138;C1232424
4678,$nmbr$ . $nmbr$ ( lo - $nmbr$ . $nmbr$ ),C0206579;C1232424
4677,eo severity by la classification at baseline ( baseline of the healing study )  n ( % ),C0332120;C0439793;C0522510;C1881447
4677,eo,C0332120
4676,p value for dm vs . no dm,C4086240
4675,tp vs no tp,C0036183;C3541334
4674,qol due to urinary symptoms,C0426359;C0518214;C0678226
4673,amputation due to diabetes — no . ( % ),C0598284;C0678226
4672,time of symptom onset to randomization ( hrs ),C1320528
4672,time of symptom onset to balloon inflation ( hrs ),C1320528
4672,time from onset of symptoms to start of fibrinolytic therapy — hr,C1320528
4672,time from onset of symptoms to randomization — days,C1320528
4672,time from onset of symptoms to presentation — hr,C1320528
4671,ho active cancer,C0006826;C0019905;C0205177;C0998265;C1306459;C1832110;C3853793;C3888249;C3889614
4671,ho,C0019905;C1832110;C3889614
4670,network,C0150775;C1513822;C1705739;C1882071
4669,work and school,C0043227
4669,percent work time missed due to asthma,C0040223;C0043227;C0439165;C3541383
4668,assigned to topiramate,C1516050;C1552601
4668,assigned to placebo,C0032042;C1516050;C1552601;C1696465;C1706408
4667,duration of assigned regimen before surgery post - randomisation characteristic * *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
4667,duration of assigned regimen before surgery post - randomisation characteristic *,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
4667,duration of assigned regimen before surgery,C0040808;C0449238;C1516050;C1552601;C2926735;C2945654
4666,cutoffs,C1442160
4665,history of percutaneous coronary intervention,C1320647;C4554713
4664,percutaneous coronary intervention or coronary - artery bypass grafting for index acute coronary syndrome — no . { % ),C1532338
4664,percutaneous coronary intervention done *,C1532338
4664,index percutaneous coronary intervention,C0600653;C0918012;C1532338;C1552854;C1637833;C2986546
4663,previous percutaneous coronary intervention  %,C0205156;C1532338;C1552607
4663,previous percutaneous coronary intervention,C0205156;C1532338;C1552607
4663,percutaneous coronary revascularization,C1532338
4663,percutaneous coronary intervention §,C1532338
4663,percutaneous coronary intervention or coronary artery bypass graft surgery  n ( % ),C1532338
4663,percutaneous coronary intervention n ( % ),C1532338
4663,percutaneous coronary intervention  n ( % ),C1532338
4662,prior percutaneous coronary intervention — no . / total no . ( % ),C0332152;C1532338;C2826257
4662,prior percutaneous coronary intervention — no . ( % ),C0332152;C1532338;C2826257
4662,prior percutaneous coronary intervention  n ( % ),C0332152;C1532338;C2826257
4662,prior percutaneous coronary intervention,C0332152;C1532338;C2826257
4662,percutaneous coronary intervention,C1532338
4661,subcutaneous unfractionated heparin,C0353681
4660,subcutaneous injections,C0021499
4659,periprocedural anticoagulant,C0003280;C0848112;C3536711
4659,intravenous anticoagulant prior to pre - pci angiography,C0002978;C0003280;C0332152;C0348016;C0740175;C0848112;C2257086;C3536711;C3669034;C4049621
4659,intravenous anticoagulant during hospitalization,C0003280;C0019993;C0348016;C0848112;C3536711
4659,intravenous anticoagulant during hospitalisation *,C0003280;C0019993;C0348016;C0848112;C3536711
4658,anti - coagulants - no . ( % ),C0848112
4658,anti - coagulants,C0848112
4657,other anticoagulant,C0003280;C0848112;C3536711
4657,concomitant anticoagulant  antithrombotic or nsaid  n ( % ),C0003280;C0521115;C0848112;C3536711
4657,any anticoagulant,C0003280;C0848112;C3536711
4657,anticoagulants,C0003280
4657,anticoagulant — no . ( % ),C0003280;C0848112;C3536711
4657,anticoagulant group ( n = $nmbr$ ),C0003280;C0441848;C0848112;C3536711
4657,anticoagulant,C0003280;C0848112;C3536711
4656,gait,C0016928
4655,therapy - fatigue ( facit - f  $nmbr$ - $nmbr$ ),C0015672;C0039798;C0087111;C1363945;C3272505;C3463815;C4050243;C4554645
4655,facit - f,C3272505
4654,paclitaxel - eluting stent use  n ( % ),C0038257;C0042153;C0144576;C0457083;C1947944
4654,paclitaxel - eluting,C0144576
4654,paclitaxel,C0144576
4653,iwqol - lite total score ( arbitrary units ) #,C0439183;C2964552
4652,iwqol - lite physical score ( arbitrary units ),C0439183;C4483112
4651,limited i -,C0021966;C0221138;C0439801;C2674459;C3542948;C4050251
4651,limited,C0439801;C2674459;C3542948;C4050251
4650,tertile $nmbr$ index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
4650,previous pci ( before index acs ),C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4049621;C4318612
4650,pci performed,C4049621
4650,index pci performed,C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
4650,before pci,C4049621
4649,pci postindex event,C0441471;C4019010;C4049621
4649,pci or cabg surgery for index event,C4049621
4649,pci for index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
4649,morphine use for index event / pci,C0242000;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010;C4049621
4648,no pci or cabg — no . ( % ),C4049621
4648,gp iib / iiia inhibitor before pci — no . ( % ),C0016011;C1999216;C4049621
4647,primary pci no .,C0205225;C0439612;C0439631;C4049621
4647,no pci,C4049621
4646,treated with pci — no . / total no . ( % ),C0332293;C4049621
4646,pci — no . { % ),C4049621
4645,pci — no . ( % ),C4049621
4645,history of pci — no . / total no . ( % ) : t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
4644,single vessel pci,C0005847;C0037179;C0087136;C0205171;C4049621
4644,multivessel pci,C4049621
4643,timi flow grade $nmbr$ of mi culprit vessel post ‐ pci,C0005847;C0441800;C0856742;C0919553;C3244287;C3272266;C4049621
4643,$nmbr$ vessel pci,C0005847;C4049621
4642,previous stenting ( % previous pci ),C0038257;C0205156;C1552607;C2348535;C4049621
4642,previous pci or cabg,C0205156;C1552607;C4049621
4642,previous pci ( % total ),C0205156;C0439175;C0439810;C1552607;C4049621
4642,previous pci  n ( % ),C0205156;C1552607;C4049621
4642,previous pci,C0205156;C1552607;C4049621
4642,pci orcabg,C4049621
4642,pci ( % ),C4049621
4642,pci  n ( % ),C4049621
4641,pci :,C4049621
4641,: mi  previous pci and chronic obstructive pulmonary disease .,C0205156;C1552607;C3810814;C4049621
4640,and after pci  median ( iqr )  d,C0549183;C0876920;C2347635;C2348144;C2939193;C4049621
4640,after pci,C4049621
4639,pci delay due to low risk,C4049621
4639,pci data,C1511726;C3245479;C3714741;C4049621
4638,ret / abx - facil . pci,C0389252;C4049621
4638,abx - facil . pci,C4049621
4637,facilitated pci ( n = $nmbr$ ),C4049621
4637,abciximab - facilitated pci ( n = $nmbr$ ),C0288672;C4049621
4637,abciximab - facilitated pci,C0288672;C4049621
4636,combo - facilitated pci,C4049621
4636,combination - facilitated pci ( % ),C0205195;C1947911;C3811910;C4049621
4635,use of pci or thrombolysis within one day of randomization,C1524063;C4049621
4634,pci revascularization,C0581603;C4049621
4633,prerandomization pci,C4049621
4633,pre - randomization pci,C0034656;C0332152;C0740175;C2257086;C3669034;C4049621
4633,pci,C4049621
4632,pi,C0122626;C0429863;C3537219;C3539772
4631,sita / pio $nmbr$ / $nmbr$,C0030800;C2347712
4631,sita $nmbr$ + pio $nmbr$,C0030800;C2347712
4631,pio $nmbr$,C0030800;C2347712
4630,xi = ° - ° $nmbr$,C1720296
4630,xi = oo  p = o - $nmbr$,C1720296
4630,xi = o - $nmbr$  p = o - $nmbr$,C1720296
4630,xi = l ’ $nmbr$  p = $nmbr$ - $nmbr$,C1720296
4630,xi = $nmbr$ . $nmbr$,C1720296
4630,xi = $nmbr$ - l  p = $nmbr$ - $nmbr$,C1720296
4630,xi = $nmbr$ - $nmbr$  p = o - l,C1720296
4630,xi = $nmbr$ - $nmbr$  p = $nmbr$ - l,C1720296
4630,xi = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,C1720296
4630,xi = $nmbr$ - $nmbr$  p = $nmbr$,C1720296
4630,xi = $nmbr$ - $nmbr$,C1720296
4630,xi = $nmbr$,C1720296
4629,vi - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
4629,vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999
4629,ff / vi $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C0205999;C4554348
4629,ff / vi $nmbr$ % ( $nmbr$ %  $nmbr$ % ),C0205999;C4554348
4629,difference ff / vi versus uc  %,C0205999;C1705241;C1705242;C4554348
4628,umec / vi $nmbr$ . $nmbr$ / $nmbr$ ( n $nmbr$ $nmbr$ ),C0205999
4628,umec / vi $nmbr$ . $nmbr$ / $nmbr$,C0205999
4628,hazard ratio  umec / vi vs . tio ( $nmbr$ % ci ),C0205999;C2985465
4628,$nmbr$ . $nmbr$ % vi . $nmbr$ . $nmbr$ %,C0205999
4628,$nmbr$ . $nmbr$ % vi  $nmbr$ . $nmbr$ %,C0205999
4627,infrequent exacerbator,C0521114
4626,influenza,C0021400;C0021403
4625,orthopnea  frequent / continuous,C0085619;C0332183;C0549178
4625,frequent or continuous,C0332183
4625,dyspnea  frequent / continuous,C0013404;C0332183;C0549178;C1963100
4625,dyspnea  % ( frequent / continuous ),C0013404;C0332183;C0549178;C1963100
4624,most frequent serious teaes,C0205393;C0205404;C0332183
4624,most frequent aesa,C0205393;C0332183
4624,frequent exacerbator,C0332183
4623,presentation to tertiary care hospital — %,C0337954;C0449450
4622,dx at presentation  n ( % ),C0449450;C3538936
4621,presentation *,C0449450
4621,acs presentation,C0449450;C0742343;C4318612
4620,syndesmophyte present  n ( % ),C0150312;C0221690;C0449450
4619,present smokerc,C0150312;C0449450
4619,present smoker,C0150312;C0337664;C0449450
4618,present,C0150312;C0449450
4618,dm present,C0011816;C0150312;C0449450;C3250443
4617,theophylline use at screening,C0220908;C0220909;C0241361;C1698960;C1710031;C1710032;C1710477;C2348164
4617,smoking status at screening,C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
4617,screening visit,C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
4617,screening prebronchodilator fev $nmbr$  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541
4617,screening absolute reversibility fev $nmbr$  ml,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,screening ( visit $nmbr$ ),C0220908;C0220909;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
4617,screening  mean ( sd ) morning pef  mean,C0030771;C0220908;C0220909;C0332170;C0444504;C1518922;C1542834;C1698960;C1710031;C1710032;C1710477;C2347634;C2348143;C2348164;C2699239
4617,screening  l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,present at screening,C0150312;C0220908;C0220909;C0449450;C1698960;C1710031;C1710032;C1710477;C2348164
4617,oad at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,no . in the $nmbr$ mo before screening,C0026544;C0220908;C0220909;C0332177;C1698960;C1710031;C1710032;C1710477;C2348164
4617,modified rankin scale at screening  $nmbr$ - $nmbr$,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2984908;C3854213
4617,mean blood pressure at screening visit ( mm hg ),C0220908;C0220909;C0428886;C0439475;C0488053;C0545082;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
4617,lama use at screening,C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
4617,laba use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
4617,laba use at screening,C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
4617,inhaled glucocorticoid use at screening,C0004048;C0017710;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
4617,background aha therapy at screening  n ( % ) §,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
4617,background aha therapy at screening  n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
4617,background aha therapy at screening  n,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
4617,background aha therapy at screening  a   n ( % ),C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
4617,background aha therapy at screening  a,C0039798;C0050451;C0087111;C0220908;C0220909;C0772110;C1363945;C1698960;C1706907;C1710031;C1710032;C1710477;C2348164
4617,at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4617,> $nmbr$ per pl at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3897966;C4049765
4617,> $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4616,screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
4616,pre - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599602;C3714541;C3887665
4616,pre - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599602
4616,postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
4616,post - bronchodilator screening fev $nmbr$ ml,C0220908;C0220909;C0439526;C1698960;C1705224;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541;C3887665
4616,post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594
4616,post - bronchodilator fev $nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3714541
4615,screening fev $nmbr$   % predicted,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
4615,screening % predicted fev $nmbr$,C0220908;C0220909;C0681842;C1698960;C1710031;C1710032;C1710477;C1882327;C2348164;C3714541
4615,predose fev ^ at screening,C0220908;C0220909;C0439565;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541;C3812758
4615,postdose fev / fvc at screening,C0220908;C0220909;C0439568;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
4615,fev $nmbr$   at screening ∗,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3714541
4614,all recurrent strokes,C1836785
4613,any recurrent stroke,C2242682
4612,current smokers    n   ( % ),C3173209;C3241966
4612,current smokers  %,C3173209;C3241966
4612,current smoker at baseline    n   ( % ),C0168634;C1442488;C3173209;C3241966
4612,current smoker  n [ % ],C3173209;C3241966
4612,current smoker  n ( % },C3173209;C3241966
4612,current smoker  %,C3173209;C3241966
4611,current smoker yes,C1549445;C1705108;C1710701;C3173209;C3241966
4611,current smoker : ex - smoker ( % ),C3173209;C3241966
4610,current smoker 一 no . ( % ),C3173209;C3241966
4610,current smoker — no . { % ),C3173209;C3241966
4610,current smoker — no . of patients ( % ),C3173209;C3241966
4610,current smoker — no . / total no . ( % ),C3173209;C3241966
4610,current smoker — no . ( % ) blood pressure — mm hg,C3173209;C3241966
4610,current smoker — no . ( % ),C3173209;C3241966
4610,current smoker at screeninga  n ( % ),C3173209;C3241966
4610,current smoker at screening  n ( % ),C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C3173209;C3241966
4610,current smoker ( n z $nmbr$ ),C3173209;C3241966
4610,current smoker ( % ),C3173209;C3241966
4610,current smoker  no . ( % ),C3173209;C3241966
4610,current smoker  no ( % ),C3173209;C3241966
4610,current smoker  n ( % of patients ),C0030705;C3173209;C3241966
4610,current smoker  n ( % ) post - bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C2599594;C3173209;C3241966
4610,current smoker  n ( % ),C3173209;C3241966
4610,current smoker,C3173209;C3241966
4610,> $nmbr$ . $nmbr$ bpm current smoker,C3173209;C3241966
4609,smoking status current smoker ( n = $nmbr$ ),C1519386;C3173209;C3241966
4609,current smokers *,C3173209;C3241966
4609,current smokers ( n = $nmbr$ ),C3173209;C3241966
4609,current smokers ( itt ) ( n = $nmbr$ ),C3173209;C3241966
4609,current smoker »,C3173209;C3241966
4609,current smoker ( n = $nmbr$ ),C3173209;C3241966
4609,current smoker ( n = $nmbr$  $nmbr$ ) former smoker ( n = $nmbr$  $nmbr$ ),C0205156;C0750523;C3173209;C3241966
4609,current smoker ( n = $nmbr$  $nmbr$ ),C3173209;C3241966
4608,current smokers ( % ),C3173209;C3241966
4608,current smokers  n ( % ) medicai history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3173209;C3241966
4608,current smokers  n ( % ),C3173209;C3241966
4608,current smokers,C3173209;C3241966
4608,current smoker  n / n ( % ),C3173209;C3241966
4607,concurrent prednisolone,C0032950;C0205420
4606,concurrent illness,C0205420;C0221423
4605,current inhaler +,C0021461;C0521116;C1705970;C1881212;C4319647
4604,currently smokes,C0521116
4604,currently smoker,C0337664;C0521116
4603,current tobacco smoker ( % ) qualifying event ( % ),C0040329;C0086707;C0441471;C0521116;C0740009;C1514624;C1705970;C3173209;C3241966;C4019010;C4505217
4603,current tobacco smoker,C0040329;C0086707;C0521116;C0740009;C1705970;C3173209;C3241966;C4505217
4602,smoker ( current / former ),C0205156;C0337664;C0521116;C0750523;C1705970
4602,former / current smoker ( n = $nmbr$ $nmbr$ ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
4602,current or former smoker,C0521116;C1705970
4601,current bone disease,C0005940;C0521116;C1705970
4600,postmenopausal  current hormone,C0019932;C0232970;C0521116;C1705970;C4521914
4600,current use of hormone therapy,C0019932;C0279025;C0521116;C1524063;C1705970;C2827774;C4521914
4599,duration of current flare  median ( range ) months ( n = $nmbr$  $nmbr$  $nmbr$ ),C0439231;C0449238;C0521116;C0549183;C0876920;C1514721;C1517205;C1705970;C2347635;C2348144;C2348147;C2926735;C2939193;C3540542;C3542016
4599,current dactylitis  n,C0239161;C0521116;C1705970
4599,current ( n   = $nmbr$  $nmbr$ ),C0521116;C1705970
4598,current prescribed medications,C0521116;C1705970;C3166216;C3202967
4598,current other ( predefined ) medical conditions,C0521116;C1705970
4597,current or previous atrial fibrillation,C0521116;C1705970
4597,current atrial fibrillation or flutter on ecg,C0004238;C0344434;C0521116;C1705970;C1963067
4597,current,C0521116;C1705970
4596,current lra use,C0521116;C1705970
4596,current laba use,C0042153;C0457083;C0521116;C1705970;C1947944
4595,current cigarette use  n ( % ),C0521116;C0694535;C1705970
4595,current cigarette use,C0521116;C0694535;C1705970
4594,current inhaled corticosteroid use,C0004048;C0239126;C0521116;C1705970
4594,current corticosteroid use  n,C0239126;C0521116;C1705970
4593,current tobacco abuse  n ( % ),C0040336;C0521116;C1705970
4593,current n z $nmbr$,C0521116;C1705970
4593,current cigarette smoker  n ( % ),C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
4593,current cigarette  n ( % ),C0521116;C0677453;C1704760;C1705970;C3890423
4593,current  n ( % ),C0521116;C1705970
4592,current angina ( % ),C0002962;C0521116;C1705970
4592,current angina,C0002962;C0521116;C1705970
4591,years  n ( % ) smoking  n ( % ) current,C0037369;C0439234;C0453996;C0521116;C1705970;C1881674
4591,smoking  % current,C0037369;C0453996;C0521116;C1705970;C1881674
4591,current smoking  n ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
4591,current smoking  %,C0037369;C0453996;C0521116;C1705970;C1881674
4591,current or prior smoking  %,C0521116;C1705970
4591,current ( % ),C0521116;C1705970
4590,currently on aha therapy,C0039798;C0050451;C0087111;C0521116;C0772110;C1363945
4590,currently,C0521116
4589,glycaemic control group,C0005802;C0009932
4588,events / control group,C0009932;C0441471;C3541888
4588,control group,C0009932
4587,grip strength < meidan,C0429271;C2598165
4587,grip strength ( kg ),C0022718;C0429271;C0439209;C2598165;C4054209
4586,p j $nmbr$ * trend,C1518835;C1521798;C4554533
4585,trend / het . test,C1521798;C4554533
4585,test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C1521798;C3831328;C4318744;C4554533
4585,pfor trend,C1151635;C1521798;C4554533
4584,pvaluefor trend,C1521798;C4554533
4584,p value for trend across tertiles,C1521798;C1709380;C4554533
4584,p value for trend *,C1521798;C1709380;C4554533
4584,p value for trend,C1521798;C1709380;C4554533
4584,p - value for trend across categories,C1521798;C1709380;C4554533
4584,p - value ( trend ),C1521798;C1709380;C4554533
4583,p trend,C0369773;C1521798;C2603361;C4554533
4583,p for trend -,C0369773;C1521798;C2603361;C4554533
4583,p for trend,C0369773;C1521798;C2603361;C4554533
4582,sleep,C0037313
4581,on step - $nmbr$ drug  %,C0013227;C1254351;C1261552;C1704379;C1705117;C2825408;C3814463
4581,. $nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463
4581,$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
4580,etn  no,C0014758;C0717758
4580,etanercept ( n = $nmbr$ ),C0717758
4580,etanercept,C0717758
4579,losartan  n / n ( % ),C0126174
4579,losartan,C0126174
4579,ci  confidence interval  esrd  end - stage renal disease  n / n  number of patients who had an event / total number of patients . aadjusted with terms including treatment ( losartan or placebo )  geographic region  genotype  and the treatment  genotype interaction . bp value for treatment  genotype interaction ( i . e .  comparison of the losartan treatment effect between the $nmbr$ genotype groups ) .,C0008107;C0009667;C0017431;C0017446;C0022661;C0030705;C0039798;C0087111;C0126174;C0205147;C0233324;C0683454;C1280500;C1515273;C1518681;C1522326;C1533734;C1704675;C1705169;C1705313;C1707455;C2348382;C2360800;C2826302;C3259781;C3538994;C3887704
4578,treated with losartan ( n = $nmbr$ ),C0126174;C0332293
4578,losartan ( n = $nmbr$ ),C0126174
4578,losartan ( n = $nmbr$  $nmbr$ ),C0126174
4577,losartan plus placebo ( n = $nmbr$ ),C0032042;C0126174;C0332287;C1696465;C1706408
4577,losartan n = $nmbr$,C0126174
4576,telmisartan group ( n = $nmbr$ ),C0248719;C0441848
4576,telmisartan ( n = $nmbr$ ),C0248719
4576,telmisartan ( n = $nmbr$  $nmbr$ ),C0248719
4576,telmisartan,C0248719
4575,irbesartan ( n = $nmbr$ ),C0288171
4575,irbesartan,C0288171
4574,tolvaptan ( n = $nmbr$ ),C1176308
4574,tolvaptan,C1176308
4573,favors dabigatran,C0309049;C2348066
4572,factors dabigatran event incidence / n,C0021149;C0220856;C0441471;C1521761;C2348066;C2827422;C4019010
4572,factors dabigatran,C1521761;C2348066;C2827422
4571,dabigatran ( n = $nmbr$ ),C2348066
4571,dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066
4571,dabigatran $nmbr$ vs . warfarin p ( inter ),C2348066
4571,dabigatran $nmbr$ mg bid events / n ( % / y ),C0024671;C0026410;C0439269;C0441471;C1960952;C2346927;C2348066;C3541888;C4321396;C4521761
4571,dabigatran $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran  $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran  $nmbr$ mg  vs . warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,dabigatran,C2348066
4571,$nmbr$ mg dabigatran ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4571,$nmbr$ mg dabigatran,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
4570,indomethacin,C0021246
4569,enoxaparin only,C0205171;C0206460;C1720467
4569,enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0206460
4569,enoxaparin / vka,C0206460
4568,extended - duration enoxaparin ( n = $nmbr$ ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
4568,extended - duration enoxaparin  n / n ( % ),C0206460;C0231448;C0231449;C0439792;C0449238;C2926735
4568,enoxaparin ( n = $nmbr$ ),C0206460
4568,enoxaparin ( n = $nmbr$  $nmbr$ ),C0206460
4567,enoxaparin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0206460;C0439269;C1960952;C2346927;C4321396;C4521761
4567,enoxaparin,C0206460
4566,doxazosin group,C0114873;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
4566,doxazosin,C0114873
4565,higher dose edoxaban regimen,C0205250;C2348331;C2975435
4564,higher - dose edoxaban ( n = $nmbr$ )  n ( % / y ),C0444956;C2975435
4564,edoxaban n = $nmbr$ n / n ( % ),C2975435
4564,edoxaban n = $nmbr$,C2975435
4564,edoxaban ( n = $nmbr$ ),C2975435
4563,ld edoxaban vs warfarin,C0694649;C2975435
4563,hd edoxaban vs warfarin,C2975435
4563,edoxaban warfarin,C0043031;C2975435
4563,edoxaban vs . warfarin,C2975435
4563,edoxaban lower dose vs warfarin,C2975435
4562,hr with edoxaban ( $nmbr$ % ci ),C0008107;C2975435;C3259781
4562,edoxaban,C2975435
4561,rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0332287;C1739768
4561,rivaroxaban plus aspirin ( n = $nmbr$ ),C0004057;C0332287;C1739768
4561,rivaroxaban plus aspirin ( $nmbr$ % cl ),C0004057;C0332287;C0596019;C1739768
4561,rivaroxaban plus,C1739768
4561,rivaroxaban ( n = $nmbr$ ),C1739768
4560,rivaroxaban +,C1739768
4560,rivaroxaban ( n   = $nmbr$ ),C1739768
4560,low - dose rivaroxaban plus aspirin ( n = $nmbr$ ),C0332287;C1739768;C2608320
4560,low - dose rivaroxaban + aspirin ( n / n ),C1739768;C2608320
4559,rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1739768;C1960952;C2346927;C4321396;C4521761
4559,rivaroxaban,C1739768
4558,apixaban vs . placebo,C1831808
4558,apixaban dose ( or matching placebo ),C0178602;C0869039;C1114758;C1831808
4558,apixaban ( n = $nmbr$ ),C1831808
4558,apixaban,C1831808
4557,nilvadipine,C0132512
4556,amlodipine / valsartan $nmbr$ / $nmbr$ vs $nmbr$ / $nmbr$ mg,C1962523
4556,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ i ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
4556,amlodipine / valsartan $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
4556,amlodipine / valsartan $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
4556,amlodipine - amlodipine / valsartan,C1962523
4555,valsartan n / n,C0216784
4555,valsartan / hctz ( n = $nmbr$ ),C0020261;C0216784
4555,valsartan / hctz  n / n ( % ),C0020261;C0216784
4555,valsartan / hctz,C0020261;C0216784
4555,valsartan ( n = $nmbr$ ),C0216784
4555,valsartan  n / n ( % ),C0216784
4555,valsartan  n ( % ),C0216784
4555,valsartan,C0216784
4554,linagliptin ( n z $nmbr$ ),C2746078
4554,linagliptin ( n = $nmbr$ ) ',C2746078
4554,linagliptin ( n = $nmbr$ ),C2746078
4554,comparator - linagliptin,C1707454;C2746078;C4553389;C4553390
4553,linagliptin  patients with events / total patients,C0030705;C0439175;C0439810;C0441471;C2746078;C3541888
4553,linagliptin,C2746078
4552,vildagliptin ( n = $nmbr$ ),C1570906
4552,vildagliptin $nmbr$ mg daily + glimepiride,C0024671;C0026410;C0061323;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
4552,vildagliptin $nmbr$ mg daily,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
4552,vildagliptin,C1570906
4551,sitagliptin ± oad,C1565750
4551,sitagliptin no . / total no .,C1565750
4551,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l ),C0202042;C0376674;C0455280;C1418888;C1565750;C2827804
4551,sitagliptin,C1565750
4550,sitagliptin n = $nmbr$,C1565750
4550,sitagliptin ( n = $nmbr$ ),C1565750
4550,sitagliptin $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1565750;C1960952;C2346927;C4321396;C4521761
4550,sitagliptin $nmbr$,C1565750
4549,unhappy,C1688635
4548,nap,C0870935;C1423800;C4283878
4547,enalapril lcz $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),C0014025
4547,enalapril dm = $nmbr$ non - dm = $nmbr$,C0011816;C0014025;C3250443
4547,enalapril ( n = $nmbr$ ),C0014025
4547,enalapril,C0014025
4546,trandolapril ( n = $nmbr$ ),C0076891
4546,trandolapril,C0076891
4545,tadalafil $nmbr$ mg mean change ( sd ),C0024671;C0026410;C0392747;C0439269;C0443172;C0444504;C1176316;C1705241;C1960952;C2346927;C2347634;C2348143;C2699239;C4319952;C4321396;C4521761
4545,tadalafil,C1176316
4544,saxagliptin ( n = $nmbr$  $nmbr$ ),C1611934
4544,saxagliptin ( % ),C1611934
4544,saxagliptin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4544,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4544,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4543,saxagliptin $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4543,saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4543,saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ ),C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4543,saxagliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1611934;C1960952;C2346927;C4321396;C4521761
4543,saxagliptin,C1611934
4542,saxagliptin ( n = $nmbr$ ),C1611934
4542,> = $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
4541,with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
4541,with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
4541,with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
4541,with alogliptin $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1958126;C1960952;C2346927;C4321396;C4521761
4541,alogliptin ( n = $nmbr$ ),C1958126
4541,alogliptin  n ( % ),C1958126
4541,alogliptin,C1958126
4540,allopurinol $nmbr$ mg ( n = $nmbr$ ) +,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
4540,allopurinol,C0002144
4539,alirocumab n = $nmbr$,C3491162
4539,alirocumab ( n = $nmbr$ ),C3491162
4539,alirocumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
4539,alirocumab,C3491162
4538,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx ( n = $nmbr$ ),C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
4538,rituximab  n = $nmbr$,C0393022
4538,rituximab,C0393022
4537,reslizumab ( n = $nmbr$ ),C1869620
4537,reslizumab $nmbr$ . $nmbr$   mg / kg ( n   = $nmbr$ ),C0439272;C1869620
4537,reslizumab $nmbr$ . $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1869620
4537,reslizumab,C1869620
4537,b reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
4537,a reslizumab $nmbr$ . $nmbr$ mg / kg n / n,C0439272;C1869620
4536,vedolizumab n = $nmbr$,C2742797
4536,vedolizumab cohort $nmbr$ ( n = $nmbr$ ),C0009247;C0599755;C2742797
4536,vedolizumab,C2742797
4535,mepolizumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
4535,mepolizumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0969324;C1960952;C2346927;C4321396;C4521761
4535,mepolizumab,C0969324
4534,denosumab ( n = $nmbr$ ) n ( % ),C1690432
4534,denosumab ( n = $nmbr$ ),C1690432
4534,denosumab,C1690432
4533,ustekinumab combined,C1608841
4533,placebo to ustekinumab $nmbr$ mgt,C0032042;C1608841;C1696465;C1706408
4532,ustekinumab ® ( n = $nmbr$ ),C1608841
4532,ustekinumab ' ’ ( n = $nmbr$ ),C1608841
4532,ustekinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1608841;C1960952;C2346927;C4321396;C4521761
4532,ustekinumab,C1608841
4531,jejunum,C0022378
4530,secukinumab pooled †   ( n   = $nmbr$ ),C1709595;C2349200;C3179547;C4522255
4530,pooled secukinumab,C1709595;C2349200;C3179547;C4522255
4530,any secukinumab ( n   = $nmbr$ ),C3179547
4529,secukinumab,C3179547
4529,placebo secukinumab pooled,C0032042;C1696465;C1706408;C3179547
4529,placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0032042;C0439269;C1696465;C1706408;C1960952;C2346927;C3179547;C4321396;C4521761
4528,stent plus abciximab,C0038257;C0288672;C0332287
4528,stent / abciximab - stent / placebo,C0032042;C0038257;C0288672;C1696465;C1706408
4528,abciximab vs . primary,C0288672
4528,abciximab no . / total ( % ),C0288672
4528,abciximab,C0288672
4527,reteplase / abciximab - facilitated pci ( n = $nmbr$ ),C0256103;C0288672;C4049621
4527,abciximab ( n = $nmbr$ ),C0288672
4527,$nmbr$ abciximab ( n = $nmbr$ ),C0288672
4526,alpha reductase inhibitors,C0439095;C0597153;C1655741;C2003941;C2350010
4525,alpha receptor antagonist,C0439095;C2003941;C2350010;C4543207
4524,no . previous alpha - blocker use,C0001641;C0042153;C0205156;C0457083;C1552607;C1947944
4524,alpha blockers,C0001641
4524,alpha - blockers,C0001641
4524,alpha - blocker / other vasodilator,C0001641
4524,alpha - blocker,C0001641
4524,alpha $nmbr$ blockers,C0001641
4523,ultra,C0728475
4522,lira,C1555441
4522,ideglira - ideg - lira,C1555441;C4308663
4521,physician global assessment of disease,C0012634;C4050369
4520,physician ' s global assessment of dis -,C0451119;C1444662;C1970187;C4050369
4519,physician ' s global assessment . mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239;C4050369
4519,physician ' s global assessment,C4050369
4518,physician ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4050369
4518,physician ' s global assessment !,C4050369
4517,mean pga score ± sd,C0016410;C2699239;C3533236;C3541266;C4050369
4516,pga subscore,C0016410;C3541266;C4050369
4516,pga score ( range ),C0016410;C0449820;C1514721;C2348147;C3541266;C3542016;C4050231;C4050369
4515,pga  $nmbr$ - $nmbr$,C0016410;C3541266;C4050369
4515,no worsening in pga  %,C0016410;C0332271;C1457868;C1546960;C3541266;C4050369
4514,bempedoic acid ( n = $nmbr$ ),C3659310
4513,acid,C0001128;C0202406
4512,serum uric acid  n,C0455272;C0700634
4512,serum uric acid  difference vs placebo ( $nmbr$ % cl ),C0455272;C0700634;C1705241;C1705242
4511,acd,C4554601
4510,ethacrynic acid,C0014963
4509,zoledronic acid arm,C0257685;C0446516;C3715044;C4553528
4509,zoledronic acid ( n = $nmbr$ ),C0257685
4509,zoledronic acid,C0257685
4508,categories of urinary acr  ^ g / mg,C0042027;C0683312;C1300563;C1412134;C1515941;C1524119
4508,acr > $nmbr$ mg / g,C1300563;C1412134;C1515941
4507,acr ( mg / g )  mean ( sd ),C0444504;C1300563;C1412134;C1515941;C2347634;C2348143;C2699239
4507,acr $nmbr$,C1412134;C1515941
4506,urine acr geometric mean ( cv % )  a  b mg / g,C0042036;C0042037;C1300563;C1412134;C1515941;C2963137;C2986759;C3538987;C4048877;C4318503
4506,urine acr > = median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
4506,urine acr < median,C0042036;C0042037;C0549183;C0876920;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
4506,urine acr ( mg / mmol ),C0042036;C0042037;C0567349;C1412134;C1515941;C2348885;C2963137
4506,urine acr ( mg / g ),C0042036;C0042037;C1300563;C1412134;C1515941;C2963137
4506,- median urine acr ( mg / g ) ( iqr ),C0042036;C0042037;C0549183;C0876920;C1300563;C1412134;C1515941;C2347635;C2348144;C2939193;C2963137
4505,sprint acr > $nmbr$ - $nmbr$,C1412134;C1515941
4505,sprint acr < $nmbr$ - $nmbr$,C1412134;C1515941
4505,accord acr > $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
4505,accord acr < $nmbr$ - $nmbr$,C0680240;C1412134;C1515941
4504,acr functional class  n ( % ),C0205245;C0456387;C0542341;C1412134;C1515941;C1518526;C1705943;C2700217
4504,acr,C1412134;C1515941
4503,evaluable for acr $nmbr$ at week $nmbr$  n,C1412134;C1515941;C1516986
4503,b . acr $nmbr$,C1412134;C1515941
4503,acr deciles,C1412134;C1515941
4503,a . acr $nmbr$,C1412134;C1515941
4502,val / hctz ( n = $nmbr$ ),C0020261;C0042285;C0523975
4502,v alsartan / hctz  n ( % ),C0020261
4502,v / hctz ( n = $nmbr$ ),C0020261
4502,v / hctz,C0020261
4501,hctz,C0020261
4501,azl - m + hctz ( n = $nmbr$ ),C0020261;C0369637;C0441923
4500,om $nmbr$ mg / hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0028971;C1319635;C1705272
4500,om $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0028971;C1319635;C1705272
4500,olmesartan medoxomil $nmbr$ mg / hctz $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0020261;C0386393;C1319635
4500,hctz * ( n = $nmbr$ ),C0020261
4499,olmesartan $nmbr$ - olmesartan $nmbr$ / hydrochlorothiazide $nmbr$ . $nmbr$,C0020261;C1098320
4498,hydrochlorothiazide,C0020261
4498,hctz = hydrochlorothiazide . * based on wilcoxon $nmbr$ - sample rank - sum tests for age and body mass index  t tests for systolic and diastolic blood and ' / $nmbr$ tests for categorical variables . t data were missing for some patients .,C0001779;C0005767;C0005768;C0012000;C0020261;C0030705;C0229664;C1551393;C1705492;C3272743
4497,hctz = hydrochlorothiazide . * based on a ' / _ $nmbr$ test  t data were missing for some patients .,C0020261
4497,hctz - hydrochlorothiazide . * data were missing for some patients .,C0020261;C1511726;C3245479;C3714741
4497,hctz *,C0020261
4496,jvp $ $nmbr$ cm h $nmbr$ o,C0455483
4496,jvd $ $nmbr$ cm h $nmbr$ o  %,C0425687;C0455483
4495,with highest hba $nmbr$ cc,C0008318;C0019016;C1522410;C1825777;C3538758;C3538933
4495,cc,C0008318;C3538933
4494,acm,C0001143;C1549040
4493,left atrial dimension  cm,C0018792;C0439534;C2950135
4492,urine p / cr,C0042036;C0042037;C0201975;C2963137;C3539604;C3711669;C4084730;C4553336;C4553337
4492,steroid - free cr - $nmbr$,C0038317;C0201975;C0332296;C1880497;C1996904;C3539604;C3711669;C4084730;C4553336;C4553337
4492,microalbuminuria  mg / g cr,C0201975;C0730345;C1300563;C3539604;C3711669;C4084730;C4553336;C4553337
4492,cr + mh + crpnorr,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
4492,cr + mh,C0026514;C0201975;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
4492,cr + crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
4492,albuminuria < $nmbr$ gram / gram cr,C0001925;C0201975;C1319635;C3539604;C3711669;C4084730;C4553336;C4553337
4491,multivariable adjusted model hr ( $nmbr$ % ci ),C0008107;C0456081;C3161035;C3259781;C3274659;C3714583;C3853906
4491,multivariable adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
4491,hr [ $nmbr$ % ci ),C0008107;C3259781
4491,hr ( $nmbr$ s % ci ),C0008107;C3259781
4491,adjusted hr * ( $nmbr$ % ci ),C0008107;C0456081;C3259781
4491,adjusted hr ( $nmbr$ % ci ) * comparing idm with bl,C0005918;C0006413;C0008107;C0270221;C0456081;C1552663;C1707455;C2827109;C3259781
4491,adjusted hr ( $nmbr$ % ci ) * compared with no diabetes at bl or at year $nmbr$,C0008107;C0456081;C3259781
4491,adjusted hr ( $nmbr$ % ci ),C0008107;C0456081;C3259781
4491,adjusted hr  $nmbr$ % ci,C0008107;C0456081;C3259781
4490,strata modelb hr  $nmbr$ % ci  p value,C0008107;C1709380;C3259781
4490,hr ( $nmbr$ % ci ) “,C0008107;C3259781
4490,hr ( $nmbr$ % ci ) p   value,C0008107;C1709380;C3259781
4490,hr ( $nmbr$ % ci ) p value for interaction *,C0008107;C1704675;C1709380;C3259781
4490,hr ( $nmbr$ % ci ) *,C0008107;C3259781
4490,hr ( $nmbr$ % ci ),C0008107;C3259781
4490,hr $nmbr$ % ci,C0008107;C3259781
4490,hr  ( $nmbr$ % ci ),C0008107;C3259781
4490,adjusted modelc hr  $nmbr$ % ci  p value,C0008107;C0456081;C1709380;C3259781
4489,heart failure  ci  confidence interval .,C0008107;C0009667;C0018801;C0018802;C3259781;C4554158
4489,* ci denotes confidence interval .,C0008107;C3259781
4488,ls mean treatment difference ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
4488,ls mean [ $nmbr$ % ci ] treatment difference vs placebo,C0008107;C0023668;C0039798;C0087111;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
4488,ls mean ( $nmbr$ % ci ) a,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
4488,ls mean ( $nmbr$ % ci )  %,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
4488,ls mean ( $nmbr$ % ci ),C0008107;C0023668;C0444504;C2347634;C2348143;C3259781
4488,ls - mean difference between treatment groups ( $nmbr$ % ci ),C0008107;C0023668;C0039798;C0087111;C0374505;C0444504;C1522326;C1533734;C1705169;C1705241;C1705242;C2347634;C2348143;C3259781;C3538994;C3887704
4488,ls - mean between - group difference ( $nmbr$ % ci ),C0008107;C0023668;C1705241;C1705242;C2347634;C3259781
4488,[ $nmbr$ % ci ] *,C0008107;C3259781
4488,( $nmbr$ % ci ) a,C0008107;C3259781
4487,lsms difference ( $nmbr$ % ci ) $nmbr$,C0008107;C1705241;C1705242;C3259781
4487,lsm ( $nmbr$ % ci ),C0008107;C3259781
4487,difference in ls means ( $nmbr$ % ci ) a,C0008107;C0023668;C1704970;C1705241;C1705242;C3259781
4487,difference ( $nmbr$ % ci ) *,C0008107;C1705241;C1705242;C3259781
4487,absolute risk difference ( ci )  % *,C0008107;C0035647;C1519101;C1549031;C1705241;C1705242;C3259781;C4552904
4487,( $nmbr$ % ci ),C0008107;C3259781
4487,$nmbr$ % ci $nmbr$,C0008107;C3259781
4486,ls - mean change from baseline ( $nmbr$ % ci ),C0008107;C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3259781;C4319952
4486,from baseline ( $nmbr$ % ci ),C0008107;C0168634;C1442488;C3259781
4486,adjusted mean change from baseline ( $nmbr$ % ci )  % [ mmol / mol ],C0008107;C0168634;C0392747;C0439190;C0443172;C0444504;C0456081;C0948922;C1442488;C1705241;C2347634;C2348143;C3259781;C3829066;C4319952
4486,( $nmbr$ % ci ] $nmbr$,C0008107;C3259781
4485,risk reduction ( %  $nmbr$ % ci ),C0008107;C1137094;C3259781
4485,reduction in risk ( $nmbr$ % ci ) %,C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
4485,reduction in risk % ( $nmbr$ % ci ),C0008107;C0035647;C0520870;C1137094;C3259781;C4552904
4485,proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c  %,C0008107;C1709707;C3259781
4485,( $nmbr$ % ci ) c,C0008107;C3259781
4485,% risk reduction ( $nmbr$ % ci ),C0008107;C1137094;C3259781
4485,$nmbr$ % ci,C0008107;C3259781
4484,hradjusted ( $nmbr$ % ci ) b,C0008107;C3259781
4484,cochranemantelehaenszel ( repeated $nmbr$ . $nmbr$ % ci ) c,C0008107;C0205341;C3259781
4484,( ci ) b,C0008107;C3259781
4484,( $nmbr$ % ci ) b,C0008107;C3259781
4483,relative risk { $nmbr$ % ci ),C0008107;C0242492;C3259781
4483,relative risk ( $nmbr$ % ci ) ofprimary end point,C0008107;C0242492;C2349179;C2826544;C3259781
4483,relative risk ( $nmbr$ % ci ),C0008107;C0242492;C3259781
4482,mean sf $nmbr$ score ( $nmbr$ % ci ),C0008107;C0037712;C3259781;C3533236
4482,mean pasi score ( $nmbr$ % ci ),C0008107;C3259781;C3533236;C4528685
4482,mean ham - d score ( $nmbr$ % ci ),C0008107;C1570167;C3259781;C3533236;C3853311
4481,hr ( $nmbr$ % ci )  univariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
4481,hr ( $nmbr$ % ci )  multivariate cox proportional - hazard regression,C0008107;C0205351;C0598697;C0684320;C0684321;C1565830;C1836830;C3259781
4481,cox hr ( $nmbr$ % ci ),C0008107;C1565830;C3259781
4480,rate estimate ( $nmbr$ % ci ),C0008107;C0750572;C0871208;C1521828;C3259781
4480,oradj ( $nmbr$ % ci ),C0008107;C3259781
4480,hradj ( $nmbr$ % ci ),C0008107;C3259781
4480,estimate ( $nmbr$ % ci ),C0008107;C0750572;C3259781
4480,$nmbr$ - y kaplan - meier rate ( $nmbr$ % ci ),C0008107;C0871208;C1521828;C3259781
4479,stratified hazard ratio ( $nmbr$ % ci ),C0008107;C0205363;C2985465;C3259781
4479,hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .,C0008107;C2985465;C3259781
4479,genotype - specific treatment effect hazard ratio ( $nmbr$ % ci ),C0008107;C0017431;C0205369;C1518681;C1552740;C2985465;C3259781
4479,% ( $nmbr$ % ci ),C0008107;C3259781
4478,etr : $nmbr$ . $nmbr$ [ $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C3259781
4478,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
4478,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  − $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     <   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
4478,etd : − $nmbr$ . $nmbr$ [ − $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ] $nmbr$ % ci  p     =   $nmbr$ . $nmbr$,C0008107;C1180255;C3259781
4478,etd ( % ) [ $nmbr$ % ci ],C0008107;C1180255;C3259781
4478,etd ( $nmbr$ % ci ),C0008107;C1180255;C3259781
4478,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) a - $nmbr$ . $nmbr$ %  * p = $nmbr$ . $nmbr$,C0008107;C3259781
4478,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ) * p = $nmbr$ . $nmbr$,C0008107;C3259781
4478,- $nmbr$ . $nmbr$ ( $nmbr$ % ci : - $nmbr$ . $nmbr$  - $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
4478,$nmbr$ . $nmbr$ ( $nmbr$ % ci : $nmbr$ . $nmbr$  $nmbr$ . $nmbr$  n = $nmbr$ ),C0008107;C3259781
4478,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0008107;C3259781
4478,$nmbr$ . $nmbr$ ( $nmbr$ % ci $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ),C0008107;C3259781
4478,$nmbr$ . $nmbr$ $nmbr$ % ci : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ p = $nmbr$ . $nmbr$,C0008107;C3259781
4478,$nmbr$ % ci $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,C0008107;C3259781
4477,vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
4477,vi $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
4477,vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781
4477,ff / vi – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
4477,ff / vi $nmbr$ % ( $nmbr$ % ci $nmbr$ – $nmbr$ % ),C0008107;C0205999;C3259781;C4554348
4476,rr ^ ( $nmbr$ % ci ),C0008107;C3259781;C4554402
4476,rr ( $nmbr$ % ci ) c,C0008107;C3259781;C4554402
4476,rr ( $nmbr$ % ci ) *,C0008107;C3259781;C4554402
4476,rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
4476,esrd only rr ( ci ) “,C0008107;C0022661;C0035078;C0205171;C1720467;C2316810;C3259781;C4554402
4476,cmh rr ( $nmbr$ % ci ),C0008107;C3259781;C4554402
4475,endothelin $nmbr$ ( pg / ml ),C0079284;C0439297
4474,kim $nmbr$ ( pg / ml ),C0439297
4474,interleukin - $nmbr$ ( ng / l ),C0021764;C0439297;C1527200
4474,interleukin $nmbr$ ( pg / ml ),C0021764;C0439297;C1527200
4474,> = $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
4474,> = $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
4474,> = $nmbr$ ng / l ( n = $nmbr$ ),C0439297
4474,> = $nmbr$ . $nmbr$ to < $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
4474,> $nmbr$ ng / l,C0439297
4474,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ) n ( % ),C0439297
4474,< $nmbr$ . $nmbr$ ng / l ( n = $nmbr$ ),C0439297
4474,$nmbr$ . $nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
4474,$nmbr$ - < $nmbr$ ng / l ( n = $nmbr$ ),C0439297
4473,tertile $nmbr$ ( > $nmbr$ . $nmbr$ pg / ml ) n - $nmbr$,C0439297
4473,tertile $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pg / ml ) n = $nmbr$,C0439297
4473,il - $nmbr$ range  ng / l,C0020898;C0021764;C0022271;C0439297;C1514721;C2348147;C3542016
4473,il - $nmbr$ ( pg / ml ),C0020898;C0021764;C0022271;C0439297
4473,il - $nmbr$  ng / l,C0020898;C0021764;C0022271;C0439297
4473,canakinumab  $nmbr$ month on - treatment il - $nmbr$ above the median value ( ≥ $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
4472,patients with level > $nmbr$ pg / ml,C0030705;C0439297;C0441889;C0456079;C1547707;C2946261
4472,> ulnand < $nmbr$ ng / l,C0439297
4471,b - natriuretic peptide . pg / ml,C0070338;C0439297;C0597421
4470,avp pg / ml,C0439297;C1098706;C1568204;C1708407
4469,n - terminal pro - brain natriuretic peptide  pg / ml,C0439297;C3272900
4468,troponin i ( pg / ml ),C0077401;C0439297
4467,tnf - alpha ( pg / ml ),C0439297;C1448177;C1456820;C1522669
4466,rage ( ng / ml ),C0034634;C0439275;C3539760;C3815186
4465,vegfr ( ng / ml ),C0439275;C1568520
4464,pigr ( ng / ml ),C0439275;C1418569
4463,esam ( ng / ml ),C0439275;C1424976
4462,psap - b ( ng / ml ),C0439275;C1418975;C1420002;C1425004
4461,procalcitonin ( ng / ml ),C0072027;C0439275
4460,galectin - $nmbr$ ( ng / ml ),C0439275;C0607430
4459,tertile $nmbr$ ( < $nmbr$ . $nmbr$ ng / ml ) n - $nmbr$,C0439275
4459,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
4459,< $nmbr$ ng / ml,C0439275
4459,< $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
4459,< $nmbr$ . $nmbr$ ng / ml,C0439275
4458,mesothelin ( ng / ml ),C0380162;C0439275;C1334533
4457,neuropilin ( ng / ml ),C0287275;C0439275
4456,gdf - $nmbr$ ( ng / ml ),C0439275;C1418244
4455,pentraxin - $nmbr$ ( ng / ml ),C0439275
4455,ngal ( ng / ml ),C0215955;C0439275;C1416806;C2346625
4454,mmp - $nmbr$ ( ng / ml ) *,C0439275;C0623362;C0919336
4454,mmp - $nmbr$ ( ng / ml ),C0439275;C0623362;C0919336
4453,ptx $nmbr$ ( ng / ml ),C0030899;C0439275
4452,wap $nmbr$ c ( ng / ml ),C0439275
4452,opg  ( ng / ml ),C0439275;C1262886;C1336645;C1412836;C1710303
4451,syndecan - $nmbr$ ( ng / ml ),C0075691;C0439275;C1419891
4450,sdc ( ng / ml ),C0439275;C1419891;C3273112
4450,sdc ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C1419891;C3273112
4450,sdc $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml,C0439275;C1419891;C3273112
4449,troy ( ng / ml ),C0439275;C1420811;C1883402
4448,proadm ( ng / ml ),C0439275
4448,nt probnp > $nmbr$ ng / ml n ( % ) §,C0439275;C1317554;C2825907;C4284038
4447,osteopontin ( ng / ml ),C0069676;C0439275;C1420369;C1505427;C4084879
4446,angiogenin ( ng / ml ),C0051844;C0439275;C1367482
4445,cholesterol ( ng / ml ),C0008377;C0439275
4444,ltbr ( ng / ml ),C0439275;C1416931
4443,ntpro - cnp ( ng / ml ),C0439275;C3889729
4443,mpo ( ng / ml ),C0439275
4442,psa level  ng / ml,C0439275;C4086720
4441,≥ $nmbr$ ng / ml,C0439275
4441,type $nmbr$ collagen  mean ( sd )  ng / ml £,C0009325;C0332307;C0439275;C0444504;C1547052;C2347634;C2348143;C2699239
4441,serum $nmbr$ ( oh ) d concentrations  ng / ml  mean ( sd ),C0220853;C0439275;C0444504;C0683149;C2347634;C2348143;C2699239
4441,mean ( sd )  ng / ml £,C0439275;C0444504;C2347634;C2348143;C2699239
4441,mean ( s . d . ) total pcsk $nmbr$  ng / ml,C0439175;C0439275;C0439810;C0444504;C2347634;C2348143
4441,mean ( s . d . ) free pcsk $nmbr$  ng / ml,C0332296;C0439275;C0444504;C1880497;C1996904;C2347634;C2348143
4441,> $nmbr$ . $nmbr$ ng / ml ( n = $nmbr$ ),C0439275
4441,> $nmbr$ . $nmbr$ ng / ml,C0439275
4440,ck - mb  ng / ml,C0010290;C0439275
4439,ctn - l  ng / ml,C0439275;C0917591
4439,ctn - i  ng / ml,C0021966;C0221138;C0439275;C0917591
4438,hmgcoa rl,C0047420;C1419337;C3539667
4437,glucose — mg / dl,C0017725;C0439269
4437,glucose ( mg / dl ),C0017725;C0439269
4437,fasting glucose — mg / dl,C0015663;C0017725;C0439269
4437,fasting glucose ( mg / dl ),C0015663;C0017725;C0439269
4437,fasting glucose  mg / dl  mean ( sd ) §,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
4437,fasting glucose  mean ( sd )  mg / dl,C0015663;C0017725;C0439269;C0444504;C2347634;C2348143;C2699239
4436,glucose  non - fasting or random ( nmol / l ),C0017725
4436,glucose  mmol / l,C0017725;C1532563
4436,fasting glucose ( mmol / l ),C0015663;C0017725;C1532563
4436,fasting glucose  mmol / l  mean ± sd,C0015663;C0017725;C0444504;C1532563;C2347634;C2348143;C2699239
4435,serum glucose ( mg / dl ),C0202041;C0439269;C3534430
4435,fasting serum glucose — mg / dl * *,C0015663;C0202041;C0439269;C3534430
4435,fasting serum glucose ( mg / dl )  median ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
4435,fasting serum glucose ( mg / dl ),C0015663;C0202041;C0439269;C3534430
4435,fasting serum glucose  mg / dl,C0015663;C0202041;C0439269;C3534430
4435,fasting serum glucose  median ( sd )  mg / dl,C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3534430
4435,fasting serum glucose  mean ( sd ) mg / dl,C0015663;C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
4435,- median fasting serum glucose ( mg / dl ) ( iqr ),C0015663;C0202041;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3534430
4434,serum glucose ( mmol / l ),C0202041;C1532563;C3534430
4434,fasting serum glucose  mmol / l  median ( q $nmbr$  q $nmbr$ ),C0015663;C0202041;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193;C3534430
4433,uacra  mg / g  gmean = gcv,C0017066;C1300563
4432,≥ $nmbr$ mg / g,C1300563
4432,uacra  mg / g  n ( % ),C1300563
4432,uacr — mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
4432,uacr *  mg / g ( q $nmbr$  q $nmbr$ ),C1300563
4432,uacr ( mg / g  median [ iqr ] ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
4432,uacr  mg / g  median ( iqr ),C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
4432,uacr  mg / g  median ( $nmbr$ th − $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1300563;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
4432,uacr  median ( iqr )  mg / g,C0549183;C0876920;C1300563;C2347635;C2348144;C2939193
4432,uac $nmbr$ - $nmbr$ mg / g,C1300563
4432,^ $nmbr$ mg / g  n ( % ),C1300563
4432,< $nmbr$ mg / g  n ( % ),C1300563
4432,$nmbr$ − $nmbr$ mg / g,C1300563
4432,$nmbr$ mg / g  n ( % ),C1300563
4432,$nmbr$ - $nmbr$ mg / g,C1300563
4431,≥ $nmbr$ to < $nmbr$ mg / g,C1300563
4431,baseline uacr > $nmbr$ mg / g,C0168634;C1300563;C1442488
4431,baseline uacr < $nmbr$ mg / g,C0168634;C1300563;C1442488
4431,> = $nmbr$ mg / g,C1300563
4431,> $nmbr$ to $nmbr$ mg / g,C1300563
4431,> $nmbr$ mg / g,C1300563
4431,< $nmbr$ mg / g,C1300563
4431,$nmbr$ to $nmbr$ mg / g,C1300563
4430,uacr ( mg / g ),C1300563
4430,uac > $nmbr$ mg / g,C1300563
4430,normoalbuminuria ( uacr < $nmbr$ mg / g ),C1300563
4430,cohort $nmbr$ ( uacr > $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
4430,cohort $nmbr$ ( uacr < $nmbr$ . $nmbr$ mg / g ),C0009247;C0599755;C1300563
4429,mg / g,C1300563
4429,mean fecal calprotectin level  mg / g stool ( sd ),C0015733;C0183622;C0441889;C0444504;C0456079;C0950624;C1300563;C1335798;C1366582;C1547707;C2347634;C2348143;C2699239;C2946261
4429,fcal  mg / g  mean ± sd,C0444504;C1300563;C2347634;C2348143;C2699239
4429,$nmbr$ mg / g,C1300563
4428,igg ( > $nmbr$ . $nmbr$ g / l )  %,C0439294;C0456615
4428,apolipoprotein a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508
4428,apoa - $nmbr$  g / l,C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
4428,apo a $nmbr$ ( g / l ),C0003592;C0439294;C0456615;C0523508;C4553344;C4553379
4428,> $nmbr$ . $nmbr$ - g / l,C0439294;C0456615
4428,$nmbr$ . $nmbr$ ( g . l ),C0439294;C0456615
4427,tni ultrapositive ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
4427,tni ultrapositive  ≥ $nmbr$ . $nmbr$ µ g / l  n   =   $nmbr$   $nmbr$,C0077401;C0439294;C0456615
4426,hemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
4426,hemoglobin  g / l,C0019046;C0439267;C0439294;C0456615;C0635222
4426,haemoglobin ( g / l ),C0019046;C0439267;C0439294;C0456615;C0635222
4425,triglycerides  mg / l,C0041004;C0439268
4425,hscrp > $nmbr$ to < $nmbr$ mg / l,C0439268
4425,hscrp > $nmbr$ mg / l,C0439268
4425,about $nmbr$ mg / l or more,C0439268
4425,about $nmbr$ mg / l,C0439268
4424,hscrp ( mg / l ) c,C0439268
4424,hscrp ( mg / l )  median ( first  third quartiles ),C0205435;C0205437;C0439268;C0549183;C0876920;C1279901;C2347635;C2348144;C2828255;C2939193
4424,hscrp ( mg / l ),C0439268
4424,hscrp  median ( iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
4423,≤ $nmbr$ mg / l,C0439268
4423,high - density lipoprotein cholesterol  mg / l,C0023822;C0439268
4422,serum cholesterol ( mg / l ) *,C0439268;C0587184
4421,upadacitinib $nmbr$ mg ( n = l $nmbr$ ),C0439268
4421,mean hscrp  mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239
4421,mean crp level  mg / l ( sd ),C0439268;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
4421,hscrp  mg / l,C0439268
4421,crp ( mg / l )  mean ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
4421,crp  mean mg / l ( sd ),C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
4421,cld $nmbr$ mg ( n = l $nmbr$ ),C0439268
4421,> $nmbr$ mg / l ( n = $nmbr$ ),C0439268
4421,< $nmbr$ mg / l ( n = $nmbr$ ),C0439268
4421,$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ ),C0439268
4420,mean ( sd ) crp  mg / l *,C0439268;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
4420,hs - crp > $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
4420,crp concentration > $nmbr$ mg / l  n ( % ) \,C0086045;C0439268;C1446561;C3827302;C3890735;C4048285
4420,crp < $nmbr$ mg / l  n,C0439268;C3890735;C4048285
4420,crp ( mg / l ) : < $nmbr$,C0439268;C3890735;C4048285
4420,crp ( mg / l ) ( cv ),C0439268;C3538987;C3890735;C4048285;C4048877;C4318503
4420,crp ( mg / l )  n,C0439268;C3890735;C4048285
4420,crp ( mg / l ),C0439268;C3890735;C4048285
4420,crp $ $nmbr$ mg / l  n,C0439268;C3890735;C4048285
4420,crp  mg / l *,C0439268;C3890735;C4048285
4420,> $nmbr$ mg / l,C0439268
4420,( ≥ $nmbr$ mg / l ),C0439268
4420,( < $nmbr$ mg / l ),C0439268
4420,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l,C0439268
4419,serum mg < $nmbr$ . $nmbr$ mmol / l ( hypomagnesemia ),C0024671;C0026410;C0151723;C0229671;C0439190;C0439268;C0439269;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761;C4552839
4419,hscrp > $nmbr$ . $nmbr$ mg / l,C0439268
4419,hscrp < $nmbr$ . $nmbr$ mg / l,C0439268
4419,baseline serum mg > = $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
4419,baseline serum mg < $nmbr$ . $nmbr$ mmol / l,C0024671;C0026410;C0168634;C0229671;C0439190;C0439268;C0439269;C1442488;C1532563;C1546774;C1550100;C1960952;C2346927;C4321396;C4521761
4419,> $nmbr$ . $nmbr$ mg / l,C0439268
4419,< $nmbr$ mg / l,C0439268
4419,< $nmbr$ . $nmbr$ mg / l,C0439268
4418,om $nmbr$ mg / aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
4418,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
4418,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg *,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
4418,om $nmbr$ / aml $nmbr$ / hctz $nmbr$ . $nmbr$ mg,C0020261;C0023465;C0023467;C0024671;C0026410;C0028971;C0439269;C1705272;C1960952;C2346927;C4321396;C4521761
4418,om $nmbr$ / aml $nmbr$ /,C0023465;C0023467;C0028971;C1705272
4418,om $nmbr$ /,C0028971;C1705272
4417,tiotropium + olodaterol $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
4417,tiotropium + olodaterol $nmbr$ / $nmbr$,C4032878
4417,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,C0030827;C0072225;C1266240;C4032878
4416,tcz $nmbr$ mg / kg n = $nmbr$,C0439272
4416,abatacept $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
4416,abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
4416,$nmbr$ mg / kg ( n = $nmbr$ ),C0439272
4415,mean ( sd )  mg / kg $nmbr$,C0439272;C0444504;C2347634;C2348143;C2699239
4415,$nmbr$ mg / kg,C0439272
4414,infliximab ( combined $nmbr$ mg / kg and $nmbr$ mg / kg )  n ( % ),C0205195;C0439272;C0666743
4414,infliximab $nmbr$ mg / kg,C0439272;C0666743
4413,≤ $nmbr$ ug / g,C0439272
4413,golimumab $nmbr$ mg / kg + mtx,C0025677;C0439272;C1417487;C2353893
4413,> $nmbr$ ug / g,C0439272
4412,≤ $nmbr$ u / kg / day,C1532634
4412,> $nmbr$ u / kg / day,C1532634
4411,baseline upgr  mg / mmole ( n = $nmbr$  $nmbr$  $nmbr$ ),C0168634;C0567349;C1442488;C2348885
4410,uacr   ≥ $nmbr$   mg / mmol ∗,C0567349;C2348885
4410,uacr   < $nmbr$   mg / mmol ∗,C0567349;C2348885
4410,uacr  mg / mmol ( interquartile range ) b,C0567349;C1711350;C2348885
4410,acr  mg / mmol,C0567349;C1412134;C1515941;C2348885
4409,mg / mmol,C0567349;C2348885
4409,bl mean  mg / dl ( mmol / $nmbr$ ),C0005918;C0006413;C0439190;C0439269;C0444504;C0567349;C1552663;C2347634;C2348143;C2348885;C2827109;C3642216
4409,> $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4409,< $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4409,. $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4409,$nmbr$ rd tertile ( > $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) d,C0439190;C0439269;C0567349;C0694666;C2348885;C3642216;C4553350
4409,$nmbr$ . $nmbr$ to # $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4409,$nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4409,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ mg / mmol,C0567349;C2348885
4408,scr  gmol / l,C1539487;C4050416
4407,phosphorus  mmol $nmbr$ $nmbr$,C0031705;C0080014;C0439190;C3714498
4406,ldl - c  mmol / l ( mg / dl ),C3642216;C3898312
4406,hdl - c  mmol / l ( mg / dl ),C3642216;C3715113;C3898312
4406,fpg  mmol / l ( mg / dl ),C3642216;C3898312
4405,tg  mmol / l [ mg / dl ],C0337445;C3642216;C3898312
4405,tg  mmol / l ( mg / dl ) [ median ],C0337445;C0549183;C0876920;C2347635;C2348144;C2939193;C3642216;C3898312
4404,plasma lipoproteins  mmol / l,C0023820;C0032105;C1532563;C1550098;C4521445
4404,plasma creatine  mg / dl,C0010286;C0032105;C0439269;C1550098;C4521445
4403,elevated creatine kinase mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
4403,elevated creatine kinase - mb ( > $nmbr$ u / l ),C0010290;C0024853;C0151576;C0205250;C0439339;C0523584;C3163633
4403,$nmbr$ mq / kq *,C0024853
4402,gamma glutamyltransferase  u / l,C0017040;C0439339
4401,peak creatine kinase - mb  u / l,C0010290;C0439339;C0444505;C0523584
4400,neutrophils  $nmbr$ / nl,C0027778;C0027950;C0560008;C3892223
4400,monocytes  $nmbr$ / nl,C0026473;C0027778;C0560008;C3892223
4400,leukocytes  $nmbr$ / nl,C0023516;C0027778;C0560008;C3892223
4399,serum total ige  iu / ml,C0439458;C1441420
4398,anti - dsdna ( > $nmbr$ iu / ml )  %,C0439458;C0741099
4397,wrist,C0043262;C1322271
4397,hip  wrist  or spine *,C0019552;C0022122;C0043262;C1322271;C1505163;C3538851;C4284725
4396,apremilast $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1678805;C1960952;C2346927;C4321396;C4521761
4396,apremilast,C1678805
4395,venous graft,C0042449;C0181074;C0332835;C0348013;C1961139
4395,vein graft stented,C0042449;C0181074;C0332835;C1961139
4395,graft  n ( % ),C0181074;C0332835;C1961139
4395,graft,C0181074;C0332835;C1961139
4394,graft occlusionsa,C0181074;C0332835;C1961139
4394,graft  pci  percutaneous coronary intervention  tia  transient,C0007787;C0181074;C0332835;C0917805;C1054154;C1532338;C1961139
4393,visit $nmbr$ ldl cholesterol strata,C0023824;C0202117;C0545082;C1512346;C2826704
4392,visit,C0545082;C1512346;C2826704
4392,sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
4392,dbp at visit $nmbr$,C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
4391,visits $nmbr$ e $nmbr$,C0545082;C1512346;C2826704
4391,ed visit related to exacerbation  n ( % ),C0545082;C1512346;C2826704;C3538926
4391,ed severity  visit $nmbr$ * *,C0439793;C0522510;C0545082;C1512346;C2826704;C3538926
4390,visit $nmbr$ blood pressures :,C0545082;C1272641;C1512346;C2826704
4390,no . with visit,C0545082;C1512346;C2826704
4389,patients with > $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C1512346;C3810541;C3811131;C4086268
4389,er visit,C0545082;C1512346;C2826704;C3810541;C3811131
4388,exacerbations in the past $nmbr$ months n,C4086268;C4331910
4387,no hospitalization in the past $nmbr$ months prior to baseline ( ref ),C0019993;C4331910
4387,hospitalization in the past $nmbr$ months prior to baseline,C0019993;C4331910
4386,previous pde $nmbr$ inhibitors,C0031638;C0205156;C1552607
4386,pde $nmbr$ inhibitors,C0031638
4386,pde $nmbr$ inhibitor monotherapy,C0031638
4385,sleeping problems in the past $nmbr$ weeks ( % ),C0700201;C2987125
4384,angina ( past $nmbr$ weeks ),C0002962;C2987125
4383,night - time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C2987125
4383,night - time awakenings in past $nmbr$ weeks ( sd ) *,C0860510;C2699239;C2987125
4382,pt . years = $nmbr$,C0032743;C0439234;C0699718
4381,pt baseline ( week $nmbr$ ),C0032743;C0168634;C0332174;C0439230;C0699718;C1442488
4381,pt,C0032743;C0699718
4380,prediabetes — no . ( % ) $nmbr$,C0362046
4380,prediabetes  n ( % ),C0362046
4380,prediabetes  %,C0362046
4380,baseline prediabetes,C0168634;C0362046;C1442488
4379,pre – diabetes mellitus  n = $nmbr$,C0362046
4379,pre – diabetes mellitus,C0362046
4378,type of end point,C0332307;C1547052;C2349179;C2826544
4377,end - point ( sd ),C2349179;C2699239;C2826544
4376,patients with end point,C0030705;C2349179;C2826544
4376,end point,C2349179;C2826544
4375,end points,C2349179
4375,combined end points,C0205195;C2349179
4375,combined end point,C0205195;C2349179;C2826544
4374,other prespecified end points,C2349179
4374,other end points,C2349179
4374,bleeding end points,C0019080;C2349179
4373,coronary endpoint,C0018787;C2349179;C2826544
4373,coronary end point,C0018787;C2349179;C2826544
4373,all randomized coronary end point,C0018787;C0034656;C2349179;C2826544;C3815594
4372,main accord endpoint,C0205225;C0680240;C1542147;C2349179;C2826544
4371,endpoints,C2349179
4371,additional endpoints,C1524062;C2349179
4370,endpoint rate,C0871208;C1521828;C2349179;C2826544
4370,endpoint *,C2349179;C2826544
4370,endpoint,C2349179;C2826544
4369,endpoint / baselinec,C2349179;C2826544
4369,endpoint / baseline,C0168634;C1442488;C2349179;C2826544
4368,three - point mace,C0205449;C0349381;C0949745;C1445339;C1552961;C2347617;C3714763
4368,( points ),C1552961;C2347617;C3714763
4368,% - point difference ( $nmbr$ % ci ) c,C0008107;C1552961;C1705241;C1705242;C2347617;C3259781;C3714763
4368,$nmbr$ - point mace ( $nmbr$ - point mace plus hospitalization for unstable angina ),C1552961;C2347617;C3714763
4368,$nmbr$ - point mace,C1552961;C2347617;C3714763
4367,oropharyngeal pain,C2363731;C4554669
4366,womac pain score,C0582148
4366,$nmbr$ % decrease in womac pain score,C0392756;C0547047;C0582148
4365,upper abdominal pain,C0232492
4364,shoulder pain,C0037011
4363,pain in extremity,C0030196;C4553007
4362,rest pain,C0234253
4362,intensity of rest pain ( mmvas )  mean ± sd,C0035253;C0234253;C0444504;C0522510;C1320357;C1622890;C2347634;C2348143;C2699239;C4085211
4361,sf - $nmbr$ bodily pain  mean change from baselinee,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
4361,sf - $nmbr$ bodily pain  mean change from baselineb,C0037712;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3890602;C4319952
4361,bodily pain,C3890602
4360,time from onset of pain to randomization — hr,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,time from onset of pain to randomization  median ( iqr )  h,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,time from onset of pain to randomization  median ( $nmbr$ th — $nmbr$ th percentiles )  n,C0030193;C0449244;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,psoriatic arthritis pain ],C0003872;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4317006;C4553004;C4554132
4360,patient assessment of pain ( $nmbr$ - $nmbr$ mm )  mean ( sd ),C0030193;C0030198;C0030705;C0444504;C0518090;C0679830;C1962977;C2347634;C2348143;C2699239;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
4360,patient ' s assessment of pain !,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,patient ' s assessment of pain,C0030193;C0030198;C0030705;C0518090;C0679830;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4360,pain  mm,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4330985;C4553004;C4554132;C4554674
4360,pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
4359,referent,C1706462
4359,reference,C1514811;C1706462
4359,no ( reference ),C1514811;C1706462
4359,< $nmbr$ mg dl ( reference ),C0439269;C1514811;C1706462
4359,$nmbr$ . $nmbr$ ( referent ),C1706462
4359,$nmbr$ . $nmbr$ ( reference ),C1514811;C1706462
4358,regadenoson ( n = $nmbr$ ),C1698215
4358,regadenoson,C1698215
4357,selexipag vs placebo hazard ratio ( $nmbr$ % cl ),C2000145
4357,selexipag patients / events n,C0030705;C0441471;C2000145;C3541888
4357,selexipag ( n = $nmbr$ ),C2000145
4357,selexipag,C2000145
4356,region  no . / total ( % ),C0017446;C0205147
4356,region  europe,C0015176;C0017446;C0205147
4356,region  %,C0017446;C0205147
4356,region,C0017446;C0205147
4356,geographic region  n ( % ),C0017446
4356,geographic region  %,C0017446
4355,region of residence ( p = $nmbr$ $nmbr$ ),C0017446;C0205147;C0237096
4355,region ( us ),C0017446;C0205147
4354,regions  n ( % ),C0017446;C0205147
4354,region 一 no . ( % ),C0017446;C0205147
4354,region — no . { % ),C0017446;C0205147
4354,region ofenrollment — %,C0017446;C0205147
4354,region of enrollment — no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
4354,region of enrollment  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
4354,region of enrollment  n ( % ) +,C0017446;C0205147;C1516879;C1696073;C3888021
4354,region of enrollment,C0017446;C0205147;C1516879;C1696073;C3888021
4354,region n ( % ),C0017446;C0205147
4354,region ( % ),C0017446;C0205147
4354,region    n   ( % ),C0017446;C0205147
4354,region  no . ( % ) c,C0017446;C0205147
4354,region  no . ( % ),C0017446;C0205147
4354,region  n ( % ) a,C0017446;C0205147
4354,region  n ( % ),C0017446;C0205147
4354,other ® region — no . ( % ),C0017446;C0205147
4354,geographical region ( % ),C0017446
4354,geographical region  n ( % ),C0017446
4354,enrollment by region  no . ( % ),C0017446;C0205147;C1516879;C1696073;C3888021
4353,region — no . ( % ),C0017446;C0205147
4353,region ofthe world,C0017446;C0205147;C2700280
4353,region of world — no . ( % ),C0017446;C0205147;C2700280
4353,region of the world,C0017446;C0205147;C2700280
4353,region - no . ( % ),C0017446;C0205147
4353,region - n ( % ),C0017446;C0205147
4353,geographic region — no . ( % ),C0017446
4352,region *,C0017446;C0205147
4352,grouped region,C0017446;C0205147;C0439745;C4319846
4351,region ( pooled ),C0017446;C0205147
4351,black region or country ( % ),C0005680;C0017446;C0027567;C0085756;C0205147;C0439541
4350,region latin american,C0017446;C0205147
4350,region :,C0017446;C0205147
4350,region  asia / paafic,C0003980;C0017446;C0205147
4350,geo graphic region : asia,C0003980;C0017446;C0017454;C0205147
4349,geographical region,C0017446
4349,geographic region ^,C0017446
4349,geographic region - other,C0017446
4349,geographic region - europe,C0015176;C0017446
4349,geographic region,C0017446
4348,geographic region — number ( % ),C0017446;C0237753;C0449788
4348,geographic region ?,C0017446
4348,geographic location,C0017446
4347,colonic area involved,C0009368;C0017446;C0205146
4346,intestinal area involved — no . ( % ),C0017446;C0021853;C0205146
4346,intestinal area involved  n ( % ) $,C0017446;C0021853;C0205146
4345,arterial area ( mm $nmbr$ ),C0003842;C0017446;C0205146;C0221464;C4330985;C4554674
4345,area of retinal thickening within the grid  mean ( sd )  dab,C0017446;C0205146;C1302690
4345,area of retinal hemorrhage within the grid  mean ( sd )  dab,C0017446;C0035317;C0205146
4345,area of fluorescein leakage within the grid  mean ( sd )  dab,C0017446;C0205146;C4476700
4345,area,C0017446;C0205146
4344,geographic site  %,C0017446
4344,abbreviations : da  disc area  e - etdrs  electronic early treatment diabetic retinopathy study  iop  intraocular pressure  oct  optical coherence tomography .,C0000723;C0011318;C0011884;C0013850;C0017446;C0021888;C0180459;C0205146;C0920367;C1547561;C1556138;C1705370;C2348299;C3161471;C3668815;C4281784
4343,triglycerides mean ( mg / dl ± sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
4343,triglycerides mean,C0041004;C0444504;C2347634;C2348143
4342,estimated mean,C0444504;C0750572;C2347634;C2348143
4342,estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
4341,mean prebronchodilation ( l ),C0444504;C2347634;C2348143
4341,mean ( s . d . ) measured ldl cholesterol,C0444504;C2347634;C2348143
4341,mean ( s . d . ) ldl particle size  nm,C0203634;C0312860;C0444504;C2347634;C2348143;C3641256;C3890923
4341,mean ( s . d . ) ldl particle number  nmol / l,C0237753;C0439282;C0444504;C0449788;C2347634;C2348143;C2612459
4341,mean ( s . d . ) calculated ldl cholesterol,C0444504;C2347634;C2348143
4341,mean ( s . d . ),C0444504;C2347634;C2348143
4341,ldl cholesterol mean,C0023824;C0202117;C0444504;C2347634;C2348143
4340,weight ( kg )  mean ( s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
4340,parameter mean ± s . d .,C0444504;C0549193;C1704769;C2347634;C2348143;C2350001
4340,mean ± s . d . fpg,C0444504;C2347634;C2348143
4340,mean ± s . d .,C0444504;C2347634;C2348143
4340,mean ( ± s . d . ),C0444504;C2347634;C2348143
4340,mean ( s . d . ) weight  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C4054209
4340,mean ( s . d . ) hbalc  %,C0444504;C2347634;C2348143
4340,mean ( s . d . ) fpg,C0444504;C2347634;C2348143
4340,mean ( s . d . ) apoc - ll $nmbr$  mg / dl,C0003594;C0444504;C2347634;C2348143
4340,hbalc  mean ( s . d . ),C0444504;C2347634;C2348143
4340,hbaic ( % )  mean ± s . d .,C0444504;C2347634;C2348143
4340,fpg ( mmol / l )  mean ± s . d .,C0439433;C0444504;C2347634;C2348143
4340,body weight ( kg )  mean ( s . d . ),C0005910;C0444504;C1275571;C1305866;C2347634;C2348143
4340,age ( years )  mean ± s . d .,C0444504;C1510829;C2347634;C2348143
4339,mean — mg / dl level — no . ( % ),C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
4339,mean — kg,C0022718;C0439209;C0444504;C2347634;C2348143;C4054209
4339,mean — %,C0444504;C2347634;C2348143
4338,mean — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
4338,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ level — no . ( % ),C0369637;C0439445;C0441889;C0441923;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
4338,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143
4338,mean — ml / min,C0439445;C0444504;C2347634;C2348143
4337,mean $nmbr$ - h sbp *,C0033727;C0085805;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
4337,mean $nmbr$ - h dbp +,C0033727;C0369286;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
4337,mean,C0444504;C2347634;C2348143
4337,baseline $nmbr$ - hour mean sbp  mm hg,C0085805;C0168634;C0439227;C0439475;C0444504;C0564385;C1442488;C2347634;C2348143
4336,weeko mean + sem,C0444504;C2347634;C2348143
4336,week $nmbr$ mean + sem,C0332174;C0439230;C0444504;C2347634;C2348143
4335,biochemical parameters at randomization  mean,C0034656;C0205474;C0444504;C0449381;C2347634;C2348143
4334,mean hbaic = • = s . d .  %,C0444504;C2347634;C2348143
4334,mean alc  %,C0444504;C1424945;C2347634;C2348143;C3811058
4333,rescue medication use  mean inhalations / previous $nmbr$ d,C0004048;C0205156;C0240320;C0354922;C0444504;C1552607;C2347634;C2348143
4333,lung function  mean,C0035245;C0444504;C2347634;C2348143
4332,mean sitting systolic blood pressure,C0444504;C2347634;C2348143
4332,mean sitting diastolic blood pressure,C0444504;C1319894;C2347634;C2348143
4332,bmi ¼ body mass index  hctz ¼ hydrochlorothiazide  msdbp ¼ mean sitting diastolic blood pressure  mssbp ¼ mean sitting systolic blood pressure  sd ¼ standard deviation,C0012727;C0020261;C0205419;C0428886;C0444504;C1305855;C1705236;C2347634;C2348143
4331,mean selena - sledai score ± sd,C0444504;C0451528;C2347634;C2348143
4331,mean asui scored,C0444504;C2347634;C2348143
4331,mean acrn,C0444504;C2347634;C2348143
4330,mean baseline ucdai score,C0168634;C0444504;C1442488;C2347634;C2348143
4330,mean baseline ei score,C0022067;C0168634;C0444504;C1414370;C1442488;C2347634;C2348143;C2348481
4330,ls mean change from baseline,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
4330,ls mean % change from baseline _ se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
4330,disease duration : < baseline mean,C0168634;C0444504;C0872146;C1442488;C2347634;C2348143
4330,baseline mean mtss,C0168634;C0444504;C1442488;C2347634;C2348143
4330,baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
4330,basdai  mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
4330,basdai  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1998004;C2347634;C2348143;C4319952
4330,< mean,C0444504;C2347634;C2348143
4330,$nmbr$ baseline mean,C0168634;C0444504;C1442488;C2347634;C2348143
4329,mean_delta,C0439097;C0444504;C1705241;C2347634;C2348143;C3146239;C3538806;C3540585;C3815527
4328,mean dose ' ’,C0178602;C0444504;C0869039;C1114758;C2347634;C2348143
4327,week $nmbr$ mean ( se ),C0036919;C0332174;C0439230;C0444504;C2347634;C2348143
4327,mean ± se ) bii ( ls mean ± se ),C0023668;C0036919;C0444504;C1413059;C2347634;C2348143
4327,mean yearly decline,C0444504;C2347634;C2348143
4327,mean change  % ( se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
4327,mean ( se ) trough l,C0036919;C0444504;C0444506;C2347634;C2348143
4327,mean ( se ) trough  l,C0036919;C0444504;C0444506;C2347634;C2348143
4327,mean ( se ) auc ^ p l,C0036919;C0376690;C0444504;C2347634;C2348143
4327,mean ( se ) auc $nmbr$ - $nmbr$  l,C0036919;C0376690;C0444504;C2347634;C2348143
4327,mean ( se ),C0036919;C0444504;C2347634;C2348143
4327,ls mean change from baseline ( se )  %,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
4327,least square mean ( se ),C0023189;C0036919;C0444504;C2347634;C2348143
4327,hscrp ( post - baseline / baseline ratio )  ls mean   ±   se,C0023668;C0036919;C0168634;C0444504;C0456603;C0687676;C1442488;C1547037;C1704687;C2347634;C2348143;C3469826
4327,fev $nmbr$ at week $nmbr$  mean ml ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0031962;C0036919;C0332174;C0439230;C0444504;C1705241;C1705242;C2347634;C2348025;C2348143;C3714541
4327,calculated annual decline  mean ± se,C0036919;C0332181;C0444504;C0444686;C1441506;C2347634;C2348143
4327,baseline mean ( se ),C0036919;C0168634;C0444504;C1442488;C2347634;C2348143
4327,adjusted mean ( se ) trough fevi  ml,C0036919;C0429706;C0439526;C0444504;C0444506;C0456081;C0849974;C1561566;C1705224;C2347634;C2348143;C3887665;C4528367
4327,% change ( mean ± se ),C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
4326,mean total serum psa,C0229671;C0444504;C1546774;C1550100;C2347634;C2348143;C2986589
4325,sf ‐ $nmbr$ pcs  ls mean change ± se,C0023668;C0036919;C0037712;C0392747;C0443172;C0444504;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
4325,ls mean difference ± seb,C0023668;C0059386;C0444504;C1309881;C1423585;C1705241;C1705242;C2347634;C2348143;C3815268
4325,ls mean difference ( se ),C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
4325,ls mean change ± sea,C0023668;C0036493;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
4325,ls mean change from baseline  ml ( se ) a,C0023668;C0036919;C0168634;C0392747;C0439526;C0443172;C0444504;C1442488;C1705224;C1705241;C2347634;C2348143;C3887665;C4319952
4325,ls mean change,C0023668;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
4325,ls mean ( se ),C0023668;C0036919;C0444504;C2347634;C2348143
4325,ls mean,C0023668;C0444504;C2347634;C2348143
4324,total daily dose of ics  mean  μ gc,C0444504;C0815320;C2347634;C2348070;C2348143;C3537453;C4281799;C4551720
4324,mean ics use at enrolment ( pg ) *,C0444504;C0815320;C2347634;C2348143;C4551720
4324,mean ics ( fluticasone propionate dpi or equivalent  pg per day ),C0117996;C0444504;C0815320;C2347634;C2348143;C4551720
4323,pav  mean ( $nmbr$ % ci ),C0008107;C0058890;C0444504;C2347634;C2348143;C3259781
4323,mean proportion ( % ),C0444504;C1709707;C2347634;C2348143
4323,mean involved bsa  % ( $nmbr$ % ci ),C0444504;C2347634;C2348143
4323,mean ( $nmbr$ % ci ) difference vs saxa + dapa + met,C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
4323,mean % predicted value prebronchodilation,C0444504;C2347634;C2348143
4323,mean % predicted fvc ( sd ),C0444504;C2347634;C2348143
4323,mean % predicted dlco * ( sd ),C0444504;C2347634;C2348143
4323,ls mean ( $nmbr$ % ci )  mmol / mol,C0008107;C0023668;C0444504;C2347634;C2348143;C3259781;C3829066
4323,difference in ls mean vs placebo ( $nmbr$ % ci )  mmol / mol,C0023668;C0444504;C1705241;C1705242;C2347634;C2348143
4323,( mean difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
4323,( mean % difference  $nmbr$ % ci ),C0008107;C0444504;C1705241;C1705242;C2347634;C2348143;C3259781
4322,total macular volume  mean ( sd )  mm $nmbr$,C0332574;C0444504;C0449468;C2347634;C2348143;C2699239;C4330985;C4554674
4322,total length of implanted stents  mm  mean ( sd ),C0021102;C0439175;C0439810;C0444504;C0449462;C2347634;C2348143;C2699239;C2828363;C4330985;C4554674
4322,mean of mean cimt  mean ( sd )  mm,C0444504;C2347634;C2348143;C2699239;C4330985;C4554674
4322,mean of jsw ( mm ),C0444504;C2347634;C2348143;C4330985;C4554674
4322,cwt  mean ( se )  mm,C0036919;C0444504;C2347634;C2348143;C4330985;C4554674
4321,mtx ( mean dose : $nmbr$ . $nmbr$ mg / wk ),C0366550;C0444504;C1881833;C2347634;C2348143
4321,mean doseb,C0444504;C2347634;C2348143
4321,mean baseline ( n ),C0168634;C0444504;C1442488;C2347634;C2348143
4321,mean ( s . e . ) t,C0444504;C2347634;C2348143
4321,mean ( s . e . ),C0444504;C2347634;C2348143
4321,baseline tjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
4321,baseline sjc  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
4321,baseline hba $nmbr$ c  mean ( s . e . ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
4321,baseline das $nmbr$  mean ( s . e . ),C0051767;C0057671;C0168634;C0444504;C1442488;C2347634;C2348143
4321,baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day )  n ( % ),C0168634;C0178602;C0439422;C0444504;C0869039;C1114758;C1442488;C2347634;C2348143
4320,years ( mean ± sd ),C0439234;C0444504;C2347634;C2348143;C2699239
4320,years  mean ( sd ),C0439234;C0444504;C2347634;C2348143;C2699239
4320,week $nmbr$ mean 士 sd,C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
4320,week $nmbr$ mean ( sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
4320,week $nmbr$ ( mean  sd ),C0332174;C0439230;C0444504;C2347634;C2348143;C2699239
4320,waist circumference  mean ( sd )  in,C0444504;C0455829;C2347634;C2348143;C2699239
4320,vital signs  mean ( sd ),C0150404;C0444504;C0518766;C2347634;C2348143;C2699239
4320,units per week  mean ( sd ),C0444504;C0560588;C2347634;C2348143;C2699239
4320,treatment duration mean ( sd ),C0444504;C0444921;C2347634;C2348143;C2699239;C3259042
4320,total periventricular wml score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552
4320,total cigarette pack - years  mean ( sd ),C0439175;C0439810;C0444504;C1303175;C2347634;C2348143;C2699239
4320,total cholesterol  mean ( sd ),C0201950;C0444504;C0543421;C2347634;C2348143;C2699239
4320,total back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0004600;C0042815;C0205095;C0439175;C0439810;C0444504;C0460009;C1995000;C2347634;C2348143;C2699239;C4330985;C4554674
4320,tg  mg / dl  mean ± sd,C0337445;C0439269;C0444504;C2347634;C2348143;C2699239
4320,tchdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,symptoms mean ( sd ),C0444504;C0683368;C1457887;C2347634;C2348143;C2699239
4320,smoking history  pack - years  mean ( sd ),C0444504;C1277691;C1519384;C2347634;C2348143;C2699239
4320,shs  mean ± sd,C0444504;C2347634;C2348143;C2699239
4320,shs  mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
4320,sgrq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
4320,serum total cholesterol ( mmol / l )  mean ( sd ),C0444504;C0587184;C1287371;C1532563;C2347634;C2348143;C2699239
4320,serum haemoglobin a $nmbr$ c concentration ( % )  mean ( sd ),C0019020;C0444504;C0683149;C2347634;C2348143;C2699239;C3889898
4320,serum creatinine - mean ( sd  n ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
4320,pulmonary function tests ( post - bronchodilator )  mean ( sd ),C0024119;C0444504;C2347634;C2348143;C2598152;C2599594;C2699239
4320,psoriasis duration  mean ± sd  years,C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
4320,previous dmards  mean ± sd,C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
4320,ppbc score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
4320,plp - c  mean ( sd )  mg / dl,C0034266;C0439269;C0444504;C1175541;C1257874;C1705623;C2347634;C2348143;C2699239
4320,physician global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4050369
4320,pga score  mean ( sd ),C0016410;C0444504;C0449820;C2347634;C2348143;C2699239;C3541266;C4050231;C4050369
4320,patients ' characteristics age ( years )  mean + sd,C0444504;C0815172;C1510829;C2347634;C2348143;C2699239
4320,patient global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
4320,patient ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4054228;C4330985;C4554674
4320,patient ' s global assessment of disease activity  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4054228
4320,partial mayo score  mean ( sd ),C0444504;C0449820;C0454788;C0728938;C1077578;C1550516;C2347634;C2348143;C2699239;C4050231
4320,pack - years  mean ( sd ),C0444504;C1277691;C2347634;C2348143;C2699239
4320,ocs dose *  mean ( sd ),C0178602;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
4320,number of implanted stents  n  mean ( sd ),C0237753;C0444504;C0449788;C0522776;C2347634;C2348143;C2699239
4320,non - hdl - c  mean ( sd )  rng / dl,C0444504;C1518422;C2347634;C2348143;C2699239;C3642216;C3715113
4320,non - hdl - c  mean ( sd ),C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
4320,nocturnal back pain  $nmbr$ – $nmbr$ mm vas  mean ± sd,C0042815;C0444504;C1970122;C2347634;C2348143;C2699239;C3536884;C3827561;C4330985;C4554674
4320,no . previous dmard  mean ( sd ),C0205156;C0242708;C0444504;C1552607;C2347634;C2348143;C2699239
4320,mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
4320,mean 土 sd ( n ),C0444504;C2347634;C2348143;C2699239
4320,mean ±   sd,C0444504;C2347634;C2348143;C2699239
4320,mean ± sd unless otherwise indicated,C0444504;C2347634;C2348143;C2699239
4320,mean ± sd triglycerides  mg / dl,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
4320,mean ± sd mg ( n = $nmbr$  $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
4320,mean ± sd fasting insulin  uu / ml,C0015663;C0021641;C0439342;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
4320,mean ± sd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
4320,mean ± sd ( yr ),C0439234;C0444504;C2347634;C2348143;C2699239
4320,mean ± sd ( n ),C0444504;C2347634;C2348143;C2699239
4320,mean ± sd  n ( % ),C0444504;C2347634;C2348143;C2699239
4320,mean ± sd  n,C0444504;C2347634;C2348143;C2699239
4320,mean ± sd,C0444504;C2347634;C2348143;C2699239
4320,mean   ±   sd,C0444504;C2347634;C2348143;C2699239
4320,mean total serum ige ( sd )  iu / ml,C0229671;C0439175;C0439458;C0439810;C0444504;C1546774;C1550100;C2347634;C2348143;C2699239
4320,mean stents per lesion ( sd ) ‡,C0038257;C0221198;C0444504;C1546698;C2347634;C2348143;C2699239
4320,mean prebronchodilator fev $nmbr$ ( sd )  % predicted,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
4320,mean or n,C0444504;C2347634;C2348143
4320,mean no . agents ( sd ) other medications,C0444504;C2347634;C2348143
4320,mean lixi dose ± sd ( lg / day ),C0023128;C0178602;C0332173;C0439228;C0439505;C0444504;C0694651;C0869039;C1114758;C2347634;C2348143;C2699239
4320,mean iglar dose ± sd ( u / day ),C0178602;C0444504;C0456683;C0869039;C1114758;C2347634;C2348143;C2699239
4320,mean fvc ± sd,C0444504;C2347634;C2348143;C2699239;C3714541
4320,mean dlco ± sd,C0444504;C1516251;C2347634;C2348143;C2699239
4320,mean change in radiographic end points shs  mean ± sd,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C2699239;C4319952
4320,mean bmi  kg / m $nmbr$ ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
4320,mean age ± sd ( years ),C0444504;C1510829;C2347634;C2348143;C2699239
4320,mean a ± sem ( % ),C0444504;C2347634;C2348143
4320,mean a ± sdt,C0444504;C2347634;C2348143
4320,mean a ± sd ( mmhg ),C0444504;C2347634;C2348143
4320,mean a ± sd  mg / dl ( mmol / $nmbr$ ),C0444504;C2347634;C2348143
4320,mean = sd,C0444504;C2347634;C2348143;C2699239
4320,mean *,C0444504;C2347634;C2348143
4320,mean ( ± sd ) change from,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C2699239;C4319952
4320,mean ( sd on loge scale ) u / ml,C0175659;C0349674;C0439340;C0444504;C1880521;C1947916;C2347634;C2348143;C2697934;C2699239;C2945590
4320,mean ( sd ) tender joint count *,C0444504;C0451530;C2347634;C2348143;C2699239
4320,mean ( sd ) sdai *,C0444504;C2347634;C2348143;C2699239;C3871128
4320,mean ( sd ) ptga vas *,C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561
4320,mean ( sd ) pre - bronchodilator,C0444504;C2347634;C2348143;C2599602;C2699239
4320,mean ( sd ) post - bronchodilator fev $nmbr$ percentage predicted,C0439165;C0444504;C1549488;C1561533;C2347634;C2348143;C2599594;C2699239;C3714541
4320,mean ( sd ) post - bronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
4320,mean ( sd ) post - bronchodilator,C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) pga vas *,C0016410;C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3541266;C3827561;C4050369
4320,mean ( sd ) pain vas *,C0042815;C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) number of exacerbations *,C0237753;C0444504;C0449788;C2347634;C2348143;C2699239;C4086268
4320,mean ( sd ) improvement from baseline to week $nmbr$ in basdai questions *,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
4320,mean ( sd ) improvement from baseline to week $nmbr$ in basdai,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C2986411
4320,mean ( sd ) fevi / evc  %,C0013903;C0429706;C0429711;C0444504;C0849974;C1414479;C1561566;C2347634;C2348143;C2699239;C4528367
4320,mean ( sd ) fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2699239;C3714541
4320,mean ( sd ) feno  ppb,C0444504;C1415800;C2347634;C2348143;C2699239
4320,mean ( sd ) change from pre - to post - bronchodilator fevi  nil,C0332152;C0442734;C0444504;C0687676;C0740175;C1704687;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034
4320,mean ( sd ) cdai *,C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
4320,mean ( sd ) aqlq,C0444504;C2347634;C2348143;C2699239;C4055434
4320,mean ( sd ) anthropometry,C0003188;C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) age,C0001779;C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) ( years ),C0439234;C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) % predicted normal fev $nmbr$,C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0444504;C2347634;C2348143;C2699239
4320,mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
4320,mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,mean ( = sd ) days since,C0439228;C0444504;C2347634;C2348143;C2699239
4320,mean $nmbr$ sd,C0444504;C2347634;C2348143;C2699239
4320,mean  sd,C0444504;C2347634;C2348143;C2699239
4320,mean  ml ( sd ),C0439526;C0444504;C1705224;C2347634;C2348143;C2699239;C3887665
4320,mayo score ( mean ± sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
4320,mayo score  mean ( sd ),C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
4320,left ventricular ejection fraction  mean ( sd )  %,C0428772;C0444504;C0488728;C2347634;C2348143;C2699239
4320,left ventricular ef  mean ( sd )  %,C0225897;C0444504;C2347634;C2348143;C2699239
4320,leeds enthesitis index  mean ( sd ) ’ ’ * ’,C0444504;C0451148;C2347634;C2348143;C2699239
4320,leeds dactylitis index - basic  mean ( sd ) ’ ' ^,C0239161;C0444504;C0600653;C0918012;C1527178;C1552854;C1637833;C2347634;C2348143;C2699239;C2986546
4320,ldl / hdl cholesterol ratio  mean ( sd ) §,C0008377;C0428621;C0444504;C2347634;C2348143;C2699239
4320,ldl - cihdl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,ldl - c in mmol / l ( mean ± sd for baseline [ n ]  mean ± se for week $nmbr$ [ n ] ),C0444504;C1532563;C2347634;C2348143;C2699239
4320,ldl - c / hdl - c ratio  mean ( sd ),C0428621;C0444504;C2347634;C2348143;C2699239
4320,ldl - c  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,jsn  mean ± sd,C0444504;C2347634;C2348143;C2699239
4320,in previous year  mean ( sd ),C0205156;C0439234;C0439508;C0444504;C1552607;C2347634;C2348143;C2699239
4320,imaging data  mean ( sd ),C0011923;C0079595;C0444504;C1511726;C2347634;C2348143;C2699239;C3245479;C3714741
4320,ibdq  mean ± sd,C0444504;C2347634;C2348143;C2699239
4320,hscrp  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,hrql mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0023822;C0439269;C0444504;C2347634;C2348143;C2699239
4320,hemoglobin a $nmbr$ c  mean ( sd )  % b,C0062248;C0444504;C2347634;C2348143;C2699239
4320,hemoglobin a $nmbr$ c  mean ( sd )  %,C0019020;C0444504;C2347634;C2348143;C2699239;C3889898
4320,hbalc ( % )  mean ( sd ) ^,C0444504;C2347634;C2348143;C2699239
4320,hbalc  %  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,hbajc ( mmol / mol ) mean ± sd,C0444504;C2347634;C2348143;C2699239;C3829066
4320,hbaie ( % ) mean ± sd,C0444504;C2347634;C2348143;C2699239
4320,hab $nmbr$ c ( mean ± sem )  %,C0444504;C2347634;C2348143
4320,fsn score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
4320,fpi  mean ( sd )  pu / rnff,C0018387;C0444504;C2347634;C2348143;C2699239
4320,fpi  mean ( sd )  pu / mlt,C0018387;C0444504;C2347634;C2348143;C2699239;C4553833
4320,fpg  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
4320,fev $nmbr$ / fvc prebronchodilator  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
4320,fev $nmbr$ / fvc  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3714541
4320,fev $nmbr$ / fvc  %  mean ( sd ) $nmbr$,C0444504;C2347634;C2348143;C2699239;C3714541
4320,femoral neck t - score ( mean = sd ),C0015815;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
4320,fasting insulin  iiiu / ml  mean ± sd,C0015663;C0021641;C0439526;C0444504;C1533581;C1579433;C1705224;C2347634;C2348143;C2699239;C3714501;C3887665
4320,exact - pro total score  mean ( sd ),C0033382;C0444504;C0523852;C2347634;C2348143;C2699239;C2828393;C2964552;C2987124;C4050514
4320,erosion  mean ± sd,C0333307;C0444504;C1880549;C1959609;C2347634;C2348143;C2699239;C3887524
4320,ejection fraction  mean ( sd )  %,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
4320,egfr — mean ( sd  n ),C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
4320,egfr +  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
4320,egfr  mean ± sd,C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
4320,ef ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,education  yrs  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
4320,education  mean ( sd )  ya,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
4320,duration of diabetes  mean ( sd )  y,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
4320,dlqi ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3899393
4320,disease duration ( yr )  mean ± sd,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
4320,disease duration  yrs  mean ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
4320,diagnosis ( y )  mean ( sd ),C0011900;C0444504;C1704338;C1704656;C2347634;C2348143;C2699239
4320,diabetesduration  mean ( sd )  y,C0444504;C2347634;C2348143;C2699239
4320,demographic characteristics  mean ± sd unless otherwise indicated,C0444504;C0683970;C2347634;C2348143;C2699239
4320,das $nmbr$ - hscrp  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
4320,das $nmbr$ - esr  mean ± sd das $nmbr$ - esr remission  %,C0051767;C0057671;C0444504;C0544452;C0687702;C2347634;C2348143;C2699239;C3811131
4320,das $nmbr$  mean ± sd,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
4320,daily “ off ” time  mean ± sd  h / dayf,C0033727;C0040223;C0332173;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C3541383;C4528284
4320,clinical dementia rating sum of boxes  mean ( sd ) f,C0444504;C0451074;C1515051;C1517104;C2347634;C2348143;C2699239
4320,cholesterol - mean ( sd  n ),C0008377;C0444504;C2347634;C2348143;C2699239
4320,bsa ( % )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,bone erosion score  mean ( sd ),C0444504;C0449820;C0587240;C2347634;C2348143;C2699239;C4050231
4320,bmi ( kg / m $nmbr$ ) mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
4320,bmi ( kg / m $nmbr$ ) : mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
4320,bmi  mean ± sd kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
4320,bmi  mean ± sd,C0444504;C0578022;C2347634;C2348143;C2699239
4320,blood oxygenation  mean ± sd,C0005767;C0005768;C0229664;C0231940;C0282636;C0444504;C2347634;C2348143;C2699239
4320,bii ( mean ± sd ),C0444504;C1413059;C2347634;C2348143;C2699239
4320,basmi ( linear )  mean ( sd ),C0205132;C0444504;C2347634;C2348143;C2699239
4320,basfi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,baseline spga  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
4320,baseline mean serum uric acid  pmol / l ( sd ),C0168634;C0439284;C0444504;C0455272;C0700634;C1442488;C2347634;C2348143;C2699239
4320,baseline mean ambulatory sbp  mm hg ( sd ) *,C0085805;C0168634;C0439475;C0439841;C0444504;C1442488;C2347634;C2348143;C2699239
4320,baseline lipids  mean ± sd ( mmol / l ),C0023779;C0168634;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
4320,baseline lipids  mean ± sd ( mmol / $nmbr$ ),C0023779;C0168634;C0439190;C0444504;C1442488;C2347634;C2348143;C2699239
4320,baseline bsa  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
4320,baseline ( mean  sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
4320,baseline  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
4320,as duration  y  mean ( sd ),C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
4320,aqlq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
4320,apo a - l ( mg / dl ) - mean ± sd,C0439269;C0444504;C1447574;C2347634;C2348143;C2699239;C4521365
4320,anthropometry : mean ( sd ),C0003188;C0444504;C2347634;C2348143;C2699239
4320,anthropometrics  mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,age mean ( yrs ± sd ),C0001779;C0444504;C2347634;C2348143;C2699239
4320,age ( years ) mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age ( years ) ( mean ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4320,age ( years )  mean   ±   sd,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age ( years )  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age  years mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age  years  mean ± sd,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age  mean ± sd years,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age  mean ± sd  years,C0444504;C1510829;C2347634;C2348143;C2699239
4320,age  mean ± sd,C0001779;C0444504;C2347634;C2348143;C2699239
4320,age  mean  years ( ± sd ),C0444504;C1510829;C2347634;C2348143;C2699239
4320,> mean,C0444504;C2347634;C2348143
4320,> $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
4320,( mean ± sd ),C0444504;C2347634;C2348143;C2699239
4320,( mean + . sd ),C0444504;C2347634;C2348143;C2699239
4320,( % )  $nmbr$ mean ( sd ),C0444504;C2347634;C2348143;C2699239
4320,% \mean ± sd,C0444504;C2347634;C2348143;C2699239
4319,£ median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,£ median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,£ median,C0549183;C0876920;C2347635;C2348144;C2939193
4319,weight — kg ( median ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
4319,weight  median ( interquartile range )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C1711350;C2347635;C2348144;C2939193;C4054209
4319,weight  median ( $nmbr$ th — $nmbr$ th percentiles )  kg,C0022718;C0039725;C0039738;C0439209;C0549183;C0552346;C0876920;C1420718;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
4319,weight  kg  median ( range ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1514721;C1705104;C2347635;C2348144;C2348147;C2939193;C3542016;C4054209
4319,urinary albumin / creatinine ratio  median mg / g ( range ),C0455271;C0549183;C0876920;C1300563;C1318330;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,triglycerides ( median  iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
4319,triglycerides  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
4319,triglycerides  median ( q $nmbr$ : q $nmbr$ ),C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
4319,triglycerides  median ( iqr )  mg / dl,C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
4319,total ige levelx ( iu / ml )  median ( range ),C0439175;C0439458;C0439810;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,time to end - of - study ivus  median ( iqr )  days,C0439548;C0444930;C0549183;C0557651;C0876920;C1456025;C2347635;C2348144;C2603343;C2746065;C2939193
4319,time from  median ( iqr )  h,C0033727;C0040223;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C3541383;C4528284
4319,tg  median ( min  max ),C0337445;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,tg  median ( interquartile range ),C0337445;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
4319,serum cholesterol  median ( iqr )  mg / dl,C0439269;C0549183;C0587184;C0876920;C2347635;C2348144;C2939193
4319,score improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411;C4050231
4319,sbp ( mm hg )  median ( iqr ),C0085805;C0439475;C0549183;C0876920;C2347635;C2348144;C2939193
4319,pra  median ( min  max )  ng / ml / h,C0033727;C0369286;C0441932;C0549183;C0564385;C0633231;C0702093;C0876920;C1141951;C1419788;C1524029;C1533072;C2347635;C2348144;C2827900;C2939193;C3274822;C3669212;C3813700;C4050009;C4283900;C4528284
4319,percent improvement  baseline to week $nmbr$  median ( iqr ),C0168634;C0332174;C0439165;C0439230;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C2986411
4319,mtss  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,mmp - $nmbr$  median ( iqr )  gg / l,C0017454;C0018370;C0549183;C0623362;C0876920;C0919336;C2347635;C2348144;C2939193
4319,medians ( iqr ),C0549183
4319,median §,C0549183;C0876920;C2347635;C2348144;C2939193
4319,median triglyceride ( mg / dl ),C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
4319,median time to event ( weeks ),C0040223;C0439230;C0441471;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383;C4019010
4319,median nt - probnp ( iqr ) – pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
4319,median n - terminal probnp ( iqr ) — pg / ml,C0439297;C0549183;C0669479;C0876920;C2347635;C2348144;C2939193
4319,median m / kg $nmbr$ ( iqr ),C0022718;C0369637;C0439209;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
4319,median feno ( ppb ) f,C0016327;C0549183;C0876920;C1415800;C2347635;C2348144;C2939193
4319,median feno  ppba,C0549183;C0876920;C2347635;C2348144;C2939193
4319,median egfr ( interquartile range ),C0549183;C0876920;C1711350;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
4319,median delay ( h ) §,C0033727;C0205421;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
4319,median cardiac troponin t ( iqr ) 一 pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
4319,median cardiac troponin t ( iqr ) — pg / ml,C0439297;C0549183;C0876920;C2347635;C2348144;C2939193;C3538889
4319,median body weight ( kg ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C3821165;C4054209
4319,median body mass index  kg / m $nmbr$ ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
4319,median bnp ( iqr ) – pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
4319,median blood eosinophil count ( cells per pl ) t,C0200638;C0549183;C0876920;C2347635;C2348144;C2939193;C3897966;C4049765
4319,median albumin / creatinine ratio ( g / mg ),C0024671;C0026410;C0439267;C0439269;C0486293;C0549183;C0876920;C1318293;C1960952;C2346927;C2347635;C2348144;C2939193;C4321396;C4521761
4319,median age  y ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,median ( sd )  mg / mmol,C0549183;C0567349;C0876920;C2347635;C2348144;C2348885;C2699239;C2939193
4319,median ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,median ( q $nmbr$ – q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,median ( q $nmbr$ : q $nmbr$ ) tgs,C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
4319,median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol,C0065055;C0337445;C0549183;C0699759;C0876920;C2347635;C2348144;C2939193
4319,median ( q $nmbr$ : q $nmbr$ ) lp ( a )  mg / dl,C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
4319,median ( q $nmbr$ : q $nmbr$ ) duration of insulin use  years,C0021641;C0439234;C0549183;C0876920;C1533581;C1579433;C1881378;C2347635;C2348144;C2826775;C2939193;C3714501
4319,median ( q $nmbr$ : q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,median ( q $nmbr$  q $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,median ( iqr ) mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use : weight,C0168634;C0444504;C0549183;C0876920;C1442488;C2347634;C2347635;C2348143;C2348144;C2939193
4319,median ( iqr ) cholesterol,C0008377;C0549183;C0876920;C2347635;C2348144;C2939193
4319,median ( iqr ) admission data,C0184666;C0549183;C0809949;C0876920;C1511726;C2347635;C2348144;C2939193;C3245479;C3714741
4319,median ( iqr )  h,C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
4319,median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,median ( interquartile range ),C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
4319,median ( days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
4319,median  y ( range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,median  iqr,C0549183;C0876920;C2347635;C2348144;C2939193
4319,mean age  y  median ( range ),C0001779;C0444504;C0549183;C0876920;C1514721;C2347634;C2347635;C2348143;C2348144;C2348147;C2939193;C3542016
4319,lp ( a )  mg / dl  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0439269;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
4319,lp ( a )  median ( q $nmbr$ : q $nmbr$ ),C0065058;C0549183;C0876920;C1439335;C2347635;C2348144;C2939193;C4553379
4319,less than the median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
4319,less than median,C0439092;C0549183;C0876920;C2347635;C2348144;C2939193
4319,ldl cholesterol ( mmol / l ) ( median  iqr ),C0023824;C0202117;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
4319,ldl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
4319,laboratory values at randomization ( median and iqr ),C0022877;C0034656;C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
4319,laboratory values at admission ( median and iqr ),C0022877;C0042295;C0184666;C0549183;C0809949;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
4319,jsn  median ( min  max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,insulin dose ( iu / day )  median,C0366513;C0439465;C0549183;C0876920;C2347635;C2348144;C2939193
4319,insulin  iu / ml  median ( q $nmbr$  q $nmbr$ ),C0021641;C0439458;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
4319,index event to randomization  median ( iqr )  h,C0033727;C0034656;C0369286;C0441471;C0441932;C0549183;C0564385;C0600653;C0876920;C0918012;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C4019010;C4528284
4319,ige ( ku / l )  median ( range ) c,C0439340;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,hscrp ( mg / l )  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
4319,hscrp  mg / l  median ( min – max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193
4319,hscrp  median ( min  max )  mg / l,C0549183;C0876920;C2347635;C2348144;C2827895;C2939193
4319,homa_ir  median ( q $nmbr$  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
4319,homa_ % b  median ( q $nmbr$  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
4319,homa . ir  median ( ql  q $nmbr$ )  % / $nmbr$,C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
4319,homa . % b  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
4319,homa - ir  median ( q $nmbr$  q $nmbr$ ),C0022065;C0022071;C0549183;C0876920;C1448132;C2347635;C2348144;C2939193
4319,hdl - c ( median  iqr )  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3715113
4319,hbalc in %  median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
4319,hbalc  median ( ql  q $nmbr$ )  %,C0549183;C0876920;C2347635;C2348144;C2939193
4319,fasting tgs  median ( q $nmbr$ : q $nmbr$ ),C0015663;C0549183;C0876920;C1156212;C1537574;C2347635;C2348144;C2939193
4319,euroscore logistic  median ( $nmbr$ th  $nmbr$ th % ) £,C0039725;C0039738;C0242415;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
4319,esr ( mm / h )  median ( min - max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
4319,esr ( mm / h )  median ( min  max ),C0033727;C0369286;C0441932;C0456680;C0549183;C0564385;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3642211;C3811131;C3813700;C4528284
4319,egfr in ml / min / $nmbr$ . $nmbr$ m ^  median ( iqr ),C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
4319,egfr ( median  iqr )  ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C1739039;C2347635;C2348144;C2939193;C3811844;C3812682
4319,dbp ( mm hg )  median ( iqr ),C0439475;C0536221;C0549183;C0876920;C2347635;C2348144;C2939193;C3813197;C4281799
4319,data represent number of patients ( % ) or mean ( standard deviation )  unless otherwise indicated . a self - reported information . bc physician - diagnosed diabetes or fasting plasma glucose ≥ $nmbr$ mg / dl or hemoglobin a $nmbr$ c ≥ $nmbr$ . $nmbr$ % . d physician - diagnosed hypertension or systolic blood pressure ≥ $nmbr$ mmhg or diastolic blood pressure ≥ $nmbr$ mmhg . median ( interquartile range ) . ldl  low - density lipoprotein  hdl  high - density lipoprotein  tg  triglyceride .,C0023820;C0031831;C0062152;C0073187;C0178587;C0205251;C0332173;C0337445;C0428883;C0439475;C0549183;C0804815;C0876920;C1305849;C1511726;C1550472;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741;C3890211;C4048187;C4321351;C4484261;C4522223
4319,crp  median ( range ) mg / literl,C0024671;C0026410;C0439269;C0549183;C0876920;C1514721;C1960952;C2346927;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285;C4321396;C4521761
4319,creatinine ( ^ mol / l ) ( median  iqr ),C0010294;C0347982;C0549183;C0876920;C1561535;C2347635;C2348144;C2939193
4319,crcl  median ( iqr )  ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
4319,cgfrby ckd - epi  ml / min / $nmbr$ . $nmbr$ m $nmbr$  median ( iqr ),C0162734;C0369637;C0439445;C0441923;C0549183;C0876920;C1561643;C2347635;C2348144;C2939193;C4281721
4319,cardiac troponin t level  median ( iqr )  pg / l,C0439278;C0441889;C0456079;C0549183;C0876920;C1547707;C2347635;C2348144;C2939193;C2946261;C3538889
4319,c - reactive protein  median ( q $nmbr$  q $nmbr$ ),C0006560;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
4319,c - peptide  median ( ql  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
4319,c - peptide  median ( q $nmbr$  q $nmbr$ )  nmol / l,C0006558;C0439282;C0549183;C0876920;C2347635;C2348144;C2939193
4319,body mass index ( median,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
4319,body mass index  median ( iqr ) b,C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
4319,body mass index  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C2347635;C2348144;C2939193
4319,body mass index  kg / m $nmbr$  median ( q $nmbr$  q $nmbr$ ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
4319,body - mass index - kg / m $nmbr$  median ( iqr ),C0005893;C0549183;C0578022;C0876920;C1305855;C1532718;C2347635;C2348144;C2939193
4319,bmi * ( kg / m $nmbr$ )  median ( q $nmbr$  q $nmbr$ ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
4319,bmi ( median  iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
4319,bmi ( kg / m $nmbr$ )  median ( range ),C0549183;C0578022;C0876920;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
4319,bmi  median ( sd )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2699239;C2939193
4319,bmi  median ( iqr )  kg / m $nmbr$,C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
4319,bmi  median ( iqr ),C0549183;C0578022;C0876920;C2347635;C2348144;C2939193
4319,bmi  kg / m $nmbr$  median ( iqr ),C0549183;C0578022;C0876920;C1532718;C2347635;C2348144;C2939193
4319,below median,C0549183;C0876920;C2347635;C2348144;C2939193
4319,baseline pos frequency per $nmbr$ days  median ( min  max ),C0168634;C0549183;C0585290;C0702093;C0876920;C1262869;C1442488;C1524029;C2347635;C2348144;C2939193;C3496112;C3496399;C3813700
4319,baseline hematocrit  median ( iqr ),C0018935;C0168634;C0518014;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4319,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$  q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
4319,baseline creatinine  median ( range ) mg / dl,C0010294;C0168634;C0439269;C0549183;C0876920;C1442488;C1514721;C1561535;C2347635;C2348144;C2348147;C2939193;C3542016
4319,albumin / creatinine ratio - mg / mmol  median ( iqr ),C0486293;C0549183;C0567349;C0876920;C1318293;C2347635;C2348144;C2348885;C2939193
4319,age y  median ( range ),C0001779;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4319,age ( y )  median ( min  max },C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,age ( y )  median ( min  max ),C0001779;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,age  y  median ( q $nmbr$ – q $nmbr$ ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4319,age  median ( interquartile range )  y,C0001779;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
4319,a median,C0549183;C0876920;C2347635;C2348144;C2939193
4319,^ median,C0549183;C0876920;C2347635;C2348144;C2939193
4319,> median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
4319,< median ( $nmbr$ kg ),C0022718;C0439209;C0549183;C0876920;C2347635;C2348144;C2939193;C4054209
4319,< $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
4319,- median tg ( iqr ),C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
4319,( median  h ),C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C2347635;C2348144;C2939193;C4528284
4318,waisvhip > = median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,sbp > median ( n = $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
4318,non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
4318,ldl - c > median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,homa > median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,hbalc > median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,hbak > median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,grip strength > = median,C0429271;C0549183;C0876920;C2347635;C2348144;C2598165;C2939193
4318,baseline tav - > = median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4318,baseline pav - > = median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4318,age > - median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4318,^ median > median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,> median ( $nmbr$ mm ),C0549183;C0876920;C2347635;C2348144;C2939193;C4330985;C4554674
4318,> median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
4318,> median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
4318,> median ( $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4318,> median ( $nmbr$ % ),C0549183;C0876920;C2347635;C2348144;C2939193
4318,> median,C0549183;C0876920;C2347635;C2348144;C2939193
4318,> = median,C0549183;C0876920;C2347635;C2348144;C2939193
4317,wt  second  median,C0205436;C0457385;C0549183;C0565930;C0876920;C1561503;C1705190;C1883559;C2347635;C2348144;C2700323;C2939193
4317,time in therapeutic range  median ( iqr )  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
4317,systolic blood pressure ( median $nmbr$ . $nmbr$ ),C0488055;C0549183;C0871470;C0876920;C1306620;C2347635;C2348144;C2939193
4317,pulse pressure ( median $nmbr$ . $nmbr$ ],C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
4317,pasi  median ( range ) * *,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4528685
4317,median time since diagnosis * ( range )  yr,C0040223;C0549183;C0876920;C2347635;C2348144;C2939193;C3541383
4317,median time in therapeutic range for warfarin recipients  %,C0040223;C0087111;C0302350;C0460097;C0549183;C0876920;C1554109;C2347635;C2348144;C2939193;C3541383
4317,median seconds,C0457385;C0549183;C0876920;C2347635;C2348144;C2939193
4317,median pasi score { range ) ' i  i ',C0021966;C0221138;C0449820;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C4050231;C4528685
4317,median change in atheroma volume  %,C0264956;C0392747;C0443172;C0449468;C0549183;C0876920;C1690016;C1705102;C1705241;C2347635;C2348144;C2700258;C2939193;C4319952
4317,median age ( iqr  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,median age  years ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,median ( iqr ) age  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,median  range,C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4317,median  iqr ),C0549183;C0876920;C2347635;C2348144;C2939193
4317,laboratory parameters  median ( iqr ),C0022877;C0449381;C0549183;C0876920;C2347635;C2348144;C2939193;C3244292;C4283904
4317,heart rate ( median $nmbr$ . $nmbr$ },C0018810;C0549183;C0876920;C2347635;C2348144;C2939193
4317,glycated hemoglobin  median ( iqr ),C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
4317,difference  % median,C0549183;C0876920;C1705241;C1705242;C2347635;C2348144;C2939193
4317,age in years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,age - years  median ( iqr ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C1510829;C2347635;C2348144;C2939193;C4282123;C4285344
4317,age ( y )  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age ( median [ iqr ] )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age ( median  years ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,age ( median  iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age  yrs  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age  years : median ( range ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4317,age  year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age  median years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,age  median ( range ) ( years ),C0549183;C0876920;C1510829;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
4317,age  median ( iqr )  years,C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4317,age  median ( iqr )  y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,age  median ( iqr ),C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4317,a $nmbr$ c > = median,C0549183;C0876920;C2347635;C2348144;C2939193
4317,a $nmbr$ c < median,C0549183;C0876920;C2347635;C2348144;C2939193
4317,a $nmbr$ c < $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
4317,a $nmbr$ = $nmbr$ . $nmbr$ % ( median ),C0549183;C0876920;C2347635;C2348144;C2939193
4317,> median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4317,> median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
4317,< median ( $nmbr$ . $nmbr$ ),C0549183;C0876920;C2347635;C2348144;C2939193
4317,< median $nmbr$ . $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
4316,waist / hip < median,C0019552;C0022122;C0230097;C0549183;C0876920;C1505163;C2347635;C2348144;C2939193;C3538851;C4284725
4316,sbp < median ( n = $nmbr$ o $nmbr$ ),C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
4316,maximum cimt < median,C0549183;C0806909;C0876920;C1552615;C2347635;C2348144;C2826546;C2939193
4316,hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
4316,hbalc < median,C0549183;C0876920;C2347635;C2348144;C2939193
4316,hbak < median,C0549183;C0876920;C2347635;C2348144;C2939193
4316,hba < median,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4316,glycated hemoglobin < median,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
4316,fastng plasma glucose < median,C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
4316,fasting plasma glucose < median,C0015663;C0202042;C0455280;C0549183;C0876920;C2347635;C2348144;C2939193
4316,diabetes durationa < median,C0011847;C0011849;C0549183;C0876920;C2347635;C2348144;C2939193
4316,baseline tav - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0279686;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4316,age < median,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
4316,age ( years ) - < median ( n = $nmbr$  $nmbr$ ),C0549183;C0876920;C1510829;C2347635;C2348144;C2939193
4316,< median { $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
4316,< median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
4316,< median,C0549183;C0876920;C2347635;C2348144;C2939193
4315,s median,C0549183;C0565930;C0876920;C2347635;C2348144;C2603362;C2939193
4315,median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
4315,median daily dose - iu ™,C0049272;C0439453;C0549183;C0694756;C0876920;C2347635;C2348070;C2348144;C2939193
4315,length of stent > median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
4315,length of stent < median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
4314,≤ median,C0549183;C0876920;C2347635;C2348144;C2939193
4314,score on nih stroke scale — median ( iqr ),C0449820;C0549183;C0876920;C1697238;C2347635;C2348144;C2939193;C3484372;C4050231
4314,score on modified mini - mental state examination — median ( iqr ),C0549183;C0876920;C2347635;C2348144;C2939193;C4304091
4314,months from mi — median ( iqr ),C0439231;C0549183;C0876920;C2347635;C2348144;C2939193;C3810814
4314,median — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
4314,median — vr,C0549183;C0876920;C2347635;C2348144;C2939193;C3476815
4314,median time delay ( interquartile range ) — min,C0522486;C0549183;C0702093;C0876920;C1524029;C1711350;C2347635;C2348144;C2939193;C3813700
4314,median age — yr §,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
4314,median age — yr,C0001779;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
4314,median age [ interquartile range ] — yr,C0001779;C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
4314,median ( iqr ) — yr,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
4314,age — year ( median ),C0001779;C0439234;C0439508;C0549183;C0876920;C2347635;C2348144;C2939193
4313,tg  median ( sdy rng / cjl,C0337445;C0549183;C0876920;C1424906;C2347635;C2348144;C2939193
4313,proprotein convertase subtil / kexin typ $nmbr$ ( ng / ml ) - baseline - > = median ( n = $nmbr$  $nmbr$ ),C0165249;C0168634;C0439275;C0549183;C0876920;C1100660;C1414185;C1442488;C2347635;C2348144;C2939193;C3811813
4313,non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = $nmbr$  $nmbr$ ),C0168634;C0439269;C0549183;C0876920;C1442488;C1535899;C2347635;C2348144;C2939193
4313,median  ml,C0439526;C0549183;C0876920;C1705224;C2347635;C2348144;C2939193;C3887665
4313,median,C0549183;C0876920;C2347635;C2348144;C2939193
4313,final median  mg / l,C0205088;C0439268;C0549183;C0876920;C1546485;C2347635;C2348144;C2939193;C3853528
4313,crp median ( se )  rng / l,C0036919;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
4313,crp [ mg / l ]  median,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
4313,crp ( mg / l ) [ b ]  median ( min - max ),C0439420;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
4313,crp ( mg / l )  median ± sd,C0439268;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193;C3890735;C4048285
4313,crp ( mg / l )  median ( min  max ),C0439268;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C3890735;C4048285
4313,crp  mg / dl  median,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
4313,crp  median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
4313,baseline median [ mg / l ],C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4313,baseline median  mg / l,C0168634;C0439268;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4313,baseline median  mg / dl,C0168634;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
4313,& median,C0549183;C0876920;C2347635;C2348144;C2939193
4312,cdr - sob,C0013404;C4521843
4311,no dyspnoea ( n = $nmbr$ ),C0013404;C1963100
4311,mmrc dyspnea scale  n ( % ),C0013404;C0175659;C0349674;C1947916;C1963100;C3826977
4311,dyspnoea ( n = $nmbr$ ),C0013404;C1963100
4311,dyspnea – mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
4311,dyspnea,C0013404;C1963100
4310,mmrc dyspnea scale score : t : t,C0013404;C1963100;C3826977;C4049715
4310,dyspnea t,C0013404;C1963100
4309,without dyspnoea,C0013404;C1963100
4309,with dyspnoea,C0013404;C1963100
4309,clopidogrel dyspnoea vs no dyspnoea *,C0013404;C0070166;C1963100
4309,cangrelor dyspnoea vs no dyspnoea *,C0013404;C1121991;C1963100
4308,previous respiratory disease other than copd — no . ( % ),C0024117;C0035204;C0035242;C0205156;C1412502;C1552607;C3714496
4308,copd — no . ( % ) medication use,C0024117;C1412502;C3714496
4308,copd ( % ),C0024117;C1412502;C3714496
4307,prior copd medicationa  n ( % ),C0024117;C0332152;C1412502;C2826257;C3714496
4307,prior copd medication,C0013227;C0024117;C0332152;C1412502;C2826257;C3244316;C3714496;C4284232
4306,copd severitya    n   ( % ),C0024117;C1412502;C3714496
4306,copd population ( n = $nmbr$ ),C0024117;C0032659;C1257890;C1412502;C3714496
4306,copd - placebo ( n = $nmbr$ ),C0024117;C0032042;C1412502;C1696465;C1706408;C3714496
4306,copd ( n = $nmbr$ ),C0024117;C1412502;C3714496
4306,copd    n   ( % ),C0024117;C1412502;C3714496
4305,mean copd duration  y ( sd ),C0024117;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
4305,mean ( sd ) duration of copd  years,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
4305,duration of copd — yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd — days ^,C0024117;C0439228;C0449238;C1412502;C2926735;C3714496
4305,duration of copd ( yr ) f,C0016327;C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd ( yr ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd ( years )  mean ( sd ),C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
4305,duration of copd ( years ),C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd  yr,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd  years,C0024117;C0439234;C0449238;C1412502;C2926735;C3714496
4305,duration of copd  y,C0024117;C0449238;C1412502;C2926735;C3714496
4305,duration of copd,C0024117;C0449238;C1412502;C2926735;C3714496
4305,copd duration  y,C0024117;C0449238;C1412502;C2926735;C3714496
4305,copd,C0024117;C1412502;C3714496
4304,copd worsening,C0024117;C0332271;C1412502;C1457868;C1546960;C3714496
4303,copd disease severity,C0024117;C0521117;C1412502;C3714496
4303,chronic obstructive pulmonary disease — no . ( % ),C0024117
4303,chronic obstructive pulmonary disease  n ( % ),C0024117
4303,chronic obstructive pulmonary disease,C0024117
4303,chronic obstructive lung disease,C0024117
4302,overall night - time copd symptom severity scorec,C0024117;C0240526;C0282416;C1319166;C1412502;C1561607;C3714496
4302,overall early - morning copd symptom severity scorec,C0024117;C0282416;C0332170;C1279919;C1319166;C1412502;C1561607;C3714496
4302,copd severityy,C0024117;C1412502;C3714496
4301,copd type,C0024117;C0332307;C1412502;C1547052;C3714496
4301,copd or asthma  ( % ),C0024117;C1412502;C3714496
4301,copd or asthma,C0024117;C1412502;C3714496
4301,clinical copd phenotype ^,C0024117;C0031437;C0205210;C1285572;C1412502;C3714496
4300,cross - clamp,C0175721;C1883710;C2828360;C3810601
4299,values are expressed as percentages unless otherwise indicated . bmi  body mass index  cabg  coronary artery bypass ischemic attack  nsaids  nonsteroidal anti - inflammatory drugs  sbp  systolic bp  dbp  diastolic bp . * history of or currently taking antidiabetic or lipid - lowering medications .,C0003209;C0003211;C0010055;C0012000;C0019664;C0019665;C0042295;C0085805;C0262512;C0262926;C0536221;C0577559;C0577573;C0600653;C0745413;C0871470;C0918012;C1096155;C1306372;C1552854;C1637833;C1705255;C2004062;C2986546;C3152252;C3539882;C3813197;C4281799;C4283905
4299,anti - inflammatory drugs,C0003209
4298,α - glucosidase inhibitor,C1512211
4298,a - glucosidase inhibitors ' $nmbr$,C1512211
4298,a - glucosidase inhibitors,C1512211
4298,a - glucosidase inhibitor,C1512211
4297,post - mi,C0856742
4296,post - dose,C0439568
4296,first dose admin . $nmbr$ - $nmbr$ h / $nmbr$ - $nmbr$ h post onset of symptoms,C0033727;C0205435;C0369286;C0439568;C0441932;C0564385;C1279901;C4084955;C4086878;C4528284
4295,no in - trial stroke n = $nmbr$  $nmbr$,C0008976;C0038454;C0150312;C0332285;C1707101;C4554100
4295,in - trial nonfatal or fatal stroke n = $nmbr$  $nmbr$,C0008976;C0150312;C0332285;C1707101
4295,in - trial and post - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0150312;C0332285;C1707101
4295,in - trial $nmbr$ - year rates per $nmbr$ ( se ) total events / number at risk,C0008976;C0036919;C0150312;C0332285;C0439175;C0439234;C0439508;C0439810;C0441471;C0871208;C1264674;C1521828;C1707101;C3541888;C4288115
4294,in - clinic uask,C0002424;C0150312;C0332285;C0442592;C1707101
4294,in - clinic uas $nmbr$,C0002424;C0150312;C0332285;C0442592;C1707101
4293,use $nmbr$ - asa compounds,C0004057;C0042153;C0205198;C0457083;C1706082;C1947944;C3853627
4293,no use of $nmbr$ - asa compounds,C0004057;C0205198;C1524063;C1706082;C3853627
4293,$nmbr$ - aminosalicylic compounds — no . ( % ),C0205198;C1706082
4292,histamine - $nmbr$ - receptor antagonist,C0019590;C4521896
4292,anti - histamines,C0019590
4291,sglt - $nmbr$ inhibitors ^,C3665045
4290,other glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
4290,hazard ratio glp - $nmbr$ analogue vs placebo [ $nmbr$ % cl ],C0018301;C0243071;C1422069;C1425391;C1539338;C2350813;C2985465
4290,glp - $nmbr$ receptor agonists,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
4290,glp - $nmbr$ receptor agonist ( other than study drug ),C0013175;C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
4290,glp - $nmbr$ receptor agonist,C0018301;C1422069;C1425391;C1539338;C2350813;C4543206
4290,glp - $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
4289,previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis,C0042487
4288,symptomatic deep - vein thrombosis,C0149871;C0231220
4288,neither deep - vein thrombosis nor pulmonary embolism §,C0149871
4288,neither deep - vein thrombosis nor pulmonary embolism ^,C0149871
4287,isolated deep - vein thrombosis,C0149871;C0205409;C1548221
4287,deep - vein thrombosis,C0149871
4287,both deep - vein thrombosis and pulmonary embolism,C0149871
4286,residual deep - vein thrombosis  no . ( % ),C0149871;C1609982
4286,deep - vein thrombosis ( % ),C0149871
4285,previous deep - vein thrombosis or pulmonary embolism,C0149871;C0205156;C1552607
4285,deep - vein thrombosis or pulmonary embolism — no . ( % ),C0149871
4284,ill -,C0231218
4283,emotional well - being,C2984554;C3641833
4282,standard treatment ( n - $nmbr$ ),C4684780
4281,on - treatment,C4684449
4280,beta - carotene ( n = $nmbr$  $nmbr$ ),C0053396;C0696105
4280,beta - carotene,C0053396;C0696105
4279,ascot - lla,C0718674
4278,no statin ( + / - llt ),C0360714;C2347090
4278,allhat - llt,C2347090
4277,abaloparatide - sc  n ( % ),C0282380;C4042342
4276,abl - sc n / n,C0023139;C0282380;C1704928;C3890208
4276,abl - sc mean,C0023139;C0282380;C0444504;C1704928;C2347634;C2348143;C3890208
4275,new - onset atrial fibrillation,C0741281
4274,non - fibrin - specific,C0015982;C0205370
4274,fibrin - specilic,C0015982
4274,fibrin - specific,C0015982
4273,peri - or postmenopausal,C0347985
4273,peri - operative cabg participants :,C0010055;C0347985;C0679646;C1882154
4272,intercourse satisfac -,C0009253
4271,pro - active intervention,C0033382;C0184661;C0205177;C0523852;C0886296;C1273869;C2987124;C3853793;C3888249
4271,patient - reported outcomes,C2987124
4270,patient status after wake - up  % of days patient woke :,C0439228;C0449437;C1170730
4269,companion : wake - up stroke,C0031268;C0038454;C0335343;C0682323;C1170730;C4554100
4268,aortic - valve replacement,C0003506
4267,post - procedure,C3272301
4266,post - menopausal without hormone replacement,C0019930
4266,post - menopausal with hormone replacement,C0019930
4265,primary safety end point : severe / life - threatening,C0036043;C0205082;C1546953;C1705187;C2826244;C2986535;C3537125;C4050465;C4050466
4265,life - threatening bleed,C0019080;C1546953;C2826244;C3537125
4265,life - threatening,C1546953;C2826244;C3537125
4264,mmse = mini - mental state examination  adas — cog = alzhei -,C0451306;C3539026
4263,baseline adas - cog $nmbr$,C0168634;C1442488;C3539026
4263,adas - cog,C3539026
4262,adcs - adl score *,C0449820;C3641947;C4050231
4262,adcs - adl,C3641947
4261,two - dimensional echocardiography,C0013524
4260,door - to - balloon time — hr,C4296144
4259,ex - drinker,C0337679
4258,non - / ex - drinker,C0457801
4258,former / non - drinker,C0205156;C0457801;C0750523
4257,perindopril - indapamide,C1273169
4256,treatment with open - label perindopril,C0136123;C3640652
4256,perindopril,C0136123
4255,renin - angiotensin - aldosterone system blocker,C0086907
4254,angiogenesis,C0302600;C1519670
4253,renin - angiotensin inhibitors,C0003018;C2917241;C3653375;C4521302
4253,angiotensin ll - receptor antagonist — no . ( % ),C0003018;C4521302
4253,angiotensin -,C0003018;C4521302
4252,angiotensin - eonverting enzyme inhibitors / angiotensin reeeptor bloekers,C0003018;C0014432;C1152555;C2756995;C4521302
4252,angiotensin - eonverting enzyme inhibitors,C0003018;C0014432;C1152555;C2756995;C4521302
4251,angiotensin receptive blocker,C0003018;C0544683;C4521302
4251,angiotensin ll - receptor blocker,C0003018;C4521302
4250,repaired s - p shunts,C0205340
4249,p - gp inhibitor,C3898062
4248,years of follow - up  mean ( sd ) [ maximum ],C0439234;C0444504;C0589120;C0806909;C1522577;C1552615;C1704685;C2347634;C2348143;C2699239;C2826546;C3274571
4248,warfarin at last follow - up,C0043031;C0589120;C1522577;C1704685;C3274571
4248,thiazide at last follow - up,C0541746;C0589120;C1522577;C1704685;C3274571
4248,statin at last follow - up,C0360714;C0589120;C1522577;C1704685;C3274571
4248,sbp during the follow - up period ( mmhg ),C0085805;C0439475;C0439531;C0589120;C1522577;C1704685;C1948053;C3274571
4248,potassium - sparing at last follow - up,C0032821;C0202194;C0304475;C0589120;C0597277;C1522577;C1704685;C3274571;C3714637
4248,loop at last follow - up,C0445022;C0589120;C1522577;C1704685;C3274571
4248,follow - up in - trial at $nmbr$ yr,C0008976;C0439234;C0589120;C1522577;C1704685;C3274571
4248,follow - up,C0589120;C1522577;C1704685;C3274571
4248,end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
4248,digoxin at last follow - up,C0012265;C0589120;C1522577;C1704685;C3274571
4248,dbp during the follow - up period ( mmhg ),C0439475;C0439531;C0536221;C0589120;C1522577;C1704685;C1948053;C3274571;C3813197;C4281799
4248,beta - blocker at last follow - up |,C0001645;C0589120;C1522577;C1704685;C3274571
4248,at end of follow - up — no . / total no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
4248,at end of follow - up — no . ( % ),C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
4248,at end of follow - up,C0444930;C0589120;C1522577;C1704685;C2746065;C3274571
4248,aspirin at last follow - up,C0004057;C0589120;C1522577;C1704685;C3274571
4248,arb at last follow - up,C0589120;C1522577;C1704685;C3274571;C3888198
4247,ipf - related,C0034069;C1800706
4247,ipf,C0034069;C1800706
4246,nph,C0020258;C0027442
4245,npi - $nmbr$ score *,C1412208;C1549728;C3539727
4245,npi,C1412208;C1549728;C3539727
4244,renin inhibitors,C2917241;C3653375
4243,renin inhibitor ( e . g . aliskerin ),C1960108;C3537174;C4521920
4243,renin inhibitor,C1960108;C3537174;C4521920
4242,gpiib - iiia inhibitors,C0016011;C0243077
4242,gp iib / iiia inhibitors,C0016011;C0243077
4242,glycoprotein iib / iiia inhibitors,C0016011;C0243077
4241,gp iib / iiia inhibitor used,C0016011;C1999216
4241,glycoprotein iib / iiia inhibitort,C0016011
4241,glycoprotein iib / iiia inhibitor use before angiography,C0002978;C0016011;C0042153;C0457083;C1947944;C1999216
4241,glycoprotein iib / iiia inhibitor,C0016011;C1999216
4240,raas inhibitors,C0243077
4240,no . of previous tne inhibitors,C0205156;C0243077;C1552607;C3896585
4239,tnf inhibitors,C0243077;C1448177
4239,non - tnf inhibitors,C0243077;C1448177;C1518422
4239,inhibitors — no . { % ) se - $nmbr$ physical functioning score ^ ^,C0243077
4238,glycoprotein llb / llla inhibitors,C0017968;C0243077
4237,gp llb / llla inhibitors,C0243077;C1705010;C3811116
4236,no ilb / iiia inhibitors,C0243077;C4697913
4236,ilb / iiia inhibitors,C0243077;C4697913
4235,raas inhibitor use,C0042153;C0457083;C1947944;C1999216
4235,raas inhibitor,C1999216
4235,gpifo ' llia inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
4235,gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944;C1999216
4234,renin – angiotensin system inhibitor,C0035096;C1999216;C2984247
4234,renin - angiotensin system inhibitor use,C0035096;C0042153;C0457083;C1947944;C1999216;C2984247
4234,inhibitor,C1999216
4233,other sglt - $nmbr$ inhibitor,C1999216
4233,dpp - $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945;C1414174;C1999216
4233,dpp - $nmbr$ inhibitor,C1414174;C1999216
4232,ace inhibitors through hospital discharge or day $nmbr$ — %,C0003015;C0586003
4231,use of ace inhibitor  arb  or both — no . ( % ),C0003015;C1524063;C3888198;C4541021
4231,no ace inhibitor / arb,C0003015;C3888198;C4541021
4231,neither ace inhibitor nor arb,C0003015;C4541021
4231,both ace inhibitor and arb,C0003015;C4541021
4231,ace inhibitors or arbs,C0003015
4231,ace inhibitors or arb,C0003015
4231,ace inhibitors and arb,C0003015
4231,ace inhibitors / arb,C0003015
4231,ace inhibitor — no . ( % ),C0003015;C4541021
4231,ace inhibitor or arb use,C0003015;C4541021
4231,ace inhibitor or arb,C0003015;C4541021
4231,ace inhibitor monotherapy,C0003015;C4541021
4231,ace inhibitor and / or arb,C0003015;C4541021
4231,ace inhibitor / arb  %,C0003015;C3888198;C4541021
4231,ace inhibitor / arb,C0003015;C3888198;C4541021
4231,ace inhibitor  n ( % ),C0003015;C4541021
4231,ace inhibitor  arb  or both,C0003015;C3888198;C4541021
4231,ace inhibitor  %,C0003015;C4541021
4231,ace - inhibitor or arb ( % ),C0003015;C4541021
4230,ace inhibitor use ( % ),C0003015;C0042153;C0457083;C1947944;C4541021
4230,ace inhibitor,C0003015;C4541021
4230,ace - inhibitor use,C0003015;C0042153;C0457083;C1947944;C4541021
4229,ace inhibitors / sartans,C0003015;C1563745
4228,peri - op ace - inhibitors / arbs : no ( n = $nmbr$ ),C0003015;C0347985;C3888198
4228,ace inhibitors,C0003015
4228,ace - inhibitors / arbs  n ( % ),C0003015;C3888198
4228,ace - inhibitors  n ( % ),C0003015
4228,ace - inhibitors,C0003015
4227,ace inhibitor or arb at enrollment,C0003015;C4541021
4227,ace inhibitor at enrollment,C0003015;C1516879;C1696073;C3888021;C4541021
4226,ace inhibitor or arb at last follow - up,C0003015;C4541021
4226,ace inhibitor at last follow - up,C0003015;C0589120;C1522577;C1704685;C3274571;C4541021
4225,ace inhibitors or angiotensin receptor blockers,C0003015
4225,ace inhibitors or angiotensin ii blockers,C0003015
4225,ace inhibitors or angiotensin ii,C0003015
4225,ace inhibitors or angiotensin - receptor blockers ^,C0003015
4225,ace inhibitors or angiotensin - receptor blockers,C0003015
4225,ace inhibitor yes,C0003015;C1549445;C1705108;C1710701;C4541021
4225,ace inhibitor or angiotensin receptor blocker,C0003015;C4541021
4225,ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021
4225,ace inhibitor or angiotensin ii receptor,C0003015;C4541021
4225,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015;C4541021
4224,dipeptidyl peptidase - $nmbr$ inhibitor,C0003015;C2757044;C3536837
4224,dipeptidyl peptidase $nmbr$ inhibitors,C0003015
4224,dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
4224,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker use ( mitt population ),C0003015;C2757044;C3536837;C4541021
4224,angiotensin - converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021
4224,angiotensin - converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
4224,angiotensin - converting - enzyme inhibitor or angiotensin - receptor blocker §,C0003015;C2757044;C3536837;C4541021
4224,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015;C2757044;C3536837;C4541021
4224,angiotensin - converting - enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
4223,angiotensin - converting enzyme inhibitors ^,C0003015;C2757044
4223,angiotensin - converting enzyme inhibitors / angiotensin receptor blockers,C0003015;C0597357;C2757044
4223,angiotensin - converting enzyme inhibitors,C0003015;C2757044
4222,number resulting in hospital admission,C0237753;C0449788
4222,number resulting in emergency department visit,C0237753;C0449788
4222,number resulting in ed visit,C0237753;C0449788
4222,number randomized,C0237753;C0449788
4222,number of antihypertensive agent reported,C0003364;C0237753;C0449788
4222,event number,C0237753;C0441471;C0449788;C4019010
4221,number of participants with an event,C0237753;C0449788;C0679646
4221,number of participants,C0237753;C0449788;C0679646
4221,number and % of participants with events  and incidence rate per $nmbr$ person - year,C0237753;C0449788
4220,number of vessels treated  index pci,C0005847;C0237753;C0449788
4220,number of vessels disease,C0042373;C0237753;C0449788
4220,number of treated vessels ( per patient ),C0005847;C0237753;C0449788;C1522326
4220,number of treated vessels,C0005847;C0237753;C0449788;C1522326
4219,number,C0237753;C0449788
4219,mean number of puffs per day,C0237753;C0444504;C0449788;C1533107;C2347634;C2348143
4219,mean number of caes in past $nmbr$ months ( number per patient ) ] |,C0237753;C0444504;C0449788;C2347634;C2348143
4219,mean ( sd ) number of albuterol per day  puff,C0001927;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
4218,number of concomitant csdmards  n ( % ),C0237753;C0449788;C0521115
4218,number of concomitant aedsc,C0237753;C0449788;C0521115
4217,number of prior csdmards  n ( % ),C0237753;C0332152;C0449788;C2826257
4217,number of prior aeds    n   ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
4217,number of prior aeds  n ( % ) b,C0180309;C0237753;C0332152;C0449788;C2826257
4217,number of prior aeds  n ( % ),C0180309;C0237753;C0332152;C0449788;C2826257
4217,number of prior aeds,C0180309;C0237753;C0332152;C0449788;C2826257
4216,number of “ off ” periods,C0237753;C0449788
4216,number of previous reported aeds,C0180309;C0205156;C0237753;C0449788;C0684224;C0700287;C1552607;C4319718
4216,number of previous dmards,C0205156;C0237753;C0242708;C0449788;C1552607
4215,non - epa number of <,C0237753;C0449788;C1518422
4214,number of pack years,C0237753;C0449788;C1277691
4214,number of pack - years,C0237753;C0449788;C1277691
4214,estimated number of pack - years,C0237753;C0449788;C0750572;C1277691
4213,number of er visits in last year prior to baseline,C0237753;C0449788;C3810541;C3811131
4213,number of e,C0237753;C0449788
4212,number ste  t > $nmbr$,C0237753;C0449788;C1420459;C3811127
4211,haq - di  number ( % ),C0237753;C0449788;C3826998;C4321476
4210,number of people ( n ),C0027361;C0237753;C0449788
4210,number of copd exacerbations within $nmbr$ months  mean ( sd ),C0237753;C0449788;C0740304
4210,number of copd exacerbations in the previous year    n   ( % ),C0237753;C0449788;C0740304
4210,number of copd exacerbations in the previous year  n ( % ),C0237753;C0449788;C0740304
4209,number of females n ( % ),C0086287;C0237753;C0449788
4209,number of co - aeds  n ( % ),C0180309;C0237753;C0449788;C3245499
4209,number of ( % ) females,C0086287;C0237753;C0449788
4209,number ( % ),C0237753;C0449788
4208,> q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,> q $nmbr$ ( $nmbr$ . $nmbr$ ) - q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,> q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,> q $nmbr$ ( $nmbr$ ) - q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,< q $nmbr$ ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,< q $nmbr$ ( $nmbr$ ) — number / n ( % ),C0237753;C0449788
4208,< median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
4208,< median ( $nmbr$ . $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
4208,< median ( $nmbr$ ) — number / n ( % ),C0237753;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
4207,limb amputation,C0002689
4206,limb ( sd ),C0015385;C2699239
4206,limb,C0015385
4205,rib,C0035561
4204,type ib,C0332307;C1547052;C2744579;C3890035;C4283819
4204,ib ( $nmbr$ . $nmbr$ ),C2744579;C3890035;C4283819
4204,complex partial ( ib ),C0439855;C0728938;C1550516;C1704241;C2744579;C3890035;C4283819
4203,group b,C4522078
4202,apolipoprotein b ^,C0003593
4202,apolipoprotein b ( g / l ),C0003593;C0439294;C0456615
4202,apolipoprotein b  mean ( sd )  g / l,C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239
4201,apolipoprotein b tx difference vs pbo  ls mean % change from baseline ( se ),C0003593;C0041403;C1705241;C1705242
4201,apolipoprotein b,C0003593
4200,b lack,C0332268
4199,exact ( b ),C2828393;C4050514
4198,b - agonists ( short - acting ) a,C0243192;C2987634
4198,b - agonists ( long - acting ) a,C0243192;C2987634
4197,non - biological systemic,C0205373;C0445097
4196,cromoglicate,C0010347
4195,prior biologic use,C0005515;C0042153;C0205460;C0332152;C0457083;C1947944;C2826257
4195,prior biologic exposure,C0005515;C0205460;C0274281;C0332152;C0332157;C2826257
4195,biologic,C0005515;C0205460
4194,prior use of biologics  n ( % ),C0005515;C0005522;C0332152;C1524063;C2826257;C4553887
4194,prior use of biologic agents,C0005515;C0332152;C1524063;C2826257
4193,previous use of other biologic agents in addition to tne,C0005515;C0205156;C1524063;C1552607
4193,other biologic agent,C0005515
4193,biologic agents,C0005515
4192,biological,C0005532;C0205460
4191,prior biologic therapeutic failures  n ( % ),C0005515;C0087111;C0205460;C0231174;C0302350;C0332152;C0680095;C2826257
4191,biologic therapeutic failure,C0005515;C0087111;C0205460;C0231174;C0302350;C0680095
4191,biologic naive,C0005515;C0205460
4190,glycemic variability  mmol / lc,C0005802;C0439190;C2827666
4189,glycemic characteristics,C0005802;C1521970
4188,oral blood glucose - lowering drug $nmbr$ ( $nmbr$ . $nmbr$ ),C0005802;C0013227;C0017725;C0018938;C0441994;C0442027;C1254351;C2003888;C4521986
4188,oral blood glucose - lowering,C0005802;C0441994;C0442027;C2003888;C4521986
4188,blood glucose lowering treatment,C0005802;C0017725;C0039798;C0087111;C0441994;C0596197;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704
4188,blood glucose - lowering treatments  n ( % ),C0005802;C0017725;C0087111;C0441994;C0596197;C2003888
4188,blood glucose,C0005802
4187,college degree or higher,C0441889;C0449286;C0542560;C0557806;C2348088
4186,some college / tech,C0557806;C1826596
4186,some college,C0557806
4185,complete ulcer healing at week $nmbr$,C0205197;C0332174;C0333293;C0439230;C0725685;C3853530;C4283785
4185,complete healinga,C0205197;C0725685;C3853530;C4283785
4185,complete clinical response at week $nmbr$,C0205197;C3853530;C4283785
4184,chlor,C0308648
4183,limited to left side of colon,C0227388;C0439801;C2674459;C3542948;C4050251
4183,left side of colon,C0227388
4182,colon or rectum,C0009368;C3888384
4182,colon ' ses - cd score  mean ( sd ),C0007928;C0009368;C0034283;C0444504;C0449820;C2347634;C2348143;C2699239;C3888384;C4050231;C4552032
4182,colon,C0009368;C3888384
4182,all of the colon,C0009368;C3888384
4181,use of clopidogrel,C0070166;C1524063
4180,timing of clopidogrel loading dose,C0070166;C0449243;C1704250;C3714444
4180,loading dose of clopidogrel or ticlopidine,C0070166;C3714444
4179,clopidogrel given before procedure,C0070166
4179,clopidogrel dose on / before pci,C0070166;C0178602;C0869039;C1114758;C4049621
4178,clopidogrel plus aspirin % / yr,C0004057;C0070166;C0332287;C0439234
4178,clopidogrel plus aspirin,C0004057;C0070166;C0332287
4178,clopidogrel no . of patients % ),C0070166
4178,aspirin - erdp clopidogrel no . of patients / total no .,C0004057;C0070166
4177,clopidogrel plus aspirin ( n = $nmbr$ ),C0004057;C0070166;C0332287
4177,clopidogrel ( n = $nmbr$ ),C0070166
4177,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166
4177,clopidogrel ( n = $nmbr$  $nmbr$ ),C0070166
4177,aspirin plus clopidogrel ( n = $nmbr$ ),C0004057;C0070166;C0332287
4176,clopidogrel or ticlopidine,C0070166
4176,clopidogrel / ticlopidine,C0040207;C0070166
4176,clopidogrel  ticlopidine  or prasugrel,C0040207;C0070166
4175,hours from clopidogrel loading  mean ( sd ),C0070166;C0439227;C0444504;C1708715;C2347634;C2348143;C2699239
4175,clopidogrel,C0070166
4174,periprocedural medications  n ( % ) clopidogrel  $nmbr$ mg *,C0013227;C0024671;C0026410;C0070166;C0439269;C0802604;C1960952;C2346927;C2598133;C4284232;C4321396;C4521761
4174,clopidogrel n / n { % ),C0070166
4174,clopidogrel n / n ( % ),C0070166
4174,clopidogrel ( n = $nmbr$ ) n / n ( % ),C0070166
4174,clopidogrel %,C0070166
4174,clopidogrel  %,C0070166
4173,cilostazol,C0055729
4172,cholesterol ( mmol / l ),C0008377;C1532563
4172,cholesterol ( % ),C0008377
4172,cholesterol  ( . $nmbr$ . $nmbr$ mmol / l )  n ( % ),C0008377;C1532563
4171,hba $nmbr$ c — % cholesterol — mmol / l,C0008377;C0019016;C1532563;C1825777;C3538758
4171,cholesterol  mmol / l,C0008377;C1532563
4170,ldl - cholesterol ( mmol / ),C0023824;C0202117;C0439190
4169,ldl cholesterol ^ :,C0023824;C0202117
4169,ldl cholesterohhdl cholesterol ratio,C0023824;C0202117;C0456603;C1547037
4168,data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance )  p $nmbr$ . $nmbr$ .,C0002780;C0023824;C0042295;C0168634;C0202117;C0369718;C0441922;C0871881;C1442488;C1511726;C1711260;C2348152;C3245479;C3714741
4168,baseline ldl cholesterol ( derived ),C0023824;C0168634;C0202117;C1442488
4168,baseline ldl cholesterol,C0023824;C0168634;C0202117;C1442488
4167,ldl cholesterol — mg / dl | |,C0023824;C0202117;C0439269
4167,ldl cholesterol — mg / dl,C0023824;C0202117;C0439269
4167,ldl cholesterol mean ( mg / dl ± sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
4167,ldl cholesterol ( sd )  mg / dl,C0023824;C0202117;C0439269;C2699239
4167,ldl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
4167,ldl cholesterol ( mg / dl ),C0023824;C0202117;C0439269
4167,ldl cholesterol  mg / dl,C0023824;C0202117;C0439269
4167,ldl cholesterol  mean ( sd )  mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
4167,ldl cholesterol,C0023824;C0202117
4167,ldl - cholesterol ( mg / dl ),C0023824;C0202117;C0439269
4167,ldl - cholesterol (,C0023824;C0202117
4167,ldl - cholesterol  mg / dl  mean ( sd ),C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
4167,ldl - cholesterol  mean ( sd ) mg / dl,C0023824;C0202117;C0439269;C0444504;C2347634;C2348143;C2699239
4167,ldl - cholesterol,C0023824;C0202117
4167,$nmbr$ mg / dl ldl cholesterol | |,C0023824;C0202117;C0439269
4166,ldl cholesterol - lowering therapy,C0023824;C0039798;C0087111;C0202117;C0441994;C1363945;C2003888
4166,- ldl cholesterol,C0023824;C0202117
4165,low - density lipoprotein cholesterol tx difference vs pbo  ls mean % change from baseline ( se ),C0023824;C0041403;C1705241;C1705242
4165,low - density lipoprotein cholesterol  %,C0023824
4164,total cholesterol - to - hdl cholesterol ratio,C0428619
4163,serum ldl cholesterol,C0428474
4162,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol,C0003591;C0003594;C0008377;C0011849;C0023824;C0039411;C0040642;C0041405;C0041698;C0392885;C0428471;C1824670;C3272447;C3715113;C4522122
4162,aldl cholesterol,C0008377
4161,ldl - to - hdl cholesterol ratio  mean ( sd ),C0008377;C0428621;C0444504;C1171408;C2347634;C2348143;C2699239
4161,cholesterol,C0008377
4160,non ‐ hdl cholesterol,C0729627;C1535899
4160,non - hdl cholesterol j,C0729627;C1535899
4160,non - hdl cholesterol ( mmol / l ),C0729627;C1532563;C1535899
4160,non - hdl cholesterol ( mg / dl ),C0439269;C0729627;C1535899
4160,elevated non - hdl cholesterol,C0205250;C0729627;C1535899;C3163633
4159,non - hdl cholesterol,C0729627;C1535899
4159,mean ( s . d . ) non - hdl cholesterol,C0444504;C0729627;C1535899;C2347634;C2348143
4158,terol  hdl - c  high - density lipoprotein cholesterol,C0023822
4158,hdl cholesterol ^ :,C0023822;C0392885
4158,hdl cholesterol  mmol / 冲,C0023822;C0392885;C0439190
4158,hdl - cholesterol,C0023822;C0392885
4157,hdl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
4157,hdl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023822;C0392885;C1532563
4157,hdl cholesterol *,C0023822;C0392885
4157,hdl cholesterol ( mmol / l ) :,C0023822;C0392885;C1532563
4157,hdl cholesterol ( mmol / l ) ( median  iqr ),C0023822;C0392885;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
4157,hdl cholesterol ( mmol / l )  mean ( sd ),C0023822;C0392885;C0444504;C1532563;C2347634;C2348143;C2699239
4157,hdl cholesterol ( mmol / l ),C0023822;C0392885;C1532563
4157,hdl cholesterol  mmol / l *,C0023822;C0392885;C1532563
4157,hdl cholesterol  mmol / l,C0023822;C0392885;C1532563
4157,hdl cholesterol  ( mmol / l ),C0023822;C0392885;C1532563
4157,hdl - cholesterol ( mmol / l ),C0023822;C0392885;C1532563
4157,hdl - cholesterol  mmol / l,C0023822;C0392885;C1532563
4157,- hdl cholesterol,C0023822;C0392885
4156,hdl cholesterol ( sd )  mg / dl,C0023822;C0392885;C0439269;C2699239
4156,hdl cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
4156,hdl cholesterol ( mg / dl ),C0023822;C0392885;C0439269
4156,hdl cholesterol  mg / dl,C0023822;C0392885;C0439269
4156,hdl cholesterol  mean ( sd )  mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
4156,hdl cholesterol,C0023822;C0392885
4156,hdl - cholesterol ( mg / dl ),C0023822;C0392885;C0439269
4156,hdl - cholesterol  mg / dl  mean ( sd ),C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
4156,hdl - cholesterol  mean ( sd ) mg / dl,C0023822;C0392885;C0439269;C0444504;C2347634;C2348143;C2699239
4155,mean ( s . d . ) hdl cholesterol,C0023822;C0392885;C0444504;C2347634;C2348143
4155,hdl cholesterol §,C0023822;C0392885
4155,hdl cholesterol mean,C0023822;C0392885;C0444504;C2347634;C2348143
4154,total cholesterol ( mmol / l ) :,C0201950;C0543421;C1532563
4154,total cholesterol ( mmol / l )  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
4154,total cholesterol ( mmol / l ),C0201950;C0543421;C1532563
4154,total cholesterol  mmol / l 本,C0201950;C0543421;C1532563
4154,total cholesterol  mmol / l ( sd ),C0201950;C0543421;C1532563;C2699239
4154,total cholesterol  mmol / l  mean ( sd ),C0201950;C0444504;C0543421;C1532563;C2347634;C2348143;C2699239
4154,total cholesterol  mmol / l,C0201950;C0543421;C1532563
4154,tertile of total cholesterol at baseline  mean ( sd )  mmol / l,C0201950;C0543421
4154,median total cholesterol  mmol / l,C0201950;C0543421;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
4153,total cholesterol,C0201950;C0543421
4153,baseline total cholesterol,C0168634;C0201950;C0543421;C1442488
4152,total cholesterol — mg / dl,C0201950;C0439269;C0543421
4152,total cholesterol ^,C0201950;C0543421
4152,total cholesterol > $nmbr$ mg / dl,C0201950;C0439269;C0543421
4152,total cholesterol - mg / dl * *,C0201950;C0439269;C0543421
4152,total cholesterol *,C0201950;C0543421
4152,total cholesterol ( sd )  mg / dl,C0201950;C0439269;C0543421;C2699239
4152,total cholesterol ( mg / dl )  mean + sd  available for $nmbr$ patients,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
4152,total cholesterol ( mg / dl ),C0201950;C0439269;C0543421
4152,total cholesterol ( median  iqr )  mg / dl,C0201950;C0439269;C0543421;C0549183;C0876920;C2347635;C2348144;C2939193
4152,total cholesterol $nmbr$ > $nmbr$ mg / dl,C0201950;C0439269;C0543421
4152,total cholesterol $nmbr$ < $nmbr$ mg / dl,C0201950;C0439269;C0543421
4152,total cholesterol  mg / dl ^,C0201950;C0439269;C0543421
4152,total cholesterol  mg / dl  mean ( sd ),C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
4152,total cholesterol  mg / dl  ^,C0201950;C0439269;C0543421
4152,total cholesterol  mg / dl,C0201950;C0439269;C0543421
4152,total cholesterol  mean ( sd )  mg / dl,C0201950;C0439269;C0444504;C0543421;C2347634;C2348143;C2699239
4152,cholesterol  mg / dl total,C0201950;C0439269;C0543421
4152,^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .,C0005910;C0011847;C0011849;C0011900;C0020443;C0020538;C0025424;C0043100;C0201950;C0237753;C0428257;C0439269;C0439475;C0439828;C0441074;C0444686;C0449788;C0488055;C0489786;C0543421;C0577559;C0577573;C0600653;C0681906;C0871470;C0918012;C1096155;C1305866;C1306372;C1306620;C1441506;C1522133;C1532563;C1552854;C1637833;C1705104;C1963138;C2347108;C2347109;C2348272;C2700446;C2986546;C3152252;C3539882;C4283905;C4524803
4151,total cholesterol ( week $nmbr$ ),C0201950;C0332174;C0439230;C0543421
4151,total cholesterol ( mmo $nmbr$ / $nmbr$ ),C0201950;C0543421
4150,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0004083;C0018787;C0027976;C0201950;C0428772;C0439849;C0543421;C0596019;C0596306;C0699792
4150,total cholesterol  %,C0201950;C0543421
4149,olodaterol $nmbr$ pg,C0030827;C0072225;C1266240;C2934193
4149,olodaterol $nmbr$ jig,C2934193
4148,olodaterol sgg,C2934193
4148,olodaterol $nmbr$ gg ( n = $nmbr$ ),C0017454;C0018370;C2934193
4148,olodaterol,C2934193
4147,hypercholesterolemia 一 no . ( % ),C0020443;C1522133
4147,hypercholesterolemia — no . ( % ) *,C0020443;C1522133
4147,hypercholesterolemia — no . ( % ),C0020443;C1522133
4147,hypercholesterolemia *,C0020443;C1522133
4147,hypercholesterolemia ( > $nmbr$ mg / dl ),C0020443;C0439269;C1522133
4147,hypercholesterolemia ( % ),C0020443;C1522133
4147,hypercholesterolemia  no . ( % ),C0020443;C1522133
4147,hypercholesterolemia  n ( % ),C0020443;C1522133
4147,hypercholesterolaemia ( % ),C0020443;C1522133
4146,hypercholesterolemia,C0020443;C1522133
4146,hypercholesterolaemia,C0020443;C1522133
4146,duration of hypercholesterolemia ( yr ),C0020443;C0439234;C0449238;C1522133;C2926735
4146,duration of hypercholesterolemia  mean ± sd ( years ),C0020443;C0439234;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
4146,duration of hypercholesterolaemia  mean ± sd ( year ),C0020443;C0439234;C0439508;C0444504;C0449238;C1522133;C2347634;C2348143;C2699239;C2926735
4145,reported high cholesterol ' !,C0020443;C0684224;C0700287;C1522133;C4319718
4145,elevated cholesterol,C0020443
4144,squamous cell carcinoma,C0007137;C1302853
4143,> $nmbr$ to < $nmbr$ cells / mm ’,C0007584;C0007634;C4330985;C4554674
4143,> $nmbr$ to < $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
4143,> $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
4143,< $nmbr$ cells / mm ^,C0007584;C0007634;C4330985;C4554674
4143,$nmbr$ to < $nmbr$ cells,C0007584;C0007634
4142,cyclo,C1172566
4141,normal function ( crcl > $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C4296962
4141,egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
4141,crcl of $nmbr$ - $nmbr$ ml min '  n ( % ),C0439445;C1846718
4141,crcl < $nmbr$ ml / min,C0439445;C1846718
4141,crcl < $nmbr$,C1846718
4141,crcl $nmbr$ - $nmbr$,C1846718
4141,> $nmbr$ crcl,C1846718
4141,$nmbr$ - $nmbr$ crcl,C1846718
4140,renal impairment ( crcl < $nmbr$ ml / min ),C0439445;C1565489;C1846718
4140,< $nmbr$ crcl  n ( % ),C1846718
4140,< $nmbr$ crcl,C1846718
4139,lcl,C3658298
4138,( $nmbr$ % ell ' ll  * non - hdl - c,C1427925;C3273466
4138,( $nmbr$ % ell ' ll,C1427925;C3273466
4137,p ( $nmbr$ % cl ),C0369773;C0596019;C2603361
4137,$nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
4136,hr ( $nmbr$ % cl ) pvalue,C0596019
4136,adjusted hr * ( $nmbr$ % cl ) pvalue,C0456081;C0596019
4135,western europe hr ( $nmbr$ % cl ),C0043129;C0596019
4135,hr  ( $nmbr$ % cl ),C0596019
4134,orc ( $nmbr$ % cl ),C0596019;C1167125
4134,oradj ( $nmbr$ % cl ),C0596019
4134,hr ( $nmbr$ % cl ) *,C0596019
4134,hr $nmbr$ . $nmbr$ ( $nmbr$ % cl $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$ *,C0596019
4133,latin america hr ( $nmbr$ % cl ),C0023122;C0596019
4133,hr $nmbr$ % cl,C0596019
4132,estimate ( $nmbr$ % cl ),C0596019;C0750572
4131,hr ( $nmbr$ % cl ),C0596019
4131,asia - pacific hr ( $nmbr$ % cl ),C0003980;C0596019
4130,hr  $nmbr$ % cl,C0596019
4130,adj . hr ( $nmbr$ % cl ) a,C0001552;C0596019;C2826286
4129,ratet ( $nmbr$ % cl ),C0596019
4129,hazard ratio with dabigatran  $nmbr$ mg ( $nmbr$ % cl ),C0024671;C0026410;C0439269;C0596019;C1960952;C2346927;C2348066;C2985465;C4321396;C4521761
4129,hazard ratio [ $nmbr$ % cl ],C0596019;C2985465
4129,hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),C0596019;C2985465
4129,hazard ratio ( $nmbr$ % cl ),C0596019;C2985465
4129,cl - $nmbr$ ],C0596019
4129,( %  $nmbr$ % cl ),C0596019
4128,rrr ( $nmbr$ % cl ),C0596019
4128,rr reduction  $nmbr$ / $nmbr$ ( $nmbr$ / $nmbr$ cl ),C0301630;C0392756;C0596019;C1293152;C4551656;C4554402
4128,rr ( cl ),C0596019;C4554402
4128,rr ( $nmbr$ % cl ),C0596019;C4554402
4128,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ b ( $nmbr$  $nmbr$ . $nmbr$ ),C0596019
4128,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),C0596019
4128,hr ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$  $nmbr$ . $nmbr$ ),C0596019
4128,hr ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$  $nmbr$ ),C0596019
4127,rr ( $nmbr$ % cl ) [ / ’ value ],C0596019;C1522609;C4554402
4127,[ $nmbr$ % cl ],C0596019
4126,warfarin ( s $nmbr$ % cl ),C0043031;C0596019
4125,absolute risk reduction ( $nmbr$ % cl ) *,C0596019;C3179139
4124,hr : $nmbr$ . $nmbr$ ( $nmbr$ % cl : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ) p = $nmbr$ . $nmbr$,C0596019
4124,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
4124,hr $nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ - $nmbr$ ),C0596019
4124,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to - $nmbr$ - $nmbr$ ),C0596019
4124,- $nmbr$ - $nmbr$ ( $nmbr$ % cl - $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
4124,( $nmbr$ % cl ) interaction,C0596019;C1704675
4124,$nmbr$ - $nmbr$ ( $nmbr$ % cl $nmbr$ - $nmbr$ to $nmbr$ - $nmbr$ ),C0596019
4124,$nmbr$ ( $nmbr$ % cl $nmbr$ to $nmbr$ ),C0596019
4123,treatment difference ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
4123,treatment difference % ( $nmbr$ % cl ),C0039798;C0087111;C0596019;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
4123,mean difference ( $nmbr$ % cl ),C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
4123,lsm difference ( $nmbr$ % cl ),C0596019;C1705241;C1705242
4123,lsm ( $nmbr$ % cl ),C0596019
4123,ls mean difference ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
4123,ls - mean difference ® ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
4123,difference in means ( $nmbr$ % cl ),C0596019;C1704970;C1705241;C1705242
4123,difference in ls mean $nmbr$ ( $nmbr$ % cl ),C0023668;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
4123,( $nmbr$ % cl ),C0596019
4123,$nmbr$ cl ),C0596019
4123,$nmbr$ ( $nmbr$ cl ),C0596019
4122,least - squares mean difference ( $nmbr$ % cl ),C0023189;C0444504;C0596019;C1705241;C1705242;C2347634;C2348143
4122,estimated mean $nmbr$ % cl,C0444504;C0596019;C0750572;C2347634;C2348143
4122,cl $nmbr$ %,C0596019
4122,change in pav  mean ( $nmbr$ % cl )  %,C0058890;C0392747;C0443172;C0444504;C0596019;C1705241;C2347634;C2348143;C4319952
4122,$nmbr$ % cl,C0596019
4121,a new vertebral fractures ( mfas ),C0080179;C0205314;C1549796;C1549980
4120,new vertebral fracture at $nmbr$ months,C0080179;C0205314;C0439231
4120,new or worsening vertebral fracture at $nmbr$ months,C0205314
4119,no new a or and no more than $nmbr$ new bilag b domain score  %,C0205314
4119,new or worsentna neohrodathv,C0205314
4119,new or worsenina neohrodathv,C0205314
4119,new or suspected thrombus,C0205314
4119,new om,C0028971;C0205314;C1705272
4118,knees ( n ),C0022742
4117,knee,C0022742;C0022745;C1963703
4117,below - knee popliteal crural,C0022742;C0022745;C0023216;C0442037;C0542339;C1140621;C1552829;C1963703
4117,below - knee popliteal,C0022742;C0022745;C0442037;C0542339;C1552829;C1963703
4116,nnt,C1417750
4115,not assessable,C1883425
4114,not available,C0686905
4113,not severe,C4316743
4112,patient ' s preference not to take vka  only reason * *,C0376409
4112,patient ' s preference not to take vka  only reason,C0376409
4112,patient ' s preference not to take,C0376409
4111,p  net difference,C0369773;C1456447;C1705241;C1705242;C2603361;C3853572;C3887809;C3890893
4111,net ep $nmbr$,C1456447;C1880476;C3853572;C3887809;C3890893;C4321526
4111,net composite,C0205199;C1456447;C1547335;C3853572;C3887809;C3890893
4111,net clinical benefit : on - treatment vte or major bleeding,C0039798;C0087111;C0630906;C0814225;C1456447;C1516635;C1522326;C1533734;C1705169;C3538994;C3853572;C3887704;C3887809;C3890893;C4684590
4111,net clinical benefit *,C1456447;C3853572;C3887809;C3890893;C4684590
4110,positive cu index test  z n ( % ),C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
4110,other antithrombotic medication for index event — no . ( % ),C0013227;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3244316;C4019010;C4284232
4110,no revascularization for index acs event  no . ( % ),C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
4110,index events : dvt n ( % ),C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C2926618;C2986546;C3541888;C3899446
4110,index events,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C3541888
4110,index event — no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4110,index event  n / n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4110,index event  n ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4110,index event  %,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4110,index acs — no . ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
4110,index acs ( % ),C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4318612
4110,cu index test  n ( % ) $nmbr$,C0022885;C0039593;C0392366;C0456984;C0600653;C0918012;C1177210;C1515976;C1552854;C1637833;C2347872;C2986546;C3831328;C4318744
4110,classification of index venous thromboembolism — no . ( % ),C0008902;C0008903;C0600653;C0678229;C0918012;C1552854;C1637833;C1997614;C2986546
4110,charlson index ( % ),C0600653;C0918012;C1552854;C1637833;C2986546
4110,at index event : no . ( % ),C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4110,at index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
4109,mass index,C0577559;C0577573;C0600653;C0918012;C1096155;C1306372;C1552854;C1637833;C2986546;C3152252;C3539882;C4283905
4109,lv mass index ( g / m $nmbr$ - $nmbr$ ),C0455825;C0456715;C0600653;C0918012;C1552854;C1637833;C2986546
4109,insulinogenic index ( dinsulino_ $nmbr$ o min / dglucoseo - $nmbr$ o min ),C0600653;C0702093;C0918012;C1524029;C1552854;C1637833;C2986546;C3813700
4109,index mi ( n - $nmbr$  $nmbr$ ),C0600653;C0918012;C1552854;C1637833;C2986546;C3810814
4109,index diagnosis,C0011900;C0600653;C0918012;C1552854;C1637833;C1704338;C1704656;C2986546
4109,homa - ir index — median ( iqr ),C0022065;C0022071;C0549183;C0600653;C0876920;C0918012;C1448132;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546
4109,homa - ir index,C0022065;C0022071;C0600653;C0918012;C1448132;C1552854;C1637833;C2986546
4108,suit index  nmol / mmol,C0600653;C0918012;C1532564;C1533073;C1552854;C1637833;C2986546
4108,revascularization during index hospitalization  %,C0019993;C0581603;C0600653;C0918012;C1552854;C1637833;C2986546
4108,positive cu index test,C0022885;C0039593;C0392366;C0439178;C0456984;C0600653;C0918012;C1177210;C1446409;C1514241;C1515976;C1552854;C1637833;C2347872;C2825490;C2986546;C3812269;C3831328;C4318744
4108,pci during index hospitalization,C0019993;C0600653;C0918012;C1552854;C1637833;C2986546;C4049621
4108,nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
4108,medical therapy during index hospitalization — %,C0019993;C0418981;C0600653;C0918012;C1552854;C1637833;C2986546
4108,mean slicc damage index score ± sd,C0010957;C0600653;C0918012;C1552854;C1637833;C1883709;C2699239;C2986546;C3533236
4108,mean preoperative abpi of the index,C0444504;C0445204;C0600653;C0918012;C1552854;C1637833;C2347634;C2348143;C2986546
4108,indication for index procedure,C0600653;C0918012;C1552854;C1637833;C2315323;C2986546
4108,eq $nmbr$ da health index status score,C0011318;C0018759;C0205163;C0439185;C0449820;C0600653;C0918012;C1552854;C1637833;C2986546;C3668815;C4050231
4108,disposition index,C0600653;C0743223;C0918012;C1552854;C1637833;C1705555;C2986546
4108,des type at index procedure,C0011702;C0455713;C0600653;C0918012;C1552854;C1637833;C2986546;C4551552
4108,coronary angiography during the index hospitalization,C0002978;C0019993;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546
4108,coronary angiography during the index hospital stay,C0002978;C0085532;C0428776;C0600653;C0918012;C1548829;C1552854;C1637833;C2986546;C3489408
4108,cornell index  pv,C0030840;C0032463;C0600653;C0918012;C1552854;C1637833;C2986546
4108,composite physiologic index §,C0205199;C0205463;C0600653;C0918012;C1547335;C1552854;C1637833;C2986546
4108,composite index of insulin sensitivity ( isi ),C0205199;C0600653;C0918012;C0920563;C1547335;C1552854;C1637833;C2986546;C4049919
4108,clinical indication at the index procedure  n ( % ),C0205210;C0600653;C0918012;C1552854;C1637833;C2315323;C2347896;C2986546
4108,characteristics of the index ml,C0439526;C0600653;C0918012;C1521970;C1552854;C1637833;C1705224;C2986546;C3887665
4108,angiography during index hospitalization,C0002978;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
4107,blood pressure at target level ( % ) §,C0005823;C0441889;C0456079;C1271104;C1272641;C1521840;C1547707;C2946261;C2986546
4107,( % of target ) ∗,C1521840;C2986546
4106,hub,C0063034;C1414372;C1708389
4105,aspirin < $nmbr$ hours,C0004057;C0439227
4104,companion : $nmbr$ - $nmbr$ hours,C0031268;C0335343;C0439227;C0682323
4104,$nmbr$ - $nmbr$ hours,C0439227
4103,$nmbr$ - hour postload glucose,C0017725;C0439227;C0564385
4102,$nmbr$ - hour masbp  mm hg,C0439227;C0439475;C0564385
4102,$nmbr$ - hour madbp  mm hg,C0439227;C0439475;C0564385
4101,charm,C0849759
4100,chads $nmbr$ scoret,C0007928;C1413373
4100,chads $nmbr$ score per outcome stroke or systemic embolism,C0007928;C1413373
4100,chads $nmbr$ score > $nmbr$,C0007928;C1413373
4100,chads $nmbr$ ^,C0007928;C1413373
4100,chads $nmbr$ < $nmbr$,C0007928;C1413373
4100,chads $nmbr$,C0007928;C1413373
4100,chad $nmbr$ > $nmbr$,C0007928;C1413373
4100,baseline chads $nmbr$ a  c,C0007928;C0168634;C1413373;C1442488
4099,chads $nmbr$ score  mean ± sd,C0007928;C1413373
4099,chads $nmbr$ score  mean ( ± sd ),C0007928;C1413373
4099,chads $nmbr$  mean ± sd,C0007928;C0444504;C1413373;C2347634;C2348143;C2699239
4098,chads score  n ( % ),C0007928;C1413373
4098,chads score,C0007928;C1413373
4098,chads - $nmbr$ score,C0007928;C1413373
4098,chads $nmbr$   score    n   ( % ),C0007928;C1413373
4098,chads $nmbr$ scoref,C0007928;C1413373
4098,chads $nmbr$ scoreb,C0007928;C1413373
4098,chads $nmbr$ score *,C0007928;C1413373
4098,chads $nmbr$ score $nmbr$ - $nmbr$  n ( % ),C0007928;C1413373
4098,chads $nmbr$ score $nmbr$,C0007928;C1413373
4098,chads $nmbr$ score  n ( % ),C0007928;C1413373
4098,chads $nmbr$ score,C0007928;C1413373
4098,> $nmbr$ ( n  % ) chads $nmbr$ score,C0007928;C0369718;C0441922;C1413373
4097,subpopulation analyses according to baseline hba $nmbr$ c,C0002778;C0019016;C0168634;C0441837;C0680240;C0936012;C1442488;C1524024;C1825777;C3538758
4097,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
4097,hba $nmbr$ c tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0019016;C0041403;C1705241;C1705242;C1825777;C3538758
4097,hba $nmbr$ c strata,C0019016;C1825777;C3538758
4097,hba $nmbr$ c at baseline :,C0019016;C0168634;C1442488;C1825777;C3538758
4097,hba $nmbr$ c at baseline  %,C0019016;C0168634;C1442488;C1825777;C3538758
4097,hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
4097,hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
4097,hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C1825777;C3538758
4097,hba $nmbr$ c ( change from baseline ),C0019016;C0168634;C0392747;C0443172;C1442488;C1705241;C1825777;C3538758;C4319952
4097,hba $nmbr$ c  > $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
4097,hba $nmbr$ c  %,C0019016;C1825777;C3538758
4097,hba $nmbr$ c,C0019016;C1825777;C3538758
4097,hba  % $nmbr$ c,C0019016;C1825777;C3538758
4097,baseline hba $nmbr$ c ≤ median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
4097,baseline hba $nmbr$ c concentration,C0019016;C0086045;C0168634;C1442488;C1446561;C1825777;C3538758;C3827302
4097,baseline hba $nmbr$ c > median $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C0549183;C0876920;C1442488;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
4097,baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
4097,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %,C0019016;C0168634;C1442488;C1825777;C3538758
4097,baseline hba $nmbr$ c,C0019016;C0168634;C1442488;C1825777;C3538758
4096,hba $nmbr$ c   at randomization,C0019016;C0034656;C1825777;C3538758
4096,hba $nmbr$ c at week $nmbr$,C0019016;C0332174;C0439230;C1825777;C3538758
4096,hba $nmbr$ c at $nmbr$ weeks *,C0019016;C0439230;C1825777;C3538758
4096,hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
4095,mean ( sd ) hba $nmbr$ c level  %,C0019016;C0441889;C0444504;C0456079;C1547707;C1825777;C2347634;C2348143;C2699239;C2946261;C3538758
4095,mean ( sd ) hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hemoglobin a    ( % ),C0019016
4095,hba „ ( % ),C0019016;C1825777;C3538758
4095,hba $nmbr$ c month $nmbr$ ( % ),C0019016;C0332177;C0439231;C1825777;C3538758
4095,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo subtracted change ( se ),C0008107;C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3259781;C3538758;C3829066;C4319952;C4553351
4095,hba $nmbr$ c ( sd )  %,C0019016;C1825777;C2699239;C3538758
4095,hba $nmbr$ c ( % )  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba $nmbr$ c  median ( sd )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2699239;C2939193;C3538758
4095,hba $nmbr$ c  mean ( sd )  % [ mmol / mol ],C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
4095,hba $nmbr$ c  mean ( sd )  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba $nmbr$ c  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba $nmbr$ c  difference vs placebo ( $nmbr$ % cl ),C0019016;C1705241;C1705242;C1825777;C3538758
4095,hba $nmbr$ c  % ( sd ),C0019016;C1825777;C2699239;C3538758
4095,hba $nmbr$ c  % ( mean $nmbr$ sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba $nmbr$ c  %  mean ( sd ) b,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba $nmbr$ c  %  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4095,hba   ( % ),C0019016;C1825777;C3538758
4094,hba $nmbr$ c in % ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4094,hba $nmbr$ c \n,C0019016;C1825777;C3538758
4094,hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
4094,hba $nmbr$ c ( n ),C0019016;C1825777;C3538758
4094,hba $nmbr$ c ( % ) ( median ( iqr ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4094,hba $nmbr$ c  median ( q $nmbr$ – q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4094,hba $nmbr$ c  median ( q $nmbr$  q $nmbr$ )  %,C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4094,hba $nmbr$ c  ( % ),C0019016;C1825777;C3538758
4094,hba $nmbr$ c  %  n ( % ) b,C0019016;C1825777;C3538758
4094,hba $nmbr$ c  %  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758
4093,screening hba $nmbr$ c ( % ),C0019016;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C1825777;C2348164;C3538758
4093,qualifying hba $nmbr$ c ( % ),C0019016;C1514624;C1825777;C3538758
4093,pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % ),C0019016;C0024671;C0026410;C0168634;C0181496;C0439269;C1424886;C1442488;C1825777;C1960952;C2346927;C2827499;C3273588;C3490348;C3538758;C4319659;C4321396;C4521761;C4522130;C4551445
4093,high ( i $nmbr$ % ) baseline hba $nmbr$ c,C0019016;C0021966;C0168634;C0205250;C0221138;C1299351;C1442488;C1825777;C2700149;C3538758;C3887512;C3889660;C4321237;C4522209
4093,hba $nmbr$ c   baseline ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
4093,hba $nmbr$ c   ( % ),C0019016;C1825777;C3538758
4093,hba $nmbr$ c category  n ( % ),C0019016;C0683312;C1825777;C3538758;C3889287
4093,hba $nmbr$ c category,C0019016;C0683312;C1825777;C3538758;C3889287
4093,hba $nmbr$ c categories  n ( % ),C0019016;C0683312;C1825777;C3538758
4093,hba $nmbr$ c ( % ) *,C0019016;C1825777;C3538758
4093,hba $nmbr$ c ( % ),C0019016;C1825777;C3538758
4093,hba $nmbr$ c % ( range ),C0019016;C1514721;C1825777;C2348147;C3538758;C3542016
4093,hba $nmbr$ c  n,C0019016;C1825777;C3538758
4093,hba $nmbr$ c  baseline mean hba $nmbr$ c  % ( sd ),C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C2699239;C3538758
4093,hba $nmbr$ c  % *,C0019016;C1825777;C3538758
4093,hba  c ( % ),C0019016;C1825777;C3538758
4093,baseline hba $nmbr$ c ≥ $nmbr$ mmol / mol ( ≥ $nmbr$ . $nmbr$ % )  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
4093,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % to < $nmbr$ . $nmbr$ % ( $nmbr$ – $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
4093,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
4093,baseline hba $nmbr$ c ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
4093,baseline hba $nmbr$ c  n ( % ),C0019016;C0168634;C1442488;C1825777;C3538758
4093,baseline hba $nmbr$ c  %,C0019016;C0168634;C1442488;C1825777;C3538758
4093,any hba $nmbr$ c,C0019016;C1825777;C3538758
4092,hba $nmbr$ c  mmol / mold,C0019016;C0369241;C0439190;C1825777;C3538758
4091,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions,C0019016;C0559546;C1708130;C1825777;C3538758;C3539617;C4050121
4091,hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
4091,hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
4091,hba $nmbr$ c > = $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c > $nmbr$ · $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c > $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
4091,hba $nmbr$ c > $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
4091,hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c < $nmbr$ % level,C0019016;C0441889;C0456079;C1547707;C1825777;C2946261;C3538758
4091,hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
4091,hba $nmbr$ c < $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c $nmbr$ - < = $nmbr$ %,C0019016;C1825777;C3538758
4091,hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ ),C0019016;C1825777;C3538758
4091,hba $nmbr$ c  < $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
4091,$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),C0019016;C1825777;C3538758
4091,$nmbr$ % < hba $nmbr$ c < = $nmbr$ %,C0019016;C1825777;C3538758
4090,week $nmbr$ hba $nmbr$ c  mean ( s . e . ),C0019016;C0332174;C0439230;C0444504;C1825777;C2347634;C2348143;C3538758
4090,mean ± s . d . hba $nmbr$ c,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
4090,mean hba $nmbr$ c ± s . d .  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
4090,mean hba $nmbr$ c  %,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758
4090,mean ( s . d . ) baseline hba $nmbr$ c  %,C0019016;C0168634;C0444504;C1442488;C1825777;C2347634;C2348143;C3538758
4090,hba $nmbr$ ca  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3887642
4090,hba $nmbr$ c  mean = sd  %,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4090,hba $nmbr$ c  % §,C0019016;C1825777;C3538758
4090,hba $nmbr$ c  % d,C0019016;C1825777;C3538758
4090,hba $nmbr$ c  % ( mean ± sd ) [ range ],C0019016;C0444504;C1514721;C1825777;C2347634;C2348143;C2348147;C2699239;C3538758;C3542016
4090,hba $nmbr$ c  %  mean ± sd,C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758
4090,hba $nmbr$ c  $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$,C0019016;C1825777;C3538758
4089,disseminated tuberculosis,C0152915
4088,bisphosphonates,C0012544;C3541401
4087,previously untreated isolated systolic hypertension,C0332155;C0745133
4087,isolated systolic hypertension ⁎,C0745133
4087,isolated systolic hypertension ^,C0745133
4087,isolated systolic hypertension  n ( ' % >,C0745133
4087,isolated systolic hypertension  n ( % ) “,C0745133
4087,isolated systolic hypertension,C0745133
4086,isolated upper gastrointestinal disease behavior  n ( % ),C0004927;C0205409;C0810300;C1548221;C2707008
4085,isolated pulmonary embolism,C0034065;C0205409;C1548221
4085,isolated impaired glucose tolerance — no .,C0205409;C1548221
4085,isolated igt,C0205409;C1548221
4084,estimated glomerular filtration,C0232809;C0750572
4083,estimated proportions ( % ) and odds ratios,C0750572;C1709707
4082,no estimate,C0750572
4082,estimated response rate and odds ratio,C0237629;C0750572
4082,estimate,C0750572
4081,estimated means and treatment differences ( % ),C0750572;C1704970
4081,estimated means and difference,C0750572;C1704970
4080,acute respiratory insufficiency,C0865850
4079,respiratory rate ( breaths / min ),C0231832;C0439386;C0489258
4079,respiratory rate  breaths / min,C0231832;C0439386;C0489258
4078,favors comparator,C0309049;C1707454;C4553389;C4553390
4078,comparator,C1707454;C4553389;C4553390
4077,vasodilator therapy,C0039798;C0042402;C0087111;C1363945;C3537240
4077,vasodilator,C0042402;C3537240
4077,other vasodilators §,C0042402
4077,other vasodilator,C0042402;C3537240
4076,iv vasodilator,C0022326;C0042402;C3537240;C4265176
4076,both iv vasodilator and inotrope,C0022326;C0042402;C3537240;C4265176
4075,patient history of disease n ( % ),C0030705;C0683519;C0730226;C0850708;C0944983
4075,patient history of disease,C0030705;C0683519;C0730226;C0850708;C0944983
4075,history of thyroid disease  n ( % ),C0040132;C0683519;C0730226;C0850708;C0944983;C3540038
4075,history of peripheral arterial disease ( % ),C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
4075,history of peripheral arterial disease,C0003842;C0205100;C0221464;C0683519;C0730226;C0850708;C0944983
4075,history of major macrovascular disease — no . ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
4075,history of major macrovascular disease  n ( % ),C0205082;C0205164;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
4075,history of macrovascular disease at baseline  n ( % ),C0683519;C0730226;C0850708;C0944983
4075,history of macrovascular disease ( % ),C0683519;C0730226;C0850708;C0944983
4075,history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
4075,history of ischemic heart disease — no . ( % ),C0018787;C0475224;C0683519;C0730226;C0850708;C0944983
4075,history of fistullzing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
4075,history of fistulizing disease  n ( % ),C0683519;C0730226;C0850708;C0944983
4075,history of fistulising disease  n [ % ],C0683519;C0730226;C0850708;C0944983
4075,history of disease refractory to treatment with tnf antagonist — no . ( % ),C0683519;C0730226;C0850708;C0944983
4075,history of coronary heart disease at,C0018787;C0683519;C0730226;C0850708;C0944983
4075,history of coronary heart disease  no . ( % ),C0018787;C0683519;C0730226;C0850708;C0944983
4075,history of coronary arteiy disease,C0018787;C0683519;C0730226;C0850708;C0944983
4075,history of carotid disease - n ( % ),C0683519;C0730226;C0741968;C0850708;C0944983
4075,history of bone disease ( predefined )  n ( % ),C0005940;C0019664;C0019665;C0262512;C0262926;C0262950;C0683519;C0730226;C0850708;C0944983;C1705255;C2004062
4075,disease history,C0683519
4074,microvascular disease history  no . ( % ),C0443258;C0683519
4074,microvascular disease history  n ( % ),C0443258;C0683519
4074,microvascular disease history,C0443258;C0683519
4074,history of microvascular eye disease 本  n ( % ),C0015392;C0015397;C0019664;C0019665;C0262512;C0262926;C0443258;C0683519;C0700042;C0730226;C0850708;C0944983;C1705255;C2004062
4074,history of microvascular disease — no . ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
4074,history of microvascular disease ( % ),C0443258;C0683519;C0730226;C0850708;C0944983
4074,history of microvascular disease,C0443258;C0683519;C0730226;C0850708;C0944983
4074,history of major microvascular disease — no . ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
4074,history of major microvascular disease  n ( % ),C0205082;C0205164;C0443258;C0683519;C0730226;C0850708;C0944983;C4318856;C4521762
4073,ccv history / condition at baseline,C0168634;C0683519;C1442488
4073,ccv history / condition,C0683519
4072,smoking history : ex - smoker,C0337664;C1519384
4071,smoking history : current smoker,C1519384;C3173209;C3241966
4071,history of smoking,C1519384
4070,smoking history — no . ( % ),C1519384
4070,smoking history ( ever ),C1519384;C3887636
4070,smoking history,C1519384
4069,smoking history    n   ( % ),C1519384
4069,smoking history  r ( % ),C0205090;C0684010;C1519384;C2603358
4069,smoking history  n ( % ),C1519384
4068,timi minor bleeding,C0019080;C0026193;C0205165
4068,minor bleeding,C0019080;C0026193;C0205165
4068,minor bleed,C0019080;C0026193;C0205165
4068,minor,C0026193;C0205165
4067,timi major / minor bleeding,C0019080;C4441842
4067,timi major / minor,C4441842
4066,pure motor hemiparesis,C0018989;C1513492;C1705994;C2247561
4065,motor weakness,C1513492;C1705994;C3714552
4064,updrs iii ( motor ),C0439070;C1513492;C1705160;C1705994;C3639721
4064,updrs  part iii ( motor ),C0439070;C0449719;C1513492;C1705160;C1705994;C1709471;C3639721
4064,motor updrs subscore ( baseline )  mean ( sd ),C0168634;C0444504;C1442488;C1513492;C1705994;C2347634;C2348143;C2699239;C3639721
4064,motor,C1513492;C1705994
4063,right coronary,C0225808
4062,right coronary artery  n ( % ),C1261316
4062,right coronary artery,C1261316
4061,coronary artery treated  no . ( % ),C0205042
4061,coronary artery osteochondrosis,C0029376;C0029429;C0205042;C0729346
4061,coronary artery,C0205042
4060,coronary events $nmbr$,C0741923
4060,acute coronary event,C0205178;C0741923
4059,voluntary,C0439656;C3543419
4058,previous coronary artery bypass surgery  no . ( % ),C2144990
4058,previous coronary artery bypass grafting,C2144990
4058,previous coronary artery bypass graft,C2144990
4058,previous coronary - artery bypass grafting,C2144990
4057,prior coronary revascularization — no . { % ),C0332152;C0877341;C2826257
4057,prior coronary revascularization  no . ( % ),C0332152;C0877341;C2826257
4057,prior coronary revascularization  n / n ( % ),C0332152;C0877341;C2826257
4057,prior coronary revascularization  n ( % ),C0332152;C0877341;C2826257
4057,prior coronary revascularization,C0332152;C0877341;C2826257
4057,coronary revascularization procedure,C0877341
4057,coronary revascularization,C0877341
4057,any coronary revascularization,C0877341
4056,previous coronary revascularization — no . ( % ),C0205156;C0877341;C1552607
4056,previous coronary revascularization,C0205156;C0877341;C1552607
4056,previous coronary revascularisation,C0205156;C0877341;C1552607
4056,coronary revascularisation,C0877341
4055,with rehospitalization  urgent coronary revascularization,C0439609;C0877341;C3272275
4055,urgent coronary revascularization,C0439609;C0877341;C3272275
4055,coronary revascularisation §,C0877341
4054,tertiary amines,C3653356
4053,tertiary endpoints :,C0205372;C2349179
4053,tertiary end points,C0205372;C2349179
4053,tertiary,C0205372
4052,sedentary,C0205254
4051,secondary endpoints :,C4528314
4051,key secondary end point : st,C0036056;C3272372;C4528314
4050,primary mace endpoint,C0349381;C0949745;C1445339;C2986535
4050,nace ( primary endpoint ),C2986535
4049,primary renal endpoint or death,C0022646;C2986535
4049,primary renal endpoint,C0022646;C2986535
4049,primary endpoint,C2986535
4048,primary end point kaplan - meier rate  %,C0871208;C1521828;C2986535
4048,primary end point *,C2986535
4048,primary end - point,C2986535
4047,primary trial end point,C0008976;C2986535
4047,primary end point |,C2986535
4047,primary end point  no . of events / total no . ( % ),C2986535
4047,primary end point,C2986535
4046,primary endpoint at $nmbr$ days,C0439228;C2986535
4046,primary endpoint ^,C2986535
4045,primary endpoint at $nmbr$ months,C0439231;C2986535
4045,primary endpoint $nmbr$,C2986535
4044,primary endpoint :,C2986535
4044,primary cardiovascular endpoint,C0007226;C2986535;C3887460
4043,primary endpoint ’,C2986535
4043,primary cv endpoint,C2986535;C3538987;C4048877;C4318503
4042,primary target vessel ( % ),C0205225;C0439612;C0439631;C0449618
4041,primary analysis,C0002778;C0205225;C0439612;C0439631;C0936012;C1524024
4041,overall cohort ( primary analysis ),C0086027;C0205225;C0282416;C0439612;C0439631;C1561607
4040,primary study joint  n ( % ),C0022417;C0205225;C0392905;C0439612;C0439631;C0557651;C1706309;C2603343
4040,primary pcit,C0205225;C0439612;C0439631
4040,primary pci n = $nmbr$,C0205225;C0439612;C0439631;C4049621
4040,primary pci ( n = $nmbr$ ),C0205225;C0439612;C0439631;C4049621
4040,primary pci,C0205225;C0439612;C0439631;C4049621
4040,primary angioplasty ( n = $nmbr$ ),C0162577;C0205225;C0439612;C0439631;C1548817
4040,primary *,C0205225;C0439612;C0439631
4040,fibrinolysis primary pci ( n = $nmbr$ ) ( n = $nmbr$ ) no . of patients / total no . ( % ),C0016017;C0205225;C0439612;C0439631;C1305868;C4049621
4040,accord primary  n ( % ),C0205225;C0439612;C0439631;C0680240
4039,second primary composite outcome,C0205199;C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1547335;C1561503;C1705190
4039,primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
4039,primary composite ^,C0205199;C0205225;C0439612;C0439631;C1547335
4039,first primary composite outcome,C0205199;C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C1547335
4039,a . primary composite outcome,C0205199;C0205225;C0439612;C0439631;C1274040;C1547335
4038,primary end points,C0205225;C0439612;C0439631;C2349179
4038,primary composite end points,C0205199;C0205225;C0439612;C0439631;C1547335;C2349179
4037,year of publication of primary results,C0034036;C0034037;C0205225;C0439234;C0439508;C0439612;C0439631;C1274040;C1546471;C1704324;C2825142
4037,primary nonresponse,C0205225;C0439612;C0439631
4037,primary cause of chf,C0015127;C0018802;C0205225;C0439612;C0439631;C1524003
4036,primary + gusto severe bleeding,C0019080;C0205082;C0205225;C0439612;C0439631;C4050465;C4050466
4036,primary + gusto moderate or severe bleeding,C0205225;C0439612;C0439631
4035,primary hemorrhagic stroke,C0205225;C0439612;C0439631;C0553692
4035,primary,C0205225;C0439612;C0439631
4034,nationality,C0027473
4033,ecg abnormality at entry,C0522055;C1705654
4033,any electrocardiographic abnormality — no . ( % ),C0522055
4032,laboratory examination,C0260877
4031,laboratory measurements,C0681902
4030,laboratory evaluations,C0022877;C0220825;C3244292;C4283904
4030,laboratory determinations,C0022877;C0680730;C3244292;C4283904
4029,laboratory data  mean ( sd ),C0022877;C0444504;C1511726;C2347634;C2348143;C2699239;C3244292;C3245479;C3714741;C4283904
4029,laboratory data,C0022877;C1511726;C3244292;C3245479;C3714741;C4283904
4028,laboratory variables at baseline,C0022877;C0168634;C0439828;C1442488;C3244292;C4283904
4028,laboratory variables,C0022877;C0439828;C3244292;C4283904
4028,laboratory values,C0022877;C0042295;C3244292;C4283904
4028,laboratory measures,C0022877;C3244292;C4283904
4028,baseline laboratory values  median ( iqr ) d,C0022877;C0042295;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C3244292;C4283904
4027,chronic pulmonary disease,C0746102
4026,pulmonary disease — no . ( % ),C0024115
4026,pulmonary disease,C0024115
4026,b . i . d .  twice daily  cat  copd assessment test  copd  chronic obstructive pulmonary disease  fev $nmbr$    forced expiratory volume in $nmbr$   s  fvc  forced vital capacity  gold  global initiative for chronic obstructive lung disease  ics  inhaled corticosteroid  mcid  minimum clinically important difference  mmrc  modified medical research council  o . d .  once daily  sd  standard deviation  sgrq - c  st . george ’ s respiratory questionnaire for copd,C0001617;C0004048;C0007450;C0016529;C0018026;C0024115;C0024117;C0034394;C0152277;C0205191;C0205246;C0325090;C0424093;C0521346;C0524517;C0549186;C0585361;C0815320;C0871420;C1304897;C1306036;C1412502;C1443200;C1546767;C1553316;C2348867;C3536709;C3665481;C3714496;C3714541;C3826872;C3826977;C4050461;C4277733;C4284282;C4551720
4025,family history of premature heart disease,C0018787;C0151526;C0205252;C0850707;C4018905
4025,family history of coronary disease,C0018787;C0850707
4024,history of coronary,C0018787;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
4024,coronary,C0018787
4023,family history of premature coronary heart disease,C0151526;C0205252;C0260520;C1313980;C2317524;C4018905
4023,family history of coronary artery disease,C2317524
4022,plus metformin,C0025598;C0332287
4021,vildagliptin + metformin ( vldm ),C0025598;C1570906
4021,metformin ( hdm ),C0025598
4020,metformin open - label *,C0025598
4020,metformin alone,C0025598
4020,baseline metformin,C0025598;C0168634;C1442488
4019,saxa $nmbr$ mg $nmbr$ metformin ( n $nmbr$ $nmbr$ ),C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
4019,metformin ( n $nmbr$ $nmbr$ ),C0025598
4018,metformin monotherapy,C0025598
4018,duration of metformin therapy ( months ),C0025598;C0439231;C0444917
4017,metformin only,C0025598;C0205171;C1720467
4017,metformin : no / yes  %,C0025598
4016,on non ‐ metformin aha,C0025598;C0050451;C0772110;C1518422
4016,not on metformin,C0025598;C1518422
4016,metformin,C0025598
4015,no metformin,C0025598
4015,metformin 一 no . ( % ),C0025598
4015,metformin — no . ( % ),C0025598
4015,metformin dose  mg,C0024671;C0025598;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
4015,metformin dose,C0025598;C0178602;C0869039;C1114758
4015,mean ( s . d . ) metformin dose †  mg / day,C0025598;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
4015,distribution of metformin dose at randomization  n ( % ),C0025598;C0178602;C0520511;C0869039;C1114758;C1704711
4014,metformin ± other oral anti - dm drugs,C0025598
4014,metformin - dose,C0025598;C0178602;C0869039;C1114758
4013,previous metformin use  %,C0025598;C0042153;C0205156;C0457083;C1552607;C1947944
4013,no metformin use,C0025598;C0042153;C0457083;C1947944
4013,metformin use  n ( % ),C0025598;C0042153;C0457083;C1947944
4013,metformin use,C0025598;C0042153;C0457083;C1947944
4013,metformin ( n = $nmbr$ ),C0025598
4013,metformin  n ( % ),C0025598
4012,metformin • pioglitazone,C1635037
4012,metformin ? pioglitazone,C1635037
4011,warfarin n = $nmbr$ n / n ( % ),C0043031
4011,warfarin n = $nmbr$,C0043031
4011,warfarin group ( n = $nmbr$ ),C0043031;C0441848
4011,warfarin ( n = $nmbr$ ),C0043031
4010,warfarin ( n - $nmbr$  $nmbr$ ),C0043031
4010,long - term warfarin ( n = $nmbr$ ),C0043031;C0443252
4010,long - term warfarin ( n - $nmbr$ ),C0043031;C0443252
4009,warfarin n / n  rate ( % ),C0043031;C0871208;C1521828
4009,warfarin ( n = $nmbr$ )  n ( % / y ),C0043031
4009,warfarin % ( n / n ),C0043031
4009,warfarin,C0043031
4008,warfarin ( % ),C0043031
4008,warfarin  no . ( % ),C0043031
4008,previous warfarin use  no . ( % ),C0043031;C0205156;C1552607
4007,warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
4007,warf,C0043031
4006,warfarin naive,C0043031
4006,in therapeutic range for warfarin subjects,C0043031;C0460097
4005,prior electrical cardioversion for af ( n = $nmbr$ $nmbr$ ),C0013778;C0332152;C0344434;C0542380;C2826257;C4049859
4005,prior af ablation  n ( % ),C0332152;C0344434;C0547070;C1261381;C2826257;C4049859
4004,af duration  n ( % ),C0344434;C0449238;C2926735;C4049859
4004,af,C0344434;C4049859
4003,persistent af  n ( % ),C0205322;C0332996;C0344434;C4049859
4003,persistent af,C0205322;C0332996;C0344434;C4049859
4003,permanent af,C0205355;C0344434;C4049859
4002,black / af rican american,C0085756;C0344434;C4049859
4001,af pattern,C0344434;C0449774;C4049859
4001,af or atrial flutter 卞,C0344434;C4049859
4001,af or atrial flutter !,C0344434;C4049859
4000,af alone refers to atrial fi - brillation without coexisting cardiovascular conditions but with left atrial dilatation . ace denotes angiotensin - con - verting enzyme  hf heart failure  and lvd left ventricular dysfunction .,C0012634;C0014442;C0018801;C0344434;C0348080;C0387288;C1705253;C3864998;C4049859;C4521602
4000,af alone,C0344434;C4049859
3999,no atrial fibrillation,C0004238;C0344434;C1963067
3999,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,C0004238;C0205435;C0332189;C0344434;C1279901;C1963067
3999,ecg atrial fibrillation  n ( % ),C0004238;C0344434;C1623258;C1963067
3999,duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % ),C0004238;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
3999,atrial fibrillation — no . ( % ),C0004238;C0344434;C1963067
3999,atrial fibrillation pattern,C0004238;C0344434;C0449774;C1963067
3999,atrial fibrillation or flutter — no . ( % ),C0004238;C0344434;C1963067
3999,atrial fibrillation or flutter ( ecg ) §,C0004238;C0344434;C1963067
3999,atrial fibrillation or flutter,C0004238;C0344434;C1963067
3999,atrial fibrillation onset,C0004238;C0206132;C0332162;C0344434;C1963067
3999,atrial fibrillation alone ),C0004238;C0344434;C1963067
3999,atrial fibrillation . no . ( % ),C0004238;C0344434;C1963067
3999,atrial fibrillation    n   ( % ),C0004238;C0344434;C1963067
3999,atrial fibrillation  duration — no . ( % ),C0004238;C0344434;C0449238;C1963067;C2926735
3998,type of atrial fibrillation — no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation - n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation ( n = $nmbr$ $nmbr$ ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation  no . / total no . ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,type of atrial fibrillation,C0004238;C0332307;C0344434;C1547052;C1963067
3998,atrial fibrillation — no . / total no . ( % ),C0004238;C0344434;C1963067
3998,atrial fibrillation type  n ( % ),C0004238;C0332307;C0344434;C1547052;C1963067
3998,atrial fibrillation ( % ),C0004238;C0344434;C1963067
3998,atrial fibrillation  n ( % ),C0004238;C0344434;C1963067
3998,atrial fibrillation  %,C0004238;C0344434;C1963067
3998,atrial fibrillation,C0004238;C0344434;C1963067
3997,rate of atrial fibrillation,C0004238;C0344434;C0871208;C1521828;C1963067
3997,atrial fibrillation !,C0004238;C0344434;C1963067
3997,> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0004238;C0332189;C0344434;C1963067
3996,qualifying risk factors — no . ( % ),C0035648;C1514624;C1553898
3996,qualifying risk factor — no . ( % ),C0035648;C1514624
3996,qualifying high - risk features — %,C1514624
3995,qualifying peripheral arterial disease,C1514624
3995,qualifying diagnosis,C0011900;C1514624;C1704338;C1704656
3994,qualifying symptomatic event  n ( % ) a,C1514624
3994,qualifying events,C0441471;C1514624;C3541888
3994,qualifying event — no . ( % ),C0441471;C1514624;C4019010
3994,qualifying event,C0441471;C1514624;C4019010
3994,qualifying acs event — no . ( % ),C0441471;C0742343;C1514624;C4019010;C4318612
3994,pciperformed for qualifying event,C0441471;C1514624;C4019010
3994,at qualifying event,C0441471;C1514624;C4019010
3994,anatomical extent of qualifying event — no . ( % ) : t,C0220784;C0439792;C0441471;C1514624;C4019010
3994,anatomic extent of qualifying event  n ( % . ) x,C0220784;C0439792;C0441471;C1514624;C4019010
3993,time from qualifying myocardial infarction,C0027051;C0040223;C0428953;C1514624;C2926063;C3541383;C3810814;C4552959
3993,time from qualifying mi  yrs,C0040223;C1514624;C3541383;C3810814
3993,time from qualifying mi  %,C0040223;C1514624;C3541383;C3810814
3993,qualifying myocardial infarction,C1514624
3992,qualifying mi type,C0332307;C1514624;C1547052;C3810814
3992,qualifying mi < $nmbr$ yrs prior,C1514624;C3810814
3992,qualifying mi $ $nmbr$ yrs prior,C1514624;C3810814
3991,number of individuals,C1549735
3990,number of visits  median,C1549755
3990,number of visits  mean ± sd,C0444504;C1549755;C2347634;C2348143;C2699239
3989,overall quality of life,C3641830
3988,quality of life,C0034380;C0518214
3988,european quality of life - $nmbr$ dimensions - $nmbr$ level ( eq - $nmbr$ d ),C0034380;C0205163;C0239307;C0439185;C0439534;C0441889;C0456079;C0518214;C1535514;C1547707;C2946261
3987,lack of efficacy with > $nmbr$ bdmard,C0235828
3987,lack of efficacy with > $nmbr$ anti - interleukin $nmbr$,C0235828
3987,lack of efficacy,C0235828
3987,lack of effectiveness,C0235828
3986,ff / vi ( n   =   $nmbr$ ),C0205999;C4554348
3986,ff / vi $nmbr$ mg / $nmbr$ mg ( n = $nmbr$ ),C0205999;C1319635;C4554348
3986,ff / vi $nmbr$ / $nmbr$ pg od,C0030827;C0072225;C0205999;C0229089;C0439164;C1266240;C1512019;C3273373;C3665488;C4554348
3986,ff / vi $nmbr$ . $nmbr$,C0205999;C4554348
3986,ff / vi,C0205999;C4554348
3986,ff $nmbr$ pgod,C4554348
3985,ff - blocker,C4554348
3985,favors ff / vi favors placebo,C0205999;C0309049;C4554348
3984,ff – $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
3984,ff - $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
3984,ff $nmbr$ % ( - $nmbr$ %  $nmbr$ % ),C4554348
3984,ff $nmbr$ % ( $nmbr$ % ci – $nmbr$ – $nmbr$ % ),C0008107;C3259781;C4554348
3983,la grade b  n ( % ) f,C0016327;C1881342
3983,f * >,C0016327
3983,$nmbr$ f $nmbr$ l % $nmbr$,C0016327
3982,$nmbr$ s f $nmbr$ ),C0016327;C0565930;C2603362
3982,$nmbr$ f $nmbr$ q % ),C0016327
3981,natalizumab ( n = $nmbr$ ) f,C0016327;C1172734
3981,f,C0016327
3981,ancestry ( % ) f,C0016327
3981,? f ? n,C0016327
3980,ica stenosis $nmbr$ % - $nmbr$ % f,C0016327;C0201519;C0678234;C1261287;C2632116
3980,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % f,C0016327
3979,f emale,C0016327
3979,f - plasma glucose  mmol / l,C0016327;C0202042;C0455280;C1532563
3979,f $nmbr$ vs placebo,C0016327
3978,gfr < $nmbr$,C0017654;C1424601
3978,gfr ( ml / min per $nmbr$ . $nmbr$ nr ),C0017654;C0027496;C0439445;C1424601;C3844738
3978,estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
3978,estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
3978,estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
3978,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
3978,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
3978,estimated gfr  ml / min,C0017654;C0439445;C0750572;C1424601
3977,gfr > $nmbr$,C0017654;C1424601
3977,by gfr stratum tor all participants  ml / min per $nmbr$ . $nmbr$ m ^ !,C0017654;C0076836;C1199517;C1419603;C1424601;C3539732
3976,gfr as assessed by mdrd,C0017654;C1424601
3976,estimated gfr — no . ( % ) ^ |,C0017654;C0750572;C1424601
3976,estimated gfr — no . ( % ) $nmbr$,C0017654;C0750572;C1424601
3976,estimated gfr ^,C0017654;C0750572;C1424601
3976,estimated gfr,C0017654;C0750572;C1424601
3975,mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
3975,gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C1424601;C3839656
3975,gfr $nmbr$ - $nmbr$,C0017654;C1424601
3975,gfr $nmbr$ $nmbr$,C0017654;C1424601
3975,estimated gfr  mean ( sd )  mlvmin per $nmbr$ . $nmbr$ m ^ *,C0017654;C0369637;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
3974,delayed reaction,C0205421;C0443286;C1545665;C3272602
3973,delayed - start group ( n = $nmbr$ ),C0205421;C0439659;C0441848;C1545665;C3272602
3973,delayed,C0205421;C1545665;C3272602
3972,delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
3972,delayed - eptifibatide group ( n = $nmbr$ ),C0205421;C0253563;C0441848;C1545665;C3272602
3971,verifynow pru - defined hpr ( % patients ),C0030705;C1337105;C1704788;C3539106
3971,other defined,C1704788;C3539106
3970,respiratory - related ^,C0439849;C0445223;C0521346;C1546767
3969,related to study druga,C0439849;C0445223
3969,drug - related teaes *,C0013227;C0439849;C0445223;C1254351
3969,drug - related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
3969,drug - related teaes,C0013227;C0439849;C0445223;C1254351
3969,drug - related ae *,C0013227;C0439849;C0445223;C1254351;C3887670
3969,> $nmbr$ drug - related aes *,C0013227;C0439849;C0445223;C1254351;C1412268;C2699274
3969,> $nmbr$ drug - related,C0013227;C0439849;C0445223;C1254351
3968,mean ( sd ) % of predicted normal fev $nmbr$,C0444504;C0520835;C0681842;C1882327;C2347634;C2348143;C2699239
3968,fev $nmbr$ % predicted ( sd ),C0681842;C1882327;C2699239;C3714541
3968,fev $nmbr$ % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2699239;C3714541
3968,% predicted value ( sd ),C0681842;C1522609;C1882327;C2699239
3968,% predicted post - bronchodilator fev $nmbr$  mean ( sd )  l,C0681842;C1882327
3968,% predicted post - bronchodilator fev  ( sd ) ml,C0681842;C1882327
3968,% predicted,C0681842;C1882327
3968,% of predicted,C0681842;C1882327
3967,> $nmbr$ % predicted to < $nmbr$ % predicted,C0681842;C1882327
3967,> $nmbr$ % predicted arr ( n = $nmbr$ ),C0681842;C1882327;C2170357;C4084934
3967,> $nmbr$ % predicted,C0681842;C1882327
3967,< $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),C0681842;C1882327;C2170357;C4084934
3967,< $nmbr$ % predicted,C0681842;C1882327
3966,pulmonary function tests  % of predicted,C0024119;C0681842;C1882327;C2598152
3965,% of predicted normal value *,C0086715;C0681842;C1882327
3964,fevj % predicted !  t,C0681842;C1882327
3964,fev $nmbr$   % of predicted normal post - bronchodilator,C0520835;C0681842;C1882327;C2599594
3963,percent of predicted value before bronchodilation ^,C1882327
3963,percent of predicted normal value,C0205307;C0231683;C0439166;C1882327;C2347086;C4553972
3962,prednisone or equivalent dose ( mg / day ),C0032952
3962,baseline prednisone or oral prednisone equivalent daily dose,C0032952;C0168634;C1442488
3961,smedian prednisone dose  n ( % ),C0032952;C0178602;C0869039;C1114758
3961,prednisone,C0032952
3961,< median prednisone dose  n ( % ),C0032952;C0178602;C0549183;C0869039;C0876920;C1114758;C2347635;C2348144;C2939193
3960,fev $nmbr$ % pred . ( post - albuterol )  %,C0001927;C0032952;C0044955;C0687676;C1704687;C3469826;C3714541
3960,% pred,C0032952;C0044955
3959,predose fev / fvc,C0439565;C3714541;C3812758
3959,predose fev -  at randomization,C0034656;C0439565;C3714541;C3812758
3959,pre - dose,C0439565;C3812758
3958,probenecid,C0033209
3957,batellna c - reective protein,C0033684
3956,high - sensitivityc - reactive protein  mg / l,C0033684;C0205250;C0205332;C0439268;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
3956,c - reactive proteinc,C0205332
3955,fecal calprotectin — pg / g * *,C0015733;C0950624;C1335798;C1366582;C1638318
3954,vasoprotectives,C0304533
3953,percutaneous transluminal coronary angioplasty,C2936173
3952,ptca only,C0205171;C1720467;C2936173
3952,ptca,C2936173
3952,both ptca and cabg,C2936173
3951,ptca or pci,C2936173
3951,prior ptca or pci,C0332152;C2826257;C2936173
3951,prior ptca or cabg,C0332152;C2826257;C2936173
3950,percentage of days without heartburn,C0439165;C0439228;C1549488;C1561533
3950,mean percentage of nights without heartburn,C0240526;C0439165;C0444504;C1549488;C1561533;C2347634;C2348143
3949,percentage points,C0439165;C1549488;C1561533
3949,percentage patients reaching target,C0030705;C0439165;C1549488;C1561533
3949,percentage of patients receiving dose adjustment,C0030705;C0439165;C1549488;C1561533
3948,percentages,C0439165;C1549488;C1561533
3948,percentage of predicted pre - bronchodilator fev ^,C0439165;C0681842;C1549488;C1561533;C1882327;C2599602;C3714541
3948,percentage of p,C0439165;C1549488;C1561533
3948,percentage of fevj reversibility,C0439165;C0449261;C1549488;C1561533
3948,percentage of females,C0086287;C0439165;C1549488;C1561533
3948,percentage of bsa involved,C0439165;C1549488;C1561533
3948,abbreviations : bmi  body mass index  cabg  coronary artery bypass graft  nsaids  nonsteroidal anti - inflammatory drugs  pci  percutaneous coronary interventions . * values expressed as number ( percentage ) unless otherwise indicated . percentages may not equal $nmbr$ due to rounding . fhistory of or currently taking antidiabetic or lipid - lowering medications . ^ history of or currently have elevated serum creatinine level but less than $nmbr$ mg / dl_ ( < $nmbr$ pmol / l ) . § patients with a history of skin  prostate  and other cancers with long survival expectancy were not excluded . | | lnsulin and / or oral hypoglycemics . ildata for women only ( n = $nmbr$ for calcium antagonist strategy and n = $nmbr$ for non - calcium antagonist strategy ) .,C0000723;C0003211;C0010055;C0033572;C0038952;C0042295;C0043210;C0205163;C0205166;C0205171;C0220921;C0237753;C0332490;C0359086;C0439165;C0444099;C0449788;C0600061;C0678226;C0679138;C0679199;C0679831;C1123023;C1305855;C1532338;C1549488;C1561533;C1706317;C1720467;C3146286;C4520765
3947,percentages of patients with event,C0030705;C0439165;C1549488;C1561533
3947,percentage of patients with event,C0030705;C0439165;C1549488;C1561533
3947,percentage of patients using ics or ics / laba on entry,C0030705;C0439165;C1549488;C1561533
3947,percent of patients,C0030705;C0439165
3946,percentage difference ( $nmbr$ % cl ),C0439165;C0596019;C1549488;C1561533;C1705241;C1705242
3946,percentage,C0439165;C1549488;C1561533
3945,percent overall work impairment due to asthma,C0439165
3945,percent impairment while working due to asthma,C0221099;C0439165;C0684336
3944,m $nmbr$ subgroup,C0369637;C0441923;C1079230;C1515021
3943,subgroup $nmbr$,C1079230;C1515021
3943,age subgroup  y,C0001779;C1079230;C1515021
3942,high eosinophil subgroup ( > $nmbr$ / ml ) ( n = $nmbr$ ),C0014457;C0439526;C1079230;C1515021;C1705224;C3887665
3942,( subgroup ),C1079230;C1515021
3941,subgroup_level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
3941,subgroup name / level,C0027365;C0441889;C0456079;C1079230;C1515021;C1547383;C1547707;C2946261;C4522128
3941,subgroup levels,C0441889;C1079230;C1515021
3941,subgroup level,C0441889;C0456079;C1079230;C1515021;C1547707;C2946261
3940,additional antihypertensive subgroup,C0003364;C1079230;C1515021;C1524062
3939,subgroup based on :,C1079230;C1515021
3939,renal subgroup,C0022646;C1079230;C1515021
3938,baseline subgroup,C0168634;C1079230;C1442488;C1515021
3938,baseline mtss subgroup,C0168634;C1079230;C1442488;C1515021
3938,baseline hba $nmbr$ c subgroup,C0019016;C0168634;C1079230;C1442488;C1515021;C1825777;C3538758
3937,ctd population subgroup,C0032659;C1079230;C1257890;C1335071;C1442905;C1515021
3936,treatment by subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3936,treatment - by - subgroup interaction  p = $nmbr$ . $nmbr$,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3936,treatment - by - subgroup interaction,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3936,subgroup treatment,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1705169;C3538994;C3887704
3936,subgroup by treatment interaction p - value,C0039798;C0087111;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
3936,subgroup,C1079230;C1515021
3936,month $nmbr$ subgroup x treatment interaction p - value,C0039798;C0087111;C0332177;C0439231;C1079230;C1515021;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
3935,outcome_subgroup,C1079230;C1274040;C1515021
3934,planned conservative therapy subgroup,C0459914;C1079230;C1301732;C1515021
3933,subgroup p valuef,C1079230;C1515021
3933,subgroup p value 本,C1079230;C1515021;C1709380
3933,subgroup p value !,C1079230;C1515021;C1709380
3933,subgroup p - value $nmbr$,C1079230;C1515021;C1709380
3932,secondary prevention subgroup,C0679699;C1079230;C1515021
3932,primary prevention subgroup,C0033144;C1079230;C1515021
3931,subgroup no .,C1079230;C1515021
3931,genetic subgroup,C0017296;C0314603;C1079230;C1515021
3930,other climate subset,C0008946;C1515021
3929,hot climate subset,C0178683;C1515021
3928,subsets,C1515021
3928,subset of patients on metformin,C0030705;C1515021
3928,subset of patients not on metformin,C0030705;C1515021
3927,total subjects,C0439175;C0439810;C0681850;C1550501;C1706203;C2349001;C2697811
3927,subjects who did receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
3927,subjects who did not receive labd prior to the study,C0681850;C1550501;C1706203;C2349001;C2697811
3927,subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811
3927,subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811
3927,number of subjects in analysis,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
3927,number of subjects,C0237753;C0449788;C0681850;C1550501;C1706203;C2349001;C2697811
3927,no . of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
3927,concomitant medications in > $nmbr$ % of subjects  no . ( % ),C0013227;C0521115;C0681850;C0802604;C1550501;C1706203;C2349001;C2598133;C2697811;C4284232
3927,abbreviations : ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by height in meters squared )  dm  diabetes mellitus  hba $nmbr$ c  hemoglobin a $nmbr$ c  hmg - coa  $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin  and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide  glibenclamide  glimepiride  glipizide  and tolazamide . cthiazolidinediones include pioglitazone  pioglitazone hydrochloride  rosiglitazone  and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0000723;C0005910;C0009226;C0011816;C0011849;C0013227;C0019016;C0019046;C0022709;C0025598;C0029167;C0032042;C0040372;C0043100;C0073187;C0175795;C0304289;C0332173;C0332287;C0439209;C0441833;C0521115;C0681850;C0687744;C0700307;C1185738;C1254351;C1257890;C1305855;C1305866;C1512211;C1519504;C1550501;C1696465;C1705104;C1705428;C1705429;C1706132;C1706203;C1706408;C1825777;C2349001;C2697811;C3250443;C3538758;C4288115;C4484261;C4553328
3926,subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
3926,subjects ( n ),C0681850;C1550501;C1706203;C2349001;C2697811
3926,subjects $ $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
3926,subjects  $nmbr$ years of age  n ( % ),C0681850;C1550501;C1706203;C2349001;C2697811
3926,subjects,C0681850;C1550501;C1706203;C2349001;C2697811
3926,subject disposition  n ( % ),C0681850;C0743223;C1550501;C1705555;C1706203;C2349001;C2697811
3926,subject completion status  n ( % ),C0205197;C0449438;C0681850;C0805732;C1550501;C1554962;C1706203;C2348577;C2349001;C2697811;C3891295
3926,non - diabetic subjects  n = $nmbr$,C0241863;C0681850;C1518422;C1550501;C1706203;C2349001;C2697811
3926,diabetic subjects  n = $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
3926,( $nmbr$ subjects ),C0681850;C1550501;C1706203;C2349001;C2697811
3925,snp,C0752046;C1527094
3924,sbp > $nmbr$ mnn hg,C0025424;C0085805;C0428257;C2347108;C2347109;C2348272
3923,seated sbp  n,C0085805;C0277814;C1283233
3922,ambulatory sbp  n,C0085805;C0439841
3921,seated sbp  mean ( sd )  mmhg,C0085805;C0277814;C0439475;C0444504;C1283233;C2347634;C2348143;C2699239
3921,sd of sbp,C0085805;C2699239
3921,sbp ( sd ),C0085805;C2699239
3920,sbp ( mmhg )  mean ( sd ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
3920,sbp ( mmghg )  mean ( sd ),C0085805;C0444504;C2347634;C2348143;C2699239
3920,sbp  mean = sd  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
3920,sbp  mean ( sd )  mmhg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
3920,sbp  last,C0085805
3920,mean change in sbp from baseline  mmhg  mean ( sd ),C0085805;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3919,sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C1705241;C1705242
3919,sbp  difference,C0085805;C1705241;C1705242
3919,sbp,C0085805
3919,difference in sbp between treatment,C0085805;C1705241;C1705242
3919,ambulatory sbp  difference vs placebo ( $nmbr$ % cl ),C0085805;C0439841;C1705241;C1705242
3918,other bp drug,C0013227;C0037623;C1254351;C1415692;C1708288;C4318478
3918,key : fc = fasting glucose  bp = * this category did not include ar have $nmbr$ of the indicated charac,C0015663;C0017725;C0037623;C1415692;C1708288;C2983605;C4318478
3918,control of sitting bp at week $nmbr$,C0037623;C0243148;C0277814;C1415692;C1550141;C1708288;C1882979;C2584297;C2587213;C3274648;C4050224;C4318478;C4553389
3918,bp in pre - treated patients,C0037623;C1415692;C1708288;C4318478
3918,bp goal at week $nmbr$,C0018017;C0037623;C0332174;C0439230;C1415692;C1571704;C1708288;C4318478
3918,bp control,C0037623;C0243148;C1415692;C1550141;C1708288;C1882979;C2587213;C3274648;C4318478;C4553389
3918,bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478
3918,bp - lowering treatments  n ( % ),C0037623;C0087111;C0441994;C1415692;C1708288;C2003888;C4318478
3917,syst . bp ( mmhg ),C0037623;C0439475;C1415692;C1708288;C4318478
3917,patientswith bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0037623;C0168634;C0332126;C0439475;C1415692;C1442488;C1449832;C1708288;C3889152;C4050156;C4283901;C4284038;C4318478
3917,patientswith bp  $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  n §,C0037623;C0168634;C0439475;C1415692;C1442488;C1708288;C4318478
3917,patients with bp $ $nmbr$ / $nmbr$ mmhg ( abpm ) at baseline  nt,C0030705;C0037623;C0439475;C1415692;C1708288;C4318478
3917,bp component ( mm hg ),C0037623;C0439475;C0449432;C1415692;C1705248;C1708288;C4318478
3917,bp < $nmbr$ / $nmbr$  n ( % ),C0037623;C1415692;C1708288;C4318478
3916,sbp / dbp mean,C0085805;C0444504;C0536221;C2347634;C2348143;C3813197;C4281799
3916,mean change in dbp from baseline  mg / dl  mean ( sd ),C0392747;C0443172;C0444504;C0536221;C1705241;C2347634;C2348143;C3813197;C4281799;C4319952
3915,dbp,C0536221;C3813197;C4281799
3915,baseline dbp  mean ± sd  mm hg,C0168634;C0439475;C0444504;C0536221;C1442488;C2347634;C2348143;C2699239;C3813197;C4281799
3915,baseline dbp,C0168634;C0536221;C1442488;C3813197;C4281799
3914,dbp ( sd ),C0536221;C2699239;C3813197;C4281799
3914,dbp ( mmghg )  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3914,dbp  mean ( sd )  mm hg glycaemic parameters,C0005802;C0439475;C0444504;C0449381;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3914,dbp  mean ( sd ),C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,visit $nmbr$ dbp  mm hg,C0439475;C0536221;C0545082;C1512346;C2826704;C3813197;C4281799
3913,seated dbp  mean ( sd )  mmhg,C0277814;C0439475;C0444504;C0536221;C1283233;C2347634;C2348143;C2699239;C3813197;C4281799
3913,sbp / dbp ( mmhg ),C0085805;C0439475;C0536221;C3813197;C4281799
3913,dbp ≥ $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
3913,dbp mm hg,C0439475;C0536221;C3813197;C4281799
3913,dbp > $nmbr$ or sbp > $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799
3913,dbp . mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,dbp ( sd )  mm   hg,C0439475;C0536221;C2699239;C3813197;C4281799
3913,dbp ( office measurement )  mmhg,C0242485;C0439475;C0442603;C0536221;C3813197;C4281799
3913,dbp ( mmhg )  mean ( sd ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,dbp ( mmhg ),C0439475;C0536221;C3813197;C4281799
3913,dbp ( mm hg ),C0439475;C0536221;C3813197;C4281799
3913,dbp  mmhg,C0439475;C0536221;C3813197;C4281799
3913,dbp  mm   hg ( sd ),C0439475;C0536221;C2699239;C3813197;C4281799
3913,dbp  mm   hg,C0439475;C0536221;C3813197;C4281799
3913,dbp  mm hg ( office measurement )  mean ( sd ),C0242485;C0439475;C0442603;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,dbp  mm hg,C0439475;C0536221;C3813197;C4281799
3913,dbp  mean ( sd ) mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,dbp  mean ( sd )  mmhg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,dbp  mean ( sd )  mm hg,C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
3913,baseline sitting dbp  * mm hg,C0168634;C0277814;C0439475;C0536221;C1442488;C2584297;C3813197;C4050224;C4281799
3913,baseline dbp ( mm hg ),C0168634;C0439475;C0536221;C1442488;C3813197;C4281799
3912,unadjusted hazard ratio ( $nmbr$ % ci ),C0008107;C1439367;C2985465;C3259781
3912,hazard ratio [ $nmbr$ % ci ],C0008107;C2985465;C3259781
3912,hazard ratio * ( and $nmbr$ % ci ),C2985465
3912,hazard ratio * ( $nmbr$ % ci ),C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ) vs . placebo,C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes,C0008107;C1320657;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ) - j -,C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ) *,C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ) $nmbr$ with vs . without psoriasis,C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % ci ),C0008107;C2985465;C3259781
3912,hazard ratio ( $nmbr$ % c,C2985465
3912,hazard ratio $nmbr$ ),C2985465
3912,hazard ratio $nmbr$,C2985465
3912,hazard ratio,C2985465
3912,adjusted ⁎ hazard ratio ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
3912,adjusted hazard ratio ≠ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
3912,adjusted hazard ratio ‡ ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
3912,adjusted hazard ratio § ( $nmbr$ % ci ),C0008107;C0456081;C2985465;C3259781
3912,adjusted hazard ratio ( $nmbr$ % ci ) †,C0008107;C0456081;C2985465;C3259781
3911,hazard ratio and $nmbr$ % confidence interval,C2985465
3911,hazard ratio ( $nmbr$ % confi dence interval ),C1272706;C1552654;C1552713;C2985465
3910,unadjusted hazard ratio ( $nmbr$ % cl ),C0596019;C1439367;C2985465
3910,hazard ratio with low ( $nmbr$ % cl ),C0205251;C0596019;C1550472;C2985465;C3890211;C4048187;C4321351;C4522223
3910,hazard ratio with,C2985465
3910,hazard ratio vs . placebo,C2985465
3910,hazard ratio or difference $nmbr$ * ( $nmbr$ % cl ) p - value,C2985465
3910,hazard ratio or difference $nmbr$ ( $nmbr$ % cl ) p - value,C2985465
3910,hazard ratio ( $nmbr$ % cl ],C0596019;C2985465
3910,hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo,C0216784;C0596019;C2985465
3910,hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo,C0596019;C0903898;C2985465
3910,hazard ratio ( $nmbr$ % cl ) *,C0596019;C2985465
3909,nonblack ( n = $nmbr$ )  adjusted hazard ratio *,C0456081;C2985465
3909,adjusted hazard ratio *,C0456081;C2985465
3909,adjusted hazard ratio ( $nmbr$ % cl ) *,C0456081;C0596019;C2985465
3909,adiusted hazard ratio *,C2985465
3908,hazard interaction,C0598697;C1704675
3908,hazard inleraction,C0598697
3907,hazard ratiof ( $nmbr$ % ci ),C0008107;C0598697;C3259781
3907,hazard ratiof,C0598697
3907,hazard,C0598697
3906,native hawaiian or other pacific islander,C0337920
3906,native hawaiian or other pacific,C0337920
3906,native hawaiian or,C0337920
3906,native hawaiian / pacific islander,C0242191;C0337920
3906,native hawaiian / other,C0337920
3906,hawaiian pacific islander,C0242191;C0337920
3906,hawaiian / pacific islander,C0242191;C0337920
3906,hawaiian / pacific,C0337920
3905,ldl : hdl ratio,C0428621
3905,ldl - c : hdl - c ratio,C0428621
3905,ldl - c / hdl - c ratio,C0428621
3904,waisthip ratio,C0205682;C0456603;C1547037
3904,waist : hip ratio,C0205682
3904,waist - to - hip ratio,C0205682
3904,waist - hip ratio,C0205682
3903,pepsinogen i / ii ratio,C0030915;C0456603;C0523817;C1547037
3902,ratio to baseline in total ige at week $nmbr$  geometric mean ( se on loge scale ) u / ml,C0168634;C0456603;C1442488;C1547037
3902,ratio to baseline in eosinophil count at week $nmbr$  geometric mean ( se on loge scale ) cells / ll,C0168634;C0456603;C1442488;C1547037
3902,ratio,C0456603;C1547037
3901,e / a ratio,C0456603;C1547037
3901,ae / e ' ratio ( per $nmbr$ unit ),C0439148;C0439453;C0456603;C1509845;C1519795;C1547037;C1704753;C1880519;C3853603;C3887670
3900,totalhdl cholesterol ratio,C0008377;C0456603;C1547037
3900,total cholesterohhdl cholesterol ratio,C0201950;C0456603;C0543421;C1547037
3899,ratio of ldl to hdl cholesterol,C0456603;C1547037
3899,ratio of ldl to hdl,C0456603;C1547037
3899,non - hdl cholesterol / apob ( ratio ),C0003593;C0456603;C0729627;C1518422;C1535899;C1547037;C2938854;C3252643
3898,ratio of hrs ( $nmbr$ % cl )  p for sex interaction,C0456603;C0596019;C1547037;C1568891
3898,hzard ratio,C0456603;C1547037
3897,cardiothoracic ratio > $nmbr$ . $nmbr$,C0456603;C1547037;C4055270
3897,cardiothoracic ratio,C0456603;C1547037;C4055270
3896,ratio of hrs ( $nmbr$ % ci )  p for sex interaction,C0008107;C0456603;C1547037;C1568891;C3259781
3896,ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C1547037;C3259781
3896,ratio ( $nmbr$ % ci ) *,C0008107;C0456603;C1547037;C3259781
3896,harzard ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
3896,harzar ratio ( $nmbr$ % ci ),C0008107;C0456603;C1547037;C3259781
3895,fevt : fvc ratio — % |,C0016529;C0456603;C1547037;C3714541
3894,ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
3894,pre - bronchodilator fev $nmbr$ / fvc ratio *,C0456603;C1547037;C2599602;C3714541
3894,post - bronchodilator ratio of fev $nmbr$ to fvc — %,C0456603;C1547037;C2599594;C3714541
3894,fev $nmbr$ : fvc ratio,C0456603;C1547037;C3714541
3894,fev $nmbr$ / fvc ratio *,C0456603;C1547037;C3714541
3893,ratio of fev $nmbr$ to fvc ( % ),C0456603;C1547037;C3714541
3893,fev $nmbr$ / fvc ratio  % ( sd ),C0456603;C1547037;C2699239;C3714541
3893,fev $nmbr$ / fvc ratio  %,C0456603;C1547037;C3714541
3892,fatty acid profile,C0015684;C1979963;C2003903
3891,fatty acid composition,C0015684;C0486616;C1555710
3890,rosuvastain + fenofibric acid   n   =   $nmbr$,C0060179
3890,rosuvastain + fenofibric acid $nmbr$ = $nmbr$,C0060179
3890,fenofibric acid   n   =   $nmbr$,C0060179
3890,fenofibric acid - i - moderate - dose statin,C0021966;C0060179;C0221138;C0360714;C1709056
3890,fenofibric acid - i - low - dose statin,C0021966;C0060179;C0221138;C0360714;C0445550;C1708745
3890,fenofibric acid $nmbr$ = $nmbr$,C0060179
3890,fenofibric acid,C0060179
3890,drosuvastatin + fenofibric acid vs . fenofibric acid monotherapy .,C0060179
3890,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0060179
3889,biguanide ( metformin ),C0005382;C0025598;C3537187;C4317165
3888,treatment with sulphonylurea + biguanide  n { % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
3888,biguanide,C0005382;C3537187;C4317165
3887,biguanides ¶,C0005382;C0360396;C3540012
3887,biguanides ( metformin ),C0005382;C0025598;C0360396;C3540012
3887,biguanides,C0005382;C0360396;C3540012
3886,taiwan,C0039260
3885,lipid trial participants - n ( % ),C0023779;C1997894;C2242969
3885,lipid trial participants #,C0023779;C1997894;C2242969
3885,lipid trial participants  no . ( % ),C0023779;C1997894;C2242969
3885,lipid trial participants,C0023779;C1997894;C2242969
3885,lioid trial participants,C1997894;C2242969
3884,type ia,C0020980;C0332307;C0694634;C1547052;C1947960
3884,simple partial ( ia ),C0020980;C0205352;C0694634;C0728938;C1550516;C1947960
3883,stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
3883,no stroke / tia,C0007787;C0038454;C0917805;C1054154;C4554100
3883,hx stroke / tia,C0007787;C0038454;C0262926;C0917805;C1054154;C3814444;C4554100
3882,prior tia,C0007787;C0332152;C0917805;C1054154;C2826257
3882,prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
3881,tia  n ( % ),C0007787;C0917805;C1054154
3881,tia,C0007787;C0917805;C1054154
3881,history of tia  n ( % ),C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
3881,hemispheric tia n = $nmbr$,C0007787;C0205139;C0917805;C1054154
3880,transient ischaemic attack — no . ( % ),C0007787;C0917805
3880,transient ischaemic attack,C0007787;C0917805
3880,prior transient ischemic attack,C0007787;C0332152;C0917805;C2826257
3879,transient ischemic attack ( % ) type of lacunar syndrome ( % ),C0007787;C0332307;C0917805;C1547052;C3178801
3879,transient ischemic attack,C0007787;C0917805
3878,estradiol quartiles,C0014912;C2828255
3877,suit quartile $nmbr$ ( b $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
3877,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
3877,suit quartile $nmbr$ ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ nmol / mmol ) ( n = $nmbr$ ),C1532564;C1533073;C2828255
3876,restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852
3876,$nmbr$ = some restrictions  no help needed,C0443288
3875,centrally acting sympathomimetics,C3653511
3874,sexually active with female,C0043210;C0086287;C0241028;C1705497;C1705498
3874,sexually active $nmbr$ ( % ),C0241028
3874,sexually active,C0241028
3873,methylxanthines,C0066447
3872,xanthines $nmbr$,C0043318;C3541955
3872,xanthines  b   n ( % ),C0043318;C3541955
3872,xanthines,C0043318;C3541955
3871,xanthine,C0043314;C0043318
3871,current xanthine derivative use,C0042153;C0043314;C0043318;C0457083;C0521116;C1527240;C1705970;C1947944
3870,on metformin ir or metformin xr $nmbr$   mg / d,C0022065;C0022071;C0025598;C1448132
3869,dmard - ir,C0022065;C0022071;C0242708;C1448132
3869,dmard - biologic ir,C0005515;C0022065;C0022071;C0205460;C0242708;C1448132
3869,bdmard - ir,C0022065;C0022071;C1448132
3868,mtx ir,C0022065;C0022071;C0025677;C1417487;C1448132
3868,mtx - ir,C0022065;C0022071;C0025677;C1417487;C1448132
3867,homa - ir score,C0022065;C0022071;C0449820;C1448132;C4050231
3867,homa - ir ( % ) b,C0022065;C0022071;C1448132
3867,homa - ir  mean ( sd ) ( mu / l $ mmol / l ) b,C0022065;C0022071;C0439190;C0439342;C0444504;C1448132;C2347634;C2348143;C2699239
3867,homa - ir  mean ( sd ),C0022065;C0022071;C0444504;C1448132;C2347634;C2348143;C2699239
3867,homa - ir,C0022065;C0022071;C1448132
3866,tnfi - ir,C0022065;C0022071;C1448132
3866,tnf - ir,C0022065;C0022071;C1448132;C1448177
3866,dmard - ir / anti - tnf - ir,C0022065;C0022071;C0242708;C1448132;C1448177
3866,anti - tnf ir,C0022065;C0022071;C1448132;C1448177
3866,anti - tnf - ir patients,C0022065;C0022071;C0030705;C1448132;C1448177
3865,pulmonary congestion ( cxr ),C0006888;C0039985;C0242073
3864,chest x - ray,C0039985
3863,r | r ' ' ' ( $nmbr$ % ci ),C0008107;C0205090;C0684010;C2603358;C3259781
3863,r elative risk ( $nmbr$ % ci ),C0008107;C0035647;C0205090;C0233492;C0684010;C2603358;C3259781;C4552904
3863,placebo r %,C0032042;C0205090;C0684010;C1696465;C1706408;C2603358
3862,r $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
3862,r $nmbr$,C0205090;C0684010;C2603358
3861,r ight coronary,C0205090;C0684010;C2603358
3861,r ight coronar y artery,C0003842;C0205090;C0226004;C0684010;C2603358
3860,r,C0205090;C0684010;C2603358
3860,n / r,C0205090;C0369718;C0441922;C0684010;C2603358
3859,right ventriculardysfunction atinclusion,C0205090;C0444532
3859,right,C0205090;C0444532
3859,c  right - sided vhd ( n = $nmbr$ ),C0205090;C0444532
3858,everolimus - eluting,C0541315
3858,everolimus,C0541315
3857,zotarolimus - eluting,C1700035
3857,zotarolimus,C1700035
3856,sirolimus eluting stent,C0038257;C0072980
3856,sirolimus - eluting stent use  n ( % ),C0038257;C0042153;C0072980;C0457083;C1947944
3856,sirolimus - eluting,C0072980
3856,sirolimus,C0072980
3855,overweight,C0497406
3855,$nmbr$ - $nmbr$ . $nmbr$ : overweight,C0497406
3855,$nmbr$ - $nmbr$ - $nmbr$  overweight,C0497406
3854,pre - procedure,C3272300
3853,subgroup w . r . t . re - cover,C0180153;C0232024;C0556581;C1079230;C1515021;C1999244;C2986904;C3888055
3853,re - medy,C0556581;C2986904
3853,re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
3853,re - cover / re - cover ii,C0180153;C0556581;C1999244;C2986904;C3888055
3853,re - cover $nmbr$ warfarin,C0180153;C0556581;C1999244;C2986904;C3888055
3853,re - cover $nmbr$ dabigatran,C0180153;C0556581;C1999244;C2986904;C3888055
3852,rolofylline rx,C0166128;C1425688;C1521941;C2709207
3851,any new anti - hyperglycemic rx,C0205314;C1425688;C1521941;C2709207
3850,alternative disability,C0231170;C1523987
3849,daily activities / social functioning,C0037395;C0871707
3849,daily activities,C0871707
3848,simplified disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869582;C4050231
3848,simplified disease activity index score,C0449820;C3869582;C4050231
3848,simplified disease activity index,C3869582
3847,clinical disease activity index score ( $nmbr$ - $nmbr$ ),C0449820;C3869583;C4050231
3847,clinical disease activity index,C3869583
3846,high disease activity : > $nmbr$ . $nmbr$  n ( % ),C0012634;C0205250;C1292728;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C4699623
3846,disease activity ( n ( % ) ),C1292728
3845,ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm )  mean ( sd ) †,C0444504;C1292728;C2347634;C2348143;C2699239;C4330985;C4554674
3845,disease activity,C1292728
3844,disease duration > $nmbr$ years  $nmbr$ [ % ] disease activity ‘ s,C0205177;C0439167;C0439234;C0441655;C0449238;C0872146;C1292728;C1561536;C2926735;C3668946;C4049938;C4049939
3844,disease activity ],C1292728
3843,eligibility risk factorsa,C0013893;C0035647;C1548635;C4552904
3842,eligibility stratum,C0013893;C1548635
3842,eligibility strata,C0013893;C1548635
3842,eligibility risk factors ’ ),C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors — n ( % ) :,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors :,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors /,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors !,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors  no . ( % ) t,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors  % t ascvo,C0013893;C0035648;C1548635;C1553898
3842,eligibility risk factors,C0013893;C0035648;C1548635;C1553898
3842,* eligibility risk factors  n ( % ) *,C0013893;C0035648;C1548635;C1553898
3841,extent of disease — no . / total no . ( % ) § ^ |,C0449279;C4553144
3841,extent of disease  n ( % ),C0449279;C4553144
3841,extent of disease  %,C0449279;C4553144
3841,extent of disease,C0449279;C4553144
3841,angiographic extent of disease,C0002978;C0449279;C4553144
3840,history of dyspepsia,C0013395;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4552968
3840,dyspepsia,C0013395;C4552968
3839,positive family history of type $nmbr$ diabetes ( % ),C0332307;C0439178;C1313937;C1446409;C1514241;C1547052;C2825490;C3812269
3839,family history ol diabetes ?,C1313937
3839,family history of diabetes ( - ),C1313937
3839,family history of diabetes ( + ),C1313937
3839,family history of diabetes ( % ) *,C1313937
3838,family history of diabetes — no . ( % ),C1313937
3838,family history of diabetes mellitus — no . { % ),C0260526;C1313937
3838,family history of diabetes mellitus — no . ( % ),C0260526;C1313937
3837,history of diabetes mellitus ( n = $nmbr$ ),C0455488
3837,history of diabetes mellitus  no . ( % ),C0455488
3837,history of diabetes mellitus  n ( % ),C0455488
3837,history of diabetes mellitus,C0455488
3836,diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
3836,diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
3835,common carotid artery sites,C0007272;C0162859;C0205145
3835,carotid artery — no . ( % ),C0007272;C0162859
3835,carotid artery diseaset,C0007272;C0162859
3835,$nmbr$ carotid artery sites,C0007272;C0162859;C0205145
3834,carotid imt,C0334121;C0741968;C1704614;C4318736
3834,carotid,C0741968
3833,ultrasound carotid arteries,C0948945
3832,carotid endarterectomy,C0014099
3831,history of carotid artery disease,C0007273;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3831,carotid artery disease,C0007273
3830,by who / simon broome criteria,C0243161;C0443058
3829,clinical criteria $nmbr$,C0205210;C0243161
3828,criterion reached first  n ( % ),C0243161
3828,criterion,C0243161
3828,criteria for subcortical vad ( by mri )  %,C0077973;C0243161;C0815275
3827,leukotriene modifier,C0023545;C0205349;C1514623;C1516451;C3542952
3826,score on modified rankin scale — no . ( % ) §,C0449820;C2984908;C3854213;C4050231
3826,score on modified rankin scale — median ( iqr ),C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C2984908;C3854213;C4050231
3826,score on modified rankin scale ( ' % / ',C0449820;C2984908;C3854213;C4050231
3826,modified rankin scale — no . ( % ) |,C2984908;C3854213
3826,modified rankin scale score,C0449820;C2984908;C3854213;C4050231
3825,unified parkinson disease,C0030567;C1521736;C1548174;C1706076
3824,unclassified,C0205426;C1546437;C2347854;C4085229
3823,unspecified,C0205370;C1549663;C2983689;C4048188
3822,pre - specified trial endpoints,C2826245
3822,pre - specified hr ( $nmbr$ % cl ),C2826245
3821,time to angiography — hr,C0002978;C0040223;C3541383
3821,time from presentation to randomization — hr,C0040223;C0449450;C3541383
3821,time from hospitalization to randomization — hr,C0019993;C0040223;C3541383
3820,time since cessation of full - dose warfarin therapy,C0040223;C3541383
3820,distribution time,C0040223;C0520511;C1704711;C3541383
3819,time since qualifying event,C0040223;C3541383
3819,time from qualifying event to randomization,C0040223;C0441471;C1514624;C3541383;C4019010
3819,time from longest event to randomisation,C0040223;C0441471;C1522425;C3541383;C4019010
3819,time from event to randomization — days,C0040223;C0441471;C3541383;C4019010
3818,time since most recent myocardial,C0040223;C3541383
3818,time from most recent qualifying,C0040223;C0332185;C1514624;C3541383
3817,time from symptoms to treatment,C0040223;C0683368;C1457887;C3541383
3817,time from symptoms to randomization  h,C0040223;C0683368;C1457887;C3541383
3817,time from symptom onset to start of fibrinolytic therapy — hr,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
3817,time from symptom onset to randomization,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
3817,time from symptom onset to enrollment,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
3817,time from symptom onset to balloon inflation,C0040223;C0449244;C1457887;C3541383;C3854129;C4086878
3816,time to first sare * ( % ),C0040223;C0205435;C1279901;C3541383
3816,time to first oral or systemic corticosteroid ( % ),C0040223;C0205435;C0442027;C1279901;C3541383;C4521986
3816,time to first morbidity / mortality event up to the end of the treatment periodd,C0026538;C0026565;C0026566;C0040223;C0205435;C0220880;C0441471;C1279901;C3541383;C4019010
3816,time to first inhaled corticosteroid ( % ),C0001617;C0004048;C0040223;C0205435;C1279901;C3536709;C3541383
3816,time to first exacerbation,C0040223;C0205435;C1279901;C3541383;C4086268
3816,time from first eval,C0040223;C0205435;C1279901;C1707957;C2698624;C3541383
3816,mean time to first subcutaneous injectiong  h in relation to surgery  hr,C0033727;C0040223;C0205435;C0369286;C0441932;C0443315;C0444504;C0564385;C1279901;C2347634;C2348143;C3541383;C4528284
3816,mean time to first oral dose postsurgeryh  hr,C0040223;C0178602;C0205435;C0442027;C0444504;C0869039;C1114758;C1279901;C2347634;C2348143;C3541383;C4521986
3816,age at time of first seizure,C0001779;C0036572;C0040223;C0205435;C1279901;C1959629;C3541383;C4553401
3815,time to rx,C0040223;C1425688;C1521941;C2709207;C3541383
3814,time from ld to pci  min  median ( q $nmbr$ – q $nmbr$ ),C0040223;C0694649;C3541383
3813,time from acs to randomization ( median  iqr ),C0040223;C0742343;C3541383;C4318612
3813,time from acs to randomization,C0040223;C0742343;C3541383;C4318612
3812,time to randomization from symptom onset,C0034656;C0040223;C3541383
3812,time to randomization ( h ),C0033727;C0034656;C0040223;C0369286;C0441932;C0564385;C3541383;C4528284
3812,time to randomization,C0034656;C0040223;C3541383
3812,time to randomisation from symptom onset ( h ),C0034656;C0040223;C3541383
3812,time since randomization,C0040223;C3541383
3812,time of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C1704675;C3541383
3812,time of randomization,C0034656;C0040223;C3541383
3812,time from randomization to pci — hr,C0034656;C0040223;C3541383
3812,time from randomization to pci ( st - elevation mi )  min,C0034656;C0040223;C3541383
3812,time from randomization to pci ( non - st - elevation mi )  h,C0034656;C0040223;C3541383
3812,time from randomization to coronary angiography — hr,C0034656;C0040223;C3541383
3812,time from randomization to cabg — hr,C0034656;C0040223;C3541383
3812,time from randomisation to $nmbr$ st balloon inflation ( h ),C0034656;C0040223;C3541383
3812,on oac at time of randomisation  n ( % ),C0034656;C0040223;C3541383
3812,at any time,C0040223;C3541383
3811,time sample drawn ( h ),C0040223;C3541383
3811,time from parkinson ’ s disease diagnosis in months  mean ( sd ),C0011900;C0030567;C0040223;C1704338;C1704656;C3541383
3810,time since prior alendronate use  n ( % ),C0040223;C3541383
3810,time ( sec ) *,C0040223;C0565930;C3541383
3809,time since start of fit  years ( meanisd ),C0040223;C3541383
3809,time since start of fit  mean ( sd )  y,C0040223;C3541383
3809,time since start insulin ( years ),C0040223;C3541383
3809,time since rheumatoid arthritis diagnosis  years,C0040223;C3541383
3809,time since psoriasis diagnosis  years $nmbr$,C0040223;C3541383
3809,time since psa onset  mean years ( sd ),C0040223;C3541383
3809,time since psa diagnosis ( years )  mean ( sd ),C0040223;C3541383
3809,time since primary diagnosis,C0040223;C3541383
3809,time since pd diagnosis  mean ± sd,C0040223;C3541383
3809,time since pah diagnosisc ( years ),C0040223;C3541383
3809,time since onset ( h ),C0040223;C3541383
3809,time since ipf diagnosisa  mean years ( sd ),C0040223;C3541383
3809,time since first psoriasis diagnosis ( y )  mean ( sd ),C0040223;C3541383
3809,time since first luts ( years ),C0040223;C3541383
3809,time since first copd diagnosis ( years ),C0040223;C3541383
3809,time since first af diagnosis  yrs,C0040223;C3541383
3809,time since epilepsy diagnosis ( years ),C0040223;C3541383
3809,time since end of fit  mean ( sd )  y,C0040223;C3541383
3809,time since diagnosis — mo,C0040223;C3541383
3809,time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
3809,time since diagnosis of type $nmbr$ diabetes - no . ( % ),C0040223;C3541383
3809,time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
3809,time since diagnosis of t $nmbr$ dm  y  n ( % ),C0040223;C3541383
3809,time since diagnosis of t $nmbr$ dm,C0040223;C3541383
3809,time since diagnosis of sle  years,C0040223;C3541383
3809,time since diagnosis of psa ( years )  mean ( sd ),C0040223;C3541383
3809,time since diagnosis of pah — yrf,C0040223;C3541383
3809,time since diagnosis of pah years #,C0040223;C3541383
3809,time since diagnosis of osteoarthritis — yr,C0040223;C3541383
3809,time since diagnosis of ln  years,C0040223;C3541383
3809,time since diagnosis of heart failure,C0040223;C3541383
3809,time since diagnosis of diabetesa  n ( % ),C0040223;C3541383
3809,time since diagnosis of diabetes — no . ( % ),C0040223;C3541383
3809,time since diagnosis of diabetes ( years ) ( median  iqr ),C0040223;C3541383
3809,time since diagnosis of diabetes  n ( % ),C0040223;C3541383
3809,time since diagnosis of diabetes  mean ( sd ),C0040223;C3541383
3809,time since diagnosis of diabetes,C0040223;C3541383
3809,time since diagnosis of copd  years,C0040223;C3541383
3809,time since diagnosis of ciu / csuf ( y ),C0040223;C3541383
3809,time since diagnosis of ciu / csu ( years ) $nmbr$,C0040223;C3541383
3809,time since diagnosis  years,C0040223;C3541383
3809,time since copd diagnosis ( yrs ),C0040223;C3541383
3809,time since cabg,C0040223;C3541383
3809,time since bph diagnosis ( years ),C0040223;C3541383
3809,time since asthma diagnosis years,C0040223;C3541383
3809,time since asthma diagnosis [ years ]  median ( range ),C0040223;C3541383
3809,time since asthma diagnosis ( years ),C0040223;C3541383
3809,time since asthma,C0040223;C3541383
3809,time since as diagnosis ( years )  mean   ±   sd,C0040223;C3541383
3809,time since as diagnosis ( years )  mean ( sd ),C0040223;C3541383
3809,time since as diagnosis  mean ( sd ) years,C0040223;C3541383
3809,mean time since diagnosis ( years ),C0040223;C0444504;C2347634;C2348143;C3541383
3809,mean time since diagnosis  y,C0040223;C0444504;C2347634;C2348143;C3541383
3809,mean time since asthma,C0040223;C0444504;C2347634;C2348143;C3541383
3809,mean time since as diagnosis  years  mean ± sd,C0040223;C0444504;C2347634;C2348143;C3541383
3808,time in trial,C0040223;C3541383
3808,percentage of time in therapeutic inr range  mean ( sd ),C0040223;C0439165;C1549488;C1561533;C3541383
3808,percent of the time that inr was in the therapeutic range,C0040223;C0439165;C3541383
3807,time in therapeutic range before inclusion,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
3807,time in therapeutic range,C0040223;C0087111;C0302350;C0460097;C1554109;C3541383
3806,components of the first cid,C0205435;C0449432;C1279901;C1707433
3805,time to first cv hospitalization or death from any cause,C0019993;C0040223;C0205435;C1279901;C3538987;C3541383;C4048877;C4318503
3805,first hospitalization for chf or cv death,C0018802;C0019993;C0205435;C1279901
3805,first hhf,C0205435;C1279901
3805,first cv hospitalization,C0019993;C0205435;C1279901;C3538987;C4048877;C4318503
3804,received first loading dose,C0205435;C1279901;C1514756;C3714444
3804,first loading dose,C0205435;C1279901;C3714444
3803,first - generation stentt,C0079411;C0205435;C1279901;C3146294
3802,first disease - progression outcome to occur §,C0205435;C0242656;C0449258;C0679250;C1274040;C1279901;C1335499;C1947900;C3542417;C4552808
3802,first diagnosed,C0205435;C1279901
3801,first co - primary outcome,C0205225;C0205435;C0439612;C0439631;C1274040;C1279901;C3245499
3801,first co - primary,C0205435;C1279901;C3245499
3800,first procedure,C0184661;C0205435;C1279901;C2700391;C3274430;C3539779
3800,first - recorded event  no . ( and % ) of patients,C0205435;C1279901
3800,first ( n = $nmbr$ ),C0205435;C1279901
3799,initial type of heparin treatment received,C0019134;C0205265;C0455708;C0770546;C1279901;C1555582;C1705685
3799,initial treatment randomization,C0034656;C0039798;C0087111;C0205265;C1279901;C1522326;C1533734;C1555582;C1705169;C1705685;C3538994;C3887704
3799,initial timi flow grade $nmbr$,C0205265;C0441800;C0919553;C1279901;C1555582;C1705685;C3244287;C3272266
3799,initial timi flow,C0205265;C1279901;C1555582;C1705685;C3272266
3799,initial heparin treatment duration on or after randomization,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
3799,initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
3799,> = $nmbr$ day s initial heparin treatment duration,C0019134;C0205265;C0332173;C0439228;C0439505;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
3799,> = $nmbr$ ^ initial heparin treatment duration,C0019134;C0205265;C0444921;C0770546;C1279901;C1555582;C1705685;C3259042
3798,initial heparin — no . ( % ) §,C0019134;C0205265;C0770546;C1279901;C1555582;C1705685
3798,initial diagnosis — no . ( % ),C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685
3797,streptokinase,C0038418
3796,degree of stenosis  % of diameter,C1301886;C4034225
3795,$nmbr$ degree of ica stenosis 丰,C0201519;C4034225
3794,extracranial carotid stenosis  n ( % ),C0007282;C0580586
3794,carotid stenosis,C0007282
3794,carotid artery stenosis  n ( % ),C0007282
3793,aortic stenosis  n ( % ),C0003507
3793,aortic stenosis,C0003507
3792,coronary artery stenosis > $nmbr$ %,C0242231
3792,> $nmbr$ % stenosis of coronary  carotid  or lower extremity arteries,C0007282;C0018787;C0242231;C0741968
3792,> $nmbr$ % coronary stenosis,C0242231
3791,osteoporosis drug,C0013227;C0029456;C1254351;C4554622
3790,prior use of osteoporosis medications  n ( % ),C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
3790,other osteoporosis medication,C0013227;C0029456;C3244316;C4284232;C4554622
3790,osteoporosis,C0029456;C4554622
3789,stricturing,C1261287
3789,maximal diameter stenosis,C0205289;C0678234;C0806909;C1261287;C1301886;C2632116;C4049713
3788,diameter stenosis  mean ( sd )  %,C0552409;C0678234;C1261287;C2632116;C2699239
3788,% stenosis ( investigator ),C0035173;C0678234;C1261287;C2632116
3788,% stenosis ( core lab ),C0678234;C1261287;C2632116;C4684837
3787,stenosis > $nmbr$ %,C0678234;C1261287;C2632116
3787,prior known stenosis > $nmbr$ %,C0205309;C0332152;C0678234;C1261287;C2632116;C2826257
3787,% stenosis  as assessed by investigator,C0678234;C1261287;C2632116
3787,% stenosis  as assessed by core laboratory,C0678234;C1261287;C2632116
3786,percent stenosis [ investigator ],C0035173;C0439165;C0678234;C1261287;C2632116
3786,percent stenosis [ core lab ],C0439165;C0678234;C1261287;C2632116;C4684837
3786,core laboratory percent stenosis,C0022877;C0439165;C0444669;C0678234;C1167518;C1261287;C1706352;C1882467;C2632116;C3244292;C3274653;C4283904
3785,steroids § §,C0038317
3785,steroids ( other ),C0038317
3785,steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
3785,steroids ( inhaled ) a,C0038317
3785,steroids  n ( % ),C0038317
3785,other steroids,C0038317
3785,no steroids ( n = $nmbr$ vs $nmbr$ ),C0038317
3784,steroid - sparing remission *,C0038317;C0544452;C0687702
3784,steroid - free remission,C0038317;C0332296;C0544452;C0687702;C1880497;C1996904
3783,statistic * *,C2348149;C2828391
3783,sample statistics,C2348149
3782,subgroup statistics,C0038215;C0600673;C1079230;C1515021
3782,statistics,C0038215;C0600673
3781,statins  n ( % ),C0360714
3781,statin without other llt,C0360714;C2347090
3781,statin with other llt,C0360714;C2347090
3781,other statin,C0360714
3781,ltt other than statin,C0360714
3781,llt other than statin at randomization,C0360714;C2347090
3781,any statin + other llt,C0360714
3781,any llt other than statins  n ( % ) b,C0360714;C2347090
3780,treatment with statins,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
3780,statins,C0360714
3780,statin treatment,C0039798;C0087111;C0360714;C1522326;C1533734;C1705169;C3538994;C3887704
3780,statin,C0360714
3779,statin monotherapy,C0360714
3779,prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
3779,no prior statin ( n = $nmbr$  $nmbr$ ),C0332152;C0360714;C2826257
3779,duration of prior statin therapy ^,C0332152;C0360714;C0444917;C2826257
3778,statin intolerant *,C0231200;C0360714
3777,moderate - dose statin,C0360714;C1709056
3777,fenofibric acid + moderate - dose statin,C0060179;C0360714;C1709056
3776,statin ( open ),C0360714
3776,peri - op statins : no ( n = $nmbr$ ),C0347985;C0360714
3775,statin ( n - $nmbr$ ),C0360714
3775,non - statin ( n = $nmbr$ ),C0360714;C1518422
3774,statin alone,C0360714
3774,no statin vs statin alone vs any statin plus other llt,C0360714
3774,no statin group,C0360714;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
3774,no statin,C0360714
3774,any statin versus no statin at randomization,C0360714
3773,statin use at study entry  n ( % ),C0360714;C0869040;C1705654
3773,statin ( % ),C0360714
3772,statin potency stratum  n ( % ),C0360714;C3245505
3772,statin  n ( % ),C0360714
3772,statin  % ( n ),C0360714
3771,taking statins  n ( % ) a,C0360714;C1515187
3771,statins 一 no . ( % ),C0360714
3771,statins  no . ( % ),C0360714
3771,statin — no . / total no . ( % ),C0360714
3770,statin only ( n = $nmbr$  $nmbr$ ),C0205171;C0360714;C1720467
3770,statin only  n ( % ),C0205171;C0360714;C1720467
3770,statin only,C0205171;C0360714;C1720467
3770,llv wlalil $nmbr$ statin,C0360714
3769,statins / ezetimibe,C0360714;C1142985
3769,statin with ezetimibe,C0360714;C1142985
3769,statin or ezetimibe,C0360714
3769,statin and / or ezetimibe,C0360714
3769,statin + ezetimibe { n = $nmbr$  $nmbr$ ),C0360714;C1142985
3769,statin + ezetimibe ( n = $nmbr$ . $nmbr$ ),C0360714;C1142985
3769,statin + ezetimibe,C0360714;C1142985
3769,statin ( n = $nmbr$ ),C0360714
3769,ezetimibe $nmbr$ mg + statin ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0360714;C0439269;C1142985;C1960952;C2346927;C4321396;C4521761
3769,eze + statin n = $nmbr$,C0360714
3768,statin with niacin,C0027996;C0360714;C1142562
3768,statin with fibrate,C0360714
3768,statin + fibrate or niacin,C0360714
3768,statin + fibrate or,C0360714
3768,statin + er niacin ( n = $nmbr$ ),C0027996;C0360714;C1142562;C3810541;C3811131
3768,niacin + statin,C0027996;C0360714;C1142562
3768,any statin ( with / without llt ),C0360714
3768,any statin,C0360714
3767,ze + statin,C0360714
3767,pbo + statin n = $nmbr$,C0031962;C0360714
3767,pbo + statin $nmbr$,C0031962;C0360714
3767,pbo + statin,C0031962;C0360714
3767,neither pbo + statin eze + statin,C0031962;C0360714
3767,eze + statin,C0360714
3766,statin use — no . { % ),C0360714
3766,statin use at baseline :,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
3766,statin use at baseline,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
3766,statin use ( % ),C0042153;C0360714;C0457083;C1947944
3766,statin use  n ( % ),C0042153;C0360714;C0457083;C1947944
3766,statin use,C0042153;C0360714;C0457083;C1947944
3766,statin usage,C0360714;C0457083
3766,statin ( s ),C0360714
3766,recurrent vte ( statin use vs non - use ),C0042153;C0360714;C0457083;C0630906;C1455761;C1947944;C2945760
3766,prior statin use ( n = $nmbr$ ),C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
3766,prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
3766,previous statin use,C0042153;C0205156;C0360714;C0457083;C1552607;C1947944
3766,no statin use,C0042153;C0360714;C0457083;C1947944
3766,no prior statin use,C0042153;C0332152;C0360714;C0457083;C1947944;C2826257
3766,high - dose statin use  n ( % ) e,C0042153;C0360714;C0444956;C0457083;C1947944
3766,baseline statin use,C0042153;C0168634;C0360714;C0457083;C1442488;C1947944
3765,use of statins,C0360714;C1524063
3765,use of statin at any follow - up visit ( % ),C0360714;C1524063
3765,statins used during follow - up,C0360714
3764,statin and / or other lipid - lowering agent therapy,C0360714
3764,combined statin and other lipid - lowering agent use,C0205195;C0360714
3763,moderate - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081855
3763,moderate - intensity statin,C0360714;C4081855
3762,high - dose statin use at screening *,C0042153;C0220908;C0220909;C0360714;C0444956;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
3762,high - dose statin,C0360714;C0444956
3761,on statins at baseline,C0168634;C0360714;C1442488
3761,baseline statin usec,C0168634;C0360714;C0439224;C1442488
3761,baseline statin,C0168634;C0360714;C1442488
3761,baseiine statin,C0360714
3760,left ventricular systolic or diastolic dysfunction,C0039155;C0225897
3759,systolic  treated at baseline,C0039155
3759,systolic  total,C0039155;C0439175;C0439810
3758,systolic pulmonary arterial pressure  mean ( sd )  mm hg,C0024109;C0039155;C0439475;C0444504;C0871470;C1168098;C2347634;C2348143;C2699239;C2707265;C2709248;C4522268
3758,systolic ( mean  sd ),C0039155;C0444504;C2347634;C2348143;C2699239
3758,systolic  mean ( sd )  mm hg h,C0025424;C0039155;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
3758,systolic,C0039155
3757,peak systolic pressure gradient,C0039155;C4687747
3756,mean systolic pressure gradient,C0039155;C4687744
3755,symbol digit score,C0449820;C0582802;C0679214;C1698987;C3241971;C4050231
3755,digit symbol substitution,C0582802;C0679214;C1555721;C1698987;C1706204;C3241971
3755,b digit symbol substitution  omega - $nmbr$ fatty acids vs placebo,C0015684;C0582802;C0679214;C1555721;C1698987;C1706204;C1719844;C3241971
3755,b digit symbol substitution  insulin glargine vs standard care,C0291665;C0582802;C0679214;C0907402;C1555721;C1698987;C1706204;C3241971
3754,systolic blood pressure subgroups,C0488055;C0871470;C1079230;C1306620
3754,systolic blood pressure  mm hq,C0488055;C0871470;C1306620;C4330985;C4554674
3754,systolic blood pressure  mean ( sd )  mm hga,C0039155;C0428886;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239;C4330985;C4554674
3754,systolic blood pressure,C0488055;C0871470;C1306620
3753,systolic blood pressure — mmhg,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure ^,C0488055;C0871470;C1306620
3753,systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0439475;C0488055;C0871470;C1306620;C1704675
3753,systolic blood pressure > $nmbr$ mm hg  n ( % ),C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure - mmhg,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure ( mmhg ),C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure  mmhg *,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure  mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
3753,systolic blood pressure  mmhg,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure  mm   hg,C0439475;C0488055;C0871470;C1306620
3753,systolic blood pressure  mm hg ^,C0439475;C0488055;C0871470;C1306620
3752,systolic pressure — mm hg,C0439475;C0871470
3752,systolic pressure  mm hg,C0439475;C0871470
3752,systolic blood pressure — mm hg,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure > $nmbr$ mm hg — no . ( % ),C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure > $nmbr$ mm hg or diastolic,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure < $nmbr$ mm hg and diastolic,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure  mm hg < $nmbr$,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure  mm hg ( sd ),C0439475;C0488055;C0871470;C1306620;C2699239
3752,systolic blood pressure  mm hg  median ( range ),C0439475;C0488055;C0549183;C0871470;C0876920;C1306620;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
3752,systolic blood pressure  mm hg  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
3752,systolic blood pressure  mm hg,C0439475;C0488055;C0871470;C1306620
3752,systolic blood pressure  ( mm hg ),C0439475;C0488055;C0871470;C1306620
3752,nob systolic blood pressure ( mm hg ),C0439475;C0488055;C0871470;C1306620
3752,mean systolic blood pressure ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
3752,mean systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
3752,mean ( s . d . ) systolic blood pressure  mm hg,C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143
3751,systolic bp at baseline :,C0168634;C0871470;C1442488
3751,systolic bp,C0871470
3751,baseline systolic bp,C0168634;C0871470;C1442488
3750,diastolic blood pressure subgroups,C0428883;C1079230;C1305849
3750,diastolic blood pressure  mm hq,C0428883;C1305849;C4330985;C4554674
3750,diastolic blood pressure  and lp ( a ),C0428883;C1305849
3749,mean ( s . d . ) diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
3749,diastolic blood pressure — mm hg,C0428883;C0439475;C1305849
3749,diastolic blood pressure - mmhg,C0428883;C0439475;C1305849
3749,diastolic blood pressure ( mmhg ),C0428883;C0439475;C1305849
3749,diastolic blood pressure ( mm hg ) medications,C0013227;C0428883;C0439475;C0802604;C1305849;C2598133;C4284232
3749,diastolic blood pressure ( mm hg ) :,C0428883;C0439475;C1305849
3749,diastolic blood pressure ( mm hg ),C0428883;C0439475;C1305849
3749,diastolic blood pressure  mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
3749,diastolic blood pressure  mmhg,C0428883;C0439475;C1305849
3749,diastolic blood pressure,C0428883;C1305849
3748,mean diastolic bp  mmhg  mean = sd,C0428883;C0439475;C0444504;C2347634;C2348143;C2699239
3748,diastolic bp ( mmhg ) *,C0428883;C0439475
3748,diastolic bp ( mmhg ),C0428883;C0439475
3748,diastolic bp ( mm hg ),C0428883;C0439475
3748,diastolic bp  mmhg ( sd ),C0428883;C0439475;C2699239
3748,diastolic bp  mmhg  mean ± sd,C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
3748,diastolic bp  mmhg,C0428883;C0439475
3748,diastolic bp  mm   hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
3748,diastolic bp  mm hg  mean ( sd ),C0012000;C0428883;C0439475;C0444504;C0488053;C2347634;C2348143;C2699239
3748,diastolic bp  mm hg,C0428883;C0439475
3748,diastolic bp,C0428883
3747,diastolic  treated at baseline,C0012000
3747,diastolic  total,C0012000;C0439175;C0439810
3746,sbp  systolic blood pressure  sd  standard deviation  dbp  diastolic blood pressure  b . p . m .  beats per minute  mi  myocardial infarction  tia  transient ischaemic attack .,C0007787;C0012000;C0033095;C0085805;C0369637;C0441923;C0460139;C0488055;C0536221;C0871420;C0871470;C1306345;C1306620;C2699239;C3813197;C4281799;C4284008
3746,diastolic,C0012000
3745,diastolic — mm hg,C0012000;C0439475
3745,diastolic — mean ( sd ) ( mm hg ),C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
3745,diastolic fmmhff ' ),C0012000
3745,diastolic blood pressure mmhg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
3745,diastolic ( mmhg ),C0012000;C0439475
3745,diastolic ( mm hg ),C0012000;C0439475
3745,diastolic  mean ( sd )  mm hg,C0012000;C0439475;C0444504;C2347634;C2348143;C2699239
3744,bronchitis,C0006277
3743,mixed chronic bronchitis and emphysema,C0008677;C0205430;C3160715
3743,chronic bronchitis ( n = $nmbr$ ),C0008677
3743,chronic bronchitis ( itt ) ( n = $nmbr$ ),C0008677
3743,chronic bronchitis ( % ),C0008677
3743,chronic bronchitis !,C0008677
3743,chronic bronchitis,C0008677
3742,spondylitis,C0038012
3742,non - spondylitis,C0038012;C1518422
3741,synovitis,C0039103
3740,chronic sinusitis + nasal polypsd  n ( % ),C0028429;C0149516;C4520890
3739,sinusitis,C0037199;C4553555
3738,minority,C0026192
3738,ethnic minority group — no . ( % ),C0015031;C0026192;C0680174;C1879937
3737,types of fibrinolytic agent,C0016018;C0332307
3737,fibrinolytic agent — no . ( % ) : t,C0016018
3736,thrombolytic agents,C0016018
3736,fibrinolytic agents before or after entry,C0016018
3736,fibrinolytic agent given,C0016018
3736,fibrinolytic agent before randomisation,C0016018;C0034656
3735,mucolytics,C0026698
3735,mucolytic agent,C0026698
3734,time from fibrinolytic therapy to study - drug administration — no . / total no . ( % ),C0013175;C0013216;C0040044;C0040223;C0040227;C0150270;C0206209;C0557651;C1611232;C2349982;C2603343;C3469597;C3541383;C3665478
3734,thrombolytic therapy,C0040044
3734,fibrinolytic therapy — no . ( % ),C0040044
3734,fibrinolytic,C0040044
3733,fibrinolytics,C0040044
3733,fibrinolytic for qualifying event,C0040044;C0441471;C1514624;C4019010
3732,pah origin / cause,C0015127;C1418251;C1524003
3731,any cause,C0015127;C1524003
3731,all cause mortality or hosp . for worsening hf hs - crp < $nmbr$ . $nmbr$ mg / l,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortality or hf hospitalization ^,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortality ( per $nmbr$ person - years ),C0015127;C0026565;C0026566;C0027361;C0439234;C0444868;C1524003;C2347489;C3539085
3731,all - cause mortality ( no . of events ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortality ( n = $nmbr$ ),C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortality,C0015127;C0026565;C0026566;C0444868;C1524003;C3539085
3731,all - cause mortalitv,C0015127;C1524003
3731,all - cause hospitalization,C0015127;C0019993;C1524003
3730,all - cause death n,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
3730,all - cause death,C0011065;C0015127;C1306577;C1524003;C4082313;C4552775
3730,all - cause,C0015127;C1524003
3729,stroke of undetermined cause,C0015127;C0038454;C1524003
3729,other cause  n ( % ),C0015127;C1524003
3729,other cause,C0015127;C1524003
3729,acute stroke of other determined cause,C0015127;C0521095;C0751956;C1524003
3728,other determined etiology,C0015127;C0521095;C1314792;C1524003
3727,range ed etiology ( n ),C0015127;C1314792;C1514721;C1524003;C2348147;C3538926;C3542016
3727,etiology ( % ),C0015127;C1314792;C1524003
3727,ed etiology  no . ( % ),C0015127;C1314792;C1524003;C3538926
3726,non - ischaemic aetiology,C0015127;C0475224;C1314792;C1518422;C1524003
3726,ischemic hf etiology,C0015127;C0018488;C0475224;C1313497;C1314792;C1524003;C1538440;C3273279
3726,ischemic etiology ( % ),C0015127;C0475224;C1314792;C1524003
3726,ischemic etiology  %,C0015127;C0475224;C1314792;C1524003
3726,ischemic etiology,C0015127;C0475224;C1314792;C1524003
3726,ischemic aetiology  n ( % ),C0015127;C0475224;C1314792;C1524003
3726,ischemic aetiology,C0015127;C0475224;C1314792;C1524003
3726,ischaemic etiology n ( % ),C0015127;C0475224;C1314792;C1524003
3726,ischaemic aetiology,C0015127;C0475224;C1314792;C1524003
3726,etiology    n   ( % ),C0015127;C1314792;C1524003
3726,etiology  n ( % ),C0015127;C1314792;C1524003
3726,etiology,C0015127;C1314792;C1524003
3726,aetiology,C0015127;C1314792;C1524003
3725,potassium - sparing diuretic,C0304490;C3536751
3724,acitretin,C0050559
3723,thiazide diuretics,C0012802
3723,thiazide diuretic *,C0012802;C3536861
3723,thiazide diuretic,C0012802;C3536861
3723,diuretic thiazide,C0012802
3723,any thiazide diuretic,C0012802;C3536861
3722,non - diabetic patients,C0241863;C1829939
3721,non - diabetics ( n = $nmbr$ ),C0241863;C1518422
3721,non - diabetics,C0241863;C1518422
3721,non - diabetic ( n = $nmbr$ ),C0241863;C1518422
3721,non - diabetic,C0241863;C1518422
3721,diabetics • no ( n = $nmbr$  $nmbr$ ),C0241863
3721,diabetics - no ( n = $nmbr$  $nmbr$ ),C0241863
3721,diabetics ( n = $nmbr$ ),C0241863
3721,diabetics,C0241863
3721,diabetic $nmbr$,C0241863
3721,diabetic,C0241863
3720,diabetic treatments !,C0087111;C0241863
3720,diabetic therapy use  n ( % ) * no therapy,C0039798;C0042153;C0087111;C0241863;C0457083;C1363945;C1947944
3720,diabetic no,C0241863
3720,diabetic ( no ),C0241863
3719,total ! by baseline diabetic status,C0168634;C0241863;C0439175;C0439810;C0449438;C1442488
3719,diabetic status,C0241863;C0449438
3719,by baseline diabetic status,C0168634;C0241863;C0449438;C1442488
3718,diabetic status  n ( % ),C0241863;C0449438
3718,diabetic  n ( % ),C0241863
3717,olmesartan along with diuretic ( n - $nmbr$ ),C0012798;C1098320
3717,diuretic ( any ),C0012798
3716,use of diuretics  n ( % ),C0012798;C1524063
3716,diuretics ( % ),C0012798
3716,diuretics  n ( % ),C0012798
3715,non diuretics,C0012798;C1518422
3715,diuretics,C0012798
3715,diuretic — no . / total no . ( % ),C0012798
3715,diuretic — no . ( % ) surgery,C0012798
3715,diuretic n ( % ),C0012798
3715,diuretic,C0012798
3714,diuretics ^,C0012798
3714,diuretics * *,C0012798
3714,diuretic subgroup,C0012798;C1079230;C1515021
3713,no - diuretics group ( n = $nmbr$ ),C0012798;C0441848
3713,diuretics group ( n = $nmbr$ ),C0012798;C0441848
3713,diuretics  %,C0012798
3712,other diuretic,C0012798
3712,diuretic use at baseline,C0012798;C0042153;C0168634;C0457083;C1442488;C1947944
3712,diuretic use,C0012798;C0042153;C0457083;C1947944
3711,median duration of diabetes ( yr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
3711,median ( q $nmbr$ : q $nmbr$ ) duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
3711,duration of diabetes in years  median ( iqr ),C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes by tertiles,C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes < $nmbr$ yrs,C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes < $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
3711,duration of diabetes ( years ) t,C0011847;C0011849;C0439234;C0449238;C2926735
3711,duration of diabetes ( years )  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,duration of diabetes ( years )  mean  ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,duration of diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
3711,duration of diabetes ( y ),C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes ( months ),C0011847;C0011849;C0439231;C0449238;C2926735
3711,duration of diabetes  yrs,C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes  years  median ( iqr ),C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
3711,duration of diabetes  years  mean ( sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,duration of diabetes  y  mean ( sd ),C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,duration of diabetes  y,C0011847;C0011849;C0449238;C2926735
3711,duration of diabetes  median ( iqr ),C0011847;C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
3711,duration of diabetes,C0011847;C0011849;C0449238;C2926735
3711,duration diabetes ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
3711,diabetes t,C0011847;C0011849
3711,diabetes duration subgroups,C0011847;C0011849;C0449238;C1079230;C2926735
3711,diabetes duration mean ± sd,C0011847;C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,diabetes duration ( years ) *,C0011847;C0011849;C0439234;C0449238;C2926735
3711,diabetes duration ( years ),C0011847;C0011849;C0439234;C0449238;C2926735
3711,diabetes duration ( y ),C0011847;C0011849;C0449238;C2926735
3711,diabetes duration ( known )  % of patients,C0011847;C0011849;C0449238;C2926735
3711,diabetes duration  years ^,C0011847;C0011849;C0439234;C0449238;C2926735
3711,diabetes duration  years ( mean ± sd ),C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
3711,diabetes duration  years,C0011847;C0011849;C0439234;C0449238;C2926735
3711,diabetes duration  ycars “,C0011847;C0011849;C0449238;C2926735
3711,diabetes duration  y,C0011847;C0011849;C0449238;C2926735
3711,diabetes duration  median ( iqr )  years,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
3711,diabetes duration,C0011847;C0011849;C0449238;C2926735
3711,diabetes ^,C0011847;C0011849
3711,diabetes $nmbr$,C0011847;C0011849
3711,diabetes  %,C0011847;C0011849
3711,diabetes,C0011847;C0011849
3710,diabetes n ( % ),C0011847;C0011849
3710,diabetes mellitus 一 no . ( % ),C0011849
3710,diabetes mellitus ( % ),C0011849
3710,diabetes mellitus  § n ( % ),C0011849
3710,diabetes mellitus  no . / total no . ( % ),C0011849
3710,diabetes mellitus  no . ( % ),C0011849
3710,diabetes mellitus  n / n ( % ),C0011849
3710,diabetes mellitus  n ( % ),C0011849
3710,diabetes mellitus  ( % ),C0011849
3710,diabetes duration  n ( % ),C0011847;C0011849;C0449238;C2926735
3710,diabetes  no . ( % ),C0011847;C0011849
3709,diabetes | | yes,C0011847;C0011849;C1549445;C1705108;C1710701
3709,diabetes | |,C0011847;C0011849
3708,no diabetes,C0011847;C0011849
3708,duration of diabetes microvascular disease — no . ( % ),C0011847;C0011849;C0443258;C0872146
3708,diabetes — no . ( % ),C0011847;C0011849
3708,diabetes mellitus — no . ( % ),C0011849
3707,new diabetes — no . ( % ),C0011847;C0011849;C0205314
3707,new diabetes,C0011847;C0011849;C0205314
3706,hx of diabetes  n ( % ),C0011847;C0011849;C0262926;C3814444
3706,history of diabetes - n ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3706,history of diabetes ( % ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3706,diabetes ( % ),C0011847;C0011849
3705,comorbidities other than diabetes,C0009488;C0011847;C0011849
3704,diabetes medication,C0011847;C0011849;C0013227;C3244316;C4284232
3704,diabetes and untreated hypertension,C0011847;C0011849
3703,short ( < $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439593
3703,long ( i $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0021966;C0221138;C0439234;C0439591
3703,long ( > $nmbr$ years ) duration of diabetes,C0011847;C0011849;C0439234;C0439591
3702,postbaseline new - onset diabetes - n ( % ),C0011847;C0011849;C0746890
3702,non - diabetes,C0011847;C0011849;C1518422
3702,no diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
3702,new - onset diabetes §,C0011847;C0011849;C0746890
3702,new - onset diabetes,C0011847;C0011849;C0746890
3702,diabetes ( n - $nmbr$  $nmbr$ ),C0011847;C0011849
3701,diabetes mellitust,C0011847;C0011849
3701,diabetes mellitus :,C0011849
3701,diabetes mellitus !,C0011849
3701,diabetes melitus,C0011847;C0011849
3701,diabetes etiology,C0011847;C0011849;C0015127;C1314792;C1524003
3700,diabetes treatment,C0011847;C0011849;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3700,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849
3699,without diabetes,C0011847;C0011849
3699,with diabetes,C0011847;C0011849
3699,patients without diabetes,C0011847;C0011849;C0030705
3699,patients with diabetes,C0011847;C0011849;C0030705
3698,diabetes with target organ disease *,C0011847;C0011849;C0012634;C0178784;C1521840;C2986546
3698,diabetes *,C0011847;C0011849
3697,high risk of diabetes,C0011847;C0011849;C0332167
3697,high risk for diabetes *,C0011847;C0011849;C0205250;C0332167;C1171304;C1299351;C2700149;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
3696,undiagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C1408353
3696,no diabetes ( n = $nmbr$  $nmbr$ ),C0011847;C0011849
3696,diagnosed diabetes ( n = $nmbr$ ),C0011847;C0011849;C0011900
3696,diabetes mellitus [ n ( % ) ],C0011849
3696,diabetes ( n [ % ] ) *,C0011847;C0011849
3696,diabetes ( n = $nmbr$ ),C0011847;C0011849
3696,diabetes  n ( % ),C0011847;C0011849
3696,diabetes  * n ( % ),C0011847;C0011849
3696,current cvd / diabetes  n ( % ),C0007222;C0011847;C0011849;C0521116;C1705970
3696,all without diabetes ( n = $nmbr$ ),C0011847;C0011849
3696,all with diabetes ( n = $nmbr$ ),C0011847;C0011849
3695,other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ ),C0011847;C0011849;C1704675
3695,no diabetes ( p = . o $nmbr$ ),C0011847;C0011849
3695,no diabetes ( p = . $nmbr$ ),C0011847;C0011849
3695,diabetes present $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849;C0150312;C0449450
3695,diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ ),C0011847;C0011849
3695,diabetes ( p = . oo $nmbr$ ),C0011847;C0011849
3695,diabetes ( p = . o $nmbr$ ),C0011847;C0011849
3695,diabetes ( p = . $nmbr$ ),C0011847;C0011849
3695,diabetes $nmbr$ ( % ),C0011847;C0011849
3695,diabetes  no . ( % ) c,C0011847;C0011849
3694,people without diabetes n = $nmbr$,C0011847;C0011849;C0027361
3694,people with diabetes n = $nmbr$,C0011847;C0011849;C0027361
3694,individuals without diabetes  n = $nmbr$  $nmbr$,C0011847;C0011849;C0027361;C0237401
3694,individuals with diabetes  n = $nmbr$,C0011847;C0011849;C0027361;C0237401
3693,diabetes mellitus classification,C0008902;C0008903;C0011849;C0678229
3692,fasting glucose mg / dl diabetes classification,C0008902;C0008903;C0011847;C0011849;C0015663;C0017725;C0439269;C0678229
3692,diabetes classificationa,C0011847;C0011849
3691,undiagnosed diabetes mellitus  n = $nmbr$,C0011849;C1408353
3691,undiagnosed diabetes mellitus,C0011849;C1408353
3690,primary and secondary prevention subgroups  adjusted for age  gender  hypertension  diabetes mellitus  and smoking . hr indicates hazard ratio  $nmbr$ % cl  $nmbr$ % confidence interval  tia  transient ischemic attack .,C0007787;C0011849;C0205225;C0439612;C0439631;C1272706;C1552654;C1552713
3690,diabetes mellitus  %,C0011849
3689,patients without diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
3689,patients with diabetes mellitus ( n = $nmbr$ ),C0011849;C0030705
3689,patients with diabetes mellitus,C0011849;C0030705
3689,diabetes mellitus n = $nmbr$  $nmbr$,C0011849
3689,diabetes mellitus  n = $nmbr$,C0011849
3689,diabetes mellitus,C0011849
3688,reported diabetes mellitus,C0011849;C0684224;C0700287;C4319718
3688,no diabetes mellitus,C0011849
3688,diabetes mellitus — no . / total no . ( % ),C0011849
3687,previous diabetes mellitus,C0011849;C0205156;C1552607
3687,previous diabetes,C0011847;C0011849;C0205156;C1552607
3687,no previous diagnosis of diabetes mellitus,C0011849;C0332132
3686,no oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
3686,insulin + oral antidiabetic medication ( s ),C0021641;C0175795;C0442027;C0935929;C1533581;C1579433;C3714501;C4521986
3686,antidiabetic medications,C0935929
3686,antidiabetic medication | |,C0935929
3686,antidiabetic medication,C0935929
3686,> $nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
3686,$nmbr$ oral antidiabetic medication,C0175795;C0442027;C0935929;C4521986
3685,previous oral antidiabetic medication use  n ( % ),C0205156;C0935929;C1527415;C1552607
3685,antidiabetic agents,C0935929
3685,antidiabetic agent,C0935929
3685,antidiabetic,C0935929
3684,no antidiabetic drug,C0935929
3684,antidiabetic drug ‘ i “ j ‘,C0021966;C0221138;C0935929
3684,antidiabetic drug,C0935929
3683,lesion characteristics,C1286326
3682,anatomic complexity characteristics,C0439855;C0502371;C1704241
3681,selected clinical characteristics — no . / total no . ( % ),C0683325;C1707391
3681,selected clinical characteristics  n ( % ),C0683325;C1707391
3681,selected clinical characteristics,C0683325;C1707391
3681,other clinical characteristics,C0683325
3681,clinical characteristics ( % ),C0683325
3681,clinical characteristics  n ( % ),C0683325
3681,clinical characteristics,C0683325
3680,% improvement in dactylitis score at week $nmbr$  n,C0239161;C0449820;C2986411;C4050231
3679,dactylitis score at baseline  median ( iqr ) week $nmbr$,C0168634;C0239161;C0332174;C0439230;C0449820;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193;C4050231
3679,dactylitis score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0239161;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
3679,dactylitis score ( $nmbr$ - $nmbr$ ),C0239161;C0449820;C4050231
3679,dactylitis score,C0239161;C0449820;C4050231
3679,dactylitis,C0239161
3678,presence of dactylitis  n ( % ),C0150312;C0239161;C0392148;C3854307
3678,dactylitis  n ( % ),C0239161
3678,dactylitis  % #,C0239161
3677,uveitis,C0042164;C1963266
3676,bursitis,C0006444
3675,ulcerative colitis,C0009324
3675,duration of ulcerative colitis,C0009324;C0449238;C2926735
3674,tendonitis,C0039503
3673,pancolitis,C0868908
3673,extensive / pancolitis,C0205231;C0868908
3672,pharyngitis,C0031350;C4553308
3671,nasopharyngitis,C0027441
3670,spondylitis with peripheral arthritis,C0038012;C0238694
3669,asymmetric peripheral arthritis,C0238694;C0332514
3668,polyarticular arthritis  no rheumatoid nodules,C0162323
3667,arthritis mutilans,C0702102
3666,dip joint arthritis,C0003864;C0932510;C4552845
3665,arthritis type *,C0003864;C0332307;C1547052;C4552845
3665,arthritis characteristics,C0003864;C1521970;C4552845
3665,arthritis,C0003864;C4552845
3664,cystitis,C0010692;C0600041;C1963088
3663,osteitis,C0029400
3662,rhinitis,C0035455
3661,diagnosis of allergic rhinitis,C0011900;C1334103;C1704338;C1704656;C2607914;C4552864
3661,allergic rhinitis — no . ( % ),C1334103;C2607914;C4552864
3660,allergic rhinitis duration  mean ± sd  y *,C0444504;C0449238;C1334103;C2347634;C2348143;C2607914;C2699239;C2926735;C4552864
3660,allergic rhinitis,C1334103;C2607914;C4552864
3659,delighted,C3830544
3658,st ( arc definite only ),C0036056;C0205171;C0439544;C1704787;C1720467;C3272372
3658,definite,C0439544;C1704787
3658,$nmbr$ days definite st,C0036056;C0439228;C0439544;C1704787;C3272372
3657,no des,C0011702;C4551552
3657,new des ( n = $nmbr$ ),C0011702;C0205314;C4551552
3657,des implantation for restenosis  n ( % ),C0011702;C0021107;C0029976;C0333186;C4551552
3656,with des,C0011702;C4551552
3656,des ( % previous stenting ),C0011702;C0038257;C0205156;C1552607;C2348535;C4551552
3656,des,C0011702;C4551552
3655,iglar ( insulin glargine l $nmbr$ u ),C0439148;C0907402
3654,insulin dose ( u ),C0366513;C0439148
3654,insulin dose  u,C0366513;C0439148
3653,cmann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
3653,amann whitney u test / wilcoxon sum rank test .,C0439148;C0667477;C0683443;C0699794;C1515051
3652,or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
3651,mtss units,C0439148;C1519795;C3853603
3651,% anti - ccp + ( > $nmbr$ units ),C0439148;C1519795;C3853603;C4318437
3650,= international prostate symptom score,C1998280
3649,total ipss,C0439175;C0439810;C1019118;C1998280;C2827405;C3811063
3649,mild / moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
3649,mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),C0439175;C0439810;C0444504;C0578022;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
3649,mean total ipss ( sd ),C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
3649,mean ipss  voiding subscore ( sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
3649,ipss voiding subscore,C1019118;C1998280;C2827405;C3811063
3649,ipss total score,C1019118;C1998280;C2827405;C2964552;C3811063
3649,ipss hrql,C1019118;C1998280;C2827405;C3811063
3649,ipss categories,C0683312;C1019118;C1998280;C2827405;C3811063
3649,ipss ( unit ),C0439148;C0439453;C1019118;C1509845;C1519795;C1704753;C1880519;C1998280;C2827405;C3811063;C3853603
3649,ipss ( mean ± sd ),C0444504;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
3649,ipss ( ls mean ± se ),C0023668;C0036919;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C3811063
3649,ipss,C1019118;C1998280;C2827405;C3811063
3649,baseline total ipss  mean ( sd ),C0168634;C0439175;C0439810;C0444504;C1019118;C1442488;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
3649,baseline total ipss,C0168634;C0439175;C0439810;C1019118;C1442488;C1998280;C2827405;C3811063
3649,( ngml ' ' ) total mean ipss score,C0439175;C0439810;C0444504;C1019118;C1998280;C2347634;C2348143;C2827405;C2964552;C3533236;C3811063
3648,mean ipss  storage sub - score ( sd ),C0337174;C0542339;C1019118;C1264637;C1698986;C1753314;C1998280;C2699239;C2827405;C3533236;C3811063
3648,ipss - v,C1019118;C1998280;C2827405;C3811063
3648,ipss - s,C1019118;C1998280;C2827405;C3811063
3648,ipss  “ / o,C1019118;C1998280;C2827405;C3811063
3647,two or more at baseline,C0205448
3647,two or more antihypertensive medications,C0205448
3647,two or more,C0205448
3647,two lesions,C0205448;C0221198
3646,ast > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1415181;C1512346;C1519815;C1707491;C3891303
3646,alt > $nmbr$ x uln on two consecutive visits,C0205448;C0545082;C1266129;C1512346;C1519815;C1707491;C4553172
3645,two of the above,C0205448
3645,two agents,C0205448;C0450442;C1254351;C1521826
3644,good / moderate response,C0205170;C4085643
3643,good control ( < $nmbr$ ),C0205170;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
3643,good,C0205170
3642,question $nmbr$ ( pain / swelling in joints other than neck / back / hips ),C0003862;C0013604;C0038999;C1522634
3641,swollen,C0038999
3641,number of swollen joints ( $nmbr$ assessed ),C0038999;C0449813
3641,number of swollen joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0038999;C0444504;C0449813;C2347634;C2348143;C2699239
3641,number of swollen joints ( $nmbr$ - $nmbr$ ),C0038999;C0449813
3640,swollen joints > $nmbr$  n ( % ),C0152031
3640,joint swelling  effusion  or both on clinical examination — no . ( % ),C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
3640,joint swelling  effusion  or both on clinical examination,C0013604;C0013687;C0038999;C0152031;C1253936;C1963136;C2317432;C4554335
3640,joint swelling,C0152031
3639,swollen joint count ( n / $nmbr$ ),C0451521
3639,swollen joint count ( $nmbr$ joints ),C0451521
3639,swollen joint count ( $nmbr$ - $nmbr$ possible joints ),C0332149;C0451521;C1705910;C2362652
3639,swollen joint count ( $nmbr$ - $nmbr$ joints ),C0451521
3639,swollen - joint count ( of $nmbr$ joints ),C0451521
3638,swollen joint count of $nmbr$ joints,C0451521
3638,swollen joint count ( range $nmbr$ - $nmbr$ joints ),C0451521;C1514721;C2348147;C3542016
3638,swollen joint count  of $nmbr$,C0451521
3638,swollen - joint count ( of $nmbr$ joints assessed ) — no .,C0451521
3638,swollen - joint count  of $nmbr$ joints examined,C0451521
3637,swollen joints ( $nmbr$ - joint count )  mean ± sd,C0444504;C0451521;C2347634;C2348143;C2699239
3637,swollen joint count ( $nmbr$ — $nmbr$  per swollen joint ),C0451521
3637,swollen joint count ( $nmbr$ – $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
3637,swollen joint count ( $nmbr$ joints )  mean ( sd ) ’,C0444504;C0451521;C2347634;C2348143;C2699239
3637,swollen joint count ( $nmbr$ joints )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
3637,swollen joint count ( $nmbr$ - $nmbr$ ),C0451521
3637,swollen joint count ( $nmbr$ )  mean ( sd ),C0444504;C0451521;C2347634;C2348143;C2699239
3637,swollen joint count,C0451521
3637,mean ( sd ) swollen joint count *,C0444504;C0451521;C2347634;C2348143;C2699239
3636,odds ‐ ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
3636,odds ratios ( $nmbr$ % ci ),C0008107;C0028873;C3259781
3636,odds ratio versus placebo ( $nmbr$ % ci ),C0028873
3636,odds ratio ( $nmbr$ % ci ),C0008107;C0028873;C3259781
3635,odds ratio and $nmbr$ % cl,C0028873
3635,odds ratio adj ( $nmbr$ % cl ),C0001552;C0028873;C0596019;C2826286
3635,odds ratio ( $nmbr$ % cl ),C0028873;C0596019
3634,odds ratio,C0028873
3634,estimated odds ratio,C0028873;C0750572
3634,ap = $nmbr$ . $nmbr$  bp $nmbr$ . $nmbr$  cp = $nmbr$ . $nmbr$ . * the study - speci ﬁ c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg ( or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm ) . the ldl - c target was $nmbr$ mg / dl or $nmbr$ mg / dl  depending on risk factor status at baseline in accordance with ncep atp iii guidelines . odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site . an interaction between treatment effect and dm status was observed for bp goal attainment ( p = $nmbr$ . $nmbr$ ) and dual bp / ldl - c goal attainment ( p = $nmbr$ . $nmbr$ ) among patients with or without dm calculated based on a mixed - effects linear model ( not adjusted for differences in baseline values ) . abbreviations : bp  blood pressure  dbp  diastolic blood pressure  dm  diabetes mellitus  ldl - c  low - density lipoprotein cholesterol  ncep atp iii  national cholesterol education program – adult treatment panel iii  or  odds ratio  sbp  systolic blood pressure,C0001675;C0002680;C0006938;C0011816;C0011849;C0023732;C0025424;C0025663;C0028873;C0030705;C0033095;C0035648;C0037623;C0039798;C0065055;C0085805;C0086858;C0087111;C0162791;C0168634;C0178587;C0205145;C0205246;C0205430;C0220845;C0282423;C0428257;C0428883;C0439070;C0439475;C0441833;C0445247;C0449438;C0449851;C0456081;C0460139;C0552449;C0680230;C0750572;C0871511;C1306345;C1415692;C1442488;C1515974;C1521840;C1522326;C1533734;C1705160;C1705169;C1705241;C1705242;C1706365;C1706450;C1708288;C1999270;C2347108;C2347109;C2348272;C2744579;C2825164;C2986546;C3160715;C3245503;C3250443;C3538994;C3887704;C3887950;C4050020;C4068104;C4284008;C4318478;C4552600
3633,method used to diagnose the incident pulmonary embolism  no . ( % ),C0025663;C0449851;C0871511
3633,method of assessing ejection fraction,C0025663;C0302131;C0336969;C0449851;C0812388;C0871511;C1264633;C1516048
3632,option,C1518601;C1550456
3631,location of ml,C0439526;C0450429;C1515974;C1705224;C3887665;C4284930;C4284931
3631,location of infarction — no . ( % ) §,C0021308;C0450429;C1515974;C4284930;C4284931
3631,location of infarction,C0021308;C0450429;C1515974;C4284930;C4284931
3631,location of disease  n ( % ),C0012634;C0450429;C1515974;C4284930;C4284931
3631,location of crohn ' s disease  %,C0010346;C0450429;C1515974;C4284930;C4284931
3631,location  n ( % ),C0450429;C1515974;C4284930;C4284931
3631,location,C0450429;C1515974;C4284930;C4284931
3631,lesion location,C0221198;C0450429;C1515974;C1546698;C4284930;C4284931
3631,infarct related artery location,C0003842;C0021308;C0226004;C0439849;C0445223;C0450429;C1515974;C4284930;C4284931
3631,infarct location — no . / total no . ( % ),C0021308;C0450429;C1515974;C4284930;C4284931
3631,infarct location anterior,C0021308;C0450429;C1515974;C4284930;C4284931
3631,infarct location ( interactsn $ : p = $nmbr$ . $nmbr$ ),C0021308;C0450429;C1515974;C4284930;C4284931
3631,infarct location,C0021308;C0450429;C1515974;C4284930;C4284931
3631,ethnicity  location,C0015031;C0243103;C0450429;C1515974;C4284930;C4284931
3631,disease location  %,C0012634;C0450429;C1515974;C4284930;C4284931
3631,anterior infarct location,C0340293;C0450429;C1515974;C2349195;C4284930;C4284931
3630,propafenone,C0033429
3629,proportion taking pulmonary medications ( % ) b,C1709707
3629,fvc ( l ) proportion taking pulmonary medications ( % ) b,C1709707;C3714541
3628,proportion of predicted normal fev $nmbr$ value   §,C0086715;C0520835;C0681842;C1522609;C1709707;C1882327;C3714541
3628,proportion,C1709707
3627,proportions  n ( % ),C1709707
3627,proportion of responders n / n ( % ),C1709707
3627,blood eosinophil proportion ( % ),C0014467;C1709707
3626,proportion of days without heartburn at week $nmbr$  percentage,C0439228;C1709707
3626,proportion of angioedema - free days from week $nmbr$ to week $nmbr$ x,C0002994;C0332296;C0439228;C1709707;C1880497;C1996904
3625,dapagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C2353951
3625,dapagliflozin  n *,C2353951
3624,dapagliflozin ( n = $nmbr$ ),C2353951
3624,dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
3624,dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ ),C0021641;C0024671;C0026410;C0439269;C1533581;C1579433;C1960952;C2346927;C2353951;C3714501;C4321396;C4521761
3624,dapagliflozin,C2353951
3623,sotagliflozin ( n = $nmbr$ ),C3896939
3623,sotagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3896939;C4321396;C4521761
3623,sotagliflozin,C3896939
3622,empagliflozin ( n   =   $nmbr$ ),C3490348
3622,empagliflozin ( n = $nmbr$ ),C3490348
3622,empagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C3490348
3622,empagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
3622,empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
3622,empagliflozin,C3490348
3622,$nmbr$ mg empagliflozin,C0024671;C0026410;C0439269;C1960952;C2346927;C3490348;C4321396;C4521761
3621,pooled empagliflozin ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
3621,empagliflozin pooled ( n = $nmbr$ ),C1709595;C2349200;C3490348;C4522255
3621,empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C3490348
3620,ertugliflozin $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin $nmbr$ mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
3620,ertugliflozin,C4079805
3619,canagliflozin dose,C0178602;C0869039;C1114758;C2974540
3619,canagliflozin ( n = $nmbr$ ),C2974540
3619,canagliflozin,C2974540
3618,without tamsulosin,C0257343
3618,with tamsulosin,C0257343
3618,tamsulosin ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0257343
3618,tamsulosin ( n = $nmbr$ ),C0257343
3618,tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
3618,tamsulosin,C0257343
3617,no digoxin scd  no . ( % / y ),C0012265
3617,no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % ),C0012265
3617,digoxin scd  no . ( % / y ),C0012265
3617,digoxin n = $nmbr$ ( $nmbr$ % ),C0012265
3617,digoxin n ( % ),C0012265
3617,digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
3617,digoxin  n ( % ),C0012265
3617,digoxin  ( % ),C0012265
3617,digoxin  % ( n ),C0012265
3617,digoxin  %,C0012265
3617,digoxin,C0012265
3616,previous use of digoxin,C0012265;C0205156;C1524063;C1552607
3616,digoxin or digitalis preparations,C0012265
3616,digoxin or digitalis preparation,C0012265
3616,digoxin or digitalis glycoside,C0012265
3615,whitea,C1021495
3614,white hispanic - n ( % ),C1533020;C1533021
3614,white hispanic,C1533020;C1533021
3613,with highest bwa,C0006041;C1522410
3613,highest killip classiciation pre - pci,C1522410
3612,highest,C1522410
3612,age of completion of highest education  years ( sd ),C0013621;C0013622;C0013658;C0039401;C0205197;C1510829;C1522410;C1554962;C2699239
3611,hrg,C1437978;C1705020
3610,hmg - coa reductase inhibitors,C0360714;C2756999;C3539119
3609,no high - intensity statin,C0360714;C4081854
3609,high ‐ intensity statins ‡,C0360714;C4081854
3609,high intensity,C4081854
3609,high - intensity statin vs medium - or low - intensity statin at randomization,C0360714;C4081854
3609,high - intensity statin use,C0042153;C0360714;C0457083;C1947944;C4081854
3609,high - intensity statin *,C0360714;C4081854
3609,high - intensity statin,C0360714;C4081854
3608,stent thrombosis *,C3897493
3608,any risk factor for stent thrombosis,C0035648;C3897493
3607,stent thrombosis or mi,C3897493
3607,stent thrombosis - related mi,C3897493
3607,non stent thrombosis - related mi,C1518422;C3897493
3606,stent thrombosis,C3897493
3606,definite acute stent thrombosis,C0205178;C0439544;C1704787;C3897493
3606,acute stent thrombosis ( definite or probable ),C0205178;C3897493
3606,acute stent thrombosis,C0205178;C3897493
3605,stent thrombosis arc definite / probable,C0033204;C0332148;C0439544;C1704787;C3897493
3605,definite stent thrombosis,C0439544;C1704787;C3897493
3604,antithrombin,C0003438;C0003440;C4521254
3603,direct thrombin inhibitors,C0003440;C3541936
3602,thrombus - containing lesion,C0087086;C0221198;C0302148;C0332256;C1546698;C2700400;C3146237
3601,thrombus aspiration done per lesion †,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
3601,thrombus aspiration,C0087086;C0220787;C0302148;C0349707;C0700198;C2712334;C2827071;C3146237
3600,increased - risk for thrombotic cardiovascular,C0007226;C0087086;C3887460;C4699158
3600,anti - thrombotics,C0087086
3599,phenytoin,C0031507;C0202454
3598,glucosamine + chondroitin sulfate,C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
3598,chondroitin,C0008454
3597,glucosamine + chondroitin sulfate ( n = $nmbr$ ),C0008454;C0008466;C0017718;C0017720;C0038720;C0474702;C0475337;C0876712;C3536965
3597,chondroitin sulfate ( n = $nmbr$ ),C0008466
3597,chondroitin sulfate,C0008466
3596,medical history of diabetic retinopathy §,C0011884;C0262926
3595,other medical history — no . / total no . ( % ),C0262926;C1704706
3595,other medical history — no . ( % ),C0262926;C1704706
3595,other medical history  no . ( % ),C0262926;C1704706
3595,medical history — no . / total no . ( % ),C0262926;C1704706
3595,medical history — no . ( % ),C0262926;C1704706
3595,medical history — %,C0262926;C1704706
3595,medical history at randomization — no . ( % ),C0034656;C0262926;C1704706
3595,medical history and risk factors — no . ( % ),C0262926;C1704706
3595,medical history and risk factors  no . / total ( % ) *,C0262926;C1704706
3595,medical history . no . ( % ),C0262926;C1704706
3595,medical history  no . ( % ),C0262926;C1704706
3594,white  n ( % ) medical history  n ( % ),C0007457;C0043157;C0220938;C0262926;C1704706
3594,medical history ( % ),C0262926;C1704706
3594,medical history    n   ( % ),C0262926;C1704706
3594,medical history  n ( % ),C0262926;C1704706
3594,medical history,C0262926;C1704706
3593,medical history and risk factors ( % ),C0262926;C1704706
3593,medical history and risk factors,C0262926;C1704706
3593,medical history : cancer,C0006826;C0262926;C0998265;C1306459;C1704706
3592,hx mi or stroke,C0262926;C3810814;C3814444
3591,hx cabg,C0010055;C0262926;C3814444
3590,htn hx,C0020538;C0262926;C3814444
3589,vascular history  %,C0005847;C0019664;C0019665;C0262512;C0262926;C1558950;C1705255;C1801960;C2004062
3589,prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1514463;C1705255;C2004062
3589,prior cv history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
3589,prior cv history,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3538987;C4048877;C4318503
3589,oad history  years,C0019664;C0019665;C0262512;C0262926;C0439234;C1705255;C2004062
3589,history of or current cardiac disorders  %,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3589,gout history  mean ± sd years,C0018099;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
3589,copd history yrs,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
3589,cardiac history  %,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
3589,cardiac history,C0018787;C0019664;C0019665;C0262512;C0262926;C1522601;C1705255;C2004062
3589,atherosclerotic vascular disease history  no . ( % ) ‡,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3588,seizure history  n ( % ),C0019664;C0019665;C0036572;C0262512;C0262926;C1705255;C1959629;C2004062;C4553401
3588,presenting history or diagnosis — no . ( % ),C0019664;C0019665;C0262512;C0262926;C0449450;C1705255;C2004062
3588,history of gi bleeding or ulcer — no . / total no . ( % ),C0017181;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3588,history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3588,copd exacerbation history in the previous year  n ( % ),C0019664;C0019665;C0205156;C0262512;C0262926;C0439234;C0439508;C0740304;C1552607;C1705255;C2004062
3588,copd exacerbation history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0740304;C1705255;C2004062
3588,clinical history — no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
3588,cad history and risk factors  n ( % ),C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
3588,baseline copd exacerbation history  * n ( % ),C0019664;C0019665;C0168634;C0262512;C0262926;C0740304;C1442488;C1705255;C2004062
3588,any cvd history ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,selective vascular history,C0005847;C0019664;C0019665;C0036576;C0262512;C0262926;C1558950;C1705255;C1707391;C1801960;C2004062
3587,revascularization history,C0019664;C0019665;C0262512;C0262926;C0581603;C1705255;C2004062
3587,prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
3587,prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257;C3810814
3587,prior history ml or stroke,C0019664;C0019665;C0262512;C0262926;C0332152;C0439526;C1705224;C1705255;C2004062;C2826257;C3887665
3587,percentage unless otherwise noted . cabg indicates coronary artery bypass graft  lvh  left ventricular hypertrophy  nsaids  nonsteroidal antiinflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ‘ history of hypercholesterolemia or reporting use of lipid - lowering medications at baseline . thistory of or currently have elevated serum creatinine level < $nmbr$ mg / dl . tbased on participant history or review of chart .,C0003211;C0007787;C0013227;C0019664;C0019665;C0020443;C0023779;C0042373;C0085096;C0149721;C0262512;C0262926;C0439165;C0441994;C0455536;C0679646;C0700287;C0802604;C0917805;C1054154;C1522133;C1524063;C1549488;C1561533;C1705255;C2003888;C2004062;C2598133;C2698741;C4284232;C4521226;C4554048
3587,pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,participants without a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
3587,participants with a history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
3587,parental history of ml before age $nmbr$ y yes,C0019664;C0019665;C0030551;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,parental history of mii,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062
3587,parental history of mi before age $nmbr$ y,C0019664;C0019665;C0030551;C0262512;C0262926;C1705255;C2004062;C3810814
3587,no history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
3587,no history of paroxysmal af,C0019664;C0019665;C0235480;C0262512;C0262926;C1705255;C2004062
3587,no history of extra - intestinal manifestations of ibd ( ref ),C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1425988;C1705255;C1883702;C2004062
3587,no history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,no history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
3587,no history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
3587,history pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,history ol mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history ol coronary revascularization *,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
3587,history ol chd at baselines,C0019664;C0019665;C0168634;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of vte * *,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
3587,history of vte,C0019664;C0019665;C0262512;C0262926;C0630906;C1705255;C2004062
3587,history of upper gi events ( perforations  ulcers and bleeding ) n ( % ),C0019664;C0019665;C0041582;C0203057;C0262512;C0262926;C0441471;C0549099;C1705255;C2004062;C3541888
3587,history of upper,C0019664;C0019665;C0262512;C0262926;C1282910;C1705255;C2004062
3587,history of tia or stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
3587,history of tia / stroke,C0007787;C0019664;C0019665;C0262512;C0262926;C0917805;C1054154;C1705255;C2004062
3587,history of symptomatic,C0019664;C0019665;C0231220;C0262512;C0262926;C1705255;C2004062
3587,history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of stroke †,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke or transient ischemic attack,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke or tia - n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke at baseline,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke / see / tia,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke * *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke *,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke $nmbr$,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke  n ( % ),C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of stroke,C0019664;C0019665;C0038454;C0262512;C0262926;C1705255;C2004062;C4554100
3587,history of statin use,C0019664;C0019665;C0262512;C0262926;C0360714;C1524063;C1705255;C2004062
3587,history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,history of pci / ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C2936173;C4049621
3587,history of pci  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4049621
3587,history of parental myocardial,C0019664;C0019665;C0027061;C0030551;C0262512;C0262926;C1522564;C1705255;C2004062
3587,history of pad,C0019664;C0019665;C0182158;C0262512;C0262926;C0332568;C1705255;C2004062;C3540603;C3669270;C3814046;C4319657
3587,history of nicotine use,C0019664;C0019665;C0028040;C0262512;C0262926;C1524063;C1705255;C2004062
3587,history of more than $nmbr$ prior mi ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,history of ml before index event,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,history of ml,C0019664;C0019665;C0262512;C0262926;C0439526;C1705224;C1705255;C2004062;C3887665
3587,history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of mi or stroke  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of mi or stroke  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history of macroalbuminuriat  n ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of lvh on electrocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
3587,history of lvh on echocardiogram,C0019664;C0019665;C0149721;C0262512;C0262926;C1705255;C2004062
3587,history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C0948008;C1705255;C2004062
3587,history of htn  %,C0019664;C0019665;C0020538;C0262512;C0262926;C1705255;C2004062
3587,history of high cholesterol ( a ) $nmbr$,C0019664;C0019665;C0020443;C0262512;C0262926;C1522133;C1705255;C2004062
3587,history of h pylori eradication *,C0019664;C0019665;C0079488;C0262512;C0262926;C1705255;C2004062
3587,history of extra - intestinal manifestations of ibd,C0019664;C0019665;C0021853;C0262512;C0262926;C1280464;C1705255;C1883702;C2004062
3587,history of diabetes { p = $nmbr$ * $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of diabetes requiring drugs,C0011847;C0011849;C0019664;C0019665;C0020616;C0262512;C0262926;C1553893;C1705255;C2004062
3587,history of diabetes nyha class,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C1882083;C2004062
3587,history of diabetes :,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of diabetes ( n = $nmbr$ ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of diabetes ( a ),C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of diabetes,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of cvd and of cv risk factors - no . ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of cvd,C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
3587,history of coronary revascularization  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
3587,history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
3587,history of copd,C0019664;C0019665;C0024117;C0262512;C0262926;C1412502;C1705255;C2004062;C3714496
3587,history of chf before index event,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of chf - n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of chf  nyha class ii or iii — no . ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C1882085;C2004062
3587,history of chf  n ( % ),C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of chf,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of chd at baseline §,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of chd at baseline d  g,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of chd at baseline  no . ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history of cardiovascular events,C0019664;C0019665;C0262512;C0262926;C0441471;C1320716;C1705255;C1880008;C2004062;C3541888
3587,history of cad / mi,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3810814;C3813548;C4284121
3587,history of cad,C0019664;C0019665;C0262512;C0262926;C1504769;C1705255;C2004062;C2239547;C3813548;C4284121
3587,history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history of bowel resections  n ( % ),C0019664;C0019665;C0262512;C0262926;C0741614;C1705255;C2004062
3587,history of bowel resection ( ref ),C0019664;C0019665;C0262512;C0262926;C0741614;C1425988;C1705255;C2004062
3587,history of atrial arrhythmia  n ( % ),C0019664;C0019665;C0085611;C0262512;C0262926;C1705255;C2004062
3587,history of amputation — no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
3587,history of amputation  no . ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
3587,history of amputation  n ( % ),C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
3587,history of amputation,C0002688;C0019664;C0019665;C0262512;C0262926;C0332840;C1546539;C1705255;C2004062
3587,history of af,C0019664;C0019665;C0262512;C0262926;C0344434;C1705255;C2004062;C4049859
3587,history of > $nmbr$ previous vte ( excluding index event ),C0019664;C0019665;C0205156;C0262512;C0262926;C0332196;C0441471;C0600653;C0630906;C0918012;C1552607;C1552854;C1637833;C1705255;C2004062;C2828389;C2986546;C4019010
3587,history of ( % ),C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3810814
3587,history coronary revascularization,C0019664;C0019665;C0262512;C0262926;C0877341;C1705255;C2004062
3587,history coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history congestive heart failure,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,history chd,C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
3587,history / presence of tophi,C0019664;C0019665;C0150312;C0221248;C0262512;C0262926;C0392148;C1705255;C2004062;C3854307
3587,heart failure history,C0018801;C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C4554158
3587,coronary artery disease history,C0010054;C0010068;C0019664;C0019665;C0262512;C0262926;C1705255;C1956346;C2004062
3587,chf history,C0018802;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,cabg history,C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,atherosclerotic vascular disease history †,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3587,all participants history of cabg,C0010055;C0019664;C0019665;C0262512;C0262926;C0679646;C1705255;C2004062
3586,total psa ‐ modified shs,C0392747;C2986589;C3889737
3585,modified total sharp score * *,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
3585,modified total sharp score,C0392747;C1444775;C1539835;C2964552;C3889737;C3890003
3584,modified has - bled score  mean ± sd,C0392747;C3889737
3584,modified has - bled > $nmbr$,C0392747;C3889737
3584,modified has - bled < $nmbr$,C0392747;C3889737
3584,modified has - bled $ $nmbr$,C0392747;C3889737
3584,modified has - bled,C0392747;C3889737
3584,modified braunwald class,C0392747;C0456387;C1518526;C1705943;C3889737
3583,third primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205437;C0392747;C0439612;C0439631;C0443172;C1705241;C3639721;C4319952
3583,systolic blood pressure ( change from baseline ),C0392747;C0443172;C1705241;C4274438;C4319952
3583,secondary ( change in total updrs score from baseline to final visit in phase $nmbr$ ),C0027627;C0175668;C0205436;C0392747;C0439175;C0439810;C0443172;C1705241;C3639721;C4319952
3583,retinal severity change,C0035298;C0392747;C0439793;C0443172;C0522510;C1705241;C4319952
3583,percent change,C0392747;C0439165;C0443172;C1705241;C4319952
3583,pbo - adjusted ls mean change ( se ),C0023668;C0031962;C0036919;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
3583,pbo - adjusted ls mean change,C0023668;C0031962;C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
3583,patients with change from baseline in total psa ‐ modified shs ≤ $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
3583,patients with change from baseline in psa - modified total shs score # $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952
3583,pain vas  mean change from baselined,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3583,pain vas  mean change from baselinea,C0042815;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3583,nominal change,C0392747;C0443172;C1705241;C4319952
3583,mean percentage change from baseline to final visit,C0168634;C0392747;C0439165;C0443172;C0444504;C1442488;C1549488;C1561533;C1705241;C2347634;C2348143;C4319952
3583,mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0439175;C0439810;C0443172;C0444504;C1705241;C2347634;C2348143;C2964552;C3533236;C3639721;C4319952
3583,mean change in sgrq,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3583,mean change in radiographic end points,C0392747;C0443172;C0444504;C0444708;C1705241;C2347634;C2348143;C2349179;C4319952
3583,mean change in acq score,C0392747;C0443172;C1705241;C2919686;C3533236;C4319952
3583,mean change from baseline in acq overall score ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3583,mean change from baseline  % ‐ points,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3583,mean change from baseline  %,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3583,mean % change in fn bmd,C0392747;C0443172;C0444504;C1570610;C1705241;C2347634;C2348143;C4319952
3583,lyear mean change from baseline,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3583,ls mean change from baseline $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3583,first primary ( change in updrs score / wk  wk $nmbr$ - $nmbr$ ),C0205225;C0205435;C0392747;C0439612;C0439631;C0443172;C1279901;C1705241;C3639721;C4319952
3583,fasting plasma glucose ( change from baseline ),C0168634;C0392747;C0443172;C0583513;C1442488;C1705241;C4319952
3583,difference in change,C0392747;C0443172;C1705241;C1705242;C4319952
3583,das $nmbr$ - crp  ls mean change from baseline ( se ) §,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
3583,changes in shs,C0392747;C0443172
3583,changes ( a ) in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C1705241;C4319952
3583,change in tg,C0337445;C0392747;C0443172;C1705241;C4319952
3583,change in tc,C0039411;C0040642;C0041405;C0041698;C0392747;C0443172;C1705241;C1824670;C3272447;C4319952;C4522122
3583,change in sbp,C0085805;C0392747;C0443172;C1705241;C4319952
3583,change in retinal pathology,C0030664;C0035298;C0205469;C0392747;C0443172;C0677042;C1705241;C4319952
3583,change in nt - probnp at $nmbr$ months ( log - transformed ),C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
3583,change in nt - probnp at $nmbr$,C0392747;C0443172;C0669479;C0754710;C1705241;C4319952
3583,change in mtss ( mean ),C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3583,change in lp ( a ),C0065058;C0392747;C0443172;C1439335;C1705241;C4319952;C4553379
3583,change in ldl ‐ c,C0392747;C0443172;C1705241;C4319952
3583,change in hdl ‐ c,C0392747;C0443172;C1705241;C3715113;C4319952
3583,change in haq - di ( mean ) t,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3826998;C4319952;C4321476
3583,change in femoral neck bmd from fit baseline to flex baseline,C0015815;C0392747;C0443172;C1705241;C4319952
3583,change in erosion score ( mean ),C0333307;C0392747;C0443172;C1705241;C1880549;C1959609;C3533236;C3887524;C4319952
3583,change from baseline to week $nmbr$ in weekly size of largest hive score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline to week $nmbr$ in weekly iss,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline to final apbm,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in sgrq,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in rescue medication use ( puffs per day ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in pre - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in post - bd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in mean $nmbr$ - h sbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in hba $nmbr$ c ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in fevj ( mb ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in das $nmbr$ - esr  mean $nmbr$ sd,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in aqlq { s ) score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in % predicted fev $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline in,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline *,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from baseline  median ( iqr ),C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
3583,change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3583,change from,C0392747;C0443172;C1705241;C4319952
3583,change,C0392747;C0443172;C1705241;C4319952
3583,body weight ( change from baseline ),C0005911;C0168634;C0392747;C0443172;C1303013;C1442488;C1705241;C4319952
3583,adjusted mean ± se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
3583,adjusted mean change from baseline ( se ),C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
3583,adjusted mean change from baseline,C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
3583,adjusted mean change,C0392747;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4319952
3583,adjusted mean _ se change from baseline,C0036919;C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
3583,adjusted change from baseline mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C0456081;C1442488;C1705241;C2347634;C2348143;C4319952
3583,adjusted change from baseline,C0168634;C0392747;C0443172;C0456081;C1442488;C1705241;C4319952
3583,% change from baseline,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3582,mean change,C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3582,ls mean change from baseline ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3582,ls mean change ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3582,ls mean ( s . e . ) primary endpoint : % change from baseline to week $nmbr$,C0023668;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2986535;C4319952
3582,fvc change,C0392747;C0443172;C1705241;C3714541;C4319952
3582,das $nmbr$ - crp  ls mean change from baseline ( se ) ¥,C0023668;C0036919;C0051767;C0057671;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C3890735;C4048285;C4319952
3582,change from baseline ( % ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3582,at c change ( % ) *,C0392747;C0443172;C1705241;C4319952
3582,adjusted mean change ( kg ),C0022718;C0392747;C0439209;C0443172;C0444504;C0456081;C1705241;C2347634;C2348143;C4054209;C4319952
3582,% change from baseline ls means ( se ),C0023668;C0036919;C0168634;C0392747;C0443172;C1442488;C1704970;C1705241;C4319952
3582,% change from baseline  mean ( s . e . ),C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3582,% change ( meantse ),C0392747;C0443172;C1705241;C4319952
3582,% change ( meanlse ),C0392747;C0443172;C1705241;C4319952
3581,subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0168634;C0392747;C0443172;C1442488;C1705241;C2986480;C4319952
3581,no change,C0392747;C0443172;C1705241;C4319952
3581,median change  %,C0392747;C0443172;C0549183;C0876920;C1705241;C2347635;C2348144;C2939193;C4319952
3581,mean change from baseline bp at week $nmbr$,C0168634;C0392747;C0443172;C0444504;C0488053;C1268766;C1442488;C1705241;C2347634;C2348143;C4319952
3581,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  % ‐ points,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
3581,mean ( $nmbr$ % ci ) change from $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ mg  %,C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
3581,change to week $nmbr$ *,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
3581,change to week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
3581,change in sesbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3581,change in sedbp  ls mean ( se ),C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3581,change in sbp ( $nmbr$ months ),C0085805;C0392747;C0439231;C0443172;C1705241;C4319952
3581,change in psa ‐ modified shs  baseline to week $nmbr$ ‡,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
3581,change in psa ‐ modified shs  baseline to week $nmbr$,C0392747;C0443172;C1705241;C3810537;C3813209;C4319952
3581,change in hbalc after $nmbr$ weeks etd ( $nmbr$ % cl ),C0392747;C0443172;C1705241;C4319952
3581,change in hba $nmbr$ c $nmbr$ to month $nmbr$ ( % ),C0019016;C0392747;C0443172;C1705241;C1825777;C3538758;C4319952
3581,change in fpg $nmbr$ to month $nmbr$ ( mg / dl ),C0392747;C0443172;C1705241;C4319952
3581,change in fev $nmbr$ at week $nmbr$,C0392747;C0443172;C1705241;C3714541;C4319952
3581,change in das $nmbr$ > $nmbr$ . $nmbr$,C0051767;C0057671;C0392747;C0443172;C1705241;C4319952
3581,change from baseline to week $nmbr$ in weekly no . of hives score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline to week $nmbr$ in dlqi scorez,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline in morning pef during weeks $nmbr$ - $nmbr$  mean l / min ( se ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline at week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline  adjusted mean ( $nmbr$ % ci )  %,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change from baseline  adjusted mean ( $nmbr$ % ci ),C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,change at week $nmbr$,C0332174;C0392747;C0439230;C0443172;C1705241;C4319952
3581,change $nmbr$,C0392747;C0443172;C1705241;C4319952
3581,before a change to the enrollment form was implemented in august $nmbr$ . bnp,C0348078;C0376315;C0392747;C0443172;C1516879;C1522492;C1696073;C1705241;C3888021;C4255237;C4319952
3581,( mean change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
3581,( mean % change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C3259781;C4319952
3581,% change median baseline crp > $nmbr$ mg / l,C0392747;C0443172;C1705241;C4319952
3581,% change from baseline to week $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
3581,% change ( median  q $nmbr$  q $nmbr$ ),C0392747;C0443172;C1705241;C4319952
3581,% change  $nmbr$ % ci ),C0008107;C0392747;C0443172;C1705241;C3259781;C4319952
3581,% change,C0392747;C0443172;C1705241;C4319952
3580,therapies,C0087111
3580,previous therapy,C0039798;C0087111;C0205156;C1363945;C1552607
3580,previous therapies  n ( % ),C0087111;C0205156;C1552607
3580,previous receipt of therapy against tnf - a — no . ( % ),C0039798;C0087111;C0205156;C1363945;C1552607
3580,no previous dmard therapy,C0039798;C0087111;C0205156;C0242708;C1363945;C1552607
3579,treatments at randomisation,C0034656;C0087111
3579,concomitant treatments at randomization,C0034656;C0087111;C0521115
3579,all treatments,C0087111
3578,treatment   ×   lipid interaction,C0023779;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3578,treatment of the index ml,C0039798;C0087111;C0439526;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C1705224;C2986546;C3538994;C3887665;C3887704
3578,treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,treatment after randomization  in the single - dummy phase — days ],C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,treatment after admission,C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
3578,treatment ( de vs warfarin ) by thrombophilia interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,total by treatment,C0039798;C0087111;C0439175;C0439810;C1522326;C1533734;C1705169;C3538994;C3887704
3578,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C0019409;C0022885;C0039593;C0039798;C0087111;C0205120;C0205448;C0242960;C0332849;C0392366;C0441833;C0456984;C0489786;C0687744;C1257890;C1515976;C1519504;C1522326;C1533734;C1552595;C1552839;C1704675;C1705169;C1705428;C1705429;C1707455;C3538994;C3831328;C3887704;C4048755;C4318744
3578,pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,other treatment assignment,C0039798;C0087111;C1516050;C1522326;C1533734;C1705169;C3538994;C3887704
3578,lipid treatment,C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,interaction between treatment and baseline bmi category,C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3578,initiated use during double - blind treatment period,C0013072;C0039798;C0042153;C0087111;C0439531;C0457083;C1522326;C1533734;C1548602;C1704686;C1705169;C1947944;C1948053;C3538994;C3887704
3578,ifx treatment,C0020823;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3578,history of omalizumab treatment :,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
3578,history of omalizumab treatment,C0019664;C0019665;C0039798;C0087111;C0262512;C0262926;C0966225;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
3578,combination treatment ifx + aza,C0004482;C0020823;C0039798;C0087111;C0205195;C1522326;C1533734;C1705169;C1947911;C3538994;C3811910;C3887704
3578,assigned treatment by sex interaction,C0009253;C0036864;C0039798;C0079399;C0087111;C0804628;C1314687;C1516050;C1522326;C1522384;C1533734;C1552601;C1704675;C1705169;C3538994;C3887704
3578,asian itt population by treatment group,C0032659;C0039798;C0078988;C0087111;C0374505;C1257890;C1522326;C1533734;C1705169;C3538994;C3887704
3578,any treatment - emergent ae,C0039798;C0087111;C0750573;C1522326;C1533734;C1705169;C3538994;C3887670;C3887704
3578,actual treatment strategy,C0039798;C0087111;C0237400;C0679199;C1522326;C1533734;C1705169;C3538994;C3887704
3578,acs treatment,C0039798;C0087111;C0742343;C1522326;C1533734;C1705169;C3538994;C3887704;C4318612
3578,ace inhibitor treatment,C0003015;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C4541021
3577,with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3577,with corticosteroid treatment > $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
3577,with corticosteroid treatment < $nmbr$,C0001617;C0039798;C0087111;C1522326;C1533734;C1705169;C3536709;C3538994;C3887704
3577,treatment with drugeluting stent,C0039798;C0087111;C1322815;C1522326;C1533734;C1705169;C3538994;C3887704
3577,treatment with anti - platelet drugs,C0039798;C0087111;C1522326;C1533734;C1705169;C2963157;C3538994;C3887704
3577,previous treatment with tnf antagonist — no . ( % ) §,C0039798;C0087111;C0205156;C0231491;C1448177;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
3577,previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
3577,pretreatment / concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1550147;C1705169;C2709094;C3538994;C3539075;C3539076;C3887704
3577,no previous treatment with infliximab,C0039798;C0087111;C0205156;C0666743;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
3577,monitoring treatment,C0039798;C0087111;C0150369;C1283169;C1522326;C1533734;C1705169;C3538994;C3887704
3577,goncomitant treatment with age inhibitors / angiotensin,C0001779;C0003018;C0039798;C0087111;C0243077;C1522326;C1533734;C1705169;C3538994;C3887704;C4521302
3577,concomitant treatment,C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
3577,chronic treatment with aspirin,C0004057;C0039798;C0087111;C0205191;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment stratum ^ :,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment groups [ n / nb ( % ) ],C0028101;C0039798;C0087111;C0441848;C0919442;C1522326;C1533734;C1705169;C1705347;C3538994;C3887704;C4553907
3576,treatment groups  n ( % ),C0039798;C0087111;C0441848;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment for latent tuberculosis ^,C0039798;C0087111;C0205275;C0749724;C1522326;C1533734;C1609538;C1705169;C3538994;C3887704
3576,treatment difference  ml,C0039798;C0087111;C0439526;C1522326;C1533734;C1705169;C1705224;C1705241;C1705242;C3538994;C3887665;C3887704
3576,treatment difference,C0039798;C0087111;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
3576,treatment diff . vs tio ( $nmbr$ % ci ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment comparison ( mg / day ) t,C0039798;C0087111;C0439422;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
3576,treatment comparison,C0039798;C0087111;C1522326;C1533734;C1705169;C1707455;C3538994;C3887704
3576,treatment before randomization  %,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment before catheterization,C0007430;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment before admission ( % ),C0039798;C0087111;C0184666;C0809949;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment at randomization — no . ( % ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment at randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment at randomisation,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,sulfasalazine treatment,C0036078;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,previous copd treatment  n ( % ) *,C0024117;C0039798;C0087111;C0205156;C1412502;C1522326;C1533734;C1552607;C1705169;C3538994;C3714496;C3887704
3576,prestudy treatment ( % ) a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,lcz $nmbr$ treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,estimated treatment difference ( % ),C0039798;C0087111;C0750572;C1522326;C1533734;C1705169;C1705241;C1705242;C3538994;C3887704
3576,epa treatment ( n = $nmbr$ ),C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3576,continuous lvef $nmbr$ treatment interaction,C0039798;C0087111;C0428772;C0488728;C0549178;C1522326;C1533734;C1704675;C1705169;C3538994;C3887704
3576,concomitant treatment 一 no . ( % ),C0039798;C0087111;C0521115;C1522326;C1533734;C1705169;C3538994;C3887704
3576,bp - lowering treatment ( n = $nmbr$ ),C0037623;C0039798;C0087111;C0441994;C1415692;C1522326;C1533734;C1705169;C1708288;C2003888;C3538994;C3887704;C4318478
3576,baseline cv treatment  n ( % ) y,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
3576,baseline cv treatment,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538987;C3538994;C3887704;C4048877;C4318503
3576,background treatment  n ( % ),C0039798;C0087111;C1522326;C1533734;C1705169;C1706907;C3538994;C3887704
3575,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age  reciprocal of serum creatinine  sbp  up excretion  treatment assignment and terms for studies $nmbr$  $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure  type of antihypertensive regimen in the control group  planned duration of follow - up  whether or not the investigators were blinded  whether or not dietary advice was given and the year of publication .,C0002778;C0003364;C0034036;C0034037;C0039798;C0040808;C0085805;C0087111;C0201976;C0221102;C0232108;C0242492;C0332307;C0439234;C0439508;C0439828;C0441833;C0504085;C0600061;C0687744;C0750591;C0936012;C0947630;C1257890;C1272641;C1274040;C1516050;C1519504;C1522326;C1524024;C1533734;C1547052;C1704324;C1705169;C1705428;C1705429;C2699704;C2945654;C3161035;C3538994;C3887704;C4288391
3575,on antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3575,antihypertensive treatments,C0003364;C0087111
3575,antihypertensive treatment  n ( % ),C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3575,antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
3574,time between cessation of full - dose warfarin therapy and enrollment ( mo ),C0039798;C0087111;C0178602;C0366686;C0682295;C0869039;C1114758;C1363945;C1880019;C4303340
3574,therapy,C0039798;C0087111;C1363945
3574,ed therapy,C0039798;C0087111;C1363945;C3538926
3573,antithrombotic therapy,C0039798;C0087111;C1363945
3573,anti platelet therapy,C0005821;C0039798;C0087111;C1363945
3573,anti - platelet therapy,C0005821;C0039798;C0087111;C1363945
3572,topical therapy,C0039798;C0087111;C0332237;C1363945
3572,no pah therapy,C0030123;C0039798;C0087111;C1363945;C3203102;C4284467
3572,no pah - specific therapy,C0030123;C0039798;C0087111;C0205369;C1363945;C1552740;C3203102;C4284467
3571,therapy at discharge,C0012621;C0030685;C0039798;C0087111;C1363945;C2926602
3571,oab therapy,C0039798;C0087111;C1363945
3571,concomitant drug therapy at discharge,C0012621;C0013216;C0013217;C0013227;C0030685;C0039798;C0087111;C0521115;C1254351;C1363945;C1707479;C2926602;C3850077
3570,refractory to such therapy — no . ( % ),C0039798;C0087111;C0205269;C1363945
3570,ineffective therapy,C0039798;C0087111;C1363945;C3242229
3570,any therapy — no . ( % ),C0039798;C0087111;C1363945
3569,noninsulin therapy,C0039798;C0087111;C1363945
3569,insulin therapy  n ( % ) 本,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
3569,insulin therapy  n ( % ),C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
3568,background therapy,C0039798;C0087111;C1363945;C1706907
3568,background lipid therapy per acc / aha definition    n   ( % ) a,C0023767;C0039798;C0087111;C1363945;C1550452;C1704788;C1706907;C3539107;C3888054;C4072694
3567,vka therapy,C0039798;C0087111;C1363945
3567,long term vka therapy,C0039798;C0087111;C0443252;C1363945
3567,long - term vka therapy,C0039798;C0087111;C0443252;C1363945
3567,h $nmbr$ blocker ( n  % ) long - term vka therapy,C0033727;C0039798;C0087111;C0369286;C0441932;C0443252;C0564385;C1363945;C4528284
3566,height  inches,C0439204;C0489786
3565,height ( cm ) ( mean ± sd ),C0444504;C0489786;C2347634;C2348143;C2699239
3565,height ( cm )  mean ( sd ) a,C0444504;C0489786;C2347634;C2348143;C2699239
3565,height ( cm )  mean ( s . e . ),C0439392;C0444504;C0489786;C2347634;C2348143
3565,height ( cm ),C0489786
3565,height '  cm,C0489786
3565,height  mean ( sd )  cm,C0444504;C0489786;C2347634;C2348143;C2699239
3565,height  cm *,C0489786
3565,height  cm ( mean ± s . d . ),C0439392;C0444504;C0489786;C2347634;C2348143
3565,height  cm  mean ( sd ),C0444504;C0489786;C2347634;C2348143;C2699239
3565,height  cm,C0489786
3564,interquartile range height — cm,C0489786;C1711350
3564,height — cm,C0489786
3563,height loss ( cm ),C0424641
3563,height loss,C0424641
3562,higher risk ( n = $nmbr$ ),C0332167;C3272283;C4050568;C4319571
3562,high risk and more symptoms ( group d ),C0332167;C3272283;C4050568;C4319571
3562,high risk and fewer symptoms ( group c ),C0332167;C3272283;C4050568;C4319571
3562,high risk *  %,C0332167;C3272283;C4050568;C4319571
3562,high risk ( ri ≥ $nmbr$ ),C0035487;C0332167;C1826843;C3272283;C4050568;C4319571
3562,high risk ( receiving treatment for ) :,C0039798;C0087111;C0332167;C1514756;C1522326;C1533734;C1705169;C3272283;C3538994;C3887704;C4050568;C4319571
3562,high risk ( n $nmbr$ $nmbr$ ),C0332167;C3272283;C4050568;C4319571
3562,high risk ( ? ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
3562,high risk ( > $nmbr$ ),C0332167;C3272283;C4050568;C4319571
3562,high risk ( - ics ),C0332167;C0815320;C3272283;C4050568;C4319571;C4551720
3562,high risk ( $nmbr$ - $nmbr$ ),C0332167;C3272283;C4050568;C4319571
3562,high risk,C0332167;C3272283;C4050568;C4319571
3562,high fracture risk stratum,C0016658;C0332167;C3272283;C4050568;C4319571
3562,high cv risk,C0332167;C3272283;C3538987;C4048877;C4050568;C4318503;C4319571
3562,high cardiovascular risk  n ( % ) ^,C0007226;C0332167;C3272283;C3887460;C4050568;C4319571
3562,high - risk cvd  n ( % ),C0007222;C0332167;C3272283;C4050568;C4319571
3562,high - risk criterion,C0243161;C0332167;C3272283;C4050568;C4319571
3562,high - risk clinical features,C0332167;C0683325;C3272283;C4050568;C4319571
3562,high - risk,C0332167;C3272283;C4050568;C4319571
3562,high ( > $nmbr$ risk factor ),C0035648;C0205250;C0332167;C1299351;C1521761;C2700149;C2827422;C3272283;C3887512;C3889660;C4050568;C4319571;C4321237;C4522209
3562,group d ( high risk  more symptoms )  n ( % ),C0332167;C0441848;C0683368;C1457887;C3272283;C4050568;C4319571
3562,> $nmbr$ ( high risk ),C0332167;C3272283;C4050568;C4319571
3561,moderately high risk without atherosclerotic vascular disease *,C0004153;C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
3561,moderately high risk,C0205081;C0332167;C1881878;C3272283;C4050568;C4085643;C4319571;C4321491
3561,high risk without atherosclerotic vascular disease +,C0004153;C0332167;C3272283;C4050568;C4319571
3560,less than high school,C0439092;C0599395;C0683862;C0870649
3560,education  high school or higher,C0683862
3559,high - school graduate or ged,C0870649;C1549971
3559,high - school graduate,C0870649;C1549971
3558,very high vs . normalb,C0442804;C4321397
3558,very high vs . normal,C0442804;C4321397
3558,very high risk,C0035647;C0332167;C0442804;C0442824;C2984081;C3272283;C4050568;C4319571;C4321397;C4552904
3558,very high ( >   $nmbr$ xuln ) n   =   $nmbr$,C0442804;C4321397
3558,very high,C0442804;C4321397
3557,symptomatic ich,C0019191;C0231220;C3272597;C3281105
3557,ich,C0019191;C3272597;C3281105
3557,gusto moderate bleeding / ich,C0019080;C0019191;C0205081;C1881878;C3272597;C3281105;C4049705;C4049706;C4085643;C4321335
3556,baseline body weight quartile,C1303013;C2828255
3555,weight at baseline,C1303013
3555,acr response by baseline weight,C0871261;C1303013;C1412134;C1515941;C1704632;C1706817;C2911692
3554,body weiqht,C0242821;C0460148;C1268086;C4082212
3554,body weighta  kg,C0022718;C0242821;C0439209;C0460148;C1268086;C4054209;C4082212
3554,body weight reduction > $nmbr$ %,C0005910;C0242821;C0301630;C0392756;C0460148;C1262477;C1268086;C1293152;C1305866;C4082212;C4551656
3554,body weight at randomization,C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
3554,> $nmbr$ kg body weight at randomization,C0005910;C0022718;C0034656;C0242821;C0439209;C0460148;C1268086;C1305866;C2985844;C4054209;C4082212
3553,per body weight  u / kg,C0005910;C1300561;C1305866
3552,mean body weight ( sd )  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
3552,body weight ( kg )  n ( % ),C0005910;C0022718;C0439209;C1305866;C4054209
3552,body weight  mean ± sd  kg,C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
3552,body weight  kg ^,C0005910;C0022718;C0439209;C1305866;C4054209
3552,body weight  kg ( mean ± sd ),C0005910;C0022718;C0439209;C0444504;C1305866;C2347634;C2348143;C2699239;C4054209
3552,body weight  kg,C0005910;C0022718;C0439209;C1305866;C4054209
3552,body weight  %,C0005910;C1305866
3552,body weight,C0005910;C1305866
3551,no body weight at randomization ( ixrs ),C0005910;C0034656;C0242821;C0460148;C1268086;C1305866;C2985844;C4082212
3551,body weight at randonization { ixrs ),C0005910;C1305866
3550,weight of < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3550,weight ab  %,C0005910;C0043100;C1305866;C1705104
3550,weight < $nmbr$ kg  n ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3550,weight < $nmbr$ kg,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3550,weight < $nmbr$,C0005910;C0043100;C1305866;C1705104
3550,weight ( kg }  median ( min  max },C0005910;C0043100;C0549183;C0876920;C1305866;C1532757;C1705104;C2347635;C2348144;C2939193
3550,weight $nmbr$ - $nmbr$,C0005910;C0043100;C1305866;C1705104
3550,weight $nmbr$ +,C0005910;C0043100;C1305866;C1705104
3550,weight $ $nmbr$ . $nmbr$ kg  n,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3550,weight $ $nmbr$ . $nmbr$ kg  < $nmbr$ . $nmbr$ kg  n,C0005910;C0043100;C1305866;C1319635;C1705104
3550,weight  mean ( sd ) lbs .,C0005910;C0043100;C0439219;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C3161851
3550,weight  lbs,C0005910;C0043100;C0439219;C1305866;C1705104;C3161851
3550,weight  kg *,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3550,total  adjusted weight of $nmbr$ . $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C0439175;C0439810;C0456081;C1305866;C1705104
3550,plasma dha  mean ( sd ) weight  %,C0005910;C0032105;C0043100;C0142831;C0444504;C1305866;C1550098;C1705104;C2347634;C2348143;C2348308;C2699239;C4521445
3549,weight — no . ( % ),C0005910;C0043100;C1305866;C1705104
3549,weight — kg cardiovascular history — no . ( % ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C1880008;C4054209
3549,weight in kg  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
3549,weight ^,C0005910;C0043100;C1305866;C1705104
3549,weight ( median [ iqr ] )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
3549,weight ( kg ) 十,C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3549,weight ( kg ) bmi ( kg / m $nmbr$ ),C0005910;C0043100;C0369637;C0441923;C0578022;C1305866;C1319635;C1705104
3549,weight ( kg )  median ( m / n  max ),C0005910;C0043100;C0549183;C0876920;C1305866;C1532718;C1705104;C2347635;C2348144;C2939193
3549,weight ( kg )  median ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
3549,weight ( kg )  mean ( s . e . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
3549,weight ( kg ),C0005910;C0022718;C0043100;C0439209;C1305866;C1705104;C4054209
3549,weight  median ( iqr )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
3549,weight  kg ( mean ± s . d . ),C0005910;C0043100;C0444504;C1275571;C1305866;C1705104;C2347634;C2348143
3549,weight,C0005910;C0043100;C1305866;C1705104
3549,median weight  kg ( iqr ),C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2939193;C4054209
3549,dose / weight ( iu / kg ),C0005910;C0043100;C0178602;C0439463;C0869039;C1114758;C1305866;C1705104
3548,weight category,C0005910;C0043100;C0683312;C1305866;C1705104;C3889287
3548,healthy weight,C0005910;C0043100;C1305866;C1705104;C3898900
3548,body weight *,C0005910;C1305866
3548,* plus - minus values are means 士 sd . race or ethnic group was self - determined . the body - mass index is the weight in kilograms divided by,C0005910;C0042295;C0043100;C0332288;C0439209;C0441833;C0687744;C1257890;C1305866;C1519504;C1705104;C1705428;C1705429
3547,thiazides,C0541746
3547,thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
3546,thiazide users,C0541746;C1706077
3546,thiazide,C0541746
3545,slowest third,C0205437;C0439834
3544,third yeart,C0205437
3544,one - third radius,C0034627;C0205437;C0205447;C1306504
3544,distal one - third of radius,C0034627;C0205437;C0205447;C0450168;C0588207;C1306504
3543,cure trial,C0008976;C1880198
3542,trial $nmbr$,C0008976
3542,ended > $nmbr$ days before trial entry,C0008976;C0439228;C1272693;C1705654;C2746065
3541,trial,C0008976
3541,( phase $nmbr$ dose - finding trial ),C0008976;C0037088;C0178602;C0205390;C0243095;C0869039;C1114758;C1710475;C2825141
3540,trial completers,C0008976
3540,completed trial,C0008976;C0205197;C3854010
3539,lipid trial participantss,C0008976;C0023779
3539,lipid trial participantsk,C0008976;C0023779
3538,pooled trials * n = $nmbr$,C0008976;C1709595;C2349200;C4522255
3538,all trials,C0008976
3537,other asian,C0078988
3537,asian or pacific islander,C0078988
3537,asian / black / white / hispanic / other ( % ) clinical parameters,C0005680;C0007457;C0027567;C0043157;C0078988;C0085756;C0220938;C0439541;C1533017;C1533018;C1533020;C1533021
3536,asian / pacific islander  n ( % ),C0078988;C0242191
3536,asian ( $nmbr$ . $nmbr$ % ),C0078988
3536,asian  n ( % ),C0078988
3535,non - asian ( n = $nmbr$ $nmbr$ ),C0078988;C1518422
3535,non - asian,C0078988;C1518422
3535,asians ( n = $nmbr$ ),C0078988
3535,asian ( n — $nmbr$ ),C0078988
3535,asian ( n   = $nmbr$ ),C0078988
3535,asian ( n = $nmbr$ ),C0078988
3535,asian ( n = $nmbr$  $nmbr$ ),C0078988
3535,asian,C0078988
3534,oriental,C0078988;C0699027
3534,asian or oriental,C0078988
3534,asian / oriental,C0078988;C0699027
3533,p - value for east asian versus non - east asian *,C0078988;C1707877;C1709380
3533,non - east asian §,C0078988;C1518422;C1707877
3533,east asian,C0078988;C1707877
3533,asian *,C0078988
3532,schwab & england score,C0014282
3531,sss score,C0037052;C0723181
3530,physical component score ( pcs ),C0449432;C1705248;C1864389;C1882368;C4483112
3530,pcs score ( $nmbr$ – $nmbr$ scale ),C1864389;C1882368
3530,pcs score,C1864389;C1882368
3529,ups score  mean ( sd ),C0334463;C3542434
3528,updrs score,C3639721
3528,total updrs score ( range  $nmbr$ — $nmbr$ ) y,C0439175;C0439810;C3639721
3528,total updrs score ( range  $nmbr$ - $nmbr$ ) 卞,C0439175;C0439810;C3639721
3527,midas score,C1309950;C1423498;C4049617
3526,gds score *,C0451184;C1149049;C1418244
3525,aqlq score  mean,C0444504;C0449820;C2347634;C2348143;C4050231;C4055434
3525,aqlq score,C4055434
3525,aqlq ( si + $nmbr$ score ’,C0449820;C4050231;C4055434
3525,aqlq ( s ) score,C0449820;C4050231;C4055434
3525,aqlq ( s ) + $nmbr$ scorets,C4055434
3525,aqlq ( s ) + $nmbr$ scored,C4055434
3525,aqlq ( s ) + $nmbr$ score : §,C0449820;C4050231;C4055434
3525,aqlq ( s ) + $nmbr$ score  mean ( sd ) c  f,C0016327;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4055434
3524,individuals with t $nmbr$ dm ( scale diabetes ),C0011816;C0011847;C0011849;C0027361;C0175659;C0237401;C0349674;C1947916;C3250443
3524,( scale obesity and prediabetes ),C0028754;C0175659;C0349674;C1947916;C1963185
3524,( scale diabetes ),C0011847;C0011849;C0175659;C0349674;C1947916
3523,total score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C1947916;C2964552
3523,pasi score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231;C4528685
3523,jsn score ( $nmbr$ – $nmbr$ scale ),C0175659;C0349674;C0449820;C1947916;C4050231
3523,haq score ( $nmbr$ – $nmbr$ scale ),C0102923;C0175659;C0349674;C0449820;C0451208;C1947916;C4050231
3523,erosion score ( $nmbr$ – $nmbr$ scale ),C0175659;C0333307;C0349674;C0449820;C1880549;C1947916;C1959609;C3887524;C4050231
3523,dactylitis score ( $nmbr$ – $nmbr$ scale ),C0175659;C0239161;C0349674;C0449820;C1947916;C4050231
3522,modified se - adl scale,C0001288;C0036919;C0175659;C0349674;C0392747;C1420005;C1947916;C3889737
3521,scale — cognitive portion  ldl — low -,C0175659;C0349674;C0449719;C1516691;C1947916
3521,pdqol scale,C0175659;C0349674;C1947916
3521,morning stiffness severity  $nmbr$ - $nmbr$ scale,C0175659;C0349674;C0439793;C0457086;C0522510;C1947916
3520,stomach,C0038351;C3714551
3519,storage subscore,C0337174;C1698986;C1753314
3519,ipss storage subscore,C0337174;C1019118;C1698986;C1753314;C1998280;C2827405;C3811063
3518,total sgrq mean total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
3518,sgrq total score,C2964552
3518,mean sgrq total score ( sd ),C0439175;C0439810;C0444504;C2347634;C2348143;C2699239;C2964552;C3533236
3518,mean sgrq total score,C0439175;C0439810;C0444504;C2347634;C2348143;C2964552;C3533236
3518,ibdq total score  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C2964552
3518,ibdq total score,C2964552
3518,baseline ibdq total score  mean,C0168634;C0444504;C1442488;C2347634;C2348143;C2964552
3517,total mayo score $ | |,C0454788;C1077578;C2964552
3517,total mayo score,C0454788;C1077578;C2964552
3517,eacit - e total score ) |,C2964552
3516,ccq total score,C2964552
3516,acq - $nmbr$ total score ∗,C2919686;C2964552
3515,total score on the sgrq - c  i,C0021966;C0221138;C2964552;C3826872
3515,sgrq total score $nmbr$,C2964552
3514,total scores ( total score range : $nmbr$ - $nmbr$ ),C1514721;C2348147;C2964552;C3542016
3514,total score < $nmbr$,C2964552
3513,total score,C2964552
3513,bdi total score ( baseline ),C0006448;C0168634;C0451022;C1442488;C2964552;C3714938;C3889415
3512,total score §,C2964552
3512,selena - sledai total score,C0451528;C2964552
3511,total vdh - s score ( $nmbr$ - $nmbr$ ) ( n ),C2964552
3511,total vdh - s score,C2964552
3511,( total ses - cd score at,C0007928;C0034283;C2964552;C4552032
3510,total score > $nmbr$,C2964552
3510,sgrq total score * *,C2964552
3510,sgrq total score * ( units ),C0439148;C1519795;C2964552;C3853603
3510,sgrq total score ( units ) : ! :,C0439148;C1519795;C2964552;C3853603
3510,sgrq total score ( units ),C0439148;C1519795;C2964552;C3853603
3510,sgrq total score  units,C0439148;C1519795;C2964552;C3853603
3510,c $nmbr$ - unit sgrq total score increase,C0439148;C0439453;C0442805;C1509845;C1519795;C1704753;C1880519;C2964552;C3853603
3509,urticaria,C0042109;C1559188
3508,weekly size of largest hives score {,C0042109;C0332174;C0443228;C0456389
3507,weekly number of hives score {,C0042109;C0237753;C0332174;C0449788
3507,weekly number of hives score $nmbr$,C0042109;C0237753;C0332174;C0449788
3506,daytime nasal symptoms score change from baseline  mean ± se,C0231918;C0332169
3506,baseline daytime nasal symptoms score  mean ± sd,C0168634;C0231918;C0332169;C1442488
3505,mean score,C3533236
3505,baseline dyspnea index  mean total score,C0439175;C0439810;C0444504;C1511069;C2347634;C2348143;C2964552;C3533236
3504,bii score,C1413059
3503,mean bdi focal score ( sd ),C0006448;C0205234;C0451022;C2699239;C3533236;C3714938;C3889415
3503,bdi focal score $nmbr$,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
3503,bdi focal score,C0006448;C0205234;C0449820;C0451022;C3714938;C3889415;C4050231
3502,migraine severity score,C0149931;C0457451
3501,dactylitis severity score ) score > $nmbr$ — no . { % ),C0239161;C0457451
3500,ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale  $nmbr$ to $nmbr$ for the stiffness,C0029040
3499,womac stiffness score,C0427008;C0449820;C4050231
3499,stiffness subscale,C0427008
3498,muscle twitching,C0015644;C0231530
3497,muscle spasms,C0037763
3496,irritative subscore,C0441723;C1706307;C2700617
3495,rectal bleeding subscore {,C0018932;C0267596
3495,rectal bleeding subscore,C0018932;C0267596
3494,timi risk score > $nmbr$  n ( % ),C0035647;C0449820;C4050231;C4552904
3494,timi risk score > $nmbr$  %,C0035647;C0449820;C4050231;C4552904
3494,timi risk score ( interaction : p = $nmbr$ . $nmbr$ ),C0035647;C0449820;C1704675;C4050231;C4552904
3494,timi risk score  n / n ( % ),C0035647;C0449820;C4050231;C4552904
3494,timi risk score  %,C0035647;C0449820;C4050231;C4552904
3494,stroke risk score,C0449820;C1277291;C4050231
3494,score $nmbr$ . $nmbr$,C0449820;C4050231
3494,framingham risk score  arbitrary units,C0035647;C0439183;C0449820;C3166866;C4050231;C4552904
3493,vascular risk score *,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
3493,tlmi risk score,C0035647;C0449820;C4050231;C4552904
3493,timi risk score — no . / total no . ( % ) f,C0035647;C0449820;C4050231;C4552904
3493,timi risk score — no . / total no . ( % ) : c,C0035647;C0449820;C4050231;C4552904
3493,timi risk score — no . ( % ) : t,C0035647;C0449820;C4050231;C4552904
3493,timi risk score — %,C0035647;C0449820;C4050231;C4552904
3493,timi risk score category — no . ( % ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
3493,timi risk score *,C0035647;C0449820;C4050231;C4552904
3493,timi risk score $nmbr$ - $nmbr$,C0035647;C0449820;C4050231;C4552904
3493,timi risk score !,C0035647;C0449820;C4050231;C4552904
3493,timi risk score,C0035647;C0449820;C4050231;C4552904
3493,st - segment deviation timi risk score  %,C0012727;C0035647;C0036056;C0205419;C0429029;C0429066;C0441635;C0449820;C1114722;C1116089;C1705236;C3272372;C4050231;C4552904
3493,framingham risk score *,C0035647;C0449820;C3166866;C4050231;C4552904
3493,framingham risk score ( % ),C0035647;C0449820;C3166866;C4050231;C4552904
3493,framingham risk score,C0035647;C0449820;C3166866;C4050231;C4552904
3493,ci - aki risk score,C0008107;C0022660;C0035647;C0330978;C0449820;C3259781;C4050231;C4552904
3492,score ( > $nmbr$ ) at $nmbr$ monthsb unadjusted or,C0449820;C4050231
3492,partial mayo score $ | |,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
3492,partial mayo score,C0449820;C0454788;C0728938;C1077578;C1550516;C4050231
3492,mayo score ( $nmbr$ - $nmbr$ ),C0449820;C0454788;C1077578;C4050231
3491,score of > $nmbr$ . $nmbr$ — %,C0449820;C4050231
3491,score > $nmbr$ . $nmbr$,C0449820;C4050231
3491,iga mod $nmbr$ score  n ( % ),C0011860;C0449820;C2825347;C4050231
3490,score 一 no . ( % ),C0449820;C4050231
3490,score of $ $nmbr$  no . ( % ),C0449820;C4050231
3490,score of # $nmbr$  no . ( % ),C0449820;C4050231
3490,score  no . ( % ),C0449820;C4050231
3490,charlson comobility score  n ( % ),C0449820;C4050231
3490,borg dyspnea score who functional class  n ( % ),C0013404;C0449820;C1963100;C4050231
3489,mmse score *,C0449820;C0451306;C4050231
3489,mmse score,C0449820;C0451306;C4050231
3488,rope score * *,C0449820;C1563164;C4050231
3488,rope score,C0449820;C1563164;C4050231
3487,shs ( $nmbr$ - $nmbr$  per $nmbr$ score ),C0449820;C4050231
3487,score $nmbr$ - $nmbr$,C0449820;C4050231
3487,score  %,C0449820;C4050231
3487,score,C0449820;C4050231
3487,oab - q score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3641332;C4050231
3487,jsn score ( $nmbr$ - $nmbr$ ),C0449820;C4050231
3487,jsn score  mean $nmbr$ sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
3487,jsn score,C0449820;C4050231
3487,ibdq score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
3487,concomitant aminosalicylates  n [ % ] concomitant corticosteroids  n [ % ] mayo score  mean [ sd ],C0001617;C0368663;C0444504;C0449820;C0454788;C0521115;C1077578;C2347634;C2348143;C2699239;C3539185;C3540725;C3540726;C3540727;C4050231
3487,comorbidity score  mean ( sd ) t,C0009488;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
3487,( sd ) l / min acq - $nmbr$ score  mean ( sd ),C0444504;C0449820;C0702093;C1524029;C2347634;C2348143;C2699239;C2919686;C3813700;C4050231
3486,crusade score,C0449820;C4050231
3486,crusade bleeding score  mean ( sd ) ^,C0019080;C0444504;C0449820;C2347634;C2348143;C2699239;C4050231
3486,crusade bleeding score,C0019080;C0449820;C4050231
3485,joint space narrowing score  mean ( sd ),C0444504;C0449820;C1859695;C2347634;C2348143;C2699239;C4050231
3485,joint space narrowing score,C0449820;C1859695;C4050231
3484,mhis score,C0449820;C4050231
3484,$nmbr$ ms score †,C0449820;C2349943;C3539704;C3713294;C4050231
3483,cha $nmbr$ s $nmbr$ score,C0449820;C1420648;C4050231
3483,cha $nmbr$ ds $nmbr$ vasc score ( % ),C0449820;C1420648;C3714751;C4050231
3483,cha $nmbr$ ds $nmbr$ vasc score,C0449820;C1420648;C3714751;C4050231
3483,cha $nmbr$ ds $nmbr$ - vasc score    n   ( % ),C0449820;C1420648;C3714751;C4050231
3483,cha $nmbr$ ds $nmbr$ - vasc score,C0449820;C1420648;C3714751;C4050231
3482,tim $nmbr$ nsk score,C0449820;C1313407;C3541335;C3711667;C3827754;C3890185;C4050231;C4319633
3481,sf - $nmbr$ score,C0037712;C0449820;C4050231
3481,sf - $nmbr$ ( health transition score ),C0037712;C0376627;C0449820;C4050231
3480,— $nmbr$ . $nmbr$ < fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
3480,— $nmbr$ . $nmbr$ < fn t - score,C0449820;C1570610;C4050231
3480,fn t - score < — $nmbr$ . $nmbr$,C0449820;C1570610;C4050231
3480,fn t - score < = - $nmbr$ . $nmbr$ ( % ),C0449820;C1570610;C4050231
3480,flex fn f - score < - $nmbr$ . $nmbr$,C0016327;C0449820;C1570610;C4050231
3480,- $nmbr$ < flex fn f - score,C0016327;C0449820;C1570610;C4050231
3480,- $nmbr$ . $nmbr$ < flex fn f - score < - $nmbr$,C0016327;C0449820;C1570610;C4050231
3479,facit - f score,C0449820;C3272505;C4050231
3479,accp score,C0449820;C4050231
3478,ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
3478,hit - $nmbr$ score,C0272285;C0332159;C0449820;C1708373;C4050231
3478,- $nmbr$ . $nmbr$ < ls t - score < — $nmbr$ . $nmbr$,C0023668;C0449820;C4050231
3478,- $nmbr$ . $nmbr$ < ls t - score,C0023668;C0449820;C4050231
3477,womac score,C0449820;C4050231
3477,womac function score,C0031843;C0449820;C0542341;C0700205;C1705273;C4050231
3477,rentrop score,C0449820;C4050231
3477,opaqb physical function score,C0031843;C0449820;C0516981;C0542341;C0700205;C1705273;C4049916;C4050231;C4483112
3476,adas — cog score,C0449820;C3539026;C4050231
3476,adas - cog score *,C0449820;C3539026;C4050231
3475,modified rankin score,C0392747;C0449820;C3889737;C4050231
3474,baseline dyspnea index score,C0449820;C1511069;C4050231
3473,crohn ' s disease activity index score ],C0449820;C0451071;C4050231
3472,score on the minnesota living with heart failure scaled,C0026183;C0449820;C0595998;C4050231;C4520849;C4551704
3472,cadillac score,C0449820;C4050231
3471,chf score ( u ),C0018802;C0439148;C0449820;C4050231
3470,chf on losartan ( % ),C0018802;C0126174
3469,previous chf — no . ( % ),C0018802;C0205156;C1552607
3469,previous chf  n ( % ),C0018802;C0205156;C1552607
3469,previous chf,C0018802;C0205156;C1552607
3469,chf ( % ),C0018802
3469,chf,C0018802
3468,previous heart failure,C0018801;C0018802;C0205156;C1552607;C4554158
3468,previous episode of heart failure,C0018801;C0018802;C0205156;C0332189;C1552607;C4554158
3468,previous congestive heart failure — no . ( % ),C0018802;C0205156;C1552607
3468,previous congestive heart failure ( % ),C0018802;C0205156;C1552607
3468,previous congestive heart failure,C0018802;C0205156;C1552607
3467,dual ii,C0205173;C1554184;C1710602;C4082587
3466,dual i extension - end of trial hba $nmbr$ c,C0008976;C0019016;C0021966;C0205173;C0221138;C0231448;C0444930;C1554184;C1825777;C1880641;C2746065;C3538758
3466,dual i extension,C0021966;C0205173;C0221138;C0231448;C1554184;C1880641
3465,dual therapy,C0039798;C0087111;C0205173;C1363945;C1554184
3465,dual antiplatelet therapy,C0205173;C1096021;C1554184
3465,dual antiplatelet,C0205173;C1554184
3464,doubling of serum creatinine,C0201976;C0205173;C0600061;C1705764
3464,doubling of baseline serum creatinine or esrd rr ( ci ) “,C0168634;C0201976;C0205173;C0600061;C1442488;C1705764
3464,composite of doubling of serum creatinine  end - stage kidney disease  or death from renal causes,C0022658;C0201976;C0205088;C0205173;C0205199;C0600061;C1547335;C1705764
3463,doubling of creatinine †,C0010294;C0205173;C1561535;C1705764
3463,doubling of creatinine,C0010294;C0205173;C1561535;C1705764
3462,severe oa symptoms at baselined,C0029408;C0436345;C3887876
3462,less severe oa symptoms at baseline,C0029408;C0168634;C0436345;C0439092;C0547044;C1442488;C3887876
3461,years duration oa,C0029408;C0439234;C0449238;C2926735;C3887876
3461,oa,C0029408;C3887876
3460,osteoarthritis,C0029408
3460,duration of osteoarthritis symptoms — yr,C0029408;C0436359;C0439234
3459,fragile,C0302113
3459,d non - vertebral fragility fractures ( fas ),C0073187;C0302113;C0332173;C0549207;C1518422;C4484261
3458,non - frail,C0871754;C1518422
3458,frail,C0871754
3457,hrqol,C4279947;C4300252
3456,health - related quality of life,C4279947
3455,distance to ldl - c goal,C0012751;C0018017;C1571704
3454,not at goal,C0018017;C1518422;C1571704
3454,goal,C0018017;C1571704
3454,at ldl - c ( bq ) goal * at baseline - no . ( % ),C0018017;C0168634;C0560038;C1442488;C1571704;C3541236
3454,at goal,C0018017;C1571704
3453,bp goal  no . ( % ),C0018017;C0037623;C1415692;C1571704;C1708288;C4318478
3453,% to goal,C0018017;C1571704
3452,ldl - c goal attainment,C0680230
3452,dual bp / ldl - c goal attainment,C0037623;C0205173;C0680230;C1415692;C1554184;C1708288;C4318478
3452,bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
3451,brachial,C0445456
3450,radial access — no . / total no . ( % ),C0442038;C0920847
3450,radial access site,C0442038;C0589360;C0920847
3450,radial access,C0442038;C0444454;C0920847;C1554204
3450,radial,C0442038;C0920847
3449,arterial access site,C3272298
3448,arterial access,C0003842;C0221464;C0444454;C1554204
3447,renal insufficiency — no . ( % ),C0035078;C1565489
3447,renal insufficiency or failure,C0035078;C1565489
3447,renal insufficiency *,C0035078;C1565489
3447,renal insufficiency $nmbr$,C0035078;C1565489
3447,renal insufficiency,C0035078;C1565489
3447,renal impairment  n ( % ),C1565489
3447,bmi  body mass index  hrt  hormone replacement therapy  lvh  left ventricular hypertrophy  nsaids  nonsteroidal anti - inflammatory drugs  pvd  peripheral vascular disease  tia  transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .,C0003211;C0007787;C0012634;C0023779;C0030685;C0035078;C0085096;C0149721;C0201976;C0282402;C0340279;C0391871;C0439180;C0441994;C0600061;C0680255;C0753208;C1283071;C1305855;C1515187;C1565489;C1704788;C1709991;C1963578;C2003888;C3539106;C3813610;C3890900;C3891546;C4521226
3446,impaired renal function †,C1565489
3446,impaired renal function §,C1565489
3446,history of impaired renal function  no . ( % ),C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
3446,history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1565489;C1705255;C2004062
3445,renal impairment,C1565489
3445,level of renal impairment ',C0441889;C0456079;C1547707;C1565489;C2946261
3445,level of renal impairment,C0441889;C0456079;C1547707;C1565489;C2946261
3444,renal impairment *,C1565489
3444,mild to moderate renal impairment *,C1299392;C1565489
3443,renal dysfunction,C1565489;C3279454
3443,non - endstage renal dysfunction *,C0205088;C1518422;C1565489;C3279454
3443,non - end - stage renal dysfunction,C0205088;C1518422;C1565489;C3279454
3443,no renal dysfunction,C1565489;C3279454
3442,renal insufficiency / failure,C0035078;C0231174;C0231179;C0680095;C1565489;C1963154
3442,renal failure,C0035078;C1963154
3441,cardio - renal risk,C0018787;C0022646;C0035647;C4552904
3440,renal parameters,C0022646;C0449381
3439,renal functionc  n ( % ),C0022646
3439,renal events,C0022646;C0441471;C3541888
3439,renal,C0022646
3438,renal impairmentt,C0022646
3438,renal impairmentf,C0022646
3438,renal composite *,C0022646;C0205199;C1547335
3437,patients without prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
3437,patients with prevalent kidney disease at baseline,C0022646;C0030705;C0227665;C0683921
3437,exploratory kidney and microvascular outcomes,C0022646;C0227665
3436,basal insulin doset,C0650607
3436,basal insulin analogue : insulin,C0205112;C0243071;C0650607;C2825028
3435,type of basal insulin  n ( % ),C0205112;C0332307;C0457592;C0650607;C1547052
3435,basal insulin,C0650607
3434,basal insulin dose at run - in ( u / day ),C0178602;C0205112;C0366513;C0456683;C0650607;C0869039;C1114758;C3274438
3434,basal,C0205112
3433,no nasal polyps,C0027430
3433,nasal polyps at baseline : yes,C0027430;C0168634;C1442488;C1549445;C1705108;C1710701
3433,nasal polyps  n ( % ),C0027430
3433,nasal polyps,C0027430
3433,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430
3433,baseline presence of nasal polyps,C0027430;C0150312;C0168634;C0392148;C1442488;C3854307
3432,fatal or nonlatal stroke,C1302234;C1705232
3432,fatal or nonlatal myocardial inlarctlon,C1302234;C1705232
3432,fatal or nonfatal stroke,C1302234;C1705232
3432,fatal or nonfatal myocardial infarction,C1302234;C1705232
3432,fatal aes,C1302234;C1412268;C1705232;C2699274
3431,fatal bleeding,C0019080;C1302234;C1705232
3431,fatal bleed,C0019080;C1302234;C1705232
3430,non - fatal ml,C0439526;C1302234;C1518422;C1705224;C1705232;C3887665
3430,fatal chd + nonfatal ml,C0280604;C0439526;C1302234;C1705224;C1705232;C3542407;C3887665
3430,fatal and nonfatal ml,C1302234;C1705232
3430,fatal / nonfatal ml,C0439526;C1302234;C1705224;C1705232;C3887665
3430,fatal,C1302234;C1705232
3429,fatal chd and nonfatal mia,C0280604;C1302234;C1705232;C3542407
3429,fatal & nonfatal ccvd,C1302234;C1705232
3428,nonfatal mi + fatal chdt,C1302234;C1705232;C3810814
3428,mi ( fatal / nonfatal ),C1302234;C1705232;C3810814
3428,fatal / nonfatal mi ( excluding silent mi ),C1302234;C1705232;C3810814
3428,fatal / nonfatal mi  n ( % ),C1302234;C1705232;C3810814
3428,chd ( nonfatal mi + fatal chd ),C0280604;C1302234;C1705232;C3542407;C3810814
3427,non - fatal mi,C1302234;C1518422;C1705232;C3810814
3427,cv death  non - fatal mi or non - fatal stroke,C0011065;C1302234;C1306577;C1518422;C1705232;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
3426,non - fatal myocardial infarction,C0027051;C0428953;C1302234;C1518422;C1705232;C2926063;C3810814;C4552959
3426,fatal or non - fatal myocardial infarction,C1302234;C1705232
3426,fatal myocardial infarction,C0027051;C0428953;C1302234;C1705232;C2926063;C3810814;C4552959
3425,non - fatal stroke,C0038454;C1302234;C1518422;C1705232;C4554100
3425,fatal or non - fatal stroke,C1302234;C1705232
3425,fatal and nonfatal stroke,C1302234;C1705232
3425,fatal & nonfatal hospitalized stroke,C0038454;C0701159;C1302234;C1705232;C4554100
3424,remission component of variable,C0439828;C0449432;C0544452;C0687702;C1705248;C4553760
3423,variable demographic characteristics,C0439828;C0683970;C4553760
3422,variable ' ! ',C0439828;C4553760
3422,variable,C0439828;C4553760
3422,baseline variable,C0168634;C0439828;C1442488;C4553760
3421,variables .,C0439828
3421,stratification variables,C0439828;C1514983
3420,variables *,C0439828
3420,abbreviations : egfr = estimated glomerular filtration rate  imt = intimal medial thickness  lv = left ventricular . * two - sample comparison t - tests were calculated based on log - transformed variables . * * geometric mean with $nmbr$ % confidence interval in parenthesis .,C0000723;C0023128;C0162864;C0205098;C0205448;C0225897;C0334121;C0370003;C0439828;C0731033;C0871472;C1256463;C1280412;C1510411;C1527178;C1704614;C1705938;C1707455;C1708728;C1739039;C1881413;C2347026;C2986759;C2986775;C3811844;C3812682;C4318736
3419,variables $nmbr$,C0439828
3419,clinical variables  median ( iqr ),C0205210;C0439828;C0549183;C0876920;C2347635;C2348144;C2939193
3418,variables,C0439828
3418,diary variables  mean ( sd ),C0376660;C0439828;C0444504;C2347634;C2348143;C2699239
3417,overall pad,C0282416;C1561607
3417,overall ctd,C0282416;C1335071;C1442905;C1561607
3416,overall hr ( $nmbr$ % cl ),C0282416;C0596019;C1561607
3416,overall ( $nmbr$  $nmbr$ ),C0282416;C1561607
3416,overall,C0282416;C1561607
3415,overall treatment effect,C0282416;C1518681;C1561607
3415,overall effect,C0282416;C1280500;C1518681;C1561607;C2348382
3414,week $nmbr$ overall population,C0032659;C0282416;C0332174;C0439230;C1257890;C1561607
3414,remission in overall population,C0032659;C0282416;C0544452;C0687702;C1257890;C1561607
3414,overall vero population,C0032659;C0282416;C1257890;C1561607
3414,overall population ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1561607
3414,overall population ( n = $nmbr$ $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032659;C0282416;C1257890;C1319635;C1418845;C1518422;C1561607
3414,overall population ( n - $nmbr$ ),C0032659;C0282416;C1257890;C1561607
3414,overall population,C0032659;C0282416;C1257890;C1561607
3414,overall pea population,C0030738;C0032659;C0069964;C0070939;C0282416;C1257890;C1262903;C1561607;C3257529
3414,overall freedom population ( n = $nmbr$ ),C0016694;C0032659;C0282416;C1257890;C1561607
3414,overall a phase population,C0282416;C1561607
3414,overall $nmbr$,C0282416;C1561607
3414,calima overall ( n = $nmbr$ ),C0282416;C1561607
3413,overall ® $nmbr$ . $nmbr$,C0282416;C1561607
3413,overall  qvai $nmbr$ - sfc,C0282416;C1561607;C4521536
3412,overall n ( n / loopy ),C0282416;C1561607
3412,overall mortality,C0026565;C0026566;C0282416;C1561607
3411,overall n = $nmbr$  $nmbr$,C0282416;C1561607
3411,overall ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0282416;C1561607
3411,overall ( pp ) ( n = $nmbr$ ),C0030375;C0063017;C0282416;C1561607;C4319755
3411,overall ( per protocol ) ( n = $nmbr$ ),C0282416;C1561607;C1698058
3411,overall ( n = u $nmbr$ ),C0282416;C0439148;C1561607
3411,overall ( n = $nmbr$ vs $nmbr$ ),C0282416;C1561607
3411,overall ( n = $nmbr$ ),C0282416;C1561607
3411,overall ( n = $nmbr$  $nmbr$ ),C0282416;C1561607
3411,overall ( itt ) ( n = $nmbr$ ),C0282416;C1561607
3411,overall  n = $nmbr$,C0282416;C1561607
3410,subgroup overall,C0282416;C1079230;C1515021;C1561607
3410,a . overall and subgroups bv statin potency - -,C0282416;C1561607
3409,overall study period,C0282416;C1561607
3409,during overall study period,C0282416;C0439531;C0557651;C1561607;C1948053;C2603343
3409,- recurrent vte during overall study period,C0282416;C0439531;C0557651;C0630906;C1455761;C1561607;C1948053;C2603343;C2945760
3408,pb,C1415801;C3819255
3407,high feno subgroup ( > $nmbr$ . $nmbr$ ppb ) ( n = $nmbr$ ),C0205250;C1079230;C1299351;C1415800;C1515021;C2700149;C3887512;C3889660;C4321237;C4522209
3407,feno — ppb,C1415800
3407,> $nmbr$ to < $nmbr$ ppb,C1415800
3407,> $nmbr$ ppb,C1415800
3407,< $nmbr$ ppb,C1415800
3406,py = $nmbr$ . $nmbr$ ),C0030428;C3538810
3406,py = $nmbr$ ),C0030428;C3538810
3406,py *,C0030428;C3538810
3406,$nmbr$ events  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C3541888
3406,$nmbr$ event  $nmbr$ . $nmbr$ per $nmbr$ py ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),C0030428;C0441471;C3538810;C4019010
3406,$nmbr$ . $nmbr$ per $nmbr$ py,C0030428;C3538810
3405,pa,C0030428;C3541314
3405,no pa,C0030428;C3541314
3404,p for i,C0021966;C0221138;C0369773;C2603361
3403,p int . f,C0016327;C0369773;C2603361;C3272375
3403,p [ int ],C0369773;C2603361;C3272375
3403,p - int .,C0369773;C2603361;C3272375
3403,p - int,C0369773;C2603361;C3272375
3402,p blocker *,C0369773;C2603361
3402,p - interactio n,C0369773;C2603361
3402,p - heterogeneity,C0019409;C0242960;C0369773;C2603361
3402,* p for heterogeneity of treatment effect between tertiles > $nmbr$ . $nmbr$ .,C0019409;C0242960;C0369773;C1518681;C2603361
3401,p vaiue ( interaction ),C0369773;C1704675;C2603361
3401,p vaiue,C0369773;C2603361
3401,p interaction ( rx arm * sex ),C0009253;C0036864;C0079399;C0369773;C0446516;C0804628;C1314687;C1425688;C1521941;C1522384;C1704675;C2603361;C2709207;C3715044;C4553528
3401,p *,C0369773;C2603361
3400,p lace of randomization ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0280109;C0369773;C0453991;C1704675;C2603361
3400,p interaction = $nmbr$ . $nmbr$,C0369773;C1704675;C2603361
3400,p . interaction,C0369773;C1704675;C2603361
3399,p inleraclion,C0369773;C2603361
3399,p / interaction,C0369773;C1704675;C2603361
3399,p $nmbr$ interaction,C0369773;C1704675;C2603361
3399,p  treatment - by - region interaction,C0017446;C0039798;C0087111;C0205147;C0369773;C1522326;C1533734;C1704675;C1705169;C2603361;C3538994;C3887704
3399,p  interaction !,C0369773;C1704675;C2603361
3398,p blockersubgroup,C0369773;C2603361
3398,p  subgroup *,C0369773;C1079230;C1515021;C2603361
3398,p,C0369773;C2603361
3397,p  regional difference *,C0369773;C0682132;C2603361
3397,p  regional difference,C0369773;C0682132;C2603361
3396,p - blocking agents  selective,C0233660;C0332206;C0369773;C0450442;C1254351;C1521826;C2603361
3396,p +,C0369773;C2603361
3395,p $nmbr$ z $nmbr$ ( n = $nmbr$ ),C0369773;C2603361
3395,p $nmbr$ y $nmbr$ inhibitor maintenance,C0024501;C0369773;C1999216;C2603361
3395,p $nmbr$ y $nmbr$ inhibitor loading dos,C0369773;C1428722;C1708715;C1999216;C2603361
3395,p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
3395,p $nmbr$ y $nmbr$ antagonists,C0243076;C0369773;C2603361
3395,p $nmbr$ y $nmbr$ antagonist,C0231491;C0369773;C2603361
3394,p vs placebo,C0369773;C2603361
3394,p ) atients with > $nmbr$ exacerbations resulting in emergency department visit,C0369773;C2603361;C4086268
3394,p $nmbr$ vs usual care,C0369773;C2603361
3394,p $nmbr$ vs placebo,C0369773;C2603361
3394,p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361
3394,p  all vs all,C0369773;C2603361
3393,p ( women vs men ),C0043210;C0369773;C2603361
3392,p blockers ( % ),C0369773;C2603361
3392,p - blocker ( % ),C0369773;C2603361
3392,p ( losartan versus placebo ),C0126174;C0369773;C2603361
3392,p ( inter ),C0369773;C2603361
3391,without p blockers,C0369773;C2603361
3391,with p blockers,C0369773;C2603361
3391,p blockers,C0369773;C2603361
3391,p blocker,C0369773;C2603361
3391,p - blockers ( % ),C0369773;C2603361
3391,p - blockers  n ( % ),C0369773;C2603361
3391,p - blockers,C0369773;C2603361
3391,p - blocker intake at randomisation ( n = $nmbr$ o ),C0034656;C0369773;C1512806;C2603361
3391,p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
3390,p inter,C0369773;C2603361
3390,p - inter,C0369773;C2603361
3390,p - inte faction,C0369773;C2603361
3390,p ( inter - action ),C0205103;C0369773;C0441472;C1548610;C2603361;C3266814
3389,p valuey,C0369773;C2603361
3389,p valuer,C0369773;C0401806;C2603361
3389,p valuej ',C0369773;C2603361
3389,p valued,C0369773;C2603361
3389,p valuec,C0369773;C2603361
3389,p valueb,C0369773;C2603361
3389,p valuea,C0369773;C2603361
3389,p for inter - act,C0369773;C2603361
3389,p - valuec,C0369773;C2603361
3389,p - valueb,C0369773;C2603361
3389,p - valuea,C0369773;C2603361
3389,p - for interaetion,C0369773;C2603361
3389,p - blocker,C0369773;C2603361
3389,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms  divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter  multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone  $nmbr$  placebo  $nmbr$  and icd  $nmbr$ ) . ace de - notes angiotensin - converting enzyme  and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups,C0015663;C0020443;C0369773;C0439209;C0439300;C0439583;C0441889;C0456079;C0456962;C0475211;C0750194;C0871208;C1316572;C1317574;C1516879;C1521828;C1522133;C1547707;C1696073;C1704788;C1707455;C1719797;C2603361;C2911648;C2919575;C2946261;C2985769;C3539106;C3888021
3388,p   vs . placebo,C0369773;C2603361
3388,p . o ),C0369773;C2603361
3388,p - val . ( $nmbr$ ),C0042285;C0369773;C0523975;C2603361
3387,p - sitosterol / total c ( | imol / mmol ),C0037215;C0220914;C0369773;C0439175;C0439190;C0439810;C2603361
3387,p - sitosterol / lathosterol,C0037215;C0064673;C0220914;C0369773;C2603361
3386,prior myocardial infarction 一 no . ( % ),C0155668
3386,prior myocardial infarction — no . { % ),C0155668
3386,prior myocardial infarction — no . / total no . ( % ),C0155668
3386,prior myocardial infarction — no . ( % ),C0155668
3386,prior myocardial infarction yes,C0155668;C1549445;C1705108;C1710701
3386,prior myocardial infarction ( % ),C0155668
3386,prior myocardial infarction  no . / total no . ( % ),C0155668
3386,prior myocardial infarction  n ( % ),C0155668
3386,prior myocardial infarction  %,C0155668
3386,prior myocardial infarction,C0155668
3386,> $nmbr$ prior myocardial infarction — no . ( % ),C0155668
3385,pfor interaction,C1151635;C1704675
3385,pfor,C1151635
3384,prior urate lowering therapies  n ( % ),C0441994;C0729829;C0935936;C1514463;C2003888
3383,prior ed therapy,C1514463;C3538926
3382,prior treatment — no . ( % ),C1514463
3382,prior treatment — %,C1514463
3382,prior corticosteroid treatment,C0001617;C1514463;C3536709
3381,prior treatment,C1514463
3381,prior therapy with tnf antagonist  n ( % ),C0231491;C0279936;C0332152;C1448177;C1514463;C2826257
3381,prior therapy  %,C1514463
3381,prior anti - tnf treatment,C1448177;C1514463
3381,any prior anti - tnf treatment failure,C0162643;C0231174;C0235828;C0332152;C0521983;C0680095;C1448177;C1514463;C1547544;C2826257
3380,prior tnfi treatment,C1514463
3380,prior tnf antagonist treatment - yes,C0231491;C1448177;C1514463;C1549445;C1705108;C1710701
3380,prior tnf antagonist treatment - no,C0231491;C1448177;C1514463
3379,proton pump inhibitor use,C0042153;C0358591;C0457083;C1947944;C3536754;C4521480
3379,proton pump inhibitor ( n  % ),C0358591;C3536754;C4521480
3379,proton pump inhibitor,C0358591;C3536754;C4521480
3379,proton - pump inhibitor,C0358591;C3536754;C4521480
3378,proton pump inhibitors,C0358591;C1384478;C3540020
3378,proton - pump inhibitors,C0358591;C1384478;C3540020
3377,regular ppi use,C0205272;C0358591;C0871125;C3811894
3377,ppi use within $nmbr$ months of randomization,C0358591;C0871125;C3811894
3377,ppi use at baseline,C0358591;C0871125;C3811894
3377,ppi use ( p = $nmbr$ . $nmbr$ t ),C0358591;C0871125;C3811894
3377,ppi use ( p = $nmbr$ - $nmbr$ t ),C0358591;C0871125;C3811894
3377,ppi use,C0358591;C0871125;C3811894
3377,ppi or h $nmbr$ receptor antagonist  n ( % ),C0358591;C0871125;C3811894
3377,ppi but no aspirin,C0358591;C0871125;C3811894
3377,ppi,C0358591;C0871125;C3811894
3377,nontrial ppi,C0358591;C0871125;C3811894
3377,non - study ppi use,C0358591;C0557651;C0871125;C1518422;C2603343;C3811894
3377,no regular ppi use,C0205272;C0358591;C0871125;C3811894
3377,no ppi,C0358591;C0871125;C3811894
3376,pbo n ( % ),C0031962
3376,pbo ( n   =   $nmbr$ ),C0031962
3376,pbo  no . ( o / o ) ^ ’,C0031962
3376,pbo  no . ( % ) ^,C0031962
3376,ind + pbo ( n = $nmbr$ ),C0031962;C4049864
3375,pbo - sc every other week ( n = $nmbr$ ),C0031962;C0282380
3375,pbo ( n - $nmbr$ ),C0031962
3375,pbo ( n $nmbr$ ),C0031962
3374,pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ ( n = $nmbr$ ),C0024671;C0026410;C0031962;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
3374,pbo ( n $nmbr$ $nmbr$ ),C0031962
3373,type $nmbr$ diabetes pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1320657
3373,pbo ( n = $nmbr$ ),C0031962
3372,pbo  n = $nmbr$,C0031962
3372,mets pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C0812270;C1705694;C2939420
3371,pbo ( n = $nmbr$ ) vs,C0031962
3371,ifg pbo ( n = $nmbr$ ) vs evomab ( n = $nmbr$ ),C0031962;C1334085;C1708411
3370,pbo,C0031962
3370,difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C1705241;C1705242;C3259781
3369,pbo + mtx to mtx,C0025677;C0031962;C1417487
3369,pbo + mtx ^ mtx,C0025677;C0031962;C1417487
3369,pbo + mtx,C0025677;C0031962;C1417487
3369,flex pbo ®,C0031962
3368,vdz / pbo [ n = $nmbr$ ],C0031962
3368,pbo n = $nmbr$,C0031962
3368,pbo + mtx n = $nmbr$,C0025677;C0031962;C1417487
3367,environmental stimuli,C0450025
3366,stable angina — no . ( % ),C0340288
3366,stable angina ( n = $nmbr$  $nmbr$ ),C0340288
3366,stable angina ( n - $nmbr$  $nmbr$ ),C0340288
3366,stable angina  n ( % ),C0340288
3366,stable angina,C0340288
3366,histor y of stable angina,C0340288
3366,chronic stable angina,C0340288
3365,primary management strategy,C0001554;C0205225;C0376636;C0439612;C0439631;C0679199;C1273870;C3273539
3365,medical management only — no . { % ),C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
3365,medical management only,C0001554;C0199168;C0205171;C0205476;C0376636;C1273870;C1720467;C3273539
3365,management of event — no . ( % ),C0001554;C0376636;C0441471;C1273870;C3273539;C4019010
3365,management distribution medical treatment,C0001554;C0030677;C0199168;C0205476;C0376636;C0520511;C0679624;C1273870;C1704711;C3273539
3365,management distribution,C0001554;C0376636;C0520511;C1273870;C1704711;C3273539
3365,managed medically — no . / total no . ( % ),C1273870
3364,metabolism and nutrition,C0025519;C0025520
3363,glucose metabolism,C0596620
3363,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . ‡ p < $nmbr$ . $nmbr$ vs . non - epa . § p < $nmbr$ . $nmbr$ vs . non - epa,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1518422;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
3362,metabolic syndromeb,C0311400;C1524026;C2707259
3361,no metabolic syndrome,C0524620
3361,metabolic syndrome — no . ( % ) ^,C0524620
3361,metabolic syndrome — no . ( % ) $nmbr$,C0524620
3361,metabolic syndrome — no . ( % ) !,C0524620
3361,metabolic syndrome characteristics  n ( % ),C0524620;C1521970
3361,metabolic syndrome ( % ) b,C0524620
3361,metabolic syndrome ( % ),C0524620
3361,metabolic syndrome  n / n ( % ) *,C0524620
3361,metabolic syndrome  ! n ( % ),C0524620
3360,ncep atp - iii metabolic syndrome features  n ( % ),C0439070;C0524620;C1705160;C2744579;C4552600
3360,metabolic syndrome * n = $nmbr$,C0524620
3360,metabolic syndrome *,C0524620
3360,metabolic syndrome ( n = $nmbr$ ),C0524620
3360,metabolic syndrome $nmbr$ *,C0524620
3360,metabolic syndrome  n ( % ),C0524620
3359,the metabolic syndrome ^,C0524620
3359,metabolic syndrome w / o t $nmbr$ dm,C0011816;C0524620;C3250443
3358,metabolic syndrome $nmbr$ baseline lipids  mg / dl,C0023779;C0168634;C0439269;C0524620;C1442488
3358,metabolic syndrome,C0524620
3357,metabolic syndrome visit $nmbr$ low - density lipoprotein cholesterol strata,C0524620
3357,high - density lipoprotein cholesterol metabolic syndrome  patients were to,C0023822;C0030705;C0524620
3356,without metabolic syndrome,C0524620
3356,with metabolic syndrome,C0524620
3356,participants without metabolic syndrome,C0524620;C0679646
3356,participants with metabolic syndrome,C0524620;C0679646
3355,characteristic / outcome,C1274040;C1521970
3354,outcome severity,C0439793;C0522510;C1274040
3354,adverse outcome,C1274040
3353,outcomes,C1274040
3353,joint damage outcomes ( mitt population ),C0010957;C0022417;C0032659;C0392905;C1257890;C1274040;C1706309;C1883709
3352,primary safety outcome -,C0036043;C0205225;C0439612;C0439631;C1274040;C1705187
3352,primary outcomes,C0205225;C0439612;C0439631;C1274040
3352,primary outcome plus revascularization or nonfatal hf,C0205225;C0332287;C0439612;C0439631;C0581603;C1274040
3352,primary outcome : $nmbr$ % decrease in womac pain score,C0205225;C0392756;C0439612;C0439631;C0547047;C0582148;C1274040
3352,primary outcome ! ( n = $nmbr$ ),C0205225;C0439612;C0439631;C1274040
3352,primary outcome !,C0205225;C0439612;C0439631;C1274040
3352,primary outcome,C0205225;C0439612;C0439631;C1274040
3352,primary efficacy outcome,C0205225;C0439612;C0439631;C1274040;C1280519;C1707887
3352,outcome,C1274040
3352,chd ( primary outcome ),C0205225;C0280604;C0439612;C0439631;C1274040;C3542407
3351,outcome - variant,C0205419;C1274040
3350,outcome type,C0332307;C1274040;C1547052
3350,outcome and metabolizer phenotype,C1274040
3349,outcome according to stage of cancer — no . / total no . ( % ),C0027646;C0680240;C1274040
3349,outcome according to primary cancer site — no . / total no . ( % ),C0680240;C0872338;C1274040
3349,outcome ( n  % },C1274040
3348,outcomes during accord,C0680240;C1274040
3348,outcome according to no . of risk factors for vte,C0035648;C0680240;C1274040;C1553898
3348,other outcomes,C1274040
3347,result,C1274040;C1546471;C2825142
3347,ancova result,C0814908;C1274040;C1546471;C2825142
3346,time from sx onset to baseline ecg  min,C0449244;C1519428;C3539997;C3815196
3345,time from symptoms onset to $nmbr$ st balloon inflation ( h ),C0449244;C0683368;C1457887
3345,time from onset to randomization  h  mean ± sd,C0449244
3345,time from onset to medication  h  mean ± sd,C0449244
3344,time to treatment  h,C0033727;C0369286;C0441932;C0564385;C3494202;C4528284
3344,time to treatment,C3494202
3343,time intervals  h,C0033727;C0369286;C0441932;C0564385;C0872291;C4528284
3343,time intervals,C0872291
3342,middle third,C0442050
3341,middle tg tertile,C0337445;C0444598;C0549183;C1552826
3341,middle tertile : > $nmbr$ . $nmbr$ to b $nmbr$ . $nmbr$,C0444598;C0549183;C1552826
3341,middle,C0444598;C0549183;C1552826
3341,canakinumab  il - $nmbr$ middle tertile,C0020898;C0021764;C0022271;C0444598;C0549183;C1552826;C2718773
3340,multiple ( $nmbr$ + ) chd risk,C0439064;C1282512
3339,other / multiple,C0439064
3339,multiple risk factors,C0035648;C0439064;C1553898
3339,multiple ( > $nmbr$ ) chd risk factors that confer a $nmbr$ - year risk of chd > $nmbr$ %,C0035648;C0280604;C0439064;C1553898;C3542407
3339,multiple,C0439064
3338,multiple tnfi and other bdmards §,C0439064
3338,multiple tnfi *,C0439064
3338,multiple diagnoses,C0011900;C0439064
3337,troponin positive ( n = $nmbr$ ),C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
3337,rf positive and acpa negative  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
3337,rf positive  no . ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
3337,positive vs . negative,C0439178;C1446409;C1514241;C2825490;C3812269
3337,positive troponin i or t  no . ( % ),C0077401;C0439178;C1446409;C1514241;C2825490;C3812269
3337,positive hla - b $nmbr$ status  n ( % ),C0439178;C0449438;C1426226;C1446409;C1514241;C2825490;C3812269
3337,positive ctnl ( n = $nmbr$ ),C0439178;C1446409;C1514241;C2825490;C3812269
3337,positive,C0439178;C1446409;C1514241;C2825490;C3812269
3337,hla ‐ b $nmbr$ positive    n   ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
3337,hla - b $nmbr$ positive at baseline  n ( % ),C0019737;C0168634;C0439178;C0550853;C1415561;C1442488;C1446409;C1514241;C2825490;C3812269
3337,hla - b $nmbr$ positive  n ( % ),C0439178;C1426226;C1446409;C1514241;C2825490;C3812269
3337,gad positive — no . ( % ) ^,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
3337,anticyclic citrullinated peptide positive ^  n ( % ),C0439178;C1320283;C1446409;C1514241;C2825490;C3812269
3337,acpa positive ( > $nmbr$ iu / ml )  n ( % ),C0439178;C0439458;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
3337,acpa positive  no . ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
3337,acpa positive  n ( % ),C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
3337,acpa positive  %,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
3337,acpa positive,C0439178;C1446409;C1514241;C1525410;C1706063;C2825490;C3812269
3336,positive atopic status,C0392707;C0439178;C0449438;C1446409;C1514241;C2825490;C3812269
3336,* * positive stress test,C0015260;C0439178;C1446409;C1514241;C2825490;C3494508;C3812269
3335,ruled out non - fatal pe with or,C1446409
3335,low complement / anti - dsdna positive ( n = $nmbr$ ),C0012854;C0311474;C0432633;C0439178;C1446409;C1514241;C2825490;C3812269;C3897137
3335,anti - gad positive ( n = $nmbr$ ),C0270549;C0432633;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
3335,anti - gad positive,C0270549;C0439178;C1414925;C1446409;C1514241;C2825490;C3812269
3335,anti - dsdna positive,C0439178;C0741099;C1446409;C1514241;C2825490;C3812269
3335,anti - ccp positive ( > $nmbr$ u / ml )  n ( % ),C0432633;C0439178;C0439340;C1446409;C1514241;C1525410;C1704514;C1880521;C2825490;C2945590;C3812269
3335,anti - ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269;C4318437
3334,local eosinophil count [ cells / µ l ]  median ( range ),C0200638;C0205276;C0347983;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
3334,local eosinophil count [ cells / ml ]  median ( range ),C0200638;C0205276;C0549183;C0750879;C0876920;C1514721;C2347635;C2348144;C2348147;C2699156;C2939193;C3542016
3334,local eosinophil count,C0200638;C0205276;C0750879
3333,mean eosinophil count  per ml,C0200638;C0439526;C0444504;C0750879;C1705224;C2347634;C2348143;C3887665
3333,eosinophil count,C0200638;C0750879
3332,central eosinophil count ( cells per pl ) t,C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
3332,central eosinophil count ( cells per pl ),C0007584;C0007634;C0200638;C0205099;C0750879;C1879652;C3897966;C4049765
3332,central eosinophil count,C0200638;C0205099;C0750879;C1879652
3331,mean blood eosinophil count ( cells per pl ),C0200638;C0444504;C2347634;C2348143;C3897966;C4049765
3331,blood eosinophils  mean ( range )  cells / mlb,C0005773;C0007584;C0007634;C0014467;C0200638;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
3331,blood eosinophil count ( $nmbr$ cells per l ),C0200638
3330,blood eosinophils  mean ( range )  cells / ml,C0014467;C0444504;C1514721;C2347634;C2348143;C2348147;C2699156;C3542016
3330,blood eosinophils  cells / ml,C0014467;C2699156
3329,blood eosinophil concentration  $nmbr$ cells per l,C0014467;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
3329,blood eosinophil,C0014467
3328,eosinophils £ $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ % ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils $nmbr$ % ( n - $nmbr$ ),C0014467;C0200638
3328,eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467;C0200638
3328,eosinophils,C0014467;C0200638
3328,blood eosinophils count,C0014467
3328,blood eosinophil count  geometric mean ( sd loge scale ) cells / ll,C0014467
3327,low eosinophil subgroup (  $nmbr$ / ml ) ( n = $nmbr$ ),C0014467;C0205251;C0439526;C1079230;C1515021;C1550472;C1705224;C3887665;C3890211;C4048187;C4321351;C4522223
3327,eosinophil low,C0014467
3327,eosinophil high,C0014467
3326,losartan plus lisinopril ( n = $nmbr$ ),C0065374;C0126174;C0332287
3326,losartan + lisinopril,C0065374;C0126174
3326,lisinopril ( n = $nmbr$ ),C0065374
3326,$nmbr$ lisinopril,C0065374
3325,lisinopril vs chlorthalidone overweight,C0065374
3325,lisinopril vs chlorthalidone obese,C0065374
3325,lisinopril vs chlorthalidone normal,C0065374
3325,lisinopril vs chlorthalidone,C0065374
3325,lisinopril vs amlodipineb,C0065374
3325,lisinopril cvd total,C0007222;C0065374;C0439175;C0439810
3325,lisinopril,C0065374
3324,poslmenopausal  ht,C0018510;C0677607
3323,premenopausal  %,C0279752
3323,premenopausal,C0279752
3322,orthopnea  ( % ),C0085619
3322,orthopnea,C0085619
3321,lymphadenopathy,C0497156;C4282165
3320,retinopathy — no . ( % ),C0035309;C1962966
3320,retinopathy — %,C0035309;C1962966
3320,retinopathy ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0035309;C0205390;C1300072;C1306673;C1962966
3320,retinopathy,C0035309;C1962966
3319,history of postmenopausal fracture *,C0232970;C1272071
3318,postmenopausal ( % ),C0232970
3318,postmenopausal,C0232970
3318,post - menopausal ( a ),C0232970
3317,postmenopausal and no ht,C0232970
3317,postmenopausal and no hrt,C0232970
3317,postmenopausal and current ht,C0232970
3317,postmenopausal and current hrt,C0232970
3317,postmenopausal  no hrt,C0232970
3317,postmenopausal  current hrt,C0232970;C0282402;C0521116;C1705970
3316,mostly satisfied,C0205393;C0750554
3316,mostly dissatisfied,C0205393;C0750554
3315,most frequent non - infectious teaesb,C0205393;C0239998;C1518422
3315,most frequent infections,C0205393;C0239998
3314,st ‐ str ≥ $nmbr$ % post pci,C0036056;C0687676;C1704687;C3272372;C3469826;C4049621
3313,post - cabg,C0010055;C0687676;C1704687;C3469826
3312,post svc,C0231957;C0687676;C1704687;C3469826
3312,post hoc analysis,C0002778;C0687676;C0936012;C1524024;C1704687;C3469826
3312,overall cohort ( post hoc analysis excluding metformin users ),C0025598;C0086027;C0282416;C0332196;C0687676;C1561607;C1704687;C1706077;C2828389;C3469826
3311,components of primary composite end point — secondary end points,C0205199;C1547335;C1882460;C4528314
3310,primary composite endpoint ‡,C0205199;C1547335;C2986535
3310,primary composite end point ‡,C0205199;C1547335;C2986535
3310,primary composite end point,C0205199;C1547335;C2986535
3309,composite vascular endpoint,C0005847;C0205199;C1547335;C1558950;C1801960;C2349179;C2826544
3309,composite ocular end point ^,C0015392;C0042789;C0205199;C0700042;C1299003;C1547335;C2349179;C2826544;C4521296
3309,composite microvascular end point *,C0205199;C0443258;C1547335;C2349179;C2826544
3309,composite endpoint of doubling of serum creatinine  esrd,C0022661;C0035078;C0201976;C0205173;C0205199;C0600061;C1547335;C1705764;C2316810;C2349179;C2826544
3309,composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ %  bp,C0037623;C0205199;C1415692;C1547335;C1708288;C2349179;C2826544;C4318478
3309,composite endpoint,C0205199;C1547335;C2349179;C2826544
3309,( composite endpoint ),C0205199;C1547335;C2349179;C2826544
3308,disease - progression composite outcome !,C0205199;C0242656;C0449258;C0679250;C1274040;C1335499;C1547335;C1947900;C3542417;C4552808
3308,composite,C0205199;C1547335
3307,geometric mean ige on loge scale — u / ml,C0175659;C0349674;C0439340;C1880521;C1947916;C2697934;C2945590;C2986759
3307,geometric mean blood eosinophil count on loge scale — cells / ^ ljj,C0175659;C0200638;C0349674;C1947916;C2697934;C2986759
3307,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$,C0175659;C0200638;C0349674;C1947916;C2697934;C2699239;C2986759;C4330985;C4554674
3307,geometric mean,C2986759
3306,geometric mean uacr,C2986759
3306,geometric mean ofcrp — mg / liter ( range ),C0024671;C0026410;C0439269;C0475211;C1514721;C1960952;C2346927;C2348147;C2986759;C3542016;C4321396;C4521761
3305,spirometry,C0037981
3305,spirometric values at baseline,C0037981;C0042295;C0168634;C0183441;C1442488
3305,baseline spirometry,C0037981;C0168634;C1442488
3304,symptomatic remissionb n / n ( % ),C0231220
3304,symptomatic hypoglycaemia,C0020615;C0231220;C4553659
3303,symptomatic infarct swelling,C0013604;C0021308;C0038999;C0231220
3303,symptomatic,C0231220
3302,symptomatic localization - related,C0231220;C0475264;C1744691
3301,symptomatic padt,C0231220
3301,symptomatic pad,C0182158;C0231220;C0332568;C3540603;C3669270;C3814046;C4319657
3300,clinical dementia rating score,C4304227
3299,romania,C0035826
3298,documented symptomatic chdb,C0231220;C1301725;C1609436
3297,documented hypoglycaemiac,C1301725;C1609436
3297,documented asymptomatic cardiac ischemiac,C0018787;C0231221;C1301725;C1522601;C1609436
3296,scarring on renal biopsy,C0005558;C0008767;C0194073;C0220797;C1700247;C2004491
3295,prostate biopsy,C0194804
3294,tophi present  n ( % ),C0221248
3294,presence of tophi  n ( % ),C0150312;C0221248;C0392148;C3854307
3294,presence of tophi,C0150312;C0221248;C0392148;C3854307
3293,type of hospitalization,C3177060
3292,type of vessel involved,C1282017
3291,type of intervention,C3274412
3290,type of index event — no . ( % ),C0600653;C0918012;C1552854;C1561488;C1637833;C2986546
3290,type of event — no . ( % ),C1561488
3290,type of event :,C1561488
3290,type of event,C1561488
3289,presence of angioedema at baseline,C0002994;C0150312;C0392148;C3854307
3288,presence of mets ( % ) a,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
3288,presence of mets,C0150312;C0392148;C0812270;C1705694;C2939420;C3854307
3288,presence of honeycombing  $nmbr$ n ( % ),C0150312;C0332468;C0349384;C0392148;C3854307
3288,presence of erosions  n ( % ),C0150312;C0333307;C0392148;C1959609;C3854307
3288,presence of enthesitis,C0150312;C0392148;C1282952;C3854307
3288,presence of dactylitis,C0150312;C0239161;C0392148;C3854307
3287,cataract removal,C0007389
3286,cataract,C0086543;C4555209
3285,total cataract extraction,C0007389;C0185115;C0439175;C0439810;C0684295;C3665439
3285,total cataract,C3665439
3284,patient global assessment of disease,C0012634;C4054229
3284,patient ' s global assessment of disease,C0012634;C4054229
3284,patient ' s global assessment of,C4054229
3283,patient ' s global assessment of response to therapy score,C0871261;C1704632;C1706817;C2911692;C4054229
3283,patient ' s global assessment,C4054229
3282,patient ' s global assessment ( vas ),C0042815;C3536884;C3827561;C4054229
3282,patient ' s global assessment !,C4054229
3281,atypical absence,C0595948
3280,dermatitis atopic,C0011603
3279,atonic,C0541791
3278,atopic at baseline : yes,C0168634;C0392707;C1442488;C1549445;C1705108;C1710701
3278,atopic,C0392707
3277,heparin plus gpi ( n = $nmbr$  $nmbr$ ),C0019134;C0332287;C0770546;C1415351
3277,heparin plus a gpi ( n = $nmbr$ ),C0019134;C0770546;C1415351
3277,gpi used during pci,C1415351
3277,bivalirudin - heparin plus gpi,C0019134;C0168273;C0770546;C1415351
3276,serious gi disorder,C0012634;C0205404;C1708130;C3539617;C4050121
3276,no gi bleed,C1708130;C3539617;C4050121
3276,most frequent gi disorders,C0012634;C0205393;C0332183;C1708130;C3539617;C4050121
3276,gi bleed,C1708130;C3539617;C4050121
3276,$nmbr$ - gi,C1708130;C3539617;C4050121
3275,health assessment questionnaire - disability index,C4321476
3275,haq di score ( range $nmbr$ - $nmbr$ )  mean ± sd,C0444504;C0449820;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4050231;C4321476
3275,haq di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
3275,haq - di score ( $nmbr$ - $nmbr$ ),C0449820;C3826998;C4050231;C4321476
3275,haq - di score,C0449820;C3826998;C4050231;C4321476
3275,haq - di mcide,C3826998;C4321476
3274,haq di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
3274,haq - di ( range $nmbr$ - $nmbr$ ),C1514721;C2348147;C3542016;C3826998;C4321476
3274,haq - di ( $nmbr$ - $nmbr$ ),C3826998;C4321476
3274,haq - di  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C3826998;C4321476
3273,haq di,C3826998;C4321476
3273,haq - di total score  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C2964552;C3826998;C4321476
3273,haq - di score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C3826998;C4050231;C4321476
3273,haq - di ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
3273,haq - di  mean [ sd ],C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
3273,haq - di  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C3826998;C4321476
3273,haq - di,C3826998;C4321476
3273,( haq - di  $nmbr$ - $nmbr$ ),C3826998;C4321476
3272,mean score on haq - di §,C3533236;C3826998;C4321476
3272,haq - di scoreff,C3826998;C4321476
3272,haq - di scored,C3826998;C4321476
3272,haq - di * *,C3826998;C4321476
3272,haq - di *,C3826998;C4321476
3271,haq - di improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3826998;C4321476
3271,haq - di improvement > $nmbr$ . $nmbr$,C2986411;C3826998;C4321476
3270,apolipoprotein a - i *,C0085201;C1677784
3270,apolipoprotein a - i,C0085201;C1677784
3270,apo a - i ( mg / dl ) *,C0085201;C0439269;C1677784
3270,apo a - i  mg / dl,C0085201;C0439269;C1677784
3270,apo a - i,C0085201;C1677784
3269,apob : apoa - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
3269,apob : apoa - i,C0003593;C0085201;C1677784;C3252643
3269,apoa - i,C0085201;C1677784
3269,apo b : apo a - i ratio,C0003593;C0085201;C0456603;C1547037;C1677784;C3252643
3268,pasi < $nmbr$ *,C4528685
3268,pasi $nmbr$,C4528685
3268,pasi  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4528685
3268,baseline pasi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C4528685
3267,pasi $nmbr$ a,C4528685
3267,pasi # $nmbr$ at week $nmbr$,C0332174;C0439230;C4528685
3266,pasi response by baseline weight  no . / total no . ( % ) * pasi $nmbr$,C0871261;C1303013;C1704632;C1706817;C2911692;C4528685
3266,pasi response by baseline mtx use  no . / total no . ( % ) * pasi $nmbr$,C0025677;C0168634;C0871261;C1417487;C1442488;C1704632;C1706817;C2911692;C4528685
3266,pasi $nmbr$ response },C0871261;C1704632;C1706817;C2911692;C4528685
3266,pasi $nmbr$  no . / total no . ( % ) $nmbr$,C4528685
3265,pasi score > $nmbr$ *,C0449820;C4050231;C4528685
3265,pasi score ( $nmbr$ - $nmbr$ ) t  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
3265,pasi score ( $nmbr$ - $nmbr$ ) d,C0449820;C4050231;C4528685
3265,pasi score ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
3265,pasi score ( $nmbr$ - $nmbr$ ),C0449820;C4050231;C4528685
3265,pasi score $nmbr$,C0449820;C4050231;C4528685
3265,pasi score ! * *,C0449820;C4050231;C4528685
3265,pasi score  mean ± sd,C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
3265,pasi score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C4050231;C4528685
3265,pasi score  $nmbr$ - $nmbr$ *,C0449820;C4050231;C4528685
3265,pasi score,C0449820;C4050231;C4528685
3265,pasi *,C4528685
3265,pasi,C4528685
3265,baseline pasi score,C0168634;C0449820;C1442488;C4050231;C4528685
3264,overall dlqi score $nmbr$,C0282416;C1561607;C3899393
3264,overall dlqi score,C0282416;C1561607;C3899393
3264,dlqi §,C3899393
3263,mean dlqi score ( $nmbr$ % ci ),C0444504;C2347634;C2348143;C3899393
3263,dlqi score,C3899393
3263,dlqi  $nmbr$ - $nmbr$ *,C3899393
3263,dlqi,C3899393
3262,measured at home with automated device,C0444706;C3541902
3262,measured at clinic visit with usual device,C0008952;C0444706;C3541902
3262,measured at clinic visit with automated device §,C0008952;C0444706;C3541902
3261,devices for heart failure at screening visit,C0018787;C0018801;C0018802;C0025078;C0025080;C0220819;C0231174;C0680095;C0699733;C2024216;C4554158
3261,devices,C0025080;C0220819;C0699733
3260,prior exposure to levetiracetam,C0274281;C0332152;C0332157;C0377265;C2826257;C3693636
3260,levetiracetam,C0377265;C3693636
3259,erysipelas,C0014733
3258,★ reported by physicians . tdata are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1709908
3258,* reported by physicians . † data are median ( iqr ) . all data are mean ( sd ) or number ( % ) unless otherwise indicated .,C0031831;C1511726;C1709908;C3245479;C3714741
3257,physician ' s judgment that vka inappropriate ],C0022423;C0031831;C0804815
3257,physician ' s judgment that vka inappropriate,C0022423;C0031831;C0804815
3257,physician ' s judgment that vka,C0022423;C0031831;C0804815
3257,physician,C0031831;C0804815
3256,physical examination,C0031809;C1744699
3255,physical examinations,C0031809
3255,physical characteristics,C0031809;C0205485;C1509143;C1521970
3255,physical and cognitive examination : ! :,C0031809;C0205485;C1509143
3254,study $nmbr$ - item short - form general health survey ( sf - $nmbr$ ) can range from $nmbr$ to $nmbr$ for the physical component and from $nmbr$ to $nmbr$ for the mental,C0031809;C0037712;C0040363;C0041260;C0205485;C0229992;C0348078;C0376315;C0449432;C0557651;C1282927;C1509143;C1522492;C1551338;C1705248;C1806781;C1883351;C2350002;C2603343;C3481509;C4255237;C4554251
3254,sf - $nmbr$ physical component summaryjj,C0031809;C0037712;C0205485;C0449432;C1509143;C1705248
3254,physical component summary,C0031809;C0205485;C0449432;C1509143;C1552616;C1705248;C1706244
3254,physical component,C0031809;C0205485;C0449432;C1509143;C1705248
3253,physical functioning,C0516981;C4049916
3253,physical function,C0516981;C4049916
3253,assessment of physical function ( $nmbr$ - $nmbr$  haq - di ),C0031809;C0031843;C0516981;C0542341;C0700205;C1261322;C1516048;C1705273;C3826998;C4049916;C4321476
3252,efficacy variable,C0439828;C1280519;C1707887;C4553760
3251,combined efficacy and safety endpoint,C0205195;C1280519;C1707887
3250,overall efficacy,C0282416;C1280519;C1561607;C1707887
3250,efficacy    n   ( % ) a,C1280519;C1707887
3250,efficacy,C1280519;C1707887
3249,peripheral limb vascular efficacy,C0015385;C0150936;C0947487;C1280519;C1707887
3249,efficacy measures,C1280519;C1707887
3248,primary / key efficacy endpoint,C1280519;C1707887;C1709665;C2349179;C2826544
3248,efficacy endpoints *,C1280519;C1707887;C2349179
3248,efficacy endpoint,C1280519;C1707887;C2349179;C2826544
3248,efficacy end points,C1280519;C1707887;C2349179
3248,efficacy and safety : net adverse clinical events *,C1280519;C1707887
3247,surgical technique,C0683469
3246,medical therapy only ( n = $nmbr$ ),C0205171;C0418981;C1720467
3246,medical therapy only,C0205171;C0418981;C1720467
3246,medical therapy ( n = $nmbr$ ),C0418981
3246,medical therapy,C0418981
3245,stenting plus medical therapy ( n = $nmbr$ ),C0038257;C0418981;C2348535
3245,stent plus medical therapy,C0038257;C0418981
3244,medical therapy before randomization — no . / total no . ( % ),C0034656;C0418981
3244,medical therapies,C0418981
3243,medical therapy alone,C0418981
3243,baseline medical therapy  n ( % ),C0168634;C0418981;C1442488
3243,baseline medical therapy,C0168634;C0418981;C1442488
3242,ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446
3241,other supraventricular tachycardia,C0039240;C1963244;C3815188
3240,supraventricular tachyarrhythmias ( incl . atrial,C1698480;C3853833
3239,ventricular tachyarrhythmias,C3827656
3238,india,C0021201;C2700456
3237,indian ( indian subcontinent ),C0454693
3236,indian ( american ) or alaska native,C0596070;C1524069
3236,indian,C1524069
3235,minimal important change threshold ( improvement ) a,C0449864;C2986411;C3845594;C3898777;C4084912
3235,medically important infectionsa,C3898777;C4084912
3234,symptom onset to first medical contact : ambulance or emergency department,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685;C4086878
3234,first medical contact — no . ( % ) §,C0199168;C0205435;C0205476;C1279901
3234,first medical contact in ambulance,C0002422;C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666;C3846685
3234,first medical contact,C0199168;C0205435;C0205476;C0332158;C0337611;C1279901;C1705415;C3812666
3233,medical historv,C0199168;C0205476
3233,medical characteristics,C0199168;C0205476;C1521970
3233,medical and lifestyle history,C0199168;C0205476
3232,american indian or native alaskan,C0002460
3232,american indian or alaskan native,C0002460
3232,american indian or alaskan,C0002460
3232,american indian or alaska native  :,C0002460
3232,american indian or alaska native,C0002460
3232,american indian or alaska,C0002460
3232,american indian or,C0002460
3232,american indian / alaskan native  n ( % ),C0002460;C0238611;C0302891;C0886378;C1524069
3232,american indian / alaskan native,C0002460;C0238611
3232,american indian /,C0002460
3232,american indian  alaskan native  or aboriginal canadian,C0002460;C0238611
3232,american indian,C0002460
3231,american ‐ indian / alaska native,C0002460
3231,american indian / native alaskan,C0002460;C0682125
3231,american indian / alaska native,C0002460
3230,native american or alaskan native,C0282204;C1515945
3230,native american or alaska native,C0282204;C1515945
3230,native american / alaskan,C0238611;C0282204;C0596070;C0682125;C1515945
3230,native american,C0282204;C1515945
3229,black / african - american ( $nmbr$ . $nmbr$ % ),C0085756
3229,african americans,C0085756
3229,african american n = $nmbr$,C0085756
3229,african american  n ( % ),C0085756
3229,african american,C0085756
3229,african - latin american,C0085756
3229,african - american / african heritage ( n = $nmbr$ ),C0085756;C2986513
3229,african - american,C0085756
3228,black or african ‐ american,C0005680;C0027567;C0085756;C0439541
3228,black or african america,C0005680;C0027567;C0085756;C0439541
3228,black / african american *,C0085756
3228,black / african american,C0085756
3228,black / african - american,C0085756
3228,african american / black,C0005680;C0027567;C0085756;C0439541
3228,african america,C0085756
3227,non - hispanic black or african - american,C0005680;C0027567;C0085756;C0439541;C1518424
3227,black or asian,C0005680;C0027567;C0085756;C0439541
3227,black or african heritage,C0005680;C0027567;C0085756;C0439541
3227,black or african american,C0005680;C0027567;C0085756;C0439541
3227,black or african - american,C0005680;C0027567;C0085756;C0439541
3227,black or african,C0005680;C0027567;C0085756;C0439541
3227,african descent,C0027567
3227,african,C0027567
3226,clinical endpoint,C2347784
3225,clinical presentation of vte at initial diagnosis — no . ( % ),C0630906;C2708283
3225,clinical presentation,C2708283
3224,no clinical or lesion rfs for st,C0205210
3224,durable clinical responseg,C0205210
3224,durable clinical remissionh,C0205210
3224,clinical responsed,C0205210
3224,clinical remissione,C0205210
3224,clinical or lesion rf for st,C0205210
3224,clinical details,C0205210;C1522508
3224,any clinical or lesion rf for st,C0205210
3223,interval between clinical evaluation and initiation oftreatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
3223,interval between clinical evaluation and initiation of treatment — no . ( % ),C0205210;C1261322;C1272706;C1552654;C1552713;C2826267;C4084924
3223,clinical and laboratory measurements,C0205210
3222,patients with any clinical,C0030705;C0205210
3222,clinical and patient - reported characteristics at baseline and randomization,C0205210
3221,plus – minus values are means ± sd . cabg denotes coronary - artery by - pass graft  ptca percutaneous transluminal coronary angioplasty  and ace angiotensin - converting enzyme . hypertension and diabetes were de - fined by clinical history . a more complete list of base - line characteristics is given in rubins et al . $nmbr$ † nitrates includes all preparations except as - needed nitroglycerin . ‡ any antianginal drug includes any nitrate ( as defined above )  calcium - channel blocker  or beta - blocker . § the body - mass index is the weight in kilograms divided by the square of the height in meters . ¶ to convert values for cholesterol to millimoles per liter  multiply by $nmbr$ . $nmbr$ . to convert values for triglycerides to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005893;C0006448;C0006539;C0008377;C0017887;C0019664;C0019665;C0020538;C0022709;C0030125;C0041004;C0042295;C0181074;C0205120;C0205210;C0262512;C0262926;C0332288;C0332835;C0439190;C0489786;C0578022;C0885378;C1305855;C1452534;C1552595;C1705255;C1820373;C1879745;C1883728;C1961139;C1963138;C2004062;C2828386;C2936173;C3854028;C4321248;C4522126
3221,clinical history  no . ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
3221,clinical history  n ( % ),C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
3221,clinical history,C0019664;C0019665;C0205210;C0262512;C0262926;C1705255;C2004062
3221,clinical,C0205210
3221,* risk reduction  $nmbr$ percent confidence interval ( ci )  and p value are derived from cox models . for risk reductions  negative numbers indicate an increase in risk . † diabetes and hypertension were defined by clinical history . ‡ a family history was defined as having one or more first - degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ . § hdl cholesterol levels are shown according to the median value ( $nmbr$ . $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¶ triglyceride levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) . ¿ ldl cholesterol levels are shown according to the median value ( $nmbr$ mg per deciliter [ $nmbr$ . $nmbr$ mmol per liter ] ) and according to the values that divide the subjects into three equal groups ( < $nmbr$  $nmbr$ to $nmbr$  and > $nmbr$ mg per deciliter [ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$  and > $nmbr$ . $nmbr$ mmol per liter ] ) .,C0008107;C0009667;C0019664;C0019665;C0205210;C0205447;C0262512;C0262926;C0332849;C0428475;C0439165;C0439190;C0439241;C0441889;C0475211;C0549183;C0567349;C0876920;C1137094;C1522609;C1705255;C2004062;C2347285;C2347635;C2348144;C2348885;C2939193;C3259781
3220,prior clinical fracture ( since age $nmbr$ ),C0016658;C0205210;C0332152;C2826257
3220,clinical fracture,C0016658;C0205210
3220,c clinical fractures ( fas ),C0016658;C0205210
3219,clinical outcome,C0205210;C1274040
3219,clinical and patient reported outcomes  % ( observed n ) unless otherwise indicated,C0205210
3218,cvd subjects,C0007222
3218,cvd events,C0007222;C0441471;C3541888
3217,combined cvd,C0007222;C0205195
3217,combined $nmbr$ - year cvd,C0007222;C0205195;C0439234;C0439508
3216,cvd  ckd,C0007222;C1561643
3215,other vascular disease ( cvd or pad )  %,C0007222;C0042373
3214,no cardiovascular disease ( n = $nmbr$ ),C0007222
3214,medical history of cv disease or heart failure  n ( % ),C0007222;C0262926
3214,history of cvd  n ( % ),C0007222;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
3214,cv disease history  no . ( % ) §,C0007222;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C2004062;C3538987;C4048877;C4318503
3214,cv disease,C0007222
3214,cardiovascular disease ( n = $nmbr$ ),C0007222
3214,$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ ),C0007222
3214,$nmbr$ - $nmbr$  cv disease ( n = $nmbr$  $nmbr$ ),C0007222
3213,cardiovascular disease n ( % ),C0007222
3213,baseline cardiovascular disease,C0007222;C0168634;C1442488
3213,any cardiovascular disease,C0007222
3212,cvd or mi,C0007222
3212,cvd / mi / stroke / urgent vascular hospitalization,C0007222;C3810814
3212,cvd / mi / stroke / urgent coronary revascularization,C0007222;C3810814
3212,cvd / mi / stroke / revascularization / urgent vascular hospitalization,C0005847;C0007222;C0019993;C0038454;C0439609;C0581603;C1558950;C1801960;C3272275;C3810814;C4554100
3212,cvd / mi / stroke,C0007222;C0038454;C3810814;C4554100
3212,cvd  mi  stroke  or recurrent ischemia - urgent revascularization  or hospitalization for unstable angina,C0007222;C0038454;C3810814;C4554100
3212,cvd  mi  stroke  or recurrent ischemia - urgent revascularization,C0007222;C0038454;C3810814;C4554100
3212,cvd  mi  or stroke,C0007222;C3810814
3211,cvd without ml ^ troke,C0007222;C0439526;C1705224;C3887665
3211,cvd without ml / stroke,C0007222;C0038454;C0439526;C1705224;C3887665;C4554100
3211,cvd without miatroke,C0007222
3210,major cvd /,C0007222;C0205082;C0205164;C4318856;C4521762
3210,cvd,C0007222
3209,prior cardiovascular disease,C0007222;C0332152;C2826257
3209,no cardiovascular disorder $nmbr$ ',C0007222
3209,cardiovascular disorder  n ( % ),C0007222
3209,cardiovascular disorder,C0007222
3209,cardiovascular disease *,C0007222
3209,cardiovascular disease,C0007222
3208,prior cvd,C0007222;C0332152;C2826257
3208,patients with no prior cvd ( primary,C0007222;C0030705;C0332152;C2826257
3208,no prior cvd,C0007222;C0332152;C2826257
3208,no cvd,C0007222
3207,baseiine ccb,C0006684
3207,arb - arb / ccb,C0006684;C3888198
3206,ccbs  ( % ),C0006684
3206,ccb,C0006684
3206,arb + ccb ( n = $nmbr$ ),C0006684;C3888198
3205,non - calcium antagonist strategy ( ncas ) ( events / n ),C0006684;C0441471;C0679199;C1413309;C1518422;C3541888;C3813543
3205,non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199;C1518422
3205,calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C0006684;C0679199
3205,calcium antagonist strategy ( cas ) ( events / n ),C0006684;C0441471;C0679199;C3541888
3205,calcium antagonist,C0006684
3204,caleium ehannel bloekers ( ccb ),C0006684
3204,calcium channel blockers  n ( % ),C0006684;C2757014
3204,calcium channel blockers,C0006684;C2757014
3204,calcium channel antagonists  n ( % ),C0006684;C2757014
3204,calcium antagonists  n ( % ),C0006684
3204,calcium antagonists,C0006684
3204,calcium antagonist — no . ( % ),C0006684
3204,calcium - channel blockers ( % ),C0006684;C2757014
3204,calcium - channel blockers,C0006684;C2757014
3204,calcium - channel antagonists,C0006684;C2757014
3203,calcium channel blocker ( % ),C0006684;C3536851;C4521885
3203,calcium channel blocker,C0006684;C3536851;C4521885
3203,calcium - channel blocker *,C0006684;C3536851;C4521885
3203,calcium - channel blocker ( ratelowering ),C0006684;C3536851;C4521885
3203,calcium - channel blocker,C0006684;C3536851;C4521885
3203,= calcium channel blocker  bmi = body,C0006684;C0242821;C0460148;C0578022;C1268086;C3536851;C4082212;C4521885
3202,ascvd as per protocol,C1698058;C3665365
3201,established ascvd or > $nmbr$ cv risk factors,C0443211;C1272684;C3665365
3201,established ascvd,C0443211;C1272684;C3665365
3201,ascvd including tia,C3665365
3200,patients with ascvd but no prior ml hr ( $nmbr$ % cl ),C0030705;C3665365
3200,other ascvd  no . ( % ),C3665365
3200,other ascvd,C3665365
3200,ascvd no prior ml,C3665365
3199,no ascvd + additional cv risk factors  n ( % ),C0035648;C1524062;C1553898;C3538987;C3665365;C4048877;C4318503
3199,no ascvd,C3665365
3199,ascvd * . n ( % ),C3665365
3199,ascvd  n ( % ),C3665365
3199,ascvd  b no . ( % ),C3665365
3199,ascvd,C3665365
3198,estimated cv risk at baseline,C0168634;C1442488;C1519101;C3538987;C4048877;C4318503
3197,history of cv disease,C0683519;C0730226;C0850708;C0944983;C3538987;C4048877;C4318503
3197,cv historya,C3538987;C4048877;C4318503
3196,cv medication  % of patients,C0013227;C0030705;C3244316;C3538987;C4048877;C4284232;C4318503
3196,cv medication,C0013227;C3244316;C3538987;C4048877;C4284232;C4318503
3195,qualifying cv event  n ( % ),C0441471;C1514624;C3538987;C4019010;C4048877;C4318503
3195,prior cv event at randomization !,C0034656;C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
3195,prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
3195,previous cv events,C0205156;C0441471;C1552607;C3538987;C3541888;C4048877;C4318503
3195,previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
3195,no prior cv event,C0332152;C0441471;C2826257;C3538987;C4019010;C4048877;C4318503
3195,no previous cv event,C0205156;C0441471;C1552607;C3538987;C4019010;C4048877;C4318503
3195,no cv event ( n = $nmbr$  $nmbr$ ),C0441471;C3538987;C4019010;C4048877;C4318503
3195,major cv event,C0205082;C0205164;C0441471;C3538987;C4019010;C4048877;C4318503;C4318856;C4521762
3195,incidence rate of cv events  n ( % ),C0441471;C1708485;C3538987;C3541888;C4048877;C4318503
3195,cv event  years,C0439234;C0441471;C3538987;C4019010;C4048877;C4318503
3195,cv,C3538987;C4048877;C4318503
3194,expanded cv endpoint,C0205229;C2349179;C2826544;C3538987;C4048877;C4318503
3194,cv endpoints n ( % ),C2349179;C3538987;C4048877;C4318503
3193,week $nmbr$ ( geometric mean  cv ),C0332174;C0439230;C2986759;C3538987;C4048877;C4318503
3193,mdrd egfr geometric mean ( cv % )  a  b ml /,C0439526;C1705224;C1739039;C2986759;C3538987;C3811844;C3812682;C3839656;C3887665;C4048877;C4318503
3193,baseline ( geometric mean  cv ),C0168634;C1442488;C2986759;C3538987;C4048877;C4318503
3192,without ckd ( $nmbr$ ),C1561643
3192,with ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
3192,with ckd ( $nmbr$ ),C1561643
3192,no ckd n,C1561643
3192,no ckd ( % ),C1561643
3192,no ckd,C1561643
3192,no - ckd intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453;C1561643
3192,ckd n,C1561643
3192,ckd  n ( % ) t,C1561643
3191,ckd at baseline,C0168634;C1442488;C1561643
3191,ckd,C1561643
3191,change from baseline stage $nmbr$ ckd,C0168634;C0597205;C0679846;C1442488;C1561643
3190,ckd prognosis by kdigo ' ',C0033325;C1561643;C3854082
3189,normal / mild ckd,C0205307;C0231683;C0439166;C1561643;C2347086;C2945599;C4553972
3189,ckd *,C1561643
3188,gfr ( ckd - epi ),C0017654;C0162734;C1424601;C1561643;C4281721
3188,baseline - ckd - epi,C0162734;C0168634;C1442488;C1561643;C4281721
3187,chronic renal failure  n ( % ),C0022661;C1561643;C2316810
3187,chronic renal failure,C0022661;C1561643;C2316810
3187,chronic renal disease — no . ( % ),C0022661;C1561643
3187,chronic renal disease,C0022661;C1561643
3186,chronic renal insufficiency  %,C0403447;C1561643
3186,chronic renal insufficiency,C0403447;C1561643
3185,vitamin c,C0003968;C2349136;C3714687;C4522080
3184,median c - reactive protein — mg / liter,C0006560;C0024671;C0026410;C0439269;C0475211;C0549183;C0876920;C1413716;C1960952;C2346927;C2347635;C2348144;C2939193;C4048285;C4321396;C4521761
3184,median c - reactive protein — mg / dl ^,C0006560;C0439269;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
3184,c - reactive protein — mg / literj,C0006560;C0024671;C0026410;C0439269;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
3184,c - reactive protein — mg / liter * *,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1960952;C2346927;C4048285;C4321396;C4521761
3184,c - reactive protein ( mg / dl_ ),C0006560;C0439269;C1413716;C4048285
3184,c - reactive protein ( mg / dl ),C0006560;C0439269;C1413716;C4048285
3183,high sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
3183,high - sensitivity c - reactive protein stratification,C0006560;C1413716;C1441604;C1514983;C4048285
3183,high - sensitivity c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C1441604;C4048285
3183,high - sensitivity c - reactive protein  mg / ltt,C0006560;C0024671;C0026410;C0439269;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
3183,high - sensitivity c - reactive protein  mg / l,C0006560;C0439268;C1413716;C1441604;C4048285
3183,c - reactive protein,C0006560;C1413716;C4048285
3182,das $nmbr$ ( c - reactive protein ),C0006560;C0051767;C0057671;C1413716;C4048285
3182,c - reactive protein concentration ( mg / l ),C0006560;C0086045;C0439268;C1413716;C1446561;C3827302;C4048285
3182,c - reactive protein ( mg / l ),C0006560;C0439268;C1413716;C4048285
3182,c - reactive protein  u / l,C0006560;C0439339;C1413716;C4048285
3182,c - reactive protein  mg / l,C0006560;C0439268;C1413716;C4048285
3182,c - reactive protein  median ( iqr )  mg / l,C0006560;C0439268;C0549183;C0876920;C1413716;C2347635;C2348144;C2939193;C4048285
3182,c - reactive protein  * mg / l,C0006560;C0439268;C1413716;C4048285
3181,group c,C0441837
3181,gold group c,C0018026;C0441837;C1304897
3180,hs - crp < $nmbr$ . $nmbr$ nlg l,C3890735;C4048285
3180,hs - crp < $nmbr$ . $nmbr$ g / l,C0439294;C0456615;C3890735;C4048285
3180,asdas - crp   <   $nmbr$ . $nmbr$,C3890735;C4048285
3180,asdas - crp δ   ≥   $nmbr$ . $nmbr$,C3890735;C4048285
3180,asdas - crp *,C3890735;C4048285
3179,crp   ≤   uln,C1519815;C3890735;C4048285
3179,crp   >   uln,C1519815;C3890735;C4048285
3178,hs - crp mg / l,C0439268;C3890735;C4048285
3178,hs - crp j $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
3178,hs - crp _ = $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
3178,hs - crp < $nmbr$ . $nmbr$ mg / l,C0439268;C3890735;C4048285
3178,hs - crp ( mg / l ),C0439268;C3890735;C4048285
3178,hs - crp ( mg / l  median ),C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
3178,hs - crp ( median  iqr )  mg / l,C0439268;C0549183;C0876920;C2347635;C2348144;C2939193;C3890735;C4048285
3178,hs - crp  mg / l,C0439268;C3890735;C4048285
3178,hs - crp,C3890735;C4048285
3177,patients with baseline crp concentration < $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
3177,crp — mg / l,C0439268;C3890735;C4048285
3177,crp  mg / l,C0439268;C3890735;C4048285
3177,crp,C3890735;C4048285
3177,baseline crp levels ≥ $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
3177,baseline crp levels < $nmbr$ mg / l,C0168634;C0439268;C0441889;C1442488;C3890735;C4048285
3177,baseline crp < $nmbr$ mg / l,C0168634;C0439268;C1442488;C3890735;C4048285
3176,geometric mean crp concentration ( mg / l ),C0086045;C0439268;C1446561;C2986759;C3827302;C3890735;C4048285
3176,crp concentration > $nmbr$ . $nmbr$ mg / dl ( $nmbr$ mg / l )  n ( % ),C0086045;C1446561;C2827881;C3642216;C3827302;C3890735;C4048285
3176,crp ( ng / ml ),C0439275;C3890735;C4048285
3175,cbz - naive,C0006949
3175,cbz - exposed,C0006949
3174,prior exposure to carbamazepine,C0006949;C0006950;C0274281;C0332152;C0332157;C0682993;C2826257
3174,carbamazepine,C0006949;C0006950;C0682993
3173,lce — l - dopa / carbidopa / entacapone  lc — l - dopa / carbidopa  pd — parkinson disease  updrs — rating scale  adl — activities of daily living  pdq - $nmbr$ — parkinson disease questionnaire .,C0001288;C0030567;C0034394;C0165921;C0353697;C0681889;C1423759;C1521736;C3273355;C3639721;C4553228;C4553229
3173,l - dopa / carbidopa - l - dopa / carbidopa / entacapone,C0165921;C0353697
3173,entacapone,C0165921
3172,albumin creatinine ratio,C0486293;C1318293
3172,albumin / creatinine ratio  n ( % ),C0486293;C1318293
3172,albumin - to - creatinine ratio ( acr ),C0486293;C1318293;C1412134;C1515941
3171,median albumin - to - creatinine ratio ( interquartile range ),C0486293;C0549183;C0876920;C1318293;C1711350;C2347635;C2348144;C2939193
3171,albumin - to - creatinine ratio,C0486293;C1318293
3170,urine albumin / creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
3170,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271;C1318330
3170,urine albumin - to - creatinine ratio,C0455271;C1318330
3170,urinary albumin : creatinine ratioa ( mg / g ),C0455271;C1300563;C1318330
3170,urinary albumin : creatinine ratio ^,C0455271;C1318330
3170,urinary albumin : creatinine ratio *,C0455271;C1318330
3170,urinary albumin : creatinine ratio ( mg / g ),C0455271;C1300563;C1318330
3170,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271;C1318330
3170,urinary albumin - to - creatinine ratio §,C0455271;C1318330
3170,urinary albumin - to - creatinine ratio ^,C0455271;C1318330
3169,urine albumin / creatinine ratio  mg / mmol,C0455271;C0567349;C1318330;C2348885
3169,urine albumin / creatinine ( mg / mmol ),C0455271;C0567349;C1318330;C2348885
3168,urinary protein - to - creatinine ratio | |,C1096054
3167,urine albumin - to - ereatinine ratio,C0001924;C0042038;C0456603;C0587185;C1273442;C1547037;C2362049
3167,urinary albumimcreatinine ratio,C1273442
3166,prior exposure to lamotrigine,C0064636;C0274281;C0332152;C0332157;C0524166;C2826257
3166,lamotrigine,C0064636;C0524166
3165,creatinine clearance category [ ml / min ],C0439445;C0683312;C0812399;C3889287
3165,creatine clearance category,C0373595;C0683312;C3889287
3164,creatine clearance category $nmbr$ to < $nmbr$ ml / min $nmbr$ / $nmbr$,C0373595;C0439445;C0683312;C3889287
3164,creatine clearance  ml / min,C0373595;C0439445
3163,creatinine clearance at admission ( ml / min ),C0151280;C0184666;C0809949
3163,creatinine clearance > $nmbr$ to < $nmbr$ ml / min — no . ( % ) f,C0151280
3162,non - hispanic / latino,C0086528;C1518424
3162,latino,C0086528
3161,not hispanie / latino,C0086528;C1518422
3161,hispanie / latino,C0086528
3160,serum creatinine ( pmol / l )  mean ( sd ),C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
3160,serum creatinine ( gmol / ),C0201976;C0600061
3160,serum creatinine  mean ( sd )  pmol / l,C0201976;C0439284;C0444504;C0600061;C2347634;C2348143;C2699239
3160,serum creatinine  gmol / ' l  mean ( sd ),C0201976;C0444504;C0600061;C2347634;C2348143;C2699239
3160,serum creatinine,C0201976;C0600061
3159,serum creatinine > $nmbr$ mmol / l  n ( % ),C0201976;C0600061;C1532563
3159,serum creatinine ( mmol / l ),C0201976;C0600061;C1532563
3158,serum creatinine  μ mol / l,C0201976;C0347982;C0600061
3158,serum creatinine  umol / lf,C0201976;C0439194;C0600061;C1416933;C2986618;C4554443
3158,serum creatinine  ^ mol / l,C0201976;C0347982;C0600061
3157,serum creatinine > $nmbr$ pmol / l . n ( % ) |,C0201976;C0439284;C0600061
3157,serum creatinine > $nmbr$ / xmol / l  n ( % ) | |,C0201976;C0600061
3157,serum creatinine  gmol / l |,C0201976;C0600061
3157,serum creatinine  / xmol / l | |,C0201976;C0600061
3157,preoperative serum creatinine > $nmbr$ pmol / l,C0201976;C0439284;C0445204;C0600061
3157,changes in serum creatinine  pmol / l,C0201976;C0392747;C0439284;C0443172;C0600061
3156,serum creatinine — pmol / liter,C0201976;C0439192;C0475211;C0600061
3156,serum creatinine level,C0600061
3155,serum creatinine — mg / dl §,C0201976;C0439269;C0600061
3155,serum creatinine — mg / dl | |,C0201976;C0439269;C0600061
3155,serum creatinine — mg / dl,C0201976;C0439269;C0600061
3155,serum creatinine . mg / dl,C0201976;C0439269;C0600061
3155,serum creatinine ( mg / dl ),C0201976;C0439269;C0600061
3155,serum creatinine  ≥ $nmbr$ . $nmbr$ mg / dl,C0201976;C0439269;C0600061
3155,serum creatinine  mg / dlb,C0024671;C0026410;C0201976;C0439269;C0600061;C0752347;C1960952;C2346927;C3890365;C4321396;C4521761
3155,serum creatinine  mg / dl,C0201976;C0439269;C0600061
3155,serum creatinine  mean ( sd ) mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
3155,serum creatinine  mean ( sd )  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
3155,serum creatinine  limo $nmbr$ $nmbr$,C0201976;C0600061
3154,first serum creatinine,C0201976;C0205435;C0600061;C1279901
3153,increase in serum creatinine,C0201976;C0442805;C0600061
3153,acute increase in serum creatinine,C0010294;C0201976;C0205178;C0442805;C0600061;C1546542;C1561535
3152,chinese subgroup,C0008120;C0152035;C1079230;C1515021
3152,chinese,C0008120;C0152035
3151,increase creatinine  > $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
3151,increase creatinine  < $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C0442805;C1561535
3151,creatinine ≥ $nmbr$ . $nmbr$ mg / dl,C0010294;C0439269;C1561535
3151,creatinine ( mg / dl )  mean ( sd ),C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
3151,creatinine ( mg / dl ),C0010294;C0439269;C1561535
3151,creatinine  mg / dl_,C0010294;C0439269;C1561535
3151,creatinine  mg / dl ( sd ),C0010294;C0439269;C1561535;C2699239
3151,creatinine  mg / dl  mean,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143
3151,creatinine  mg / dl,C0010294;C0439269;C1561535
3151,creatinine  mean ( sd )  mg / dl,C0010294;C0439269;C0444504;C1561535;C2347634;C2348143;C2699239
3150,estimated creatinine clearancet,C0010294;C0750572;C1561535
3150,creatinine,C0010294;C1561535
3149,creatinine — mg / dl urinary albumin - to - creatinine ratio §,C0010294;C0439269;C0456603;C1547037;C1561535;C2362049
3149,creatinine — mg / dl,C0010294;C0439269;C1561535
3148,creatinine ( µ mol / l ),C0010294;C0347982;C1561535
3148,creatinine ( p  mol / l ),C0010294;C0347982;C1561535
3147,creatinine  mmol 八,C0010294;C0439190;C1561535
3146,creatinine clearanceb  ml / min,C0010294;C0439445;C1561535
3146,creatinine ciearance,C0010294;C1561535
3146,creatinine  pmol / l,C0010294;C0439284;C1561535
3145,creatinine ratio $nmbr$ - $nmbr$,C0010294;C0456603;C1547037;C1561535
3145,creatinine ratio,C0010294;C0456603;C1547037;C1561535
3144,current weekly alcohol use ( % ),C0001948;C0332174;C0521116;C1705970
3144,current alcohol use  n ( % ),C0001948;C0521116;C1705970
3144,alcohol use  n ( % ),C0001948
3144,alcohol use,C0001948
3143,alcohol use ( % ),C0001948
3143,alcohol use ( %  > $nmbr$ / day ),C0001948;C0332173;C0439228;C0439505
3142,drinking  n ( % ) lipid values  mmol / l,C0001948;C0023779;C0042295;C0684271;C1532563
3142,drinking  n ( % ),C0001948;C0684271
3142,drinking,C0001948;C0684271
3141,no alcohol consumption  on average,C0001948;C1510992;C2825518
3140,regular alcohol consumption per week  no . ( % ),C0001948;C0205272;C0332174;C0439230
3140,alcohol intake ( a ),C0001948
3140,alcohol intake ( + ) ( % ),C0001948
3140,alcohol intake,C0001948
3140,alcohol consumption ( % ),C0001948
3140,alcohol consumption  no . ( % ),C0001948
3140,alcohol consumption  n ( % ),C0001948
3139,alcohol consumption *,C0001948
3139,alcohol consumption ( yes ) ( n ),C0001948;C1549445;C1705108;C1710701
3139,alcohol consumption,C0001948
3138,alcohol consumption at baseline,C0001948;C0168634;C1442488
3138,alcohol consumption > once weekly,C0001948
3138,alcohol consumption !,C0001948
3137,alcohol use  drinks / wk *,C0001948
3137,alcohol use  drinks / wk,C0001948
3137,alcohol intake  drinks / week,C0001948
3137,alcohol consumption ( % ) < $nmbr$ drink / dav,C0001948;C0009830;C0452428;C0556297;C1947907
3137,alcohol  % with > $nmbr$ drink / d,C0001948;C0556297
3136,score at week $nmbr$  mean ( se ) difference mepo - pbo ( $nmbr$ % ci ),C0008107;C0031962;C0036919;C0332174;C0439230;C1705241;C1705242;C3259781;C3533236
3136,ls mean difference ( se ) vs placebo,C0023668;C0036919;C0444504;C1705241;C1705242;C2347634;C2348143
3136,difference ( se ),C0036919;C1705241;C1705242
3136,( se ),C0036919
3136,% ( se ),C0036919
3135,baseline insulin dose ( u = kg ) [ lsm ( se ) ],C0036919;C0168634;C0366513;C1300561;C1442488
3135,( se ] t *,C0036919
3135,( se ] t,C0036919
3135,( se ) t *,C0036919
3134,( se ] tf total - c,C0036919;C0439175;C0439810;C4048299;C4048587
3134,( se ] tf hdl - c,C0036919;C3715113;C4048299;C4048587
3134,( se ] tf,C0036919;C4048299;C4048587
3134,( se ] +,C0036919
3133,se,C0036919
3133,mean ± se,C0036919;C0444504;C2347634;C2348143
3133,ls mean ± se,C0023668;C0036919;C0444504;C2347634;C2348143
3133,hscrp  exp ls mean change ± se ‡,C0023668;C0036919;C0392747;C0443172;C0444504;C1417055;C1705241;C2347634;C2348143;C4319952
3133,asqol  ls mean change ± se,C0023668;C0036919;C0392747;C0443172;C0444504;C1705241;C2347634;C2348143;C4319952
3133,asqol  ls mean change from baseline   ±   se,C0023668;C0036919;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
3132,use of low - dose aspirin ( < $nmbr$,C1524063;C2608320
3131,recent use of allopurinol ( within $nmbr$ days of,C0002144;C0332185;C1524063
3130,diabetes with use of oral diabetes drugs,C0011847;C0011849;C0020616;C0029167;C0175795;C0304289;C0442027;C1524063;C4521986
3130,diabetes with no use of diabetes drugs,C0020616;C1524063
3129,concomitant use of nsaids to week $nmbr$,C0003211;C0521115;C1524063
3128,postoperative use of p - blocker,C0032790;C1524063
3127,new use of gpa,C0205314;C1524063;C3495801;C4553145
3127,continued use of gpa,C0549178;C1524063;C3495801;C4553145
3126,use of proton inhibitors  n ( % ),C0033727;C0243077;C1524063
3125,use of ticagrelor,C1524063;C1999375
3124,use of ace inhibitor,C0003015;C1524063;C4541021
3124,current use of an ace inhibitor,C0003015;C0521116;C1524063;C1705970;C4541021
3123,use of methotrexate at randomization —,C0025677;C1524063
3122,use of systemic glucocorticoid at random -,C0017710;C0205373;C1524063
3121,use of high - dose inhaled glucocorticoid — no . { % ),C0444956;C1524063
3120,previous use of niacin or niaspan §,C0027996;C0205156;C1142562;C1524063;C1552607
3120,previous use of antiarrhythmic drugs,C0003195;C0205156;C1524063;C1552607
3120,previous use of amiodarone,C0002598;C0205156;C1524063;C1552607
3119,using hrt or raloxifene at baseline ( % ),C1524063
3119,using alendronate at baseline ( % ),C1524063
3119,previous use of nonbiologic systemic therapy  n ( % ),C0205156;C1515119;C1524063;C1552607
3119,previous use of biologic systemic therapy  n ( % ),C0005515;C0005527;C0205156;C0205373;C0205460;C1515119;C1524063;C1552607
3118,us resident,C1320928;C1549439;C2347958;C3835651
3117,heparin use,C0239945
3116,spacer use during the study,C0221874;C0869040
3115,rescue medication use  inh / d {,C0022209;C0240320
3114,use of rescue medication,C0240320
3114,use of other medications — no . ( % ),C0240320
3114,concomitant medication use,C0240320;C0521115
3113,no use ofdiabetes drugs — no . ( % ),C0240320
3113,medication use before enrollment  no . ( % ),C0240320;C1516879;C1696073;C3888021
3112,medication use at entry ( % ),C0240320;C1705654
3111,medication use at baseline - n ( % ),C0168634;C0240320;C1442488
3111,medication use at baseline  n ( % ),C0168634;C0240320;C1442488
3111,medication use ( % ),C0240320
3111,medication use,C0240320
3110,medication use  n ( % ),C0240320
3110,diabetes - related medication use    n   ( % ),C0011847;C0011849;C0240320;C0439849;C0445223
3109,alcohol abuse,C0085762;C4050601
3108,history of alcohol use,C0551571;C0552479
3107,corticosteroid use at randomization    n   ( % ),C0034656;C0239126
3107,corticosteroid use at randomization,C0034656;C0239126
3107,corticosteroid use  n ( % ),C0239126
3107,corticosteroid use  %,C0239126
3106,oral corticosteroid use at baseline,C0001617;C0168634;C0239126;C0442027;C1442488;C1527415;C3536709;C4521986
3106,corticosteroid use at baseline - no,C0168634;C0239126;C1442488
3106,corticosteroid use at baseline,C0168634;C0239126;C1442488
3106,corticosteroid use,C0239126
3105,oral corticosteroid use  n ( % ),C0001617;C0239126;C0442027;C1527415;C3536709;C4521986
3105,corticosteroid use  $nmbr$ n ( % ),C0239126
3104,concomitant corticosteroid use  n ( % ),C0239126;C0521115
3104,concomitant corticosteroid use,C0239126;C0521115
3103,tobacco abuse,C0040336
3102,tobacco use — no . ( % ),C0040335;C0543414;C0841002;C3853727
3102,tobacco use ( % ),C0040335;C0543414;C0841002;C3853727
3102,tobacco use  yes  n ( % ),C0040335;C0543414;C0841002;C1549445;C1705108;C1710701;C3853727
3102,tobacco use  n ( % ),C0040335;C0543414;C0841002;C3853727
3102,tobacco use,C0040335;C0543414;C0841002;C3853727
3102,prior tobacco use  n ( % ),C0040335;C0332152;C0543414;C0841002;C2826257;C3853727
3102,no current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
3102,current tobacco use,C0040335;C0521116;C0543414;C0841002;C1705970;C3853727
3102,baseline tobacco use,C0040335;C0168634;C0543414;C0841002;C1442488;C3853727
3101,tobacco user,C3853727
3101,non - / ex - tobacco user,C1518422;C3853727
3100,steroid use  %,C0281991
3100,previous use of systemic steroids for ciu / csu,C0205156;C0205373;C0281991;C1552607
3100,previous use of systemic steroids  n ( % ),C0205156;C0205373;C0281991;C1552607
3099,used,C1273517
3099,never used lev,C0023556;C1273517;C2003901
3098,use oforal glucose - lowering agent — no . ( % ),C0042153;C0457083;C1947944
3098,total antihypertensive use,C0003364;C0042153;C0439175;C0439810;C0457083;C1947944
3098,antiplatelet use,C0042153;C0457083;C1947944
3098,antihypertensive use,C0003364;C0042153;C0457083;C1947944
3098,antihypertensive agent use,C0003364;C0042153;C0457083;C1947944
3097,potent phosphorylated glycoprotein inhibitor use,C0017968;C0042153;C0457083;C1947944;C1999216;C3245505
3097,any use,C0042153;C0457083;C1947944
3097,any glycoprotein iib / iiia inhibitor use,C0016011;C0042153;C0457083;C1947944;C1999216
3096,rescue use : mean no . of inhalations / d,C0042153;C0444504;C0457083;C1947944;C2347634;C2348143
3096,bosentan use :,C0042153;C0252643;C0457083;C1947944
3095,ezetimibe use,C0042153;C0457083;C1142985;C1947944
3095,cox - $nmbr$ selective inhibitor use,C0036576;C0042153;C0085387;C0457083;C1707391;C1947944
3094,cholinesterase inhibitor use at baseline  no . ( % ),C0008425;C0042153;C0168634;C0457083;C1442488;C1947944;C3536756;C4521309
3094,cholinesterase inhibitor use,C0008425;C0042153;C0457083;C1947944;C3536756;C4521309
3093,long - acting bronchodilator use at screening,C0006280;C0042153;C0079613;C0205166;C0220908;C0220909;C0457083;C1698960;C1704930;C1706317;C1710031;C1710032;C1710477;C1869853;C1947944;C2348164;C3890007;C4048375
3093,before bronchodilator use,C0006280;C0042153;C0457083;C1947944
3093,after bronchodilator use,C0006280;C0042153;C0457083;C1947944
3092,preoperative use p - blocker,C0042153;C0445204;C0457083;C1947944
3092,preoperative p - blocker use yes,C0042153;C0445204;C0457083;C1549445;C1705108;C1710701;C1947944
3092,p - gp use,C0042153;C0369773;C0457083;C1705010;C1947944;C2603361;C3811116
3092,p - blocker use,C0042153;C0369773;C0457083;C1947944;C2603361
3091,other llt use,C0042153;C0457083;C1947944;C2347090
3090,triple therapy use at screening  n ( % ),C0039798;C0042153;C0087111;C0457083;C1363945;C1947944;C2121434
3090,therapy use,C0039798;C0042153;C0087111;C0457083;C1363945;C1947944
3089,sulfasalazine use at randomization    n   ( % ),C0034656;C0036078;C0042153;C0457083;C1947944
3089,sulfasalazine use at randomization,C0034656;C0036078;C0042153;C0457083;C1947944
3089,aspirin use at randomization,C0004057;C0034656;C0042153;C0457083;C1947944
3088,systemic glucocorticoid use at randomization  n ( % ),C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
3088,systemic glucocorticoid use at randomisation,C0017710;C0034656;C0042153;C0205373;C0457083;C1947944
3088,systemic corticosteroid use,C0042153;C0205373;C0239126;C0457083;C1947944;C4053960
3087,use at baseline  n,C0042153;C0168634;C0457083;C1442488;C1947944
3087,use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944
3087,sulfonylurea use at baseline,C0038766;C0042153;C0168634;C0457083;C1442488;C1947944;C3536898
3087,no baseline immunosuppressant use,C0021081;C0042153;C0168634;C0457083;C1442488;C1947944
3087,methotrexate use at baseline,C0025677;C0042153;C0168634;C0457083;C1442488;C1947944
3087,memantine use at baseline  no . ( % ),C0025242;C0042153;C0168634;C0457083;C1442488;C1947944
3087,low - dose aspirin use at baseline yes,C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944;C2608320
3087,low - dose aspirin use at baseline,C0042153;C0168634;C0457083;C1442488;C1947944;C2608320
3087,csdmard use at baseline ^,C0042153;C0168634;C0457083;C1442488;C1947944
3087,biguanide use at baseline,C0005382;C0042153;C0168634;C0457083;C1442488;C1947944;C3537187;C4317165
3087,baseline aspirin use strata,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
3087,baseline aspirin use,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
3087,aspirin use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944
3087,asa use at baseline  n ( % ),C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
3087,asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
3086,no concomitant cortcosteroid use,C0042153;C0457083;C0521115;C1947944
3086,concomitant statin use,C0042153;C0360714;C0457083;C0521115;C1947944
3086,concomitant mao - b inhibitor use,C0042153;C0457083;C0521115;C0595265;C1947944;C2917433
3086,concomitant conventional dmard use,C0042153;C0242708;C0439858;C0457083;C0521115;C1947944
3086,concomitant aspirin use,C0004057;C0042153;C0457083;C0521115;C1947944
3086,concomitant antibiotic use  n [ % ],C0003232;C0042153;C0457083;C0521115;C1947944
3085,mtx use at randomization  n ( % ),C0025677;C0034656;C0042153;C0457083;C1417487;C1947944
3085,methotrexate use at randomization    n   ( % ),C0025677;C0034656;C0042153;C0457083;C1947944
3085,methotrexate use at randomization,C0025677;C0034656;C0042153;C0457083;C1947944
3085,methotrexate use at randomisation,C0025677;C0034656;C0042153;C0457083;C1947944
3085,methotrexate use,C0025677;C0042153;C0457083;C1947944
3085,concomitant mtx use  n ( % ),C0025677;C0042153;C0457083;C0521115;C1417487;C1947944
3085,cgm use,C0042153;C0457083;C1947944
3085,anorexigen use,C0042153;C0457083;C1947944
3085,. $nmbr$ kg mtx use,C0022718;C0025677;C0042153;C0439209;C0457083;C1417487;C1947944;C4054209
3084,laba use at enrolment,C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
3084,antithrombotic use before enrollment  no . ( % ),C0042153;C0457083;C1516879;C1696073;C1947944;C3888021
3084,antithrombotic use,C0042153;C0457083;C1947944
3083,saba use  occasions / weekt,C0042153;C0457083;C1947944
3083,days without albuterol use  * %,C0001927;C0042153;C0439228;C0457083;C1947944
3083,aldosterone use,C0002006;C0042153;C0457083;C1947944
3083,albuterol use,C0001927;C0042153;C0457083;C1947944
3082,use ( % ),C0042153;C0457083;C1947944
3082,rotablator use  n ( % ),C0042153;C0457083;C1260867;C1947944
3082,prednisone use  %,C0032952;C0042153;C0457083;C1947944
3082,patients with prior dmard use  n ( % ) a,C0030705;C0042153;C0242708;C0332152;C0457083;C1947944;C2826257
3082,oam use [ n ( % ) ],C0042153;C0457083;C1947944
3082,oad use  n ( % ),C0042153;C0457083;C1947944
3082,mesalamine use  n ( % ) a,C0042153;C0127615;C0457083;C1947944
3082,immunosuppressive use  n ( % ),C0021081;C0042153;C0457083;C1947944
3082,immunosuppressant use  %,C0021081;C0042153;C0457083;C1947944
3082,baseline dmard use  n ( % ),C0042153;C0168634;C0242708;C0457083;C1442488;C1947944
3082,anticholinergic use  n ( % ),C0042153;C0242896;C0457083;C1947944;C3537004
3081,thienopyridine use,C0042153;C0457083;C1120149;C1947944
3081,postmenopausal hormone use,C0019932;C0042153;C0232970;C0457083;C1947944;C4521914
3081,postmenopausal  current hormone therapy use,C0019932;C0042153;C0232970;C0279025;C0457083;C0521116;C1705970;C1947944;C2827774;C4521914
3080,use,C0042153;C0457083;C1947944
3080,prior vka use for > $nmbr$ d  %,C0042153;C0332152;C0457083;C1947944;C2826257
3080,prior sulfasalazine use *,C0036078;C0042153;C0332152;C0457083;C1947944;C2826257
3080,prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
3080,prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
3080,prior nsaid use,C0003211;C0042153;C0332152;C0457083;C1947944;C2826257;C3536840
3080,prior mesalazine use *,C0042153;C0127615;C0332152;C0457083;C1947944;C2826257
3080,prior asa use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257;C3853627
3080,no use,C0042153;C0457083;C1947944
3080,no prior oma use ( n = $nmbr$ ),C0042153;C0332152;C0457083;C1947944;C2826257
3080,no prior oma use,C0042153;C0332152;C0457083;C1947944;C2826257
3079,low - dose aspirin use strata * n ( % ),C0042153;C0457083;C1947944;C2608320
3079,low - dose aspirin use . strata *  n ( % ),C0042153;C0457083;C1947944;C2608320
3079,low - dose aspirin use,C0042153;C0457083;C1947944;C2608320
3078,background laba use - yes  n ( % ),C0042153;C0457083;C1549445;C1705108;C1706907;C1710701;C1947944
3078,background laba use,C0042153;C0457083;C1706907;C1947944
3077,regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
3077,prior aspirin use,C0004057;C0042153;C0332152;C0457083;C1947944;C2826257
3077,no regular aspirin use,C0004057;C0042153;C0205272;C0457083;C1947944
3077,aspirin use n ( % ),C0004057;C0042153;C0457083;C1947944
3077,aspirin use before screening — no . { % ),C0004057;C0042153;C0220908;C0220909;C0457083;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
3077,aspirin use at randomization - n ( % ),C0004057;C0034656;C0042153;C0457083;C1947944
3077,aspirin use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
3077,aspirin use ( p = $nmbr$ - $nmbr$ 十 ),C0004057;C0042153;C0457083;C1947944
3077,aspirin use ( p = $nmbr$ - $nmbr$ t ),C0004057;C0042153;C0457083;C1947944
3077,aspirin use ( % ),C0004057;C0042153;C0457083;C1947944
3077,aspirin use,C0004057;C0042153;C0457083;C1947944
3076,previous vka use ( stratified randomization ),C0042153;C0205156;C0457083;C1552607;C1947944;C4687737
3076,previous vka use,C0042153;C0205156;C0457083;C1552607;C1947944
3076,previous digoxin use ( % ),C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
3076,previous digoxin use,C0012265;C0042153;C0205156;C0457083;C1552607;C1947944
3075,duration alendronate use  years ( meanisd ),C0042153;C0102118;C0439234;C0449238;C0457083;C1947944;C2926735
3075,current alendronate use,C0042153;C0102118;C0457083;C0521116;C1705970;C1947944
3074,symptom score ( sd ),C2699239;C3476546
3073,selena - sledai mean score ( sd ),C0451528;C2699239;C3533236
3073,mean ucsd - sobq score * ( sd ),C2699239;C3533236
3073,mean mayo score ( sd ),C0454788;C1077578;C2699239;C3533236
3072,mean ( sd ) nonstudy eye e - etdrs visual acuity letter score,C0015392;C0042812;C0700042;C1096774;C2360551;C2699239;C3533236
3072,mean ( sd ) e - etdrs visual acuity letter score ( snellen equivalent ),C0042812;C0183370;C0205163;C0439185;C1096774;C2360551;C2699239;C3533236
3071,sd or %,C2699239
3071,mean baseline ibdq score ( sd ) § crp concentration  mg / l,C0086045;C0168634;C0439268;C1442488;C1446561;C2699239;C3533236;C3827302;C3890735;C4048285
3071,mean ( ± sd ) baseline score,C0168634;C1442488;C2699239;C3533236
3071,hba $nmbr$ c in patients with baseline hba $nmbr$ c > $nmbr$ % ( > $nmbr$ mmol / mol )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
3071,baseline mean ( sd )  % [ mmol / mol ],C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3829066
3071,baseline ( sd ),C0168634;C1442488;C2699239
3071,( sd ),C2699239
3070,hr  bpm ( sd ),C2699239
3070,bloodpressure  mean ( sd )  m m hg,C0025424;C0428257;C0428886;C1709500;C2347108;C2347109;C2348272;C2699239
3069,weight in kg ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0022718;C0332174;C0439209;C0439230;C0444504;C1303013;C2347634;C2348143;C2699239;C4054209
3069,weight ( kg )  mean ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,weight  median ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0549183;C0876920;C1305866;C1705104;C2347635;C2348144;C2699239;C2939193;C4054209
3069,weight  mean ( sd ) kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,weight  mean ( sd ) ( kg ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,weight  mean ( sd )  kgb,C0005910;C0043100;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239
3069,weight  mean ( sd )  kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,weight  mean $nmbr$ sd kg,C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,weight  kg ( mean $nmbr$ sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3069,mean weight  kg ( sd ),C0005910;C0022718;C0043100;C0439209;C0444504;C1305866;C1705104;C2347634;C2348143;C2699239;C4054209
3068,van der heijde mtss  mean ( sd ),C0444504;C0557775;C1511780;C2347634;C2348143;C2699239
3068,tjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,tjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,tc  mean ( sd )  rrig / dl,C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C3642216;C4522122
3068,tc  mean ( sd ),C0039411;C0040642;C0041405;C0041698;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
3068,sjc ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,sjc  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,sf - $nmbr$ v $nmbr$ pcs  mean [ sd ],C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
3068,sf - $nmbr$ v $nmbr$ mcs  mean [ sd ],C0037712;C0444504;C2347634;C2348143;C2699239
3068,sesbp ( mmhg ) [ mean _sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
3068,sesbp ( mmhg ) [ mean - sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
3068,ses - cd  mean ( sd ),C0007928;C0034283;C0444504;C2347634;C2348143;C2699239;C4552032
3068,sedbp ( mmhg ) [ mean_ sd ] a,C0439475;C0444504;C2347634;C2348143;C2699239
3068,sedbp ( mmhg ) [ mean _sd ] d,C0439475;C0444504;C2347634;C2348143;C2699239
3068,sd,C2699239
3068,scsbp  mean ( sd )  mmhge,C0444504;C2347634;C2348143;C2699239
3068,scdbp  mean ( sd )  mmhgf,C0444504;C2347634;C2348143;C2699239
3068,sbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0085805;C0428257;C0444504;C0456680;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239
3068,post - salbutamol fev $nmbr$ / fvcb  mean ( sd ),C0001927;C0444504;C0687676;C1704687;C2347634;C2348143;C2699239;C3469826;C3714541
3068,mtss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,msasss  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,ms  mean [ sd ],C0444504;C2347634;C2348143;C2349943;C2699239;C3539704;C3713294
3068,mnapsi  mean [ sd ] d,C0444504;C2347634;C2348143;C2699239
3068,mnapsi  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,mean diastolic blood pressure ( sd )  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143;C2699239
3068,mean age ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
3068,mean age ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
3068,mean ( sd ) d,C0444504;C2347634;C2348143;C2699239
3068,mean ( sd ) age  years,C0444504;C1510829;C2347634;C2348143;C2699239
3068,mean ( sd ) [ range ],C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
3068,mean ( sd )  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143;C2699239
3068,mases ( $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C2347634;C2348143;C2699239
3068,lei  mean [ sd ] c,C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
3068,ldi  mean [ sd ] b,C0444504;C2347634;C2348143;C2699239
3068,ldi  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239
3068,fas  range $nmbr$ - $nmbr$  mean ( sd ),C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
3068,enthesitis score ( mases  $nmbr$ - $nmbr$ )  mean ( sd ),C0444504;C0449820;C1282952;C2347634;C2348143;C2699239;C4050231
3068,dietary calcium intake  mean ( sd )  mg / d,C0439422;C0444504;C0489458;C2347634;C2348143;C2699239
3068,diastolic blood pressure ( mm hg )  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
3068,diastolic blood pressure  mm hg  mean ( sd ),C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
3068,diastolic ( mean  sd ),C0012000;C0444504;C2347634;C2348143;C2699239
3068,dha intake on food frequency questionnaire  mean ( sd )  mg / d,C0034394;C0142831;C0439422;C0444504;C1286336;C1512806;C2347634;C2348143;C2348308;C2699239;C2986698
3068,demographics age  years  mean ( sd ),C0011298;C0444504;C1510829;C1704791;C2347634;C2348143;C2699239
3068,dbp  mm hg ( mean $nmbr$ h )  mean ( sd ),C0025424;C0428257;C0444504;C0456680;C0536221;C2347108;C2347109;C2347634;C2348143;C2348272;C2699239;C3813197;C4281799
3068,das $nmbr$ ( esr )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
3068,das $nmbr$  range $nmbr$ - $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
3068,das $nmbr$  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239
3068,d - dimer level  mean ( sd )  ng / mld,C0017887;C0023522;C0028074;C0060323;C0441889;C0444504;C0456079;C1539265;C1547707;C2347634;C2348143;C2699239;C2946261;C3539688;C3539689
3068,crp  mean [ sd ] mg / $nmbr$,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C3890735;C4048285;C4321396;C4521761
3068,change from baseline  mg / dl  mean ( sd ),C0168634;C0392747;C0439269;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C2699239;C4319952
3068,cdai  mean [ sd ],C0444504;C0683448;C1413248;C2347634;C2348143;C2699239;C3273706
3068,body massindex  mean ( sd ) a,C0242821;C0444504;C0460148;C1268086;C2347634;C2348143;C2699239;C4082212
3068,body mass index  mean ( sd ) t,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
3068,body mass index  mean ( sd ) d,C0005893;C0444504;C0578022;C1305855;C2347634;C2348143;C2699239
3068,body mass index  mean ( sd ) [ range ] a,C0005893;C0444504;C0578022;C1305855;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
3068,body mass index  mean ( sd ) ( kg m ) $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
3068,body mass index  kg / m $nmbr$  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
3068,blood pressure : systolic / diastolic ( mm hg ) ( mean  sd ),C0439475;C0444504;C2347634;C2348143;C2699239;C2704328
3068,baseline sesbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
3068,baseline sedbp  mean ( sd )  mm hg §,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
3068,baseline hbi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
3068,baseline dlqi  mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3899393
3068,at femoral neck  mean ( sd ),C0015815;C0444504;C2347634;C2348143;C2699239
3068,apo a - $nmbr$  mean ( sd )  mg / dl,C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
3068,apo a $nmbr$  mean ( sd ),C0003592;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
3068,age at first seizure  years  mean ( sd ),C0036572;C0205435;C0444504;C1279901;C1510829;C1959629;C2347634;C2348143;C2699239;C4553401
3068,age ( years )  mean ( sd ),C0444504;C1510829;C2347634;C2348143;C2699239
3068,age  mean ( sd )  yearsa,C0001779;C0444504;C2347634;C2348143;C2699239
3068,age  mean ( sd )  years,C0444504;C1510829;C2347634;C2348143;C2699239
3068,age  mean ( sd ),C0001779;C0444504;C2347634;C2348143;C2699239
3068,[ sd ],C2699239
3067,± sd .,C2699239
3067,highest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1522410;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
3067,baseline . mean _ sd . mg / mg,C0168634;C0444504;C1319635;C1442488;C2347634;C2348143;C2699239
3067,baseline . mean _ sd . mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
3066,su monotherapy,C0038642;C1705534
3066,metformin ? su,C0025598;C0038642;C1705534
3066,metformin + su + tzd,C0025598;C0038642;C1705534
3066,metformin + su,C0025598;C0038642;C1705534
3065,su / met,C0038642;C1705534
3065,met / su / tzd,C0038642;C0428210;C1550543;C1705534;C4317104
3064,su / tzd,C0038642;C1705534
3064,su  n ( % ),C0038642;C1705534
3064,su,C0038642;C1705534
3064,baseline su dose > $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
3064,baseline su dose < $nmbr$ / $nmbr$ maximal,C0038642;C0168634;C0178602;C0869039;C1114758;C1442488;C1705534
3063,east asia,C0015631
3062,aphasia,C0003537
3061,residence in asia  n ( % ),C0003980;C0237096
3061,asia pacific ( n = $nmbr$ ),C0003980
3061,asia / pacific / other,C0003980
3061,asia / pacific ( % ),C0003980
3061,asia / pacific,C0003980
3061,asia ( n = $nmbr$ ),C0003980
3061,asia ( n = $nmbr$  $nmbr$ ),C0003980
3061,asia,C0003980
3060,asia pacific or other,C0003980
3060,asia pacific and other,C0003980
3060,asia  pacific and other,C0003980
3060,africa  asia  or the middle east,C0001737;C0003980
3059,getgoal - l - asia,C0003980
3059,asia pacific and south africa,C0003980
3059,asia pacific and africa,C0003980
3059,asia pacific,C0003980
3059,asia and pacific islands,C0003980
3059,asia - pacific region and south africa,C0003980;C0017446;C0205147
3059,asia - pacific and south africa,C0003980
3059,asia - pacific,C0003980
3059,asia #,C0003980
3058,malaysia,C0024552
3057,alaska native,C0682125
3056,basdai responses at week $nmbr$,C0332174;C0439230;C0871261;C1998004
3055,randomised patients with basdai assessment at baseline and week $nmbr$  n,C0679830;C1998004
3055,basdai ⁎ ⁎,C1998004
3054,total basdai score  mean   ±   sd,C0439175;C0439810;C1998004
3054,total basdai score  mean ( sd ),C0439175;C0439810;C1998004
3054,total basdai  mean ( sd ),C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
3054,basdai score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
3054,basdai score  mean ( sd ),C1998004
3054,basdai question $nmbr$ score ( $nmbr$ - $nmbr$ )  mean ( sd ),C1998004
3054,basdai $nmbr$  n ( % ),C1998004
3054,basdai $nmbr$  %,C1998004
3054,basdai  total  mean ± sd,C0439175;C0439810;C0444504;C1998004;C2347634;C2348143;C2699239
3053,aspirin and thienopyridine therapy,C0004057
3053,aspirin + thienopyridine,C0004057;C1120149
3052,rivaroxaban + aspirin,C0004057;C1739768
3052,rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od,C0004057;C0229089;C0439164;C1319635;C1512019;C1739768;C3273373;C3665488
3051,on aspirin at baseline,C0004057;C0168634;C1442488
3051,no aspirin at baseline,C0004057;C0168634;C1442488
3051,baseiine aspirin,C0004057
3051,aspirin dose at baseline  mg,C0004057;C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4086581;C4321396;C4521761;C4696290
3051,aspirin at baseline,C0004057;C0168634;C1442488
3050,aspirin or other antiplatelet or anticoagulant agent,C0004057
3050,aspirin or other antiplatelet drug,C0004057
3050,aspirin or other antiplatelet agents,C0004057
3050,aspirin or other antiplatelet agent,C0004057
3050,aspirin and other antiplatelet,C0004057
3050,aspirin / other antiplatelet agents  n ( % ),C0004057
3050,aspirin / antiplatelet medication,C0004057;C0013227;C0085826;C3244316;C4284232
3050,aspirin / antiplatelet,C0004057
3049,without aspirin ( n = $nmbr$  $nmbr$ ),C0004057
3049,with aspirin ( n = $nmbr$  $nmbr$ ),C0004057
3049,aspirin ( n = $nmbr$ ) no . of participants with events ( % ),C0004057
3049,aspirin ( n = $nmbr$ ),C0004057
3049,aspirin ( n = $nmbr$ $nmbr$ ),C0004057
3049,aspirin ( n = $nmbr$  $nmbr$ ),C0004057
3049,aspirin $nmbr$ mg ( n = $nmbr$ ),C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
3049,$nmbr$ aspirin ( n = $nmbr$ $nmbr$ ),C0004057
3048,aspirin group ( n = $nmbr$ ),C0004057;C0441848
3048,aspirin - erdp ( n = $nmbr$  $nmbr$ ),C0004057
3048,aspirin $nmbr$  $nmbr$,C0004057
3047,clopidogrel + aspirin ( n = $nmbr$ ),C0004057;C0070166
3047,aspirin i clopidogrel ( n = $nmbr$  $nmbr$ ),C0004057;C0021966;C0070166;C0221138
3047,aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0070166
3047,aspirin ( n  % ),C0004057
3047,aspirin $nmbr$ clopidogrel,C0004057;C0070166
3047,aspirin $nmbr$,C0004057
3047,aspirin  no . ( % ),C0004057
3047,aspirin  n ( % ),C0004057
3046,combinations of aspirin and ppi use ( p = $nmbr$ . $nmbr$ t ),C0004057;C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036
3046,aspirin and ppi,C0004057
3045,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
3045,aspirin alone ( n / n ),C0004057;C0205171;C0439044;C0679994
3045,aspirin alone,C0004057
3044,high - dose aspirin,C0004057;C0444956
3044,acetylsalicylic acid,C0004057
3044,acetyl - salicylic acid,C0004057
3043,prior aspirin,C0004057;C0332152;C2826257
3043,no prior aspirin,C0004057;C0332152;C2826257
3043,no aspirin or ppi,C0004057
3043,aspirin but no ppi,C0004057
3043,aspirin,C0004057
3042,use of aspirin at time of qualifying event ( % ),C0004057;C1524063
3042,aspirin or thienopyridines ( % ),C0004057
3041,medication use ( % ) aspirin,C0004057;C0240320
3041,aspirin ( % ),C0004057
3040,aspirin alone group no of events / total n ( % ),C0004057;C2826346
3040,aspirin ( any dose ),C0004057
3039,long - term treatment with aspirin — no . / total no . ( % ),C0004057;C0023977
3038,no aspirin,C0004057
3038,initial aspirin — no . ( % ),C0004057;C0205265;C1279901;C1555582;C1705685
3038,aspirin 一 no . ( % ),C0004057
3038,aspirin — no . ( % ),C0004057
3037,asas partial remission    n   ( % ),C0004057;C1521726;C3853627;C4552913;C4552914
3037,asas partial remission  %,C0004057;C1521726;C3853627;C4552913;C4552914
3037,asas $nmbr$ / $nmbr$    n   ( % ),C0004057;C3853627
3037,asas $nmbr$ / $nmbr$    %,C0004057;C3853627
3037,asas $nmbr$    %,C0004057;C3853627
3037,asas $nmbr$  %,C0004057;C3853627
3037,asas $nmbr$,C0004057;C3853627
3036,asa  n ( % ),C0004057;C3853627
3036,$nmbr$ - asa compounds  n ( % ),C0004057;C0205198;C1706082;C3853627
3035,therapy ( asa $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
3035,therapy ( asa $nmbr$  $nmbr$ / placebo $nmbr$ ),C0004057;C0032042;C0039798;C0087111;C1363945;C1696465;C1706408;C3853627
3035,pfo + asa,C0004057;C3853627
3035,aspirin ( asa ) ( » = $nmbr$ $nmbr$ ),C0004057;C3853627
3034,s - asa compounds at baseline,C0004057;C0010139;C0043474;C0168634;C1442488;C3853627
3034,no asa use at baseline,C0004057;C0042153;C0168634;C0457083;C1442488;C1947944;C3853627
3034,no asa,C0004057;C3853627
3034,asa or antiplatelet agent,C0004057;C3853627
3034,asa,C0004057;C3853627
3033,other atherosclerotic cvdd  e,C0333482;C1859330
3032,other atherosclerotic event,C0333482;C0441471;C4019010
3032,other atherosclerotic,C0333482
3031,other atherosclerotic cvd st depression on,C0007222;C0333482;C0520887
3031,other atherosclerotic cvd * *,C0007222;C0333482
3031,other atherosclerotic cvd,C0007222;C0333482
3031,atherosclerotic cvdj,C0333482
3031,atherosclerotic cvd §,C0007222;C0333482
3031,atherosclerotic cvd,C0007222;C0333482
3030,qualifying type of atherosclerosis — no . ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
3030,qualifying atherosclerosis,C0003850;C0004153;C1514624
3030,atherosclerosis ^  n ( % ),C0003850;C0004153
3030,arteriosclerosis,C0003850
3029,large - artery atherosclerosis,C0003850;C0004153;C0226003
3029,atherosclerosis,C0003850;C0004153
3028,piroxicam,C0031990
3027,meloxicam,C0083381
3026,aerobic exercise,C0001701
3026,aerobic activity,C0001701
3025,chronic cox $nmbr$ inhibitors,C0085387;C0205191
3024,chronic cvd,C0007222;C0205191
3023,patients without chronic,C0030705;C0205191
3023,patients with chronic,C0030705;C0205191
3023,chronic bronchitist,C0205191
3022,estonia,C0014908
3021,tonic – clonic,C3543842
3021,tonic,C3543842
3020,cholecystitis chronic,C0008325;C1963083;C4553186
3019,functional assessment of chronic illness,C0008679;C0278372
3018,troponin or ckmb value,C0041199
3018,positive troponin or ck - mb,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
3017,troponin $nmbr$ at baseline *,C0041199;C0168634;C1442488
3017,troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
3017,troponin,C0041199
3016,elevated troponin — %,C0041199;C0205250;C3163633
3016,elevated troponin ( > $nmbr$ . $nmbr$ mg / l )  %,C0041199;C0205250;C0439268;C3163633
3016,elevated troponin,C0041199;C0205250;C3163633
3015,troponin ( - ),C0041199
3015,elevated troponin ( > $nmbr$ . $nmbr$ pg / l ),C0041199;C0205250;C0439278;C3163633
3014,troponin ( + ),C0041199
3014,elevation of troponin levels — no . / total no . ( % ),C0041199;C0439775;C0441889;C0702240
3013,bifurcation per lesion ‡,C0184906;C0221198;C1546698;C3146289
3013,bifurcation lesion with side branch ≥ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
3013,bifurcation lesion with side branch $ $nmbr$ . $nmbr$ mm stented,C0184906;C0205384;C0221198;C0441987;C1253959;C1546698;C1881507;C2700383;C2826234;C3146289;C4330985;C4554674
3013,bifurcation lesion,C0184906;C0221198;C1546698;C3146289
3012,stents per lesion  n,C0038257;C0221198;C1546698
3012,stented lesions,C0038257;C0221198
3012,stent length per lesion  mm,C0038257;C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
3012,mean stent diameter per lesion  mm ( sd ) †,C0038257;C0221198;C0552409;C1546698;C2699239;C4330985;C4554674
3012,lesions treated per patient,C0221198
3011,t $nmbr$ lesion volume  mm ',C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
3011,t $nmbr$ lesion volume  mm $nmbr$,C0221198;C0449468;C1546698;C1690016;C1705102;C2603360;C2700258;C4330985;C4554674
3011,mean total stent length per lesion  mm ( sd ) ‡,C0038257;C0221198;C0439175;C0439810;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
3011,lesion length ≥ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
3011,lesion length > $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
3011,lesion length $ $nmbr$ mm,C0221198;C1444754;C1546698;C1706316;C4330985;C4554674
3011,lesion length  mean ( sd )  mm,C0221198;C0444504;C1444754;C1546698;C1706316;C2347634;C2348143;C2699239;C4330985;C4554674
3011,lesion ( s ),C0221198;C1546698
3010,lesions b $nmbr$ / c,C0221198;C1546698
3010,lesions,C0221198
3010,age > $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
3010,age > $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
3010,age < $nmbr$ gd lesion > $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
3010,age < $nmbr$ gd lesion = $nmbr$ n = $nmbr$,C0001779;C0221198;C1546698
3010,age / gd lesion,C0001779;C0221198;C1546698
3009,complex lesions ^,C0221198;C0439855;C1704241
3008,intervention in complex lesions,C0221198;C1292781
3007,treated lesions ‡,C0221198;C1522326
3007,no . of treated lesions,C0221198;C1522326
3006,stratum $nmbr$ : inadequate response or intolerance to > $nmbr$ bdmards of same moa or > $nmbr$ of multiple moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
3006,stratum $nmbr$ : inadequate response or intolerance to $nmbr$ - $nmbr$ bdmards of same moa,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
3006,sri response  %,C0871261;C1420401;C1704632;C1706817;C2911692
3006,mean eq - $nmbr$ d response ( $nmbr$ % ci ),C0008107;C0205163;C0439185;C0444504;C0871261;C1704632;C1706817;C2347634;C2348143;C2911692;C3259781
3006,inadequate response or intolerance to > $nmbr$ anti - tnfdrug,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
3006,inadequate response / intolerance to prior therapy  %,C0039798;C0087111;C0205412;C0231199;C0332152;C0439856;C0871261;C1363945;C1704632;C1706817;C1744706;C2355652;C2911692
3006,inadequate response,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
3006,eular good response,C0205170;C0871261;C1704632;C1706817;C2911692
3006,bronchodilator response  ml,C0006280;C0439526;C0871261;C1704632;C1705224;C1706817;C2911692;C3887665
3006,acr response  % acr $nmbr$,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
3006,acr response  %,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
3006,acr $nmbr$ response  n / n ( % ),C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
3006,acr $nmbr$ response,C0871261;C1412134;C1515941;C1704632;C1706817;C2911692
3005,trough fvc response ( l ) !,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
3005,trough fvc response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
3005,trough fev | response ( l ),C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
3005,trough fev $nmbr$   response,C0444506;C0871261;C1704632;C1706817;C2911692;C3714541
3005,peak fev $nmbr$ ( $nmbr$ - $nmbr$ h )   response,C0033727;C0369286;C0441932;C0444505;C0564385;C0871261;C1704632;C1706817;C2911692;C3714541;C4528284
3004,previous loss of response to infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
3004,previous loss of response to and intolerance of infliximab  n ( % ) *,C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
3004,patients with previous loss of response to infliximab,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
3004,patients with previous loss of response to and intolerance of infliximab *,C0030705;C0205156;C0871261;C1517945;C1552607;C1704632;C1706817;C2911692
3004,omeract - oarsi response,C0871261;C1704632;C1706817;C2911692
3004,loss of response ‘ s,C0871261;C1517945;C1704632;C1706817;C2911692
3004,loss of response ®,C0871261;C1517945;C1704632;C1706817;C2911692
3004,loss of response : ! : : ! :,C0871261;C1517945;C1704632;C1706817;C2911692
3004,loss of response,C0871261;C1517945;C1704632;C1706817;C2911692
3003,planned thienopyridine at enrollment,C1120149;C1709561
3002,thienopyridine at baseline,C0168634;C1120149;C1442488
3002,thienopyridine alone,C1120149
3002,planned thienopyridine at baseline,C0168634;C1120149;C1301732;C1442488
3001,thienopyridine n = $nmbr$,C1120149
3001,thienopyridine ( n = $nmbr$ ),C1120149
3001,no thienopyridine,C1120149
3001,continued thienopyridine n = $nmbr$ subjects,C0549178;C1120149
3001,continued thienopyridine ( n = $nmbr$ ),C0549178;C1120149
3001,continued thienopyridine ( n $nmbr$ $nmbr$ ),C0549178;C1120149
3000,thienopyridine drug at start of open - label period,C0439531;C1120149;C1709323;C1948053;C2348346
3000,- thienopyridine,C1120149
2999,thienopyridine,C1120149
2999,prior thienopyridine ( - ),C0332152;C1120149;C2826257
2999,prior thienopyridine ( + ),C0332152;C1120149;C2826257
2999,+ thienopyridine,C1120149
2998,non - dihydropyridine ccbs,C0006684;C0012315;C0220821;C1518422
2998,dihydropyridine ccbs,C0006684;C0012315;C0220821
2998,dihydropyridine,C0012315;C0220821
2997,immunosuppressive agents only,C0021081;C0205171;C1720467
2997,immunosuppressants onlyff,C0021081
2997,immunosuppressants only,C0021081;C0205171;C1720467
2997,immunosuppressants and antimalarials only,C0021081
2997,any immunosuppressive agent,C0021081
2996,immunosuppressants,C0021081
2996,corticosteroids . immunosuppressants . and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727
2995,prior immunosuppressant failurec,C0021081;C0332152;C2826257
2995,prior immunosuppressant failure,C0021081;C0231174;C0332152;C0680095;C2826257
2995,immunosuppressant ^ ^,C0021081
2995,immunosuppressant ^,C0021081
2995,immunosuppressant ( with or without corticosteroid ),C0021081
2994,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
2994,concomitant immunosuppressive and / or prior anti - tnf use,C0021081;C0521115
2993,inferior mi *  %,C0340305;C3542426
2992,anterior mi,C3536746
2991,inferior or posterior,C0542339;C0678975
2991,inferior / posterior,C0205095;C0542339;C0678975
2991,inferior ( n  % ),C0542339;C0678975
2991,inferior ( % ),C0542339;C0678975
2991,inferior,C0542339;C0678975
2990,nonfatal myocardiail infarction,C0021308
2990,nonfatai myocardiai infarction,C0021308
2990,myocardiai infarction,C0021308
2990,carotid infarct,C0021308;C0741968
2989,infarct localization  n ( % ),C0021308;C0475264;C1744691
2989,infarct localization,C0021308;C0475264;C1744691
2989,infarct localisation,C0021308;C0475264;C1744691
2988,no infarct visible,C0021308
2988,infarct size,C0021308;C0456389
2987,any relevant infarct,C0021308;C2347946
2987,any infarct,C0021308
2986,vertebrobasilar infarct,C0021308;C0545733
2985,q waves in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
2985,q wave in the infarct territory at baseline *  %,C0021308;C0429089;C1301808;C1305738;C2983136
2985,infarct territory ( % ),C0021308;C1301808;C2983136
2985,infarct - related vessel ( % ),C0021308
2984,previous infarction ( % of group ),C0021308;C0205156;C0441833;C0687744;C1257890;C1519504;C1552607;C1705428;C1705429
2984,previous infarction,C0021308;C0205156;C1552607
2984,cardioembolic infarction  n ( % ),C0021308
2984,atherothrombotic infarction  n ( % ),C0021308
2983,inclusion findings ( % ),C0007637;C1512693;C2607943;C2926606;C3539655
2983,accp bleeding risk at inclusion  no . ( % ) f,C0007637;C1512693;C3251812
2982,inclusion criteria — no . ( % ),C1512693
2982,inclusion criteria,C1512693
2982,cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
2981,interim analysis ( all patients ),C4684691
2981,interim analysis,C4684691
2980,( incl . uncertain ),C0268281;C1418854
2979,uncertain,C0087130;C4085655
2978,interruption ( n = $nmbr$ ),C0332453;C1512900
2978,interruption,C0332453;C1512900
2977,time from end of fit  years ( meanisd ),C0036572;C0439234;C1522314;C2349186;C4048158;C4553125
2976,convulsion,C0036572;C4048158
2975,type of insulin therapy — no . ( % ) $nmbr$,C0039798;C0087111;C0457592;C1363945
2975,type of insulin,C0457592
2975,insulin type  n ( % ),C0457592
2974,induction - trial group assignment — no . ( % ),C0205263;C0857127;C1320290;C1516050
2974,inducing,C0205263
2973,baseline of induction )  n ( % ),C0168634;C0205263;C0857127;C1442488
2973,baseline of induction,C0168634;C0205263;C0857127;C1442488
2972,ugt induction status : per aeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
2972,ugt induction status : as randomizeda  n ( % ),C0205263;C0449438;C0857127;C1420188;C4284131
2972,octave induction $nmbr$ and $nmbr$,C0205263;C0857127
2972,octave induction $nmbr$,C0205263;C0857127
2971,potential predictor,C2698872;C3245505
2970,nice secondary prevention onlyb,C0679699;C4087029
2969,nice primary prevention onlyb,C0033144;C4087029
2968,placebo ‐ controlled period,C0439531;C1706408;C1948053
2967,period ii,C0439531;C1710602;C1948053;C4082587
2966,additional investigations,C2359834
2965,laboratory investigations,C0022877;C1261322;C3244292;C4283904
2965,investigations,C1261322
2964,investigator - reported hypoglycaemia *,C0035173
2964,investigator - reported hypoglycaemia,C0035173
2964,investigator - reported aes,C0035173;C0684224;C0700287;C1412268;C2699274;C4319718
2964,investigator - determined myocardial infarction,C0035173
2964,investigator - defined drug - related aes,C0035173
2963,central nervous system,C3540014;C3714787
2962,neuraxial anaesthesia,C0002903;C0002912;C0002930;C3714787;C4049933
2962,neuraxial alonee,C3714787
2961,geometric c $nmbr$ concentration  mg / dl,C0086045;C0439269;C0449829;C1446561;C3827302
2960,blood leucocyte concentration ( $nmbr$ cells per l ),C0023516;C0086045;C0347983;C0427728;C0699870;C1313904;C1446561;C3827302
2959,non - hdlc concentration,C0086045;C1446561;C1518422;C1704429;C3827302
2959,ldl - c concentration,C0086045;C1446561;C3827302
2959,hdlc - concentration,C0086045;C1446561;C1704429;C3827302
2958,serum creatinine concentration and randomization to losartan,C0010294;C0086045;C0201976;C0600061;C0683149;C1446561;C1561535;C3827302
2957,study end concentration,C0086045;C0444930;C0557651;C1446561;C2603343;C2746065;C3827302
2956,observation,C0302523;C0700325;C1964257;C3889687
2955,mouth ulceration,C0149745
2954,st - segment elevation mi,C0520886;C3810814
2954,st - elevation mi,C0520886;C3810814
2954,non - st — elevation mi,C0520886;C1518422;C3810814
2954,non - st - segment elevation mi,C0520886;C1518422;C3810814
2954,non - st - elevation mi,C0520886;C1518422;C3810814
2953,non - st - segment elevation acs,C0520886;C0742343;C1518422;C4318612
2953,non - st - segment elevation,C0520886;C1518422
2952,• ml without st - segment elevation,C0439526;C0520886;C1705224;C3887665
2952,• ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2952,st segment elevation,C0520886
2952,st elevation,C0520886
2952,st - segment elevation,C0520886
2952,non - st - elevation ml,C0439526;C0520886;C1518422;C1705224;C3887665
2952,ml without st - segment elevation !,C0439526;C0520886;C1705224;C3887665
2952,ml with st - segment elevation,C0439526;C0520886;C1705224;C3887665
2951,inversion,C0021943;C0021945;C1705687;C2349984
2950,t wave inversion,C0520888
2950,t - wave inversion only,C0205171;C0520888;C1720467
2950,t - wave inversion,C0520888
2949,symmetric t wave inversions,C0332516;C0520888;C2699744
2949,symmetric t - wave inversions,C0332516;C0520888;C2699744
2948,perfusion defectsatinclusion,C0031001;C4281794
2947,no reperfusion,C0035124;C0684253
2947,acute reperfusion,C0035124;C0205178;C0684253
2946,st - segment depression or t - wave inversion on ecg,C0520887
2946,st - depression only,C0205171;C0520887;C1720467
2946,st - depression and t - wave inversion,C0520887
2945,st segment depression,C0520887
2945,st - segment depression > $nmbr$ . $nmbr$ mv on admission  %,C0520887;C1454484;C1705503;C4281602
2945,st - segment depression > $nmbr$ . $nmbr$ mv,C0520887;C1454484;C1705503;C4281602
2945,st - segment depression < $nmbr$ . $nmbr$ mv  %,C0520887;C1454484;C1705503;C4281602
2945,st - segment depression,C0520887
2944,st depression or elevation,C0520887
2944,no st depression or elevation,C0520887
2944,major st depression or t - wave inversion,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
2944,major st depression or t - wave,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
2944,major st depression or,C0036056;C0041696;C0205082;C0205164;C0520887;C1269683;C3272372;C4318856;C4521762
2943,required hospitalization,C1708385
2942,catecholamines or corticosteroids without hospitalization,C0007412
2941,number of hospitalizations in last year prior to baseline,C4086639
2941,mean number of combined visits / hospitalizations †,C0205195;C0444504;C0545082;C1512346;C2347634;C2348143;C4086639
2940,antimalarial,C0003374;C3536844;C4552582
2939,parenteral anticoagulation,C0003281;C0030547;C2917212;C2919015;C3537050;C4522267
2939,intended duration of anticoagulation,C0003281;C0449238;C1283828;C1551357;C2917212;C2919015;C2926735;C3537050
2938,arthralgia,C0003862;C4551938
2937,rheumatoid arthritis,C0003873
2937,duration of rheumatoid arthritis — yr,C0003873;C0439234;C0449238;C2926735
2937,duration of rheumatoid arthritis ( years ),C0003873;C0439234;C0449238;C2926735
2937,duration of rheumatoid arthritis  year,C0003873;C0439234;C0439508;C0449238;C2926735
2936,number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0237881;C0349790;C0449788;C0750502;C1546944
2936,mean number of clinically significant asthma exacerbations †,C0237753;C0237881;C0349790;C0444504;C0449788;C0750502;C1546944;C2347634;C2348143
2936,asthma exacerbations,C0349790
2935,extracranial,C0580586
2934,intracranial disease of major artery 寸,C0205082;C0205164;C0524466;C0852949;C4318856;C4521762
2934,intracranial,C0524466
2933,intrathoracic or intraperitoneal surgery,C0595836
2932,intraperitoneal,C0442120
2931,social interaction,C0037420
2930,teaes of special interest,C0205555;C0543488
2930,special interest categories,C0205555;C0543488;C0683312
2929,bail ‐ out use of glycoprotein iib / iiia inhibitors,C0175673
2928,brazil,C0006137
2927,infarct on brain imaging 丰,C0751955
2927,infarct on brain imaging ^,C0751955
2926,traditional nsaid,C0003211;C0443324;C1548559;C3536840
2926,nsaid   at   least   once,C0003211;C3536840
2925,traditional nsaid use,C0003211;C3536840;C3897349
2925,nsaid use — no . / total no . ( % ),C0003211;C3536840
2924,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0003211;C0032790;C3536840
2924,postoperative nsaid or glucocorticoid use,C0003211;C0032790;C3536840
2924,other nsaids,C0003211
2923,cox - $nmbr$ selective nsaid use,C0003211;C0036576;C0042153;C0457083;C1565830;C1707391;C1947944;C3536840
2923,cox - $nmbr$ selective nsaid,C0003211;C0036576;C1565830;C1707391;C3536840
2922,nsaid,C0003211;C3536840
2922,cumulative nsaid score  mean   ±   sd,C0003211;C0444504;C0449820;C1511559;C2347634;C2348143;C2699239;C3536840;C4050231
2921,non - steroidal anti - inflammatory drugs,C0003211
2921,chronic non - steroidal antiinflammatory drugs,C0003211;C0205191
2920,vte / vte - related deathsb  n / n ( % ),C0439849;C0445223;C0630906
2920,vte / vte - related deathsa  n / n ( % ),C0439849;C0445223;C0630906
2920,unprovoked vte n ( % ),C0630906
2919,any vte or vte - related death — no . ( % ),C0630906
2919,any vte - related death,C0425043;C0630906
2918,p - value ( ■ nt ),C0332126;C1449832;C1709380;C3889152;C4050156;C4283901;C4284038
2918,nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
2917,ta ( n = $nmbr$ ),C0039297;C1506978;C1705538;C3272501;C4553364
2917,ta,C0039297;C1506978;C1705538;C3272501;C4553364
2917,combined ( dutasteride / ta msu losi n ),C0024776;C0039297;C0205195;C0754659;C1412759;C1506978;C1705538;C3272501;C4553364
2916,italy ( n = $nmbr$ ),C0022277
2916,italy,C0022277
2915,stating,C1301808;C1442792;C3148680
2915,state,C1301808;C1442792;C3148680
2914,diabetes status  no . ( % ),C1317301
2914,diabetes status  n ( % ),C1317301
2914,diabetes status,C1317301
2914,diabetes mellitus status,C1317301
2913,aed inducer status,C0449438;C0887457;C3898767
2912,other glucose status,C0017725;C0449438
2911,frailty status,C0424594;C0449438
2911,cortteosterom relrsclory status,C0449438
2910,hormonal status,C0449438;C0458083
2909,smokinq status,C0449438
2909,emotional status,C0013987;C0449438;C0849912
2908,status ( spmsq > $nmbr$,C0449438
2908,status ( spmsq < $nmbr$,C0449438
2908,aha status at screeningb  n ( % ),C0050451;C0449438;C0772110
2907,ish status  n ( % ),C0449438
2907,h . pylori status  n ( % ),C0079488;C0449438
2906,intravenous dobutamine,C0012963;C0348016
2905,intravenous nitrates,C0028125;C0348016
2904,intravenous inotropes or vasopressors ( % ),C0348016;C1258199
2903,secukinumab intravenous $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0348016;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
2903,intravenous ( n = $nmbr$ ),C0348016
2902,ttf - fv,C1332112;C1705840;C4087167
2901,tt,C1452561;C4554543
2901,estimated glomerular filtration rate - ml / min / $nmbr$ . $nmbr$ m $nmbr$ tt,C0369637;C0439445;C0441923;C1452561;C3811844;C4554543
2900,tnf - naive patientsa,C1448177
2900,anti - tnf - naive patients $nmbr$,C0030705;C1448177
2900,anti - tnf - naive patients,C0030705;C1448177
2900,anti - tnf - experienced patients,C0030705;C1448177
2899,tnf - naivea,C1448177
2899,anti - tnf - naive  n ( % ),C0432633;C1448177
2898,tnf antagonist - naive ®,C0231491;C1448177
2898,tnf antagonist - naive subgroup ( n - $nmbr$ ),C0231491;C1079230;C1448177;C1515021
2898,tnf antagonist - naive ' ’,C0231491;C1448177
2898,tnf antagonist - exposed,C0231491;C1448177
2897,tnf antagonist - failure population ( n - $nmbr$ ),C0032659;C0231174;C0231491;C0680095;C1257890;C1448177
2897,tnf - failurea,C1448177
2897,tnf - failure patientsa,C0231174;C0680095;C1448177
2897,prior tnf antagonist failure - yes,C0231174;C0231491;C0332152;C0680095;C1448177;C1549445;C1705108;C1710701;C2826257
2897,prior tnf antagonist failure - no,C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
2896,tnf inhibitor,C1448177;C1999216
2896,prior tnf inhibitor exposure  no . ( % ),C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
2896,prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
2896,no prior tnf inhibitor exposure,C0274281;C0332152;C0332157;C1448177;C1999216;C2826257
2895,reason for discontinuation of previous tnfa inhibitor,C0205156;C0392360;C0457454;C1444662;C1448177;C1552607;C1710304;C1999216;C4552847
2895,number of previous tnfa inhibitors,C0205156;C0237753;C0243077;C0449788;C1448177;C1552607;C1710304
2895,number of previous anti - tnf treatments for psoriatic arthritis,C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
2895,number of previous anti - tnf treatments for psa  n ( % ),C0087111;C0205156;C0237753;C0449788;C1448177;C1552607
2895,anti - tnf,C1448177
2894,tpm subgroup  n = $nmbr$,C0076829;C1079230;C1515021
2894,tpm - naive,C0076829
2894,tpm - exposed,C0076829
2893,topiramate,C0076829
2893,prior exposure to topiramate,C0076829;C0274281;C0332152;C0332157;C2826257
2892,r - tpa,C0032143
2891,alteplase group ( n = $nmbr$ ),C0032143;C0441848
2891,alteplase ( n = $nmbr$ ),C0032143
2891,alteplase,C0032143
2890,phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1547052;C1656262;C3539996
2889,type ic,C0020750;C0332307;C1547052;C4554818
2888,any type  according to daily dose * *,C0332307;C0680240;C1547052;C2348070
2887,type of hospital care,C0259945;C0332307;C1547052
2886,type of concomitant statin by daily dose - no . ( % ),C0332307;C0360714;C0521115;C1547052
2886,type of concomitant statin by daily dose,C0332307;C0360714;C0521115;C1547052
2886,type of concomitant statin,C0332307;C0360714;C0521115;C1547052
2885,thienopyridine type,C0332307;C1120149;C1547052
2884,type / no . of valves repaired / replaced mitral,C0332307;C1547052
2884,predominant type of heparin,C0019134;C0332307;C0770546;C1542147;C1547052
2883,type of des at index procedure,C0011702;C0332307;C1547052;C4551552
2883,type of des,C0011702;C0332307;C1547052;C4551552
2883,des type,C0011702;C0332307;C1547052;C4551552
2883,> $nmbr$ type,C0332307;C1547052
2883,> $nmbr$ des type,C0011702;C0332307;C1547052;C4551552
2882,type of mi ( % ),C0332307;C1547052;C3810814
2882,type of mi,C0332307;C1547052;C3810814
2882,type,C0332307;C1547052
2882,mi type unknown ( % ),C0332307;C1547052;C3810814
2881,type $nmbr$  n ( % ),C0332307;C1547052
2881,qualifying type of atherosclerosis  n ( % ),C0003850;C0004153;C0332307;C1514624;C1547052
2880,type of af  n ( % ),C0332307;C0344434;C1547052;C4049859
2880,type of af,C0332307;C0344434;C1547052;C4049859
2880,af type — no . ( % ),C0332307;C0344434;C1547052;C4049859
2880,af type,C0332307;C0344434;C1547052;C4049859
2879,antiepileptic drug type at baseline,C0003299;C0168634;C0332307;C0457591;C1442488;C1547052;C3537002
2878,type of stent at index procedure,C0038257;C0332307;C1547052
2878,type of drug - eluting stent  n ( % ),C0038257;C0332307;C0457591;C1322815;C1547052
2878,stent type implanted,C0038257;C0332307;C1547052
2878,stent type,C0038257;C0332307;C1547052
2877,types of antihypertensive medications at last visit   §,C0003364;C0332307
2876,types of antihypertensive medications at $nmbr$ year   †,C0003364;C0332307
2876,barc types $nmbr$  $nmbr$  or $nmbr$,C0332307
2875,< $nmbr$ months in - $nmbr$ kill,C0162388;C0439231;C0681205;C1550555
2874,$nmbr$ - $nmbr$ months fn = $nmbr$ . $nmbr$ ),C0439231;C1570610
2873,intensified $nmbr$ months ( n - $nmbr$ ),C0439231
2873,canakinumab  hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
2873,canakinumab  hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0439231;C0439268;C2718773
2873,> $nmbr$ months ( n = $nmbr$  $nmbr$ ),C0439231
2873,$nmbr$ - < $nmbr$ months  n ( % ),C0439231
2873,$nmbr$ - $nmbr$ months ( n = $nmbr$ ),C0439231
2873,$nmbr$ - $nmbr$ months  n ( % ),C0439231
2873,$nmbr$ - $nmbr$ months,C0439231
2872,poor outcome at $nmbr$ months,C0439231;C3806166
2871,> $nmbr$ per pl in $nmbr$ months before screening,C0439231;C3897966;C4049765
2870,duration of dementia symptoms  months,C0011265;C0436359;C0439231;C0497327
2869,duration of prior alendronate use  months,C0102118;C0332152;C0439231;C1881378;C2826257;C2826775
2869,duration of previous use of vka  months,C0205156;C0439231;C1552607;C1881378;C2826775
2868,fall in last $nmbr$ months ( % ),C0085639;C0238715;C0439231;C4553726
2867,> $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
2867,> $nmbr$ months  n ( % ),C0439231
2867,> $nmbr$ months,C0439231
2867,< $nmbr$ months — number / n ( % ),C0237753;C0439231;C0449788
2867,< $nmbr$ months  n ( % ),C0439231
2866,$nmbr$ tob $nmbr$ months  n ( % ),C0439231;C1420851
2866,$nmbr$ tob $nmbr$ months,C0439231;C1420851
2865,duration of sulphonylurea use ( months )  mean ± s . d .,C0038766;C0439231;C0444504;C1881378;C2347634;C2348143;C2826775;C3536898
2865,< $nmbr$ months  mean ( sd ),C0439231;C0444504;C2347634;C2348143;C2699239
2865,< $nmbr$ months,C0439231
2865,$nmbr$ months,C0439231
2864,months since ra was first diagnosed  mean ( sd ),C0439231
2864,months since first ra symptom  mean ( sd ) f,C0439231
2864,kccq ( $nmbr$ months ),C0439231;C3476798
2864,^ $nmbr$ months,C0439231
2863,recent treatment ( < $nmbr$ months mmf / ggs ),C0039798;C0083765;C0087111;C0209368;C0332185;C0439231;C1522326;C1533734;C1705169;C3538994;C3848524;C3887704
2863,$nmbr$ – $nmbr$ months,C0439231
2862,months ( log - transformed ),C0439231
2862,duration of chf ( months ),C0018802;C0439231;C0449238;C2926735
2861,azathioprine monotherapy,C0004482
2861,azathioprine ( n = $nmbr$ ),C0004482
2861,azathioprine,C0004482
2860,ifx + aza ( n = $nmbr$ ),C0004482;C0020823
2860,aza ( n = $nmbr$ ),C0004482
2859,age at onset  y,C0206132;C3870509
2859,age at disease onset  n ( % ) *,C0012634;C0206132;C3870509
2858,age of onset < $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
2858,age of onset $nmbr$ years ( n = $nmbr$ ),C0206132;C0439234;C3175530
2858,age of onset,C0206132;C3175530
2858,age of asthma onset  years,C0004096;C0206132;C0439234;C2984299;C3175530
2857,onset of chest pain,C0024902;C0206132;C0332162
2857,onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
2856,tion  os = overall satisfaction  qmax = maximal urinary flow rate .,C0229090;C0230028;C0262950;C0393706;C0429784;C1561953;C4086680
2856,os domain,C0229090;C0230028;C0262950;C0393706;C1561953;C1880389;C1883221;C3541951
2856,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . os ),C0229090;C0230028;C0262950;C0393706;C1561953
2855,\bl - sc n / n,C0005918;C0006413;C0282380;C1552663;C2827109
2854,bl mean ( mmhg ),C0005918;C0006413;C0439475;C0444504;C1552663;C2347634;C2348143;C2827109
2854,bl mean ( cm ),C0005918;C0006413;C0444504;C1552663;C2347634;C2348143;C2827109
2854,bl bml > $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
2854,bl bml > $nmbr$ ke / m ^,C0005918;C0006413;C0022558;C0369637;C0441923;C1552663;C2827109
2854,bl bml < $nmbr$ kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
2854,bl bmioo kg / m ^,C0005918;C0006413;C1532718;C1552663;C2827109
2854,bl bm $nmbr$ < $nmbr$ kg / m ^,C0005918;C0006413;C0006416;C1532718;C1552663;C2827109
2854,bl,C0005918;C0006413;C1552663;C2827109
2853,diabetes bl,C0005918;C0006413;C0011847;C0011849;C1552663;C2827109
2853,bl updrs : low,C0005918;C0006413;C1552663;C2827109;C3639721
2853,bl updrs : high,C0005918;C0006413;C1552663;C2827109;C3639721
2853,bl h / y : unilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
2853,bl h / y : bilateral,C0005918;C0006413;C0033727;C0369286;C0441932;C0564385;C1552663;C2827109;C4528284
2852,bb after randomisation,C0004739;C0034656;C0332297
2852,bb,C0004739;C0332297
2852,- < — ■ bb — - ►,C0004739;C0332297
2851,asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
2850,ast increased,C1415181;C3891303
2850,ast  u / l,C0439339;C1415181;C3891303
2849,statin intensity per acc / ahac,C0175754;C0282160;C0360714;C0522510;C3541413
2848,modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C0392747;C3541413;C3889737
2847,apolipoprotein a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508
2847,apolipoprotein a,C0003592;C0523508
2846,apo b / apo a - l ratio ( mean ),C0003592;C0444504;C0456603;C0523508;C1447574;C1547037;C2347634;C2348143;C4521365;C4553344
2846,apo b / apo a - l,C0003592;C0523508;C1447574;C4521365;C4553344
2845,sbp indicates systolic blood pressure  dbp  diastolic blood pressure  aa  arachidonic acid  epa  eicosapentaenoic acid . values for age  bmi  total cholesterol  ldl cholesterol  hdl cholesterol  sbp  dbp  aa  epa  and epa / aa ratio represent the mean values represent the median ( interquartile range ) . p values are for the differences between the no epa and epa groups .,C0000545;C0003695;C0085805;C0282379;C0439175;C0439632;C0439810;C0456603;C0536221;C0578022;C1235746;C1547037;C1709380;C1711350;C1882141;C2316832;C2699193;C3813197;C4281799;C4554792
2845,epa / aa ratio,C0282379;C0456603;C1235746;C1547037;C1882141;C4554792
2845,aa / g,C0282379;C0439267;C1235746;C1882141;C4554792
2845,aa,C0282379;C1235746;C1882141;C4554792
2844,apo b *,C0003593;C3252643
2844,apo b ( mg / dl ) - mean ± sd,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
2844,apo b ( mg / dl ) * *,C0003593;C0439269;C3252643
2844,apo - b,C0003593;C3252643
2843,apo b  mg / dl  mean ( sd ),C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
2843,apo b  mean ( sd )  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C2699239;C3252643
2843,apo b  mean ( sd ),C0003593;C0444504;C2347634;C2348143;C2699239;C3252643
2843,apo b,C0003593;C3252643
2842,apob  g / l  mean ( sd ),C0003593;C0439294;C0444504;C0456615;C2347634;C2348143;C2699239;C3252643
2842,apob  g / l,C0003593;C0439294;C0456615;C3252643
2842,apob,C0003593;C3252643
2842,apo b ( g / l ),C0003593;C0439294;C0456615;C3252643
2841,apob : apoal ratio,C0003593;C0456603;C1547037;C3252643
2841,apob : apoal,C0003593;C3252643
2841,apob : apoa - l ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
2840,apob : apoa - $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
2840,apob : apoa $nmbr$ ratio,C0003592;C0003593;C0456603;C0523508;C1547037;C3252643;C4553344;C4553379
2840,apob : apoa $nmbr$,C0003592;C0003593;C0523508;C3252643;C4553344;C4553379
2840,apob $nmbr$,C0003593;C3252643
2840,< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio,C0003592;C0003593;C0456603;C0475211;C0523508;C1532563;C1547037;C3252643;C4553344;C4553379
2839,arb  %,C3888198
2839,ace = angiotensin - converting enzyme . arb = angiotensin receptor blockers .,C0022709;C0597357;C3888198
2839,abbreviations : acei  angiotensin - converting enzyme inhibitor  arb  angiotensin receptor blocker  bpm  beats per minute  ccb  calcium channel blocker  msdbp  mean sitting diastolic blood pressure  mssbp  mean sitting systolic blood pressure . values are no . ( % ) unless otherwise indicated . amean ± sd . bmore severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg  less severe  > $nmbr$ and < $nmbr$ mm hg / > $nmbr$ and < $nmbr$ mm hg . blood pressure at baseline is with monotherapy ( ie  before switch to amlodipine / valsar - tan therapy ) .,C0000723;C0003015;C0006684;C0014122;C0022067;C0025424;C0042295;C0428257;C0439385;C0439453;C0444504;C0597357;C1319894;C1881173;C2347108;C2347109;C2347634;C2348143;C2348272;C2757044;C3536837;C3536851;C3888198;C4521885;C4541021;C4554371
2838,previously on acei + arb,C3888198
2838,arb at enrollment,C1516879;C1696073;C3888021;C3888198
2837,prior bb plus acbi plus arb use,C0004739;C0042153;C0332152;C0332287;C0332297;C0457083;C1947944;C2826257;C3888198
2837,arb,C3888198
2836,arb monotherapy,C3888198
2836,ace inhibitor / arb therapy,C1444755;C3888198
2835,arb ( n  % ),C3888198
2835,arb  n ( % ),C3888198
2835,acei / arb therapy  n ( % ),C0039798;C0087111;C1363945;C3888198
2834,use of ace inhibitors / arbs  n ( % ),C0003015;C1524063;C3888198
2834,arbs,C3888198
2834,aceis / arbs,C3888198
2834,ace inhibitors / arbs  n ( % ),C0003015;C3888198
2834,ace inhibitors / arbs,C0003015;C3888198
2833,without acei / arb,C3888198
2833,with acei / arb,C3888198
2833,no ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
2833,baseiine acei / arb,C3888198
2833,acei / arb and bb after randomisation,C3888198
2833,acei / arb,C3888198
2833,ace / arb users,C1452534;C1706077;C3888198;C4284014
2833,ace / arb use,C1452534;C3888198;C4284014
2833,ace - l / arbs,C1452534;C3888198;C4284014
2833,ace - i / arb  ( % ),C0021966;C0221138;C1452534;C3888198;C4284014
2833,ace - i / arb,C0021966;C0221138;C1452534;C3888198;C4284014
2832,arbs or ace inhibitors,C3888198
2832,arb or ace inhibitor  n ( % ),C3888198
2832,arb or ace inhibitor,C3888198
2832,arb / ace,C1452534;C3888198;C4284014
2832,ace / arb medication ( % ),C0013227;C1452534;C3244316;C3888198;C4284014;C4284232
2832,ace / arb,C1452534;C3888198;C4284014
2831,modmy al randcnxzaton,C0202311
2830,om $nmbr$ mg / aml $nmbr$ mg ( n = $nmbr$ ),C0023465;C0023467;C0028971;C1319635;C1705272
2830,om $nmbr$ mg / aml $nmbr$ mg,C0023465;C0023467;C0028971;C1319635;C1705272
2830,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2830,om $nmbr$ mg + aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C0028971;C1319635;C1705272
2830,aml $nmbr$ mg / hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
2830,aml $nmbr$ mg + hctz $nmbr$ mg,C0020261;C0023465;C0023467;C1319635
2830,aml,C0023465;C0023467
2829,aml / hctz ( n = $nmbr$ ),C0020261;C0023465;C0023467
2829,aml ( n = $nmbr$ ),C0023465;C0023467
2829,aml $nmbr$ mg + hctz $nmbr$ mg ( n = $nmbr$ ),C0020261;C0023465;C0023467;C1319635
2829,a / aml ( n = $nmbr$ ),C0023465;C0023467
2828,aml vs . lis,C0023465;C0023467
2828,aml vs . chl,C0023465;C0023467
2828,aml / val $nmbr$ / $nmbr$ mg,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761
2828,aml / val  $nmbr$ / $nmbr$ mg rr = $nmbr$ *,C0023465;C0023467;C0024671;C0026410;C0042285;C0439269;C0523975;C1960952;C2346927;C4321396;C4521761;C4554402
2828,aml $nmbr$ /,C0023465;C0023467
2827,baseline abi  affected limb,C0168634;C1328319;C1442488;C3888326
2827,abi > $nmbr$ . $nmbr$,C1328319;C3888326
2827,abi < $nmbr$ . $nmbr$,C1328319;C3888326
2827,abi # $nmbr$ . $nmbr$,C1328319;C3888326
2827,abi,C1328319;C3888326
2826,ankle / brachial index,C1328319;C3888326
2826,ankle - brachial index £ $nmbr$ . $nmbr$,C1328319;C3888326
2826,ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % ),C1328319;C3888326
2826,ankle - brachial index < $nmbr$ . $nmbr$,C1328319;C3888326
2825,haematological,C0018943;C0200627
2824,hematologic,C0018943;C0205488
2823,pathological q waves,C0429090
2823,pathologic q waves — no . ( % ),C0429090
2823,pathologic q waves  n ( % ),C0429090
2822,atenolol - losartan,C0004147;C0126174
2821,atenolol strategy ( n = $nmbr$ ),C0004147;C0679199
2821,atenolol strategy ( n = $nmbr$  $nmbr$ ),C0004147;C0679199
2821,atenolol strategy,C0004147;C0679199
2821,atenolol *,C0004147
2820,treated with atenolol ( n = $nmbr$ ),C0004147;C0332293
2820,atenolol n = $nmbr$ no . ( % ),C0004147
2820,atenolol n = $nmbr$,C0004147
2820,atenolol ( « = $nmbr$ $nmbr$ ),C0004147
2820,atenolol ( no . = $nmbr$ ),C0004147
2820,atenolol ( n = $nmbr$ ),C0004147
2820,atenolol ( n = $nmbr$  $nmbr$ ),C0004147
2820,atenolol,C0004147
2819,alcohol ^,C0001962;C0001975
2819,alcohol > $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
2819,alcohol < = $nmbr$ / wk,C0001962;C0001975;C0332174;C0439230
2818,current alcohol use — no . / total no . ( % ),C0001962;C0001975;C0521116;C1705970
2818,current alcohol  n ( % ),C0001962;C0001975;C0521116;C1705970
2818,alcohol usef  n ( % ),C0001962;C0001975
2818,alcohol useb,C0001962;C0001975
2818,alcohol,C0001962;C0001975
2817,valproate,C0080356
2816,duration of alendronate use  mean ( sd )  y,C0102118;C0444504;C1881378;C2347634;C2348143;C2699239;C2826775
2816,alendronate ( n = $nmbr$ ),C0102118
2816,alendronate,C0102118
2815,alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
2814,alt or ast > $nmbr$ x uln $nmbr$,C1266129;C4553172
2814,alt increased,C1266129;C4553172
2814,alt and / or ast > $nmbr$ times uln consecutive #,C1266129;C4553172
2814,alt ( units / l ),C0439339;C1266129;C4553172
2814,alt  u / l,C0439339;C1266129;C4553172
2813,absolute ( l ),C0205344
2813,absolute  litres,C0205344;C0475211
2812,absolute difference estimate vs placebo ( $nmbr$ % ci ),C0750572;C1549031
2812,absolute change,C1549031
2811,absence,C0332197;C1689985
2810,absent ( < $nmbr$ mg / dl ),C0332197;C0439269;C4285062
2810,absent,C0332197;C4285062
2809,treated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
2809,treated at baseline  mean ( sd )  mm hg,C0168634;C0439475;C0444504;C1442488;C1522326;C2347634;C2348143;C2699239
2809,treated at baseline,C0168634;C1442488;C1522326
2809,treated,C1522326
2808,untreated at baseline  mean ( sd )  mm hg,C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
2808,untreated at baseline,C0168634;C0332155;C1442488
2808,untreated,C0332155
2807,heart rate 一 beats / min,C0018810
2807,$nmbr$ - lead ecg heart rate  beats / min,C0018810;C0179504
2806,heart rate < $nmbr$ bpm,C0018810
2806,< $nmbr$ mm hg heart rate,C0018810;C0439475
2805,heart rate ( min − $nmbr$ ),C0018810;C0702093;C1524029;C3813700
2805,heart rate  min_ $nmbr$ ( mean ),C0018810;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
2805,heart rate  beats / min  mean ± sd,C0018810
2805,heart rate  / min,C0018810;C0702093;C1524029;C3813700
2804,heart rate > $nmbr$ bpm,C0018810
2804,heart rate ( sd )  bpm,C0018810;C2699239
2804,heart rate ( sd ),C0018810;C2699239
2804,heart rate ( bpm ) *,C0018810
2804,heart rate ( bpm ),C0018810
2804,heart rate ( bpm $nmbr$ ) *  * *,C0018810
2804,heart rate ( b . p . m . )  mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
2804,heart rate  mean ± sd ( b . p . m . ),C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
2804,heart rate  mean ( sd ) [ range ]  beats / min,C0018810;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016
2804,heart rate  mean ( sd )  bpm ( n = $nmbr$ $nmbr$ ),C0018810;C0444504;C2347634;C2348143;C2699239
2804,heart rate  mean ( sd )  beats / min,C0018810;C0444504;C2347634;C2348143;C2699239
2804,heart rate  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
2804,heart rate  bpm  mean ( sd ),C0018810;C0444504;C2347634;C2348143;C2699239
2804,heart rate  bpm,C0018810
2804,heart rate  beats per minute,C0018810
2804,heart rate  beats per min,C0018810
2804,heart rate  beats / min,C0018810
2804,heart rate  b . p . m . mean ± sd,C0018810;C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
2804,heart rate,C0018810
2803,heart rate — bpm,C0018810
2803,heart rate — beats / min,C0018810
2803,heart rate at rest — beats / min,C0018810;C0035253;C1622890
2803,heart rate at rest in the supine position ( beats / min ),C0018810;C0035253;C1622890
2803,heart rate ( beats / min ),C0018810
2802,preoperative heart rate ( beats per minute ),C0018810;C0445204
2802,heart rate ( beats per minute ),C0018810
2802,heart rate ( beats per min ),C0018810
2801,heart rates ( beats / minutes ),C0018810
2801,heart rate at baseline ( bpm,C0018810;C0168634;C1442488
2801,heart rate at baseline  bpm,C0018810;C0168634;C1442488
2801,heart - rate group at baseline,C0018810;C0168634;C0441833;C0687744;C1257890;C1442488;C1519504;C1705428;C1705429
2801,baseline heart rate ( beats / min ),C0018810;C0168634;C1442488
2801,baseline heart rate,C0018810;C0168634;C1442488
2800,intertrochanteric,C0745355
2799,trochanter,C0162370
2798,median ( interquartile range ) — yr,C0439234;C0549183;C0876920;C1711350;C2347635;C2348144;C2939193
2798,interquartile range — yr,C0439234;C1711350
2797,interquartile range,C1711350
2797,data are reported as percentage or mean ± standard deviation  unless otherwise indicated . ng  normoglycemia  igm  impaired glucose metabolism  ldl  low - density lipoprotein  hdl  high - density lipoprotein  fpg  fasting plasma glucose . a median ( interquartile range ) . * p < $nmbr$ . $nmbr$ vs . ng . † p < $nmbr$ . $nmbr$ vs . ng .,C0015663;C0017725;C0017887;C0023820;C0023821;C0028074;C0178587;C0202042;C0221099;C0455280;C0549183;C0580545;C0596620;C0876920;C1154908;C1444656;C1511726;C1706005;C1711350;C2347635;C2348144;C2939193;C3245479;C3714741
2797,* interquartile range,C1711350
2796,≥ $nmbr$ ae,C3887670
2796,laboratory ae  n ( % },C0022877;C3244292;C3887670;C4283904
2796,ae / a ratio ( per $nmbr$ . $nmbr$ unit ),C3887670
2795,clinical ae  n ( % },C0205210;C3887670
2795,any clinical ae,C0205210;C3887670
2794,due to ae,C3887670
2794,discontinuations due to ae,C0457454;C0678226;C3887670
2793,any drug - related ae  n ( % ),C0013227;C0439849;C0445223;C1254351;C3887670
2793,any ae leading to discontinuation  n ( % ),C3887670
2793,any ae  n ( % ) ‡,C3887670
2793,any ae,C3887670
2792,because of drug ‐ relateda   ae,C0013227;C1254351;C3887670
2792,because of ae,C3887670
2791,rash,C0015230
2790,erythrocyte sedimentation rate ( mm / h ),C0456680;C1176468;C1619634
2789,erythrocyte sedimentation rate — mm / hr | |,C1176468;C1619634;C4330985;C4554674
2789,erythrocyte sedimentation rate  mm / hour,C0439227;C0564385;C1176468;C1619634;C4330985;C4554674
2788,rarely / never,C4035880
2787,rarely,C0522498
2787,alcohol intake never / rarely,C0001948;C0522498;C2003901
2786,k ( rate ),C0597277;C0871208;C1521828;C1708601
2785,rate ‡,C0871208;C1521828
2785,health - care use rate ( peryear ),C0814514;C0871208;C1521828
2784,rate difference ( lebrikizumab - placebo ),C0032042;C0871208;C1521828;C1696465;C1705241;C1705242;C1706408;C2981360
2784,rate * ( n ),C0871208;C1521828
2784,placebo n ( rate ) *,C0032042;C0871208;C1521828;C1696465;C1706408
2783,rosuvastatin of patients ( rate ),C0030705;C0871208;C0965129;C1521828
2783,rosuvastatin n ( rate ) *,C0871208;C0965129;C1521828
2783,rosuvastatin n ( rate ) $nmbr$,C0871208;C0965129;C1521828
2783,rosuvastatin n ( rate ),C0871208;C0965129;C1521828
2783,rosuvastatin  n ( rate ),C0871208;C0965129;C1521828
2783,> $nmbr$ % responder rate  n ( % ),C0871208;C1521828
2782,km rates { % ) p / s,C0234833;C0722388;C0871208;C1521828;C3887676
2782,km rates { % ) e / s,C0871208;C1521828;C3887676
2782,km rate ( % ),C0871208;C1521828;C3887676
2782,km event rate ( % ),C0441471;C0871208;C1521828;C3887676;C4019010
2781,w event ( rate ),C0441471;C0871208;C1521828;C4019010
2781,vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2781,rates,C0871208;C1521828
2781,rate †,C0871208;C1521828
2781,overall event rate,C0282416;C0441471;C0871208;C1521828;C1561607;C4019010
2781,overal event rate,C0441471;C0871208;C1521828;C4019010
2781,no vhd event rate / year ( n ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2781,n event ( rate ),C0369718;C0441471;C0441922;C0871208;C1521828;C4019010
2781,event rates  %,C0441471;C0871208;C1521828;C4019010
2781,event rate ( per $nmbr$ person years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
2781,event rate ( per $nmbr$ person - years ),C0027361;C0439234;C0441471;C0871208;C1521828;C2347489;C4019010
2781,event rate ( per $nmbr$,C0441471;C0871208;C1521828;C4019010
2781,event rate ( % / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C4019010
2781,event rate ( % / vr ),C0441471;C0871208;C1521828;C3476815;C4019010
2781,event rate ( % ) of primary endpoints,C0441471;C0871208;C1521828;C2986535;C4019010
2781,event rate,C0441471;C0871208;C1521828;C4019010
2780,mean annualized exacerbation rate,C0444504;C0871208;C1521828;C2347634;C2348143;C4086268
2779,mod / sev exacerbation rates,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
2779,mod / sev exacerbation rate,C0011860;C0439793;C0458216;C0871208;C1521828;C2983285;C4086268
2778,annual exacerbation rate,C0332181;C0871208;C1521828;C4086268
2778,annual asthma exacerbation rates,C0332181;C0349790;C0871208;C1521828
2777,rate of sares,C0871208;C1521828
2777,rate / $nmbr$ pyo,C0033809;C0871208;C1521828
2777,adjusted rate of fev $nmbr$   decline ( se )  ml / yr,C0036919;C0439234;C0439526;C0456081;C0871208;C1521828;C1705224;C3714541;C3887665
2776,rate in all participants  % / y,C0679646;C0871208;C1521828
2776,rate  % / y,C0871208;C1521828
2776,$nmbr$ - yr rate / $nmbr$ participants,C0439234;C0679646;C0871208;C1521828
2775,filtration rate $nmbr$ - $nmbr$,C0016107;C0871208;C1521828
2775,$nmbr$ - y rate per $nmbr$ persons ( se )  n,C0027361;C0036919;C0871208;C1521828
2774,rate of non - progression ( defined as cfb in mtss £ $nmbr$ . $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
2774,rate of non - progression ( defined as cfb in mtss £ $nmbr$ )  n / n ( % ) *,C0871208;C1521828;C3839460
2774,rate *,C0871208;C1521828
2774,edoxaban n / n  rate ( % ),C0871208;C1521828;C2975435
2774,crude rate,C0871208;C1521828
2773,proportion of > = $nmbr$ % responder rates,C0871208;C1521828;C1709707
2772,rate ratio { $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
2772,rate ratio vs placebo ( $nmbr$ % ci ),C0456603;C0871208;C1521828;C1547037
2772,rate ratio mepo / pbo ( $nmbr$ % ci ),C0008107;C0031962;C0456603;C0871208;C1521828;C1547037;C3259781
2772,rate ratio ( lebrikizumab vs placebo  $nmbr$ % cl ),C0456603;C0871208;C1521828;C1547037;C2981360
2772,rate ratio ( $nmbr$ % cl ),C0456603;C0596019;C0871208;C1521828;C1547037
2772,rate ratio ( $nmbr$ % ci ),C0008107;C0456603;C0871208;C1521828;C1547037;C3259781
2772,rate ratio,C0456603;C0871208;C1521828;C1547037
2772,rate,C0871208;C1521828
2772,bsl  baseline  cl  confidence interval  esrd  end - stage renal disease  hb  hemoglobin  k ( rate )  # of events per $nmbr$ patient - years of follow - up  rrr  relative risk reduction  yr  year . ^ treatment effect of losartan versus placebo . interaction test between treatment group and hemoglobin group ( < $nmbr$ or > $nmbr$ g i - $nmbr$ ) . cmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin as covariates . dmultivariate cox model with baseline log urinary albumimcreatinine ratio  serum albumin  serum creatinine  and hemoglobin and change in hemoglobin at year $nmbr$ as covariates .,C0001924;C0009667;C0010294;C0019046;C0022661;C0036773;C0080103;C0126174;C0168634;C0201976;C0205345;C0229671;C0242492;C0301630;C0392756;C0439234;C0439508;C0441471;C0456603;C0486293;C0589120;C0596019;C0597277;C0600061;C0728877;C0871208;C1137094;C1293152;C1442488;C1518681;C1521828;C1522577;C1546774;C1547037;C1547039;C1549954;C1550100;C1561535;C1626828;C1704685;C1708601;C1708728;C2986775;C3274571;C3541888;C4281686;C4551656
2771,$nmbr$ - wk kaplan - meier rate  %,C0332174;C0439230;C0871208;C1521828
2770,kaplan - meier rates  % i i,C0021966;C0221138;C0871208;C1521828
2770,kaplan - meier rates  %,C0871208;C1521828
2769,race nonwhitet,C0034510;C1706779;C3853635
2769,race : white,C0034510;C1706779;C3853635
2769,race : non - white,C0034510;C1706779;C3853635
2769,race - nonwhite,C0034510;C1706779;C3853635
2769,race - non - white,C0034510;C1706779;C3853635
2769,race ( non - white ) ( % ),C0034510;C1706779;C3853635
2769,race  nonwhite,C0034510;C1706779;C3853635
2769,race  % nonwhite,C0034510;C1706779;C3853635
2769,nonwhite race !,C0034510;C1706779;C3853635
2769,nonwhite race,C0034510;C1706779;C3853635
2769,female race white,C0007457;C0034510;C0043157;C0043210;C0086287;C0220938;C1705497;C1705498;C1706779;C3853635
2768,race or ethnicity,C0034510;C1706779;C3853635
2768,race or ethnic origin,C0034510;C1706779;C3853635
2768,race or ethnic group — no . f,C0034510;C1706779;C3853635
2768,race or ethnic group — no . / total no . ( % ) f,C0034510;C1706779;C3853635
2768,race or ethnic group — no . ( % ) f,C0034510;C1706779;C3853635
2768,race or ethnic group ( % ) f,C0034510;C1706779;C3853635
2768,race or ethnic group ( % ),C0034510;C1706779;C3853635
2768,race or ethnic group  no . ( % ),C0034510;C1706779;C3853635
2768,race or ethnic group  n ( % ) *,C0034510;C1706779;C3853635
2768,race or ethnic group,C0034510;C1706779;C3853635
2768,mean ( sd ) values are presented for all variables  except medical history  race or ethnic group  and sex ( n  % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0019664;C0019665;C0034510;C0042295;C0043100;C0262512;C0262926;C0439209;C0441074;C0444504;C0457987;C0475211;C0486293;C0549183;C0557651;C0577559;C0577573;C0600653;C0724655;C0750572;C0876920;C0918012;C1096155;C1305866;C1306372;C1318293;C1514721;C1552854;C1637833;C1705104;C1705255;C1706779;C1719797;C2004062;C2347634;C2347635;C2348143;C2348144;C2348147;C2603343;C2699239;C2911648;C2939193;C2986546;C3152252;C3539882;C3542016;C3853635;C4283905
2768,male sex ( % ) race or ethnic group ( % ) f,C0034510;C0086582;C1706779;C3853635
2767,race §,C0034510;C1706779;C3853635
2767,race / ethnicity n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
2767,race / ethnicity chinese,C0008120;C0015031;C0034510;C0152035;C0243103;C1706779;C3853635
2767,race / ethnicity  n ( % ),C0015031;C0034510;C0243103;C1706779;C3853635
2767,race / ethnicity,C0015031;C0034510;C0243103;C1706779;C3853635
2767,female race / ethnicity,C0015031;C0034510;C0043210;C0086287;C0243103;C1705497;C1705498;C1706779;C3853635
2766,race or ethnicity  n ( % ),C0034510;C1706779;C3853635
2766,race - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
2766,race - non - white ( n = $nmbr$  $nmbr$ ),C0034510;C1706779;C3853635
2766,race ( p = o - $nmbr$ ),C0034510;C1706779;C3853635
2766,race $nmbr$,C0034510;C1706779;C3853635
2766,race  white  n ( % of patients ),C0034510;C1706779;C3853635
2766,race  while,C0034510;C1706779;C3853635
2766,race  non - white,C0034510;C1706779;C3853635
2766,race  n ( % ],C0034510;C1706779;C3853635
2766,race  n ( % ) ’,C0034510;C1706779;C3853635
2766,race  n ( % ) y,C0034510;C1706779;C3853635
2766,race  n ( % ) t,C0034510;C1706779;C3853635
2766,race  n ( % ) a,C0034510;C1706779;C3853635
2766,race  * ’ n ( % ),C0034510;C1706779;C3853635
2766,race  % of patients,C0030705;C0034510;C1706779;C3853635
2766,race  % caucasian,C0034510;C1706779;C3853635
2766,race  %,C0034510;C1706779;C3853635
2766,other race  n ( % ),C0034510;C1706779;C3853635
2766,other race,C0034510;C1706779;C3853635
2766,mean ( sd ) age  y race  n ( % ) *,C0001779;C0034510;C0444504;C1706779;C2347634;C2348143;C2699239;C3853635
2765,racial group  n ( % ),C0034510;C0441848;C1706779;C3669213;C3853635
2765,race_white  %,C0034510;C1706779;C3853635
2765,race n ( % ),C0034510;C1706779;C3853635
2765,race / ethnicity  zz ( % ),C0015031;C0034510;C0243103;C1706779;C2347310;C3853635
2765,race - n ( % ),C0034510;C1706779;C3853635
2765,race    n   ( % ),C0034510;C1706779;C3853635
2765,race  zz ( % ),C0034510;C1706779;C3853635
2765,race  no . / total ( % ),C0034510;C1706779;C3853635
2765,race  no . ( % ) white,C0034510;C1706779;C3853635
2765,race  no . ( % ) c,C0034510;C1706779;C3853635
2765,race  no . ( % ) b,C0034510;C1706779;C3853635
2765,race  no . ( % ),C0034510;C1706779;C3853635
2765,race  n ( % ) b,C0034510;C1706779;C3853635
2765,race  n ( % ) +,C0034510;C1706779;C3853635
2765,race  black or african - american  n ( % ),C0034510;C1706779;C3853635
2765,race  % white,C0034510;C1706779;C3853635
2764,range race  n ( % ),C0034510;C1514721;C1706779;C2348147;C3542016;C3853635
2764,race — no . { % ) - i -,C0034510;C1706779;C3853635
2764,race — no . { % ) ' i ',C0034510;C1706779;C3853635
2764,race — no . / total no . ( % ) f,C0034510;C1706779;C3853635
2764,race — no . ( % ) 卞,C0034510;C1706779;C3853635
2764,race — no . ( % ) |,C0034510;C1706779;C3853635
2764,race — no . ( % ) f,C0034510;C1706779;C3853635
2764,race — no . ( % ) : t,C0034510;C1706779;C3853635
2764,race — no . ( % ) : c,C0034510;C1706779;C3853635
2764,race — no . ( % ) ' (,C0034510;C1706779;C3853635
2764,race — no . ( % ),C0034510;C1706779;C3853635
2764,race white,C0034510;C1706779;C3853635
2764,race or ethnic group — no . { % ) ■ ' ( white,C0034510;C1706779;C3853635
2764,race or ethnic group — no . ( % ) : t,C0034510;C1706779;C3853635
2764,race or ethnic background — no . ( % ) f,C0034510;C1706779;C3853635
2764,race :,C0034510;C1706779;C3853635
2764,race / ethnicity  no . ( % ) *,C0015031;C0034510;C0243103;C1706779;C3853635
2764,race - no . ( % ),C0034510;C1706779;C3853635
2764,race *,C0034510;C1706779;C3853635
2764,race ( white  n [ % ] ),C0034510;C1706779;C3853635
2764,race ( % white ),C0034510;C1706779;C3853635
2764,race ( % ) white,C0034510;C1706779;C3853635
2764,race ( % ) *,C0034510;C1706779;C3853635
2764,race ( % ) ) ',C0034510;C1706779;C3853635
2764,race ( % ) $,C0034510;C1706779;C3853635
2764,race ( % ),C0034510;C1706779;C3853635
2764,race  white ( % ),C0034510;C1706779;C3853635
2764,race  white    n   ( % ),C0034510;C1706779;C3853635
2764,race  white  n ( % ),C0034510;C1706779;C3853635
2764,race  no . ( % ) *,C0034510;C1706779;C3853635
2764,race  n ( % ) :,C0034510;C1706779;C3853635
2764,race  n ( % ) *,C0034510;C1706779;C3853635
2764,race  n ( % ),C0034510;C1706779;C3853635
2764,race  asian  n ( % ),C0034510;C1706779;C3853635
2763,racial category *,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
2763,racial category,C0034510;C0683312;C1706779;C3669213;C3853635;C3889287
2763,multi - racial,C0034510;C0439064;C1706779;C3266262;C3669213;C3853635
2762,race and ss at baseline,C0034510;C1706779;C3853635
2762,race,C0034510;C1706779;C3853635
2762,$ race was determined by the investigator during the patient ' s interview .,C0034510;C1706779;C3853635
2761,radiate,C0332301
2760,college graduate or more,C0682187
2759,ohs graduate,C0268353;C1861455
2758,hs graduate / ged,C0588053;C1547183;C1880947
2757,nerd grade,C0441800;C0919553;C3244287
2757,mmrc grade  n ( % ),C0441800;C0919553;C3244287;C3826977
2757,mmrc grade,C0441800;C0919553;C3244287;C3826977
2757,mean mmrc grade  units ( sd ),C0439148;C0441800;C0444504;C0919553;C1519795;C2347634;C2348143;C2699239;C3244287;C3826977;C3853603
2757,grade > $nmbr$,C0441800;C0919553;C3244287
2757,grade $nmbr$ ( severe copd )  n ( % ),C0441800;C0919553;C3244287
2757,grade $nmbr$ ( moderate copd )  n ( % ),C0441800;C0919553;C3244287
2757,grade $nmbr$,C0441800;C0919553;C3244287
2757,dyspnoea - mmrc grade  n ( % ),C0013404;C0441800;C0919553;C1963100;C3244287;C3826977
2756,rankin grade,C0441800;C0919553;C3244287
2756,grade of hypertension,C0020538;C0441800;C0919553;C1963138;C3244287
2755,range of sbp,C0085805;C1514721;C2348147;C3542016
2754,quintile  range  mg / dl,C0439269;C1508496;C1514721;C2348147;C3542016
2754,hscrp range  mg / l,C0439268;C1514721;C2348147;C3542016
2754,crp  mg / l : median ( range ),C0439268;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3890735;C4048285
2753,fpg ( range ) ( mmol / l ),C1514721;C1532563;C2348147;C3542016
2752,triglycerides  median ( range ),C0041004;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,seizure frequency during $nmbr$ ‐ week baseline  median ( range ),C0149775;C0168634;C0332174;C0439230;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,range,C1514721;C2348147;C3542016
2752,median dose ( range ) b,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,median dose ( range ) ' ’,C0178602;C0549183;C0869039;C0876920;C1114758;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,median ( range ) treatment duration  d,C0444921;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3259042;C3542016
2752,median ( range ) total ige level ( iuml ~ ’ ) $nmbr$,C0439175;C0439810;C0441889;C0456079;C0549183;C0876920;C1514721;C1547707;C2347635;C2348144;C2348147;C2939193;C2946261;C3542016
2752,median ( range ) duration of hospital stayi  d,C0019994;C0449238;C0549183;C0876920;C1510665;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
2752,median ( iq range ),C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,baseline median ( iq range ),C0168634;C0549183;C0876920;C1442488;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
2752,( range ),C1514721;C2348147;C3542016
2752,$nmbr$ - month follow - up median ( iq range ),C0332177;C0439231;C0549183;C0589120;C0876920;C1514721;C1522577;C1704685;C2347635;C2348144;C2348147;C2939193;C3274571;C3542016
2751,uc duration  y  mean ( range ),C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2926735;C3542016
2751,selena - sledai ( range u - $nmbr$ u $nmbr$ ) t,C0439148;C0451528;C1514721;C2348147;C3542016
2751,motor subscale ( range  $nmbr$ - $nmbr$ ),C1513492;C1514721;C1705994;C2348147;C3542016
2751,mean age  y ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
2751,health assessment questionnaire ( $nmbr$ - $nmbr$ range ),C0451208;C1514721;C2348147;C3542016
2751,facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ ),C0015672;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3463815;C3476791;C3542016;C4050243;C4554645
2751,age range  y,C0001779;C1514721;C2348147;C3542016
2751,age range,C0001779;C1514721;C2348147;C3542016
2751,age ( y )  mean ( range ),C0001779;C0444504;C1514721;C2347634;C2348143;C2348147;C3542016
2751,$nmbr$ . $nmbr$ range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
2751,$nmbr$ . $nmbr$  range $nmbr$ - $nmbr$,C1514721;C2348147;C3542016
2750,ala carriers,C0007294;C0523459;C3888236
2749,carrier ( n = $nmbr$ ),C0007294;C0560175;C1325398;C1706209;C3273162
2749,apolipoprotein e carrier,C0003595;C0007294;C0560175;C1325398;C1706209;C3273162
2748,apoe   ε $nmbr$ carrier,C0003595;C0007294;C0523511;C0560175;C1325398;C1412481;C1706209;C3273162
2748,apoe e $nmbr$ carriers  no . ( % ),C0003595;C0007294;C0523511;C1412481
2747,treatment with candesartan,C0039798;C0087111;C0717550;C1522326;C1533734;C1705169;C3538994;C3887704
2747,other - candesartan,C0717550
2747,candesartan,C0717550
2746,candesartan group ( n = $nmbr$ ),C0441848;C0717550
2746,candesartan $nmbr$ / $nmbr$,C0717550
2745,aldosterone blockers,C0002006
2745,aldosterone blocker  %,C0002006
2745,aldosterone blocker,C0002006
2744,enalapril + aliskiren ( n = $nmbr$ ),C0014025;C1120110
2744,aliskiren ( n = $nmbr$ ),C1120110
2744,aliskiren,C1120110
2743,salmeterol ( n [ $nmbr$ ),C0073992
2743,salmeterol ( n = $nmbr$ ),C0073992
2743,salmeterol $nmbr$ gg bid,C0017454;C0018370;C0073992
2743,salmeterol,C0073992
2742,pro / pro homozygotes,C0019904;C1120626
2741,elevated creatinine ( > $nmbr$ pmol / l ),C0151578;C0439284;C0700225
2740,estradiol ( pmol / l ),C0014912;C0439284
2740,estradiol ( e $nmbr$ ) ( pmol / l ),C0014912;C0439284
2739,$nmbr$ rd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284;C0694666;C4553350
2739,$nmbr$ nd : $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ pmol / l,C0439284
2738,kdl cholesterol ( mmol / ),C0008377;C0439190
2737,fpg ( mmol / $nmbr$ ),C0439190
2737,$nmbr$ - h pg ( mmol / l ),C0030827;C0072225;C0439190;C1266240;C2827798;C2827804
2736,homa - ir ( mu / l ^ mmol / l ),C0022065;C0022071;C0439190;C0439342;C1448132
2736,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
2736,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
2736,> $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
2736,> $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
2736,< $nmbr$ . $nmbr$ mu / l - mmol / l,C0439190;C0439342
2736,< $nmbr$ . $nmbr$ mu / l $ mmol / l,C0439190;C0439342
2736,( mu / l $ mmol / l ) b,C0439190;C0439342
2735,hbalc £ $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2735,hbalc £ $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2735,hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2735,alc ( mmol / mol ),C1424945;C3811058;C3829066
2735,> = $nmbr$ . $nmbr$ % ( > = $nmbr$ mmol / mol ),C3829066
2735,> = $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
2735,> $nmbr$ % ( > $nmbr$ mmol / mol ),C3829066
2734,mean ( s . d . ) hbalc  mmol / mol,C0444504;C2347634;C2348143;C3829066
2734,hbalc ( mmol / mol ),C3829066
2733,≥   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
2733,≤   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
2733,hbalc > $nmbr$ - < $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2733,hbalc < $nmbr$ mmol / mol ( £ $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2733,hbalc < $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2733,>   $nmbr$ – <   $nmbr$   mmol / mol ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ % )    n   ( % ),C3829066
2733,< $nmbr$ . $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
2733,< $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
2733,< $nmbr$ % ( < $nmbr$ mmol / mol ),C3829066
2733,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
2732,≥ $nmbr$ . $nmbr$ % ( ≥ $nmbr$ mmol / mol ),C3829066
2732,mmol / mol,C3829066
2732,mean hba $nmbr$ c  mmol / mol †,C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
2732,hbalc £ $nmbr$ mmol / mol ( < $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),C3829066
2732,hbalc < $nmbr$ % ( < $nmbr$ mmol / mol )  n ( % ),C3829066
2732,hbalc < $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
2732,hbalc  mmol / mol,C3829066
2732,hbaj ( - ( %  mmol / mol ),C3829066
2732,hba ] c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ ca  % ( mmol / mol ),C0019016;C1825777;C3538758;C3829066;C3887642
2732,hba $nmbr$ c   ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c ( sd )  mmol / mol,C0019016;C1825777;C2699239;C3538758;C3829066
2732,hba $nmbr$ c ( mmol / mol [ se ] ),C0019016;C0036919;C1825777;C3538758;C3829066
2732,hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ % ( $nmbr$ - $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c  mmol / mole,C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c  mmol / mol ( mean ),C0019016;C0444504;C1825777;C2347634;C2348143;C3538758;C3829066
2732,hba $nmbr$ c  mmol / mol  median ( q $nmbr$  q $nmbr$ ),C0019016;C0549183;C0876920;C1825777;C2347635;C2348144;C2939193;C3538758;C3829066
2732,hba $nmbr$ c  mmol / mol  mean ( sd ),C0019016;C0444504;C1825777;C2347634;C2348143;C2699239;C3538758;C3829066
2732,hba $nmbr$ c  mmol / mol,C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c  ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
2732,hba $nmbr$ c  % [ mmol / mol ],C0019016;C1825777;C3538758;C3829066
2732,baseline hba $nmbr$ c ≥ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),C0019016;C0168634;C1442488;C1825777;C3538758;C3829066
2732,a $nmbr$ c ( mmol / mol ),C3829066
2732,a $nmbr$ c  % ( mmol / mol ),C3829066
2732,< $nmbr$ % ( $nmbr$ mmol / mol ),C3829066
2732,% hba $nmbr$ c ( mmol / mol ),C0019016;C1825777;C3538758;C3829066
2731,black / african,C0337824
2730,sacubitril / valsartan ( n = $nmbr$ ),C4033631
2730,sacubitril / valsartan,C4033631
2729,eosinophil count ( cells / microlitre ),C0200638;C0439378;C0750879
2729,> $nmbr$ cells / ul,C0439378
2729,< $nmbr$ cells / ul $nmbr$ $nmbr$,C0439378
2728,antithrombotic / coagulant,C0009117
2727,linagliptin / metformin,C3264599
2726,glycoprotein ilb / iiia inhibitor before pci ],C0017968;C1999216;C4049621;C4697913
2726,glycoprotein iib / iiiareceptorinhibitor,C0017968
2725,glycoprotein llb / llla receptor inhibitor,C0017968;C0597357;C1999216
2725,glycoprotein llb / llia inhibitor,C0017968;C1999216
2725,glycoprotein llb / illa inhibitor,C0017968;C1999216
2724,lu / kg,C0022718;C0024171;C0024176;C0439209;C2697939;C4054209
2724,insulin dose — lu / day,C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
2724,insulin dose ( lu / day ),C0024171;C0024176;C0332173;C0366513;C0439228;C0439505;C2697939
2724,daily total dose of insulin — lu / kg,C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2723,ipah / hpah,C0152171;C0340543;C0637939;C1150929
2722,pin /,C0175718;C1168556;C1704584
2721,uae ( p  g / min ),C0560021;C1519789
2720,urinary albumin : creatinine ratio ( pg / mg )  median ( iqr ),C0455271;C0549183;C0876920;C1318330;C1627892;C2347635;C2348144;C2939193
2720,uacr  pg / mg,C1627892
2720,( pg / mg ),C1627892
2719,very g ood / ex cellent,C0439267;C0442824;C2984081;C4267693
2718,large / very large,C0442824;C0549177;C2984081
2717,itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ ),C0165330;C0439422
2716,simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ ),C0074554;C0439422
2716,simvastatin ( $nmbr$ / $nmbr$ mg / d ),C0074554;C0439422
2716,placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ ),C0032042;C0074554;C0439422;C1696465;C1706408
2716,$nmbr$ mg / d ( n = $nmbr$ ),C0439422
2715,no . of $nmbr$ - mg acetaminophen tablets / day,C0439422;C1243102
2714,rsg $nmbr$ mg / day,C0439422
2714,rasagiline  $nmbr$ mg / day,C0439422;C0525678
2714,< $nmbr$ mg / day,C0439422
2714,< $nmbr$ mg / d peq,C0439422
2713,$nmbr$ mg / day early - start - delayed start,C0439422
2713,$nmbr$ mg / day early - start - delayed - start,C0439422
2713,$nmbr$ mg / day early - start,C0439422
2713,$nmbr$ mg / day delayed - start,C0439422
2713,$nmbr$ mg / day - placebo,C0032042;C0439422;C1696465;C1706408
2712,aspirin dose  mg / d,C0439422;C4696290
2711,brv dosage  mg / d,C0155502;C0178602;C0439422;C2986497
2711,brv > $nmbr$ mg / day,C0155502;C0439422
2711,brv $nmbr$   mg / day,C0155502;C0439422
2711,brv $nmbr$ mg / day ( n = $nmbr$ ),C0155502;C0439422
2711,brv $nmbr$ mg / day ( n =,C0155502;C0439422
2711,> $nmbr$ mg / day,C0439422
2711,> $nmbr$ mg / d peq,C0439422
2711,> $nmbr$ . $nmbr$ mg / day  %,C0439422
2710,mg / day,C0439422
2710,mean dose ( sd ) ( mg / day ),C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
2710,levodopa dose  mean ± sd  mg / day,C0023570;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143;C2699239
2710,leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day ),C0063041;C0178602;C0439422;C0444504;C0869039;C1114758;C2347634;C2348143
2710,dose ( mg / day ),C0178602;C0439422;C0869039;C1114758
2710,$nmbr$ mg / day,C0439422
2709,plac,C0048838
2708,place of randomization,C0034656;C0442504;C1533810;C1704765;C1882509
2708,place !,C0442504;C1533810;C1704765;C1882509
2707,double - dummy phase * *,C0205390;C1710475;C4684647
2706,participation in phase a,C0205390;C0679823;C1710475
2705,pah - ssc,C0030123;C3203102;C3897657;C4284467
2705,pah - sle,C0024141;C0030123;C3203102;C4284467
2705,pah - mctd / ctd - other,C0026272;C0030123;C1335071;C1442905;C3203102;C4284467
2705,pah - ctd,C0030123;C1335071;C1442905;C3203102;C4284467
2704,pah etiology :,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
2704,pah etiology,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
2704,aetiology of pah,C0015127;C0030123;C1314792;C1524003;C3203102;C4284467
2703,trough seated sbp ( mmhg ) a,C0085805;C0277814;C0439475;C0444506;C1283233
2703,trough seated hr ( bpm ) a,C0277814;C0444506;C1283233
2703,trough seated dbp ( mmhg ) a,C0277814;C0439475;C0444506;C0536221;C1283233;C3813197;C4281799
2702,group a,C0441835;C4522145
2702,gold group a,C0018026;C0441835;C1304897;C4522145
2701,lp ( a ) §,C0065058;C1439335;C4553379
2701,lp ( a ) ( μ mol / l ),C0065058;C0347982;C1439335;C4553379
2701,lp ( a ) ( pmol / l ),C0065058;C0439284;C1439335;C4553379
2701,lp ( a )  nmol / l  mean ( sd ),C0065058;C0439282;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
2701,lp ( a )  mean ( sd ),C0065058;C0444504;C1439335;C2347634;C2348143;C2699239;C4553379
2700,lipoprotein ( a ) ( nmol / l ),C0065058;C0125953;C0439282;C1096202;C1439335
2700,lipoprotein ( a ) ( mmol / l ),C0065058;C0125953;C1096202;C1439335;C1532563
2700,lipoprotein ( a ) ( mg / dl ),C0065058;C0125953;C0439269;C1096202;C1439335
2700,lipoprotein ( a )  median ( ql  q $nmbr$ )  nmol / l,C0065058;C0125953;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
2700,lipoprotein ( a )  median ( qi  q $nmbr$ )  nmol / l,C0065058;C0125953;C0376586;C0439282;C0549183;C0876920;C1096202;C1439335;C2347635;C2348144;C2939193
2700,baseline lipoprotein ( a ) ( nmol / l )  median ( iqr ),C0065058;C0125953;C0168634;C0439282;C0549183;C0876920;C1096202;C1439335;C1442488;C2347635;C2348144;C2939193
2699,late load,C0205087
2698,oma / oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
2698,oma / oat,C0028753;C0331496;C0939905;C3539067;C3897364
2698,oat ( n   =   $nmbr$ ),C0028753;C0331496;C0939905;C3539067;C3897364
2698,oat,C0028753;C0331496;C0939905;C3539067;C3897364
2697,unadjusted p - value for interaction,C1439367;C1704675;C1709380
2697,p values,C1709380
2697,p - value for interaction $nmbr$ . $nmbr$,C1704675;C1709380
2697,p - value for interaction,C1704675;C1709380
2697,p - value for,C1709380
2697,p - value $nmbr$,C1709380
2697,interactior p - value,C1709380
2697,interaction p values are as follows : amlodipine vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . lisinopril vs . chlorthalidone : age  p = $nmbr$ . $nmbr$  gender  p = $nmbr$ . $nmbr$  race  p = $nmbr$ . $nmbr$  history of chd  p = $nmbr$ . $nmbr$  history of diabetes  p = $nmbr$ . $nmbr$ . peripheral arterial disease refers to in - trial hospitalization or lower extremity revascularization procedure .,C0011847;C0011849;C0015385;C0019664;C0019665;C0034510;C0065374;C0079399;C0085096;C0184661;C0262512;C0262926;C0280604;C0369773;C0581603;C1522384;C1704436;C1704675;C1705255;C1706779;C1709380;C2004062;C2603361;C2700391;C3274430;C3539779;C3542407;C3853635
2697,interaction p value $nmbr$ . $nmbr$,C1704675;C1709380
2697,interaction p - value $nmbr$,C1704675;C1709380
2697,adjusted p - value for interaction,C0456081;C1704675;C1709380
2696,p value interaction,C1704675;C1709380
2696,nteraction p value,C1709380
2696,interaction p value 中,C1704675;C1709380
2696,interaction p value ∗,C1704675;C1709380
2696,interaction p value !,C1704675;C1709380
2696,interaction : treatment by psoriasis p value $nmbr$,C1704675;C1709380;C3258078
2695,p — value for interaction,C1704675;C1709380
2695,p value for interactiont,C1709380
2695,p value for interaction  dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
2695,p value for interaction,C1704675;C1709380
2694,p value § ® ( w,C1709380
2694,p value for interaction ( age groups ) *,C0027362;C1704675;C1709380
2694,p value for interaction ( age continuous ),C0001779;C1704675;C1709380
2694,p value fo interactio,C1709380
2694,p value *,C1709380
2694,p - value for interaction *,C1704675;C1709380
2694,interaction p value §,C1704675;C1709380
2694,interaction p value *,C1704675;C1709380
2694,interaction p - value *,C1704675;C1709380
2693,p value ( interaction ),C1704675;C1709380
2693,p - value ( lnteraction ),C1709380
2693,p - value ( interaction ) ≠,C1704675;C1709380
2693,no p value for ischemia ischemia hr ( $nmbr$ % ci ) interaction,C0008107;C0022116;C1704675;C1709380;C3259781;C4321499
2693,interaction p value,C1704675;C1709380
2693,interaction p - value,C1704675;C1709380
2692,use of cgm interaction test p - value ^ =,C0022885;C0039593;C0392366;C0456984;C1515976;C1524063;C1704675;C1709380;C3831328;C4318744
2692,test for interaction ( p value ),C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C1709380;C3831328;C4318744
2692,p   values of interaction,C1704675;C1709380
2692,p   values for interaction,C1704675;C1709380
2692,p   value for interaction,C1704675;C1709380
2692,p   value,C1709380
2692,p value,C1709380
2692,p - value interaction,C1704675;C1709380
2691,p ‐ value *,C1709380
2691,p ‐ value,C1709380
2691,* the p ‐ value is from the test statistic for testing the interaction between the treatment group and diabetes group .,C0039593;C0392366;C1709380
2690,p value c,C1709380
2690,bonferroni - adjusted p value  d vs a,C1709380;C1879894
2690,bonferroni - adjusted p value  c vs a,C1709380;C1879894
2690,bonferroni - adjusted p value  b vs a,C1709380;C1879894
2689,univariate p - value,C1709380
2689,p - value ¶,C1709380
2689,p - value vs . placebo,C1709380
2689,p - value low vs . high nfs ^,C1709380
2689,p - value for variance,C1709380;C1711260;C2348152
2689,multivariate p - value,C1709380
2688,p - value },C1709380
2688,p - value for trend *,C1521798;C1709380;C4554533
2688,p - value * ' ',C1709380
2688,p - value *,C1709380
2688,p ' value,C1709380
2687,two - sided p - value for hetero - geneity,C0205448;C0441987;C1709380
2686,p value f,C0016327;C1709380
2686,p value ( on vs off omt ),C1709380
2685,p value $nmbr$ . $nmbr$,C1709380
2685,p - value ( ancova treatment difference ) a,C0039798;C0087111;C0814908;C1522326;C1533734;C1705169;C1705241;C1705242;C1709380;C3538994;C3887704
2685,p - value,C1709380
2685,* rate is number of events per $nmbr$ patient - years of follow - up . fthe p value for number of patients from log - rank  for total number of hospitalizations from permutation test . ^ by treatment comparing the,C0039798;C0087111;C0439175;C0439810;C0589120;C0667477;C0699794;C0871208;C1521828;C1522326;C1522577;C1533734;C1704685;C1705169;C1708728;C1709380;C2360800;C2986775;C3274571;C3538994;C3887704;C4086639
2684,p - value ‘ ’,C1709380
2684,chi - square p value,C1552646;C1709380
2683,p - value ( vs placebo ),C1709380
2683,p - value ( anova ),C0753802;C1709380
2682,p - value n / n ( % ),C1709380
2682,p - value ( overall ),C0282416;C1561607;C1709380
2681,p value ( vs . previous time point ),C1709380
2681,p value ( inter ),C1709380
2681,p value ( int ),C1709380;C3272375
2681,p - value ( int ),C1709380;C3272375
2680,p value versus placebo,C1709380
2680,p value ( cangrelor versus clopidogrel in women ),C1121991;C1709380
2680,p value ( cangrelor versus clopidogrel in men ),C1121991;C1709380
2679,p value ( nominal ),C1709380
2679,p value ( men versus women ),C0025266;C1709380
2678,p value § ( < $nmbr$ vs . > = $nmbr$ years ),C1709380
2678,p value ( aged > $nmbr$ vs . < $nmbr$ years ),C0001779;C0001792;C1709380;C1999167
2678,p value $nmbr$,C1709380
2677,rr ( $nmbr$ aci ) [ p value ],C0814206;C1510682;C1709380;C2346870;C4050575;C4554402
2677,rr ( $nmbr$ % cl ) p value,C0596019;C1709380;C4554402
2677,$nmbr$ p value,C1709380
2676,p value for adjusted hr,C0456081;C1709380
2676,p value for,C1709380
2675,unadjusted p value,C1439367;C1709380
2675,unadjusted model hr  $nmbr$ % ci  p value,C0008107;C1439367;C1709380;C3161035;C3259781;C3274659;C3714583;C3853906
2674,p value ∥,C1709380
2674,difference ( $nmbr$ % ci  p value ),C0008107;C1705241;C1705242;C1709380;C3259781
2674,( $nmbr$ % ci ) p value,C0008107;C1709380;C3259781
2673,p value between groups,C0441833;C0441849;C0687744;C1257890;C1519504;C1522609;C1552839;C1705428;C1705429;C1709380
2673,p value * $nmbr$,C1709380
2673,p value *  placebo group p value *  hyponatremia normonatremic group  tolvaptan vs hyponatremic vs placebo,C0020625;C0032042;C0441833;C0687744;C1176308;C1257890;C1519504;C1696465;C1705428;C1705429;C1706408;C1709380;C4553967
2673,* p value,C1709380
2672,p value 十,C1709380
2672,p value heart failure vs no heart failure,C0018801;C0018802;C1709380;C4554158
2671,value *,C1522609
2671,l ’ - value ’,C0439394;C1522609;C1706495;C3642217
2671,/ ’ - value $nmbr$ ’,C1522609
2671,/ ’ - value,C1522609
2670,d - value,C1522609
2670,ap - value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group .,C0002680;C0814908;C1522609;C3887950
2669,value for nteraction,C1522609
2669,value,C1522609
2669,post - bronchodilator fev $nmbr$  reversibility percentage of baseline value,C0168634;C0439165;C0449261;C1442488;C1522609;C1549488;C1561533;C2599594;C3714541
2669,baseline value,C0168634;C1442488;C1522609
2668,chronic respiratory failure,C0264492
2667,chronic heart failure class ii - iii,C0018802;C0264716;C0439070;C0441886;C0441887;C1705160;C1710602;C2698968;C2698969;C4082587
2667,chronic heart failure,C0018802;C0264716
2666,recurrent heart failure,C0018801;C0018802;C1455761;C2945760;C4554158
2666,prior heart failure — no . { % ),C0018801;C0018802;C0332152;C2826257;C4554158
2666,prior heart failure yes,C0018801;C0018802;C0332152;C1549445;C1705108;C1710701;C2826257;C4554158
2666,prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
2666,prior heart failure  n / n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
2666,prior heart failure  n ( % ),C0018801;C0018802;C0332152;C2826257;C4554158
2666,prior heart failure  %,C0018801;C0018802;C0332152;C2826257;C4554158
2666,prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
2666,no prior heart failure ( n = $nmbr$  $nmbr$ ),C0018801;C0018802;C0332152;C2826257;C4554158
2666,no prior heart failure,C0018801;C0018802;C0332152;C2826257;C4554158
2666,histor y of heart failure,C0018801;C0018802;C4554158
2666,heart failure criteria met,C0018801;C0018802;C0243161;C4554158
2666,heart failure  n ( % ),C0018801;C0018802;C4554158
2665,hospitalized heart failure,C0018801;C0018802;C0701159;C4554158
2665,hospitalized for heart failure during that time period,C0018801;C0018802;C0701159;C4554158
2665,hospitalized / fatal heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
2665,heart failure ( treated / hospitalized / fatal ),C0018801;C0018802;C4554158
2665,heart failure  hospitalized or fatal,C0018801;C0018802;C4554158
2665,fatal & nonfatal hospitalized heart failure,C0018801;C0018802;C0701159;C1302234;C1705232;C4554158
2664,worsening heart failure,C0018801;C0018802;C0332271;C1457868;C1546960;C4554158
2664,participants without heart failure,C0018801;C0018802;C0679646;C4554158
2664,participants with heart failure,C0018801;C0018802;C0679646;C4554158
2664,heart failure *,C0018801;C0018802;C4554158
2664,congestive heart failure §,C0018802
2664,cardiac failure *,C0018801;C0018802
2663,heart failure or lvef < $nmbr$ % associated with index acs event,C0018801;C0018802;C4554158
2663,heart failure  lvef < $nmbr$ %  or both,C0018801;C0018802;C0428772;C0488728;C4554158
2662,previous hospital admission for heart failure,C0018801;C0018802;C0184666;C0205156;C1552607;C4554158
2662,hospital admission for heart failure,C0018801;C0018802;C0184666;C4554158
2662,heart failure $nmbr$ yr before admission,C0018801;C0018802;C0184666;C0439234;C0809949;C4554158
2662,heart failure $nmbr$ month before admission,C0018801;C0018802;C0184666;C0332177;C0439231;C0809949;C4554158
2662,heart failure $nmbr$ mo before admission,C0018801;C0018802;C0026544;C0184666;C0332177;C0809949;C4554158
2661,previous heart failure — no . ( % ),C0018801;C0018802;C0205156;C1552607;C4554158
2661,no heart failure,C0018801;C0018802;C4554158
2661,histor y of congestive heart failure — no . ( % ),C0018802
2661,heart failure ‡,C0018801;C0018802;C4554158
2661,heart failure — no . / total no . ( % ),C0018801;C0018802;C4554158
2661,heart failure — no . ( % ),C0018801;C0018802;C4554158
2661,heart failure at entry  no . ( % ),C0018801;C0018802;C1705654;C4554158
2661,heart failure ( hf )  ( % ),C0018488;C0018801;C0018802;C1313497;C1538440;C3273279;C4554158
2661,heart failure  no . / total no . ( % ),C0018801;C0018802;C4554158
2661,duration of heart failure ( years ),C0018801;C0018802;C0439234;C0449238;C2926735;C4554158
2661,congestive heart failure — no . ( % ) | |,C0018802
2661,congestive heart failure — no . ( % ) |,C0018802
2661,congestive heart failure — no . ( % ),C0018802
2661,congestive heart failure — %,C0018802
2661,cardiac failure —,C0018801;C0018802
2660,heart failure ( class l - lll ),C0018801;C0018802;C0456387;C1261077;C1518526;C1705943;C4554158
2660,heart failure,C0018801;C0018802;C4554158
2659,primary cause of heart failure,C0015127;C0018801;C0018802;C0205225;C0439612;C0439631;C1524003;C4554158
2659,main etiology of heart failure,C0015127;C0018801;C0018802;C0205225;C1314792;C1524003;C1542147;C4554158
2659,ischemic heart failure etiology,C0015127;C0018801;C0018802;C0475224;C1314792;C1524003;C4554158
2659,heart failure cause,C0015127;C0018801;C0018802;C1524003;C4554158
2659,cause of heart failure — no . ( % ),C0015127;C0018801;C0018802;C1524003;C4554158
2659,cause of heart failure,C0015127;C0018801;C0018802;C1524003;C4554158
2658,combined cardiac failure  cardiomyopathy or other cardiac disorder  n ( % ) luts severity  n ( % ),C0018801;C0018802;C0205195;C0878544
2658,cardiac failure §,C0018801;C0018802
2658,cardiac failure  n ( % ),C0018801;C0018802
2658,cardiac failure,C0018801;C0018802
2657,congestive heart failure at randomisation,C0018802;C0034656
2656,congestive heart failure †,C0018802
2656,congestive heart failure ( chf ) ( in past $nmbr$ weeks ),C0018802;C2987125
2656,congestive heart failure,C0018802
2655,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme  arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .,C0018802;C0033727;C0034787;C0038894;C0038895;C0042153;C0369286;C0439228;C0441932;C0457083;C0543467;C0564385;C1274039;C1511726;C1622222;C1947944;C3245479;C3714741;C3888198;C4528284
2655,congestive heart failure  n ( % ),C0018802
2654,congestive heart failure ( definite ),C0018802
2654,congestive heart failure ( < $nmbr$ wk ),C0018802;C0332174;C0439230
2653,heat failure,C0018837;C0231174;C0680095
2652,prior immunnosupressive failure but no anti - tnf failure,C0231174;C0332152;C0680095;C2826257
2652,prior corticosteroid failure only,C0001617;C0205171;C0231174;C0332152;C0680095;C1720467;C2826257;C3536709
2652,prior anti - tnf failure,C0231174;C0332152;C0680095;C1448177;C2826257
2652,failure,C0231174;C0680095
2651,type of tnf failure  n ( % ) b,C0231174;C0332307;C0680095;C1547052;C3887647
2651,type of tnf antagonist failure  n ( “ / o ) ”,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
2651,type of tnf antagonist failure  n ( % ) ' ’,C0231174;C0231491;C0332307;C0680095;C1448177;C1547052
2651,> $nmbr$ failure,C0231174;C0680095
2650,insulin sensitivity — % §,C0920563;C4049919
2649,insulins and analogs,C0021641;C3537244;C4049919
2649,insulins,C0021641;C3537244;C4049919
2648,method of insulin administration,C0025663;C0199782;C0449851;C0871511
2648,insulin administration,C0199782
2647,insulin aspart ( mealtime ),C0123677;C0587119;C1708521
2647,insulin aspart,C0123677;C1708521
2646,insulin treatment  n ( % ),C0745343
2646,insulin treatment,C0745343
2645,prior insulin use ( years ),C0240016;C0332152;C0439234;C2826257
2645,insulin use    n   ( % ),C0240016
2644,insulin use at baseline,C0168634;C0240016;C1442488
2644,insulin use,C0240016
2643,yes  insulin - treated,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
2643,without insulin or insulin - modifying therapy,C0021641;C1533581;C1579433;C3714501
2643,treated with insulin,C0021641;C0332293;C1533581;C1579433;C3714501
2643,receiving insulin therapy,C0021641;C0039798;C0087111;C1363945;C1514756;C1533581;C1579433;C3714501
2643,premixed insulin with oads ( % ),C0021641;C1533581;C1579433;C3714501
2643,insulin treated,C0021641;C1533581;C1579433;C3714501
2643,insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
2643,insulin dependentc,C0021641;C1533581;C1579433;C3714501
2643,insulin based,C0021641;C1533581;C1579433;C3714501
2643,insulin - treated dm,C0021641;C1533581;C1579433;C3714501
2643,insulin - treated diabetes  %,C0021641;C1533581;C1579433;C3714501
2643,insulin - treated diabetes,C0021641;C1533581;C1579433;C3714501
2643,insulin - treated,C0021641;C1533581;C1579433;C3714501
2643,insulin - requiring diabetes,C0011847;C0011849;C0021641;C1533581;C1579433;C3714501
2643,insulin - requiring,C0021641;C1533581;C1579433;C3714501
2643,insulin - na ' ive,C0021641;C0597484;C1272460;C1533581;C1546968;C1579433;C1879645;C3435805;C3714501;C4049872;C4552882;C4554334
2643,insulin - dependent,C0021641;C0429964;C0429986;C0851827;C1533581;C1579433;C1701901;C3244310;C3714501;C4321395
2643,insulin + oad,C0021641;C1533581;C1579433;C3714501
2643,insulin + metformin,C0021641;C0025598;C1533581;C1579433;C3714501
2643,insulin,C0021641;C1533581;C1579433;C3714501
2642,total daily insulin dose ( u / day ),C0021641;C0456683;C1533581;C1579433;C2348070;C3714501
2642,total daily insulin dose ( lu / kg ),C0021641;C0022718;C0024171;C0024176;C0439209;C1533581;C1579433;C2348070;C2697939;C3714501;C4054209
2642,total daily insulin dose  units / kgt,C0021641;C0439148;C1519795;C1533581;C1579433;C2348070;C3714501;C3853603
2642,total daily insulin dose  u,C0021641;C0439148;C1533581;C1579433;C2348070;C3714501
2642,total baseline insulin dose,C0021641;C0168634;C0366513;C0439175;C0439810;C1442488;C1533581;C1579433;C2986497;C3714501
2642,oad plus insulin,C0021641;C1533581;C1579433;C3714501
2642,median ( q $nmbr$ : q $nmbr$ ) total daily insulin dose $nmbr$,C0021641;C0549183;C0876920;C1533581;C1579433;C2347635;C2348070;C2348144;C2939193;C3714501
2642,insulin secretagogue,C0021641;C1533581;C1579433;C3714501;C4704833
2642,insulin plus oral,C0021641;C0442027;C1533581;C1579433;C3714501;C4521986
2642,insulin plus > $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2642,insulin plus $nmbr$ oral agent,C0021641;C0442027;C0450442;C1254351;C1521826;C1533581;C1579433;C3714501;C4521986
2642,insulin glargin arm,C0021641;C0446516;C1533581;C1579433;C3714501;C3715044;C4553528
2642,insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501
2642,insulin alone,C0021641;C1533581;C1579433;C3714501
2642,insulin : glucose ratio,C0017725;C0021641;C0456603;C1533581;C1547037;C1579433;C3714501
2642,initiation of insulin,C0021641;C0589507;C1158830;C1533581;C1579433;C1704686;C3714501
2642,baseline insulin daily dose / kg,C0021641;C0022718;C0168634;C0332173;C0366513;C0439209;C1442488;C1533581;C1579433;C2348070;C3714501;C4054209
2642,baseline insulin,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
2641,insulin — / tu / ml,C0021641;C0041400;C0439526;C1532464;C1533581;C1579433;C1705224;C2700314;C3714501;C3811255;C3887665
2641,insulin ( pmol / l ) t vital signs,C0021641;C0150404;C0439284;C0518766;C1533581;C1579433;C3714501
2641,insulin ( pmol / l ),C0021641;C0439284;C1533581;C1579433;C3714501
2641,insulin ( mu / ml ),C0021641;C0439339;C1533581;C1579433;C3714501
2641,insulin  pmol / l,C0021641;C0439284;C1533581;C1579433;C3714501
2641,insulin  median ( ql  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
2641,insulin  median ( q $nmbr$  q $nmbr$ )  pmol / l,C0021641;C0439284;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
2641,fasting insulin — pmol / liter,C0015663;C0021641;C0439192;C0475211;C1533581;C1579433;C3714501
2641,fasting insulin — / tiu / ml §,C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2641,fasting insulin ( pmol / l ),C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
2641,fasting insulin ( miu / ml ),C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
2641,fasting insulin ( giu / ml ),C0015663;C0021641;C0439526;C1533581;C1579433;C1705224;C3714501;C3887665
2641,fasting insulin  pmol / l ( mean ± sd ),C0015663;C0021641;C0439284;C0444504;C1533581;C1579433;C2347634;C2348143;C2699239;C3714501
2641,fasting insulin  * median ( iqr )  gu / ml,C0015663;C0021641;C0120446;C0439526;C0549183;C0876920;C1533581;C1579433;C1705224;C2347635;C2348144;C2939193;C3714501;C3887515;C3887665
2641,fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
2641,$nmbr$ - h postprandial insulin ( miu / ml ),C0021641;C0033727;C0369286;C0376674;C0439457;C0441932;C0564385;C1533581;C1579433;C3714501;C4528284
2640,premixed insulin only ( % ),C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2640,median fasting insulin ( iqr ) — pu per milliliter,C0015663;C0018387;C0021641;C0439242;C0549183;C0876920;C1533581;C1579433;C2347635;C2348144;C2939193;C3714501
2640,insulin 一 no . ( % ),C0021641;C1533581;C1579433;C3714501
2640,insulin — iu,C0021641;C0049272;C0439453;C0694756;C1533581;C1579433;C3714501
2640,insulin only,C0021641;C0205171;C1533581;C1579433;C1720467;C3714501
2640,insulin - naive  n ( % ),C0021641;C1533581;C1579433;C3714501
2640,insulin ( % ),C0021641;C1533581;C1579433;C3714501
2640,insulin  n ( % ),C0021641;C1533581;C1579433;C3714501
2639,sbp at baseline,C0085805;C0168634;C1442488
2639,baseline sbp { p = o - $nmbr$ ),C0085805;C0168634;C1442488
2639,baseline sbp ( mm ),C0085805;C0168634;C1442488;C4330985;C4554674
2639,baseline sbp,C0085805;C0168634;C1442488
2638,sbp  baseline,C0085805;C0168634;C1442488
2638,baseline sbp  mean ± sd  mm hg,C0085805;C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
2637,baseline tbp,C0168634;C1442488
2637,baseline nbp,C0168634;C1442488
2637,baseline bp  mean ( sd ) *,C0168634;C0488053;C1442488;C2699239
2636,week o ( baseline ) mean 士 sd,C0168634;C0332174;C0439230;C0444504;C1442488;C2347634;C2348143;C2699239
2636,mean change from baseline in fev $nmbr$ % predicted  % ( sd ) *,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
2636,mean ( sd ) baseline scores,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
2636,mean ( sd ) baseline,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
2636,fbg baseline,C0168634;C1442488
2636,baseline pssi score  mean ( sd ),C0168634;C1442488
2636,baseline ppasi score  mean ( sd ),C0168634;C1442488
2636,baseline mean 士 sd,C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
2636,baseline mean ( sd ),C0168634;C0444504;C1442488;C2347634;C2348143;C2699239
2636,baseline fpg  mean ( s . e . ),C0168634;C0444504;C1442488;C2347634;C2348143
2636,baseline fpg,C0168634;C1442488
2636,baseline bii  mean ( sd ),C0168634;C0444504;C1413059;C1442488;C2347634;C2348143;C2699239
2636,baseline % predicted fev $nmbr$,C0168634;C1442488
2636,activities of daily living updrs subscore ( baseline )  mean ( sd ),C0001288;C0168634;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721;C4050548
2635,mean baseline bmi,C0168634;C0444504;C0578022;C1442488;C2347634;C2348143
2635,baseline bmi,C0168634;C0578022;C1442488
2634,randomisation visit ( baseline ),C0034656;C0168634;C0545082;C1442488;C1512346;C2826704
2633,baseline height ( cm ),C0168634;C0489786;C1442488
2632,baseline ptga,C0168634;C1442488
2632,atrial fibrillation on baseline ecg  n ( % ),C0168634;C0344434;C1442488
2631,intensified baseline ( n - $nmbr$ ),C0168634;C1442488
2631,baseline dad ( n   = $nmbr$ + $nmbr$ ),C0168634;C1442488;C3641946
2631,baseline cdr - sb ( n   = $nmbr$ + $nmbr$ ),C0038111;C0168634;C1442488;C3811240;C4521843
2630,baseline vfx,C0168634;C1442488
2630,baseline use of adm  n ( % ),C0168634;C0215825;C1442488;C1524063;C4521767
2630,baseline numberf of adm classes  n ( % ),C0168634;C0215825;C0456387;C1442488;C1518526;C1705943;C4019422;C4521767
2630,baseline los angeles grade of eo  n ( % ),C0024015;C0168634;C1442488
2629,baseline tophusa,C0168634;C1442488
2629,baseline % bsa involvement,C0168634;C1314939;C1442488
2628,hypertension severity at baseline  n ( % ),C0168634;C1442488;C4013784
2628,fistula at baseline  n ( % ),C0016169;C0168634;C1442488
2628,baseline serum calcium level  n ( % ),C0036785;C0168634;C0728876;C1442488
2628,baseline diabetes mellitus therapy  n ( % ),C0168634;C0948092;C1442488
2628,baseline ( n ),C0168634;C1442488
2628,baseline  % ( n ),C0168634;C1442488
2628,baseline,C0168634;C1442488
2628,( baseline ),C0168634;C1442488
2627,baseline glycated hemoglobin ( % ),C0017853;C0168634;C1442488
2627,baseline glycated,C0168634;C1442488
2626,baseline hbalc > $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ),C0168634;C1442488;C3829066
2626,baseline hbalc > $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
2626,baseline hbalc > $nmbr$ % to < $nmbr$ %,C0168634;C1442488
2626,baseline hbalc > $nmbr$ %,C0168634;C1442488
2626,baseline hbalc < $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ) $nmbr$,C0168634;C1442488;C3829066
2626,baseline hbalc < $nmbr$ %,C0168634;C1442488
2626,baseline hbalc,C0168634;C1442488
2625,fev $nmbr$   at baseline ( randomization ) ∗,C0034656;C0168634;C1442488;C3714541
2625,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no concurrent tiotropium,C0168634;C1442488
2625,baseline post - bronchodilator % predicted fev  > $nmbr$ % and concurrent tiotropium use,C0168634;C1442488
2625,baseline post - bronchodilator % predicted fev  < $nmbr$ %,C0168634;C1442488
2625,baseline fev $nmbr$ % predicted,C0168634;C1442488;C3714541
2625,baseline fev $nmbr$ #,C0168634;C1442488;C3714541
2625,baseline fev $nmbr$,C0168634;C1442488;C3714541
2624,supplementary table $nmbr$ . change from baseline in urine albumin - to - creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria .,C0019016;C0039224;C0168634;C0392747;C0443172;C0456603;C0730345;C1442488;C1547037;C1705241;C1706074;C1825777;C3538758;C4319952
2624,mean change from baseline in the number of,C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
2624,changes from baseline in mssbp and msdbp are shown as least - squares mean sem . * p $nmbr$ . $nmbr$ vs $nmbr$ y .,C0168634;C0392747;C0443172;C1442488
2624,changes at baseline,C0168634;C0392747;C0443172;C1442488
2624,change from baseline to week $nmbr$ in uas $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline to eos  uu / ml,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline to eos  mg / dl,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline in mean $nmbr$ - h dbp  mmhg,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline in acq - $nmbr$ score,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline in acq - $nmbr$,C0168634;C0392747;C0443172;C1442488;C1705241;C4319952
2624,change from baseline  mmhg,C0168634;C0392747;C0439475;C0443172;C1442488;C1705241;C4319952
2624,baseline uas $nmbr$,C0168634;C1442488
2624,a from baseline,C0168634;C1442488
2623,baseline cardiovascular assessment,C0007226;C0168634;C0846600;C1442488;C3887460;C4684571
2622,without baseline vertebral fracture,C0080179;C0168634;C1442488
2622,with baseline vertebral fracture,C0080179;C0168634;C1442488
2622,vertebral fractures at baseline,C0080179;C0168634;C1442488
2622,baseline vertebral fracture,C0080179;C0168634;C1442488
2621,baseline outcomes,C0168634;C1274040;C1442488
2620,available baseline blood specimen n,C0168634;C0178913;C0470187;C1442488
2619,baseline hb $nmbr$ g i $nmbr$ n = $nmbr$,C0062408;C0086706;C0168634;C1442488
2618,flex baseline bmd  g / cm ^ ( meanisd ),C0168634;C0439267;C1442488
2618,baseline hb < $nmbr$ g $nmbr$ $nmbr$ n = $nmbr$,C0062408;C0168634;C0439267;C1442488
2617,baseline hbalc ^,C0168634;C1442488
2617,baseline hba ^ c,C0019016;C0168634;C1442488;C1825777;C3538758
2617,baseline hba $nmbr$ c ^,C0019016;C0168634;C1442488;C1825777;C3538758
2616,normonatremic ( > $nmbr$ meq / l ) at baseline,C0168634;C0439375;C1442488
2616,hyponatremic ( < $nmbr$ meq / l ) at baseline,C0168634;C0439375;C0857122;C1442488
2616,baseline serum k +  meq / l,C0168634;C0302353;C0439375;C1442488
2615,iee at baseline : < $nmbr$ iu / l,C0168634;C0439457;C1442488
2615,baseline pcsi < $nmbr$ a,C0168634;C1442488
2615,baseline microalbumin : < $nmbr$,C0168634;C0201838;C1442488;C2362049
2615,baseline ecro < $nmbr$ mumin,C0168634;C1442488
2615,baseline albumin : < $nmbr$,C0001924;C0168634;C1442488
2614,baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1262869;C1442488;C3496112;C3496399
2613,improvement from baseline ≥   $nmbr$,C0168634;C1442488;C2986411
2613,dlqi improvement from baseline to week $nmbr$,C0168634;C1442488;C2986411;C3899393
2612,baseline post - bronchodilator % predicted fev  > $nmbr$ % and prior ics use,C0168634;C1442488
2612,baseline post - bronchodilator % predicted fev  > $nmbr$ % and no prior ics use,C0168634;C1442488
2612,baseline ics,C0168634;C0815320;C1442488;C4551720
2611,baseline a $nmbr$ c ( % ) [ lsm ( se ) ],C0036919;C0168634;C1442488
2611,baseline a $nmbr$ c ( % ),C0168634;C1442488
2610,triglycerides at baseline,C0041004;C0168634;C1442488
2610,baseline triglycerides in $nmbr$ classes,C0041004;C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
2610,baseline triglycerides,C0041004;C0168634;C1442488
2609,estimated gfr at baseline  ml • min $nmbr$,C0017654;C0168634;C0439445;C0750572;C1424601;C1442488
2609,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile,C0017654;C0023779;C0168634;C0369637;C0439445;C0441923;C0750572;C1424601;C1442488;C1979963;C2003903
2609,crcl at baseline < $nmbr$ ml / min,C0168634;C0439445;C1442488;C1846718
2609,crcl at baseline  ml / min,C0168634;C0439445;C1442488;C1846718
2609,baseline estimated gfr,C0168634;C1442488
2609,baseline ecrcl $nmbr$ $nmbr$ ml / min,C0168634;C0439445;C1442488
2609,baseline ecrcl,C0168634;C1442488
2609,baseline crcl  ml / min,C0168634;C0439445;C1442488;C1846718
2609,at baseline,C0168634;C1442488
2608,baseline uric acid,C0041980;C0168634;C1442488
2607,baseline ezetimibe usec,C0168634;C0439224;C1142985;C1442488
2606,baseline dipeptidyl peptidase $nmbr$,C0022709;C0168634;C1442488
2605,creatinine > $nmbr$ x baseline,C0010294;C0168634;C1442488;C1561535
2605,creatinine > $nmbr$ . $nmbr$ x baseline and above uln,C0010294;C0168634;C1442488;C1561535
2604,baseline pfd  m,C0016065;C0168634;C0369637;C0441923;C1442488;C1839454;C2827389;C3889643
2604,baseline mwd  m,C0168634;C0369637;C0441923;C1442488
2603,> $nmbr$ med at baseline cardiac disorder *,C0018799;C0168634;C1442488;C4321267
2603,$nmbr$ med at baseline,C0168634;C1442488;C4321267
2602,mean baseline nasal congestion score,C0027424;C0168634;C1442488;C3533236;C4554631
2601,baseline tava,C0168634;C1442488
2601,baseline pava,C0135567;C0168634;C1442488
2600,baseline fecal caicrctectin,C0015733;C0168634;C1442488
2599,baseline hstni,C0168634;C1442488
2599,baseline basfi,C0168634;C1442488
2599,baseline basdai,C0168634;C1442488;C1998004
2598,baseline who functional class,C0168634;C1442488
2598,baseline who function class,C0168634;C1442488
2598,baseline erosion,C0168634;C0333307;C1442488;C1880549;C1959609;C3887524
2597,for baseline hemoglobin < $nmbr$ g $nmbr$ ',C0168634;C1319312;C1442488
2597,for baseline hemoglobin $nmbr$ g $nmbr$ ’,C0168634;C1319312;C1442488
2596,selected baseline medications,C0013227;C0168634;C0802604;C1442488;C1707391;C2598133;C4284232
2596,pulmonary medication during baseline ! ',C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2596,baseline pulmonary medications,C0013227;C0024109;C0168634;C0802604;C1442488;C2598133;C2707265;C2709248;C4284232;C4522268
2596,baseline pulmonary medication  n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2596,baseline pulmonary medication  b n ( % ),C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2596,baseline pulmonary medication,C0013227;C0024109;C0168634;C1442488;C2707265;C2709248;C3244316;C4284232;C4522268
2596,baseline medication,C0013227;C0168634;C1442488;C3244316;C4284232
2596,baseline cv medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
2596,baseline cv medications,C0013227;C0168634;C0802604;C1442488;C2598133;C3538987;C4048877;C4284232;C4318503
2595,remission by : baseline duration of steroid,C0038317;C0168634;C0814126;C1442488
2595,on steroid at baseline,C0038317;C0168634;C1442488
2595,baseline steroids,C0038317;C0168634;C1442488
2594,corticosteroid use at baseline - yes,C0168634;C0239126;C1442488;C1549445;C1705108;C1710701
2594,coiticosieroids at baseline,C0168634;C1442488
2594,baseline ocs use : yes,C0168634;C1442488
2594,baseline calcium yes,C0006675;C0006726;C0168634;C1442488;C1549445;C1705108;C1710701;C2936886;C3540037;C3714611
2593,treatment at baseline,C0039798;C0087111;C0168634;C1442488;C1522326;C1533734;C1705169;C3538994;C3887704
2593,pah therapy at baseline,C0030123;C0039798;C0087111;C0168634;C1363945;C1442488;C3203102;C4284467
2593,baseline treatments  n ( % ) a,C0087111;C0168634;C1442488
2593,baseline therapy,C0039798;C0087111;C0168634;C1363945;C1442488
2593,baseline lipid therapy,C0023779;C0039798;C0087111;C0168634;C1363945;C1442488
2592,no mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
2592,no mtx at baseline,C0025677;C0168634;C1417487;C1442488
2592,mtx use at baseline,C0025677;C0042153;C0168634;C0457083;C1417487;C1442488;C1947944
2592,mtx at baseline,C0025677;C0168634;C1417487;C1442488
2592,baseline  no . ( % ),C0168634;C1442488
2592,acr response by baseline mtx use  no . / total no . ( % ) acr $nmbr$,C0025677;C0168634;C0871261;C1412134;C1417487;C1442488;C1515941;C1704632;C1706817;C2911692
2591,ss at baseline,C0168634;C1442488;C2699257;C3891295;C4551874
2591,mtss at baseline observed case,C0168634;C1442488
2591,medication use at baseline — no . ( % ),C0168634;C0240320;C1442488
2591,at baseline — no . ( % ),C0168634;C1442488
2590,steroid use at baseline ( mg / day ),C0168634;C0281991;C0439422;C1442488
2590,steroid use at baseline  n ( % ),C0168634;C0281991;C1442488
2590,steroid use at baseline,C0168634;C0281991;C1442488
2590,killip at baseline,C0168634;C1442488
2589,diabetic retinopathy at baseline,C0011884;C0168634;C1442488
2588,diabetes duration at baseline,C0011847;C0011849;C0168634;C0449238;C1442488;C2926735
2588,diabetes at baseline,C0011847;C0011849;C0168634;C1442488
2588,c - reactive protein ( high - sensitivity assay )  mitt = modified intent - to - treat  pbo cholesterol  cl = confidence intervals  hdl - c = high - density lipoprotein cholest = national cholesterol education program adult treatment panel y patients with diabetes ( fc > _ $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having acteristics described in methods ( ncep atp iii definition )  + baseline values are rr d hs - crr for which medians are presented  * * p < $nmbr$ . $nmbr$  § p = $nmbr$ . $nmbr$  * p = $nmbr$ . $nmbr$ . nteractions were not statistically significant ( p > $nmbr$ . $nmbr$ ) .,C0001675;C0005507;C0006560;C0011847;C0011849;C0030705;C0042295;C0065055;C0087111;C0150375;C0168634;C0243073;C0369773;C0679841;C1292734;C1413716;C1441604;C1442488;C1510438;C1522326;C1706450;C2603361;C2983605;C3245503;C3642216;C3898312;C4048285
2588,baseline diabetes,C0011847;C0011849;C0168634;C1442488
2587,percent atheroma volume at baseline,C0168634;C0264956;C1442488;C1690016;C3887614
2586,insulin at baseline,C0021641;C0168634;C1442488;C1533581;C1579433;C3714501
2586,a $nmbr$ c at baseline ≥ $nmbr$ . $nmbr$ %,C0168634;C1442488
2586,a $nmbr$ c at baseline < $nmbr$ . $nmbr$ %,C0168634;C1442488
2586,> $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
2586,< $nmbr$ % blood eosinophils at baseline,C0014467;C0168634;C1442488
2585,no mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
2585,mra at baseline,C0168634;C0243032;C1442488;C1609165;C3891069
2585,mmrc at baseline,C0168634;C1442488;C3826977
2584,no chd at baseline,C0168634;C0280604;C1442488;C3542407
2584,chd at baseline,C0168634;C0280604;C1442488;C3542407
2583,none at baseline,C0168634;C1442488
2583,non - smokers ( at baseline ),C0168634;C0337672;C1442488;C4554605
2583,biomarkers at baseline,C0005516;C0168634;C1442488
2583,b - blockers at baseline,C0168634;C1442488
2582,age at baseline years,C0168634;C1442488;C1510829
2582,age at baseline ( years ),C0168634;C1442488;C1510829
2581,pad at baseline,C0168634;C0182158;C0332568;C1442488;C3540603;C3669270;C3814046;C4319657
2581,ocs at baseline,C0168634;C1442488
2581,no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
2581,immunosuppressive agents at baseline,C0021081;C0168634;C1442488
2580,one at baseline,C0168634;C0205447;C1442488
2580,hscrp at baseline,C0168634;C1442488
2580,asthma control test score at baseline,C0168634;C1442488;C2733224
2579,no glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
2579,glucocorticoids at baseline,C0017710;C0168634;C1442488;C3540777;C3540778
2578,parameters at baseline,C0168634;C0449381;C1442488
2578,hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0168634;C0449381;C1442488;C4281788
2578,characteristic at baseline,C0168634;C1442488;C1521970
2578,baseline characteristic,C0168634;C1442488
2577,in remission at maintenance study baseline,C0024501;C0168634;C0544452;C0557651;C0687702;C1442488;C2603343
2577,common study baseline,C0168634;C0205214;C0557651;C1442488;C1522138;C2603343;C3245511
2576,nvf at flex baseline - $nmbr$ < flex fn t - score,C0168634;C0449820;C1442488;C1570610;C4050231
2576,flex baseline bmd t score,C0168634;C0449820;C1442488;C4050231
2575,baseline sgrq total score,C0168634;C1442488;C2964552
2575,baseline sgrq score,C0168634;C1442488
2574,adjusted for all baseline variables and interaction between acei and baseline upb,C0168634;C0439828;C0456081;C1442488
2574,adjusted for all baseline variables $nmbr$,C0168634;C0439828;C0456081;C1442488
2573,baseline cardiac biomarkers elevated,C0168634;C1442488;C2735101;C2735102
2573,baseline cardiac biomarkers,C0168634;C1442488;C2735101;C2735102
2572,baseline lipid / lipoprotein values,C0042295;C0168634;C0443602;C1442488
2571,baseline sitosterol / lathosterol,C0037215;C0064673;C0168634;C0220914;C1442488
2571,baseline sitosterol / cholesterol,C0008377;C0037215;C0168634;C0220914;C1442488
2571,baseline sitosterol,C0037215;C0168634;C0220914;C1442488
2570,baseline trig > $nmbr$ millycerides g / dl,C0168634;C0202236;C0439267;C1442488;C1519533
2569,baseline / concomitant therapies,C0168634;C1442488;C1707479
2568,ldl - c at baseline :,C0168634;C1442488
2568,baseline low - density lipoprotein cholesterol ( mg / dl ),C0023824;C0168634;C0439269;C1442488
2568,baseline ldl - c :,C0168634;C1442488
2568,baseline - - mdrd,C0168634;C1442488;C3839656
2567,hdl - c at baseline .,C0168634;C1442488;C3715113
2567,baseline ldl - c strata  n ( ° / o ),C0168634;C1442488
2567,baseline ldl - c,C0168634;C1442488
2567,baseline hdl - c level ( n = $nmbr$ » $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
2567,baseline hdl - c,C0168634;C1442488;C3715113
2567,baseline fc - ldl - c,C0168634;C1442488;C2983605
2566,baseline hs - crp tertiles ( mg / i ],C0021966;C0024671;C0026410;C0168634;C0221138;C0439269;C1442488;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
2566,baseline high - sensitivity crp,C0168634;C1441604;C1442488;C3890735;C4048285
2566,baseline crp category ( mg / l ),C0168634;C0439268;C0683312;C1442488;C3889287;C3890735;C4048285
2566,baseline crp ( mg / dl ),C0168634;C0439269;C1442488;C3890735;C4048285
2566,baseline crp,C0168634;C1442488;C3890735;C4048285
2566,baseline asdas - crp,C0168634;C1442488;C3890735;C4048285
2566,baseline - adjusted hr,C0168634;C1442488
2566,> $nmbr$ mg / dl baseline high - sensitivity crp,C0168634;C0439269;C1441604;C1442488;C3890735;C4048285
2565,patients with baseline crp concentration £ $nmbr$ mg / l,C0030705;C0086045;C0168634;C0439268;C1442488;C1446561;C3827302;C3890735;C4048285
2565,concentrations at baseline,C0086045;C0168634;C1442488
2565,baseline concentration,C0086045;C0168634;C1442488;C1446561;C3827302
2564,median ( iqr ) change from baseline to week $nmbr$ in psa - modified total shs score,C0168634;C0392747;C0443172;C0549183;C0876920;C1442488;C1705241;C2347635;C2348144;C2939193;C4319952
2564,baseline shs ( $nmbr$ - $nmbr$ ),C0168634;C1442488
2564,baseline scales  median ( range ),C0168634;C1442488
2564,baseline pav - < median ( n = $nmbr$  $nmbr$ ),C0058890;C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
2564,baseline median,C0168634;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
2563,gm  geometric mean  gmr  geometric mean ratio over baseline  uacr  urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change  with change calculated as difference between time indicated and baseline as measured for each participant  difference of changes between treatment groups . cp - values compare differences from no change .,C0017480;C0168634;C0301630;C0392747;C0392756;C0443172;C0456603;C0679646;C1273442;C1293152;C1442103;C1442488;C1522544;C1547037;C1547049;C1704695;C1705241;C1705242;C1707455;C2698741;C2986759;C3854019;C4551656;C4554048
2563,geometric mean of baseline,C0168634;C1442488;C2986759
2563,baseline geometric mean ( $nmbr$ ® / l ),C0168634;C1442488;C2986759
2562,baseline if have $nmbr$ yr follow - up *,C0168634;C1442488
2562,baseline $nmbr$ - mlnute walk distance :,C0168634;C0429886;C1442488
2562,baseline $nmbr$ - asa,C0004057;C0168634;C1442488;C3853627
2561,baseline rst - segment elevation  mm,C0168634;C0439775;C0441635;C0702240;C1425219;C1442488;C4330985;C4554674
2561,baseline rst - segment,C0168634;C0441635;C1425219;C1442488
2560,baseline ldl - c > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
2560,baseline ldl - c $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmol / lc,C0168634;C0439190;C1442488
2560,baseline hbalc ’,C0168634;C1442488
2560,baseline dlco . mmol kpa - ’ -,C0168634;C0263428;C0439190;C0439474;C1442488;C1516251
2559,nsclc,C0007131
2558,non – small - cell lung cancer,C0007131;C2984258;C3539721
2557,unstable but no rest angina,C0443343;C1883468
2557,unstable anginat,C0443343;C1883468
2557,unstable anginad,C0443343;C1883468
2557,unstable,C0443343;C1883468
2557,hospitalization for unstable ap,C0002680;C0019993;C0443343;C1883468;C3887950
2556,quintile ( n ),C1508496
2556,quintile $nmbr$ ( $nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ % ) ( n = $nmbr$ ),C1508496
2556,baseline trl - c by quintiles,C0168634;C1442488;C1508496
2556,baseline triglycerides by quintiles,C0041004;C0168634;C1442488;C1508496
2555,inhaled anticholinergic §,C0004048;C0242896;C3537004
2554,inhaled j $nmbr$ - agonist §,C0004048;C2987634
2554,inhaled ^,C0004048
2553,inhaled §,C0004048
2553,daily dose of inhaled glucocorticoid — no . ( % ) §,C0004048;C0017710;C2348070
2552,sd = standard deviation  bmi = body mass index  ed = erectile,C0871420;C1305855;C2699239;C3538926
2551,mild ed severe ed,C0205082;C2945599;C3538926;C4050465;C4050466
2551,mild ed,C2945599;C3538926
2550,ind / gly n = $nmbr$,C0017890;C0523677;C4049864
2550,ind / gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
2550,ind / gly $nmbr$ / $nmbr$ pg o . d . n = $nmbr$,C0017890;C0523677;C2827928;C4049864
2550,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
2550,ind / gly $nmbr$ / $nmbr$ mg once daily ( n = $nmbr$  $nmbr$ ),C0017890;C0024671;C0026410;C0332173;C0439269;C0523677;C1960952;C2346927;C4049864;C4321396;C4521761
2550,ind / gly,C0017890;C0523677;C4049864
2550,ind + gly ( n = $nmbr$ ),C0017890;C0523677;C4049864
2549,gly,C0017890;C0523677
2549,annualized rate ind / gly sfc,C0017890;C0523677;C0871208;C1521828;C4049864;C4521536
2548,gly $nmbr$ μ g bid,C0017890;C0439267;C0523677
2547,abbreviations :   teae  treatment - emergent adverse event  gly  glycopyrrolate inhalation solution  bid  twice daily .,C0000723;C0017890;C0017970;C0523677;C0585361;C1154181;C4684800
2546,triglyceride ( mg / dl ) d,C0041004;C0439422;C3642216
2545,triglycerides * ( mg / dl ),C0041004;C0439269
2545,triglycerides ( mg / dl ) * *,C0041004;C0439269
2545,triglyceride a,C0041004
2545,triglyceride ( mg / dl ) $nmbr$,C0041004;C0439269
2545,triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ],C0041004;C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
2545,triglyceride ( median  mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |,C0041004;C0439269;C0549183;C0876920;C1264641;C2347635;C2348144;C2939193
2544,triglycerides ( sd )  mg / dl,C0041004;C0439269;C2699239
2544,triglycerides ( mg / dl )  mean + sd  available for $nmbr$ patients,C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
2544,triglycerides ( mg / dl ),C0041004;C0439269
2544,triglycerides  mg / dl,C0041004;C0439269
2544,triglyceride ( mg / dl ),C0041004;C0439269
2544,triglyceride  mg / dl  mean ( sd ),C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
2544,fasting triglycerides  mean ( sd ) mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
2543,triglycerides — mmol / l,C0041004;C1532563
2543,triglycerides > $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
2543,triglycerides < $nmbr$ - $nmbr$ mmol / l,C0041004;C1532563
2543,triglycerides ( mmol / l ) :,C0041004;C1532563
2543,triglycerides ( mmol / l )  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
2543,triglycerides ( mmol / l ),C0041004;C1532563
2543,triglycerides  mmol / l ®,C0041004;C1532563
2543,triglycerides  mmol / l  mean ± sd,C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
2543,triglycerides  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
2543,triglycerides  mmol / l,C0041004;C1532563
2543,triglycerides,C0041004
2543,- triglycerides,C0041004
2542,triglycerides $nmbr$ st third,C0036056;C0041004;C0205437;C3272372
2542,triglycerides $nmbr$ nd third,C0041004;C0205437
2542,triglycerides $nmbr$  d third,C0041004;C0205437
2541,triglycerides * *,C0041004
2541,triglycerides *,C0041004
2541,triglycerides  mmolt $nmbr$ ( gm * ),C0017480;C0041004;C3854019
2540,triglyceride,C0041004
2540,key : tc = triglyceride  hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose  ncep atp * this category did not include ar to have > _ $nmbr$ of the indicated char least - square means  except tc an note : all treatment by subgroup,C0015663;C0017725;C0023823;C0039411;C0040642;C0041004;C0041405;C0041698;C1436327;C1824670;C2744579;C2983605;C2986463;C3272447;C3884535;C3890735;C4048285;C4521369;C4522122;C4552600
2539,deviation  tg  triglyceride .,C0012727;C0041004;C0205419;C1705236
2538,± standard deviation . triglyceride,C0041004;C0871420
2537,> $nmbr$ days warfarin,C0043031;C0439228
2536,duration of last qualifying episode of atrial fibrillation > $nmbr$ days,C0004238;C0332189;C0344434;C0439228;C0449238;C1514624;C1963067;C2926735
2536,> $nmbr$ days,C0439228
2535,median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline,C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0806909;C0871396;C0876920;C1442488;C1524031;C1552614;C1552615;C1561548;C1705502;C2347635;C2348144;C2826545;C2826546;C2939193;C3898838;C4321352
2535,baseline focal seizure frequency / $nmbr$ days  median ( q $nmbr$ - q $nmbr$ ),C0149775;C0168634;C0205234;C0376249;C0439228;C0439603;C0549183;C0751495;C0871396;C0876920;C1442488;C1561548;C1705502;C2347635;C2348144;C2939193;C3898838;C4321352
2535,> = medion ( $nmbr$ days ),C0439228
2535,> = median ( $nmbr$ days ),C0439228;C0549183;C0876920;C2347635;C2348144;C2939193
2535,> = $nmbr$ days,C0439228
2535,$nmbr$ days,C0439228
2535,$nmbr$ - $nmbr$ days,C0439228
2534,subacute ( $nmbr$ - $nmbr$ days ),C0205365;C0439228
2533,recent cardioversion ( within $nmbr$ days before randomization ) — no . ( % ),C0013778;C0332185;C0439228
2533,recent cardioversion ( within $nmbr$ days before randomization ) —,C0013778;C0332185;C0439228
2533,$nmbr$ — $nmbr$ days,C0439228
2533,$nmbr$ days stroke ( ischemic ),C0439228
2532,coronary revascularization $nmbr$ days after randomization,C0034656;C0439228;C0877341
2532,^ $nmbr$ days,C0439228
2531,index stroke > $nmbr$ days before randomization — no . ( % ),C0034656;C0439228;C0456712
2531,> $nmbr$ days ( % ),C0439228
2530,symptom - free days in the past $nmbr$ weeks ( % ),C0332296;C0439228;C0677547;C1444637;C1457887;C1880497;C1996904;C2987125;C3854129;C4284302
2530,saba use in past $nmbr$ days,C0042153;C0439228;C0457083;C1444637;C1947944;C4284302
2530,$nmbr$ - $nmbr$ days ( % ),C0439228
2529,infarction > $nmbr$ days previously,C0021308;C0439228
2529,infarction $nmbr$ - $nmbr$ days,C0021308;C0439228
2529,infarct ion w ithin previous $nmbr$ day s,C0021308;C0022023;C0205156;C0332173;C0439228;C0439505;C1552607;C1700702
2528,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) : ! :,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
2528,elevated natriuretic peptides in previous $nmbr$ days — no . ( % ) $,C0205156;C0205250;C0439228;C1144709;C1552607;C3163633
2528,< $nmbr$ days ( % ),C0439228
2527,as - needed inhalations / day,C0004048;C0332173;C0354922;C0439228;C0439505;C1879745;C1883728
2526,current smoker ( > $nmbr$ cigarettes / day ) — no . ( % ),C0332173;C0439228;C0439505;C0677453;C3173209;C3241966
2526,current ( $nmbr$ + cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
2526,current (  $nmbr$ cigs / day ),C0332173;C0439228;C0439505;C0521116;C1570610;C1705970
2526,> $nmbr$ / day,C0332173;C0439228;C0439505
2526,$nmbr$ / day,C0332173;C0439228;C0439505
2525,use of rescue albuterol  puffs / day *,C0001927;C0332173;C0439228;C0439505;C1524063;C1533107
2525,saba puffs per day at baseline,C0332173;C0439228;C0439505;C1533107
2525,albuterol use ( sd )  puffs / day,C0001927;C0042153;C0332173;C0439228;C0439505;C0457083;C1533107;C1947944;C2699239
2524,vte at day $nmbr$ +,C0332173;C0439228;C0439505;C0630906
2524,net adverse clinical events at day $nmbr$,C0205210;C0332173;C0439228;C0439505;C0877248;C1456447;C1705413;C3853572;C3887809;C3890893
2524,every day,C0332173;C0439228;C0439505
2523,methotrexate dose on day $nmbr$ — mg per wl < $nmbr$,C0025677;C0178602;C0332173;C0439228;C0439422;C0439505;C0869039;C1114758;C4086581
2523,aspirin < $nmbr$ day,C0004057;C0332173;C0439228;C0439505
2523,< $nmbr$ days ( n = $nmbr$ ),C0439228
2523,< $nmbr$ days,C0439228
2523,$nmbr$ day l,C0332173;C0439228;C0439505
2522,day $nmbr$ oral glucocorticoid use — no . { % ),C0017710;C0332173;C0439228;C0439505;C0442027;C4521986
2521,a ngina > $nmbr$ day s previously *,C0332173;C0439228;C0439505
2521,$nmbr$ - day mortality,C0026565;C0026566;C0332173;C0439228;C0439505
2521,$nmbr$ - day cce,C0332173;C0439228;C0439505
2521,$nmbr$ - $nmbr$ / day,C0332173;C0439228;C0439505
2520,slo days,C0439228;C1416602;C3539661
2519,hospital stay ( days ),C0439228;C3489408
2519,hospital stay  days,C0439228;C3489408
2518,number of symptom days per week,C0237753;C0439228;C0449788;C1457887;C3854129
2517,placebo ( symptom days a week ),C0032042;C0439228;C1457887;C1696465;C1706408;C3854129
2517,no . of days to randomization — median ( iqr ),C0439228
2517,no . of days to homa - ir testing — median ( iqr ),C0439228
2517,days with heartburna ( days ),C0439228
2517,budesonide { symptom days a week ),C0054201;C0439228;C1457887;C3854129
2517,budesonide ( symptom days a week ),C0054201;C0439228;C1457887;C3854129
2517,baseline symptom days perweek,C0168634;C0439228;C1442488;C1457887;C3854129
2517,( iqr ) — days,C0439228
2516,ssomgdayp . eq .,C0205163;C0439185
2516,eq - $nmbr$ d ( visual analog score ),C0205163;C0234621;C0243071;C0439185;C0449820;C4050231
2516,< $nmbr$ mgday p . eq .,C0205163;C0439185
2515,eq - $nmbr$ dprofile - mobility  n ( % ),C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
2515,eq - $nmbr$ d mobility,C0080078;C0205163;C0425245;C0439185;C0449580;C4318935
2515,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortf,C0205163;C0439185
2515,eq - $nmbr$ d - $nmbr$   l  no pain or discomfortc,C0205163;C0439185
2514,coronary heart disease risk equivalents  n ( % ) c,C0439185;C1277690;C4049980
2514,chd risk equivalents  n ( % ),C0439185;C1282512;C4049980
2513,caribbean,C0043122;C0206155;C1331005
2512,cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901
2512,cardiogenic shock,C0036980
2511,aborted cardiac arrest,C1550015;C1609614;C4085625;C4318470
2510,cardiac catheterization,C0018795
2510,cardiac catheterisation or pci for index event,C0018795
2509,cardiac glycosides,C0007158
2508,other cardiac surgery  n ( % ),C0018821;C0524727
2508,cardiac surgery type,C0018821;C0332307;C0524727;C1547052
2507,cardiac therapy §,C3654025
2507,cardiac therapy  n ( % ) d,C3654025
2507,cardiac therapy,C3654025
2506,prior cardiac resynchronization therapy  n ( % ),C0332152;C1167956;C2826257
2506,cardiac resynchronization therapy n ( % ),C1167956
2506,cardiac resynchronization therapy,C1167956
2505,hypertrophic cardiomyopathy,C0007194;C4551472
2504,combined cardiac failure  cardiomyopathy or other cardiac disorders,C0018801;C0018802;C0205195;C0878544
2504,cardiomyopathy,C0878544
2503,nonischemic cardiomyopathy — no . ( % ),C0878544
2503,nonischemic cardiomyopathy,C0878544
2502,dilated cardiomyopathy,C0007193;C2984282
2501,non - ischaemic dilated cardiomyopathy,C1518422;C1960867
2501,ischaemic dilated cardiomyopathy,C1960867
2500,non - ischaemic cardiomyopathy,C0349782;C1518422
2500,ischemic cardiomyopathy,C0349782
2500,ischaemic cardiomyopathy,C0349782
2499,randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079
2498,randomisation scheme,C0034656;C1519193
2497,randomization to end of study,C0034656
2497,randomization to,C0034656
2497,length of stay ( randomization to discharge  h ),C0023303;C0034656
2496,to randomization,C0034656
2496,randomization to arterial sheath insertion,C0003842;C0021107;C0034656;C0221464;C0227952;C0441587;C1512796;C1883719
2495,randomization to angiography,C0002978;C0034656
2495,randomization - to - angiography distribution time,C0002978;C0034656;C0681683
2495,randomization - to - angiography,C0002978;C0034656
2494,symptom onset - to - randomization,C0034656;C4086878
2494,randomization - to -,C0034656
2493,randomization stratum,C0034656
2493,duration of pre - randomization anticoagulant therapy,C0034656;C0332152;C0740175;C2257086;C2711563;C3669034
2492,treatmentofpulmonary embolismpriorto randomization,C0034656
2492,treatment duration before randomization — days,C0034656;C0439228;C0444921;C3259042
2491,treatment randomization,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
2491,treatment before randomization — days,C0034656;C0039798;C0087111;C0439228;C1522326;C1533734;C1705169;C3538994;C3887704
2491,thrombolytic treatment before randomization,C0016018;C0034656;C0039798;C0087111;C0520997;C1522326;C1533734;C1705169;C3538994;C3887704
2491,randomization,C0034656
2490,malignancy at randomization,C0006826;C0034656;C1306459;C4282132
2489,creatinine clearance at randomization ( ixrs ),C0034656;C0812399
2489,creatinine clearance at randomization,C0034656;C0812399
2489,at randomization,C0034656
2488,age at randomization,C0001779;C0034656
2488,age at randomisation,C0001779;C0034656
2488,age at lipid randomization ( y ),C0001779;C0034656;C0065033
2487,randomization ),C0034656
2487,iglar dose at randomization ( u / day ),C0034656;C0178602;C0456683;C0869039;C1114758
2486,renal function at randomization,C0034656;C0232804
2485,medications at timing of randomization  n ( % ),C0034656;C2359859
2484,randomization  n ( % ),C0034656
2484,immobilization at randomization  n ( % ),C0020944;C0034656;C4048292
2483,edoxaban at randomization  n ( % ),C0034656;C2975435
2483,asastoppedat randomization  n,C0034656
2482,other llt at randomization,C0034656;C2347090
2481,randomisation,C0034656
2481,no p - blocker intake at randomisation ( n = $nmbr$ ),C0034656;C0369773;C1512806;C2603361
2480,diabetes at randomization,C0011847;C0011849;C0034656
2480,antiplatelet at randomization,C0034656
2479,nihss at randomization  $nmbr$ - $nmbr$,C0034656;C1697238
2479,nihss at randomization,C0034656;C1697238
2478,electrocardiographic findings at randomization,C0034656;C0438154
2477,thienopyridine at randomization,C0034656;C1120149
2476,killip class iv at randomization,C0034656;C2697847
2475,vka at randomization,C0034656
2475,no vka at randomization,C0034656
2475,labs at randomization,C0034656;C0587081
2474,randomized to receive aspirin yes,C0034656;C3815594
2474,randomized to aspirin use,C0004057;C0034656;C0042153;C0457083;C1947944;C3815594
2474,no . randomized,C0034656;C3815594
2473,randomized to receiveaspirin,C0034656;C3815594
2473,randomized to receive vitamin e,C0034656;C3815594
2473,randomized to receive beta carotene,C0034656;C3815594
2473,randomized to canakinumab $nmbr$ mg,C0034656;C3815594
2473,randomized to active yitamin e,C0034656;C0205177;C3815594;C3853793;C3888249
2472,randomized < $nmbr$ hr after presentation — %,C0034656;C0449450;C3815594
2471,total randomized  n,C0034656;C0439175;C0439810;C3815594
2471,randomized  double - blind reversal phase ( baseline = week $nmbr$ ),C0034656;C3815594
2470,randomized treatments  n ( % ),C0034656;C0087111;C3815594
2470,randomized treatment  % ( n ),C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
2470,randomized treatment,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3815594;C3887704
2470,randomized,C0034656;C3815594
2469,randomized patients,C0030705;C0034656;C3815594
2469,all randomized patients ( range ),C0030705;C0034656;C1514721;C2348147;C3542016;C3815594
2469,all randomized patients,C0030705;C0034656;C3815594
2468,subject characteristics,C0681884;C1519021;C1706465
2467,patients ' characteristics,C0815172
2467,patient characteristics at randomization,C0034656;C0815172
2467,patient characteristics,C0815172
2466,radiographic characteristics at baseline and randomization,C0444708;C4684572
2465,table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C0039224;C0168634;C0370003;C0947343;C1315074;C1442488;C1706074;C2347026;C4684572
2465,no baseline characteristics,C4684572
2464,baseline characteristics  mean ( sd ) a,C0444504;C2347634;C2348143;C2699239;C4684572
2464,baseline characteristics,C4684572
2463,organic,C0747055
2462,time from psoriatic arthritis diagnosis [ a ]  years,C0003872;C0011900;C0040223;C1704338;C1704656;C3541383
2462,psoriatic arthritis  %,C0003872
2462,psoriatic arthritis,C0003872
2461,psoriatic arthropathy,C0003872
2461,disease characteristics duration of psoriatic arthritis — yr,C0003872;C0439234;C0449238;C0599878;C0872146;C1521970;C2926735
2460,congestive heart,C0018787;C0742742
2459,symptomatic heart fail,C0018787;C0231220
2459,hospitaiization for heart faiiure,C0018787
2459,heart failurea,C0018787
2458,urgent cor revasc,C0018787;C0056331;C0378365;C0439609;C3272275
2458,cv death  ml  ischemic stroke  hosp . for hf  cor . revasc .  ua,C0011065;C0018488;C0018787;C0041580;C0042014;C0056331;C0378365;C0439526;C0948008;C1306577;C1313497;C1538440;C1705224;C3273279;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
2458,cor revasc,C0018787;C0056331;C0378365
2457,cardiac risk,C0018787;C0035647;C1522601;C4552904
2457,cardiac failurec,C0018787;C1522601
2457,cardiac enzyates raised,C0018787;C1522601
2456,prior cardiac surgery  n ( % ),C0018787;C0018821;C0332152;C0455610;C0524727;C1522601;C2826257
2456,cardiac,C0018787;C1522601
2455,predominant cardiac diagnosis — no . ( % ),C0011900;C0018787;C1522601;C1542147;C1704338;C1704656
2455,cardiac diseasec,C0018787;C1522601
2454,cardiac stretch,C0018787;C0600080;C1522601
2453,cardiac parameters,C0018787;C0449381;C1522601
2453,cardiac and echocardiography parameters,C0018787;C1522601
2453,bmi ( kg / m $nmbr$ ) cardiac parameters,C0018787;C0449381;C0578022;C1522601;C1532718
2452,pre - operative cardiac medications *,C0018787;C1522601;C1882154;C2347660
2452,cardiac mediations,C0018787;C0680727;C1522601
2451,psa ‐ modified shs of hands and feet,C0018563;C0392747;C1552914;C3810537;C3813209;C3889737
2451,hand,C0018563;C1552914
2450,total hands score,C0018563;C0439175;C0439810;C1552914
2450,hands,C0018563;C1552914
2449,canada or united states,C0006823
2449,canada,C0006823
2448,stratified log - rank   p   value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
2448,stratified log - rank p value,C0205363;C0667477;C0699794;C1708728;C1709380;C2986775
2448,rank based on treatment   =   placebo,C0667477;C0699794
2448,log rank p - value,C0667477;C0699794;C1708728;C1709380;C2986775
2448,log - rank p value,C0667477;C0699794;C1708728;C1709380;C2986775
2448,log - rank,C0667477;C0699794;C1708728;C2986775
2447,transfusions,C0005841;C0199960;C1879316
2447,transfusion ≥ $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C0439148;C1519795;C1879316;C3853603
2447,transfusion,C0005841;C0199960;C1879316
2446,blood transfusion,C0005841;C0281867
2446,any blood transfusion,C0005841;C0281867
2446,any blood product transfusion,C0005841;C0199960;C0281867;C0456388;C1514468;C1547007;C1704444;C1879316
2445,transient st elevation,C0040704;C0205374;C0520886
2444,associated with transient or reversible risk factor,C0040704;C0205374;C0332281
2443,transient,C0040704;C0205374
2443,non - transient risk factors for recurrent vte  n ( % ),C0035648;C0040704;C0205374;C0439597;C0630906;C1553898
2442,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448;C0042469;C0201660;C0521143;C0748398;C1547111;C3714652;C4321495
2442,seronegative ( rf - ve and acpa - ve ) subgroup,C0035448;C0042469;C0201660;C0521144;C0748398;C1547111;C3714652;C4321495
2442,rf positive — number ( % ),C0035448;C0201660;C0748398;C1547111;C3812269
2442,rf positive ( > $nmbr$ iu / ml )  n ( % ),C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,rf positive  n ( % ),C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,rf positive  %,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,rf positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,rf or acpa positive,C0035448;C0201660;C0748398;C1547111
2442,rf and acpa positive  n ( % ),C0035448;C0201660;C0748398;C1547111
2442,rf and acpa negative $nmbr$,C0035448;C0201660;C0748398;C1547111
2442,rf and acpa negative  n ( % ),C0035448;C0201660;C0748398;C1547111
2442,rf - positive  > $nmbr$ iu / ml  %,C0035448;C0201660;C0439178;C0439458;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,rf  % positive,C0035448;C0201660;C0439178;C0748398;C1446409;C1514241;C1547111;C2825490;C3812269
2442,% rf +,C0035448;C0201660;C0748398;C1547111
2441,rf ( mg / dl ),C0035448;C0201660;C0439269;C0748398;C1547111
2441,rf ( mg / dl  per unit ),C0024671;C0026410;C0035448;C0201660;C0439148;C0439269;C0439453;C0748398;C1509845;C1519795;C1532632;C1547111;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C4321396;C4521761
2441,rf ( iu / ml ),C0035448;C0201660;C0439458;C0748398;C1547111
2440,rheumatoid factor positive §  n ( % ),C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2440,rheumatoid factor positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2440,rheumatoid factor or acpa positive  or both,C0035448;C0201660
2440,rheumatoid factor and acpa positive,C0035448;C0201660
2440,rheumatoid factor - positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2440,rheumatoid factor !,C0035448;C0201660
2440,positive for rheumatoid factor — no . ( % ) : t,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
2440,positive for rheumatoid factor  anti - cyclic citrullinated peptide antibodies  or both — % ff,C0003241;C0035448;C0201660;C0439178;C0439596;C0741132;C1320283;C1446409;C1511572;C1514241;C2825490;C3812269;C4505301
2439,patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,mdrd egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
2439,egfr — ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
2439,egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C0683312;C1739039;C3811844;C3812682;C3889287
2439,egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr -,C1739039;C3811844;C3812682
2439,egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0441923;C1739039;C3811844;C3812682
2439,egfr ( ml / min per $nmbr$ - $nmbr$ m ^ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ ),C0369637;C0439402;C0441923;C1739039;C3811844;C3812682
2439,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
2439,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr  ml / minute / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439232;C0439526;C0441923;C0700321;C0702093;C1282918;C1705224;C1739039;C2347166;C3811844;C3812682;C3887665
2439,egfr  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682;C3839656
2439,egfr  ml / kg per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439526;C0441923;C1300574;C1532718;C1705224;C1739039;C3811844;C3812682;C3887665
2439,egfr  * ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,egfr  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2439,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
2439,baseline egfr  ml / min / $nmbr$ . $nmbr$   m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
2439,baseline egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
2438,prevalent kidney disease ( egfr < $nmbr$ ml / min / usm ^ or maeroalbuminuria uacr > $nmbr$ mg / g ),C0022658;C0033105;C0220900;C0439445;C1739039;C3811844;C3812682
2438,mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
2438,egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
2438,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr > $nmbr$,C1739039;C3811844;C3812682
2438,egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min per $nmbr$ - $nmbr$ m ' ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min per $nmbr$ + $nmbr$ m ”,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2438,egfr ( ml / min / $nmbr$ - $nmbr$ mz ),C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
2438,egfr $nmbr$ - $nmbr$,C1739039;C3811844;C3812682
2438,egfr  ml / min / bsa,C0439445;C1739039;C3811844;C3812682
2438,> $nmbr$ to < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0040363;C0041260;C0369637;C0439445;C0441923;C1739039;C1883351;C3811844;C3812682
2438,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2437,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2437,patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n,C0030705;C1739039;C3811844;C3812682
2437,egfr and albuminuria,C1739039;C3811844;C3812682
2437,albuminuria and previous maerovaseular disease plus established renal disease ( egfr $nmbr$ - $nmbr$ ml / min / l $nmbr$ in - with an uacr > $nmbr$ mg / g or egfr $nmbr$ - < $nmbr$ ml / inin / l $nmbr$ in - with any uacr mg / g ),C0001925;C0702093;C1524029;C1635169;C1739039;C3811844;C3812682;C3813700
2436,egfr using cg / mdrd formulae  % of patients,C1739039;C3811844;C3812682
2436,egfr at baseline  $nmbr$ ml / min ( % ) b,C0168634;C0439445;C1442488;C1739039;C3811844;C3812682
2436,egfr < $nmbr$,C1739039;C3811844;C3812682
2436,egfr,C1739039;C3811844;C3812682
2436,baseline mdrd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
2436,baseline egfr ≥ $nmbr$ to < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
2436,baseline egfr < $nmbr$,C0168634;C1442488;C1739039;C3811844;C3812682
2436,baseline egfr,C0168634;C1442488;C1739039;C3811844;C3812682
2435,treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
2434,estimated glomerular filtration rate | |,C3811844
2434,estimated glomerular filtration rate,C3811844
2434,aceis  angiotensin - converting enzyme inhibitors  c  candesartan  des  drug - eluting stent  egfr  estimated glomerular filtration rate  hdl  high - density lipoprotein  ldl  low - density lipoprotein  nc  non - candesartan .,C0003015;C0011702;C0023823;C0027964;C0028407;C0038257;C0067895;C0265987;C0717550;C1518422;C1739039;C2757044;C3811844;C3812682;C4551552
2433,severe impairment ( egfr < $nmbr$ )  n ( % ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
2433,renal function ( egfr ) according to mdrd  n ( % ),C0232804;C0680240;C1739039;C3811844;C3812682;C3839656
2433,normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0205307;C0231683;C0369637;C0439166;C0439445;C0441923;C1739039;C2347086;C3811844;C3812682;C4553972
2433,normal ( egfr > $nmbr$ ),C0205307;C0231683;C0439166;C1739039;C2347086;C3811844;C3812682;C4553972
2433,moderate impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
2433,mild impairment ( egfr $nmbr$ – $nmbr$ )  n ( % ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
2433,egfr category  n ( % ),C0683312;C1739039;C3811844;C3812682;C3889287
2433,egfr category,C0683312;C1739039;C3811844;C3812682;C3889287
2433,egfr > $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
2433,egfr > $nmbr$  n ( % ),C1739039;C3811844;C3812682
2433,egfr < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
2433,egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
2433,egfr < $nmbr$  n ( % ),C1739039;C3811844;C3812682
2433,egfr ( mdrd )  n ( % ),C1739039;C3811844;C3812682;C3839656
2433,egfr $nmbr$ to < $nmbr$ ml / min  n ( % ),C0439445;C1739039;C3811844;C3812682
2433,egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C1739039;C3811844;C3812682
2433,egfr  n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ ),C0205307;C0231683;C0439166;C0439445;C1739039;C2347086;C3811844;C3812682;C4553972
2432,estimated glomerular filtration rate — no . ( % ),C3811844
2432,estimated glomerular filtration rate < $nmbr$,C3811844
2432,estimated glomerular filtration rate - no . ( % ) : :,C3811844
2432,estimated glomerular filtration rate  n ( % ),C3811844
2432,ckd ( egfr < $nmbr$ b ),C1561643;C1739039;C3811844;C3812682
2432,ckd ( egfr < $nmbr$ )  n ( % ),C1561643;C1739039;C3811844;C3812682
2432,bp = blood pressure  egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ )  hdl = high - density lipoprotein .,C0005823;C1739039;C3811844;C3812682
2431,current drinker,C0556297
2431,alcohol > $nmbr$ drinks per week,C0332174;C0439230;C0556297
2430,current alcohol drinking  n ( % ),C0001948;C0521116;C0556297;C1705970
2430,alcohol users  n ( % ),C0556297
2429,undetermined etiology  n ( % ),C0478157
2429,undetermined etiology,C0478157
2428,drinker ( % ) a,C0556338
2428,drinker ( % ),C0556338
2428,drinker  n ( % ),C0556338
2428,alcohol drinker  n ( % ),C0001962;C0001975;C0556338
2428,alcohol drinker,C0001962;C0001975;C0556338
2427,drinker ( $nmbr$ to $nmbr$ drinks / week ),C0332174;C0439230;C0452428;C0556338
2427,drinker ( $nmbr$ - $nmbr$ drinks / week ),C0556338
2426,ref §,C1425988
2426,no steroid use at baseline ( ref ),C0168634;C0281991;C1425988;C1442488
2426,( ref ),C1425988
2426,$nmbr$ . $nmbr$ ( ref . ),C1425988
2426,$nmbr$ ( ref ),C1425988
2425,ref .,C1425988
2425,( e ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
2425,( d ) aza treatment ( ref ),C0004482;C0039798;C0073187;C0087111;C0332173;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704;C4484261
2425,( c ) ' ' kza treatment ( ref ),C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
2425,( b ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
2425,( a ) aza treatment ( ref ),C0004482;C0039798;C0087111;C1425988;C1522326;C1533734;C1705169;C3538994;C3887704
2424,phenobarbital,C0031412
2423,community hospital ( % ),C0020003
2423,community hospital  n ( % ),C0020003
2423,community hospital,C0020003
2422,inguinal hernia repair,C0021446
2421,hiatus hernia,C3489393
2421,hiatal hernia ( yes ) ( n ),C1549445;C1705108;C1710701;C3489393
2421,esophageal hiatal hernia *,C3489393
2420,= cerebrospinal fluid .,C0007806;C0007807
2419,gemfibrozil ( n = $nmbr$,C0017245
2419,gemfibrozil,C0017245
2418,phospholipid omega - $nmbr$ levels : < $nmbr$ % ( n = $nmbr$ ),C0031676;C0202177;C0441889;C1719844
2417,omega - $nmbr$ fa intake $nmbr$ st third,C0036056;C0205437;C1512806;C1719844;C3272372
2417,omega - $nmbr$ fa intake $nmbr$ nd third,C0205437;C1512806;C1719844
2417,omega - $nmbr$ fa intake $nmbr$  d third,C0205437;C1512806;C1719844
2417,omega - $nmbr$ fa,C1719844
2416,omega $nmbr$ allocation,C1706778;C1719844
2415,omega - $nmbr$ fatty acids,C0015684;C1719844
2415,omega - $nmbr$ fatty acid ( n = $nmbr$ ),C0015684;C1719844
2415,omega - $nmbr$ fa ( n = $nmbr$ ),C1719844
2415,a mini - mental state examination  omega - $nmbr$ fatty acids vs placebo,C0015684;C0451306;C1719844
2414,omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl ),C0015684;C1719844
2414,omega - $nmbr$ fatty acid,C0015684;C1719844
2414,number omega - $nmbr$ number placeb fatty acid,C0015684;C0237753;C0449788;C1719844
2413,colombia,C3245499
2412,patients with > $nmbr$ co - aeds,C0030705;C0180309;C3245499
2412,patients with $nmbr$ co - aeds,C0030705;C0180309;C3245499
2412,patients with $nmbr$ co - aed,C0030705;C0887457;C3245499
2411,olmesartan / ccb - olmesartan / diuretic,C0006684;C1098320
2410,olmesartan along with ccb ( n - $nmbr$ ),C0006684;C1098320
2410,olmesartan ( n = $nmbr$ ),C1098320
2409,prior lev use,C0023556;C0332152;C2826257
2409,prior lev,C0023556;C0332152;C2826257
2409,lev - naive,C0023556
2409,lev - exposed,C0023556
2408,prior lev treatment    n   ( % ),C0023556;C1514463
2408,prior lev treatment,C0023556;C1514463
2407,lev status  n ( % ),C0023556;C0449438
2407,lev status,C0023556;C0449438
2407,lev ( n   =   $nmbr$ ),C0023556
2406,lv systolic dysfunction  n ( % ),C0023128;C0731033;C0749225;C1881413
2406,lv diastolic dysfunction  n ( % ),C0023128;C0520863;C0731033;C1881413
2405,lv ejection fractionb,C0023128;C0302131;C0336969;C0731033;C0812388;C1881413
2405,lv ejection fraction > $nmbr$ % and < $nmbr$ %,C0023128;C0489482;C0731033;C1881413;C2700378
2405,lv ejection fraction ( % ),C0023128;C0489482;C0731033;C1881413;C2700378
2405,lv ejection fraction  % ( n = $nmbr$ ),C0023128;C0489482;C0731033;C1881413;C2700378
2405,lv ejection fraction,C0023128;C0489482;C0731033;C1881413;C2700378
2404,lv heart structure,C0018787;C0023128;C0731033;C1881413
2404,latvia,C0023128
2403,trough fevi l,C0429706;C0444506;C0849974;C1561566;C4528367
2403,fevi auc $nmbr$ - $nmbr$ l,C0376690;C0429706;C0849974;C1561566;C4528367
2403,fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
2403,fevi  l *,C0429706;C0849974;C1561566;C4528367
2403,fevi  l  mean ( sd ) $nmbr$,C0429706;C0444504;C0849974;C1561566;C2347634;C2348143;C2699239;C4528367
2403,fevi  l,C0429706;C0849974;C1561566;C4528367
2402,fevi percent predicted ( % ),C0429706;C0439165;C0849974;C1561566;C4528367
2402,fevi  % predicted  mean ( sd ) $nmbr$,C0849974;C1561566;C4528367
2402,$nmbr$ ( fevi ^ $nmbr$ % pred ),C0849974;C1561566;C4528367
2402,$nmbr$ ( fevi $nmbr$ - < $nmbr$ % pred ),C0849974;C1561566;C4528367
2401,post - bronchodilator fevi $nmbr$ % predicted,C0849974;C1561566;C2599594;C4528367
2401,post - bronchodilator fevi  n ( % ),C0429706;C0849974;C1561566;C2599594;C4528367
2401,fevi  % predicted *,C0849974;C1561566;C4528367
2400,linear regression,C0023733;C2346679
2399,radiographic progression based on change from baseline > sdc,C0242656;C0444708;C0449258
2398,progression of albuminuria,C0001925;C0242656;C0449258
2398,albuminuria progression,C0001925;C0242656;C0449258
2397,progression to diabetes,C1735364
2396,progestins,C0033306
2395,logistic regression,C0206031
2395,bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828
2395,aunivariate logistic regression .,C0206031
2394,univariate logistic modela,C0242415
2394,multivariate logistic modelb,C0242415
2393,risk level at admission,C0184666;C0809949;C2923839
2392,admission grace score,C0184666;C0809949
2392,admission crcl,C0184666;C0809949;C1846718
2391,statin during admission,C0184666;C0360714;C0809949
2391,no statin during admission,C0184666;C0360714;C0809949
2390,p blocker before admission,C0184666;C0369773;C0809949;C2603361
2389,medical therapy before admission,C0184666;C0418981;C0809949
2389,before admission )  %,C0184666;C0809949
2389,aspirin before admission,C0004057;C0184666;C0809949
2389,$nmbr$ blocker before admission,C0184666;C0809949
2388,acute infection without septic shock,C0036983;C0275518
2387,serious infections,C0205404;C3714514
2387,infections and infestations,C3714514
2387,infections,C3714514
2386,potential injection site reactions,C0151735;C3245505
2385,injection - site reaction  n ( % ),C0151735;C4551923
2384,contusion,C0009938
2383,infusion administered — no . / total no . ( % ),C0574032;C1827465
2383,glyceryl trinitrate infusion,C0017887;C0574032;C1827465
2382,time - to - first infusion,C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
2382,time - to - first - infusion from hip surgery ( days )  n ( % ),C0040223;C0205435;C0574032;C1279901;C1827465;C3541383
2382,core study to first infusion,C0205435;C0444669;C0557651;C0574032;C1167518;C1279901;C1706352;C1827465;C1882467;C2603343;C3274653
2381,primary indication,C1549995
2380,pci indication,C0392360;C3146298;C4049621
2380,indication for pci,C0392360;C3146298;C4049621
2380,indication for index pci,C0392360;C0600653;C0918012;C1552854;C1637833;C2986546;C3146298;C4049621
2379,indication for stent,C0038257;C0392360;C3146298
2379,indication,C0392360;C3146298
2378,helicobacter pylori infection ( + ) ( n ),C0850666
2378,h . pylori infection,C0850666
2377,heterozygous familial hypercholesterolemia †,C0342882
2377,heterozygous familial hypercholesterolemia,C0342882
2376,familial,C0015576;C0241888
2376,diagnosis of heterozygous familial hypercholester,C0011900;C0015576;C0019425;C0241888;C1704338;C1704656
2375,family history of vte,C0241889;C0630906
2375,family history ^,C0241889
2374,family history of premature chdj,C0151526;C0205252;C0241889;C4018905
2374,family history of premature chd * *,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2374,family history of premature chd,C0151526;C0205252;C0241889;C0280604;C3542407;C4018905
2374,family history of premature,C0151526;C0205252;C0241889;C4018905
2373,no family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
2373,family history of chd ( n = $nmbr$  $nmbr$ ),C0241889;C0280604;C3542407
2373,family history  n ( % ),C0241889
2372,family history of venous thromboembolism ( % ),C0015576;C0042449;C0241889;C0348013;C0455533;C1704727;C1997614
2372,family history of cancerf,C0241889
2372,family history of cancera,C0241889
2371,fasting tgs §,C0015663;C1156212;C1537574
2370,fasting triglycerides > $nmbr$ mg / dl *,C0015663;C0041004;C0439269
2370,fasting triglycerides  mg / dl,C0015663;C0041004;C0439269
2370,fasting triglycerides  mean ( sd )  mg / dl,C0015663;C0041004;C0439269;C0444504;C2347634;C2348143;C2699239
2370,fasting triglycerides,C0015663;C0041004
2369,fasting triglyceride level  mean ( sd )  mg / dl,C0015663;C0428475;C0439269;C0444504;C2347634;C2348143;C2699239
2369,fasting,C0015663
2368,fasting glucose > $nmbr$ mg / dl *,C0015663;C0017725;C0439269
2368,fasting glucose > $nmbr$ mg / dl  n ( % ),C0015663;C0017725;C0439269
2368,fasting glucose *,C0015663;C0017725
2368,fasting glucose  mg / dl ',C0015663;C0017725;C0439269
2368,fasting glucose  mg / dl,C0015663;C0017725;C0439269
2368,fasting glucose,C0015663;C0017725
2367,fasting lipid levels  mmol / l,C0015663;C0428460;C1532563
2366,fasting lipids ( mmol / $nmbr$ ),C0015663;C0023779;C0439190
2365,fasting indices,C0015663;C4033634
2364,fasting proinsulin ( pmol / l ),C0015663;C0033362;C0439284;C3813208
2364,fasting free fatty acids ( ^ mol / liter ),C0015663
2363,fastest third,C0015663;C0205437;C0456962;C2985769
2362,faster aspart   +   basal,C0015663;C0123677;C0205112;C0456962;C2985769
2362,faster aspart ( mealtime ),C0015663;C0123677;C0456962;C0587119;C2985769
2362,faster aspart,C0015663;C0123677;C0456962;C2985769
2361,white race  n ( % ),C0007457;C0043157
2361,white race  %,C0007457;C0043157
2361,white or caucasian  n ( % ),C0007457;C0043157;C0220938
2361,white ( $nmbr$ . $nmbr$ % ),C0007457;C0043157;C0220938
2361,white  no . ( % ),C0007457;C0043157;C0220938
2361,white  n / n ( % ),C0007457;C0043157;C0220938
2361,white  n ( % ),C0007457;C0043157;C0220938
2361,white  %,C0007457;C0043157;C0220938
2361,race  n ( % ) white,C0007457;C0034510;C0043157;C0220938;C1706779;C3853635
2361,caucasian  n ( % ) *,C0007457;C0043157
2361,caucasian  n ( % ),C0007457;C0043157
2361,caucasian  %,C0007457;C0043157
2360,white race ( n = $nmbr$ $nmbr$ ),C0007457;C0043157
2360,white mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
2360,white ( n — $nmbr$ ),C0007457;C0043157;C0220938
2360,white ( n   = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
2360,white ( n = $nmbr$ ),C0007457;C0043157;C0220938
2360,white ( n = $nmbr$  $nmbr$ ),C0007457;C0043157;C0220938
2359,white not of hispanic origin,C0007457;C0043157;C0220938
2359,white ethnicity,C0007457;C0015031;C0043157;C0220938;C0243103
2359,white ethnic origin,C0007457;C0015031;C0043157;C0220938
2359,white / other,C0007457;C0043157;C0220938
2359,race / ethnicity white,C0007457;C0015031;C0034510;C0043157;C0220938;C0243103;C1706779;C3853635
2359,ethnic origin white,C0007457;C0015031;C0043157;C0220938
2358,white race — no . { % ) t,C0007457;C0043157;C0220938
2358,white race — no . { % ) - i -,C0007457;C0043157;C0220938
2358,white race — no . { % ) ' i ',C0007457;C0043157;C0220938
2358,white race — no . { % ) $,C0007457;C0043157;C0220938
2358,white race — no . / total no . ( % ) f,C0007457;C0043157;C0220938
2358,white race — no . / total no . ( % ) $,C0007457;C0043157;C0220938
2358,white race — no . ( % ) y left ventricular ejection fraction — %,C0007457;C0043157;C0220938
2358,white race — no . ( % ) f,C0007457;C0043157;C0220938
2358,white race — no . ( % ) : t,C0007457;C0043157;C0220938
2358,white race — no . ( % ) :,C0007457;C0043157;C0220938
2358,white race,C0007457;C0043157
2358,white non - hispanic - n ( % ),C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
2358,white non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
2358,white,C0007457;C0043157;C0220938
2358,racea white,C0007457;C0043157;C0220938
2358,non - hispanic white,C0007457;C0043157;C0220938;C1518424
2357,white  non - hispanic,C0007457;C0043157;C0220938;C1518422;C1518424;C1533020;C1533021
2357,non white,C0007457;C0043157;C0220938;C1518422
2357,non - white raceb,C0007457;C0043157;C0220938;C1518422
2357,non - white race,C0007457;C0043157;C1518422
2357,non - white,C0007457;C0043157;C0220938;C1518422
2356,white race — number ( % ),C0007457;C0043157;C0237753;C0449788
2356,caucasian race ( % ),C0007457
2356,caucasian race,C0007457
2356,caucasian ( % ),C0007457;C0043157
2355,white / caucasian,C0043157
2355,non - caucasian simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
2355,non - caucasian simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
2355,non - caucasian simva,C0007457;C0043157;C1518422
2355,non - caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157;C1518422
2355,non - caucasian eze / simva,C0007457;C0043157;C1518422
2355,non - caucasian,C0007457;C0043157;C1518422
2355,caucasian simva,C0007457;C0043157
2355,caucasian eze / simva,C0007457;C0043157
2354,non - caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157;C1518422
2354,caucasians ( n = $nmbr$ ),C0007457;C0043157
2354,caucasians,C0007457;C0043157
2354,caucasian simva ( „ = $nmbr$ },C0007457;C0043157
2354,caucasian simva ( n = $nmbr$ ),C0007457;C0043157
2354,caucasian n = $nmbr$  $nmbr$,C0007457;C0043157
2354,caucasian eze / simva ( „ = $nmbr$ },C0007457;C0043157
2354,caucasian eze / simva ( n = $nmbr$ ),C0007457;C0043157
2354,caucasian $nmbr$,C0007457;C0043157
2353,caucasian ethnicity,C0007457;C0015031;C0043157;C0243103
2353,caucasian,C0007457;C0043157
2352,prior hospitalization for hf  %,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
2352,prior hf hospitalization ( n = $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
2352,hospitalizations,C0019993
2352,hospitalization for hf previous year  ( % ),C0018488;C0019993;C0205156;C0439234;C0439508;C1313497;C1538440;C1552607;C3273279
2352,hospitalization for hf,C0018488;C0019993;C1313497;C1538440;C3273279
2352,hospitalization for,C0019993
2352,hf hospitalizations  median ( iqr ),C0018488;C0019993;C0549183;C0876920;C1313497;C1538440;C2347635;C2348144;C2939193;C3273279
2352,hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
2352,hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
2351,prior hospitalizations  n ( % ),C0019993;C0332152;C2826257
2351,hospitalizations  n,C0019993
2351,hospitalization stratum  n ( % ),C0019993
2351,hospitalization  n ( % ),C0019993
2351,hospitalization,C0019993
2351,hospitalisation related to exacerbation  n ( % ),C0019993
2351,hospitalisation,C0019993
2350,hospitalization for acute limb ischemia,C0019993;C0205178;C2945695
2349,hospitalisation for chf within $nmbr$ years of randomisation,C0018802;C0019993
2348,hospitalization for acs,C0019993;C0742343;C4318612
2348,hospitalization for / due to,C0019993
2347,hospitalized for an exacerbation,C0701159;C4086268
2347,hospitalized exacerbation rates,C0701159;C0871208;C1521828;C4086268
2347,hospitalized !,C0701159
2346,hospitalized for asthma  n ( % ) *,C0004096;C0701159;C2984299
2346,hospitalized,C0701159
2345,ambition,C0870128
2344,low dose combination therapy,C0009429;C0445550;C0556895;C1708745
2344,combination therapy * *,C0009429;C0556895
2344,combination therapy ( n = $nmbr$ ),C0009429;C0556895
2344,combination therapy  n = $nmbr$,C0009429;C0556895
2343,sustain $nmbr$ : semaglutide vs . sitagliptin $nmbr$ mg,C0443318;C2732140
2343,sustain $nmbr$ : semaglutide vs . placebo,C0443318;C2732140
2343,sustain $nmbr$ : semaglutide vs . iglar,C0443318;C2732140
2343,sustain $nmbr$ : semaglutide vs . exenatide er $nmbr$ . $nmbr$ mg,C0443318;C2732140
2343,sustain $nmbr$ : semaglutide add ‐ on to insulin vs . placebo,C0443318;C2732140
2343,sustain $nmbr$,C0443318;C2732140
2343,sustain,C0443318;C2732140
2342,sulfasalazine ( mean dose : $nmbr$ . $nmbr$ g / day ),C0036078;C0178602;C0439417;C0444504;C0869039;C1114758;C2347634;C2348143
2342,sulfasalazine,C0036078
2341,exetimibe / simvastatin,C0074554
2341,chd  coronary heart disease  eze / simva  ezetimibe / simvastatin combination tablet  fpg  fasting plasma glucose  pvd  peripheral vascular disease,C0010068;C0015663;C0039225;C0074554;C0085096;C0202042;C0455280;C1532737;C1705223;C4319774
2340,simvastatin,C0074554
2340,pooled simvastatin factorial studies,C0074554;C1709595;C2349200;C2826344;C4522255
2339,simvastatin monotherapy ( n = $nmbr$  $nmbr$ * ),C0074554
2339,simvastatin ( n = $nmbr$ . $nmbr$ ),C0074554
2339,simvastatin ( n = $nmbr$ ),C0074554
2339,simvastatin ( n = $nmbr$  $nmbr$ ),C0074554
2339,simvastatin $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
2339,simvastatin  n ( % ),C0074554
2338,pravastatin n = $nmbr$,C0085542
2338,pravastatin ( n = $nmbr$ >,C0085542
2338,pravastatin ( n = $nmbr$ ),C0085542
2338,diet - i - pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0021966;C0085542;C0221138;C1519433;C2983588;C3668949
2337,pravastatin $nmbr$ mg,C0024671;C0026410;C0085542;C0439269;C1960952;C2346927;C4321396;C4521761
2337,pravastatin,C0085542
2337,i moderate  $nmbr$ mg of pravastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0085542;C0205081;C0221138;C0439269;C1881878;C1960952;C2346927;C4049705;C4049706;C4085643;C4321335;C4321396;C4521761
2336,pravastatin vs usual care,C0085542
2336,clow - potency stratum : simvastatin $nmbr$ mg  pravastatin $nmbr$ mg  fluvastatin $nmbr$ mg  atorvastatin $nmbr$ mg  high - potency stratum : simvastatin $nmbr$ mg  atorvastatin,C0074554;C0082608;C0085542;C0205250;C0286651;C1299351;C1319635;C2700149;C2985073;C3245505;C3887512;C3889660;C4321237;C4522209
2336,atorvastatin - pravastatin,C0085542;C0286651
2335,patients on atorvastatin  rosuvastatin  or simvastatin at,C0030705;C0286651;C0965129
2334,rosuvastatin  events / patients ( % ),C0030705;C0441471;C0965129;C3541888
2334,rosuvastatin,C0965129
2333,rosuvastatin + fenofibric acid,C0060179;C0965129
2333,rosuvastatin +,C0965129
2332,rosuvastatin   n   =   $nmbr$,C0965129
2332,$nmbr$ mg  rosuvastatin $nmbr$ mg .,C0965129;C1319635
2331,rosuvastatin n = $nmbr$,C0965129
2331,rosuvastatin ( n = $nmbr$ . $nmbr$ ),C0965129
2331,rosuvastatin ( n = $nmbr$ ),C0965129
2331,rosuvastatin ( n = $nmbr$  $nmbr$ ),C0965129
2331,rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
2330,rosuvastatin  n ( % ),C0965129
2330,copd - rosuvastatin ( n = $nmbr$ ),C0024117;C0965129;C1412502;C3714496
2330,copd - rosuvastatin ( $nmbr$ pt ) n . ( % ),C0024117;C0032743;C0699718;C0965129;C1412502;C3714496
2329,atorvastatin factorial study,C0286651;C2826344
2328,i intensive  $nmbr$ mg of atorvastatin ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0162425;C0221138;C0286651;C0439269;C0522510;C1283828;C1550453;C1960952;C2346927;C4321396;C4521761
2328,atorvastatin monotherapy ( n = $nmbr$ * ),C0286651
2328,atorvastatin ls means difference $nmbr$ mg ( $nmbr$ % ci ) a ( n = $nmbr$ ),C0008107;C0023668;C0024671;C0026410;C0286651;C0439269;C1704970;C1705241;C1705242;C1960952;C2346927;C3259781;C4321396;C4521761
2328,atorvastatin $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0043476;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2328,atorvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2328,atorvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2328,atorvastatin $nmbr$ mg,C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
2328,atorvastatin  n ( % ),C0286651
2328,atorvastatin,C0286651
2327,atorvastatin { n = $nmbr$  $nmbr$ ),C0286651
2327,atorvastatin ( n = $nmbr$  $nmbr$ ),C0286651
2327,atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0286651;C1142985;C1319635
2326,calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
2325,heavy calcification,C0006660;C0006663;C0175895;C0439539;C1533591;C1879982;C2242558
2325,calcification  n ( % ),C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
2324,classification of epilepsy type  n ( % ),C0008902;C0008903;C0014544;C0332307;C0678229;C1547052
2324,classification of af  no . ( % ),C0008902;C0008903;C0344434;C0678229;C4049859
2323,pah classification — no . ( % ),C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
2323,pah classification,C0008902;C0008903;C0030123;C0678229;C3203102;C4284467
2322,intermittent claudication,C0021775
2322,claudication only,C0021775;C0205171;C0311395;C1456822;C1720467
2322,claudication,C0021775;C0311395;C1456822
2321,toast classification of qualifying stroke ( % ),C0038454;C1514624;C1710306;C4521230;C4554100
2321,toast classification of qualifying stroke  no . ( % ),C1514624;C1710306;C4521230
2321,toast classification of qualifying stroke,C0038454;C1514624;C1710306;C4521230;C4554100
2321,toast classification,C1710306;C4521230
2320,prior amputation,C0002688;C0332152;C0332840;C1546539;C2826257
2320,amputations  n ( % ),C0002688
2320,amputation — no . ( % ),C0002688;C0332840;C1546539
2320,amputation,C0002688;C0332840;C1546539
2319,resection performed — no . { % ),C0015252;C0728940
2319,resection performed  %,C0015252;C0728940
2318,medication effects,C1319171
2317,medications at discharge or day $nmbr$  if earlier ( % ),C0806915
2317,medications at discharge,C0806915
2317,cardiac medications at discharge  %,C0018787;C0806915;C1522601
2316,cardiovascular medication usage,C0007220;C0457083
2315,cardiovascular medications  %,C0007220
2315,cardiovascular medications,C0007220
2315,baseline concomitant cardiovascular medications,C0007220;C0168634;C0521115;C1442488
2315,baseline cardiovascular medications  n ( % ),C0007220;C0168634;C1442488
2315,baseline cardiovascular medication  c n ( % ),C0007220;C0168634;C1442488
2315,baseline cardiovascular medication,C0007220;C0168634;C1442488
2314,medication adherence,C2364172
2313,current medication — no . ( % ),C0746467
2313,current medication use,C0042153;C0240320;C0457083;C0521116;C0746467;C1705970;C1947944
2313,current medication  n ( % ),C0746467
2312,years of education *,C0013621;C0013622;C0013658;C0039401;C0439234
2312,education level,C0013621;C0013658
2312,education in years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
2312,education > $nmbr$ yr ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
2312,education > $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
2312,education > $nmbr$ y,C0013621;C0013622;C0013658;C0039401
2312,education < $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
2312,education < $nmbr$ y,C0013621;C0013622;C0013658;C0039401
2312,education *,C0013621;C0013622;C0013658;C0039401
2312,education ( years ),C0013621;C0013622;C0013658;C0039401;C0439234
2312,education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
2312,education  y  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
2312,education  y,C0013621;C0013622;C0013658;C0039401
2312,education  mean ( sd ) years,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
2312,education  mean ( sd )  y,C0013621;C0013622;C0013658;C0039401;C0444504;C2347634;C2348143;C2699239
2312,education,C0013621;C0013622;C0013658;C0039401
2312,> $nmbr$ years education,C0013621;C0013622;C0013658;C0039401;C0439234
2311,education — no . ( % ),C0013621;C0013622;C0013658;C0039401
2311,education ( % ),C0013621;C0013622;C0013658;C0039401
2311,< $nmbr$ yr of education — no . ( % ),C0013621;C0013622;C0013658;C0039401;C0439234
2310,posterior circulation,C0005775;C0205095;C1516559
2309,total population n,C3258257
2309,total population ( n = $nmbr$ ),C3258257
2309,total ho population ( n = $nmbr$ ),C0019905;C1832110;C3258257;C3889614
2309,total carmelina population,C3258257
2308,total study population,C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2308,total study itt population ( n = $nmbr$ ),C0439175;C0439810;C0557651;C2348561;C2603343;C3258257
2308,total population,C3258257
2307,boost intensify premix i ( global patient population ),C1511253;C1874596
2307,boost intensify all ( pan - asian patient population ),C1511253;C1874596
2306,constitutional,C1511487
2305,constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
2304,no regular consumption,C0009830;C0205272;C1947907
2303,open - label population,C0032659;C1257890;C1709323
2302,uplift ® population,C0032659;C1257890
2302,population,C0032659;C1257890
2302,patient population,C0030705;C0032659;C1257890
2302,itt population,C0032659;C1257890
2302,figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd  chronic obstructive pulmonary disease  fev $nmbr$  forced expiratory volume in $nmbr$ s  ics  inhaled corticosteroid  itt  intent to treat  laba  long - acting b $nmbr$ - agonist .,C0001617;C0004048;C0016529;C0032042;C0032659;C0040363;C0041260;C0332152;C0740175;C0815320;C1257890;C1306036;C1696465;C1706408;C1883351;C2257086;C3536709;C3669034;C4551720
2301,safety population  n ( % ),C0032659;C0036043;C1257890;C1705187
2301,safety population,C0032659;C0036043;C1257890;C1705187
2300,week $nmbr$ ( itt population ),C0032659;C0332174;C0439230;C1257890
2300,populations :,C0032659;C1257890
2299,severe exacerbations  itt population  n ( % ),C0032659;C0205082;C1257890;C4050465;C4050466;C4086268
2299,mitt population ( n = $nmbr$ ),C0032659;C1257890
2299,mitt population,C0032659;C1257890
2299,itt population  n,C0032659;C1257890
2298,subpopulation,C1257890
2298,indian subpopulation,C1257890;C1524069
2297,duration of full - dose warfarin therapy before enrollment ( mo ),C0366686;C0443225;C0444917
2296,full po pulatio n,C0443225;C0946289
2295,full population,C0032659;C0443225;C1257890
2294,lm bifurcation treated,C0184906;C1261082;C1551056;C3146289
2294,lm bifurcation not treated,C0184906;C1261082;C1551056;C3146289
2294,bifurcation  n ( % ),C0184906;C3146289
2294,bifurcation,C0184906;C3146289
2293,revascularisation but no antiplatelets  lipid - lowering agents  or p blockers,C0581603
2293,no revascularisation,C0581603
2293,carotid revascularization,C0581603;C0741968
2292,peripheral arterial revascularization,C0003842;C0205100;C0221464;C0581603
2292,arterial revascularization,C0003842;C0221464;C0581603
2291,with revascularisation,C0581603
2291,peripheral artery revascularization without amputation,C0002688;C0332840;C0489868;C0581603;C1546539
2290,revascularization,C0581603
2290,revascularisation  n ( % ),C0581603
2290,prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
2290,prior revascularization ( % ),C0332152;C0581603;C2826257
2290,prior revascularization,C0332152;C0581603;C2826257
2290,no prior revascularization ( n = $nmbr$  $nmbr$ ),C0332152;C0581603;C2826257
2289,urgent peripheral revascularization,C0205100;C0439609;C0581603;C3272275
2289,peripheral revascularisation,C0205100;C0581603
2289,any revascularization,C0581603
2289,any peripheral revascularization,C0205100;C0581603
2288,• urgent coronaiy revascularization > $nmbr$ days,C0439228;C0439609;C0581603;C3272275
2288,revascularization in $nmbr$ days,C0439228;C0581603
2288,$nmbr$ days urgent revascularization,C0439228;C0439609;C0581603;C3272275
2287,patients with > $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030673;C4086268
2286,patients with > $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268
2286,patients with > $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268
2286,patients with > $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268
2286,> $nmbr$ exacerbations,C4086268
2286,$ $nmbr$ exacerbations,C4086268
2285,median time to first exacerbation ( months [ $nmbr$ % ci ] ),C0008107;C0205435;C0549183;C0556969;C0876920;C1279901;C2347635;C2348144;C2939193;C3259781;C4086268
2285,$nmbr$ exacerbation,C4086268
2284,number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C4086268
2284,number of exacerbations in the last $nmbr$ months  mean ± sd,C0237753;C0449788;C4086268
2284,number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C4086268
2284,number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C4086268
2284,number of exacerbations in last $nmbr$ months,C0237753;C0449788;C4086268
2284,number of exacerbations $nmbr$ months before randomisation,C0237753;C0439231;C0449788;C4086268
2284,number of exacerbation in the previous $nmbr$ months  n ( % ),C0237753;C0449788;C4086268
2284,exacerbation historyh  n ( % ),C4086268
2283,number of exacerbations in previous year  mean ( sd ),C0237753;C0449788;C4086268
2283,number of exacerbations in previous $nmbr$   months,C0237753;C0449788;C4086268
2283,number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C4086268
2283,number of exacerbations,C0237753;C0449788;C4086268
2283,mean number of exacerbations in previous y ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2283,mean number of exacerbations in previous $nmbr$ months ( sd ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2283,mean number of exacerbations ( per patient - year [ $nmbr$ % ci ] ),C0237753;C0444504;C0449788;C2347634;C2348143;C4086268
2283,$nmbr$ exacerbations,C4086268
2282,no . of exacerbations in past year,C4086268
2282,exacerbations requiring oral steroids / antibiotics ( past year ) ( % ),C4086268
2282,exacerbations requiring hospitalisation ( past year ) ( % ),C4086268
2282,exacerbations in past $nmbr$ mo — no . ( % ),C0026544;C0332177;C1444637;C4086268;C4284302
2281,exacerbations in previous $nmbr$ mo ( n )  mean ( sd ),C0026544;C0205156;C0332177;C0444504;C1552607;C2347634;C2348143;C2699239;C4086268
2281,exacerbations,C4086268
2281,exacerbation within previous $nmbr$ mo  no . ( % ),C0026544;C0205156;C0332177;C1552607;C4086268
2281,exacerbation within $nmbr$ mo  %,C0026544;C0332177;C4086268
2280,cornell voltage - duration product ( mmxmsec ) *,C0449238;C0598352;C1514468;C1704444;C2926735
2279,mean duration of pd  yr,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C4553228;C4553229
2279,duration of pd  y,C0449238;C2926735;C4553228;C4553229
2278,ed duration  visit $nmbr$ * *,C0449238;C0545082;C1512346;C2826704;C2926735;C3538926
2278,ed duration,C0449238;C2926735;C3538926
2277,duration of diabetes mellitus  y  mean ( sd ) §,C0011849;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
2277,duration of diabetes mellitus  y,C0011849;C0449238;C2926735
2277,duration of diabetes mellitus  median ( iqr )  y,C0011849;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
2277,duration of diabetes mellitus,C0011849;C0449238;C2926735
2277,diabetes mellitus duration ( sd )  y,C0011849;C0449238;C2699239;C2926735
2277,diabetes mellitus duration  y ( sd ),C0011849;C0449238;C2699239;C2926735
2277,diabetes mellitus duration  y,C0011849;C0449238;C2926735
2276,median crohn ' s disease duration  y ( range ),C0010346;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C3542016
2276,duration of crohn ’ s disease ( yrs ),C0010346;C0449238;C2926735
2276,duration of crohn ' s disease ( yrs ),C0010346;C0449238;C2926735
2276,crohn ' s disease duration,C0010346;C0449238;C2926735
2275,median ( range ) duration of asthma ( years ),C0004096;C0439234;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
2275,median ( range ) duration of asthma ( y ),C0004096;C0449238;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2926735;C2939193;C2984299;C3542016
2275,duration of asthma — yr,C0004096;C0439234;C0449238;C2926735;C2984299
2275,duration of asthma > $nmbr$ years,C0004096;C0439234;C0449238;C2926735;C2984299
2275,duration of asthma ( years ),C0004096;C0439234;C0449238;C2926735;C2984299
2275,duration of asthma  years,C0004096;C0439234;C0449238;C2926735;C2984299
2275,duration of asthma  y,C0004096;C0449238;C2926735;C2984299
2275,duration of asthma,C0004096;C0449238;C2926735;C2984299
2274,duration of infusion — hr,C0449238;C0574032;C1827465;C2926735
2274,duration of infusion during medical management — hr,C0449238;C0574032;C1827465;C2926735
2274,duration of infusion before pci — hr,C0449238;C0574032;C1827465;C2926735
2274,duration of infusion before cabg — hr,C0449238;C0574032;C1827465;C2926735
2274,duration of infusion after pci — hr,C0449238;C0574032;C1827465;C2926735
2273,duration of hypertension ( years ),C0020538;C0439234;C0449238;C1963138;C2926735
2273,duration of hypertension ( months ),C0020538;C0439231;C0449238;C1963138;C2926735
2273,duration of hypertension  y,C0020538;C0449238;C1963138;C2926735
2273,duration of hypertension  n ( % ),C0020538;C0449238;C1963138;C2926735
2273,duration of,C0449238;C2926735
2272,weight  kg duration of pah  n ( % ),C0005910;C0022718;C0030123;C0043100;C0439209;C0449238;C1305866;C1705104;C2926735;C3203102;C4054209;C4284467
2272,duration of as  n ( % ),C0449238;C2926735
2271,pci duration in min ( median  iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
2271,pci duration,C0449238;C2926735;C4049621
2271,duration of pci — min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2271,duration of pci ( min )  median n ( iqr ),C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
2271,duration of pci ( min )  median,C0449238;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2926735;C2939193;C3813700;C4049621
2271,duration of pci  min,C0449238;C0702093;C1524029;C2926735;C3813700;C4049621
2270,psa duration ( years )  mean ( sd ),C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3810537;C3813209
2270,psa duration ( years ),C0439234;C0449238;C2926735;C3810537;C3813209
2270,psa duration  years,C0439234;C0449238;C2926735;C3810537;C3813209
2270,duration since diagnosis ( years ),C0449238;C2926735
2269,median duration oftype $nmbr$ diabetes ( iqr ) — yr,C0011847;C0011849;C0439234;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
2269,duration — yr,C0439234;C0449238;C2926735
2269,duration ofdiabetes — yr,C0439234;C0449238;C2926735
2269,duration of diabetes — yr ^,C0011847;C0011849;C0439234;C0449238;C2926735
2269,duration of diabetes — yr,C0011847;C0011849;C0439234;C0449238;C2926735
2268,mean ± s . d . duration of diabetes  years,C0011847;C0011849;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
2268,duration of rat  years,C0034693;C0034721;C0439234;C0449238;C2926735
2268,duration of epilepsy  years  mean ( sd ),C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
2268,duration of epilepsy  years,C0014544;C0439234;C0449238;C2926735
2268,duration of epilepsy  mean ( sd )  years,C0014544;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
2268,duration of diabetes > $nmbr$ years,C0011847;C0011849;C0439234;C0449238;C2926735
2268,duration of diabetes  years,C0011847;C0011849;C0439234;C0449238;C2926735
2268,duration of as  years,C0449238;C2926735
2268,duration,C0449238;C2926735
2267,known duration of diabetes  yr,C0011847;C0011849;C0205309;C0439234;C0449238;C2926735
2267,known duration,C0205309;C0449238;C2926735
2266,psoriasis duration ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
2266,psoriasis duration  yrs *,C0033860;C0449238;C2926735
2266,psoriasis duration  years,C0033860;C0439234;C0449238;C2926735
2266,duration of psoriasis ( years )  mean ( sd ),C0033860;C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
2266,duration of psoriasis  years,C0033860;C0439234;C0449238;C2926735
2265,t $nmbr$ dm duration ( years ),C0011816;C0439234;C0449238;C2603360;C2926735;C3250443
2265,t $nmbr$ dm duration  y,C0011816;C0449238;C2603360;C2926735;C3250443
2265,mean ( sd ) duration of t $nmbr$ dm  y,C0011816;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3250443
2265,mean ( s . d . ) duration of t $nmbr$ dm  years,C0011816;C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3250443
2265,known duration of t $nmbr$ dm  y,C0011816;C0205309;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm > $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm < $nmbr$ years,C0011816;C0439234;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm ( % ),C0011816;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm  years,C0011816;C0439234;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm  y,C0011816;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ dm,C0011816;C0449238;C2926735;C3250443
2265,duration of t $nmbr$ d  y,C0449238;C2926735
2265,duration of dm - years,C0011816;C0439234;C0449238;C2926735;C3250443
2265,duration dm in dm ( years ),C0011816;C0439234;C0449238;C2926735;C3250443
2265,dm duration  years,C0011816;C0439234;C0449238;C2926735;C3250443
2265,dm duration,C0011816;C0449238;C2926735;C3250443
2264,pvaluefor interaction $nmbr$ - $nmbr$,C1704675
2264,p value for interaction - dosage with dabigatran  $nmbr$ mg,C0178602;C1704675;C1709380;C2986497
2264,p - value for interaction $nmbr$ :,C1704675;C1709380
2264,interaction p vaiue,C1704675
2264,interaction p - vaiue,C1704675
2263,interaction j $nmbr$ - valuet,C1704675
2263,age - interaction,C0001779;C1704675
2262,rvalue for interaction,C1704675
2262,p value for interaction ® vertebral fracture at flex baseline :,C0080179;C1704675;C1709380
2262,p value for interaction ®,C1704675;C1709380
2262,p value for interaction by region,C1704675;C1709380
2262,p value for interaction ^,C1704675;C1709380
2262,lue for interaction,C1704675
2261,p interaction women vs men,C0043210;C0369773;C1704675;C2603361
2261,p interaction,C0369773;C1704675;C2603361
2261,p for interaction between rhtn and no rhtn and treatmenta,C0369773;C1704675;C2603361
2261,p for interaction *,C0369773;C1704675;C2603361
2261,p for interaction,C0369773;C1704675;C2603361
2261,p : interaction,C0369773;C1704675;C2603361
2261,p - interaction,C0369773;C1704675;C2603361
2261,p $nmbr$ interaction women vs men,C0043210;C0369773;C1704675;C2603361
2261,interaction p - valuef,C1704675
2261,interaction - p,C1704675
2260,albuminuria_p_interaction,C0001925;C1704675
2259,time to randomisation [ hours ] ( interaction : p = $nmbr$ . $nmbr$ ),C0034656;C0040223;C0439227;C1704675;C3541383
2259,interaction p = $nmbr$ . $nmbr$,C1704675
2258,yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005910;C0022718;C0043100;C0439209;C1305866;C1549445;C1704675;C1705104;C1705108;C1710701;C4054209
2258,interaction p,C1704675
2257,test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
2257,test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C1704675;C3831328;C4318744
2257,interaction,C1704675
2256,interaction $nmbr$,C1704675
2256,adjusted for all baseline variables  interaction between acei and baseline up  and declines in sbp and up,C0168634;C0439828;C0456081;C1442488;C1704675
2255,interaction : treatment by psoriasis p valueb,C1704675;C3258078
2254,interaction pf,C1704675;C3815179
2253,egfr_p_interaction,C1704675;C1739039;C3811844;C3812682
2253,/ ’ interaction,C1704675
2252,haemodynamics and lv function,C0019010;C4281788
2251,normal renal function,C0232805
2250,deterioration in renal function ( investigator reported ),C0035173;C0232804;C0868945
2249,renal function : ! : n ( % ),C0232804
2249,baseline renal function ( eclcr ),C0168634;C0232804;C1442488
2248,renal function ( ml / min ),C0232804;C0439445
2248,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
2248,renal function ( egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  according to mdrd )  n ( % ),C0232804;C0369637;C0439445;C0441923;C0680240;C1739039;C3811844;C3812682;C3839656
2247,renal function  severe,C0232804
2247,renal function  moderate,C0232804
2247,renal function  bn ( % ),C0005005;C0034700;C0232804;C1706574;C4551963
2246,renal functionb,C0022646
2246,renal functiona,C0022646
2246,outcome according to renal function level ( in ml / min ),C0022646;C0232804;C0441889;C0456079;C0680240;C0935587;C1274040;C1547707;C2946261
2245,renal function : creatinine clearance,C0232804;C0812399
2245,renal function *,C0232804
2244,renal function,C0232804
2244,estimated gfr renal function stage,C0017654;C0205390;C0232804;C0750572;C1300072;C1306673;C1424601
2243,erectile dysfunction,C0242350;C1961100
2242,right ventricular dysfunction — no . / total no . ( % ) §,C0242707;C1556315
2242,right ventricular dysfunction  n / n ( % ) j,C0242707;C1556315
2241,severe dysfunction,C3274777
2240,moderate dysfunction ( crcl $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274776
2240,moderate dysfunction,C3274776
2239,elective procedure,C0747973
2238,duration of procedure,C2346509
2237,ejection fraction : < $nmbr$ % ( n = $nmbr$ ),C0489482;C2700378
2237,ejection fraction ( % ),C0489482;C2700378
2237,ejection fraction  percent ( sd ),C0439165;C0489482;C2699239;C2700378
2237,ejection fraction  % nyha class  n ( % ),C0489482;C1882083;C2700378
2237,ejection fraction  %,C0489482;C2700378
2236,ejection fraction group,C0441833;C0489482;C0687744;C1257890;C1519504;C1705428;C1705429;C2700378
2236,ejection fraction based on local reading,C0489482;C2700378
2235,lv ejection fraction  mean ( sd ) [ range ]  %,C0023128;C0444504;C0489482;C0731033;C1514721;C1881413;C2347634;C2348143;C2348147;C2699239;C2700378;C3542016
2235,ejection fraction — mean ± sd,C0444504;C0489482;C2347634;C2348143;C2699239;C2700378
2235,ejection fraction *,C0489482;C2700378
2235,ejection fraction ( mean ),C0444504;C0489482;C2347634;C2348143;C2700378
2235,ejection fraction,C0489482;C2700378
2234,functional outcome ( mrs $nmbr$ - $nmbr$ ),C0205245;C0542341;C1274040;C1522706;C2349188;C2700217;C3714939;C3854213
2233,nyha functional class i,C0205245;C0542341;C1882084;C2700217
2232,nyha functional classification — no . ( % ) i,C0205245;C0542341;C1275491;C2700217
2232,nyha functional classification — no . ( % ),C0205245;C0542341;C1275491;C2700217
2231,who functional class — no . ( % ) : c,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
2231,who functional class,C0205245;C0456387;C0542341;C1518526;C1705943;C2700217
2231,ara functional class — no . ( % ),C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
2231,ara functional class,C0205245;C0325983;C0456387;C0542341;C1518526;C1705943;C2316832;C2700217;C3890184;C4282437;C4321455
2230,social functioning,C0037395
2230,social function,C0037395
2229,physical function ( $nmbr$ - $nmbr$  short form - $nmbr$ subscale ),C0031843;C0348078;C0376315;C0516981;C0542341;C0597240;C0700205;C0700329;C1282927;C1522492;C1705273;C1806781;C2350002;C2964478;C4049916;C4255237
2229,lv function > $nmbr$ . $nmbr$ and < $nmbr$ . $nmbr$  n ( % ) medications  n ( % of patients ),C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
2229,lv function,C0023128;C0031843;C0542341;C0700205;C0731033;C1705273;C1881413
2229,function subscale,C0031843;C0542341;C0700205;C1705273
2229,erectile function  ipss,C0030847;C0031843;C0542341;C0700205;C1019118;C1705273;C1998280;C2827405;C3811063
2229,emotional function,C0013987;C0031843;C0542341;C0700205;C0849912;C1705273
2229,dysfunction  ef = erectile function  iief = i,C0021966;C0030847;C0031843;C0031847;C0221138;C0277785;C0542341;C0700205;C1705273;C3641331;C3887504;C3887505
2228,predictive factor,C0683956
2227,stratification factors,C1514984
2227,stratification factor : menopausal status  n ( % ),C1513126;C1514984
2226,temporary factors,C0205374;C1521761;C1548539;C2827422;C3245481
2226,factors that confer a,C1521761;C2827422
2225,factor at baseline,C0168634;C1442488;C1521761;C2827422
2225,factor,C1521761;C2827422
2225,baseline factor,C0168634;C1442488;C1521761;C2827422
2224,risk factor for venous thromboembolism  no . ( % ),C1521761;C2827422;C3495424;C3496592
2223,factor present,C0150312;C0449450;C1521761;C2827422
2223,factor absent,C1521761;C2827422
2222,hospital factor # $nmbr$,C0019994;C1510665;C1521761;C2827422
2222,factor *,C1521761;C2827422
2221,factor xa inhibitor,C2825027;C4553708
2220,factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419
2220,factor v leiden ( % ),C0380964;C0584960;C1414509;C3542419
2219,fevi reversibility — %,C3830088
2218,pre - bronchodilator fevi / fvc  %,C0802741;C2599602;C3815113
2217,mean ( sd ) fevi / fvc  %,C0444504;C0802741;C2347634;C2348143;C2699239;C3815113
2217,fevi / fvc ( % ),C0802741;C3815113
2216,safety variable,C0036043;C0439828;C1705187;C4553760
2216,safety    n   ( % ) b,C0036043;C1705187
2216,safety  %,C0036043;C1705187
2215,severity ofhypertension [ n ( % ) ] b,C0439793;C0522510
2215,severity of hypertensionb,C0439793;C0522510
2215,hypertension severity,C0020538;C0439793;C0522510;C1963138
2214,severity n ( % ),C0439793;C0522510
2214,ed severity * *  n ( % ) :,C0439793;C0522510;C3538926
2214,ed severity  no . ( % ) a,C0439793;C0522510;C3538926
2213,severity of heartburnb,C0439793;C0522510
2213,severity of copda  combined assessment of copd  n ( % ),C0439793;C0522510
2213,severity of copd — no . ( % ) f,C0024117;C0439793;C0522510;C1412502;C3714496
2213,severity of copd *  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
2213,severity of copd  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
2213,severity of copd  n ( % ) ( gold $nmbr$ ) : moderate,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2213,severity of copd  combined assessment  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
2213,severity of copd  ( gold $nmbr$ )  %,C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2213,severity of copd,C0024117;C0439793;C0522510;C1412502;C3714496
2213,nice classification of copd severity of obstruction  n ( % ) [ $nmbr$ ],C0008902;C0008903;C0024117;C0028778;C0439793;C0522510;C0678229;C1412502;C1882136;C3714496;C4087029
2213,copd severity stage ( gold ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
2213,copd severity : severe / very severe,C0024117;C0439793;C0442824;C0522510;C1412502;C2984081;C3714496
2213,copd severity : mild / moderate,C0024117;C0439793;C0522510;C1412502;C3714496
2213,copd severity ( gold stage ),C0018026;C0024117;C0205390;C0439793;C0522510;C1300072;C1304897;C1306673;C1412502;C3714496
2213,copd severity ( gold $nmbr$ ),C0018026;C0024117;C0439793;C0522510;C1304897;C1412502;C3714496
2213,copd severity  n ( % ) a,C0024117;C0439793;C0522510;C1412502;C3714496
2213,copd severity  n ( % ) *,C0024117;C0439793;C0522510;C1412502;C3714496
2213,copd severity  n ( % ),C0024117;C0439793;C0522510;C1412502;C3714496
2213,copd severity  %,C0024117;C0439793;C0522510;C1412502;C3714496
2213,copd severity,C0024117;C0439793;C0522510;C1412502;C3714496
2212,severity of copda  airflow limitation  n ( % ),C0231999;C0439793;C0443288;C0449295;C0522510
2212,severity of copd  airflow limitation  n ( % ),C0024117;C0231999;C0439793;C0443288;C0449295;C0522510;C1412502;C3714496
2212,severity of airflow obstruction,C0028778;C0231999;C0439793;C0522510;C1882136
2212,severity of airflow limitation,C0231999;C0439793;C0443288;C0449295;C0522510
2211,nocturnal heartburn severity,C0018834;C0240526;C0439793;C0522510
2211,heartburn severity during the run - in periodt,C0018834;C0439793;C0522510;C3274438
2210,luts severity,C0439793;C0522510;C0574785
2210,bph - luts severity,C0005001;C0439793;C0522510;C0574785;C1704272
2209,severity,C0439793;C0522510
2209,baseline luts severity * :,C0168634;C0439793;C0522510;C0574785;C1442488
2209,baseline luts severity  n ( % ) :,C0168634;C0439793;C0522510;C0574785;C1442488
2209,baseline heart failure severity amongthose with priorheartfailure  %,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C4554158
2209,baseline ed severity * * :,C0168634;C0439793;C0522510;C1442488;C3538926
2209,any severity,C0439793;C0522510
2208,statin intensity $nmbr$ * $nmbr$,C0360714;C0522510
2208,intensity $nmbr$,C0522510
2208,baseline statin intensity,C0168634;C0360714;C0522510;C1442488
2207,lowzmedium intensity,C0522510
2207,intensive therapy ( n = $nmbr$ ),C0039798;C0087111;C0162425;C0522510;C1283828;C1363945;C1550453
2207,intensive glycemia lowering,C0005802;C0162425;C0441994;C0522510;C1283828;C1550453;C2003888
2207,intensive ( n = $nmbr$ ),C0162425;C0522510;C1283828;C1550453
2206,intense physical activity,C0015259;C0026606;C0522510
2206,intense,C0522510
2205,mean ( sd ) esr  mm / h *,C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
2205,esr ( mm / h )  mean ( sd ),C0444504;C0456680;C2347634;C2348143;C2699239;C3811131
2205,esr ( mm / h ),C0456680;C3811131
2204,esr  mean ± sd mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239;C3811131
2204,esr,C3811131
2203,gene / chr / snp,C0017337;C0043459;C0752046;C1527094;C1861559;C3890034;C4050175
2203,gene,C0017337
2202,concomitant use of bosentan  n ( % ),C0252643;C0521115;C1524063
2202,bosentan ( n = $nmbr$ ),C0252643
2202,bosentan,C0252643
2201,country : argentina ( n = $nmbr$ ),C0003761;C0454664;C1504311;C1511538
2201,argentina,C0003761;C1504311
2200,unadjusteda beta ( se ),C0036919;C0330390;C0439096;C2004068
2200,beta bloekers,C0330390;C0439096;C2004068
2200,beta $nmbr$ selective,C0330390;C0439096;C2004068
2200,adjustedb  c beta ( se ),C0036919;C0330390;C0439096;C2004068
2199,ni,C0028075;C2348274;C3869926;C3869927
2199,> $nmbr$ ml / niin / l $nmbr$ ni -,C0028075;C1635169;C2348274;C3869926;C3869927
2199,< $nmbr$ ml / min / $nmbr$ . $nmbr$ ni -,C0028075;C0439445;C2348274;C3869926;C3869927
2198,phosphatase  mean ( sd )  ng / ' mlf,C0017887;C0028074;C0031678;C0066495;C0444504;C1149880;C2347634;C2348143;C2699239;C4522024
2198,ng ( n = $nmbr$  $nmbr$ ),C0017887;C0028074
2198,ng,C0017887;C0028074
2197,nt - probnp $nmbr$ pmol - l - $nmbr$,C0439284;C0669479;C0754710
2197,nt - probnp  pmol / l ^,C0439284;C0669479;C0754710
2197,nt - probnp  pmol / l,C0439284;C0669479;C0754710
2196,nt - pro bnp,C0669479;C0754710
2196,nt - pro - bnp — pmol / literf,C0439192;C0669479;C0754710
2196,nt - pro - bnp — pmol / liter - j -,C0439192;C0475211;C0669479;C0754710
2196,nt - pro - bnp,C0669479;C0754710
2195,ntprobnp ( pg / ml ),C0439297;C0669479;C0754710
2195,nt - probnp — pg / ml * *,C0439297;C0669479;C0754710
2195,nt - probnp — pg / ml,C0439297;C0669479;C0754710
2195,nt - probnp ( pg / ml ) h,C0030827;C0033727;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C0669479;C0754710;C1266240;C1705224;C2827929;C3887665;C4528284
2195,nt - probnp ( pg / ml ) ( q $nmbr$ - q $nmbr$ ),C0439297;C0669479;C0754710
2195,nt - probnp ( pg / ml ),C0439297;C0669479;C0754710
2195,nt - probnp  pg / ml,C0439297;C0669479;C0754710
2195,nt - probnp  median pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
2195,nt - probnp  median ( iqr )  pg / ml,C0439297;C0549183;C0669479;C0754710;C0876920;C2347635;C2348144;C2939193
2195,n - terminal pro - bnp — pg / ml §,C0439297;C0669479
2194,no smo king,C1311076;C1364142;C1423784
2193,no po,C0032729;C0442027
2192,no . of infusions,C0574032
2192,median infusions — no . ( range ),C0549183;C0574032;C0876920;C2347635;C2348144;C2939193
2191,acarbose 一 no . ( % ),C0050393
2190,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631
2189,no . fingernails,C0222001
2188,anterior myocardial infarction — no . / total no . ( % ),C0340293
2188,anterior myocardial infarction — no . ( % ),C0340293
2187,septal anomaly — no . ( % ),C0332447;C0442004;C1704258
2186,lone atrial fibrillation — no . ( % ) §,C0340489
2185,tics — no . ( % ),C0040188;C0278076;C2169806;C3889970
2184,p . b “ int,C1539794;C3272375
2184,p . b * int,C1539794;C3272375
2184,int . p *,C3272375
2183,voiding subscore,C0042034;C4067975
2182,vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
2181,sitting systolic blood pressure ( mm hg ),C0277814;C2584297;C4050224
2181,sitting pulse  bpma,C0232117;C0277814;C0391850;C1947910;C2584297;C4050224
2180,walking,C0080331;C4283795;C4321241;C4321242
2179,fasting blood glucose > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0428568;C0439269;C1261430;C1532563
2179,fasting blood glucose > $nmbr$ mg / dl,C0428568;C0439269;C1261430
2179,fasting blood glucose ( mg / dl ),C0428568;C0439269;C1261430
2179,fasting blood glucose  mean ( sd )  mg / dlt,C0024671;C0026410;C0428568;C0439269;C0444504;C1261430;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
2179,fasting blood glucose,C0428568;C1261430
2178,missing hb at yr $nmbr$,C0019046;C0439234;C1551393;C1705492;C3272743
2177,missing *,C1551393;C1705492;C3272743
2177,data missing or no drug given,C1511726;C1551393;C1705492;C3245479;C3272743;C3714741
2176,missing ed duration ( y ),C0449238;C1551393;C1705492;C2926735;C3272743;C3538926
2176,missing  n ( % ) a,C1551393;C1705492;C3272743
2175,other / missing,C1551393;C1705492;C3272743
2175,missing — number / n ( % ),C0237753;C0449788;C1551393;C1705492;C3272743
2175,missing,C1551393;C1705492;C3272743
2174,additional radiographic findings at week $nmbr$,C0332174;C0439230;C0444708;C1524062;C2607943;C2926606;C3539655
2173,angiographic findings | |,C0002978;C2607943;C2926606;C3539655
2172,electrocardiographic findings — no . ( % ),C0438154
2172,ecg findings at baseline — no . ( % ),C0168634;C0438154;C1442488
2172,ecg findings,C0438154
2171,coping,C0009967
2170,current cigarette smoking  no . ( % ),C0239059;C0521116;C0700219;C1705970
2170,current cigarette smoking,C0239059;C0521116;C0700219;C1705970
2170,cigarette smoking  n ( % ),C0239059;C0700219
2170,cigarette smoking,C0239059;C0700219
2169,use of compression stockings  no . ( % ),C0038348;C1524063
2169,compression stockings,C0038348
2168,smoking status — no . { % ),C1519386
2168,smoking status — no . ( % ),C1519386
2168,smoking status . no . ( % ),C1519386
2168,smoking status ( % ),C1519386
2168,smoking status  no . ( % ),C1519386
2168,smoking status,C1519386
2168,cigarette smoking status,C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2168,cigarette - smoking status — no . ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2168,cigarette - smoking status ( % ),C0239059;C0449438;C0677453;C0700219;C1519386;C1704760;C3890423
2167,smoking status current,C0521116;C1519386;C1705970
2167,smoking status  n [ % ] ®,C1519386
2166,smoking status *,C1519386
2166,smoking status ( ongoing ) ( n ),C0549178;C1519386
2165,smoking status  n ( % ) former,C1519386
2165,smoking status  n ( % ) *,C1519386
2165,smoking status  n ( % ),C1519386
2165,baseline smoking status,C0168634;C1442488;C1519386
2164,smoking status at screening  n ( % ),C0037369;C0220908;C0220909;C0421330;C0453996;C1519386;C1698960;C1710031;C1710032;C1710477;C1881674;C2348164
2164,smoking classification  n ( % ),C0008902;C0008903;C0037369;C0453996;C0678229;C1881674
2164,smoking ( ever ),C0037369;C0453996;C1881674
2164,smoking ( current ),C0037369;C0453996;C0521116;C1705970;C1881674
2164,smoking ( % ),C0037369;C0453996;C1881674
2164,smoking  n ( % ),C0037369;C0453996;C1881674
2164,current smoking ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
2163,smoking  mean,C0037369;C0444504;C0453996;C1881674;C2347634;C2348143
2163,smoking,C0037369;C0453996;C1881674
2163,mean ( sd ) duration of smoking  pack years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
2163,cigarette smoking  mean pack - years ( sd ),C0037369;C0444504;C0453996;C1303175;C1881674;C2347634;C2348143;C2699239
2162,smoking — current,C0037369;C0453996;C0521116;C1705970;C1881674
2162,smoking : current smoker,C0037369;C0453996;C1881674
2162,smoking *,C0037369;C0453996;C1881674
2162,no smoking,C0037369;C0453996;C1881674
2162,no current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
2162,current smoking — no . / total no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
2162,current smoking — no . ( % ),C0037369;C0453996;C0521116;C1705970;C1881674
2162,current smoking *,C0037369;C0453996;C0521116;C1705970;C1881674
2162,current smoking,C0037369;C0453996;C0521116;C1705970;C1881674
2161,smoking pack - yearsb  n ( % ),C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
2161,smoking pack - yearsa,C0037369;C0453996;C1881674;C1968515;C2825051;C2828395
2161,smoking index — pack - yr §,C0037369;C0439234;C0453996;C0600653;C0918012;C1552854;C1637833;C1881674;C1968515;C2825051;C2828395;C2986546
2161,smoking : ex - smoker,C0037369;C0453996;C1881674
2161,smoking  %,C0037369;C0453996;C1881674
2160,smoking pack year ( years ) fl,C0037369;C0439234;C0439508;C0453996;C1277691;C1300812;C1708024;C1881674
2160,smoking pack year ( years ) ^,C0037369;C0439234;C0439508;C0453996;C1277691;C1881674
2160,smoking ( a ),C0037369;C0453996;C1881674
2159,smoking ' ! ',C0037369;C0453996;C1881674
2158,smoking in the past year,C0037369;C0453996;C1881674;C4086728
2157,normal bnp  ^ $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205307;C0231683;C0439166;C0439297;C1095989;C1417808;C2347086;C2982014;C4553972
2157,nesiritide ( n = $nmbr$ ),C0054015
2157,nesiritide  % z,C0054015
2157,elevated bnp  > $nmbr$ pg / ml ( n = $nmbr$  $nmbr$ ),C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
2157,bnp indicates brain natriuretic peptide  and nyha  new york heart association .,C0054015;C1095989;C1417808;C2982014
2157,bnp / ntbnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
2157,bnp ( n = $nmbr$ ),C0054015;C1095989;C1417808;C2982014
2156,nptercile $nmbr$ ( bnp $nmbr$ - $nmbr$ pg / ml  nt - probnp $nmbr$ - $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0439297;C1095989;C1317554;C1417808;C2825907;C2982014;C4284038
2156,np tercile $nmbr$ ( bnp > $nmbr$ pg / ml  nt - probnp > $nmbr$  $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
2156,np tercile $nmbr$ ( bnp < $nmbr$ pg / ml  nt - probnp < $nmbr$ pg / ml ) ( n - $nmbr$ ),C0054015;C0065827;C0439297;C1095989;C1317554;C1417808;C1706141;C2825907;C2982014;C3887659;C4284038
2156,mean ( $nmbr$ th to $nmbr$ thquartile ) bnp ( pg / ml ),C0039725;C0039738;C0054015;C0439297;C0444504;C1095989;C1417808;C1420718;C2347634;C2348143;C2982014;C4282123;C4285344
2156,elevated bnp ( $nmbr$ pg / ml )  %,C0054015;C0205250;C0439297;C1095989;C1417808;C2982014;C3163633
2156,elevated bnp,C0054015;C0205250;C1095989;C1417808;C2982014;C3163633
2156,bnp — pg / ml  i,C0021966;C0023806;C0030827;C0054015;C0072225;C0221138;C0439297;C1095989;C1266240;C1417808;C2982014
2156,bnp — pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp o $nmbr$ pg / ml or nt pro - bnp o $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp > $nmbr$ pg / ml or nt pro - bnp > $nmbr$ pg / ml  n ( % ),C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp > $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp > $nmbr$ pg / ml  n   =   $nmbr$   $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp > $nmbr$ pg / ml  n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp < $nmbr$ pg / ml n = $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp / nt - probnp,C0054015;C0669479;C0754710;C1095989;C1417808;C2982014
2156,bnp ( pg / ml ) h,C0030827;C0033727;C0054015;C0072225;C0369286;C0439297;C0439391;C0439526;C0441932;C0564385;C1095989;C1266240;C1417808;C1705224;C2827929;C2982014;C3887665;C4528284
2156,bnp ( pg / ml ),C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp  pg / mlt,C0030827;C0054015;C0072225;C1095989;C1266240;C1417808;C2982014;C4553833
2156,bnp  pg / ml,C0054015;C0439297;C1095989;C1417808;C2982014
2156,bnp  median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
2156,bnp  * median ( iqr )  pg / ml,C0054015;C0439297;C0549183;C0876920;C1095989;C1417808;C2347635;C2348144;C2939193;C2982014
2156,bnp,C0054015;C1095989;C1417808;C2982014
2156,baseline bnp concentration ( pg / ml ),C0054015;C0086045;C0168634;C0439297;C1095989;C1417808;C1442488;C1446561;C2982014;C3827302
2155,antidiabetes drug usage [ % ( n ) ],C0242510
2154,nc group ( n = $nmbr$ ),C0027964;C0028407;C0067895;C0265987;C0441848
2154,nc,C0027964;C0028407;C0067895;C0265987
2153,type b $nmbr$ / c lesions  n ( % ),C4264484
2152,pulmonary embolismb  n / n ( % ),C0024109;C2707265;C2709248;C4522268
2152,pulmonary embolisma  n / n ( % ),C0024109;C2707265;C2709248;C4522268
2151,alprostadil n / n %,C0002335
2151,alprostadil n / n,C0002335
2151,alprostadil ( n = $nmbr$ ),C0002335
2150,inconsistent fao ( n [ $nmbr$ ),C0016457;C0442809
2149,notatincreased fall risk ( n - $nmbr$  $nmbr$ ),C1268740
2149,at increased fall risk ( n - $nmbr$ ),C0085639;C0205217;C0238715;C0442805;C1268740;C4553726;C4699158
2148,dpi ( other than diskus )  n,C1553480
2148,diskus only  n,C0205171;C1553480;C1720467
2147,self - reported descent  n ( % ),C0681906;C2700446
2146,no mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
2146,mvd ( n - $nmbr$  $nmbr$ ),C1417507;C3272839
2145,phi ( n = $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
2145,phi ( n - $nmbr$ ),C1333690;C1704947;C1706536;C2975867;C4084801
2145,pgi - s  n ( % ) y :,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
2144,canrenone ( n z $nmbr$ ),C0006882
2143,very elderly patients ( n - $nmbr$ ),C0442824;C0870602;C2984081
2143,elderly patients ( n — $nmbr$ ),C0870602
2142,remission at maintenance - trial entry — no . ( % ),C0008976;C0024501;C0544452;C0687702;C1705654
2142,maintenance use — no . ( % ),C0024501
2142,maintenance ocs use  n ( % ),C0024501
2141,ne,C0027608;C0028219;C3538705
2141,( ne  ne ),C0027608;C0028219;C3538705
2141,$nmbr$ . $nmbr$ ( ne  ne ),C0027608;C0028219;C3538705
2140,fluindione  no . ( % ),C0117899
2139,residual perfusion defect > $nmbr$ % on lung scan  no . ( % ),C1457869;C1518040;C1609982
2138,nos $nmbr$ $nmbr$ c . t  n ( % ),C0326287;C1518425
2138,nos $nmbr$ $nmbr$ a . g  n ( % ),C0326287;C1518425
2137,dopamine agonist use  no . ( % ),C0178601;C3536925
2136,pace  no . ( $nmbr$ ),C0287990;C1552930;C4048252
2135,yes  no,C1512698
2135,( yes / no ),C1512698
2134,n_,C0369718;C0441922
2134,n nt,C0332126;C0369718;C0441922;C1449832;C3889152;C4050156;C4283901;C4284038
2134,n / pyr,C0369718;C0441922
2134,n / n   ( % ),C0369718;C0441922
2134,n / n ( % ),C0369718;C0441922
2134,n / n,C0369718;C0441922
2133,other ( n — $nmbr$ ),C0369718;C0441922
2133,> $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
2133,> $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
2133,< $nmbr$ . $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
2133,< $nmbr$ ( n — $nmbr$ ),C0369718;C0441922
2133,< $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
2133,$nmbr$ to < $nmbr$ ( n z $nmbr$ ),C0369718;C0441922
2133,$nmbr$ n qi,C0369718;C0376586;C0441922
2132,≥ $nmbr$ a ( n = $nmbr$ ),C0369718;C0441922
2132,us n = $nmbr$,C0369718;C0441922
2132,us ( n = $nmbr$ ),C0369718;C0441922
2132,other ( n = $nmbr$  $nmbr$ ],C0369718;C0441922
2132,other ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
2132,none ( n = $nmbr$ ),C0369718;C0441922
2132,neither n = $nmbr$  $nmbr$,C0369718;C0441922
2132,n = $nmbr$ lesions,C0369718;C0441922
2132,n = $nmbr$,C0369718;C0441922
2132,n .,C0369718;C0441922
2132,n - $nmbr$ fatty acit,C0369718;C0441922
2132,n - $nmbr$ fatty acids slope lsm ± se ( mm / year ),C0015684;C0369718;C0441922
2132,n - $nmbr$ fatty acids ( n = $nmbr$ ),C0015684;C0369718;C0441922
2132,n - $nmbr$ fatty acids,C0015684;C0369718;C0441922
2132,n - $nmbr$ allocation,C0369718;C0441922;C1706778
2132,n $nmbr$ yrs,C0369718;C0441922
2132,all n = $nmbr$,C0369718;C0441922
2132,all ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0369718;C0441922
2132,all ( n = $nmbr$ ),C0369718;C0441922
2132,all ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
2132,a $nmbr$ n = $nmbr$,C0369718;C0441922
2132,a $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2132,> $nmbr$ ( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
2132,> $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2132,> $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
2132,< $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2132,< $nmbr$ % ( n = $nmbr$ ),C0369718;C0441922
2132,( n = l $nmbr$ ),C0369718;C0441922
2132,( n = $nmbr$ l $nmbr$ ),C0369718;C0441922
2132,$nmbr$ - $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2132,$nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2131,without ( n = $nmbr$ $nmbr$ ),C0369718;C0441922
2131,other * ( n = $nmbr$ ),C0369718;C0441922
2131,no ( n = $nmbr$ ),C0369718;C0441922
2131,no ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
2131,n - $nmbr$ pufa events / patients ( % ),C0030705;C0032615;C0369718;C0441471;C0441922;C3541888
2131,n - $nmbr$ pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
2131,n - $nmbr$ pufa,C0032615;C0369718;C0441922
2131,n - $nmbr$ - pufa ( n = $nmbr$ ),C0032615;C0369718;C0441922
2131,n + v ( n = $nmbr$ ),C0369718;C0441922
2131,n *,C0369718;C0441922
2131,all ( n = $nmbr$ * ),C0369718;C0441922
2131,( n = $nmbr$ ),C0369718;C0441922
2131,( n $nmbr$ $nmbr$ ),C0369718;C0441922
2131,$nmbr$ to < $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2131,$nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
2131,$nmbr$ ( n = $nmbr$  $nmbr$ ),C0369718;C0441922
2131,$nmbr$ ( n $nmbr$ $nmbr$ ),C0369718;C0441922
2131,$ $nmbr$ to  $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2131,$ $nmbr$ ( n = $nmbr$ ),C0369718;C0441922
2130,n / n $nmbr$ / $nmbr$,C0369718;C0441922
2130,n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo ),C0032042;C0369718;C0441922;C1319635;C1696465;C1706408;C1722260
2130,n $nmbr$ / n $nmbr$,C0369718;C0441922
2130,n $nmbr$,C0369718;C0441922
2130,$nmbr$ n / n,C0369718;C0441922
2129,n observed,C0369718;C0441922
2129,n events / n subjects,C0369718;C0441471;C0441922;C3541888
2129,n events / n at risk,C0369718;C0441471;C0441922;C3541888
2129,n analysed,C0369718;C0441922
2129,n,C0369718;C0441922
2128,n o diabetes,C0011847;C0011849;C0369718;C0441922
2128,n o,C0369718;C0441922
2127,with ( n = $nmbr$ ),C0369718;C0441922
2127,other { n = $nmbr$ ),C0369718;C0441922
2127,other ( n   = $nmbr$ ),C0369718;C0441922
2127,other ( n = $nmbr$ ),C0369718;C0441922
2127,n = $nmbr$ t,C0369718;C0441922
2127,n =,C0369718;C0441922
2127,all n = $nmbr$ $nmbr$,C0369718;C0441922
2127,all n = $nmbr$  $nmbr$,C0369718;C0441922
2127,all ( n = $nmbr$ f ),C0016327;C0369718;C0441922
2127,( n = ms ),C0369718;C0441922;C2349943;C3539704;C3713294
2127,( n = $nmbr$ ) ( n = $nmbr$ ),C0369718;C0441922
2127,( n = $nmbr$ )  ' ( n = $nmbr$ ),C0369718;C0441922
2127,( n = $nmbr$,C0369718;C0441922
2126,n ( stented lesions ),C0369718;C0441922
2126,n ( lesions ),C0369718;C0441922
2126,n ( iqr ),C0369718;C0441922
2126,n ( % ) blood pressure - mean ( sd ) mm hg,C0369718;C0428886;C0439475;C0441922;C2699239
2125,other n ( % ),C0369718;C0441922
2125,other ( n  % ),C0369718;C0441922
2125,other  n ( % ),C0369718;C0441922
2125,n t % ),C0369718;C0441922
2125,n ( % ) unless otherwise specified,C0369718;C0441922
2125,n ( % ) responders,C0369718;C0441922
2125,n ( % ),C0369718;C0441922
2125,n %,C0369718;C0441922
2125,> $nmbr$ . $nmbr$  n ( % ),C0369718;C0441922
2125,> $nmbr$ %  n ( % ),C0369718;C0441922
2125,> $nmbr$  n ( % ) gender  n ( % ),C0079399;C0369718;C0441922;C1522384
2125,> $nmbr$  n ( % ),C0369718;C0441922
2125,< $nmbr$ %  n ( % ),C0369718;C0441922
2125,< $nmbr$  n ( % ),C0369718;C0441922
2125,$ $nmbr$ %  n ( % ),C0369718;C0441922
2124,alleles,C0002085
2123,platelet aggregation inhibitors excluding heparin,C0032177
2123,platelet aggregation inhibitors  n ( % ),C0032177
2122,glomerular,C0022663;C0268731
2121,glomerular filtration rate §,C0017654;C1561549
2121,glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ ma,C0017654;C0024443;C0439445;C1561549;C3887485
2120,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C3811844
2120,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area §,C0017446;C0205146;C0369637;C0439445;C0441923;C0489451;C3811844
2120,estimated glomerular filtration rate §,C3811844
2120,estimated glomerular filtration rate ^,C3811844
2119,atrial flutter,C0004239;C0344423;C1963068
2118,atrial flutter / fibrillation,C0155709
2118,atrial fibrillation / flutter  n ( % ),C0155709
2118,atrial fibrillation / flutter,C0155709
2118,atrial fibrillation / atrial flutter  %,C0155709
2117,history of atrial fibrillation / flutter  ( % ),C0016385;C0232197;C0729790;C1998417;C2242390
2117,fibrillation / flutter ),C0016385;C0232197;C2242390
2117,arial flutter or fibrillation,C0016385;C2242390
2116,cluster seizures,C0036572;C1555715;C1704332
2116,cluster $nmbr$ : reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
2116,cluster $nmbr$ : not reversible  no diuretic ( n = $nmbr$ ),C1555715;C1704332
2116,cluster $nmbr$ : diuretic ( n = $nmbr$ ),C1555715;C1704332
2115,lung neoplasm malignant,C0024121
2114,lung infection,C0876973;C4552950
2113,lung,C0024109
2113,high - probability ventilation / perfusion lung scanning,C0024109;C0560738;C4699572
2112,repaired congenital shunts,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
2112,repaired congenital shunt,C0009678;C0205340;C0232180;C0542331;C1442858;C1744681
2112,congenital shunts,C0009678;C0232180;C0542331;C1442858;C1744681
2112,assoc  with corrected congenital shunts,C0009678;C0205202;C0232180;C0542331;C1442858;C1744681
2111,pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
2111,pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C0549177;C1442858
2111,large shunt,C0232180;C0542331;C0549177;C1442858
2110,urgent revascularization because of unstable angina,C0002965;C0439609;C0581603;C3272275
2110,urgent revascularizati on,C0439609;C3272275
2109,recent surgery or trauma,C0038894;C0038895;C0332185;C0543467;C1274039
2109,recent,C0332185
2108,prevalence of each metabolic syndrome criterion,C0033105;C0220900;C0243161;C0524620
2107,prevalent cvd,C0007222;C0033105;C0220900
2106,fracture status prevalent vertebral fractured,C0016658;C0033105;C0220900;C0449438;C0549207;C4554413
2105,pregnancy,C0032961
2104,stool frequency subscore,C0015733;C0183622;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
2103,legend,C2729544
2102,any dynamic st - segment shift,C0333051;C0429029;C0729333;C2347509
2101,czech repumc,C0337799
2100,surgical repair of vsd or pda > $nmbr$ - year duration,C0018818;C0374711
2099,valve replacement / repair with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
2099,valve repair / replacement with or without cabg,C0035139;C0043240;C0184252;C0374711;C0559956;C1186983;C1555302;C1704414;C3888056;C4319951;C4553149
2099,valve repair / replacement only,C0035139;C0043240;C0184252;C0205171;C0374711;C0559956;C1186983;C1555302;C1704414;C1720467;C3888056;C4319951;C4553149
2098,puerperium,C0034042;C0086839;C1879329
2097,rectum and sigmoid colon only,C0034896
2097,rectum,C0034896
2096,values were calculated using t tests for continuous variables and chi - square,C0042295
2096,* plus - minus values are means ± sd . there were no significant differences ( at,C0042295;C0332288
2095,tg  triglycerides . * median values ( standard deviation for medians ) .,C0041004;C0042295;C0399532;C0549183;C1442989;C2828392
2095,( $nmbr$ . $nmbr$ % )  values were not collected for $nmbr$ patients ( $nmbr$ . $nmbr$ % ) who were enrolled,C0042295
2094,values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295
2094,nt - probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0042295;C0669479;C0754710
2093,western friroce,C1705493
2093,western,C1705493
2093,the square of the height in meters . patient ' s and physician ' s global assessment scores can range from $nmbr$ to $nmbr$ . scores for the western,C0205120;C0449820;C0489786;C1552595;C1705493;C4050369
2092,p value for heterogeneity （ rosiglitazone versus metformin ）,C0019409;C0242960;C0289313;C1709380
2092,p value for heterogeneity,C0019409;C0242960;C1709380
2092,heterogeneity p value,C0019409;C0242960;C1709380
2092,heterogeneity or trend p value,C0019409;C0242960
2092,heterogeneity or trend p vaiue,C0019409;C0242960
2091,pvalue for heterogeneity,C0019409;C0242960
2091,pfor heterogeneity,C0019409;C0242960;C1151635
2090,main effect baseline hormone,C0019932;C0168634;C0205225;C1280500;C1442488;C1518681;C1542147;C2348382;C4521914
2089,treatment effect ( hr ),C1518681
2089,effect estimate,C0750572;C1280500;C1518681;C2348382
2088,effect of covariates on slopes,C1280500;C1518681;C2348382
2088,consistency of effect,C0332529;C1280500;C1518681;C1547017;C2348382
2087,puerto rican,C0034043
2086,irregular or ulcerated ica plaquef,C0205271
2086,irregular or ulcerated ica p ) laque : [ :,C0205271
2085,catheterization performed for qualifying event,C0007430
2085,catheterization laboratory in center,C0007430;C0022877;C0205099;C3244292;C4283904;C4534362
2085,catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
2084,reported in ecrf,C0684224;C0700287;C4319718;C4551412
2083,cigarette smoking in the past year,C0239059;C0700219;C4086728
2082,pneumonia in past year,C0032285;C4086728
2082,over past $nmbr$ years  n ( % ),C4086728
2081,combined end poir,C0205195;C0444930;C2746065
2080,end of trial,C0008976;C0444930;C2746065
2080,dual iv - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444972;C1554184;C1825777;C2746065;C3538758
2080,dual ii - end of trial hba $nmbr$ c,C0008976;C0019016;C0205173;C0444930;C0444967;C1554184;C1825777;C2746065;C3538758
2079,presenting signs and symptoms,C0220912;C0220913;C0311392;C0449450
2079,no . of ' signs or symptoms of chff,C0220912;C0220913;C0311392
2078,beyond popliteal pedal,C0016504;C0442037;C0687080
2077,total feet score,C0016504;C0347981;C2964552
2077,feet,C0016504;C0347981
2076,selected key secondary efficacy endpoints,C1280519;C1707391;C1707887;C4528314
2076,select lipids and lipoproteins,C1707391
2075,percent activity impairment due to asthma,C0004096;C0221099;C0439167;C0678226;C0684336;C2984299
2075,impaired fasting glucosex,C0221099
2075,impaired fasting giucose levei ( n = $nmbr$ ),C0221099
2074,stent placement,C0522776
2074,stent implanted — no . ( % ),C0522776
2074,stent implanted,C0522776
2073,events requiring assistance,C0441471;C3541888
2073,cumulative events,C0441471;C1511559;C3541888
2072,events consistent with volume depletion,C0441471;C3541888
2072,events consistent with uti,C0441471;C3541888
2072,events consistent with genital infection,C0441471;C3541888
2072,composite events,C0205199;C0441471;C1547335;C3541888
2071,with events ( % ),C0441471;C3541888
2071,patients with hospitalized pneumonia events  n ( % ),C0032285;C0441471;C0870668;C3541888
2071,neurologicai events,C0441471;C3541888
2071,hospitalized pneumonia events  n,C0032285;C0441471;C0701159;C3541888
2070,no . of events / sample size i i,C0441471;C3541888
2070,no . of events / sample size,C0441471;C3541888
2070,frequency of events,C0376249;C0439603;C0441471;C0871396;C1561548;C1705502;C3541888;C3898838;C4321352
2070,freqency of events,C0441471;C3541888
2069,no of events womenmen *,C0441471;C3541888
2069,no of events women men *,C0025266;C0043210;C0441471;C3541888
2068,warfarin events / n ( % / y ),C0043031;C0441471;C3541888
2068,rosuvastatin events / patients ( % ),C0030705;C0441471;C0965129;C3541888
2068,events ( % ),C0441471;C3541888
2067,patients / events n,C0030705;C0441471;C3541888
2067,number of events / patients,C0030705;C0441471;C2360800;C3541888;C4330837
2067,no . of events / totol no . ( % ),C0441471;C3541888
2067,no . of events / total no . ( % ),C0441471;C3541888
2067,no . of events / total no . $nmbr$ % ),C0441471;C3541888
2067,no . of events / total,C0441471;C3541888
2067,no . of events / patients % / yr,C0030705;C0439234;C0441471;C3541888
2067,no . of events / patients,C0030705;C0441471;C3541888
2067,no . of events / no . of patients,C0441471;C3541888
2067,no . of events,C0441471;C3541888
2067,events / n,C0441471;C3541888
2067,events,C0441471;C3541888
2067,$nmbr$ no . of events,C0441471;C3541888
2066,ophthalmologic events,C0029087;C0205481;C0441471;C3541888
2065,biochemical events,C0205474;C0441471;C3541888
2064,bleeding events during the entire study,C0019080;C0439751;C0441471;C0444667;C0557651;C2603343;C3541888
2063,bleeding events during first $nmbr$ days of treatmen,C0019080;C0205435;C0439228;C0441471;C1279901;C3541888
2062,no ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
2062,no . of events ( rate ),C0441471;C0871208;C1521828;C3541888
2062,epa hr events ( % ),C0441471;C3541888
2062,ckd rate ( # events ),C0441471;C0871208;C1521828;C1561643;C3541888
2062,adjusted rate of pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0871208;C1521828;C3541888
2062,adjusted rate of hospitalized pneumonia events ( per patient - year )  mean ( $nmbr$ % ci ),C0032285;C0441471;C0456081;C0701159;C0871208;C1521828;C3541888
2061,events treatment ( $nmbr$ ),C0039798;C0087111;C0441471;C1522326;C1533734;C1705169;C3538994;C3541888;C3887704
2061,$nmbr$ s = scandinavian simvastatin survival study . $nmbr$ woscops = west of scotland coronary prevention study . $nmbr$ care = cholesterol and recurrent events . $nmbr$ post - cabg = post - coronary artery bypass graft . $nmbr$ afcaps / texcaps = air force / texas coronary atherosclerosis prevention study . $nmbr$ lipid = long - term intervention with pravastatin in ischaemic disease . $nmbr$ gissi prevention = gruppo italiano per lo studio della sopravvivenza nell ’ infarto miocardico . $nmbr$ lips = lescol intervention prevention study . $nmbr$ hps = heart protection study . $nmbr$ prosper = prospective study of pravastatin in the elderly at risk . $nmbr$ allhat - llt = antihypertensive and lipid - lowering treatment to prevent heart attack trial . $nmbr$ ascot - lla = anglo - scandinavian cardiac outcomes trial - lipid lowering arm . $nmbr$ alert = assessment of lescol in renal transplantation . $nmbr$ cards = collaborative atorvastatin diabetes study . $nmbr$ s = simvastatin . l = lovastatin . p = pravastatin . f = ﬂ uvastatin . a = atorvastatin . * mean duration of follow - up based on survival times within each trial . overall mean is weighted by trial - speci ﬁ c variances of logrank ( o – e ) for major vascular events . † all trials included dietary intervention : woscops  gissi prevention  lipid  $nmbr$ s  lips  and hps provided dietary advice  afcaps / texcaps  post - cabg  care  allhat  alert  cards  and prosper used american heart association ( aha ) step $nmbr$ diet and care intensi ﬁ ed to step $nmbr$ diet if ldl cholesterol $nmbr$ · $nmbr$ mmol / l ( $nmbr$ mg / dl ) . ‡ other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi ( as already counted in mi column ) . § other vascular includes history of intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  and peripheral artery disease . ¶ none includes individuals without a history of mi  symptomatic chd  intracerebral bleed  transient ischaemic attack  ischaemic stroke  unknown stroke  or peripheral artery disease,C0001792;C0005847;C0008377;C0008976;C0010054;C0010055;C0012171;C0016327;C0018787;C0019664;C0019665;C0022671;C0023759;C0023779;C0023981;C0024027;C0035647;C0036453;C0038454;C0038952;C0039711;C0039798;C0074554;C0085542;C0085565;C0086153;C0087111;C0150158;C0184661;C0199176;C0204932;C0205082;C0205164;C0206579;C0220921;C0231220;C0239110;C0240951;C0242994;C0262512;C0262926;C0277793;C0280604;C0282416;C0420180;C0439394;C0439673;C0441471;C0441994;C0444504;C0446516;C0475224;C0489835;C0557651;C0565930;C0589120;C0591720;C0679698;C0680782;C0687676;C0745413;C0886296;C0948008;C1232424;C1260596;C1261512;C1273869;C1304680;C1522326;C1522577;C1522601;C1533734;C1545588;C1558950;C1561607;C1704685;C1704687;C1705169;C1705255;C1705493;C1706420;C1706495;C1736144;C1801960;C1947933;C1999167;C1999230;C2003888;C2004062;C2004580;C2347090;C2347634;C2348143;C2603343;C2603362;C2700409;C2930619;C2937358;C3274571;C3275277;C3469826;C3538994;C3541433;C3541888;C3542407;C3642216;C3642217;C3665546;C3669039;C3715044;C3810814;C3887704;C3898312;C4050014;C4084853;C4318856;C4521762;C4552904;C4553014;C4553528;C4554100
2061,$nmbr$ events,C0441471;C3541888
2060,pioglitazone events / n ( % ),C0071097;C0441471;C3541888
2060,n events ( % ),C0369718;C0441471;C0441922;C3541888
2060,icosapent ethyl ( events / n ( % ) ),C0058978;C0441471;C3541888
2060,events  n ( % / y ),C0441471;C3541888
2060,events  n ( % ),C0441471;C3541888
2059,previous events  no . ( % ),C0205156;C0441471;C1552607;C3541888
2059,events  no .,C0441471;C3541888
2059,$nmbr$ events [ $nmbr$ . $nmbr$ ],C0441471;C3541888
2058,gastrointestinal event,C0441471;C0521362;C4019010
2057,patients with event / patients analyzed,C0030705;C0441471;C4019010
2057,patients with event / patients analysed,C0030705;C0441471;C4019010
2057,patients with event / analyzed,C0030705;C0441471;C4019010
2057,patients with any clinical event,C0030705;C0205210;C0441471;C4019010
2057,patients with an event per $nmbr$ patient - years,C0030705;C0441471;C4019010
2057,no . ( % ) with event [ incidence rate per $nmbr$ patient - y ],C0030705;C0441471;C1708485;C4019010
2057,atients with event,C0441471;C4019010
2057,any event,C0441471;C4019010
2056,empagliflozin n with event / n,C0441471;C3490348;C4019010
2055,patients with pneumonia event  n ( % ) #,C0030705;C0032285;C0441471;C4019010
2055,patients with event ( n  % ),C0030705;C0441471;C4019010
2055,event { n ( % ),C0441471;C4019010
2054,event during overall,C0282416;C0441471;C1561607;C4019010
2054,event during on -,C0441471;C4019010
2053,km event ( % ) at $nmbr$ y,C0441471;C3887676;C4019010
2052,placebo event rate ( n = $nmbr$ )  %,C0032042;C0441471;C0871208;C1521828;C1696465;C1706408;C4019010
2052,event ( p = $nmbr$ . $nmbr$ o + ),C0441471;C4019010
2052,event  n ( % ),C0441471;C4019010
2051,probability  of event %,C0033204;C0441471;C4019010
2050,hazard ratio for event ( $nmbr$ % ci ),C0008107;C0441471;C2985465;C3259781;C4019010
2050,event ( % ),C0441471;C4019010
2049,risk factor profile index event,C0035648;C0441471;C0600653;C0918012;C1552854;C1637833;C1979963;C2003903;C2986546;C4019010
2049,qualifying index event as pe,C0070939;C0441471;C0600653;C0918012;C1514624;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
2049,procedures for index event,C0025664;C0184661;C0441471;C0600653;C0918012;C1552854;C1637833;C2700391;C2986546;C3538935;C4019010
2049,prior to index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,presentation of index event,C0441471;C0449450;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,no revascularization for index acs event,C0441471;C0581603;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
2049,interval after index event,C0441471;C0600653;C0918012;C1272706;C1552654;C1552713;C1552854;C1637833;C2986546;C4019010
2049,index pe : event during,C0070939;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4019010;C4284304
2049,index event subtype,C0441471;C0449560;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,index event not confirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,index event information,C0441471;C0600653;C0918012;C1533716;C1552854;C1637833;C2986546;C4019010
2049,index event asymptomatic or unconfirmed,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,index event,C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
2049,for treatment of index event,C0039798;C0087111;C0441471;C0600653;C0918012;C1522326;C1533734;C1552854;C1637833;C1705169;C2986546;C3538994;C3887704;C4019010
2049,extent of index event,C0439792;C0441471;C0600653;C0918012;C1552854;C1637833;C2986546;C4019010
2049,event,C0441471;C4019010
2049,before index acs event,C0441471;C0600653;C0742343;C0918012;C1552854;C1637833;C2986546;C4019010;C4318612
2048,immunologic,C0152036;C0205470
2047,imm ( without corticosteroid ),C0001617;C0205470;C3536709
2047,imm,C0205470
2047,corticosteroid ( without imm )  n,C0001617;C0205470;C3536709
2047,corticosteroid ( without imm ),C0001617;C0205470;C3536709
2046,ifg / prediabetes ^,C0362046;C1334085;C1708411
2045,ifg and igt,C1334085;C1708411
2045,ada ifg,C1060325;C1334085;C1708411;C3811629
2044,who / idf ifg,C1334085;C1708411
2044,igt / ifg,C1334085;C1708411
2044,ifg / igt,C1334085;C1708411
2044,ifg,C1334085;C1708411
2044,baseline ifg ( fpg $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C1334085;C1442488;C1532563;C1708411
2043,dual iv,C0022326;C0205173;C1554184;C4265176
2042,total diuretic dose ( iv + oral ) on day $nmbr$  mg,C0012798;C0022326;C2986497;C4265176
2042,iv ( n z $nmbr$ ),C0022326;C4265176
2042,iv ( $nmbr$ ),C0022326;C4265176
2041,killip class ii - iv  n ( % ),C0022326;C1710602;C2697845;C2697847;C4082587;C4265176
2041,ii - iv ( % ),C0022326;C1710602;C4082587;C4265176
2041,ii - iv,C0022326;C1710602;C4082587;C4265176
2040,iv nitrates,C0022326;C4265176
2040,class iv / iv - v,C0022326;C0457166;C1880098;C4265176
2039,iv - $nmbr$ mg,C0022326;C0024671;C0026410;C0439269;C1960952;C2346927;C4265176;C4321396;C4521761
2039,iv,C0022326;C4265176
2038,killip class lll - iv,C1261077;C2697847
2037,nyha lll - iv,C0022326;C1261077;C1275491;C4265176
2037,lll / iv,C0022326;C1261077;C4265176
2037,lll - iv,C0022326;C1261077;C4265176
2036,i or ii,C0021966;C0221138
2036,i % $nmbr$,C0021966;C0221138
2036,ace - i or angiotensin receptor blocker,C0021966;C0221138;C1452534;C4284014
2036,ace - i ( n  % ),C0021966;C0221138;C1452534;C4284014
2035,ffa / i,C0015688;C0021966;C0221138
2035,favors ffa / i favors placebo,C0015688;C0021966;C0032042;C0221138;C0309049;C1696465;C1706408
2034,pde - $nmbr$ i monotherapy,C0021966;C0221138
2034,pde - $nmbr$ i,C0021966;C0221138
2034,mean daily dose ( range ) — mg  i,C0021966;C0024671;C0026410;C0221138;C0439269;C0444504;C1514721;C1960952;C2346927;C2347634;C2348070;C2348143;C2348147;C3542016;C4321396;C4521761
2034,i idl cholesterol ( mg / dl ),C0021966;C0123167;C0221138;C0439269;C0523559;C0619865
2034,i - $nmbr$ mg / d ( n = $nmbr$ ),C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C4321396;C4521761
2034,i $nmbr$ i,C0021966;C0221138
2034,$nmbr$ - i,C0021966;C0221138
2033,$nmbr$ — — bh — i,C0004684;C0004952;C0021966;C0221138;C1412800;C2986890;C4284594;C4321407
2032,$nmbr$ tq - fi ' i,C0021966;C0221138;C3555502;C4050619
2031,i amiodarone,C0002598;C0021966;C0221138
2031,antithrombotic ! i,C0021966;C0221138
2030,infliiimab i,C0021966;C0221138
2030,$nmbr$ - aminosalicylates ’ i  i ‘,C0021966;C0221138;C0368663
2029,other ' i ',C0021966;C0221138
2029,albumin - to - creatinine ratio ' i  /,C0021966;C0221138;C0486293;C1318293
2028,< $nmbr$ kg ' i ',C0021966;C0022718;C0221138;C0439209;C4054209
2027,bm i < $nmbr$,C0006416;C0021966;C0221138
2026,ciass i,C0021966;C0221138
2026,blood pressure  pbo y patients with diabe teristics ( ncep atp i,C0005823;C0021966;C0030705;C0031962;C0221138;C1271104;C1272641;C2744579;C4552600
2026,( i - blocker,C0021966;C0221138
2025,i,C0021966;C0221138
2025,europe i,C0015176;C0021966;C0221138
2024,i $nmbr$ years of age,C0021966;C0221138;C1510829
2024,aqe i $nmbr$,C0021966;C0221138
2023,period i,C0021966;C0221138;C0439531;C1948053
2022,pasi ^ i,C0021966;C0221138;C4528685
2022,i - ^ w « - i - $nmbr$,C0021966;C0221138
2021,i / ii,C0021966;C0221138;C1710602;C4082587
2021,i $nmbr$ ± i $nmbr$,C0021966;C0221138
2021,i $nmbr$ ± $nmbr$ ii,C0021966;C0221138;C1710602;C4082587
2021,i $nmbr$ ± $nmbr$ i,C0021966;C0221138
2021,i $nmbr$ i ± i $nmbr$,C0021966;C0221138
2021,i $nmbr$ i $nmbr$ ± $nmbr$,C0021966;C0221138
2021,asteria i / ii,C0021966;C0221138;C1093020;C1710602;C4082587
2021,$nmbr$ . i ± ii . $nmbr$,C0021966;C0221138;C1710602;C4082587
2020,stratum i,C0021966;C0221138
2020,i rosuvastatin ( n = $nmbr$ ),C0021966;C0221138;C0965129
2020,i lisinopril ( n = $nmbr$ ),C0021966;C0065374;C0221138
2019,previous pde $nmbr$ - i therapy  no . ( % ),C0021966;C0039798;C0087111;C0205156;C0221138;C1363945;C1552607
2019,$nmbr$ i $nmbr$ ( $nmbr$ i . $nmbr$ ),C0021966;C0221138
2018,stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient  respectively . chf  congestive,C0007591;C0017654;C0021966;C0023806;C0221138;C0332257;C0369637;C0439445;C0441766;C0441923;C0456533;C0702093;C1424601;C1524029;C3813700
2018,i no . of events,C0021966;C0221138
2018,> i,C0021966;C0221138
2018,$nmbr$ . $nmbr$ to . $nmbr$ . i . iot,C0006196;C0021966;C0221138
2017,i . $nmbr$ i ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
2017,i . $nmbr$ ( $nmbr$ . $nmbr$ - i . $nmbr$ ),C0021966;C0221138
2017,i ( $nmbr$ . i ),C0021966;C0221138
2017,i $nmbr$ i ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
2017,i $nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,C0021966;C0221138
2017,i $nmbr$ ( i $nmbr$ . i ),C0021966;C0221138
2017,i $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138
2017,- f $nmbr$ . $nmbr$ ( - i - $nmbr$ . $nmbr$ ),C0016327;C0021966;C0221138
2017,$nmbr$ . i $nmbr$ ( $nmbr$ . $nmbr$ i - $nmbr$ . $nmbr$ ),C0021966;C0221138
2017,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ) a,C0021966;C0221138
2017,$nmbr$ . $nmbr$ i $nmbr$ . $nmbr$ ( n = $nmbr$ ),C0021966;C0221138
2017,$nmbr$ . $nmbr$ ( io . i ),C0021966;C0221138;C1046794;C3146236
2017,$nmbr$ . $nmbr$ ( i $nmbr$ . s ),C0021966;C0221138
2017,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . i $nmbr$ i ),C0021966;C0221138
2017,$nmbr$ ( $nmbr$ i . i ),C0021966;C0221138
2016,i u - uj,C0021966;C0221138;C0439148
2015,> o - $nmbr$ - i - i,C0021966;C0221138;C0483204
2015,- b - i —,C0021966;C0221138
2015,- b - i -,C0021966;C0221138
2015,$nmbr$ o - i $nmbr$ mm hg,C0021966;C0221138;C0439475;C0483204
2015,$nmbr$ - $nmbr$ fo - $nmbr$ - o - q ^ i,C0021966;C0221138
2015,$nmbr$ - $nmbr$ ( o - $nmbr$ s - i - $nmbr$ ),C0021966;C0221138;C0483204
2015,$nmbr$ - $nmbr$ ( o - $nmbr$ i - o - $nmbr$ ),C0021966;C0221138;C0483204
2015,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
2015,$nmbr$ - $nmbr$ ( o - $nmbr$ - i - $nmbr$ ),C0021966;C0221138;C0483204
2015,$nmbr$ - $nmbr$ ( o $nmbr$ o - i - i $nmbr$ ),C0021966;C0221138;C0483204
2015,$nmbr$ $nmbr$ ( o - $nmbr$ - i - o $nmbr$ ),C0021966;C0221138;C0483204
2014,idm,C0270221
2013,id genotype,C0009450;C0017431;C0600091;C1441613
2013,id ( n = $nmbr$ ),C0009450;C0600091;C1441613
2013,id,C0009450;C0600091;C1441613
2013,( id,C0009450;C0600091;C1441613
2012,of variation )  iu,C0049272;C0205419;C0439453;C0694756
2011,iuss score  mean ( sd ),C0439453
2011,iu,C0049272;C0439453;C0694756
2011,insulin glargine dose at screening visit  iu,C0049272;C0178602;C0220908;C0220909;C0366513;C0439453;C0545082;C0694756;C0869039;C0907402;C1114758;C1512346;C1698960;C1710031;C1710032;C1710477;C2348164;C2826704
2011,dose ( iu ),C0049272;C0178602;C0439453;C0694756;C0869039;C1114758
2011,daily insulin dose  mean ( sd )  iu,C0021641;C0049272;C0332173;C0366513;C0439453;C0444504;C0694756;C1533581;C1579433;C2347634;C2348070;C2348143;C2699239;C3714501
2010,angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
2009,class ii ( b - blockers ),C0441886;C2698968
2009,class ii,C0441886;C2698968
2009,class > ii,C0441886;C2698968
2008,type ii diabetes,C0011860
2008,diabetes type ii  n ( % ),C0011860
2007,lor ii,C1416897;C1416899;C1710602;C2986770;C4082587
2006,sr ii b $nmbr$ - cjl $nmbr$,C0753208;C1709991;C1710602;C3813610;C3890900;C3891546;C4082587
2005,lavolta ii,C1710602;C4082587
2005,gold ii,C0018026;C1304897;C1710602;C4082587
2004,ii chiorthaiidone amiodipine,C1710602;C4082587
2004,europe ii,C0015176;C1710602;C4082587
2003,ii lisinopril i,C0021966;C0065374;C0221138;C1710602;C4082587
2003,ii lisinopril,C0065374;C1710602;C4082587
2002,ii ( n = $nmbr$ ),C1710602;C4082587
2002,ii $nmbr$ ( ii . $nmbr$ ),C1710602;C4082587
2002,ii $nmbr$ ( i $nmbr$ . $nmbr$ ),C0021966;C0221138;C1710602;C4082587
2001,updrs total ( ii + iii ),C0439070;C0439175;C0439810;C1705160;C1710602;C3639721;C4082587
2001,stratum ii,C1710602;C4082587
2001,ii - iii,C0439070;C1705160;C1710602;C4082587
2001,heart failure nyha ii - iii,C0018801;C0018802;C0439070;C1275491;C1705160;C1710602;C4082587;C4554158
2000,insulin detemir,C0537270
1999,insulin - dependent diabetes mellitus,C0011854
1999,insulin - dependent diabetes,C0011854
1998,placebo - ideglira,C0032042;C1696465;C1706408;C4308663
1998,ideglira - ideg,C4308663
1998,ideglira,C4308663
1997,insufficient,C0205412;C0231180;C0439856
1996,inadequate response ( > $nmbr$ months mmf / ggs ),C0083765;C0205412;C0209368;C0439231;C0439856;C0871261;C1704632;C1706817;C2911692;C3848524
1996,inadequate response ' ’ ',C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1996,inadequate response ' ^,C0205412;C0439856;C0871261;C1704632;C1706817;C2911692
1996,inadequate,C0205412;C0439856
1995,reversibility ( anticholinergic )  %  mean ( sd ) $,C0242896;C0444504;C0449261;C2347634;C2348143;C2699239;C3537004
1995,anticholinergic drug,C0242896
1995,anticholinergic,C0242896;C3537004
1994,baseline short - acting anticholinergics,C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
1994,anticholinergics,C0242896;C3537307;C3540711
1994,anti - cholinergics ( short - acting ) a,C0242896
1994,anti - cholinergics ( long - acting ),C0242896
1993,took prior antihyperglycemic agent ( any ),C1515187
1993,taking antihypertensive treatment at,C1515187
1993,taking antihypertensive medication at baseline  no . ( % ) e,C1515187
1992,use of antiplatelet agents — no . / total no . ( % ),C0085826;C1524063
1992,use of antiplatelet agents ^,C0085826;C1524063
1992,use of antiplatelet agents  n ( % ),C0085826;C1524063
1992,other antiplatelet agents  n ( % ),C0085826
1992,other antiplatelet agents,C0085826
1992,other antiplatelet agent 一 no . ( % ),C0085826
1992,antiplatelets agents,C0085826
1992,antiplatelet agents ( % ),C0085826
1992,antiplatelet agents,C0085826
1992,antiplatelet agent or anticoagulant,C0085826
1992,antiplatelet agent n ( % ),C0085826
1992,antiplatelet agent,C0085826
1991,previous use of antiplatelet drugs,C0085826;C0205156;C1524063;C1552607;C2963157
1991,previous chronic use of antiplatelet drugs,C0085826;C0205156;C0205191;C1524063;C1552607;C2963157
1991,antiplatelet drugs,C0085826;C2963157
1990,aspirin orother antiplatelet drug,C0004057;C0013227;C0085826;C1254351
1990,antiplatelet drug,C0085826
1989,nonaspirin antiplatelet agent,C0085826;C0722138
1989,nonaspirin antiplatelet,C0722138
1988,no . ( % ) of individuals *,C0027361;C0237401
1988,individual intended study duration — no . ( % ),C0027361;C0237401;C0489652;C1283828;C1551357
1987,other individual and exploratory end points,C0027361;C0237401
1987,individual endpoints,C0027361;C0237401;C2349179
1986,proportion ( % ) of individuals • control alirocumab,C0027361;C0237401;C1709707
1986,proportion ( % ) of individuals a alirocumab • placebo,C0027361;C0237401;C1709707
1985,teaes in a $nmbr$ % of individuals,C0027361;C0237401
1985,individuals with prediabetes,C0027361;C0237401;C0362046
1985,individuals with pre - diabetes  n ( % ),C0027361;C0237401;C0362046
1984,angina with documented ischemia,C0002962;C0022116;C1301725;C1609436;C4321499
1983,anti - ischaemia agents *,C0022116;C0040616;C4321499
1982,severe recurrent ischemia,C0022116;C0205082;C1455761;C2945760;C4050465;C4050466;C4321499
1982,recurrent ischemia - urgent revascularization,C0022116;C0439609;C0581603;C1455761;C2945760;C3272275;C4321499
1982,recurrent ischemia,C0022116;C1455761;C2945760;C4321499
1982,ischemia driven revascularization,C0022116;C4321499
1982,ischemia - driven revascularization,C0022116;C4321499
1981,rec . ischemia requiring revasc,C0022116;C0378365;C1424025;C2606415;C4321499
1981,rec . ischemia leading to hosp,C0022116;C1424025;C2606415;C4321499
1981,rec . ischemia leading to hasp,C0022116;C1424025;C2606415;C4321499
1981,rec . ischemia,C0022116;C1424025;C2606415;C4321499
1980,ischemia on cecg ( % ),C0022116;C4321499
1980,global ischemia ( % ) * *,C0022116;C0205246;C2348867;C4321499
1980,global ischemia,C0022116;C0205246;C2348867;C4321499
1979,no ischemia ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1979,modified hachinski ischemia scale  mean ( sd ) c,C0022116;C0175659;C0349674;C0392747;C0444504;C1947916;C2347634;C2348143;C2699239;C3889737;C4321499
1979,ischemia on cecg ( n = $nmbr$  $nmbr$ ),C0022116;C4321499
1979,ischemia,C0022116;C4321499
1978,other ischaemic heart disease ( non - infarction ),C0010054;C0021308;C0151744;C1518422
1978,myocardial ischaemia,C0010054;C0151744
1978,ischaemic heart disease,C0010054;C0151744
1977,ischemic heart disease *,C0010054;C0151744
1977,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744;C0205195
1976,ihd,C0151744
1975,previous ischemic heart disease — no . ( % ),C0010054;C0151744;C0205156;C1552607
1975,ischemic heart disease ( % ),C0010054;C0151744
1975,ischemic heart disease  no . ( % ),C0010054;C0151744
1975,ischemic heart disease  ( % ),C0010054;C0151744
1975,ischemic heart disease,C0010054;C0151744
1974,ischemic heart disease indicator no ( n = $nmbr$ l ),C0010054;C0021212;C0151744;C1235732;C1522602
1974,ischemic heart disease  n ( % ),C0010054;C0151744
1974,ischemic heart disease  %,C0010054;C0151744
1974,ischaemic heart disease or cerebrovascular disorder  n ( % ),C0010054;C0151744
1974,ischaemic heart disease  n ( % ),C0010054;C0151744
1973,neither ace - i nor arb use,C0021966;C0221138;C1452534;C4284014
1973,ace ‐ i or arb,C0021966;C0221138;C1452534;C4284014
1973,ace or arb,C1452534;C4284014
1973,ace - lorarb,C1452534;C4284014
1973,ace - i or arb use at baseline,C0021966;C0221138;C1452534;C4284014
1973,ace - i or arb use,C0021966;C0221138;C1452534;C4284014
1973,ace - i or arb  % ( n ),C0021966;C0221138;C1452534;C4284014
1973,ace - i or arb,C0021966;C0221138;C1452534;C4284014
1973,ace,C1452534;C4284014
1972,values are mean ± sd  median [ quartile range ]  or % . ace indicates angiotensin - converting enzyme  arb  angiotensin receptor blocker  bnp  b - type natriuretic peptide  bp  blood pressure  bun  blood urea nitrogen  lvef  left ventricular ejection fraction  and nt - probnp  n - terminal pro - b - type natriuretic peptide .,C0005823;C0022709;C0042295;C0054015;C0332307;C0428772;C0488728;C0597357;C0600137;C1095989;C1144709;C1291218;C1417808;C1452534;C1547052;C2709270;C2982014;C3537020;C3683557;C3888198
1972,angiotensin - converting enzyme or angiotensin receptor blocker,C0022709;C1452534
1971,magnetic resonance angiography,C0243032
1970,p value for mra vs no mra,C0243032;C1609165;C1709380;C3891069
1970,mra use,C0243032;C1609165;C3891069
1969,menopausal status and use of ht,C1513126
1969,menopausal status and use of hrt ( % ) y,C1513126
1969,menopausal status and hormone therapy use premenopausal,C1513126
1969,menopausal status and hormone therapy use,C1513126
1968,menopause and ht,C0025320;C0567312
1968,menopause and hrt,C0025320;C0567312
1967,nausea and / or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1967,nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
1966,ttr ( warfarin arm only ),C0032923;C0043031;C0205171;C0446516;C1421224;C1720467;C3715044;C4553528
1966,three arm,C0205449;C0446516;C3715044;C4553528
1965,two arm,C0205448;C0446516;C3715044;C4553528
1965,arm,C0446516;C3715044;C4553528
1964,treatment arm ( zoledronate ) ( % ),C0392938;C1522541
1964,treatment arm,C1522541
1964,by treatment arm,C1522541
1963,leisure,C0086542
1962,seizure worry,C0036572;C0233481;C1959629;C4553401
1961,seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401
1961,seizure types reported during baseline  n ( % ) a,C0036572;C0332307;C1959629;C4553401
1961,seizure types reported during baseline  b n ( % ),C0036572;C0332307;C1959629;C4553401
1960,seizure reduction from baseline,C0036572;C0168634;C0301630;C0392756;C1293152;C1442488;C1959629;C4551656;C4553401
1960,baseline monthly pos seizure rate,C0036572;C0168634;C0332177;C0871208;C1262869;C1442488;C1521828;C1959629;C3496112;C3496399;C4553401
1959,outcome measure,C0086749
1958,patient - reported outcome measures,C4277735
1957,medical history before index acute coronary syndrome — no . { % ),C0262926;C0600653;C0918012;C0948089;C1552854;C1637833;C1704706;C2986546
1957,index inclusion acute coronary syndrome,C0007637;C0600653;C0918012;C0948089;C1512693;C1552854;C1637833;C2986546
1957,index acute coronary syndrome — no . { % ),C0600653;C0918012;C0948089;C1552854;C1637833;C2986546
1957,acute coronary syndrome $nmbr$,C0948089
1956,time from acute coronary syndrome to randomization ( days ),C0040223;C0948089;C3541383
1956,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0040223;C0549183;C0600653;C0876920;C0918012;C0948089;C1552854;C1637833;C2347635;C2348144;C2939193;C2986546;C3541383
1956,acute coronary syndrome,C0948089
1955,obstructive subscore,C0549186
1955,chronic obstructive pulmonary,C0024109;C0205191;C0549186;C2707265;C2709248;C4522268
1954,propionic acid derivatives,C0033482;C0695274;C3540752
1953,dopa and dopa derivativese,C0013023
1952,sulphonamides  urea derivatives,C0038760;C0041942;C0243072
1951,adamantane derivatives,C3653470
1950,rv and pulmonary vascular,C0035190;C3889272
1949,pulmonary vascular resistance  dyne • s • cm $nmbr$,C0308914;C0456261;C0488644;C0600130
1948,non - q - wave myocardial infarction,C0542269;C3537181
1947,q wave,C0429089;C1305738
1947,non - q wave,C0429089;C1305738;C1518422
1947,non - q - wave ml,C0429089;C0439526;C1305738;C1518422;C1705224;C3887665
1946,q wave mi,C0861151
1946,q - wave mi,C0861151
1946,death / q - wave mi / idr,C0011065;C0861151;C1306577;C4082313;C4552775
1946,death  q wave mi or ischemia - driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775
1945,flex aln ^,C0729594;C2681220
1944,angina symptoms ^,C0858277
1943,score on st . george ' s respiratory questionnaire ^ ^,C3472502
1942,albumin measurements ^ ^,C0201838
1941,flex ain ' ’,C0347129
1940,ain  no . ( % ) “ *,C0347129
1940,ain  no . ( % ) * *,C0347129
1939,urgent revascularisation due to unstable angina,C0002965;C0439609;C0581603;C0678226;C3272275
1939,unstable angina §,C0002965
1938,worsening angina,C0002965
1938,rec . ischemia due worsening angina,C0002965;C0022116;C0678226;C1424025;C2606415;C3146286;C4321499
1938,due worsening angina,C0002965;C0678226;C3146286
1937,rest angina past $nmbr$ h,C0002965;C0033727;C0152172;C0369286;C0441932;C0564385;C1444637;C4284302;C4528284
1937,rest angina but not past $nmbr$ h,C0002965;C0152172
1937,rest angina,C0002965;C0152172
1937,no rest angina,C0002965;C0152172
1936,unstable angina — no . ( % ),C0002965
1936,unstable angina age,C0001779;C0002965
1936,unstable angina *,C0002965
1936,* * * unstable angina,C0002965
1935,unstable angina ( n = $nmbr$  $nmbr$ ),C0002965
1935,unstable angina ( biomarker negative ),C0002965;C0005516;C0205160;C1513916;C2825415;C2825491;C3853545
1935,unstable angina  n ( % ),C0002965
1935,unstable angina,C0002965
1934,unstable angina requiring hospitalization,C0002965;C0019993
1934,previous hospitalization for unstable angina,C0002965;C0019993;C0205156;C1552607
1934,histor y of unstable angina,C0002965
1933,• unstable angina,C0002965
1933,• hospitalization for unstable angina,C0002965;C0019993
1933,hospitalization for unstable angina,C0002965;C0019993
1933,cv death  ml  ischemic stroke  hospitalization for unstable angina  revascularization or heart failure,C0002965;C0011065;C0019993;C0439526;C0581603;C0948008;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1932,hospitalized angina,C0002962;C0701159
1932,hospitaiization for angina,C0002962
1932,angina or positive stress test,C0002962
1931,angina class at baseline,C0002962;C0168634;C0456387;C1442488;C1518526;C1705943
1931,angina,C0002962
1930,angina status — no . ( % ),C0002962;C0449438
1930,angina .,C0002962
1929,in patients with a history of chronic angina who have presented with an acute,C0002962;C0205191;C0679831
1929,angina or acute mi,C0002962
1928,previous angina pectoris,C0002962;C0205156;C1552607
1928,previous angina  n ( % ),C0002962;C0205156;C1552607
1928,angina pectorisf,C0002962
1928,angina pectoris 本,C0002962
1928,angina pectoris *,C0002962
1928,angina  n ( % ),C0002962
1927,prior angina pectoris — no . / total no . ( % ),C0002962;C0332152;C2826257
1927,prior angina pectoris,C0002962;C0332152;C2826257
1927,prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
1927,prior angina  n / n ( % ),C0002962;C0332152;C2826257
1927,prior angina,C0002962;C0332152;C2826257
1927,no prior angina ( n = $nmbr$  $nmbr$ ),C0002962;C0332152;C2826257
1927,angina pectoris — no . ( % ),C0002962
1927,angina pectoris  ( % ),C0002962
1927,angina pectoris,C0002962
1926,anakinra,C0245109
1925,canakinumab  il - $nmbr$ top tertilec,C0020898;C0021764;C0022271;C1704458;C2718773
1925,canakinumab  il - $nmbr$ lowest tertile,C0020898;C0021764;C0022271;C1708760;C2718773
1925,canakinumab  $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C0020898;C0021764;C0022271;C0039798;C0087111;C0332177;C0439231;C0439297;C0549183;C0876920;C1522326;C1522609;C1533734;C1705169;C2347635;C2348144;C2718773;C2939193;C3538994;C3887704
1925,canakinumab,C2718773
1925,all canakinumab,C2718773
1924,benralizumab q $nmbr$ w ( n = $nmbr$ ),C2982078
1924,benralizumab q $nmbr$ w ( n - $nmbr$ ),C2982078
1924,benralizumab,C2982078
1924,b . benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
1923,previous acute hypersensitivity reaction to infliximab — no . of patients ( % ),C0205156;C0413234;C0666743;C1552607
1923,infliximab - naive ( n = $nmbr$ ),C0666743
1923,infliximab - experienced ( n = $nmbr$ ),C0666743
1923,infliximab ( n = $nmbr$ ),C0666743
1923,infliximab,C0666743
1923,inflix  no,C0666743
1922,previous intolerance of infliximab  n ( % ) *,C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1922,patients with previous intolerance of infliximab,C0030705;C0205156;C0231199;C0666743;C1552607;C1744706;C2355652
1922,infliximab monotherapy,C0666743
1921,poland,C0032356
1920,new zealand,C0027978;C0324547
1920,austral ia / new zealand,C0020980;C0027978;C0324547;C0694634;C1947960
1919,detected during tumor evaluation,C0027651;C0220825;C0442726;C1261322;C1511790;C1578706;C3273930
1918,neoplasia  n ( % ),C0027651;C1882062
1918,neoplasia,C0027651;C1882062
1917,bivalirudin used during pci,C0168273
1917,bivalirudin used,C0168273
1917,bivalirudin only,C0168273;C0205171;C1720467
1916,bivalirudin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0016011;C0168273;C0243077
1916,bivalirudin ( n = $nmbr$ ),C0168273
1916,bivalirudin ( n = $nmbr$  $nmbr$ ),C0168273
1916,bivalirudin,C0168273
1915,ivabradine group ( n = $nmbr$ ),C0257190;C0441848
1915,ivabradine group,C0257190;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
1915,ivabradine ( n = $nmbr$ ),C0257190
1915,ivabradine,C0257190
1914,postprandial indices,C0376674;C4033634
1913,$nmbr$ - h postprandial proinsulin ( pmol / l ),C0033362;C0376674;C2827799;C3813208
1912,other / multiracial,C1881928
1912,multiracial or other,C1881928
1912,multiracial  n ( % ),C1881928
1912,multiracial,C1881928
1911,myalgia,C0231528;C4552646
1910,parental history of myocardial infarction before age $nmbr$ y yes,C0030551;C1275835
1910,parental history of myocardial infarction before age $nmbr$ y,C0030551;C1275835
1910,parental history of myocardial infarction before $nmbr$ yr of age ( % ),C0030551;C1275835
1910,history of myocardial infarction ( % ),C1275835
1910,history of myocardial infarction  n ( % ),C1275835
1910,history of myocardial infarction,C1275835
1910,history myocardial infarction,C0155668;C1275835
1909,vitality,C0424589
1908,mortality  shock or congestive heart failure within $nmbr$ days,C0026565;C0026566;C0036974
1907,shfm annual mortality,C0026565;C0026566;C0332181
1906,mortality outcomes,C0026565;C0026566;C1274040
1905,all - causa mortality,C0026565;C0026566;C3903827
1904,total mortality all,C0026565;C0026566;C0439175;C0439810
1904,total mortality,C0026565;C0026566;C0439175;C0439810
1904,mortality,C0026565;C0026566
1903,non - cvd mortality,C0007222;C0026565;C0026566;C1518422
1903,cvd mortality,C0007222;C0026565;C0026566
1902,non cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1902,non - cv mortality,C0026565;C0026566;C1518422;C3538987;C4048877;C4318503
1902,cv mortality,C0026565;C0026566;C3538987;C4048877;C4318503
1901,intracerebral,C0442111
1900,intracranial hemorrhage †,C0151699;C4554169
1900,intracranial hemorrhage  n ( % ),C0151699;C4554169
1900,intracranial hemorrhage,C0151699;C4554169
1900,intracranial bleeding,C0151699
1900,intracranial bleed,C0151699
1899,intensification of antianginal therapy,C1511484;C1874267;C3537168
1898,new anti - anginal therapy,C1874267;C3242274;C3537168
1897,no antianginal drug,C0013227;C1254351;C1874267;C3537168
1897,any antianginal drug !,C0013227;C1254351;C1874267;C3537168
1897,$nmbr$ antianginal drug,C0013227;C1254351;C1874267;C3537168
1896,ras antagonist  %,C0034678;C0231491;C0525678
1895,prior tnf antagonist failure  n [ % ],C0231174;C0231491;C0332152;C0680095;C1448177;C2826257
1895,prior tnf antagonist  n [ % ] ‘ *,C0231491;C0332152;C1448177;C2826257
1894,prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
1894,antagonist,C0231491
1894,$nmbr$ prior tnf antagonist failures  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
1894,$nmbr$ prior tnf antagonist failure  n ( % ) b,C0231174;C0231491;C0332152;C0680095;C2826257;C3887647
1893,tnf antagonist,C0231491;C1448177
1893,no history of tnf antagonist treatment — no . ( % ),C0019664;C0019665;C0039798;C0087111;C0231491;C0262512;C0262926;C1448177;C1522326;C1533734;C1705169;C1705255;C2004062;C3538994;C3887704
1893,history of tnf antagonist treatment failure — no . ( % ) * *,C0019664;C0019665;C0162643;C0231491;C0235828;C0262512;C0262926;C0521983;C1448177;C1547544;C1705255;C2004062
1892,adp antagonist,C0231491;C0523452
1891,miami k antagonist received,C0231491;C0597277;C1551421;C1708601
1890,mineralocorticoid receptor antagonists,C1373021;C1579268
1890,mineralocorticoid receptor antagonist n ( % ),C1579268
1890,mineralocorticoid receptor antagonist,C1579268
1890,aldosterone receptor antagonists,C1579268
1889,mineralcorticoid receptor antagonist,C4543207
1889,beta receptor antagonist,C0330390;C0439096;C2004068;C4543207
1888,general anaesthesia,C0002915;C2930406
1887,regional anaesthesia,C0002911
1886,paresthesia,C0030554;C4553220
1885,anaesthesia / analgesia,C0002905
1884,anemia — no . ( % ) | |,C0002871;C1000483;C4554633
1884,anemia ( % ),C0002871;C1000483;C4554633
1884,anemia  no . / total ( % ) ”,C0002871;C1000483;C4554633
1884,anemia  %,C0002871;C1000483;C4554633
1883,no anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1883,new anemia bsl hb > $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0205314;C0221138;C0439234;C1000483;C1319635;C1549954;C4554633
1883,anemia,C0002871;C1000483;C4554633
1882,or for cana vs pbo ( $nmbr$ % ci ) §,C1418845
1882,or for cana vs pbo ( $nmbr$ % ci ) | |,C1418845
1882,non - cana ( n = $nmbr$ ),C1418845;C1518422
1882,cana $nmbr$ / met ( n = $nmbr$ ),C1418845
1882,cana $nmbr$ ( n = $nmbr$ ),C1418845
1882,cana,C1418845
1882,all cana,C1418845
1881,china / tjapan,C0008115
1881,china / japan,C0008115;C0022341
1881,china,C0008115
1880,laa length,C1444754;C1706316
1879,laa ostium,C0444567
1878,lama +,C0999593;C1416775
1878,lama ( tiotropium )  b   n ( % ),C0213771;C0999593;C1416775
1877,lama use at screening  n ( % ),C0042153;C0220908;C0220909;C0457083;C0999593;C1416775;C1698960;C1710031;C1710032;C1710477;C1947944;C2348164
1877,lama use  n ( % ),C0042153;C0457083;C0999593;C1416775;C1947944
1877,lama,C0999593;C1416775
1877,current lama use,C0042153;C0457083;C0521116;C0999593;C1416775;C1705970;C1947944
1876,laba / lama / ics,C0815320;C0999593;C1416775;C4551720
1876,laba / lama,C0999593;C1416775
1875,macro - albuminuria,C0001925;C2984010
1874,normal albuminuria ( uacr < $nmbr$ ),C0001925;C0205307;C0231683;C0439166;C2347086;C4553972
1874,any albuminuria — no . ( % ),C0001925
1874,any albuminuria,C0001925
1874,albuminuria,C0001925
1873,baseline albuminuria,C0001925;C0168634;C1442488
1873,albuminuria and previous maerovaseular disease without established renal disease,C0001925
1872,albuminuria ( g / g ),C0001925;C1319635
1872,albuminuria ( acr > $nmbr$ m . g / g ) at baseline to normoalbuminuria,C0001925;C0168634;C0369637;C0441923;C1319635;C1412134;C1442488;C1515941
1871,$nmbr$ - h plasma glucose during ogtt ( mmol / l ),C0029161;C0202042;C0455280;C2827804
1870,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ fasting plasma glucose ( fpg ) ( mmol / l ),C0015663;C0202042;C0455280;C1532563;C1565750
1870,fasting plasma glucose ( mmol / l ) $nmbr$,C0015663;C0202042;C0455280;C1532563
1870,fasting plasma glucose ( mmol / l ),C0015663;C0202042;C0455280;C1532563
1870,fasting plasma glucose ( mg / dl ) $nmbr$,C0015663;C0202042;C0439269;C0455280
1870,fasting plasma glucose ( mg / dl ),C0015663;C0202042;C0439269;C0455280
1870,fasting plasma glucose $nmbr$ medan,C0015663;C0202042;C0455280
1870,fasting plasma glucose  mg / dl  mean ( sd ) b,C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
1870,fasting plasma glucose  mg / dl  mean ( sd ),C0015663;C0202042;C0439269;C0444504;C0455280;C2347634;C2348143;C2699239
1870,fasting plasma glucose  mg / dl,C0015663;C0202042;C0439269;C0455280
1870,fasting plasma glucose,C0015663;C0202042;C0455280
1870,fascng plasma glucose a medan,C0202042;C0455280
1870,baseline fasting plasma glucose,C0015663;C0168634;C0202042;C0455280;C1442488
1869,fasting plasma glucose categories  n ( % ),C0015663;C0202042;C0455280;C0683312
1869,fasting plasma glucose *,C0015663;C0202042;C0455280
1868,fasting plasma glucose — mg / dl,C0015663;C0202042;C0439269;C0455280
1868,casual plasma glucose ( mg / dl ),C0202042;C0439269;C0455280
1868,$nmbr$ - hr plasma glucose — mg / dl,C0202042;C0439269;C0455280
1867,agi,C1299007
1866,alpha glucosidase inhibitors,C1299007;C2756986;C3539108
1866,alpha - glucosidase inhibitors,C1299007;C2756986;C3539108
1865,micral test result,C0456984;C0587081
1864,laboratory findings,C0587081
1863,within last $nmbr$ d,C1517741
1863,last study visit,C1517741
1863,last infusion in the horizon - pft,C0024119;C0053122;C0279232;C0574032;C1517741;C1827465
1862,卞 at discharge .,C0012621;C0030685;C2926602
1862,thienopyridine at discharge,C0012621;C0030685;C1120149;C2926602
1861,missing data — no . / total no . ( % ),C4684714
1861,missing data initial diagnosis — no .,C0011900;C0205265;C1279901;C1555582;C1704338;C1704656;C1705685;C4684714
1861,missing data,C4684714
1860,lifestyle modifications,C0870811;C2960841
1859,lifestyle behaviours,C0004927;C0023676;C0677505
1859,lifestyle behaviors,C0004927;C0023676;C0677505
1859,lifestyle,C0023676
1858,medial - distal - diag,C0205098;C0205108;C0348026;C4522154
1857,distal lower,C0205108;C0441994;C1548802;C2003888;C4522154
1857,distal,C0205108;C4522154
1856,diet plus pravastatin group ( n = $nmbr$ ),C0012155;C0012159;C0085542;C0332287;C0441848;C1519433;C2983588;C3668949
1856,diet only,C0012155;C0012159;C0205171;C1519433;C1720467;C2983588;C3668949
1856,diet group ( n = $nmbr$ ),C0012155;C0012159;C0441848;C1519433;C2983588;C3668949
1856,diet diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1856,diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949
1856,diet alone,C0012155;C0012159;C1519433;C2983588;C3668949
1856,diet + pravastatin ( n = $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1856,diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1856,diet + pravastatin,C0012155;C0012159;C0085542;C1519433;C2983588;C3668949
1856,diet ( n 二 $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1856,diet ( n = $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1856,diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155;C0012159;C1519433;C2983588;C3668949
1856,diet,C0012155;C0012159;C1519433;C2983588;C3668949
1855,due to drug - relateda ae,C0013227;C1254351;C3887670
1855,drug ‐ relateda,C0013227;C1254351
1855,drug - relateda,C0013227;C1254351
1854,lipid - modulating drug,C0013227;C0023779;C0443264;C1254351
1854,drug eluting,C0013227;C1254351
1854,drug - eluting,C0013227;C1254351
1853,ipah / fpah / drug and toxin,C0013227;C0152171;C1254351;C1419079
1853,drug and insulint,C0013227;C1254351
1852,epilepsy drug,C0013227;C0014544;C1254351
1851,drug naive,C0013227;C1254351
1851,antithrombotic drug use at time of event,C0013227;C0040223;C0441471;C1254351;C1524063;C3541383;C4019010
1850,ticlopidine after completion of study drug,C0013175;C0013227;C0040207;C0205197;C1254351;C1554962;C2348557
1850,open - label clopidogrel after completion of study drug,C0013227;C0070166;C0205197;C1254351;C1554962;C1709323
1849,glycemic drugs,C0005802;C0013227;C3687832
1848,diuretic drugs ( excluding antialdosterone ),C0012798;C0013227;C3687832
1848,diuretic drugs  n ( % ),C0012798;C0013227;C3687832
1848,diuretic drugs,C0012798;C0013227;C3687832
1847,number of antidiabetes drugs at screening  n ( % ),C0013227;C0237753;C0449788;C3687832
1847,drugs used in diabetes  n ( % ),C0013227;C3687832
1847,drugs used in diabetes,C0013227;C3687832
1846,other drugs — no . ( % ),C0013227;C3687832
1846,other drugs,C0013227;C3687832
1846,no . of previous anti - tnf drugs — no . ( % ),C0013227;C0205156;C1448177;C1552607;C3687832
1846,no . of drugs,C0013227;C3687832
1845,no glucose lowering drugs,C0013227;C0017725;C0441994;C2003888;C3687832
1845,lowering drugs,C0013227;C0441994;C2003888;C3687832
1845,drugs and toxins,C0013227;C3687832
1845,blood glucose - lowering drugs  excluding insulin  n ( % ),C0005802;C0013227;C0017725;C0018938;C0441994;C2003888;C3687832
1844,immunomodulatory drugs,C0013227;C3687832
1844,concomitant drugs  %,C0013227;C0521115;C3687832
1844,concomitant drugs,C0013227;C0521115;C3687832
1844,concomitant antihyperglycaemic drugs  n ( % ),C0013227;C0020616;C0521115;C3687832
1843,annanginal drugs ( $nmbr$ / l / s » $nmbr$ ) ^,C0013227;C3687832
1843,$nmbr$ antianginal drugs,C0013227;C1874267;C3537168;C3687832
1842,on bp medication  n ( % ),C0013227;C0037623;C1415692;C1708288;C3244316;C4284232;C4318478
1842,medication prior to admission  ( % ),C0013227;C0184666;C0332152;C0809949;C3244316;C4284232
1842,medication at entry ( % ),C0013227;C1705654;C3244316;C4284232
1842,medication  n ( % ),C0013227;C3244316;C4284232
1842,medication,C0013227;C3244316;C4284232
1842,lipid medication  n ( % ),C0013227;C0023779;C3244316;C4284232
1842,dm medication  n ( % ) c,C0011816;C0013227;C3244316;C3250443;C4284232
1842,discharge medication  n ( % ),C0012621;C0013227;C0030685;C2926602;C3244316;C4284232
1841,use of medication from randomization through $nmbr$ hr — no . / total no . ( % ),C0013227;C1524063;C3244316;C4284232
1841,use of medication at baseline — no . ( % ),C0013227;C1524063;C3244316;C4284232
1841,study medication — no . ( % ),C0013227;C0557651;C2603343;C3244316;C4284232
1841,medication — no . ( % ),C0013227;C3244316;C4284232
1841,medication use — no . { % ),C0013227;C3244316;C4284232
1841,medication use — no . ( % ) ^ |,C0013227;C3244316;C4284232
1841,medication use — no . ( % ),C0013227;C3244316;C4284232
1841,medication use  no . / total no . ( % ),C0013227;C3244316;C4284232
1841,medication $nmbr$ ( $nmbr$ . $nmbr$ ),C0013227;C3244316;C4284232
1841,concomitant medication — no . ( % ),C0013227;C0521115;C3244316;C4284232
1841,concomitant medication ( % ),C0013227;C0521115;C3244316;C4284232
1841,concomitant medication  no . ( % ),C0013227;C0521115;C3244316;C4284232
1840,any ulcerative colitis medication,C0009324;C0013227;C3244316;C4284232
1840,any pulmonary medication  n ( % ),C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
1840,any pulmonary medication,C0013227;C0024109;C2707265;C2709248;C3244316;C4284232;C4522268
1840,any medication,C0013227;C3244316;C4284232
1839,other lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1839,lipid - lowering medication ( % ),C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1839,lipid - lowering medication,C0013227;C0023779;C0441994;C2003888;C3244316;C4284232
1839,iop - lowering medication,C0013227;C0441994;C0578862;C2003888;C3244316;C4284232
1838,copd medication taken for at least $nmbr$ months before study entry,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1838,copd medication taken for at least $nmbr$ months before st,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1838,any copd medication,C0013227;C0024117;C1412502;C3244316;C3714496;C4284232
1837,medication in use at the baseline,C0013227;C3244316;C4284232
1837,antihyperglycaemic medication at baseline,C0013227;C0020616;C0168634;C1442488;C3244316;C4284232
1836,study medication  pre - dose,C0013227;C0557651;C2603343;C3244316;C4284232
1835,medication within $nmbr$ days before enrolment,C0013227;C0439228;C3244316;C4284232
1835,medication continued into double - blind treatment period,C0013227;C3244316;C4284232
1835,concurrent medication,C0013227;C0205420;C3244316;C4284232
1834,statin medication,C0013227;C0360714;C3244316;C4284232
1834,other medication usage,C0013227;C0457083;C3244316;C4284232
1834,medication taken alone or in combination,C0013227;C3244316;C4284232
1834,antihyperglycemic medication usage,C0013227;C0020616;C0457083;C3244316;C4284232
1833,use of medication for pah,C0013227;C1524063;C3244316;C4284232
1833,use of cardiac medication *,C0013227;C0018787;C1522601;C1524063;C3244316;C4284232
1833,use of blood pressure lowering medication *,C0013227;C0020649;C1524063;C3244316;C4284232
1833,medication useb,C0013227;C3244316;C4284232
1832,medication at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1832,medication at time of randomization,C0013227;C0034656;C0040223;C3244316;C3541383;C4284232
1832,medication at randomization  n ( % ),C0013227;C0034656;C3244316;C4284232
1832,medication at randomization  %,C0013227;C0034656;C3244316;C4284232
1832,medication at randomization,C0013227;C0034656;C3244316;C4284232
1832,concomitant medications after randomization,C0013227;C0034656;C0521115;C0802604;C2598133;C4284232
1832,concomitant medication after randomisation,C0013227;C0034656;C0521115;C3244316;C4284232
1831,concomitant medication — no . { % ) | ace inhibitor,C0013227;C0521115;C3244316;C4284232
1831,concomitant medication | |,C0013227;C0521115;C3244316;C4284232
1831,concomitant medication ( > $nmbr$ % ),C0013227;C0521115;C3244316;C4284232
1831,concomitant medication  n [ % ],C0013227;C0521115;C3244316;C4284232
1831,concomitant medication  n ( % ) d,C0013227;C0521115;C3244316;C4284232
1831,concomitant medication  n ( % ),C0013227;C0521115;C3244316;C4284232
1831,concomitant medication,C0013227;C0521115;C3244316;C4284232
1831,> $nmbr$ concomitant medication,C0013227;C0521115;C3244316;C4284232
1830,use of medications for pah — no . ( % ),C0013227;C0802604;C1524063;C2598133;C4284232
1830,systemic sle medications  n ( % ),C0013227;C0024141;C0205373;C0802604;C2598133;C4284232
1830,selected medications — no . ( % ),C0013227;C0802604;C1707391;C2598133;C4284232
1830,pulmonary medications ( % ),C0013227;C0024109;C0802604;C2598133;C2707265;C2709248;C4284232;C4522268
1830,previous medications  n ( % ),C0013227;C0205156;C0802604;C1552607;C2598133;C4284232
1830,periprocedural medications  n ( % ),C0013227;C0802604;C2598133;C4284232
1830,periprocedural medications,C0013227;C0802604;C2598133;C4284232
1830,op concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,medications — no . ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications on admission  %,C0013227;C0802604;C2598133;C4284232
1830,medications in use at baseline  n ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications in the hospital after randomization — no . ( % ),C0013227;C0019994;C0802604;C1510665;C2598133;C4284232
1830,medications at time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1830,medications at the time of randomization — no . ( % ),C0013227;C0034656;C0040223;C0802604;C2598133;C3541383;C4284232
1830,medications at baseline  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1830,medications . no . ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications *,C0013227;C0802604;C2598133;C4284232
1830,medications ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications  no . ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications  n ( % ),C0013227;C0802604;C2598133;C4284232
1830,medications  n,C0013227;C0802604;C2598133;C4284232
1830,concomitant medications — no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications for ulcerative colitis — no . ( % ),C0009324;C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications  no . ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications  n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications  * n ( % ),C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant medications  %,C0013227;C0521115;C0802604;C2598133;C4284232
1830,concomitant asthma medications  n ( % ),C0004096;C0013227;C0521115;C0802604;C2598133;C2984299;C4284232
1830,baseline medications ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1830,baseline medications  n ( % ),C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1830,baseline antihyperglycemic medications  n ( % ),C0013227;C0020616;C0168634;C0802604;C1442488;C2598133;C4284232
1830,antithrombotic medications  n ( % ),C0013227;C0802604;C2598133;C4284232
1829,periprocedural medications — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
1829,periprocedural medications — no . / total no .,C0013227;C0802604;C2598133;C4284232
1829,medications — no . { % ) * *,C0013227;C0802604;C2598133;C4284232
1828,prior use of osteoporosis medications,C0013227;C0029456;C0332152;C0802604;C1524063;C2598133;C2826257;C4284232;C4554622
1828,prior medications,C0013227;C0332152;C0802604;C2598133;C2826257;C4284232
1828,other medications at enrollment,C0013227;C0802604;C1516879;C1696073;C2598133;C3888021;C4284232
1828,other medications,C0013227;C0802604;C2598133;C4284232
1828,medications through day $nmbr$,C0013227;C0332173;C0439228;C0439505;C0802604;C2598133;C4284232
1828,medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232
1828,medications in use at baseline — no . / total no . ( % ),C0013227;C0802604;C2598133;C4284232
1828,medications in use at baseline — no . ( % ),C0013227;C0802604;C2598133;C4284232
1828,medications for crohn ' s disease taken at baseline — no . ( % ),C0010346;C0013227;C0802604;C2598133;C4284232
1828,medications during hospitalization or at discharge,C0013227;C0019993;C0802604;C2598133;C4284232
1828,medications before admission,C0013227;C0184666;C0802604;C0809949;C2598133;C4284232
1828,medications at randomization,C0013227;C0034656;C0802604;C2598133;C4284232
1828,medications at baselinet,C0013227;C0802604;C2598133;C4284232
1828,medications antihypertensive drugs,C0003364;C0013227;C0802604;C2598133;C4284232
1828,medications,C0013227;C0802604;C2598133;C4284232
1828,lipids medications,C0013227;C0023779;C0802604;C2598133;C4284232
1828,lipid - lowering medications ^,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
1828,lipid - lowering medications,C0013227;C0023779;C0441994;C0802604;C2003888;C2598133;C4284232
1828,creatinine $nmbr$ . $nmbr$ mg / dl medications,C0010294;C0013227;C0439269;C0802604;C1561535;C2598133;C4284232
1828,concurrent medications,C0013227;C0205420;C0802604;C2598133;C4284232
1828,concomitant pd medications at baseline  n ( % ) c  d,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232;C4553228;C4553229
1828,concomitant medications at baseline,C0013227;C0168634;C0521115;C0802604;C1442488;C2598133;C4284232
1828,concomitant medications,C0013227;C0521115;C0802604;C2598133;C4284232
1828,cardiac medications during indexhospitalization and / or discharge,C0013227;C0018787;C0802604;C1522601;C2598133;C4284232
1828,cardiac medications during index hospitalization — no . ( % ),C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
1828,cardiac medications during index hospitalization  %,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
1828,cardiac medications during index hospitalization,C0013227;C0019993;C0428776;C0802604;C2598133;C4284232
1828,cardiac medications during index hospital stay and / or discharge,C0013227;C0428776;C0802604;C2598133;C3489408;C4284232
1828,cancer medications,C0006826;C0013227;C0802604;C0998265;C1306459;C2598133;C4284232
1828,blood - pressure medications at randomization — no . / total no . ( % ),C0005823;C0013227;C0033095;C0034656;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
1828,baseline medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1828,baseline crohn ' s disease medications,C0010346;C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1828,baseline anti - hyperglycemic medications  n ( % ),C0013227;C0168634;C0432633;C0802604;C1442488;C2598133;C4284232
1828,baseline anti - hyperglycemic medications,C0013227;C0168634;C0802604;C1442488;C2598133;C4284232
1828,antihyperglycemic medications,C0013227;C0020616;C0802604;C2598133;C4284232
1828,antianginal medications,C0013227;C0802604;C1874267;C2598133;C3537168;C4284232
1828,anti - arthritic medications,C0013227;C0802604;C2598133;C4284232
1827,baseline alc category,C0168634;C0683312;C1424945;C1442488;C3811058;C3889287
1827,baseline alc < $nmbr$ . $nmbr$ %,C0168634;C1424945;C1442488;C3811058
1827,alc < $nmbr$ . $nmbr$ % at baseline  n ( % ),C0168634;C1424945;C1442488;C3811058
1827,alc < $nmbr$ . $nmbr$ %,C1424945;C3811058
1827,alc ( % ),C1424945;C3811058
1826,alc at weeko ( % ),C1424945;C3811058
1826,alc at week $nmbr$ ( % ),C0332174;C0439230;C1424945;C3811058
1825,bl alc < $nmbr$ . $nmbr$ %,C0005918;C0006413;C1424945;C1552663;C2827109;C3811058
1825,alc > = $nmbr$ . $nmbr$ %,C1424945;C3811058
1825,alc > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,C1424945;C3811058
1824,hemoglobin ale *,C0019046;C0678386;C2632076
1824,hemoglobin ale  %  median ( iqr ),C0019046;C0549183;C0678386;C0876920;C2347635;C2348144;C2632076;C2939193
1824,ale < $nmbr$,C0678386;C2632076
1824,ale,C0678386;C2632076
1823,lm $nmbr$ bid ( n = $nmbr$ ),C1261082;C1551056
1823,lm $nmbr$ $nmbr$,C1261082;C1551056
1822,left main coronary artery  n ( % ),C1261082
1822,left main coronary artery,C1261082
1821,qmaxi rn l / s,C2827110;C3540639;C4281819
1820,elevated bun ( > $nmbr$ . $nmbr$ meq / l ),C0151539;C0439375
1819,serum potassium level  mean ( sd )  meq / l,C0302353;C0439375;C0444504;C0543465;C2347634;C2348143;C2699239
1819,serum potassium  meq / l,C0302353;C0439375;C0543465
1818,eos serum k +  meq / l,C0302353;C0439375;C1623465;C1861303
1818,baseline : > $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1818,baseline : > $nmbr$ . $nmbr$ meq / l eos : < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1818,baseline : < $nmbr$ . $nmbr$ meq / l eos : > $nmbr$ . $nmbr$ or < $nmbr$ . $nmbr$ meq / l,C0168634;C0439375;C1442488;C1623465;C1861303
1817,serum sodium . meq / l,C0439375;C0523891
1817,serum sodium  meq / l,C0439375;C0523891
1816,triacylglycerol  mmol / le,C0023190;C0041004;C0439090;C0439190;C1423767;C2697858
1816,total cholesterol  mmol / le,C0023190;C0201950;C0439090;C0439190;C0543421;C1423767;C2697858
1816,hdl - cholesterol  mmol / le,C0023190;C0023822;C0392885;C0439090;C0439190;C1423767;C2697858
1816,fema le,C0023190;C0439090;C1423767;C2697858
1815,baseline tg < $nmbr$ . $nmbr$ mmol / l,C0168634;C0337445;C1442488;C1532563
1815,baseline normoglycaemia ( fpg < $nmbr$ . $nmbr$ mmol / l ) - n,C0168634;C0580545;C1442488;C1532563
1815,< $nmbr$ . $nmbr$ mmol / l,C1532563
1815,< $nmbr$ - $nmbr$ mmol / l,C1532563
1814,mean baseline ldl - c ( mmol / l ),C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
1814,ldl - c in mmol / l ( baseline : mean ( sd ) [ n ]  wk $nmbr$ and change : mean ( se ) [ n ] ),C0168634;C0332174;C0439230;C0444504;C1442488;C1532563;C2347634;C2348143;C2699239
1814,baseline ( mmol / l ),C0168634;C1442488;C1532563
1813,ldl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
1813,ldl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0023824;C0202117;C1532563
1813,ldl cholesterol ( mmol / l )  mean ( sd ),C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1813,ldl cholesterol ( mmol / l ),C0023824;C0202117;C1532563
1813,ldl cholesterol  mmol / l 丰,C0023824;C0202117;C1532563
1813,ldl cholesterol  mmol / l *,C0023824;C0202117;C1532563
1813,ldl cholesterol  mmol / l  mean ± sd,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1813,ldl cholesterol  mmol / l  mean ( sd ) §,C0023824;C0202117;C0444504;C1532563;C2347634;C2348143;C2699239
1813,ldl cholesterol  mmol / l,C0023824;C0202117;C1532563
1813,ldl - cholesterol  mmol / l,C0023824;C0202117;C1532563
1813,ldl - c < $nmbr$ . $nmbr$ mmol / l,C1532563
1813,ldl - c  mmol / l,C1532563
1813,> $nmbr$ - $nmbr$ mmol / l,C1532563
1812,ldl cholesterol at baseline ( mmol / l ) * ldl cholesterol at screening,C0023824;C0168634;C0202117;C1442488;C1532563
1812,ldl cholesterol ( mmol / l ) :,C0023824;C0202117;C1532563
1812,ldl - cholesterol ( mmol / l ),C0023824;C0202117;C1532563
1812,ldl - c   *   ( mmol / l ),C1532563
1812,ldl - c * ( mmol / l ),C1532563
1811,triglycerides ( mmol / l ) ( median  iqr ),C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,triglycerides  median ( ql  q $nmbr$ )  mmol / l,C0041004;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,triglycerides  median ( qi  q $nmbr$ )  mmol / l,C0041004;C0376586;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,tg ( mmol / l  median ),C0337445;C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,fpg  median ( ql  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,fpg  median ( q $nmbr$  q $nmbr$ )  mmol / l,C0549183;C0876920;C1532563;C2347635;C2348144;C2939193
1811,fbg  mmol / l,C1532563
1811,fasting plasma glucose in mmol / l ( median ( q $nmbr$  q $nmbr$ ) [ n ] ),C0549183;C0583513;C0876920;C1532563;C2347635;C2348144;C2939193
1811,( mmol / l ],C1532563
1810,k ( mmol / l ),C0597277;C1532563;C1708601
1810,k  mmol / l,C0597277;C1532563;C1708601
1810,admission k  mmol / l,C0184666;C0597277;C0809949;C1532563;C1708601
1809,serum calcium  mmol / l,C0036785;C0728876;C1532563
1808,elevated serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0553704;C1532563
1808,> $nmbr$ mmol / l,C1532563
1807,serum potassium : < $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C0302353;C0543465;C1532563
1807,serum potassium ( mmol / l ),C0302353;C0543465;C1532563
1807,serum potassium  mean ( sd ) mmol / l,C0302353;C0444504;C0543465;C1532563;C2347634;C2348143;C2699239
1807,serum potassium  > $nmbr$ . $nmbr$ mmol / l,C0302353;C0543465;C1532563
1807,serum biochemistry potassium  mmol / l,C0005477;C0302353;C0543465;C1532563
1807,hyperkalaemia ( serum potassium > $nmbr$ . $nmbr$ mmol / l ),C0020461;C0302353;C0543465;C1532563;C4552983
1807,< $nmbr$ mmol / l,C1532563
1806,mdg ( mmol / l ),C0024443;C1417239;C1532563;C2986643
1805,mg / dl fpg ( mmol / l ),C0439269;C1532563
1805,ldl - c < $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
1805,hdl - c > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563;C3715113
1805,fc > $nmbr$ mg / dl ( > _ $nmbr$ . $nmbr$ mmol / l ) or history of diabetes,C0439269;C1532563;C2983605
1805,fbg ( mmol / l ),C1532563
1805,change  mg / dl ( mmol / l ),C0392747;C0439269;C0443172;C1532563;C1705241;C4319952
1805,< $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0439269;C1532563
1805,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mmol / l,C1532563
1804,£ $nmbr$ . $nmbr$ mmol / l,C1532563
1804,men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0025266;C0439269;C1532563
1804,baseline  mg / dl ( mmol / l ),C0168634;C0439269;C1442488;C1532563
1804,[ $nmbr$ . $nmbr$ mmol / l ] ),C1532563
1804,> $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ) + +,C0439269;C1532563
1804,> $nmbr$ . $nmbr$ mmol / l ( n = $nmbr$ ),C1532563
1804,> $nmbr$ . $nmbr$ mmol / l,C1532563
1804,> $nmbr$ + $nmbr$ mmol / l,C1532563
1804,> $nmbr$ ' $nmbr$ mmol / l,C1532563
1804,( < $nmbr$ . $nmbr$ mmol / l ),C1532563
1804,( $ $nmbr$ mg / dl [ $nmbr$ . $nmbr$ mmol / l ] ),C0439269;C1532563
1803,haemoglobin ( mmol / l ),C0019046;C0439190;C0635222;C1532563
1802,free fatty acids ( mmol / l ),C0015688;C1532563
1802,ffa ( mmol / l ),C0015688;C1532563
1801,serum phosphate  mmol / l,C0036820;C1532563
1800,serum total cholesterol  mmol / l ( sd ),C0587184;C1287371;C1532563;C2699239
1799,ldl - c  mmol / l ( sd ),C1532563;C2699239
1799,high - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023822;C0444504;C1532563;C2347634;C2348143;C2699239
1799,$nmbr$ - $nmbr$ mmol / l,C1532563
1798,phosphate ( mmol / l ),C0031603;C0031701;C1532563;C1601799
1797,triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
1797,triglycerides  mmol / l §,C0041004;C1532563
1797,triglycerides  * mmol / l,C0041004;C1532563
1797,triglyceride  mmol / l,C0041004;C1532563
1796,triglyceride ( mmol / l ) t,C0041004;C1532563
1796,triglyceride ( mmol / l ) * blood pressure,C0005823;C0041004;C1271104;C1272641;C1532563
1796,triglyceride ( mmol / l ),C0041004;C1532563
1795,triacylglycerol  mmol / l  mean ( sd ),C0041004;C0444504;C1532563;C2347634;C2348143;C2699239
1795,total c ( mmol / l  mean ),C0439175;C0439810;C0444504;C1532563;C2347634;C2348143
1795,serum hdl cholesterol ( mmol / l )  mean ( sd ),C0428472;C0444504;C1532563;C2347634;C2348143;C2699239
1795,mmol / l [ n ],C1532563
1795,mmol / l ),C1532563
1795,mmol / l,C1532563
1795,mean fpg  mmol / l,C0444504;C1532563;C2347634;C2348143
1795,mean change ‘ s in fasting blood glucose [ mg / dl ( mmol / l ) ],C0392747;C0428568;C0443172;C0444504;C1261430;C1532563;C1705241;C2347634;C2348143;C2827883;C3642216;C4319952
1795,mean ( s . d . ) baseline fpg  mmol / l,C0168634;C0444504;C1442488;C1532563;C2347634;C2348143
1795,low - density lipoprotein cholesterol  mean ( sd )  mmol / l,C0023824;C0444504;C1532563;C2347634;C2348143;C2699239
1795,ldl - c ( mmol / l ),C1532563
1795,ldl - c ( mmol / l  mean ),C0444504;C1532563;C2347634;C2348143
1795,ldl - c  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1795,ldl ( mmol / l ),C1532563
1795,fpg ( mmol / l )  mean ( sd ) 、,C0444504;C1532563;C2347634;C2348143;C2699239
1795,fpg ( mmol / l )  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1795,fpg ( mmol / l ),C1532563
1795,fpg  mmol / l ( mean ± sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1795,fpg  mmol / l  mean ( sd ),C0444504;C1532563;C2347634;C2348143;C2699239
1795,fpg  mmol / l,C1532563
1795,fpg  mean ( sd )  mmol / l,C0444504;C1532563;C2347634;C2348143;C2699239
1795,fpg  ( mmol / l ),C1532563
1795,bun  mmol / l,C1532563
1795,( mmol / l ),C1532563
1794,l . l ± $nmbr$ . $nmbr$,C3539687
1794,l ( < l ),C3539687
1794,< $nmbr$ . $nmbr$ l - g / l,C0439267;C3539687
1794,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ l ),C3539687
1794,$nmbr$ l . $nmbr$ ( l $nmbr$ . $nmbr$ ),C3539687
1794,$nmbr$ l ( l $nmbr$ ),C3539687
1794,$nmbr$ . l ( $nmbr$ l . $nmbr$ ),C3539687
1794,$nmbr$ . l ( $nmbr$ . l ),C3539687
1794,$nmbr$ . $nmbr$ ± l . l,C3539687
1794,$nmbr$ . $nmbr$ ( $nmbr$ l . l ),C3539687
1794,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - l . l ),C3539687
1793,l compared wit,C0439394;C1706495;C3642217
1793,l compared wi,C0043193;C0439394;C1520135;C1706495;C1707455;C3642217
1793,l / ll,C0439394;C1706495;C3642217
1793,l / c,C0439394;C1706495;C3642217
1792,l eft anterior descending coronary artery,C0226032;C0439394;C0451214;C1706495;C3642217
1792,l eft anterior descending,C0205094;C0205386;C0439394;C0451214;C1547177;C1706495;C3642217
1791,l vs . c,C0439394;C1706495;C3642217
1791,$nmbr$ . $nmbr$ ± l . ot,C0439394;C1318464;C1418208;C1705587;C1706495;C3642217
1790,l . i ( $nmbr$ . $nmbr$ ),C0021966;C0221138;C0439394;C1706495;C3642217
1790,l ( % ),C0439394;C1706495;C3642217
1790,( l ) t,C0439394;C1706495;C3642217
1789,l $nmbr$ - $nmbr$ vs placebo,C0439394;C1706495;C3642217
1789,l $nmbr$ - $nmbr$ vs l $nmbr$ - $nmbr$ - $nmbr$,C0439394;C1706495;C3642217
1789,l $nmbr$,C0439394;C1706495;C3642217
1789,l,C0439394;C1706495;C3642217
1789,> l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1789,< l $nmbr$ years,C0439234;C0439394;C1706495;C3642217
1788,non ‐ elderly,C0001792;C1518422;C1999167
1787,elderly ( > $nmbr$ years ),C0001792;C0439234;C1999167
1787,elderly,C0001792;C1999167
1786,rhabdomyolysis or myopathy,C0035410;C4552660
1786,rhabdomyolysis ( n = $nmbr$ ),C0035410;C4552660
1786,rhabdomyolysis  myopathy  or myalgia with ck elevation > $nmbr$ x uln,C0026848;C0035410;C4552660
1786,rhabdomyolysis  myopathy  or elevated creatine phosphokinase > $nmbr$ x upper limit of normal ( n = $nmbr$ ),C0026848;C0035410;C4552660
1786,rhabdomyolysis,C0035410;C4552660
1785,basal alone,C0205112;C0205171;C0439044;C0679994
1784,lived alone,C0205171;C0439044;C0679994;C1548795;C1634625;C2982691
1783,rivaroxaban alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0205171;C0439044;C0679994;C1739768
1783,rivaroxaban alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C1739768
1783,pci alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C4049621
1783,heparin alone ( n = $nmbr$ ),C0019134;C0205171;C0439044;C0679994;C0770546
1783,fluticasone alone ( n = $nmbr$ ),C0082607;C0205171;C0439044;C0679994
1783,bivalirudin alone ( n = $nmbr$ ),C0168273;C0205171;C0439044;C0679994
1783,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057;C0205171;C0439044;C0679994
1783,aspirin alone ( n = $nmbr$ ),C0004057;C0205171;C0439044;C0679994
1783,alone,C0205171;C0439044;C0679994
1782,single vessel disease,C0037179;C0042373;C0087136;C0205171
1782,single - vessel disease  n ( % ),C0037179;C0042373;C0087136;C0205171
1782,single - vessel disease,C0037179;C0042373;C0087136;C0205171
1782,single,C0037179;C0087136;C0205171
1781,only cerebrovascular disease,C0007820;C0205171;C1720467
1780,image only,C0205171;C1704254;C1704922;C1720467;C3542466
1779,females only,C0086287;C0205171;C1720467
1778,legs only,C0205171;C1140621;C1720467
1777,class v only,C0205171;C0457166;C1720467;C1880098
1776,pioglitazone only,C0071097;C0205171;C1720467
1775,jbs - $nmbr$ secondary prevention only $nmbr$,C0175692;C0205171;C0679699;C0795841;C1416527;C1720467
1775,jbs - $nmbr$ primary prevention only $nmbr$,C0033144;C0175692;C0205171;C0795841;C1416527;C1720467
1774,sulphonylureas only,C0038766;C0205171;C1720467
1773,pulmonary embolism only,C0034065;C0205171;C1720467
1772,previous ics only,C0205156;C0205171;C0815320;C1552607;C1720467;C4551720
1772,ics only,C0205171;C0815320;C1720467;C4551720
1771,only dvt,C0149871;C0205171;C1720467;C2926618;C3899446
1771,dvt only,C0149871;C0205171;C1720467;C2926618;C3899446
1770,patients with deep - vein thrombosis only,C0030705;C0149871;C0205171;C1720467
1770,deep vein thrombosis only,C0149871;C0205171;C1720467
1770,deep - vein thrombosis only,C0149871;C0205171;C1720467
1769,unfractionated only,C0205171;C1720467
1769,unfractionated heparin only,C0019134;C0205171;C1720467;C2825026
1769,heparin only,C0019134;C0205171;C0770546;C1720467
1768,cortical only,C0001613;C0007776;C0022655;C0205171;C1720467
1767,oral hypoglycemic drugs only,C0205171;C0359086;C1720467
1767,oral hypoglycaemics only,C0205171;C0359086;C1720467
1767,oad only,C0205171;C1720467
1766,basal only,C0205112;C0205171;C1720467
1765,lieum only  n ( % ),C0205171;C1720467
1765,$nmbr$ ( only $nmbr$ distal ),C0205108;C0205171;C1720467;C4522154
1764,handihaler only  n,C0205171;C1720467
1764,antimalarials only,C0003374;C0205171;C1720467
1763,aspirin only ( n = $nmbr$  $nmbr$ ),C0004057;C0205171;C1720467
1763,aspirin only,C0004057;C0205171;C1720467
1762,colon only  n ( % ),C0009368;C0205171;C1720467;C3888384
1762,colon only  ' n ( % ),C0009368;C0205171;C1720467;C3888384
1762,colon only,C0009368;C0205171;C1720467;C3888384
1761,imm only,C0205171;C0205470;C1720467
1760,ileum only  n ( % ),C0020885;C0205171;C1720467
1760,ileum only,C0020885;C0205171;C1720467
1759,ufh only,C0205171;C1720467
1759,pool of long term ( hefh patients only ) and high fh,C0030705;C0205171;C0337051;C0443252;C1509144;C1720467;C2349200
1758,cabg only,C0010055;C0205171;C1720467
1757,lama ( only monotherapy ),C0205171;C0999593;C1416775;C1720467
1757,laba ( only monotherapy ),C0205171;C1720467
1756,concomitant drug treatment,C0150270;C0521115;C3469597
1755,on drug treatment ( % ),C0150270;C3469597
1755,days of study - drug administration ( % ) * * $nmbr$ day,C0150270;C2826182;C3469597
1754,treatment with any bp lowering drugs,C0037623;C0441994;C1415692;C1708288;C2003888;C3469597;C4318478
1754,treatment with antiplatelet drugs,C3469597
1753,at least one drug - eluting stent,C0205447;C1322815
1752,non - drug - eluting stent,C1322815;C1518422
1752,drug eluting stent,C1322815
1752,drug - eluting stent — no . ( % ),C1322815
1752,drug - eluting stent implanted — no . ( % ),C1322815
1752,drug - eluting stent  n ( % ),C1322815
1752,drug - eluting stent,C1322815
1751,received drug - eluting stent,C1322815;C1514756
1751,drug - eluting stent implanted ( at least one ),C1322815
1751,drug - eluting stent implanted,C1322815
1750,pretreatment triglycerides,C0041004;C1550147;C2709094;C3539075;C3539076
1750,pretreatment hdl - c,C1550147;C2709094;C3539075;C3539076;C3715113
1750,pre - treatment [ n ( % ) ] c,C1550147;C2709094;C3539075;C3539076
1750,duration of clopidogrel pretreatment 一 hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1750,duration of clopidogrel pretreatment — hr median,C0070166;C0449238;C0549183;C0876920;C1550147;C2347635;C2348144;C2709094;C2926735;C2939193;C3539075;C3539076
1750,clopidogrel pretreatment duration,C0070166;C0449238;C1550147;C2709094;C2926735;C3539075;C3539076
1749,with laba  n ( % ) pretreatment,C1550147;C2709094;C3539075;C3539076
1749,no pretreatment,C1550147;C2709094;C3539075;C3539076
1749,$nmbr$ prolonged antithrombotic pretreatment ( n = $nmbr$ ),C0439590;C1550147;C2709094;C3539075;C3539076
1748,methotrexate treatment !,C0746573
1747,hypertension requiring treatment,C0578998
1746,active treatment,C1704532
1745,action tested is between the continuous variable and treatment .,C0441472;C3266814
1744,planned treatment strategy,C0599880;C0679199
1743,type of reference treatment strategy,C0455708;C0679199;C1514811;C1706462
1743,strategy,C0679199
1742,treatment satisfaction,C3476649
1741,treatment duration  days,C0439228;C0444921;C3259042
1741,duration of treatment in the healing study  n,C0444921
1740,prior treatment status,C0332152;C0449438;C0749659;C1514463;C2826257
1740,prestudy treatment status,C0749659
1739,conventional treatment ( n = $nmbr$ ),C2945704
1739,conventional treatment,C2945704
1738,medical treatment  n ( % ),C0679624
1738,medical treatment,C0679624
1737,subjects with imputed value for end ‐ of ‐ treatment body weight,C0681850;C1522609;C1550501;C1706203;C2349001;C2697811;C2699638
1737,imputed,C2699638
1736,responders of three - item end point at $nmbr$ weeks *,C0205449;C1551338;C2349179;C2826544;C4554251
1736,item,C1551338;C4554251
1735,reduction of hba $nmbr$ c from baseline ≥ $nmbr$ . $nmbr$ %,C0019016;C0301630;C0392756;C1293152;C1825777;C3538758;C4551656
1735,reduction in odds %,C0301630;C0392756;C1293152;C4551656
1735,rate reduction ( % ),C0301630;C0392756;C0871208;C1293152;C1521828;C4551656
1735,mild reduction in egfr,C0301630;C0392756;C1293152;C1739039;C2945599;C3811844;C3812682;C4551656
1735,dose reduction at randomization — no . ( % )  i,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1735,dose reduction at randomization  %,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1735,dose reduction at randomization,C0034656;C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1735,dose reduction  n ( % ),C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1735,composite of $nmbr$ % reduction in egfr  end - stage kidney disease  or death from renal causes,C0205199;C0301630;C0392756;C1293152;C1547335;C4551656
1735,any dose reduction,C0178602;C0301630;C0392756;C0869039;C1114758;C1293152;C4551656
1735,% reduction,C0301630;C0392756;C1293152;C4551656
1735,$nmbr$ ‐ point reduction in selena – sledai score  %,C0301630;C0392756;C0451528;C1293152;C1552961;C2347617;C3714763;C4551656
1734,reduced ef,C0392756
1734,hf without known reduced ef ( n = $nmbr$ ),C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1734,hf without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1734,hf ' without known reduced ef,C0018488;C0205309;C0392756;C1313497;C1538440;C3273279
1733,diabetes therapy at baseline ( alone or in combination ),C0168634;C1442488;C3274787;C3539002
1733,diabetes therapy  n ( % ),C3274787;C3539002
1733,diabetes therapy,C3274787;C3539002
1732,no diuretic therapy,C0948575
1732,diuretic therapy,C0948575
1731,standard therapy ( n = $nmbr$ ),C2936643
1731,standard therapy,C2936643
1730,pharmacotherapy,C0013216;C0013217
1730,other drug therapy  n ( % ),C0013216;C0013217
1730,drug therapy at admission 一 no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
1730,drug therapy at admission — no . ( % ) aspirin,C0013216;C0013217;C0184666;C0809949
1730,drug therapy  no . ( % ),C0013216;C0013217
1730,drug therapy  n ( % ),C0013216;C0013217
1730,drug therapy,C0013216;C0013217
1729,hormone therapy use,C0042153;C0279025;C0457083;C1947944
1729,hormonal therapy — no . ( % ),C0279025
1728,hormone therapy,C0279025
1728,baseline use of hormone therapy ( % ),C0168634;C0279025;C1442488;C1524063
1727,phototherapy previous systemic treatment  n ( % ),C0031765;C0205156;C0678812;C1552607
1727,phototherapy,C0031765
1726,anticoagulant therapy,C0150457
1725,no antiplatelet therapy,C1096021
1725,long - term antiplatelet therapy,C0443252;C1096021
1725,antiplatelet therapy §,C1096021
1725,antiplatelet therapy dual,C1096021
1725,antiplatelet therapy,C1096021
1724,antihypertensive therapy — no . ( % ),C0585941
1724,antihypertensive therapy  n ( % ),C0585941
1724,antihypertensive therapy,C0585941
1724,anti - hypertensive therapy - no . ( % ),C0585941
1724,anti - hypertensive therapy,C0585941
1723,estrogen therapy,C0279494
1722,statin therapy,C1278454
1722,prerandomization statin therapy,C1278454
1722,intensity of statin therapy at baseline — no . { % ),C0522510;C1278454
1722,intensity of statin therapy,C0522510;C1278454
1721,serms,C0732611
1720,other forms of atherosclerosis ’,C0003850;C0004153;C0348078;C0376315
1720,other forms of atherosclerosis ^,C0003850;C0004153;C0348078;C0376315
1720,other forms of,C0348078;C0376315
1719,others  n ( % ),C1955473;C3539125
1719,others,C1955473;C3539125
1719,all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C2975435;C3539125;C4086581
1719,all others  n ( % ),C1955473;C3539125
1719,all others,C1955473;C3539125
1718,peripheral vasodilators,C0724804
1717,peripheral revascularization ( n = $nmbr$ ),C0205100;C0581603
1717,peripheral revascularization,C0205100;C0581603
1717,peripheral,C0205100
1717,no peripheral revascularization ( n = $nmbr$  $nmbr$ ),C0205100;C0581603
1717,elective peripheral revascularization,C0205100;C0206058;C0439608;C0581603
1716,peripheral artery disease details,C1704436;C4025272
1716,peripheral artery disease - -,C1704436;C4025272
1716,peripheral artery disease *,C1704436;C4025272
1716,peripheral arterial stenosis,C4025272
1716,peripheral - artery stenosis,C4025272
1716,peripheral - artery disease ( % ),C1704436;C4025272
1716,peripheral - artery disease,C1704436;C4025272
1716,only peripheral artery disease,C0205171;C1704436;C1720467;C4025272
1715,peripheral artery disease 一 no . ( % ),C1704436;C4025272
1715,peripheral artery disease — no . ( % ),C1704436;C4025272
1715,peripheral artery disease,C1704436;C4025272
1715,peripheral - artery disease — no . ( % ),C1704436;C4025272
1715,baseline peripheral artery disease,C0168634;C1442488;C1704436;C4025272
1714,parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
1713,use of parenteral antithrombotic agents — no . ( % ),C0030547;C1524063;C1704311;C4522267
1713,use of parenteral antithrombotic,C0030547;C1524063;C4522267
1712,prasugrel or ticagrelor,C1620287
1712,prasugrel,C1620287
1711,lateral,C0205093
1710,bilateral disease ( % ) ' j ' ' j ',C1511113
1709,prior peripheral arterial disease,C0085096;C0332152;C1704436;C2826257
1709,peripheral vascular disease  n ( % ),C0085096
1709,peripheral vascular disease,C0085096
1709,peripheral arterial disease ( n = $nmbr$ $nmbr$ ),C0085096;C1704436
1709,peripheral arterial disease  n ( % ),C0085096;C1704436
1709,peripheral arterial disease,C0085096;C1704436
1708,peripheral arterial disease — no . ( % ) §,C0085096;C1704436
1708,peripheral arterial disease — no . ( % ),C0085096;C1704436
1708,peripheral arterial disease §,C0085096;C1704436
1708,any peripheral arterial disease,C0085096;C1704436
1708,any established peripheral arterial disease,C0085096;C0443211;C1272684;C1704436
1707,structural,C0678594
1706,structural heart disease — no . ( % ) f,C1290384
1706,structural heart disease §,C1290384
1706,structural heart disease,C1290384
1705,age at menopause ( yr ),C0439234;C1625754;C1629609
1704,$nmbr$ - yr risk of coronary heart disease ( % ) ^ |,C0439234;C1277690
1704,$nmbr$ - $nmbr$ yr ( % ),C0439234
1703,age s * $nmbr$ yr,C0001779;C0439234
1703,age > $nmbr$ yr — no . ( % ),C0001779;C0439234
1703,age > $nmbr$ yr  no . ( % ),C0001779;C0439234
1703,age ( yr )  mean ( sd ) bmd t - score  mean ( sd ),C0001779;C0439234;C2699239;C3533236
1703,age $nmbr$ * $nmbr$ yr,C0001779;C0439234
1703,> $nmbr$ yr — no . ( % ),C0439234
1703,> $nmbr$ yr ( % ),C0439234
1703,$nmbr$ - $nmbr$ yr,C0439234
1702,x $nmbr$ years,C0439234
1702,diabetic history ( years ) x,C0019664;C0019665;C0241863;C0262512;C0262926;C0439234;C1705255;C2004062
1701,history of clinical fracture ( > $nmbr$ years old ),C0205210;C0439234;C1272071
1701,history of clinical fracture ( > $nmbr$ years ),C0205210;C0439234;C1272071
1701,> $nmbr$ years old,C0439234
1700,diagnosis ( years ),C0011900;C0439234;C1704338;C1704656
1700,af first diagnosis > $nmbr$ years  n ( % ),C0011900;C0205435;C0344434;C0439234;C1279901;C1704338;C1704656;C4049859
1700,> $nmbr$ years $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0439234
1699,n / n ( % / yr ),C0369718;C0439234;C0441922
1699,% / yr,C0439234
1698,year from randomization,C0034656;C0439234;C0439508
1697,recurrent infections ( > $nmbr$ per year ),C0239998;C0439234;C0439508
1697,> = $nmbr$ yr,C0439234
1697,> = $nmbr$ years ( n = $nmbr$ ),C0439234
1697,> = $nmbr$ years,C0439234
1697,> $nmbr$ yr ( n = $nmbr$ ),C0439234
1697,> $nmbr$ years simva ( n = $nmbr$ ),C0439234
1697,> $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1697,> $nmbr$ years ( n = $nmbr$ ),C0439234
1697,> $nmbr$ year,C0439234;C0439508
1696,duration < $nmbr$ year  n ( % ),C0439234;C0439508;C0449238;C2926735
1696,> $nmbr$ years or < $nmbr$ crcl  n ( % ),C0439234
1696,< $nmbr$ yr,C0439234
1696,< $nmbr$ years ( % ),C0439234
1696,< $nmbr$ years  n ( % ),C0439234
1696,< $nmbr$ years,C0439234
1696,< $nmbr$ year,C0439234;C0439508
1696,$nmbr$ moto < $nmbr$ yr  n ( % ),C0439234
1695,rate difference ( events / year ),C0439234;C0439508;C0441471;C0871208;C1521828;C1705241;C1705242;C3541888
1695,rate ( % per year ),C0439234;C0439508;C0871208;C1521828
1695,rate ( % / year ),C0439234;C0439508;C0871208;C1521828
1695,mean ( se ) $nmbr$ - year rates per $nmbr$ population,C0036919;C0439234;C0439508;C0871208;C1521828;C2347634
1695,exacerbation rate per year,C0439234;C0439508;C0871208;C1521828;C4086268
1695,% / year,C0439234;C0439508
1694,years modified hoehn and yahr stage  n ( % ),C0439234
1694,year  n ( % ),C0439234;C0439508
1694,average age ( year ),C0001779;C0439234;C0439508;C1510992;C2825518
1694,age ( year )  mean ± sd,C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
1694,age ( year ),C0001779;C0439234;C0439508
1694,age  year,C0001779;C0439234;C0439508
1694,age  mean ± sd ( year ),C0001779;C0439234;C0439508;C0444504;C2347634;C2348143;C2699239
1694,< = $nmbr$ year  n ( % ),C0439234;C0439508
1693,standard care slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C1442989;C1947933;C2828392;C4330985;C4554674
1693,placebo slope lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C0807955;C1696465;C1706408;C4330985;C4554674
1693,insulin glargine slope lsm ± se ( mm / year ),C0036919;C0439234;C0439508;C0807955;C0907402;C4330985;C4554674
1692,≤ $nmbr$   year,C0439234;C0439508
1692,≤ $nmbr$ years,C0439234
1692,£ $nmbr$ yr,C0439234
1692,£ $nmbr$ years,C0439234
1692,£ $nmbr$ to < $nmbr$ years,C0439234
1692,year $nmbr$,C0439234;C0439508
1692,baseline to year $nmbr$,C0168634;C0439234;C0439508;C1442488
1692,> $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1692,> $nmbr$ to   ≤   $nmbr$ years vs .   ≤   $nmbr$ years,C0439234
1692,$nmbr$ year mean change from baseline,C0168634;C0392747;C0439234;C0439508;C0443172;C0444504;C1442488;C1705241;C2347634;C2348143;C4319952
1691,exacerbations in the year before study,C0439234;C0439508;C4086268
1691,exacerbations in the prev . year : $nmbr$,C0439234;C0439508;C1552852;C4086268
1690,severe episodes in previous year — no . / patient,C0205082;C0205156;C0332189;C0439234;C0439508;C1552607;C4050465;C4050466
1690,necessitating hospitalization in previous year — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1690,hospitalization in previous year with management of heart failure as major component — no . ( % ),C0019993;C0205156;C0439234;C0439508;C1552607
1690,hospitalization in previous year with management of heart failure,C0019993;C0205156;C0439234;C0439508;C1552607
1690,exacerbations in the previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1690,exacerbations in previous year requiring hospitalization and / or ed visit  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1690,exacerbations in previous year requiring hospitalization  n ( % ),C0019993;C0205156;C0439234;C0439508;C1552607;C4086268
1690,exacerbations in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1690,exacerbation rate in the previous year ( range ),C0205156;C0439234;C0439508;C0871208;C1514721;C1521828;C1552607;C2348147;C3542016;C4086268
1690,exacerbation in previous year,C0205156;C0439234;C0439508;C1552607;C4086268
1690,copd exacerbations during the previous year,C0205156;C0439234;C0439508;C0740304;C1552607
1689,first year *,C0205435;C0439234;C0439508;C1279901
1688,» $nmbr$ yr,C0439234
1688,» $nmbr$ years,C0439234
1688,$nmbr$ - year risk of chd  % # < $nmbr$ . $nmbr$,C0439234;C0439508;C1282512
1688,$nmbr$ - year risk of chd  % #,C0439234;C0439508;C1282512
1688,$nmbr$ - year risk for chd,C0439234;C0439508;C1282512
1688,$nmbr$ - year framingham chd risk ( % ) $nmbr$ mean / sd ),C0439234;C0439508;C0444504;C1282512;C2347634;C2348143;C2699239;C3166866
1688,$nmbr$ - year framingham chd risk  %,C0439234;C0439508;C1282512;C3166866
1688,$nmbr$ - year framingham chd risk,C0439234;C0439508;C1282512;C3166866
1688,# $nmbr$ year,C0439234;C0439508
1687,$nmbr$ - year predicted risk ( % ) of,C0439234;C0439508
1687,$nmbr$ - year km %,C0439234;C0439508;C3887676
1686,year - $nmbr$,C0439234;C0439508
1686,ukpds $nmbr$ - year risk score > $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1686,ukpds $nmbr$ - year risk score < $nmbr$ %,C0035647;C0439234;C0439508;C0449820;C4050231;C4552904
1686,mean $nmbr$ - year cvd risk *,C0007222;C0035647;C0439234;C0439508;C0444504;C2347634;C2348143;C4552904
1686,framingham $nmbr$ - year cv risk score,C0035647;C0439234;C0439508;C0449820;C3166866;C3538987;C4048877;C4050231;C4318503;C4552904
1686,> year $nmbr$,C0439234;C0439508
1685,all - cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C0439234;C0439508;C0444868;C1524003;C3539085
1685,$nmbr$ years or more,C0439234
1685,$nmbr$ year or more,C0439234;C0439508
1685,$nmbr$ - year mortality,C0026565;C0026566;C0439234;C0439508
1684,older than $nmbr$ years,C0439234;C0580836
1684,> = medan ( $nmbr$ year - old ),C0439234;C0439508;C0580836
1684,< median ( $nmbr$ year - old ),C0439234;C0439508;C0549183;C0580836;C0876920;C2347635;C2348144;C2939193
1684,$nmbr$ years or older,C0439234
1683,〉 $nmbr$ years,C0439234
1683,education $nmbr$ - $nmbr$ years,C0013621;C0013622;C0013658;C0039401;C0439234
1682,■ $nmbr$ years,C0439234
1682,formal education  years,C0439234;C0681344
1681,difference $nmbr$ years - baseline *,C0168634;C0439234;C1442488;C1705241;C1705242
1681,difference $nmbr$ years - baseline,C0168634;C0439234;C1442488;C1705241;C1705242
1681,> $nmbr$ years eze / simva baseline ldl - c,C0168634;C0439234;C1442488
1681,> $nmbr$ years baseline ldl - c,C0168634;C0439234;C1442488
1681,> $nmbr$ - $nmbr$ years,C0439234
1681,$nmbr$ - $nmbr$ years,C0439234
1680,person - years,C0027361;C0439234;C2347489
1680,no . / $nmbr$ person - yr,C0027361;C0439234;C2347489
1680,incidence  $nmbr$ person - year,C0021149;C0027361;C0220856;C0439234;C0439508;C2347489
1680,event / patients in group ( incidence / $nmbr$ person - year ),C0021149;C0027361;C0030705;C0220856;C0439234;C0439508;C0441471;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2347489;C4019010
1680,cardiovascular mortality ( per $nmbr$ person - years ),C0007226;C0026565;C0026566;C0027361;C0439234;C2347489;C3887460
1679,aspirin group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0004057;C0027361;C0439234;C0441848;C2347489
1679,> $nmbr$ years n z $nmbr$,C0439234
1679,< $nmbr$ years n z $nmbr$,C0439234
1679,$nmbr$ years ( n = $nmbr$ ),C0439234
1679,$ $nmbr$ years ( n = $nmbr$ ),C0439234
1679,$ $nmbr$ years,C0439234
1678,rates per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1678,rate per $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1678,rate per $nmbr$ - patient - years ( control vs alirocumab ) i,C0030705;C0439234;C0871208;C1521828
1678,rate per $nmbr$ - patient - years ( control vs alirocumab ) *,C0030705;C0439234;C0871208;C1521828
1678,rate / $nmbr$ patient - years,C0030705;C0439234;C0871208;C1521828
1678,patient years,C0030705;C0439234
1678,event rates per $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C0441471;C0871208;C1521828;C3259781;C4019010
1677,patients per $nmbr$ patient - years,C0030705;C0439234
1677,evenls per $nmbr$  $nmbr$ palienl - years,C0439234
1677,ard per $nmbr$ $nmbr$ patient - years ( $nmbr$ % ci ),C0008107;C0030705;C0439234;C1817569;C1826411;C3259781
1677,ard ( $nmbr$ % cl ) per $nmbr$ patient - years,C0030705;C0439234;C0596019;C1817569;C1826411
1676,patient - years ) hr ( unadjusted ),C0030705;C0439234
1676,number ol ( % ) patients > $nmbr$ years,C0030705;C0237753;C0439234;C0449788
1675,non - elderly ( < $nmbr$ years ),C0001792;C0439234;C1518422;C1999167
1675,$nmbr$ - < $nmbr$ years,C0439234
1674,≥ $nmbr$ years,C0439234
1674,aged ≥ $nmbr$ years,C0001779;C0001792;C0439234;C1999167
1673,age at diagnosis s $nmbr$ years,C0439234;C1828181;C3173302
1673,age at diagnosis of sle  years,C0024141;C0439234;C1828181;C3173302
1673,a $nmbr$ years,C0439234
1672,at $nmbr$ years,C0439234
1672,age at disease onset  years *,C0012634;C0206132;C0439234;C3870509
1671,women > $nmbr$ years,C0043210;C0439234
1671,women < $nmbr$ years,C0043210;C0439234
1671,> $nmbr$ years simva ( „ = $nmbr$ },C0439234
1671,> $nmbr$ years simva,C0439234
1671,> $nmbr$ years eze / simva ( „ = $nmbr$ },C0439234
1671,< $nmbr$ years simva ( n = $nmbr$ },C0439234
1671,< $nmbr$ years simva ( n = $nmbr$ ),C0439234
1671,< $nmbr$ years simva,C0439234
1671,< $nmbr$ years eze / simva ( n = $nmbr$ },C0439234
1671,< $nmbr$ years eze / simva ( n = $nmbr$ ),C0439234
1671,< $nmbr$ years eze / simva,C0439234
1671,$nmbr$ — < $nmbr$ years,C0439234
1671,$nmbr$ — $nmbr$ years,C0439234
1670,years since last gout flare,C0439234
1670,ss years,C0439234;C2699257;C3891295;C4551874
1669,≥ $nmbr$ . $nmbr$ years,C0439234
1669,asubset of the ≥ $nmbr$ years subgroup .,C0439234;C1079230;C1515021
1668,years since symptom onset,C0439234
1668,time from symptom onset of ra  years  median,C0439234;C1320528;C3538806;C4048756
1667,years,C0439234
1667,prior years taking warfarin,C0332152;C0439234;C2826257
1666,median duration of symptoms ( range )  yr,C0436359;C0439234;C0549183;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1666,age yr  range,C0001779;C0439234;C1514721;C2348147;C3542016
1666,> $nmbr$ yr since menopause,C0439234
1666,< $nmbr$ yr since menopause,C0439234
1665,years [ range ],C0439234;C1514721;C2348147;C3542016
1665,mean ( sd ) [ range ] duration of epilepsy  years,C0014544;C0439234;C0444504;C0449238;C1514721;C2347634;C2348143;C2348147;C2699239;C2926735;C3542016
1664,years since pd diagnosis  mean ± sd,C0439234
1664,years since pah diagnosis,C0439234
1664,years since myocardial infarction,C0439234
1664,years since mi ( median,C0439234
1664,years since menopause,C0439234
1664,years since diagnosis of type $nmbr$ diabetes  n ( % ),C0439234
1664,years since diagnosis  mean,C0439234
1664,years since diagnosis,C0439234
1664,mean years since menopause,C0439234;C0444504;C2347634;C2348143
1664,mean duration offollow - up ( years ) *,C0439234;C0444504;C0449238;C2347634;C2348143;C2926735
1663,mean — yr age group — no . ( % ),C0027362;C0439234;C0444504;C2347634;C2348001;C2348143
1663,mean — yr,C0439234;C0444504;C2347634;C2348143
1663,mean age ( yr ),C0001779;C0439234;C0444504;C2347634;C2348143
1663,characteristic age mean ± sd — yr,C0001779;C0439234;C0444504;C1521970;C2347634;C2348143;C2699239
1662,ra duration ( years )  mean ( s . e . ),C0439234;C0444504;C0449238;C2347634;C2348143;C2926735;C3538806;C4048756
1662,education in years  mean,C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143
1662,disease duration [ year ]  mean ± sda,C0276477;C0439234;C0439508;C0444504;C0872146;C1428349;C1553165;C2347634;C2348143
1662,disease duration  mean yr ( sd ),C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1662,disease duration  mean [ sd ] years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1662,copd duration  mean ( sd )  yr *,C0024117;C0439234;C0444504;C0449238;C1412502;C2347634;C2348143;C2699239;C2926735;C3714496
1662,age [ year ]  mean ± sda,C0001779;C0276477;C0439234;C0439508;C0444504;C1428349;C1553165;C2347634;C2348143
1662,$nmbr$ yr,C0439234
1662,$nmbr$ e $nmbr$ years,C0439234
1661,years of education  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1661,years ),C0439234
1661,years ( sd ),C0439234;C2699239
1661,type $nmbr$ diabetes duration  mean ( sd )  years,C0439234;C0444504;C0449238;C1320657;C2347634;C2348143;C2699239;C2926735
1661,mean ( sd ) years daily ocs use  n ( % ),C0332173;C0439234;C0444504;C2347634;C2348143;C2699239
1661,education  years  mean ( sd ),C0013621;C0013622;C0013658;C0039401;C0439234;C0444504;C2347634;C2348143;C2699239
1661,duration of paod ( years )  mean ± sd,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1661,duration  mean ( sd )  years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735
1661,diabetes history  mean ( sd )  years,C0011847;C0011849;C0019664;C0019665;C0262512;C0262926;C0439234;C0444504;C1705255;C2004062;C2347634;C2348143;C2699239
1661,( years ),C0439234
1661,$nmbr$ years  n ( % ),C0439234
1660,years with gouty arthritis,C0003868;C0439234
1659,years with gout  mean ± sd,C0018099;C0439234;C0444504;C2347634;C2348143;C2699239
1659,years with gout,C0018099;C0439234
1658,> $nmbr$ yr — no . { % ),C0439234
1658,< $nmbr$ yr — no . { % ),C0439234
1658,< $nmbr$ yr — no . ( % ),C0439234
1658,$nmbr$ to < $nmbr$ yr — no . { % ),C0439234
1658,$nmbr$ to < $nmbr$ yr — no . ( % ),C0439234
1658,$nmbr$ mo to $nmbr$ yr,C0026544;C0332177;C0439234
1658,$nmbr$ = $nmbr$ yr — no . ( % ),C0439234
1658,$nmbr$ - $nmbr$ yr — no . ( % ),C0439234
1657,interval of > $nmbr$ yr since diagnosis of type $nmbr$ diabetes — no . ( % ),C0439234;C1272706;C1552654;C1552713
1657,> $nmbr$ yr — %,C0439234
1656,number of patients > $nmbr$ years ( % ),C0439234;C2360800
1656,number of ( % ) patients > $nmbr$ years,C0439234;C2360800
1656,> $nmbr$ years ( % ),C0439234
1655,> median ( $nmbr$ . $nmbr$ years ) — number / n ( % ),C0237753;C0439234;C0449788;C0549183;C0876920;C2347635;C2348144;C2939193
1655,$nmbr$ $nmbr$ years  n ( % ),C0439234
1654,> $nmbr$   years,C0439234
1654,> $nmbr$ years bmi,C0439234;C0578022
1654,> $nmbr$ to $nmbr$   years,C0439234
1653,赛 $nmbr$ years,C0439234
1653,≥ $nmbr$ to < $nmbr$ years,C0439234
1653,≥ $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ years,C0439234
1653,t $nmbr$ d duration  years,C0439234;C0449238;C2603360;C2926735
1653,duration of t $nmbr$ d ( years ),C0439234;C0449238;C2926735
1653,duration > $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1653,duration > $nmbr$ to < $nmbr$ years  n ( % ),C0439234;C0449238;C2926735
1653,asthma duration ( sd )  years,C0004096;C0439234;C0449238;C2699239;C2926735;C2984299
1653,> = $nmbr$ years and < $nmbr$ years,C0439234
1653,> $nmbr$ years to < $nmbr$ years ( n = $nmbr$ ),C0439234
1653,> $nmbr$ years to < $nmbr$ years,C0439234
1653,> $nmbr$ years  n ( % ),C0439234
1653,> $nmbr$ years,C0439234
1653,> $nmbr$ to < = $nmbr$ years  n ( % ),C0439234
1653,> $nmbr$ to < $nmbr$ yr,C0439234
1653,> $nmbr$ to < $nmbr$ years,C0439234
1653,> $nmbr$ to $nmbr$ years,C0439234
1653,$nmbr$ to < $nmbr$ yr,C0439234
1653,$nmbr$ to < $nmbr$ years,C0439234
1653,$nmbr$ to $nmbr$ yr,C0439234
1653,$nmbr$ to $nmbr$ years,C0439234
1652,ed duration > $nmbr$ yr  n ( % ),C0439234;C0449238;C2926735;C3538926
1652,ed > $nmbr$ yr  no . ( % ),C0439234;C3538926
1652,> $nmbr$ yr  n ( % ),C0439234
1652,> $nmbr$ yr,C0439234
1651,median disease duration — yr,C0439234;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1651,duration of disease — yr : t,C0439234;C0872146
1651,duration of disease ( yr ),C0439234;C0872146
1651,duration of disease ( years ),C0439234;C0872146
1651,disease duration ( yr ),C0439234;C0872146
1651,disease duration ( years ),C0439234;C0872146
1651,disease duration  years : median ( range ),C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1651,disease duration  year ( median ),C0439234;C0439508;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
1651,disease duration  median ( range ) years,C0439234;C0549183;C0872146;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1650,percentage with disease duration < $nmbr$ years,C0439165;C0439234;C0872146;C1549488;C1561533
1650,< $nmbr$ . $nmbr$ years,C0439234
1649,mean duration of disease  years,C0439234;C0444504;C0872146;C2347634;C2348143
1649,mean disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143
1649,mean ( sd ) disease duration  years,C0439234;C0444504;C0872146;C2347634;C2348143;C2699239
1649,duration of disease  years,C0439234;C0872146
1649,disease duration b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1649,disease duration > $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1649,disease duration ( years )  mean ± s . d .,C0439234;C0444504;C0872146;C2347634;C2348143
1649,disease duration $nmbr$ to b $nmbr$ years ( n = $nmbr$ ),C0439234;C0872146
1649,disease duration  years,C0439234;C0872146
1649,$nmbr$ years,C0439234
1648,duration of disease — yr ^ mean,C0439234;C0444504;C0872146;C2347634;C2348143
1648,duration of disease — yr,C0439234;C0872146
1647,dabigatran $nmbr$ mg $nmbr$ mg % per yr,C0439234;C1319635;C2348066
1646,persistent anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ < $nmbr$ g i $nmbr$,C0019046;C0021966;C0221138;C0439234;C0741008;C1319635;C1549954
1646,improving anemia bsl hb < $nmbr$ g i - $nmbr$  yr $nmbr$ > $nmbr$ g i - $nmbr$,C0002871;C0019046;C0021966;C0221138;C0439234;C1000483;C1272745;C1319635;C1549954;C4554633
1646,> $nmbr$ - < $nmbr$ years,C0439234
1646,> $nmbr$ - $nmbr$ yr,C0439234
1645,vorapaxar placebo $nmbr$ - yr . km %,C0032042;C0439234;C1696465;C1706408;C2974521;C3887676
1645,vorapaxar placebo $nmbr$ - yr %,C0032042;C0439234;C1696465;C1706408;C2974521
1645,placebo $nmbr$ yr km %,C0032042;C0439234;C1696465;C1706408;C3887676
1645,$nmbr$ - yr %,C0439234
1644,< = $nmbr$ yr,C0439234
1644,< $nmbr$ yr ( n = $nmbr$ ),C0439234
1644,< $nmbr$ years ( placebo n = $nmbr$  $nmbr$  saxagliptin n = $nmbr$  $nmbr$ ),C0032042;C0439234;C1611934;C1696465;C1706408
1644,< $nmbr$ years ( n = $nmbr$ ),C0439234
1643,$nmbr$ - yr km mortality rate,C0026565;C0205848;C0439234;C3887676
1642,pbo / simva - $nmbr$ yr km rale ( % ),C0031962;C0034642;C0439234;C3887676
1642,eze / simva - $nmbr$ yr km rale ( % ),C0034642;C0439234;C3887676
1641,vorapaxar placebo $nmbr$ - yr . km % rate,C0032042;C0439234;C0871208;C1521828;C1696465;C1706408;C2974521;C3887676
1641,n ( $nmbr$ yr km event rate  % ),C0369718;C0439234;C0441471;C0441922;C0871208;C1521828;C3887676;C4019010
1641,$nmbr$ yr km % ( n ),C0439234;C3887676
1641,$nmbr$ yr . km rate,C0439234;C0871208;C1521828;C3887676
1640,angiotensin receptor blocker yes,C0034787;C1549445;C1622222;C1705108;C1710701
1640,angiotensin receptor blocker and / or ace,C0034787;C1622222
1640,angiotensin receptor blocker,C0034787;C1622222
1639,angiotensin receptor,C0034787;C1622222
1639,angiotensin il - receptor blocker,C0003018;C0020898;C0021764;C0022271;C0034787;C1149183;C1622222;C4521302
1639,angiotensin - receptor blocker,C0034787;C1622222
1639,angiotensin - receptor,C0034787;C1622222
1638,angiotensin receptor blockers,C0521942;C0815017
1638,angiotensin ii receptor blockers,C0521942;C2757003
1637,arb = angiotensin ii receptor blocker  ccb,C0006684;C0521942;C3536793;C3888198
1637,angiotensin ii receptor blocker,C0521942;C3536793
1636,leukotriene - receptor antagonist,C0595726;C3537183;C4521995
1635,leukotriene receptor antagonists,C0595726;C2757015;C3542962
1634,endothelin - receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C0031638;C0332307;C1134681;C1547052;C1656262;C2266875;C3539996
1634,endothelin - receptor antagonists,C1134681;C2266875
1633,receptor blockers  n ( % ),C0597357
1633,receptor blockers,C0597357
1633,gpiib / iiia receptor inhibitor,C0016011;C0597357;C1999216
1632,receptor blocker,C0597357
1632,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015;C0597357;C2757044;C3536837;C4541021
1631,received an oral aha within $nmbr$ weeks prior to screening,C1514756
1631,received $nmbr$ prior biologic therapy  n,C0278947;C1514756
1631,received $nmbr$ prior biologic therapies  n,C0278947;C1514756
1630,received > $nmbr$ prior anti - tnf therapies  n,C0279936;C0332152;C0432633;C1514756;C2826257
1630,received $nmbr$ prior anti - tnf therapy  n,C0279936;C0332152;C0432633;C1514756;C2826257
1629,receiving concomitant nsaids and / or cox - $nmbr$ inhibitors,C1514756
1629,receiving concomitant corticosteroids,C1514756
1629,received pci,C1514756;C4049621
1628,receiving antihypertensive treatment -,C1514756
1628,receiving antihypertensive treatment  n ( % ) blood pressure  mm hg  mean ( sd ),C1514756
1628,receiving antihypertensive,C1514756
1628,hypertension  receiving treatment  n ( % ),C0578998;C1514756
1627,$nmbr$ - h postprandial c - peptide ( ng / ml ),C0006558;C0376674;C2827809
1626,fasting c - peptide ( ng / ml ),C0006558;C0015663;C0439275
1626,fasting c - peptide  ng / ml,C0006558;C0015663;C0439275
1625,fasting c - peptide ( nmol / l ) c,C0006558;C0015663;C0439282
1625,c peptide  nmol / l * ',C0006558;C0439282
1624,c - peptide tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0006558;C0041403;C1705241;C1705242
1624,c - peptide,C0006558
1623,mercaptopurine,C0000618
1623,corticosteroid - azathioprine / $nmbr$ - mercaptopurine,C0000618;C0001617;C0004482;C3536709
1623,azathioprine / $nmbr$ - mercaptopurine,C0000618;C0004482
1623,$nmbr$ - mercaptopurine / azathioprine,C0000618;C0004482
1623,$nmbr$ - mercaptopurine,C0000618
1622,interventional or surgical procedures,C0184661;C3274035
1621,procedures in the hospital — no . ( % ),C0019994;C0025664;C0184661;C1510665;C2700391;C3538935
1621,procedures after discharge — no . ( % ),C0012621;C0025664;C0030685;C0184661;C2700391;C2926602;C3538935
1621,peak procedural act — sec,C0025664;C0184661;C0444505;C2700391;C3274430;C3538935;C3539779
1620,unsuccessful procedure,C0184661;C1272705;C2700391;C3274430;C3539779
1620,time  mean ( sd )  min procedure,C0040223;C0184661;C0444504;C0702093;C1524029;C2347634;C2348143;C2699239;C2700391;C3274430;C3539779;C3541383;C3813700
1620,procedure * *,C0184661;C2700391;C3274430;C3539779
1620,procedure,C0184661;C2700391;C3274430;C3539779
1620,pci procedure,C0184661;C2700391;C3274430;C3539779;C4049621
1620,non pci procedure,C0184661;C1518422;C2700391;C3274430;C3539779;C4049621
1620,cystoscopic procedure,C0184661;C0560573;C2700391;C3274430;C3539779
1620,baseline procedure  n ( % ),C0168634;C0184661;C1442488;C2700391;C3274430;C3539779
1619,prior carotid intervention,C0184661;C0332152;C0741968;C0886296;C1273869;C2826257
1619,carotid artery intervention *,C0007272;C0162859;C0184661;C0397581;C0741968;C0886296;C1273869
1618,prior coronary intervention or coronary artery bypass grafting,C0018787;C0184661;C0332152;C0886296;C1273869;C2826257
1618,previous coronary intervention,C0018787;C0184661;C0205156;C0886296;C1273869;C1552607
1618,coronary intervention,C0018787;C0184661;C0886296;C1273869
1617,previous intervention ( % ),C0184661;C0205156;C0886296;C1273869;C1552607
1617,percutaneous intervention,C0184661;C0522523;C0886296;C1273869
1617,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l  for europa > $nmbr$ mg / l or on a lipid - lowering treatment  for peace  data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055;C0023779;C0039798;C0087111;C0184661;C0189695;C0242751;C0392347;C0441994;C0522523;C0545743;C0680443;C0886296;C1273869;C1511726;C1522326;C1533734;C1705169;C2003888;C2827881;C3245479;C3538994;C3714741;C3887704;C4049621
1617,multivessel intervention  n ( % ),C0184661;C0886296;C1273869
1617,intervention .,C0184661;C0886296;C1273869
1617,intervention,C0184661;C0886296;C1273869
1616,with dm ( n proactive intervention ( n = $nmbr$ a ),C0011816;C0184661;C0886296;C1273869;C3250443
1616,proactive intervention ( n = $nmbr$ a ),C0184661;C0886296;C1273869
1616,intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869
1616,intervention ( n = $nmbr$ ),C0184661;C0886296;C1273869
1616,experimental intervention group ( n = $nmbr$ ),C0184661;C0441848;C0886296;C1273869;C1517586
1615,gastroduodenal,C0450199
1614,gastroduodenum,C0391900
1613,major gastro - intestinal bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
1613,gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
1613,gastrointestinal bleeding,C0017181
1612,gastroenteritis,C0017160
1611,involved gastrointestinal,C0521362;C1314939
1611,gastrointestinal area involved — no . / total no . ( % ),C0017446;C0205146;C0521362
1611,gastrointestinal area involved  n / total n ( % ),C0017446;C0205146;C0521362
1610,glucose test,C0337438;C0595310
1609,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C0271650
1609,impaired glucose tolerance or impaired fasting glucose,C0271650
1609,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C0271650
1608,intensive blood glucose control,C0162425;C0522510;C1283828;C1550453;C3267174
1608,blood - glucose control,C3267174
1607,haplotype,C0018591
1606,previous labd alone,C0205156;C0396059;C1552607
1606,labd alone,C0396059
1605,aldosterone antagonists ( e . g . spironolactone ),C0002007;C2757004
1605,aldosterone antagonists,C0002007;C2757004
1605,aldosterone antagonist,C0002007;C2757004;C3536833
1604,ras - aldosterone inhibitor ^,C0002006;C0002007;C0034678;C0525678;C1514727
1604,aldosterone inhibitor,C0002007
1603,pre - bronchodilator fvc ’ % pred,C2599602;C3714541
1603,pre - bronchodilator fev  % predicted,C2599602;C3714541
1603,% predicted pre - bronchodilator fev $nmbr$  % *,C0681842;C1882327;C2599602;C3714541
1602,pre - bronchodilator fevr l,C1708033;C2599602
1602,pre - bronchodilator fevr % pred,C1708033;C2599602
1601,pre - bronchodilator fvc ( l ),C2599602;C3714541
1601,pre - bronchodilator fevj,C2599602
1601,pre - bronchodilator fev i ( l ),C0021966;C0221138;C2599602;C3714541
1601,pre - bronchodilator fev ^ ( l ),C2599602;C3714541
1601,fvc pre - bronchodilator,C2599602;C3714541
1600,prebronchodilator fev $nmbr$ ( l ) t,C2599602;C3714541
1600,prebronchodilator fev $nmbr$ ( l ),C2599602;C3714541
1600,prebronchodilator fev $nmbr$  mean ( sd )  l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1600,prebronchodilator fev $nmbr$  l,C2599602;C3714541
1600,prebronchodilator,C2599602
1600,pre - bronchodilator mean ( sd ) fev $nmbr$  . l,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1600,pre - bronchodilator fev $nmbr$ ( l ),C2599602;C3714541
1600,pre - bronchodilator fev $nmbr$,C2599602;C3714541
1600,pre - bronchodilator fev  ( l ),C2599602;C3714541
1600,pre - bronchodilator,C2599602
1600,mean ( sd ) change from pre - to post - bronchodilator fev $nmbr$  l,C0332152;C0392747;C0443172;C0444504;C0687676;C0740175;C1704687;C1705241;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3669034;C3714541;C4319952
1600,fev $nmbr$ prebronchodilator [ l ]  mean ± sd,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1600,fev $nmbr$ pre - bronchodilator ( l )  mean ( sd ) c,C0444504;C2347634;C2348143;C2599602;C2699239;C3714541
1600,fev $nmbr$ pre - bronchodilator,C2599602;C3714541
1600,fev $nmbr$ ( l ) pre - bronchodilator,C2599602;C3714541
1599,prebronchodilator fevj ( % predicted ),C2599602
1599,prebronchodilator fevi — liters,C0429706;C0475211;C0849974;C1561566;C2599602;C4528367
1599,prebronchodilator fevi ( % predicted ),C0849974;C1561566;C2599602;C4528367
1599,pre - bronchodilator fevi change,C0849974;C1561566;C2599602;C4528367
1599,a prebronchodilator fevl ( % predicted ),C2599602
1598,before bronchodilation — liters §,C0475211;C1371299;C3537072
1598,before bronchodilation,C1371299;C3537072
1597,spirometry after bronchodilation §,C0037981;C1371299;C3537072
1597,after bronchodilation,C1371299;C3537072
1596,postbronchodilator fevj ( % predicted ),C2599594
1596,postbronchodilator fev $nmbr$ / fvc  %,C2599594;C3714541
1596,postbronchodilator $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C2599594
1596,postbronchodilator,C2599594
1596,post - bronchodilator fevx ( l ),C2599594
1596,post - bronchodilator fev $nmbr$ ( l ) a,C2599594;C3714541
1596,post - bronchodilator fev $nmbr$ ( l ) *,C2599594;C3714541
1596,post - bronchodilator fev $nmbr$ ( l ),C2599594;C3714541
1596,post - bronchodilator fev $nmbr$ ( % predicted * ),C2599594;C3714541
1596,post - bronchodilator fev $nmbr$ % predictedb,C2599594;C3714541
1596,post - bronchodilator fev $nmbr$  l *,C2599594;C3714541
1596,post - bronchodilator fev $nmbr$  l  mean ( sd ) c,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1596,post - bronchodilator fev $nmbr$  l  mean ( sd ),C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1596,post - bronchodilator fev $nmbr$  l,C2599594;C3714541
1596,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ) c,C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1596,post - bronchodilator fev $nmbr$  % predicted  mean ( sd ),C0444504;C0681842;C1882327;C2347634;C2348143;C2599594;C2699239;C3714541
1596,post - bronchodilator fev $nmbr$  % predicted,C2599594;C3714541
1596,post - bronchodilator fev  ( l ),C2599594;C3714541
1596,post - bronchodilator fev  % predicted,C2599594;C3714541
1596,post - bronchodilator fev   % predicted,C2599594;C3714541
1596,post - bronchodilator,C2599594
1596,mean ( sd ) postbronchodilator fev $nmbr$ / fvc  %,C0444504;C2347634;C2348143;C2599594;C2699239;C3714541
1596,b postbronchodilator fevl ( % predicted ),C2599594
1595,bumetanide,C0006376
1594,budesonide — no . ( % ),C0054201
1594,budesonide mmx $nmbr$ mg  ( n = $nmbr$ ),C0024671;C0026410;C0054201;C0439269;C1960952;C2346927;C4321396;C4521761
1594,budesonide,C0054201
1593,budesonide ( n = $nmbr$ ),C0054201
1593,budesonide $nmbr$ ^ g ( n = $nmbr$ ),C0054201;C0439267
1593,budesonide  n ( % ),C0054201
1592,lixisenatide ( n = $nmbr$ o ),C2973895
1592,lixisenatide ( n = $nmbr$ ),C2973895
1592,lixisenatide,C2973895
1591,lacosamide,C0893761
1590,glucosamine ( n = $nmbr$ ),C0017718
1590,glucosamine,C0017718
1589,flecainide,C0016229
1588,nateglinide n / n,C0903898
1588,nateglinide and repaglinide,C0903898
1588,nateglinide ( n = $nmbr$ ),C0903898
1587,pleased,C3829994;C4264468
1586,elevated high - sensitivity crp — no . { % ) * *,C0742906;C1441604
1585,elevated crp ( > ulnt )  n ( % ),C0742906
1585,elevated crp  n ( % ),C0742906
1585,elevated baseline crp,C0168634;C0742906;C1442488
1584,exenatide ± oad,C0167117
1584,exenatide no . of events / total no . ( % ),C0167117
1584,exenatide n = $nmbr$,C0167117
1584,exenatide lar,C0167117
1584,exenatide er,C0167117;C3810541;C3811131
1584,exenatide,C0167117
1583,dutasteride ( w = $nmbr$ )  $nmbr$ / $nmbr$,C0754659
1583,dutasteride ( n = $nmbr$ ),C0754659
1583,dutasteride,C0754659
1582,rivastigmine ( n = $nmbr$ ),C0649350
1582,rivastigmine,C0649350
1581,pramlintide,C0537551
1580,liraglutide ( n = $nmbr$ ),C1456408
1580,liraglutide ( n = $nmbr$  $nmbr$ ),C1456408
1580,liraglutide $nmbr$ . $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
1580,liraglutide $nmbr$ . $nmbr$ mg ls means ( n ),C0023668;C0024671;C0026410;C0439269;C1456408;C1704970;C1960952;C2346927;C4321396;C4521761
1580,liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1580,liraglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1580,liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1580,liraglutide,C1456408
1579,liraglutide ( « = $nmbr$ ),C1456408
1579,liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ ),C0439422;C1456408
1578,n ( % ) liraglutide $nmbr$ placebo,C0032042;C0369718;C0441922;C1456408;C1696465;C1706408
1578,liraglutide n ( % ),C1456408
1577,meglitinides ( glinides ),C0065880;C1579432;C3537178
1577,meglitinide,C0065880
1576,glinide 一 no . ( % ),C2266929
1576,glinide,C2266929
1575,glipizide ( n = $nmbr$ ),C0017642
1575,glipizide,C0017642
1574,glyburide dose duringthe study ( mg ),C0017628;C0024671;C0026410;C0178602;C0439269;C0557651;C0869039;C1114758;C1960952;C2346927;C2603343;C4321396;C4521761
1574,glyburide ( n = $nmbr$ ),C0017628
1574,glyburide,C0017628
1573,tiotropium ( n = $nmbr$ ),C0213771
1573,tiotropium,C0213771
1573,placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0032042;C0213771;C1518422;C1696465;C1706408
1573,non - tiotropium,C0213771;C1518422
1573,formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0060657;C0213771;C1518422
1573,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ ),C0213771;C1518422
1573,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$,C0213771;C1518422
1572,tiotropium vs . salmeterol,C0213771
1572,tiotropium salmeterol no . of patients / total no .,C0073992;C0213771
1571,tiotropium + placeb ( n [ $nmbr$ ),C0213771
1571,indacaterol + tiotropium ( n [ $nmbr$ ),C0213771;C1722260
1571,differences between indacaterol + tiotropium versus tiotropium + placebo,C0213771;C1705241;C1705242;C1722260
1570,tiotropium ( nz $nmbr$ ),C0027978;C0213771
1569,tiotropium ( n z $nmbr$ ),C0213771
1569,tiotropium $nmbr$ mg respimat ® ( n z $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1568,with tiotropium,C0213771
1568,tiotropium $nmbr$ meg ( n = $nmbr$ ),C0024489;C0025175;C0072225;C0213771
1567,tiotropium $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1567,tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ ),C0213771;C0439267
1567,tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ ),C0213771;C0439267
1566,no corticosteroid  no imm,C0001617;C3536709
1566,no corticosteroid,C0001617;C3536709
1566,inhaled corticosteroid - yes  n ( % ),C0001617;C0004048;C1549445;C1705108;C1710701;C3536709
1566,inhaled corticosteroid,C0001617;C0004048;C3536709
1566,immy ( without corticosteroid )  n,C0001617;C3536709
1565,no corticosteroid + no imm  n,C0001617;C3536709
1565,imm + corticosteroid  n,C0001617;C0205470;C3536709
1565,corticosteroid + imm,C0001617;C0205470;C3536709
1564,corticosteroid or azathioprine / $nmbr$ - mercaptopurine,C0001617;C3536709
1564,corticosteroid - free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
1563,required corticosteroid and / or antibiotic ( without hospitalization ),C0001617;C1514873;C3536709
1563,neither corticosteroid nor immunosuppressant,C0001617;C3536709
1563,corticosteroid or immunosuppressant,C0001617;C3536709
1563,corticosteroid and immunosuppressant,C0001617;C3536709
1563,corticosteroid ( with or without immunosuppressants ),C0001617;C3536709
1562,corticosteroid dose ( prednisone,C0001617;C0032952;C0178602;C0869039;C1114758;C3536709
1562,corticosteroid,C0001617;C3536709
1561,refractory to corticosteroids  n ( % ),C0001617;C0205269;C3539185;C3540725;C3540726;C3540727
1561,oral corticosteroids,C0001617;C0442027;C3539185;C3540725;C3540726;C3540727;C4521986
1561,no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1561,no baseline corticosteroids,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1561,inhaled corticosteroids,C0001617;C0004048;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids only,C0001617;C0205171;C1720467;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids ( excluding budesonide ),C0001617;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids ' $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
1561,corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
1561,concomitant use of corticosteroids,C0001617;C0521115;C1524063;C3539185;C3540725;C3540726;C3540727
1561,concomitant oral corticosteroids  n ( % ) * *,C0001617;C0442027;C0521115;C3539185;C3540725;C3540726;C3540727;C4521986
1561,baseline corticosteroids *,C0001617;C0168634;C1442488;C3539185;C3540725;C3540726;C3540727
1561,> $nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727
1560,central europe,C0682369
1559,eastern and central europe,C1707877
1559,central / eastern europe and russia hr ( $nmbr$ % cl ),C0015177;C0205099;C0682369;C1707877;C1879652
1558,neutropenia,C0023530;C0027947;C0853697
1557,leukopenia,C0023530;C0750394
1556,southern europe,C0037724
1555,western europe plus other,C0043129
1555,western europe and other,C0043129
1555,western europe and lebanon,C0043129
1555,western europe and israel,C0043129
1555,western europe and australia,C0043129
1555,western europe ( n   = $nmbr$  $nmbr$ ),C0043129
1555,western europe ( n = $nmbr$ ),C0043129
1555,western europe ( including south africa ),C0043129
1555,western europe ( % ),C0043129
1555,western europe  australia  new zealand  middle east,C0026068;C0043129;C4289954
1555,western europe  australia  new zealand  middle eai,C0043129;C0444598;C0549183;C1552826;C4289954
1555,western europe  australia  new zealand  and middle east,C0043129;C4289954
1555,western europe  australia  new zealand,C0043129;C4289954
1555,western europe,C0043129
1554,eastern european,C0239309
1553,eastern europe and africa,C0015177
1553,eastern europe ( n   = $nmbr$  $nmbr$ ),C0015177
1553,eastern europe ( n = $nmbr$ ),C0015177
1553,eastern europe ( % ),C0015177
1553,eastern europe  africa,C0001737;C0001741;C0015176;C0015177
1553,eastern europe,C0015177
1552,european subcategories,C0239307;C1515010;C1535514
1551,white / european,C0007457;C0043157;C0220938;C0239307;C1535514
1551,european,C0239307;C1535514
1550,european trial,C0008976;C0239307;C1535514
1550,european or arab,C0239307;C1535514
1549,non - european trial,C0008976;C0239307;C1518422;C1535514
1549,non - european,C0239307;C1518422;C1535514
1548,western europe  israel  australia  or south africa,C0004340;C0015176;C0022271;C0043128;C0043129
1548,europe $nmbr$ ¶,C0015176
1548,europe $nmbr$,C0015176
1548,europe  israel  or australia,C0015176;C0022271
1547,non europe,C0015176;C1518422
1547,europe n z $nmbr$,C0015176
1547,europe,C0015176
1546,europe ( zone $nmbr$ ),C0015176;C1710706
1546,europe $nmbr$ +,C0015176
1546,europe $nmbr$ ( n = $nmbr$ ),C0015176
1546,europe $nmbr$ ( n = $nmbr$  $nmbr$ ),C0015176
1545,europe and russia,C0015176
1545,europe and canada,C0015176
1545,europe and australia,C0015176
1545,* other - europe ( n = $nmbr$ )  australia ( n = $nmbr$ ) and india ( n = $nmbr$ ) - the data from these regions were collapsed due to the small numbers,C0004340;C0015176;C0017446;C0205147;C0237753;C0449788;C1511726;C3245479;C3714741
1544,europe / lsrael,C0015176
1544,east europe,C0015176;C1707877
1544,e europe,C0015176
1544,e . europe,C0015176
1543,w europe,C0015176
1543,w est europe,C0015176;C3811127;C3890902
1543,w . europe,C0015176
1542,west europe,C0015176;C1705493
1542,europe ( including south africa ),C0015176
1541,western eu  australia  new zealand,C0015179;C0027978;C0043128;C0324547;C1705493;C3665627;C4289954
1541,eastern eu,C0015179;C1707877;C3665627
1540,europe ( non - eu ),C0015176;C0015179;C1518422;C3665627
1540,europe ( eu ),C0015176;C0015179;C3665627
1540,eu,C0015179;C3665627
1539,region  europe union,C0015179;C0017446;C0205147
1539,european union,C0015179
1538,number of draining fistulae per patient  n,C0237753;C0449788;C0544791
1538,no draining fistulas *,C0544791
1537,sinus tracts / perforation  ' ^ n ( % ),C0544791;C0549099;C0854572;C1185740;C1881710
1537,draining fistulae  n ( % ),C0544791
1536,patients with fistulas at baseline,C0016169;C0030705
1536,fistula  ' n ( % ),C0016169
1535,dilatative  n ( % ),C0002940;C0012359;C0700124;C1322279
1535,dilatative,C0002940;C0012359;C0700124;C1322279
1534,digitalis  n ( % ),C0012252;C0304520
1534,digitalis,C0012252;C0304520
1533,placebo + pioglitazone ( n = $nmbr$ ),C0032042;C0071097;C1696465;C1706408
1533,pioglitazone ( n = $nmbr$ ),C0071097
1533,pioglitazone ( n = $nmbr$  $nmbr$ ),C0071097
1532,pioglitazone dose  mean ( sd )  mg,C0024671;C0026410;C0071097;C0178602;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1532,pioglitazone,C0071097
1531,pulse — beats / min,C0232117;C0391850;C1947910
1531,pulse in beats / minute  mean ( sd ),C0232117;C0391850;C0439385;C0444504;C1947910;C2347634;C2348143;C2699239
1531,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117;C0391850;C1947910
1531,pulse  beats / min,C0232117;C0391850;C1947910
1530,pulse rate ( mean $nmbr$ h )  bpm *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1530,pulse rate ( bpm ),C0232117
1530,pulse rate  bpm ( mean $nmbr$ h )  mean ( sd ) *,C0033727;C0232117;C0369286;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1529,withdrew consent,C2349954
1529,withdrawals  n / n ( % ),C1710677;C2349954;C2825032;C3812880;C4049634
1528,inflotmas io mgluj versus piecew,C1046794;C3146236
1528,$nmbr$ ( io - $nmbr$ % ),C1046794;C3146236
1527,qol,C0518214
1527,mean ipss qol ( sd ),C0444504;C0518214;C1019118;C1998280;C2347634;C2348143;C2699239;C2827405;C3811063
1527,ipss qol ( ls,C0023668;C0518214;C1019118;C1998280;C2827405;C3811063
1527,ipss qol,C0518214;C1019118;C1998280;C2827405;C3811063
1526,oil,C0028908;C0032085;C1517288;C3541397
1526,- oil,C0028908;C0032085;C1517288;C3541397
1525,fish oil ( n = $nmbr$ ),C0016157
1525,fish oil,C0016157
1524,mild ( fev  > $nmbr$ % predicted ),C2945599;C3714541
1523,mild or no dysfunction ( crcl > $nmbr$ ml / min  n = $nmbr$ $nmbr$  [ $nmbr$ . $nmbr$ % ] ),C2945599
1523,mild ( n = $nmbr$ ),C2945599
1523,mild ( n $nmbr$ = $nmbr$ ) $nmbr$,C2945599
1523,mild ( gold $nmbr$ ),C0018026;C1304897;C2945599
1522,mild ( ipss < $nmbr$ ),C1019118;C1998280;C2827405;C2945599;C3811063
1522,mild,C2945599
1521,mild ( iief - ef $nmbr$ - $nmbr$ ),C2945599;C3641331
1520,mild decrease in gfr ( $nmbr$ - $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0017654;C0392756;C0439526;C0547047;C1417190;C1424601;C1705224;C2945599;C3815103;C3887665
1520,$nmbr$ - $nmbr$ ( mild ),C2945599
1519,patients with mild pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0278138;C0449820;C0582148;C2945599;C4050231;C4522280
1519,mild teaes,C2945599
1518,mild impairment ( £ $nmbr$ to,C0221099;C0684336;C2945599
1518,mild impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C2945599;C3811844;C3812682
1518,mild impairment ( egfr $nmbr$ - $nmbr$ ),C0221099;C0684336;C1739039;C2945599;C3811844;C3812682
1518,mild impairment ( $nmbr$ to < $nmbr$ ),C0221099;C0684336;C2945599
1518,mild impairment ( $nmbr$ to $nmbr$ ml / min ),C0221099;C0439445;C0684336;C2945599
1518,mild impairment  < $nmbr$ to < $nmbr$,C0221099;C0684336;C2945599
1518,mild impairment,C0221099;C0684336;C2945599
1518,mild ( > $nmbr$ to < $nmbr$ ),C2945599
1518,mild ( < $nmbr$ ),C2945599
1518,mild ( $nmbr$ - $nmbr$ ),C2945599
1518,< mild,C2945599
1517,mildly impaired,C0750532;C2945599
1517,mild or moderate copd,C2945599
1516,descent,C0205386;C0680043
1515,left anterior descending  n ( % ),C0205386;C0441998;C1547177
1515,left anterior descending,C0205386;C0441998;C1547177
1514,left anterior descending coronary artery,C0226032
1514,left anterior descending artery  n ( % ),C0226032
1514,left anterior descending artery,C0226032
1513,unprotected left main stented,C0038257;C0205091;C0205225;C0443246;C1542147;C1552822
1513,left main treated,C0205091;C0205225;C0443246;C1522326;C1542147;C1552822
1513,left main disease  n ( % ),C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
1513,left main disease,C0012634;C0205091;C0205225;C0443246;C1542147;C1552822
1513,left main artery,C0003842;C0205091;C0205225;C0226004;C0443246;C1542147;C1552822
1513,left main,C0205091;C0205225;C0443246;C1542147;C1552822
1513,left - sided colitisz,C0205091;C0443246
1512,normal left ventricular ejection fraction — no . ( % ) j,C0205091;C0205307;C0231683;C0428772;C0439166;C0443246;C0488728;C1535947;C1552822;C2347086;C4553972
1512,left side  n ( % ),C0205091
1512,left,C0205091;C0443246;C1552822
1511,left shoulder,C0524469
1510,left side only,C3842976
1510,left - sided disease only,C0012634;C3842976
1509,left sided colitis,C2887821
1509,left - sided colitis,C2887821
1508,size of left atrium normal — no . ( % ) £,C0225860;C0456389
1507,left atrial diameter  mm ( sd ),C0225860;C0225861;C1301886;C2699239;C4330985;C4554674
1507,left atrial diameter,C0225860;C0225861;C1301886
1507,left atrial anteroposterior diameter — mm,C0225860;C0225861;C1301886;C4330985;C4554674
1506,ment,C0084844;C1538994
1505,met ( n = $nmbr$ ),C0428210;C1550543;C4317104
1505,met % △ ( se ),C0036919;C0428210;C1550543;C4317104
1504,no longer met study criteria,C0205166;C0243161;C0428210;C0557651;C1550543;C1706317;C2603343;C4317104
1504,met criterion at finalt,C0243161;C0428210;C1550543;C4317104
1504,met criterion at final ( n [ % ] ),C0205088;C0243161;C0428210;C1546485;C1550543;C3853528;C4317104
1504,met criterion at blt ( n [ % ] ),C0243161;C0428210;C1550543;C1563149;C1708627;C4317104
1504,met criterion at bl ( n [ % ] ),C0005918;C0006413;C0243161;C0428210;C1550543;C1552663;C2827109;C4317104
1503,met / tzd,C0428210;C1550543;C4317104
1503,add - on to met + su $nmbr$,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1503,add - on to met + su,C0038642;C0428210;C1550543;C1705534;C1883712;C4317104
1503,add - on to met $nmbr$,C0428210;C1550543;C1883712;C4317104
1503,add - on to met,C0428210;C1550543;C1883712;C4317104
1502,study period fatal pe,C0070939;C0439531;C0557651;C1302234;C1705232;C1880476;C1948053;C2603343;C4284304
1501,symptomatic pe,C0070939;C0231220;C1880476;C4284304
1501,initial symptomatic pe,C0070939;C0205265;C0231220;C1279901;C1555582;C1705685;C1880476;C4284304
1500,pe only,C0070939;C0205171;C1720467;C1880476;C4284304
1499,pe,C0070939;C1880476;C4284304
1499,extent of index pe ' ( n  % of pe patients ),C0030705;C0070939;C0439792;C0600653;C0918012;C1552854;C1637833;C1880476;C2986546;C4284304
1498,pre ' rtous eptscde ( s } d dvt / pe,C0070939;C0149871;C0332152;C0740175;C1880476;C2257086;C2926618;C3669034;C3899446;C4284304
1498,pe ± dvt,C0070939;C0149871;C1880476;C2926618;C3899446;C4284304
1498,pe with / without dvt,C0070939;C1880476;C4284304
1498,pe associated with dvt at diagnosis,C0070939;C1880476;C4284304
1498,pe and dvt,C0070939;C1880476;C4284304
1498,pe ( with or without dvt ),C0070939;C1880476;C4284304
1498,neither pe nor dvt,C0070939;C1880476;C4284304
1498,index events : pe ± dvt n ( % ),C0070939;C0149871;C0441471;C0600653;C0918012;C1552854;C1637833;C1880476;C2926618;C2986546;C3541888;C3899446;C4284304
1497,pm pef ( sd )  l / min,C0030266;C0030771;C0702093;C1518922;C1524029;C1542834;C2699239;C3813700;C4049155
1497,pef at baseline  l_ / min,C0030771;C0168634;C0702093;C1442488;C1518922;C1524029;C1542834;C3813700
1497,pef !,C0030771;C1518922;C1542834
1497,pef  post - bronchodilator  % predicted normal,C0030771;C1518922;C1542834
1496,• iii : death from cv causes  nonfatal mi  hospitalization for ua  all revascularization > $nmbr$ days  nonfatal stroke,C0011065;C0439070;C1306577;C1705160;C3538987;C4048877;C4082313;C4318503;C4552775
1496,• ii : death from coronary heart disease  nonfatal mi  coronary revascularization > $nmbr$ days,C0011065;C0018799;C0439228;C0545743;C0581603;C1306577;C1710602;C3810814;C4082313;C4082587;C4552775
1496,• $nmbr$ : death from any cause  major coronary event  or nonfatal stroke,C0011065;C1306577;C4082313;C4552775
1496,vascular death,C0005847;C0011065;C1306577;C1558950;C1801960;C4082313;C4552775
1496,noncardiovascular death,C0011065;C1306577;C4082313;C4552775
1496,noncardiac death,C0011065;C1306577;C4082313;C4552775
1496,malignancy death,C0006826;C0011065;C1306459;C1306577;C4082313;C4282132;C4552775
1496,leading to death,C0011065;C0332152;C1306577;C1522538;C4082313;C4552775
1496,hazard ratio for cardiovascular death  stroke  or myocardial infarction ( $nmbr$ % ci ),C0011065;C0027051;C1306577;C2985465;C4082313;C4552775
1496,hazard ratio for cardiovascular death,C0007226;C0011065;C1306577;C2985465;C3887460;C4082313;C4552775
1496,death or myocardial infarction,C0011065;C1306577;C4082313;C4552775
1496,death or mi at $nmbr$ days,C0011065;C1306577;C4082313;C4552775
1496,death or disabling stroke,C0011065;C1306577;C4082313;C4552775
1496,death or absolute fvc decrease > $nmbr$ %,C0011065;C1306577;C4082313;C4552775
1496,death or $nmbr$ mwd decrease > $nmbr$ m,C0011065;C1306577;C4082313;C4552775
1496,death due to renal failure ®,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1496,death due to renal failure or sustained esrd,C0011065;C0035078;C0678226;C1306577;C1963154;C4082313;C4552775
1496,death *,C0011065;C1306577;C4082313;C4552775
1496,death  with pe not,C0011065;C0070939;C1306577;C1880476;C4082313;C4284304;C4552775
1496,death  mi  idr  st or gusto severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1496,death  mi  idr  st  or gusto moderate / severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1496,death  mi  idr  st  or gusto mod / sev bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1496,death  mi  idr  st  or any timi bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1496,death  mi  idr  or st,C0011065;C1306577;C3810814;C4082313;C4552775
1496,cvd death,C0007222;C0011065;C1306577;C4082313;C4552775
1496,cv death  myocardial infarction  stroke,C0011065;C0027051;C0038454;C0428953;C1306577;C2926063;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4552959;C4554100
1496,coronary heart disease death,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
1496,cardiovascular death ®,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death or nonfatal myocardial infarction,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death or nonfatal mi ( excluding silent mi ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death or hospitalized hf,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death or heart failure hospitalization,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death and hospital admission for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death *,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death !,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cardiovascular death  nonfatal myocardial infarction  or nonfatal stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
1496,cardiovascular death  nonfatal mi ( excluding silent mi )  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
1496,cardiovascular death  myocardial infarction  or stroke,C0007226;C0011065;C0027051;C0428953;C1306577;C2926063;C3810814;C3887460;C4082313;C4552775;C4552959
1496,cardiovascular death  mi  or stroke,C0007226;C0011065;C1306577;C3810814;C3887460;C4082313;C4552775
1496,cardiovascular death,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,cad death,C0011065;C1306577;C1504769;C2239547;C3813548;C4082313;C4284121;C4552775
1496,any death,C0011065;C1306577;C4082313;C4552775
1496,all death,C0011065;C1306577;C4082313;C4552775
1496,a cardiovascular death or hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1496,* per $nmbr$ participant years . composite of first occurrence death ( all cause )  nonfatal ml  or nonfatal stroke . cardiovascular death excluding those classified as “ unable to determine . ”,C0008902;C0011065;C0015127;C0205199;C0205435;C0243132;C0439234;C0566415;C0679646;C1279901;C1299582;C1306577;C1524003;C1547335;C1554210;C2698741;C2745955;C4048706;C4082313;C4321405;C4552775;C4554048
1495,• death from cv causes  major coronary event  or nonfatal stroke,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,death or ich,C0011065;C1306577;C4082313;C4552775
1495,death from,C0011065;C1306577;C4082313;C4552775
1495,death,C0011065;C1306577;C4082313;C4552775
1495,cv death or ml,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death or hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death or hf hospitalization n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death or hf hosp .,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death or first hhf,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death n,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death / hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death + hf hospitalization,C0011065;C0018488;C0019993;C1306577;C1313497;C1538440;C3273279;C3538987;C4048877;C4082313;C4318503;C4552775
1495,cv death  ml  or stroke,C0011065;C0439526;C1306577;C1705224;C3538987;C3887665;C4048877;C4082313;C4318503;C4552775
1495,cv death  mi  stroke  recurrent ischemia,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1495,cv death  mi  stroke,C0011065;C0038454;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775;C4554100
1495,cv death  mi  or stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1495,cv death  mi  or ischemic stroke,C0011065;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1495,cv death  mi  ischemic stroke  hospitalization for hf  coronary revascularization  ua,C0011065;C0018488;C0019993;C0041580;C0042014;C0376297;C0581603;C0877341;C0948008;C1306577;C1313497;C1538440;C3273279;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1495,cv death  mi  ischemic stroke,C0011065;C0948008;C1306577;C3538987;C3810814;C4048877;C4082313;C4318503;C4552775
1495,cv death,C0011065;C1306577;C3538987;C4048877;C4082313;C4318503;C4552775
1494,primary endpoint death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1494,primary end point : death / mi / idr / st,C0011065;C0036056;C1306577;C2986535;C3272372;C3810814;C4082313;C4552775
1494,death or stent thrombosis,C0011065;C1306577;C4082313;C4552775
1494,death / udmi / idr,C0011065;C1306577;C4082313;C4552775
1494,death / st,C0011065;C0036056;C1306577;C3272372;C4082313;C4552775
1494,death / q - ml / stent thrombosis,C0011065;C0439526;C1306577;C1705224;C3887665;C3897493;C4082313;C4552775
1494,death / q - mi / idr,C0011065;C1306577;C3810814;C4082313;C4552775
1494,death / mi / idr / st / gusto - defined moderate or severe bleeding,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1494,death / mi / idr / st,C0011065;C0036056;C1306577;C3272372;C3810814;C4082313;C4552775
1494,composite of death / mi / urg ent revasc,C0011065;C0205199;C0378365;C0919420;C1306577;C1367721;C1547335;C1705448;C3810814;C3889152;C4082313;C4552775
1494,composite of death / mi / stro ke / urgent revasc / definit e acute stent thrombosis,C0011065;C0022558;C0155626;C0205199;C0378365;C0439609;C1306577;C1547335;C3272275;C3897493;C4082313;C4552775
1494,$nmbr$ days composite of death / new mi / urgent revascularization and definite st,C0011065;C0205199;C0439609;C0581603;C1306577;C1547335;C3272275;C3810814;C4082313;C4552775;C4689466
1493,deaths  n ( % ),C0011065;C1306577
1493,deaths,C0011065;C1306577
1493,death ( all cause ),C0011065;C1306577;C4082313;C4552775
1493,death ( all - cause ),C0011065;C1306577;C4082313;C4552775
1493,death  n ( % ),C0011065;C1306577;C4082313;C4552775
1493,dead ( n = $nmbr$ ),C0011065
1493,data are reported as n ( % ) . event rates in parentheses are kaplan - meier estimates ( % ) at $nmbr$ year . * cardiovascular ( cv ) death  myocardial infarction ( mi )  or recurrent ischemia . † cv death  mi  or severe recurrent ischemia,C0007226;C0011065;C0022116;C0027051;C0428953;C0439234;C0439508;C1306577;C1511726;C1720943;C2926063;C3245479;C3538987;C3714741;C3810814;C3887460;C4048877;C4082313;C4318503;C4321499;C4552775;C4552959
1493,cardiovascular death ( n = $nmbr$ ),C0007226;C0011065;C1306577;C3887460;C4082313;C4552775
1492,non - cvd deaths,C0007222;C0011065;C1306577;C1518422
1492,no . of deaths,C0011065;C1306577
1492,cvd deaths,C0007222;C0011065;C1306577
1491,self - rated health status,C0018759;C0036588;C0871208;C1551994
1490,health practices,C0018684
1489,mental health,C0025353
1488,general health vas  $nmbr$ - $nmbr$ mm,C0042815;C0424575;C3536884;C3827561;C4018875;C4330985;C4554674
1488,general health ( self - reported ),C0424575;C4018875
1488,general health  self - reported,C0424575;C4018875
1488,general health,C0424575;C4018875
1487,benign prostatic hyperplasia,C1704272
1486,other bph - luts therapy,C0005001;C0039798;C0087111;C0574785;C1363945;C1704272
1486,bph - related health status,C0005001;C1704272
1485,pfo with mild - to - moderate shunt and atrial septal aneurysm,C0232180;C0542331;C1299392;C1442858
1485,mild - < moderate,C1299392
1484,mild to moderate,C1299392
1484,mild - to - moderate ( ipss < $nmbr$ ),C1019118;C1299392;C1998280;C2827405;C3811063
1483,severe / moderate,C1299393
1483,moderate - to - severe copd exacerbation,C0740304;C1299393
1483,gusto severe / moderate,C1299393
1482,morphometric vertebral,C0200760;C0549207
1481,cerebral hemorrhage,C2937358
1480,cerebral embolism,C0007780
1479,cerebral thrombosis,C0079102;C0151945;C0795687
1478,cerebral ischemia,C0007785;C0917798
1477,chd plus cerebral infarction,C0007785;C0280604;C3542407
1477,cerebral infarction,C0007785
1476,terminal ileum,C0227327
1476,disease location / type : terminal ileum,C0227327;C0450429;C0457464;C1515974;C4284930;C4284931
1475,global trial population,C0008976;C0032659;C0205246;C1257890;C2348867
1474,scores for global and pain assessments §,C0205246;C0449820;C2348867
1473,partial evolving to secondarily generalized ( ic ),C0020750;C0205246;C0332253;C0728938;C1550516;C4554818
1473,generalized,C0205246
1472,general andthoracic epidural,C0205246;C0228134;C0812144;C3812897;C3891294;C4521767
1472,general and lumbar epidural,C0205246;C3812897;C3891294;C4521767
1472,general alone,C0205171;C0205246;C0439044;C0679994;C3812897;C3891294;C4521767
1472,general allergic events,C0205246;C0441471;C0700624;C3541888;C3812897;C3891294;C4521767
1472,general,C0205246;C3812897;C3891294;C4521767
1471,mental status ( baseline spmsq scores )  n ( % ),C0168634;C0278060;C1442488
1471,mental status,C0278060
1470,mental activities updrs subscore ( baseline )  mean ( sd ),C0168634;C0229992;C0441655;C0444504;C1442488;C2347634;C2348143;C2699239;C3639721
1470,mental,C0229992
1469,dermal,C0221928;C1522447
1468,dental procedure,C0011331
1467,medal,C0524670
1466,bare metal,C0025552
1466,bare - metal,C0025552
1465,t - score at femoral neck,C0015815;C3854607
1464,mean femoral neck t score,C0015815;C3533236
1463,flex baseline bmd t - score at femoral neck ( meanisd ),C0015815;C0168634;C0449820;C1442488;C4050231
1463,femoral neck t - score,C0015815;C0449820;C4050231
1463,femoral neck f - score at flex baseline,C0015815;C0016327;C0168634;C0449820;C1442488;C4050231
1463,femoral neck bmd t - score,C0015815;C0449820;C4050231
1463,femoral neck,C0015815
1463,baseline t - score at femoral neck  n ( % ),C0015815;C0168634;C0449820;C1442488;C4050231
1463,baseline bmd t score at femoral neck,C0015815;C0168634;C0449820;C1442488;C4050231
1462,requiring assistance,C0018896;C1269765
1461,$nmbr$ = help needed  still independent,C1269765;C1552861
1460,patients without clinically evident vascular disease,C0030705;C0042373;C3887511
1460,patients with clinically evident vascular disease,C0030705;C0042373;C3887511
1460,evidence or thombus  n ( % ),C3887511
1460,clinically evident vascular disease,C0042373;C3887511
1459,headache,C0018681;C4553197
1458,health assessment questionnaire score,C2960025
1457,health habits,C0679786
1456,previous hospitalization for heart failure,C0205156;C1552607;C3898876
1456,hospitalization for heart failure within previous $nmbr$ mo — no . ( % ),C3898876
1456,hospitalization for heart failure within $nmbr$ mo,C3898876
1456,hospitalization for heart failure n ( % ),C3898876
1456,hospitalization for heart failure,C3898876
1456,hospitalisation for heart failure,C3898876
1455,hospitalization for heart failure or cv death,C3898876
1455,hospitalization for heart failure or cv,C3898876
1455,heart failure hospitalizations,C3898876
1455,heart failure hospitalisation or cv death,C3898876
1455,cardiovascular death / hospitalization for heart failure,C0007226;C0011065;C1306577;C3887460;C3898876;C4082313;C4552775
1454,no . of coronary vessels with > $nmbr$ % diameter stenosis,C0010075
1453,vessels with stenosis > $nmbr$ %,C0679403
1453,> $nmbr$ vessels with > $nmbr$ % stenosis,C0679403
1452,stented vessels,C0183521
1452,stented vessel,C0183521
1451,patients with specific disease characteris -,C0205369;C0683521;C1552740
1450,patients with remission,C1277626
1449,associated with an atrial septal defect,C0018817;C0332281
1448,associated with ctd,C0332281;C1335071;C1442905
1447,associated with hiv infection,C0019693;C0332281
1446,associated with corrected - congenital shunts,C0009678;C0205202;C0232180;C0332281;C0542331;C1442858;C1744681
1446,associated with corrected,C0205202;C0332281
1445,associated with drug / toxin,C0013221;C0332281
1444,associated with drug or toxin exposure,C0013227;C0332281;C1254351
1443,demographic data,C4684639
1442,demographic features,C0683970
1442,demographic feature,C0683970
1442,demographic characteristics  mean ( sd )  unless otherwise stated,C0444504;C0683970;C2347634;C2348143;C2699239
1442,demographic characteristics,C0683970
1441,demographic factors,C0011292;C0011298
1440,demographic characteristic,C0011298;C1521970
1439,demography,C0011298
1439,demographic / disease characteristics at baseline,C0011298;C0012634;C0168634;C0599878;C0683970;C1442488;C4684572
1438,demographic variable,C0011298;C0439828;C4553760
1438,demographic and medical variables,C0011298
1437,patient demographics age — yr,C0011298;C0439234;C1704791;C4698447
1436,demographics and clinical characteristics,C0011298;C1704791
1436,demographics,C0011298;C1704791
1436,demographic and clinical characteristics,C0011298
1436,demographic and clinical,C0011298
1436,demographic $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),C0011298
1436,demographic,C0011298
1436,baseline demographics,C0011298;C0168634;C1442488;C1704791
1436,( a ) demographics,C0011298;C1704791
1435,dmard − ( n   =   $nmbr$ ),C0242708
1435,dmard user,C0242708;C1548600;C1706077
1435,dmard or corticosteroid,C0242708
1435,dmard + ( n   =   $nmbr$ ),C0242708
1434,other dmards,C0242708
1434,other dmard use,C0042153;C0242708;C0457083;C1947944
1433,dmard | |,C0242708
1433,dmard at baseline,C0168634;C0242708;C1442488
1433,conventional synthetic dmard use at baseline,C0042153;C0168634;C0242708;C0439858;C0457083;C1442488;C1883254;C1947944
1432,prior use of synthetic dmards  n ( % ),C0242708;C0332152;C1524063;C1883254;C2826257
1432,prior use of synthetic dmards,C0242708;C0332152;C1524063;C1883254;C2826257
1432,prior conventional synthetic dmards  n ( % ),C0242708;C0332152;C0439858;C1883254;C2826257
1432,concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate,C0242708;C0439858;C0521115;C1524063;C1883254
1431,war,C0043027
1430,cardiovascu lar subg roup,C0276828;C1419115;C3814448
1429,usual care ( n = $nmbr$ la ),C0023031;C0023749;C0230347;C1947933;C2346906;C3538928;C4553351
1429,usual care ( n = $nmbr$ a ),C1947933;C3538928
1429,usual care ( n = $nmbr$ ),C1947933;C3538928
1429,usual care,C1947933;C3538928
1428,care use,C0042153;C0457083;C1947933;C1947944
1428,care,C1947933
1427,patients with cardiac disorders  n ( % ) §,C0012634;C0018799;C0030705;C0741926
1427,patients with cardiac disorders  n ( % ) c,C0012634;C0018799;C0030705;C0741926
1427,no cardiac disease,C0018799
1427,cardiac disorders ( soc ),C0018799
1427,cardiac disorder  n ( % ) §,C0018799
1427,cardiac disorder,C0018799
1427,cardiac disease,C0018799
1426,no apparent heart disease,C0018799;C0750489
1426,isehemie heart disease,C0018799
1425,early use intended,C1279919
1425,early clopidogrel intended,C0070166;C1279919
1424,patients with early cd ( n = $nmbr$ ),C0007928;C0030705;C0034283;C1279919;C4552032
1424,early  n ( % ),C1279919
1424,early,C1279919
1423,early eptifibatide,C0253563;C1279919
1423,early - start group ( n = $nmbr$ ),C1279919
1423,early - eptifibatide group ( n = $nmbr$ ),C0253563;C0441848;C1279919
1423,early ( n = $nmbr$ ),C1279919
1422,early routine,C0205547;C1279919
1421,non - early crohn ' s disease,C0010346;C1279919;C1518422
1421,early load,C1279919
1421,early crohn ' s disease *,C0010346;C1279919
1420,end - stage renal disease,C0022661;C2316810
1419,sustained esrd  death due to kidney failure  or sustained decrease of > $nmbr$ % in egfr from baseline,C0011065;C0022661;C0035078;C0443318;C0678226;C1306577;C2316810;C4082313;C4552775
1419,esrd or death,C0022661;C0035078;C2316810
1419,esrd or $nmbr$ % dedine in gfr,C0022661;C0035078;C2316810
1419,esrd or $nmbr$ % decline in gfr,C0022661;C0035078;C2316810
1418,esrd on placebo ( % ),C0022661;C0032042;C0035078;C1696465;C1706408;C2316810
1418,esrd on losartan ( % ),C0022661;C0035078;C0126174;C2316810
1418,esrd *,C0022661;C0035078;C2316810
1418,esrd ',C0022661;C0035078;C2316810
1418,esrd,C0022661;C0035078;C2316810
1417,migraine without aura,C0338480
1416,migraine with aura,C0154723
1415,migraine — no . ( % ) $,C0149931
1415,migraine occurrence ( days / month ),C0149931;C0243132;C0556971;C1554210;C2745955
1414,mitral regurgitation  n ( % ),C0026266
1414,mitral regurgitation  ( % ),C0026266
1414,mitral insufficiency  n ( % ),C0026266
1414,mitral insufficiency,C0026266
1413,nitrates ( oral or topical ),C0028125;C0699857;C3848573
1413,nitrates ( % ),C0028125;C0699857;C3848573
1413,nitrates  n ( % ),C0028125;C0699857;C3848573
1413,nitrates  ( % ),C0028125;C0699857;C3848573
1413,nitrates,C0028125;C0699857;C3848573
1413,nitrate — no . ( % ),C0028125;C0699857;C3848573
1413,nitrate use,C0028125;C0042153;C0457083;C0699857;C1947944;C3848573
1413,nitrate ( oral or topical ),C0028125;C0699857;C3848573
1413,nitrate ( oral or intravenous ),C0028125;C0699857;C3848573
1413,nitrate,C0028125;C0699857;C3848573
1412,kidney disease ( usrds ),C0022658
1412,duration of chronic kidney disease * ( years ),C0022658;C0205191;C0439234;C0449238;C2926735
1411,renal disease ),C0022658
1411,renal disease,C0022658
1411,previous renal disease  n ( % ),C0022658;C0205156;C1552607
1410,nephropathy,C0022658
1410,contrast nephropathy risk score,C0009924;C0022658;C0035647;C0449820;C1979874;C4050231;C4552904
1409,omeprazole,C0028978
1408,brv overalla ( n = $nmbr$ ),C0155502
1408,brv overall ( n = $nmbr$ ),C0155502;C0282416;C1561607
1408,brv overall,C0155502
1407,terrible,C3827840
1406,reversible to albuterolc  d  n ( % ),C0205343
1406,reversible ( % ),C0205343
1406,non - reversible ( % ),C0205343;C1518422
1405,reversible to bronchodilator  b %,C0006280;C0205343
1405,reversible,C0205343
1404,undetermined  other  or cardioembolism,C0205258;C3536725;C4082977
1404,undetermined,C0205258;C3536725;C4082977
1404,indeterminate or unknown,C0205258
1403,indeterminate nfs - $nmbr$ . $nmbr$ < nfs < $nmbr$ . $nmbr$ ! n = $nmbr$ ),C0205258;C1513839
1403,indeterminate ! !,C0205258
1402,moderately impaired,C0205081;C1881878;C4085643;C4321491
1401,pedal edema  slight / moderate / marked,C0205081;C0522501;C0574002;C1706089;C1881878;C2937276;C2945599;C4049705;C4049706;C4050469;C4085643;C4321335
1401,patients with moderate - to - severe pain ( womac pain score  $nmbr$ - $nmbr$ ),C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate renal impairment  n ( % ) *,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate renal impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate impairment ( $nmbr$ to $nmbr$ ml / min ),C0205081;C0221099;C0439445;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate impairment  < $nmbr$ to < $nmbr$,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate impairment,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate disease activity : > $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$  n ( % ),C0012634;C0205081;C1292728;C1513375;C1881878;C3833417;C4049705;C4049706;C4085643;C4321335
1401,moderate decrease ( $nmbr$ - < $nmbr$ mlymin per $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C0369637;C0392756;C0441923;C0547047;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate / severe exacerbations  patient subgroups  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate / severe exacerbations  itt population  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate / severe exacerbation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate / low,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate - to -,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate - < severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate ( s $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate ( > $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1401,moderate ( $nmbr$ % < fev  < $nmbr$ % predicted ),C0205081;C1881878;C3714541;C4049705;C4049706;C4085643;C4321335
1401,moderate ( $nmbr$ % . < $nmbr$ % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate trs : $nmbr$ - $nmbr$ ( n = $nmbr$  $nmbr$ ),C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate severe ( n = $nmbr$ ) ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate risk ( > $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
1400,moderate risk ( $nmbr$ - $nmbr$ ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
1400,moderate risk,C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
1400,moderate or severe renal disease  n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate or severe renal disease  b   n ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C0205081;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
1400,moderate impairment ( egfr $nmbr$ - $nmbr$ ),C0205081;C0221099;C0684336;C1739039;C1881878;C3811844;C3812682;C4049705;C4049706;C4085643;C4321335
1400,moderate impairment ( $nmbr$ to < $nmbr$ ),C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate disease,C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate copdb [ n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( n = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( n $nmbr$ = $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( ipss < $nmbr$ ) ( n = $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
1400,moderate ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
1400,moderate ( iief - ef $nmbr$ - $nmbr$ ),C0205081;C1881878;C3641331;C4049705;C4049706;C4085643;C4321335
1400,moderate ( gold $nmbr$ ),C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( > $nmbr$ to < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( > $nmbr$ and < $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205081;C0369637;C0439445;C0441923;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( $nmbr$ risk factor ),C0035648;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate ( $nmbr$ < ipss < $nmbr$ ),C0205081;C1019118;C1881878;C1998280;C2827405;C3811063;C4049705;C4049706;C4085643;C4321335
1400,moderate ( $nmbr$ - $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate  n ( % ) a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate  gold $nmbr$,C0018026;C0205081;C1304897;C1881878;C4049705;C4049706;C4085643;C4321335
1400,moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,> $nmbr$ - $nmbr$ ( moderate risk ),C0035647;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C4552904
1400,> $nmbr$ ( moderate or high bleeding risk )  no . / total ( % ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,$nmbr$ - $nmbr$ ( moderate ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1400,$nmbr$ ( moderate disease ),C0012634;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
1399,no . of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate ’,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate severity,C0205081;C0439793;C0522510;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or severe exacerbations in the previous year ( range ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or severe decrease in gfr { < $nmbr$ ml / mln per $nmbr$ . $nmbr$ m ^ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate copd,C0024117;C0205081;C1412502;C1881878;C3714496;C4049705;C4049706;C4085643;C4321335
1399,moderate ckd at randomization,C0034656;C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate chronic kidney disease,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1399,moderate / severe reduction in egfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
1398,passive smoker,C0425309
1397,current cigarette smoker or within past year,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1397,current cigarette smoker,C0337667;C0521116;C0677453;C1704760;C1705970;C3173209;C3241966;C3890423
1397,cigarette smoker *,C0337667
1397,cigarette smoker  no . ( % ),C0337667
1397,cigarette smoker,C0337667
1396,current non - smoker,C0425311
1395,non - smokers receiving lipid lowering drugs  ( $nmbr$ blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
1395,non - smokers receiving lipid - lowering drugs  p blockers  and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605
1395,non - smokers receiving lipid - lowering drugs  p blockers,C0337672;C4554605
1395,current nonsmokers,C0337672;C0521116;C1705970;C4554605
1395,current nonsmoker,C0337672;C0425293;C0521116;C1705970;C4554605
1394,prior smoker,C0337671
1394,previous smokers,C0337671
1394,previous smoker,C0337671
1394,former smokers,C0337671
1394,former smoker — no . { % ),C0337671
1394,former smoker — no . ( % ),C0337671
1394,former smoker ( n = $nmbr$ ),C0337671
1394,former smoker ( n = $nmbr$  $nmbr$ ),C0337671
1394,former smoker  n ( % ),C0337671
1394,former smoker,C0337671
1394,exsmoker,C0337671;C4555205
1394,ex - smokers ( n = $nmbr$ ),C0337671;C4555205
1394,ex - smokers ( itt ) ( n = $nmbr$ ),C0337671;C4555205
1394,ex - smokers,C0337671;C4555205
1394,ex - smoker / smoker  %,C0337671;C4555205
1394,ex - smoker / current,C0337671;C0521116;C1705970;C4555205
1394,ex - smoker ( n z $nmbr$ ),C0337671;C4555205
1394,ex - smoker,C0337671;C4555205
1394,ex - / current smoker,C0337671;C0521116;C1704625;C1705970;C3173209;C3241966;C4555205
1393,ex - smokers : qvai $nmbr$ - sfc,C0337671;C4521536;C4555205
1393,ex - smokers $nmbr$,C0337671;C4555205
1392,noncurrent smoker,C0337664
1392,ever - smoker,C0337664;C3887636
1391,smokers  no . ( % ),C0337664
1391,smokers  n ( % ),C0337664
1391,smokers  %,C0337664
1391,smoker or ex - smoker  n ( % ),C0337664
1391,smoker ( % ) a,C0337664
1391,smoker ( % ),C0337664
1391,smoker  n ( % ),C0337664
1391,smoker  %,C0337664
1391,smoker  ! n ( % ),C0337664
1391,past smoker  n ( % ),C0337664;C1444637;C4284302
1390,smokers ( at baseline ),C0168634;C0337664;C1442488
1390,smoker at baseline,C0168634;C0337664;C1442488
1390,smoker,C0337664
1389,smokers,C0337664
1389,> $nmbr$ kg / m $nmbr$ smokers,C0337664;C1532718
1388,nonsmoker  n ( % ),C0337672;C0425293;C4554605
1388,nonsmoker,C0337672;C0425293;C4554605
1388,non - smoker ( n = $nmbr$  $nmbr$ ),C0337672;C0425293;C4554605
1388,non - smoker,C0337672;C0425293;C4554605
1388,never smoker,C0425293
1387,severe oab subgroup,C0205082;C1079230;C1515021;C4050465;C4050466
1386,severe exacerbations,C0205082;C4050465;C4050466;C4086268
1386,risk of moderate / severe exacerbations,C0205082;C0332166;C4050465;C4050466;C4086268
1386,first severe asthma exacerbation,C0205082;C0205435;C0349790;C0581126;C1279901;C4050465;C4050466;C4086268
1385,severe hyperkalemiac,C0205082;C4050465;C4050466
1385,severe hyperkalemia ‘ s,C0020461;C0205082;C4050465;C4050466;C4552983
1385,severe hyperkalemia ' s,C0020461;C0205082;C4050465;C4050466;C4552983
1384,severe or worse airflow limitation,C0205082;C4050465;C4050466
1384,severe or moderate,C0205082;C4050465;C4050466
1384,severe copd,C0024117;C0205082;C1412502;C3714496;C4050465;C4050466
1383,more severe ^,C0205082;C0205172;C4050465;C4050466
1383,more severe,C0205082;C0205172;C4050465;C4050466
1382,severe / lite threatening,C0205082;C4050465;C4050466
1382,severe / life ttireatening,C0205082;C0376558;C4050465;C4050466
1382,severe / life threatening,C0205082;C1546953;C2826244;C3537125;C4050465;C4050466
1381,severe ed,C0205082;C3538926;C4050465;C4050466
1381,severe ( iief - ef < $nmbr$ ),C0205082;C3641331;C4050465;C4050466
1381,severe ( iief - ef $nmbr$ - $nmbr$ )  n ( % ),C0205082;C3641331;C4050465;C4050466
1381,$nmbr$ - $nmbr$ ( severe ),C0205082;C4050465;C4050466
1380,severe ( n $nmbr$ = $nmbr$ ),C0205082;C4050465;C4050466
1380,severe ( itt ) ( n = $nmbr$ ),C0205082;C4050465;C4050466
1380,severe ( gold $nmbr$ ),C0018026;C0205082;C1304897;C4050465;C4050466
1380,severe ( fev  < $nmbr$ % predicted ),C0205082;C3714541;C4050465;C4050466
1380,severe ( < $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0205082;C0369637;C0439445;C0441923;C4050465;C4050466
1380,severe  n ( % ) b,C0205082;C4050465;C4050466
1380,severe  gold $nmbr$,C0018026;C0205082;C1304897;C4050465;C4050466
1379,severe teaes,C0205082;C4050465;C4050466
1379,severe n z $nmbr$,C0205082;C4050465;C4050466
1379,severe copdc [ n z $nmbr$ ],C0205082;C4050465;C4050466
1379,severe aes,C0205082;C1412268;C2699274;C4050465;C4050466
1379,less severe $nmbr$,C0205082;C0439092;C0547044;C4050465;C4050466
1379,less severe,C0205082;C0439092;C0547044;C4050465;C4050466
1379,at least $nmbr$ severe flare,C0205082;C1517205;C3540542;C4050465;C4050466
1378,severe or very severe smoking status,C0205082;C4050465;C4050466
1378,severe or very severe copd,C0205082;C4050465;C4050466
1378,severe or very severe,C0205082;C4050465;C4050466
1378,severe / very severea,C0205082;C0442824;C2984081;C4050465;C4050466
1378,severe - very severe,C0205082;C0442824;C2984081;C4050465;C4050466
1377,severe ( ipss > $nmbr$ ) age group,C0027362;C0205082;C1019118;C1998280;C2348001;C2827405;C3811063;C4050465;C4050466
1377,severe ( ipss > $nmbr$ ) ( n = $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
1377,severe ( ipss > $nmbr$ ),C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
1377,severe ( > $nmbr$ ),C0205082;C4050465;C4050466
1376,severely impaired,C0205082
1376,severe to end - stage impairment ( $nmbr$ ml / min ),C0205082;C0205088;C0221099;C0439445;C0684336;C4050465;C4050466
1376,severe renal impairment,C0205082;C1565489;C4050465;C4050466
1376,severe impairment ( egfr < $nmbr$ ml / min / m ^ ),C0205082;C0221099;C0369637;C0439445;C0441923;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
1376,severe impairment ( egfr < $nmbr$ ),C0205082;C0221099;C0684336;C1739039;C3811844;C3812682;C4050465;C4050466
1376,severe impairment ( < $nmbr$ ),C0205082;C0221099;C0684336;C4050465;C4050466
1376,severe,C0205082;C4050465;C4050466
1375,previous major bleeding,C0019080;C0205082;C0205156;C0205164;C1552607;C4318856;C4521762
1375,minor / major,C0026193;C0205082;C0205164;C0205165;C4318856;C4521762
1375,major secondary end pointf,C0027627;C0175668;C0205082;C0205164;C0205436;C0444930;C2746065;C4318856;C4521762
1375,major or clinically relevant non - major bleeding,C0205082;C0205164;C4318856;C4521762
1375,major or clinically relevant non - major bleed,C0205082;C0205164;C4318856;C4521762
1375,major macrovascular events,C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
1375,major gl bleeding,C0018229;C0019080;C0205082;C0205164;C1423073;C1427674;C4318856;C4521762
1375,major coronary event,C0205082;C0205164;C0741923;C4318856;C4521762
1375,major coronary,C0018787;C0205082;C0205164;C4318856;C4521762
1375,major clinical response,C0205082;C0205164;C4055223;C4318856;C4521762
1375,major cerebrovascular,C0205082;C0205164;C1880018;C4318856;C4521762
1375,major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1375,major cardiovascular event *,C0205082;C0205164;C1320716;C4318856;C4521762
1375,major cardiovascular event,C0205082;C0205164;C1320716;C4318856;C4521762
1375,major cardiovascular,C0007226;C0205082;C0205164;C3887460;C4318856;C4521762
1375,major bleeding events *,C0019080;C0205082;C0205164;C0441471;C3541888;C4318856;C4521762
1375,major bleeding ( statin use vs non - use ),C0019080;C0042153;C0205082;C0205164;C0360714;C0457083;C1947944;C4318856;C4521762
1375,major bleeding ( mb ),C0019080;C0024853;C0205082;C0205164;C4318856;C4521762
1375,major bleeding,C0019080;C0205082;C0205164;C4318856;C4521762
1375,major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
1375,major and crnm bleeds,C0205082;C0205164;C4318856;C4521762
1375,major amputationsb,C0205082;C0205164;C4318856;C4521762
1375,major amputations at week $nmbr$,C0002688;C0205082;C0205164;C0332174;C0439230;C4318856;C4521762
1375,major adverse cardiovascular events,C0007226;C0205082;C0205164;C0877248;C1705413;C3887460;C4318856;C4521762
1375,major / crnm bleed,C0205082;C0205164;C4318856;C4521762
1375,major,C0205082;C0205164;C4318856;C4521762
1375,history of major cardiovascular disease  n ( % ),C0205082;C0205164;C0455539;C4318856;C4521762
1375,gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
1375,e major non - vertebral fragility fractures ( fas ),C0205082;C0205164;C0302113;C0549207;C1518422;C4318856;C4521762
1375,combined major macrovascular events .,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
1375,combined major macrovascular events  neohrodathv . and all - cause mortalitv ■,C0205082;C0205164;C0205195;C0441471;C3541888;C4318856;C4521762
1375,b major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1375,as major component — no . ( % ),C0205082;C0205164;C0449432;C1705248;C4318856;C4521762
1375,all major cardiovascular events,C0205082;C0205164;C1320716;C4318856;C4521762
1375,abbreviations : chd  coronary heart disease  cl  confidence interval  ml  myocardial infarction  rr  relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml  nonfatal stroke  or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg  a diastolic blood pressure > $nmbr$ mm hg  or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .,C0000723;C0005910;C0008377;C0009667;C0010068;C0011847;C0011849;C0021308;C0031831;C0033095;C0035647;C0038454;C0043100;C0043210;C0168634;C0201950;C0205082;C0205164;C0242492;C0439209;C0439269;C0439475;C0439526;C0441074;C0449820;C0460139;C0475209;C0543421;C0596019;C0804815;C1305866;C1306345;C1320716;C1442488;C1532563;C1705104;C1705224;C1706378;C2700400;C3887665;C4050231;C4284008;C4318856;C4521762;C4552904;C4554100;C4554402
1375,> $nmbr$ % stenosis of major artery  n ( % ),C0038449;C0205082;C0205164;C4318856;C4521762
1375,- major bleed,C0019080;C0205082;C0205164;C4318856;C4521762
1374,elevation of cardiac biomarker levels — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1374,elevation of cardiac biomarker levels or st - seg - ment deviation > $nmbr$ mm — no . / total no . ( % ),C0439775;C0441889;C0702240;C1271630
1374,cardiac biomarker elevation,C0439775;C0702240;C1271630
1374,cardiac biomarker  n ( % ),C1271630
1373,cardiac biomarker status !,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1373,cardiac - biomarker status 一 no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1373,cardiac - biomarker status — no . / total no . ( % ) $,C0005516;C0018787;C0449438;C0449442;C1271630;C1522601;C1999091;C2735302
1373,biomarker status,C0449442
1372,sle markers  n ( % ),C0005516;C0024141
1371,biomarker levels,C0005516;C0441889
1370,biomarker low ( periostin < $nmbr$ ng / ml or blood eosinophils < $nmbr$ cells per pl )  na,C0005516;C0205251;C0219433;C0439275;C1424662;C1550472;C3812270;C3890211;C4048187;C4321351;C4522223
1370,biomarker low,C0005516
1370,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl )  na,C0005516;C0205250;C0219433;C0439275;C1299351;C1424662;C2700149;C3812270;C3887512;C3889660;C4321237;C4522209
1370,biomarker high,C0005516
1369,acute rheumatic disorders,C0001314
1368,liver disorder,C0023895
1368,hepatic disorders,C0023895
1367,neurocognitive disorders,C0029227;C4041080
1366,gastrointestinal disorders,C0017178
1366,gastrointestinal ( gi ) disorders,C0017178;C1708130;C3539617;C4050121
1365,upper tertile : > $nmbr$ . $nmbr$,C1282910
1365,upper,C1282910
1365,history of upper gl events ( perforations  ulcers  bleeding )  n ( % ),C0018229;C0019664;C0019665;C0041582;C0262512;C0262926;C0441471;C0549099;C1282910;C1423073;C1427674;C1705255;C2004062;C3541888
1364,none of the above,C1282910;C1552828
1364,any of the above,C1282910;C1552828
1364,all of the above,C1282910;C1552828
1363,bladder,C0005682;C4319531
1362,pacific islander,C0242191
1362,other pacific islander,C0242191
1361,tender and swollen joints — mean no . : :,C0234234
1361,question $nmbr$ ( discomfort from any areas tender to touch / pressure ),C0152054;C0205146;C0234234;C0439815;C0702221;C1522634;C2364135;C4319729
1360,tender - or painful - joint count ( of $nmbr$ joints assessed ) — no .,C0234234
1360,tender,C0234234
1360,number of tender joints ( $nmbr$ assessed ),C0234234;C0449813
1360,number of tender joints ( $nmbr$ - $nmbr$ )  mean ( sd ),C0234234;C0444504;C0449813;C2347634;C2348143;C2699239
1360,number of tender joints ( $nmbr$ - $nmbr$ ),C0234234;C0449813
1359,target vessel diameter,C0449618;C1301886
1358,target vessel,C0449618
1358,target - vessel revascularization,C0449618;C0581603
1357,number of target vessels,C0237753;C0449618;C0449788
1357,no . of target vessels,C0449618
1356,large vessel atherosclerosis,C0003850;C0004153;C0225990
1356,large vessel,C0225990
1355,tests for categoric,C0589061
1354,past treatment for paod,C2945691
1353,teaes  cases per $nmbr$ - patient years ( ci ),C0008107;C0030705;C0439234;C0868928;C1533148;C3259781
1353,no cases,C0868928;C1533148
1353,cases,C0868928;C1533148
1352,dates of recruitment,C0011008;C2348077;C2949735
1351,infarction  date not reported,C0011008;C0021308;C2348077
1350,mae,C0286540;C4085238
1349,male patients *,C0150904
1349,male patients  n ( % ),C0150904
1348,female patients ^,C0150905
1348,female patients  n ( % ),C0150905
1347,base,C0002055;C0178499;C1880279
1346,bare metal stent  n ( % ),C2825200
1346,bare metal stent,C2825200
1346,bare - metal stent — no . ( % ),C2825200
1346,bare - metal stent,C2825200
1346,all bare metal stents,C2825200
1345,pulse pressure ( mmhg ),C0439475;C0949236
1345,pulse pressure ( mm hg ),C0439475;C0949236
1345,- median pulse pressure ( mm hg ) ( iqr ),C0439475;C0549183;C0876920;C0949236;C2347635;C2348144;C2939193
1344,pulse pressure,C0949236
1344,mean pulse pressure  mmhg ( s . d . ) “,C0232117;C0391850;C0444504;C0445074;C0949236;C1947910;C2347155;C2347634;C2348143
1343,pfo closure group ( n = $nmbr$ ),C0185003;C0441848;C1521802
1343,pfo closure,C0185003;C1521802
1343,laa closure ( n = $nmbr$ ),C0185003;C1521802
1343,laa closure ( n - $nmbr$ ),C0185003;C1521802
1343,laa closure,C0185003;C1521802
1343,closure,C0185003;C1521802
1342,threatened abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1342,abrupt vessel closure,C0005847;C0185003;C1276802;C1521802
1341,diff_measure ( dm added this as table had multiple headings ),C0011816;C0079809;C0242485;C3250443
1340,lipid measure *,C0023779;C0079809;C0242485
1339,measures ( mmol / l ),C0079809;C0242485;C1879489
1338,measure,C0079809;C0242485
1338,dynamic measure of β - cell function ( ϕ s ) ( change from baseline ) – assessed for mmtt subset only,C0007613;C0079809;C0242485;C0392747;C0443172;C0729333;C1705241;C4319952
1337,measurements,C0242485
1337,baseline measurements,C0168634;C0242485;C1442488
1336,measures of lung function,C0035245;C0079809;C1879489
1335,physiological measures,C0079809;C0205463;C1879489
1335,ipeated - measures state examinatioi,C0079809;C1879489
1334,measures ( % ),C0079809;C1879489
1334,measures,C0079809;C1879489
1334,biochemical measures  mean ( sd ),C0079809;C0205474;C0444504;C1879489;C2347634;C2348143;C2699239
1333,systoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1333,pressure ( mm hg ),C0033095;C0439475;C0460139;C1306345;C4284008
1333,diastoiic biood pressure  mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
1332,treatment with any blood - pressure -,C0005823;C0033095;C0039798;C0087111;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C3538994;C3887704;C4284008
1332,pressure,C0033095;C0460139;C1306345;C4284008
1332,blood pressure - lowering treatment,C0005823;C0033095;C0039798;C0087111;C0441994;C0460139;C0596197;C1271104;C1272641;C1306345;C1522326;C1533734;C1705169;C2003888;C3538994;C3887704;C4284008
1331,postbaseline binding antibodies,C0003241;C1145667;C1167622
1330,anti - ccp antibody ( u /,C0003241;C0003242;C0021027;C0439148;C1167408;C1525410;C1704514;C3665580;C4318437
1330,anti - ccp antibodies *,C0003241;C1525410;C1624602;C1704514;C4318437
1329,known t ' rc - iitoji cccndilon,C0205309;C1167159;C1419366
1328,known tiromtcch * c ccndifeon,C0205309
1328,known prothrombotic genotype,C0017431;C0205309
1327,no known frtrontxtfufoc cond aon,C0205309
1327,known chd,C0205309;C0280604;C3542407
1326,non - enzyme inducing,C0014442;C1518422;C4521602
1326,enzyme inducing,C0014442;C4521602
1325,converting enzyme inhibitor,C0014432;C0919438;C4521603
1325,angiotension converting enzyme - inhibitor,C0014432;C0919438;C4521603
1324,genotyping,C1285573
1324,by genotyping,C1285573
1323,genotype - by - treatment interaction p values *,C0017431;C0039798;C0087111;C1522326;C1533734;C1704675;C1705169;C1709380;C3538994;C3887704
1323,genotype,C0017431
1322,non - hdlc,C1518422;C1704429
1321,non - hdl - c in $nmbr$ classes,C0456387;C1518422;C1518526;C1705943;C3715113;C4019422
1321,non - hdl - c *,C1518422;C3715113
1321,non - c,C1518422
1320,non - hdl - c / hdl - c,C1518422;C3715113
1320,non - hdl - c ( mmol / l  mean ),C0444504;C1518422;C1532563;C2347634;C2348143;C3715113
1320,non - hdl - c  mmol / l  mean ( sd ),C0444504;C1518422;C1532563;C2347634;C2348143;C2699239;C3715113
1320,non - hdl - c  mmol / l,C1518422;C1532563;C3715113
1320,non - hdl - c  mg / dl,C0439269;C1518422;C3715113
1320,non - hdl - c,C1518422;C3715113
1320,non - hdl,C1518422;C3715113
1319,non - hdl choleslerol,C1518422;C3715113
1319,baseline non - hdl - ca,C0168634;C1442488;C1518422;C3715113;C3887642
1318,not treated,C1518422
1318,not tested,C1518422
1318,not reported in ecrf,C1518422
1318,not reported / unknown,C1518422
1318,not reported,C1518422
1318,not provided,C1518422
1318,not present at screening  but within previous year,C1518422
1318,not perfused,C1518422
1318,not on an aha,C0050451;C0772110;C1518422
1318,not localized,C1518422
1318,not hospitalized for heart failure in the year prior to study enrollment,C1518422
1318,not estimable,C1518422
1318,not collected ^,C1518422
1317,non - rollover,C0517067;C0543436;C1518422
1317,no . of non - tnfi,C1518422
1316,non - rheumatic valvular heart disease,C0264757;C1518422
1316,non - hispanicwhite,C1518422
1316,non - hishnic,C1518422
1315,non - trial treatment during hospital stay,C0008976;C0039798;C0087111;C1518422;C1522326;C1533734;C1705169;C3489408;C3538994;C3887704
1315,non - trial p blocker,C0008976;C1518422
1315,non - trial antiplatelet,C0008976;C1518422
1314,non - east asianf,C1518422;C1707877
1313,non - u . s .,C1518422
1313,non - cortical,C0001613;C0007776;C0022655;C1518422
1312,not receiving,C1518422
1312,clinically relevant non,C1518422;C2347946
1311,non - lad artery,C0003842;C0226004;C1518422
1311,non - lad,C1518422
1310,non - stenotic vessels  n ( % ),C0679403;C1518422
1310,non - epa ( n = $nmbr$ ),C1518422
1309,non - us ( n = $nmbr$ ),C1518422
1309,non - us,C1518422
1309,non - inhaled steroid use  n ( % ),C0586793;C1518422
1308,non - mtx,C0025677;C1417487;C1518422
1308,non - metsyn,C1518422
1308,$nmbr$ non - mtx,C0025677;C1417487;C1518422
1307,sitting blood pressure — mmhg,C0439475;C0580946
1306,mean blood pressure  mm hg,C0428886;C0439475;C0488053
1306,diastolic blood pressure  mm hg  mean ± sd,C0012000;C0428883;C0428886;C0439475;C0444504;C1305849;C2347634;C2348143;C2699239
1306,blood pressure in mm hg  mean ( sd ),C0428886;C0439475;C0488053;C2699239
1306,blood pressure  mmhg  mean ( sd ),C0428886;C0439475;C2699239
1306,blood pressure  mm hg  mean ( sd ),C0428886;C0439475;C2699239
1306,blood pressure  mean ± sd mm hg,C0428886;C0439475;C2699239
1306,blood pressure  mean ( sd ) [ range ]  mm hg,C0428886;C0439475;C1514721;C2348147;C2699239;C3542016
1306,blood pressure  mean ( sd )  mm hg systolic,C0428886;C0439475;C2699239
1306,blood pressure  mean ( sd )  mm hg,C0428886;C0439475;C2699239
1305,diastolic pressure  mm hg,C0428883;C0439475
1305,diastolic blood pressure > $nmbr$ mm hg,C0428883;C0439475;C1305849
1305,diastolic blood pressure  mm   hg,C0428883;C0439475;C1305849
1305,diastolic blood pressure  mm hg ^,C0428883;C0439475;C1305849
1305,diastolic blood pressure  mm hg ( sd ),C0428883;C0439475;C1305849;C2699239
1305,diastolic blood pressure  mm hg  median ( range ),C0428883;C0439475;C0549183;C0876920;C1305849;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016
1305,diastolic blood pressure  mm hg,C0428883;C0439475;C1305849
1305,diastolic blood pressure  ( mm hg ),C0428883;C0439475;C1305849
1305,^ $nmbr$ mm hg,C0439475
1305,< $nmbr$ . $nmbr$ mm hg diastolic blood pressure,C0428883;C0439475;C1305849
1304,mean pulmonary artery pressure  mm hg,C0439475;C3854605
1303,less than $nmbr$ mm hg,C0439092;C0439475
1303,> $nmbr$ mm hg — no . ( % ),C0439475
1303,> $nmbr$ mm hg,C0439475
1303,> $nmbr$ . $nmbr$ mm hg,C0439475
1303,< $nmbr$ mm hg — no . ( % ),C0439475
1303,< $nmbr$ . $nmbr$ mm hg,C0439475
1302,pao $nmbr$ at rest  mm hg,C0035253;C0232555;C0439475;C1423784;C1427155;C1622890;C4318615
1302,aapo $nmbr$ at rest  mm hg,C0035253;C0439475;C1622890
1301,at home systolic pressure > $nmbr$ mm hg,C0439475;C0871470;C4534363
1301,at home systolic pressure < $nmbr$ mm hg,C0439475;C0871470;C4534363
1301,at home diastolic pressure > $nmbr$ mm hg,C0428883;C0439475;C4534363
1301,at home diastolic pressure < $nmbr$ mm hg,C0428883;C0439475;C4534363
1300,at clinic systolic pressure > $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
1300,at clinic systolic pressure < $nmbr$ mm hg,C0002424;C0439475;C0442592;C0871470
1300,at clinic diastolic pressure > $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
1300,at clinic diastolic pressure < $nmbr$ mm hg,C0002424;C0428883;C0439475;C0442592
1299,change in bp  mm hg,C0439475;C1268766
1298,intensive bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0162425;C0439475;C0441994;C0522510;C1283828;C1415692;C1550453;C1708288;C2003888;C4318478
1298,hba $nmbr$ c < $nmbr$ . $nmbr$ %  bp < $nmbr$ / $nmbr$ mm hg  ldl - c < $nmbr$ mg / dl,C0019016;C0037623;C0439269;C0439475;C1415692;C1708288;C1825777;C3538758;C4318478
1298,bp variable  mm hg,C0037623;C0439475;C0439828;C1415692;C1708288;C4318478;C4553760
1298,< $nmbr$ mm hg,C0439475
1298,< $nmbr$ / < $nmbr$ mm hg,C0439475
1298,< $nmbr$ / $nmbr$ mm hg +,C0439475
1298,< $nmbr$ / $nmbr$ mm hg,C0439475
1298,$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg,C0439475
1297,hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication ),C0020538;C0037623;C0439475;C1415692;C1708288;C1963138;C4318478
1297,hypertension ( > $nmbr$ / $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
1297,> $nmbr$ / > $nmbr$ mm hg,C0439475
1296,visit $nmbr$ sbp  mm hg,C0085805;C0439475;C0545082;C1512346;C2826704
1296,sbp > $nmbr$ mm hg and / or dbp > $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
1296,sbp > $nmbr$ mm hg,C0085805;C0439475
1296,sbp < $nmbr$ mm hg and dbp < $nmbr$ mm hg $nmbr$ / $nmbr$,C0085805;C0439475
1296,sbp < $nmbr$ mm hg,C0085805;C0439475
1296,sbp ( sd )  mm   hg,C0085805;C0439475;C2699239
1296,sbp  mm   hg ( sd ),C0085805;C0439475;C2699239
1296,sbp  mm   hg,C0085805;C0439475
1296,sbp  mm hg,C0085805;C0439475
1295,iop  mm hg,C0439475;C0578862
1295,> $nmbr$ to < $nmbr$ mm hg,C0439475
1295,$nmbr$ to < $nmbr$ mm hg — no . { % ),C0439475
1295,$nmbr$ to < $nmbr$ mm hg,C0439475
1295,$nmbr$ to $nmbr$ mm hg,C0439475
1295,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg,C0439475
1294,seated sbp at $nmbr$ weeks  mmhg + * *,C0085805;C0277814;C0439230;C0439475;C1283233
1294,seated sbp at $nmbr$ weeks  mmhg +,C0085805;C0277814;C0439230;C0439475;C1283233
1294,sbp  mmhg,C0085805;C0439475
1293,symptomatic hypotension with sbp < $nmbr$ mm   hg,C0020649;C0085805;C0231220;C0439475;C3163620
1293,symptomatic hypotension ( sbp < $nmbr$ mmhg ),C0020649;C0085805;C0231220;C0439475;C3163620
1293,sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
1293,sbp < $nmbr$ mmhg and dbp < $nmbr$ mmhg,C0085805;C0439475
1293,sbp < $nmbr$ mmhg,C0085805;C0439475
1293,sbp ( mmhg ) < $nmbr$,C0085805;C0439475
1293,mssbp < $nmbr$ mmhg,C0439475
1293,< $nmbr$ mmhg,C0439475
1293,$nmbr$ < sbp < $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
1292,mssbp  mm hg,C0439475
1292,baseline sitting sbp  $nmbr$ mm hg,C0085805;C0168634;C0277814;C0439475;C1442488;C2584297;C4050224
1292,baseline mssbp / msdbp  mm hg,C0168634;C0439475;C1442488
1292,baseline mean seated sbp  mm hg ( sd ),C0085805;C0168634;C0277814;C0439475;C0444504;C1283233;C1442488;C2347634;C2348143;C2699239
1292,baseline  mm hg,C0168634;C0439475;C1442488
1291,sbp ( office measurement )  mmhg,C0085805;C0242485;C0439475;C0442603
1291,sbp ( mmhg ) *,C0085805;C0439475
1290,untreated at baseline  mm hg : sbp  mean ( sd ),C0085805;C0168634;C0332155;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1290,sbp ( mm hg ),C0085805;C0439475
1290,mm hg,C0439475
1290,baseline sbp ( mm hg ),C0085805;C0168634;C0439475;C1442488
1289,sbp . mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1289,sbp ( mmhg ),C0085805;C0439475
1289,sbp  mm   hg,C0085805;C0439475
1289,sbp  mm hg ( office measurement )  mean ( sd ),C0085805;C0242485;C0439475;C0442603;C0444504;C2347634;C2348143;C2699239
1289,sbp  mm hg  mean + sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
1289,sbp  mean ( sd ) mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1289,sbp  mean ( sd )  mm hg,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1289,mssbp ( mm hg ),C0439475
1289,msdbp ( mm hg ),C0439475
1289,daytime mean sbp ( abpm ) at week $nmbr$  mmhg,C0085805;C0332169;C0332174;C0439230;C0439475;C0444504;C2347634;C2348143
1289,$nmbr$ mm hg,C0439475
1288,systolic bp ( mmhg ) *,C0439475;C0871470
1288,systolic bp ( mmhg ),C0439475;C0871470
1288,systolic bp ( mm hg ),C0439475;C0871470
1288,systolic bp  mmhg ( sd ),C0439475;C0871470;C2699239
1288,systolic bp  mmhg,C0439475;C0871470
1288,systolic bp  mm   hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1288,systolic bp  mm hg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1288,systolic bp  mm hg,C0439475;C0871470
1288,mean systolic bp  mmhg  mean = sd,C0439475;C0444504;C0871470;C2347634;C2348143;C2699239
1287,systolic — mm hg,C0039155;C0439475
1287,systolic — mean ( sd ) ( mm hg ),C0039155;C0439475;C0444504;C2347634;C2348143;C2699239
1287,systolic pressure at ankle level ( mmhg )  mean ± sd,C0003086;C0003087;C0039155;C0439475;C0441889;C0444504;C0445074;C0456079;C0871470;C1547707;C2347634;C2348143;C2699239;C2946261
1287,systolic blood pressure mmhg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1287,systolic blood pressure ( mmhg )  mean ± sd,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1287,systolic blood pressure ( mm hg )  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1287,systolic blood pressure  mm hg  mean ( sd ),C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1287,systolic blood pressure  mean ( sd )  mm hg,C0039155;C0428886;C0439475;C0444504;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1287,systolic ( mmhg ),C0039155;C0439475
1287,systolic ( mm hg ),C0039155;C0439475
1287,mean systolic blood pressure  mm hg ( sd ),C0039155;C0428886;C0439475;C0444504;C0488053;C0488055;C0871470;C1306620;C2347634;C2348143;C2699239
1286,systolic bp  mmhg  mean ( sd ),C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1286,mean — mm hg level — no . ( % ),C0439475;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2946261
1286,mean — mm hg,C0439475;C0444504;C2347634;C2348143
1286,mean sitting sbp ( mmhg ),C0085805;C0277814;C0439475;C0444504;C2347634;C2348143;C2584297;C4050224
1286,mean sitting dbp ( mmhg ),C0277814;C0439475;C0444504;C0536221;C2347634;C2348143;C2584297;C3813197;C4050224;C4281799
1286,mean bp ( mmhg ),C0037623;C0439475;C0444504;C1415692;C1708288;C2347634;C2348143;C4318478
1285,sl $nmbr$ mm hg,C0439475
1285,sbp  mm hg  mean ± sdc,C0085805;C0439475;C0444504;C1419891;C2347634;C2348143;C3273112
1285,msdbp  mm hg,C0439475
1285,mean ± sd msdbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1285,mean ± sd $nmbr$ - h adbp  mm hg,C0033727;C0168370;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1285,mean sd mssbp  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239
1285,mean sd $nmbr$ - h asbp  mm hg,C0033727;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C2699239;C4528284
1285,mean diastolic blood pressure  mm hg,C0012000;C0428883;C0428886;C0439475;C0444504;C0488053;C1305849;C2347634;C2348143
1285,dbp  mm hg  mean ± sdc,C0439475;C0444504;C0536221;C1419891;C2347634;C2348143;C3273112;C3813197;C4281799
1285,baseline diastolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274392
1284,systolic bp  mmhg  mean ± sd,C0039155;C0439475;C0444504;C0488053;C0871470;C2347634;C2348143;C2699239
1284,sbp ( mmhg )  mean ± sd,C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1284,sbp  mean ± sd ( mmhg ),C0085805;C0439475;C0444504;C2347634;C2348143;C2699239
1284,mssbp ± sd  mmhg,C0439475;C2699239
1284,mssbp  mmhg ( sd ),C0439475;C2699239
1284,msdbp ± sd  mmhg,C0439475;C2699239
1284,msdbp  mmhg ( sd ),C0439475;C2699239
1284,mean ( sd )  mmhg,C0439475;C0444504;C2347634;C2348143;C2699239
1284,dbp  mean ± sd ( mmhg ),C0439475;C0444504;C0536221;C2347634;C2348143;C2699239;C3813197;C4281799
1284,baseline mssbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1284,baseline msdbp ( mmhg )  mean ± sd,C0168634;C0439475;C0444504;C1442488;C2347634;C2348143;C2699239
1284,$nmbr$ mmhg,C0439475
1283,> = $nmbr$ - < $nmbr$ mmhg,C0439475
1283,> $nmbr$ - < $nmbr$ mmhg,C0439475
1283,$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
1282,sbp ≥ $nmbr$ mmhg,C0085805;C0439475
1282,sbp > $nmbr$ mmhg or dbp > $nmbr$ mmhg,C0085805;C0439475
1282,sbp > $nmbr$ mmhg n = $nmbr$,C0085805;C0439475
1282,sbp > $nmbr$ mmhg and / or dbp > $nmbr$ mmhg,C0085805;C0439475
1282,sbp > $nmbr$ mmhg,C0085805;C0439475
1282,sbp / dbp $ $nmbr$ / $ $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
1282,mssbp > $nmbr$ mmhg,C0439475
1282,> = $nmbr$ mmhg,C0439475
1282,> $nmbr$ mmhg,C0439475
1281,dbp < $nmbr$ mmhg,C0439475;C0536221;C3813197;C4281799
1281,$nmbr$ to < $nmbr$ mmhg,C0439475
1281,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg,C0439475
1280,sitting diastolic blood pressure ( mm hg ),C0439475;C1319894
1279,baseline diastolic blood pressure ( mm hg ),C0439475;C4274392
1278,map ( mmhg ),C0024779;C0439475;C1706473;C4050322
1278,apasp ( per mmhg ),C0439475
1277,platelets xlooo / mm ^,C0005821;C0443116;C1963076;C4330985;C4554674
1276,blood eosinophil count — cells / mm ’,C0005773;C0200638;C0750879;C4330985;C4554674
1275,blood eosinophil count cells / mm $nmbr$ no .,C0005773;C0200638;C0750879;C4330985;C4554674
1275,blood eosinophil count > $nmbr$ / mm $nmbr$ in $nmbr$ months before screening — no . ( % ),C0005767;C0005768;C0014467;C0200638;C0229664;C0439231;C0750480;C0750879;C1705566;C4330985;C4554674
1275,blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % ),C0200638;C0750879;C1511226;C4330985;C4554674
1275,> $nmbr$ . $nmbr$ mm,C4330985;C4554674
1274,esr — mm / hr,C3811131;C4330985;C4554674
1274,esr ( mm / hour ) git config - - global user . name  your name,C0205246;C0439227;C0564385;C1418224;C1548600;C1706077;C2348867;C2827597;C3811131;C4330985;C4554674
1274,esr ( mm / hour ),C0439227;C0564385;C3811131;C4330985;C4554674
1274,esr ( mm / hour  per unit ),C0456685;C3811131;C4330985;C4554674
1274,esr  mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
1274,esr  median ( range ) mm / hour,C0439227;C0549183;C0564385;C0876920;C1514721;C2347635;C2348144;C2348147;C2939193;C3542016;C3811131;C4330985;C4554674
1274,esr  $nmbr$ - $nmbr$ mm / hour,C0439227;C0564385;C3811131;C4330985;C4554674
1273,platelet count  x $nmbr$ mm $nmbr$,C0032181;C1287267;C4330985;C4554674
1272,st depression > $nmbr$ mm,C0520887;C4330985;C4554674
1272,st - segment depression > $nmbr$ mm — no . ( % ),C0520887;C4330985;C4554674
1272,st - segment depression > $nmbr$ mm,C0520887;C4330985;C4554674
1272,deviation  mm,C0012727;C0205419;C1705236;C4330985;C4554674
1272,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
1272,$nmbr$ - $nmbr$ . $nmbr$ mm,C4330985;C4554674
1271,patient assessment of disease activity  mm,C0679830;C1292728;C4330985;C4554674
1271,patient assessment of arthritis pain  mm,C0679830;C4317006;C4330985;C4554674
1270,stent diameter < $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
1270,stent diameter $ $nmbr$ mm,C0038257;C1301886;C4330985;C4554674
1270,left atrial diameter : < $nmbr$ mm ( n = $nmbr$ ),C0225860;C0225861;C1301886;C4330985;C4554674
1270,< = $nmbr$ . $nmbr$ mm,C4330985;C4554674
1270,< $nmbr$ mm,C4330985;C4554674
1269,baseline £ std  mm,C0168634;C1442488;C4330985;C4554674
1269,baseline ste in worst lead  mm,C0023175;C0168634;C0181586;C1420459;C1442488;C1442948;C1522166;C1522538;C2348269;C3275067;C3811127;C4330985;C4554674
1269,baseline ^ ste  mm,C0168634;C1420459;C1442488;C3811127;C4330985;C4554674
1268,st change > $nmbr$ mm,C0036056;C0392747;C0443172;C1705241;C3272372;C4319952;C4330985;C4554674
1268,st - segment deviation > $nmbr$ mm — no . / total no . ( % ),C0012727;C0036056;C0205419;C0429029;C0429066;C0441635;C1114722;C1116089;C1705236;C3272372;C4330985;C4554674
1268,> $nmbr$ mm,C4330985;C4554674
1267,cornell voltage x duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1267,cornell voltage - duration product  mm × ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1267,cornell voltage - duration product  mm x ms,C0449238;C0598352;C1514468;C1704444;C2349943;C2926735;C3539704;C3713294;C4330985;C4554674
1267,corneii product  mm - ms,C1514468;C1704444;C2349943;C3539704;C3713294;C4330985;C4554674
1266,sokolow - lyon voltage  mm,C0598352;C4330985;C4554674
1266,sokolow - lyon  mm,C4330985;C4554674
1265,volume change  mm ^,C0392747;C0443172;C0449468;C1690016;C1705102;C1705241;C2700258;C4319952;C4330985;C4554674
1265,fibrofatty  mm ^,C4330985;C4554674
1264,r wave in avl ( mm ),C0429091;C0449216;C4330985;C4554674
1263,ptgada ( mm ),C4330985;C4554674
1263,phgada ( mm ),C4330985;C4554674
1263,patient global assessment of pain ( vas $nmbr$ - $nmbr$ mm ),C0042815;C4054229;C4330985;C4554674
1263,pain vas  range $nmbr$ - $nmbr$ mm  mean ( sd ),C0042815;C0444504;C1514721;C2347634;C2348143;C2348147;C2699239;C3542016;C4330985;C4554674
1263,pain vas  $nmbr$ - $nmbr$ mm,C0042815;C4330985;C4554674
1263,pain ( $nmbr$ mm vas ),C0042815;C4330985;C4554674
1263,pain ( $nmbr$ - $nmbr$ mm vas ),C0042815;C4330985;C4554674
1263,pain  $nmbr$ - $nmbr$ mm vas,C0042815;C4330985;C4554674
1262,physician global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
1262,physician global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4050369;C4330985;C4554674
1262,physician ' s global assessment of disease activity ( $nmbr$ - $nmbr$ mm vas )  mean ( sd ),C0042815;C0444504;C2347634;C2348143;C2699239;C3536884;C3827561;C4050369;C4330985;C4554674
1262,patient global assessment of disease activity ( vas $nmbr$ - $nmbr$ mm ),C0042815;C3536884;C3827561;C4054228;C4330985;C4554674
1262,patient global assessment ( $nmbr$ - $nmbr$ mm vas ),C0042815;C3536884;C3827561;C4054229;C4330985;C4554674
1262,$nmbr$ - $nmbr$ mm,C4330985;C4554674
1261,stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
1261,no stsd > $nmbr$ mm on admission ( n = $nmbr$  $nmbr$ ),C0184666;C0809949;C4330985;C4554674
1260,long ( > $nmbr$ mm ) stenting yes ( n = $nmbr$ ),C0038257;C0205166;C1549445;C1705108;C1706317;C1710701;C2348535;C4330985;C4554674
1260,> $nmbr$ mm ( n = $nmbr$ ),C4330985;C4554674
1259,sokolow - lyon ( mm ) *,C4330985;C4554674
1259,imt ( mm ),C0334121;C1704614;C4318736;C4330985;C4554674
1259,( interquartile range ) ( mm ),C1711350;C4330985;C4554674
1258,triglyceride ( mm,C0041004;C4330985;C4554674
1257,subcortical wml load diameter  mm  mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
1257,subcortical wml load diameter  mm   mean ( sd ),C0552409;C0815275;C1550025;C1704782;C1708715;C2699239;C4330985;C4554674
1257,lvdd ( mm ),C4330985;C4554674
1256,mssbp  mm hga,C4330985;C4554674
1256,msdbp  mm hga,C4330985;C4554674
1256,blood pressure  mean ( sd )  mm hgt,C0428886;C2699239;C4330985;C4554674
1255,gmr,C1522544;C1704695
1254,dexlansoprazole mr ( n = $nmbr$ ),C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1254,dexlansoprazole mr $nmbr$ mg  n = $nmbr$,C0024485;C0024671;C0026410;C0439269;C1417249;C1960952;C2346927;C2347167;C2348248;C3254418;C4050513;C4321396;C4521761
1254,dexlansoprazole mr,C0024485;C1417249;C2347167;C2348248;C3254418;C4050513
1253,patients with only mrf hr ( $nmbr$ % cl ),C0030705;C0205171;C0312443;C0596019;C1412879;C1720467
1253,mrf subjects,C0312443;C1412879
1253,mrf,C0312443;C1412879
1252,mri substudy ( n = $nmbr$ ),C0024485;C1824234;C3890166
1251,wml load at follow - up mri stratified by baseline severity of wml load,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1251,wml load at follow - up mri,C0024485;C0589120;C1522577;C1550025;C1704685;C1704782;C1708715;C1824234;C3274571;C3890166
1251,wml load at baseline mri,C0024485;C0168634;C1442488;C1550025;C1704782;C1708715;C1824234;C3890166
1250,sokolow – lyon voltage ( mv ),C0598352;C1454484;C1705503;C4281602
1250,sokoiow - lyon voitage  mv,C1454484;C1705503;C4281602
1250,cornell voltage duration ( mv × ms ),C0449238;C0598352;C1454484;C1705503;C2349943;C2926735;C3539704;C3713294;C4281602
1249,voided volume  ml,C0042034;C0439526;C0449468;C1552835;C1690016;C1705102;C1705224;C2700258;C3887665
1249,normalized volume measures,C0449468;C1690016;C1705102;C1882115;C2700258
1249,contrast volume > $nmbr$ ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1249,contrast volume  ml,C0009924;C0439526;C0449468;C1690016;C1705102;C1705224;C1979874;C2700258;C3887665
1248,hyperkalemia * ’,C0020461;C4552983
1248,hyperkalemia ( > $nmbr$ . $nmbr$ meq / l ),C0020461;C0439375;C4552983
1248,hyperkalemia  n ( % ),C0020461;C4552983
1247,hyperkalaemia ( investigator reported ),C0020461;C0035173;C4552983
1247,hyperkalaemia,C0020461;C4552983
1246,hypokalemia,C0020621;C4553966
1246,hypokalaemia,C0020621;C4553966
1245,hyperlipidemia § yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
1245,hyperlipidemia §,C0020473;C0428465;C4555212
1245,hyperlipidemia | | yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
1245,hyperlipidemia | |,C0020473;C0428465;C4555212
1245,hyperlipidemia ^,C0020473;C0428465;C4555212
1245,hyperlipidemia ( % ) §,C0020473;C0428465;C4555212
1245,hyperlipidemia,C0020473;C0428465;C4555212
1244,hyperlipidemia — no . / total no . ( % ),C0020473;C0428465;C4555212
1244,hyperlipidemia — no . ( % ),C0020473;C0428465;C4555212
1244,hyperlipidemia ( % ),C0020473;C0428465;C4555212
1244,hyperlipidemia  n / n ( % ),C0020473;C0428465;C4555212
1244,hyperlipidemia  n ( % ),C0020473;C0428465;C4555212
1244,hyperlipidemia  %,C0020473;C0428465;C4555212
1244,hyperlipidaemia therapy use  n ( % ) * no lipid - lowering agent therapy,C0020473;C0039798;C0042153;C0087111;C0428465;C0457083;C1363945;C1947944;C4555212
1244,hyperlipidaemia ( % ),C0020473;C0428465;C4555212
1244,hyperlipidaemia  n ( % ) yes,C0020473;C0428465;C1549445;C1705108;C1710701;C4555212
1244,hyperlipidaemia,C0020473;C0428465;C4555212
1243,dyslipidemia — no . { % ),C0242339
1243,dyslipidemia — no . ( % ) |,C0242339
1243,dyslipidemia — no . ( % ),C0242339
1243,dyslipidemia $nmbr$,C0242339
1243,dyslipidemia  n ( % ),C0242339
1243,dyslipidaemia 本,C0242339
1243,dyslipidaemia — no . ( % ),C0242339
1243,dyslipidaemia including hypercholesterol — no . ( % ),C0242339
1243,dyslipidaemia and hypertensiont,C0242339
1243,dyslipidaemia and hypertension  n ( % ),C0242339
1243,dyslipidaemia  n ( % ),C0242339
1243,baseline dyslipidemia,C0168634;C0242339;C1442488
1242,history of dyslipidemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1242,history of dyslipidaemia,C0019664;C0019665;C0242339;C0262512;C0262926;C1705255;C2004062
1242,dyslipidemia,C0242339
1242,dyslipidaemia,C0242339
1241,centrilobular emphysema,C0221227
1240,emphysema ( n = $nmbr$ ),C0013990;C0034067
1240,emphysema ( itt ) ( n = $nmbr$ ),C0013990;C0034067
1240,emphysema ( % ),C0013990;C0034067
1240,emphysema,C0013990;C0034067
1239,empty,C1880497
1238,empa,C2699863
1237,— b - h —,C0033727;C0369286;C0441932;C0564385;C4528284
1237,pre - h,C0033727;C0332152;C0369286;C0441932;C0564385;C0740175;C2257086;C3669034;C4528284
1237,nt - probnp ， pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1237,nt - probnp  pmol / h,C0033727;C0369286;C0439192;C0441932;C0564385;C0669479;C0754710;C4528284
1237,in - h,C0033727;C0369286;C0441932;C0564385;C4528284
1237,i - h,C0021966;C0033727;C0221138;C0369286;C0441932;C0564385;C4528284
1237,baseline $nmbr$ - h ppg,C0033727;C0168634;C0369286;C0441932;C0564385;C1418888;C1442488;C4528284
1237,$nmbr$ — e - h,C0033727;C0369286;C0441932;C0564385;C4528284
1237,$nmbr$ - h pmg ( mg / dl ),C0033727;C0369286;C0439269;C0441932;C0564385;C4528284
1237,$nmbr$ - $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1236,sbp ( mean over $nmbr$ h )  mmhg,C0033727;C0085805;C0369286;C0439475;C0441932;C0444504;C0564385;C2347634;C2348143;C4528284
1236,migraine duration ( h ),C0033727;C0149931;C0369286;C0441932;C0449238;C0564385;C2926735;C4528284
1236,h,C0033727;C0369286;C0441932;C0564385;C4528284
1236,dbp ( mean over $nmbr$ h )  mmhg,C0033727;C0369286;C0439475;C0441932;C0444504;C0536221;C0564385;C2347634;C2348143;C3813197;C4281799;C4528284
1235,within $nmbr$ h after first procedure,C0033727;C0184661;C0205435;C0369286;C0441932;C0564385;C1279901;C2700391;C3274430;C3539779;C4528284
1235,within $nmbr$ h after,C0033727;C0369286;C0441932;C0564385;C4528284
1235,within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1235,use of h $nmbr$ bloekers  n ( % ),C0033727;C0369286;C0441932;C0564385;C1524063;C4528284
1235,urgency episodes / $nmbr$ h,C0033727;C0332189;C0369286;C0439609;C0441932;C0564385;C4528284
1235,symptom onset to pci  h,C0033727;C0369286;C0441932;C0564385;C4049621;C4086878;C4528284
1235,ptca < $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C2936173;C4528284
1235,nocturia episodes / $nmbr$ h,C0028734;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
1235,micturitions / $nmbr$ h,C0033727;C0042034;C0369286;C0441932;C0564385;C4528284
1235,interval from clopidogrel loading  h,C0033727;C0070166;C0369286;C0441932;C0564385;C1272706;C1552654;C1552713;C1708715;C4528284
1235,incontinence episodes / $nmbr$ h,C0021167;C0033727;C0332189;C0369286;C0441932;C0564385;C4528284
1235,h $nmbr$ receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
1235,h $nmbr$ - receptor antagonist,C0033727;C0369286;C0441932;C0564385;C4528284;C4543207
1235,duration of symptoms  h,C0033727;C0369286;C0436359;C0441932;C0564385;C4528284
1235,b + h ( n = $nmbr$ ),C0033727;C0369286;C0441932;C0564385;C4528284
1235,after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1235,> = $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1235,> $nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
1235,> $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
1235,> $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1235,< $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
1235,< $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
1235,( $nmbr$ % ci ] h,C0008107;C0033727;C0369286;C0441932;C0564385;C3259781;C4528284
1235,$nmbr$ to < $nmbr$ h  n ( % ),C0033727;C0369286;C0441932;C0564385;C4528284
1234,ct  calcitonin  cv  cardiovascular  egfr  estimated glomerular filtration rate  hbalc  glycated hemoglobin  h $nmbr$  histamine $nmbr$  iqr  interquartile range  n  number of patients  sd  standard deviation .,C0006668;C0007226;C0019588;C0030705;C0033727;C0062408;C0237753;C0369286;C0441932;C0449788;C0564385;C0871420;C1711350;C1739039;C2699239;C3538987;C3666909;C3811844;C3812682;C3887460;C4048877;C4318503;C4528284
1234,$nmbr$ . $nmbr$ f $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
1233,without hx of hf,C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1233,recurrent hf hospitalization,C0018488;C0019993;C1313497;C1455761;C1538440;C2945760;C3273279
1233,recurrent hf,C0018488;C1313497;C1455761;C1538440;C2945760;C3273279
1233,prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1233,previous hf hospitalization  n ( % ),C0018488;C0019993;C0205156;C1313497;C1538440;C1552607;C3273279
1233,previous hf,C0018488;C0205156;C1313497;C1538440;C1552607;C3273279
1233,pharmacological therapy for hf,C0013217;C0018488;C1313497;C1538440;C3273279
1233,participants without hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1233,participants with hf at baseline,C0018488;C0679646;C1313497;C1538440;C3273279
1233,no prior hf hospitalization ( n   = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1233,no prior hf hospitalization ( n = $nmbr$  $nmbr$ ),C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1233,no prior hf hospitalization,C0018488;C0019993;C0332152;C1313497;C1538440;C2826257;C3273279
1233,no history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1233,new hf medication,C0013227;C0018488;C0205314;C1313497;C1538440;C3244316;C3273279;C4284232
1233,history of hf or lvef b $nmbr$ % with index event  no . ( % ),C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1233,history of hf hospitalization,C0018488;C0551577;C1313497;C1538440;C3273279
1233,history of hf,C0018488;C0019664;C0019665;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1233,history of chronic hf,C0018488;C0019664;C0019665;C0205191;C0262512;C0262926;C1313497;C1538440;C1705255;C2004062;C3273279
1233,hf or lvef < $nmbr$ % associated with index event,C0018488;C1313497;C1538440;C3273279
1233,hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279
1233,hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
1233,hf  total,C0018488;C0439175;C0439810;C1313497;C1538440;C3273279
1233,hf  lvd  or both,C0018488;C1313497;C1538440;C3273279
1233,hf,C0018488;C1313497;C1538440;C3273279
1233,clinical features of hf,C0018488;C0683325;C1313497;C1538440;C3273279
1233,admission for hf in previous year  n ( % ),C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
1233,admission for hf in previous year,C0018488;C0184666;C0809949;C1313497;C1538440;C3273279
1232,prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1232,prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1232,no prior hf n = $nmbr$,C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1232,no prior hf ( n = $nmbr$  $nmbr$ ),C0018488;C0332152;C1313497;C1538440;C2826257;C3273279
1232,no hx of hf ( n = $nmbr$ ),C0018488;C0262926;C1313497;C1538440;C3273279;C3814444
1232,hf duration  y  n ( % ),C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1232,duration of hf  y,C0018488;C0449238;C1313497;C1538440;C2926735;C3273279
1231,stroke / m l / hf hospitalization,C0018488;C0019993;C0038454;C0456616;C1313497;C1538440;C3273279;C4554100
1231,hospitalized hf !,C0018488;C0701159;C1313497;C1538440;C3273279
1231,hospitalized hf,C0018488;C0701159;C1313497;C1538440;C3273279
1231,hosp . worsening hf,C0018488;C0332271;C1313497;C1457868;C1538440;C1546960;C3273279
1231,hosp . for hf,C0018488;C1313497;C1538440;C3273279
1231,hf symptoms and signs,C0018488;C0683368;C1313497;C1457887;C1538440;C3273279
1231,hf symptomatic improvement,C0018488;C0231220;C1313497;C1538440;C2986411;C3273279
1231,hf symptom worsened,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
1231,hf symptom unchanged,C0018488;C1313497;C1457887;C1538440;C3273279;C3854129
1231,hf signs and symptoms,C0018488;C0220912;C0220913;C0311392;C1313497;C1538440;C3273279
1231,hf hosp .,C0018488;C1313497;C1538440;C3273279
1231,hf cause,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279
1231,enrolment through hf,C0018488;C1313497;C1516879;C1538440;C1696073;C3273279;C3888021
1231,congestive hf,C0018488;C0742742;C1313497;C1538440;C3273279
1231,all ~ cause mort / hf hosp .,C0015127;C0018488;C1313497;C1524003;C1538440;C3273279;C3815322
1230,hc,C0020268;C0262499;C1413512
1229,$nmbr$ hr after glucose challenge,C3840385
1228,chl,C0019829
1227,baseline cha $nmbr$ ds $nmbr$ - vascb  c,C0168634;C1420648;C1442488;C3714751
1226,cha $nmbr$ ds $nmbr$ - vasc score ( median  iqr ),C0449820;C0549183;C0876920;C1420648;C2347635;C2348144;C2939193;C3714751;C4050231
1226,cha $nmbr$ ds $nmbr$ - vasc > $nmbr$,C1420648;C3714751
1226,cha $nmbr$ ds $nmbr$ - vasc < $nmbr$,C1420648;C3714751
1226,cha $nmbr$ ds $nmbr$ - vasc $ $nmbr$,C1420648;C3714751
1226,cha $nmbr$ ds $nmbr$ - vasc # $nmbr$,C1420648;C3714751
1226,cha $nmbr$ ds $nmbr$ - vasc,C1420648;C3714751
1225,cha $nmbr$ ds $nmbr$ - vasc score  mean ± sd,C0444504;C0449820;C1420648;C2347634;C2348143;C2699239;C3714751;C4050231
1225,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ - $nmbr$,C1420648;C3714751
1225,cha $nmbr$ ds $nmbr$ - vasc $nmbr$ $nmbr$,C1420648;C3714751
1225,cha $nmbr$ ds $nmbr$ - vasc  mean ± sd,C0444504;C1420648;C2347634;C2348143;C2699239;C3714751
1224,chd + cl all,C0280604;C0596019;C3542407
1223,repaired chd,C0205340;C0280604;C3542407
1223,chd risk - no . ( % ),C0280604;C3542407
1222,chd + cerebral infarction,C0007785;C0280604;C3542407
1222,chd,C0280604;C3542407
1221,no chd eze / simva ( n = $nmbr$ ),C0280604;C3542407
1221,no chd eze / simva $nmbr$ = $nmbr$ },C0280604;C3542407
1221,no chd eze / simva,C0280604;C3542407
1221,no chd,C0280604;C3542407
1221,chd simva,C0280604;C3542407
1221,chd men,C0025266;C0280604;C3542407
1221,chd eze / simva ( n = $nmbr$ ],C0280604;C3542407
1221,chd eze / simva,C0280604;C3542407
1221,chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0007820;C0025266;C0280604;C3542407
1220,chd disease death,C0011065;C0012634;C0280604;C1306577;C3542407;C4082313;C4552775
1220,chd deaths,C0011065;C0280604;C1306577;C3542407
1220,chd death,C0011065;C0280604;C1306577;C3542407;C4082313;C4552775
1219,chd status §,C0280604;C0449438;C3542407
1219,chd status,C0280604;C0449438;C3542407
1219,> $nmbr$ mg / dl chd status,C0280604;C0439269;C0449438;C3542407
1218,no chd simva ( „ = $nmbr$ ),C0280604;C3542407
1218,no chd simva ( n = $nmbr$ ],C0280604;C3542407
1218,no chd simva,C0280604;C3542407
1218,history of chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1218,chd simva ( „ = $nmbr$ ),C0280604;C3542407
1218,chd simva $nmbr$ = $nmbr$ ],C0280604;C3542407
1218,chd history  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1705255;C2004062;C3542407
1218,chd eze / simva ( „ = $nmbr$ ),C0280604;C3542407
1218,chd *  n ( % ),C0280604;C3542407
1218,chd  n ( % ),C0280604;C3542407
1217,other chd,C0280604;C3542407
1217,history ot chd  n ( % ),C0019664;C0019665;C0262512;C0262926;C0280604;C1318464;C1418208;C1705255;C1705587;C2004062;C3542407
1217,family history ot chd  n ( % ),C0241889;C0280604;C1318464;C1418208;C1705587;C3542407
1216,amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),C0002598
1216,amiodarone vs . placebo,C0002598
1216,amiodarone use at baseline yes $nmbr$  $nmbr$,C0002598;C0042153;C0168634;C0457083;C1442488;C1549445;C1705108;C1710701;C1947944
1216,amiodarone use at baseline,C0002598;C0042153;C0168634;C0457083;C1442488;C1947944
1216,amiodarone ote at baseline,C0002598;C0168634;C1442488
1215,peri - op amiodarone : no ( n = $nmbr$ ),C0002598;C0347985
1215,no amiodarone,C0002598
1215,amiodarone ( n = $nmbr$ ),C0002598
1215,amiodarone ( n  % ),C0002598
1215,amiodarone  n ( % ),C0002598
1215,amiodarone,C0002598
1214,apolipoprotein,C0003591
1214,= placebo  eze = ezetimibe  erol  apo = apolipoprotein  metabolic syndrome  patients were eans and percentage changes are,C0003591;C0030705;C0032042;C0524620;C1142985;C1696465;C1706408
1213,chylomicron triglycerides,C0008731;C0041004;C1325761
1212,chylomicron cholesterol,C0008377;C0008731;C1325761
1211,micro / macroalbuminuria,C0085672;C1553035;C3811161;C4049106
1211,micro / macroaibuminuria,C0085672;C1553035;C3811161;C4049106
1211,micro - or macroalbuminuria  no . ( % ),C0085672;C1553035;C3811161;C4049106
1211,micro - or macroalbuminuria  n ( % ) §,C0085672;C1553035;C3811161;C4049106
1211,micro - albuminuria,C0001925;C0085672;C1553035;C3811161;C4049106
1211,micro - / macro - albuminuria  ckd and / or retinopathy,C0001925;C0085672;C1553035;C1561643;C2984010;C3811161;C4049106
1211,combined macro + micro,C0085672;C0205195;C1553035;C2984010;C3811161;C4049106
1210,benazepril / hydrochlorothiazide - benazepril / amlodipine,C0051696;C0717481
1209,telmisartan / amlodipine - telmisartan / amlodipine / hydrochlorothiazide,C0020261;C0051696;C0939233;C2733369
1209,amlodipine and valsartan,C0051696
1208,amlodipine vs chlorthalidone overweight,C0051696
1208,amlodipine vs chlorthalidone obese,C0051696
1208,amlodipine vs chlorthalidone normal,C0051696
1208,amlodipine / lisinopril / chlorthalidone comparison,C0008294;C0051696;C0065374;C1707455
1208,amlodipine / chlorthalidone,C0008294;C0051696
1207,ii $nmbr$ amlodipine - lisinopril - chlorthalidone chlorthalidone,C0008294;C0051696;C0065374;C1710602;C4082587
1207,$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
1207,$nmbr$ amlodipine - chlorthalidone,C0008294;C0051696
1206,amlodipine / vaisartan ( n = $nmbr$ ),C0051696
1206,amlodipine / lisinopril $nmbr$,C0051696;C0065374
1205,benazepril - amlodipine group ( n = $nmbr$ ),C0051696;C0053091;C0441848
1205,amlodipine,C0051696
1204,amlodipine ( n = $nmbr$ ),C0051696
1204,amlodipine $nmbr$ to $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
1204,! amlodipine,C0051696
1203,lis,C2247545
1202,lips,C0023759
1201,all mis *,C0687670;C1333208;C1412384;C3538735
1201,all mis,C0687670;C1333208;C1412384;C3538735
1200,• ? sd ml / min,C0439445;C2699239
1199,ecrcl < $nmbr$ ml / min,C0439445
1199,ecrcl  ml / min,C0439445
1199,baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C1442488
1199,baseline ecrcl k $nmbr$ to < $nmbr$ ml / min,C0168634;C0439445;C0597277;C1442488;C1708601
1199,$nmbr$ to < $nmbr$ ml / min,C0439445
1198,mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min  n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C0439445;C1846718;C3274775
1198,crcl > $nmbr$ ml / min,C0439445;C1846718
1198,crcl > $nmbr$ - < $nmbr$ ml / min,C0439445;C1846718
1198,crcl ( sd ) ml / min,C0439445;C1846718;C2699239
1198,crcl ( ml / min ),C0439445;C1846718
1198,crcl  ml / min mean ( sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
1198,crcl  ml / min,C0439445;C1846718
1198,crcl  mean  ml / min ( ± sd ),C0439445;C0444504;C1846718;C2347634;C2348143;C2699239
1198,> $nmbr$ ml / min ( n = $nmbr$ ),C0439445
1198,< = $nmbr$ ml / min,C0439445
1198,< $nmbr$ ml / min ( n = $nmbr$ ),C0439445
1198,$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ ),C0439445
1198,$nmbr$ ml / min,C0439445
1198,$nmbr$ ( $nmbr$ to < $nmbr$ ml / min ),C0439445
1197,crcl at randomization - ml / min,C0034656;C0439445;C1846718
1197,crcl at randomization  ml / min,C0034656;C0439445;C1846718
1197,crcl ( ml / min ) at randomization,C0034656;C0439445;C1846718
1196,creat clearance > $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
1196,creat clearance < $nmbr$ ml / min,C0201975;C0439445;C0449297;C1382187;C2825073;C4554548
1195,stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
1195,stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
1195,stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439445;C0456533
1194,estimated creatinine clearance — ml / min §,C0439445;C0750572;C0812399
1194,estimated creatinine clearance — ml / min  i,C0021966;C0023806;C0221138;C0439445;C0702093;C0750572;C0812399;C1524029;C3813700
1194,estimated creatinine clearance < $nmbr$ ml / min *,C0439445;C0750572;C0812399
1194,estimated creatinine clearance ( ml / min ),C0439445;C0750572;C0812399
1194,creatinine clearance ， : : $nmbr$ ml / min  %,C0439445;C0812399
1194,creatinine clearance — ml / min,C0439445;C0812399
1194,creatinine clearance < $nmbr$ ml / min ( % ),C0439445;C0812399
1194,creatinine clearance < $nmbr$ ml / min  no . / total ( % ),C0439445;C0812399
1194,creatinine clearance < $nmbr$ ml / min,C0439445;C0812399
1194,creatinine clearance ( ml / min ),C0439445;C0812399
1194,creatinine clearance  ml / min - $nmbr$ *,C0439445;C0812399
1194,creatinine clearance  ml / min,C0439445;C0812399
1194,$nmbr$ – ≤ $nmbr$ ml / min,C0439445
1194,$nmbr$ – < $nmbr$ ml / min,C0439445
1193,interquartile range — ml / min,C0439445;C1711350
1192,median — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0549183;C0876920;C2347635;C2348144;C2939193
1192,median — ml / min,C0439445;C0549183;C0876920;C2347635;C2348144;C2939193
1192,median crcl — ml / min,C0439445;C0549183;C0876920;C1846718;C2347635;C2348144;C2939193
1192,estimated glomerular filtration rate - ml / min  median ( iqr ) ',C0439445;C0549183;C0876920;C2347635;C2348144;C2939193;C3811844
1192,$nmbr$ - $nmbr$ ( < $nmbr$ ml / min ),C0439445
1191,£ $nmbr$ ml / min,C0439445
1191,renal function < $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0232804;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C0030705;C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,mean ( sd ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,mean ( s . d . ) egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C3811844;C3812682
1191,egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
1191,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0071744;C0439445;C1413772;C1739039;C3811844;C3812682
1191,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
1191,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$  geometric mean [ se ] ),C0010294;C0439445;C1561535;C1739039;C3811844;C3812682
1191,egfr > $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C0026655;C0439445;C1705291;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ml / min,C0439445;C1739039;C3811844;C3812682
1191,egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr < $nmbr$  ml / min / m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr ( ml / min ),C0439445;C1739039;C3811844;C3812682
1191,egfr ( mdrd )  ml / min / $nmbr$ . $nmbr$ m * *,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
1191,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
1191,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445;C1739039;C3811844;C3812682
1191,egfr  ml / min per $nmbr$ · $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,egfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd ),C0369637;C0439445;C0441923;C1739039;C2699239;C3811844;C3812682
1191,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
1191,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ± sd,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ),C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1191,egfr  ml / min ( mdrd ),C0439445;C1739039;C3811844;C3812682;C3839656
1191,egfr  ml / min,C0439445;C1739039;C3811844;C3812682
1191,egfr  median ( sd )  ml / min,C0439445;C0549183;C0876920;C1739039;C2347635;C2348144;C2699239;C2939193;C3811844;C3812682
1191,egfr  mean = sd  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,egfr  mean ( sd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C0444504;C1739039;C2347634;C2348143;C2699239;C3811844;C3812682
1191,chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0007591;C0439445;C0456533;C1561643;C1739039;C3811844;C3812682;C4553188
1191,baseline mdrd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682;C3839656
1191,baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
1191,baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
1191,> $nmbr$ ml / min,C0439445
1191,< $nmbr$ ml / min,C0439445
1190,〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
1190,rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C0871208;C1521828
1190,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1190,estimated gfr  ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601;C2699239
1190,estimated gfr  < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$  n ( % ) a,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
1190,egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$,C0369637;C0439445;C0441923
1190,egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$  n ( % ),C0369637;C0439445;C0441923
1190,egfrmdrd  ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$,C0369637;C0439445;C0441923
1190,baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
1190,> $nmbr$ ml min ) $nmbr$,C0439445
1190,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
1190,< $nmbr$ ml / min — %,C0439445
1190,< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
1190,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . { % ),C0369637;C0439445;C0441923
1190,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . ( % ),C0369637;C0439445;C0441923
1190,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
1190,. $nmbr$ . $nmbr$ ml / s / m $nmbr$ ( $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  n ( % ),C0369637;C0439445;C0441923
1190,$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0369637;C0439445;C0441923
1190,$nmbr$ - $nmbr$ ml min ) $nmbr$,C0439445
1189,mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0392756;C0439445;C0441923;C0547047;C2945599
1189,mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ )  n ( % ),C0369637;C0439445;C0441923;C2945599
1189,( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
1189,( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
1189,(  $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923
1189,$nmbr$ ( $ $nmbr$ ml / min ),C0439445
1188,≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,≥ $nmbr$ ml / min,C0439445
1188,estimated glomerular filtration rate — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1188,estimated glomerular filtration rate < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1188,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ — no . / total no . ( % ) §,C0369637;C0439445;C0441923;C3811844
1188,estimated glomerular filtration rate ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C3811844
1188,estimated glomerular filtration rate ( mdrd )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
1188,estimated glomerular filtration rate  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1188,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$  mean ( sd ) §,C0369637;C0439445;C0441923;C0444504;C2347634;C2348143;C2699239;C3811844
1188,estimated glomerular filtration rate  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844
1188,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr — ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr ( ckd - epi  cystatinc )  ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0162734;C0369637;C0439445;C0441923;C1561643;C1739039;C3811844;C3812682;C4281721
1188,egfr ( ckd - epi  cystatin c )  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0071744;C0162734;C0369637;C0439445;C0441923;C1413772;C1561643;C1739039;C3811844;C3812682;C4281721
1188,egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr  ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr  ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$  ‡,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C0369637;C0439445;C0441923
1188,ecfr  ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,cgfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c,C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
1188,baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ ),C0168634;C0369637;C0439445;C0441923;C1442488;C1739039;C3811844;C3812682
1188,baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0168634;C0369637;C0439445;C0441923;C1442488;C1561643;C1739039;C3811844;C3812682
1188,^ $nmbr$ ml / min,C0439445
1188,> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
1188,> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,> $nmbr$ ml / min / $nmbr$ . $nmbr$,C0439445
1188,> $nmbr$ egfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
1188,> $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,< $nmbr$ ml / min / $nmbr$  $nmbr$ m ^,C0369637;C0439445;C0441923
1188,< $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C0369637;C0439445;C0441923
1188,$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1188,$nmbr$ - $nmbr$ ml / min,C0439445
1187,mean — ml / min / $nmbr$ . $nmbr$ m $nmbr$ of body - surface area,C0017446;C0205146;C0369637;C0439445;C0441923;C0444504;C0489451;C2347634;C2348143
1187,estimated gfr  ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area,C0017446;C0017654;C0205146;C0369637;C0439445;C0441923;C0489451;C0750572;C1424601
1187,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1187,> $nmbr$ to < $nmbr$ ml / min,C0439445
1187,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ nt - pro - bnp,C0369637;C0439445;C0441923;C0669479;C0754710
1187,$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$,C0439445
1187,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
1187,$nmbr$ - < $nmbr$ ml / min,C0439445
1187,$nmbr$ - $nmbr$ ml min  $nmbr$,C0439445
1186,morning peak expiratory flow — liters / min,C0332170;C0475211;C0702093;C1518922;C1524029;C3813700
1185,pifr l / min,C0702093;C1524029;C3813700
1185,baseline in - check * ’ pifr ( l / min ),C0168634;C0702093;C1283174;C1442488;C1524029;C1555524;C3813700;C4321547
1185,baseline heart rate ( beat / min ),C0168634;C0425583;C0702093;C0871208;C1442488;C1521828;C1524029;C3813700
1184,pasi [ c ]  median ( min - max ),C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700;C4528685
1184,[ min  max ],C0702093;C1524029;C3813700
1184,> $nmbr$ months  median ( min  max ),C0439231;C0549183;C0702093;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
1184,> $nmbr$ min,C0702093;C1524029;C3813700
1183,stiffness ( min ),C0427008;C0702093;C1524029;C3813700
1183,pefpm   ( l / min ) ∗,C0702093;C1524029;C3813700
1183,pefam   ( l / min ) ∗,C0702093;C1524029;C3813700
1183,( min ) *,C0702093;C1524029;C3813700
1182,time to treatment initiation ( min ),C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1182,time to treatment initiation ( min,C0589507;C0702093;C1158830;C1524029;C1704686;C3494202;C3813700
1182,time to treatment ( min ) t,C0702093;C1524029;C3494202;C3813700
1181,qrs > $nmbr$ msec $nmbr$ - min walk test,C0439223;C0702093;C1524029;C3813700;C4277740
1181,> $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1180,symptoms onset to first balloon inflation  min,C0021398;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700;C4086878
1180,randomization to first balloon inflation  min,C0021398;C0034656;C0205435;C0336867;C0441144;C0702093;C1279901;C1318493;C1524029;C3813700
1179,morning stiffness duration  min,C0449238;C0457086;C0702093;C1524029;C2926735;C3813700
1179,min  max,C0702093;C1524029;C3813700
1179,mean duration of surgery ± sd  min,C0038894;C0038895;C0444504;C0449238;C0543467;C0702093;C1274039;C1524029;C2347634;C2348143;C2699239;C2926735;C3813700
1179,iduration of symptoms > $nmbr$ min,C0683368;C0702093;C1457887;C1524029;C3813700
1179,duration of symptoms > $nmbr$ min,C0436359;C0702093;C1524029;C3813700
1179,duration of ra  mean ( min - max ) ( yrs ),C0444504;C0449238;C0702093;C1524029;C2347634;C2348143;C2926735;C3538806;C3813700;C4048756
1179,$nmbr$ min,C0702093;C1524029;C3813700
1178,range : min  max,C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1178,range ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1178,range  ( min  max ),C0702093;C1514721;C1524029;C2348147;C3542016;C3813700
1178,min – max,C0702093;C1524029;C3813700
1178,min - max age,C0001779;C0702093;C1524029;C3813700
1178,min - max,C0702093;C1524029;C3813700
1178,mean score ( min  max range ),C0702093;C1514721;C1524029;C2348147;C3533236;C3542016;C3813700
1177,> $nmbr$ to < $nmbr$ ml / min / l $nmbr$ nr,C0027496;C0702093;C1524029;C1635169;C3813700;C3844738
1177,> $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1177,< $nmbr$ mi / min,C0702093;C1524029;C3810814;C3813700
1176,p $nmbr$ min twice / week,C0332174;C0369773;C0439230;C0702093;C1524029;C1720725;C1948050;C2603361;C3813700
1176,$nmbr$ min twice / week,C0332174;C0439230;C0702093;C1524029;C1720725;C1948050;C3813700
1175,time to balloon / needle  min *,C0027551;C0040223;C0336867;C0441144;C0702093;C1524029;C1882041;C3541383;C3813700
1175,time to admission  min,C0702093;C1524029;C3813700;C3854258;C3854259
1175,min - ’,C0702093;C1524029;C3813700
1175,cross - damp time : < l : llhrs : min ( n = $nmbr$ ),C0040223;C0205381;C0702093;C1524029;C2828360;C3541383;C3813700;C3891560
1175,$nmbr$ min / time ),C0040223;C0702093;C1524029;C3541383;C3813700
1175,$nmbr$ - $nmbr$ min,C0702093;C1524029;C3813700
1174,£ $nmbr$ min,C0702093;C1524029;C3813700
1174,£ $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1174,min per $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923;C0702093;C1524029;C3813700
1174,estimated glomerular filtration rate < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ : i : §,C0021966;C0023806;C0221138;C0369637;C0439445;C0441923;C0702093;C1524029;C3811844;C3813700
1174,crcb - ( ml / min )  mean ( s . e . ),C0439390;C0439445;C0444504;C0702093;C1524029;C2347634;C2348143;C3813700
1174,< $nmbr$ min,C0702093;C1524029;C3813700
1174,< $nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1174,$nmbr$ . $nmbr$ min,C0702093;C1524029;C3813700
1173,£ $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1173,supine after $nmbr$ minutes change from baseline,C0038846;C0439232;C0700321;C0702093;C1282918;C2347166
1173,standing after $nmbr$ minutes change from baseline,C0231472;C0439232;C0700321;C0702093;C1282918;C2347166
1173,standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0439232;C0443172;C0700321;C0702093;C1282918;C1705241;C2347166;C4319952
1173,normal ( £ $nmbr$ ml / minute ),C0205307;C0231683;C0439166;C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347086;C2347166;C3887665;C4553972
1173,minutes from symptom onset to prehospital ecg  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C2347166;C4086878
1173,minutes from prehospital ecg to pci  median ( iqr ),C0439232;C0700321;C0702093;C1282918;C1623258;C2347166
1173,minutes from pre - pci angiography to post - pci angiography  median ( iqr ),C0002978;C0332152;C0439232;C0700321;C0702093;C0740175;C1282918;C2257086;C2347166;C3669034;C4049621
1173,< $nmbr$ ml / minute ),C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1173,< $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1173,( < $nmbr$ ml / minute ) *,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1173,$nmbr$ to < $nmbr$ ml / minute,C0439232;C0439526;C0700321;C0702093;C1282918;C1705224;C2347166;C3887665
1172,daily bowel movements,C0011135;C0332173
1172,bowel function,C0011135
1171,mycophenolate mofetil - cyclophosphamide,C0010583;C0209368
1171,mycophenolate mofetil,C0209368
1170,in - hospital medication,C0013227;C0019994;C1510665;C3244316;C4284232
1170,in - hospital,C0019994;C1510665
1169,in hospital ticagrelor,C0019994;C1510665;C1999375
1169,in - hospital ticagrelor ( n = $nmbr$ ),C0019994;C1510665;C1999375
1168,pci - hospital,C0019994;C1510665;C4049621
1168,non - pci hospital / ambulance,C0002422;C0019994;C1510665;C1518422;C3846685;C4049621
1167,time from hospital admission to pci  h  median ( q $nmbr$  q $nmbr$ ),C0019994;C0040223;C1510665;C1959907;C3541383
1167,time from hospital admission to enrollment,C0019994;C0040223;C1510665;C1959907;C3541383
1167,duration from hospital admission to pci  h ( median  iqr ),C0019994;C0449238;C1510665;C1959907;C2926735
1166,topical prescription,C0033080;C0332237;C1521941
1166,topical non - prescription,C0033080;C0332237;C1518422;C1521941
1166,topical,C0332237
1165,placebo - control study,C0683952
1164,budesonide - formoterol ( n = $nmbr$ ),C1276807
1164,budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807;C1319635
1164,budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C0439267;C1276807
1164,budesonide - budesonide / formoterol,C1276807
1163,small - artery occlusion ( lacune ),C0001168;C0011382;C0028778;C0226001;C0241970;C0264995;C0441597;C0700321;C1110554;C1947917
1163,small - artery occlusion,C0001168;C0011382;C0028778;C0226001;C0264995;C0441597;C0700321;C1110554;C1947917
1162,sotalol,C0037707
1162,beta - blocker ( except sotalol ),C0001645;C0037707
1161,unrelated to effectiveness,C0445356;C1280519;C1704623;C4553491
1160,greater than or equal to $nmbr$ mm hg,C0439093
1160,greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439093
1160,greater than or equal to $nmbr$ %,C0439093
1159,ggt increased,C1415053
1158,tgt,C1421391;C1428265;C4321338
1157,intended durat - sm of antccagubficn,C0036154;C1283828;C1551357;C4553627
1156,intent of conservative strategy  %,C0162425;C0679199;C1283828;C1550453
1155,intent to use gp iib / iiia,C0162425;C1283828;C1550453
1155,intent to use glycoprotein iib / iiia inhibitor,C0162425;C1283828;C1550453
1155,intent to use dti,C0162425;C1283828;C1550453
1155,intent to use direct thrombin,C0162425;C1283828;C1550453
1154,metrex overall modified intention - to - treat population ? :,C0032659;C0087111;C0162425;C0282416;C0392747;C1257890;C1283828;C1292734;C1522326;C1561607;C3889737
1154,metreo modified intention - to - treat population §,C0032659;C0087111;C0162425;C0392747;C1257890;C1283828;C1292734;C1522326;C3889737
1154,intention to treat,C0162425;C1283828
1154,intention - to - treat without st - segment - elevation myocardial infarction,C0162425;C1283828
1154,intention - to - treat with st - segment - elevation myocardial infarction,C0162425;C1283828
1154,intention - to - treat,C0162425;C1283828
1154,intent - to - treatb,C0162425;C1283828;C1550453
1154,intent - to - treat population  n ( % ),C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1154,intent - to - treat population,C0032659;C0087111;C0162425;C1257890;C1283828;C1292734;C1522326;C1550453
1153,symptom onset to hospital admission,C0184666;C4086878
1152,symptom onset to randomization,C0034656;C4086878
1152,symptom onset - to -,C4086878
1152,symptom onset,C4086878
1151,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C4086878
1151,symptom onset to enrollment,C1516879;C1696073;C3888021;C4086878
1150,symptom onset to hospitalization,C0019993;C4086878
1149,symptom onset to hospital arrival  median ( iqr )  h,C0019994;C0033727;C0369286;C0441932;C0549183;C0564385;C0876920;C1510665;C1555577;C1706079;C2347635;C2348144;C2939193;C4086878;C4528284
1149,symptom onset to hospital arrival  hours,C0019994;C0439227;C1510665;C1555577;C1706079;C4086878
1149,symptom onset to arrival in catheterization laboratory,C1555577;C1706079;C4086878
1148,interval from randomization to angiography,C0034656;C1272706;C1552654;C1552713
1147,interval pain onset to admission,C0184666;C0809949;C1272706;C1507009;C1552654;C1552713
1146,interval study drug to pci,C0013175;C1272706;C1552654;C1552713;C4049621
1146,interval clopidogrel to pci,C0070166;C1272706;C1552654;C1552713;C4049621
1145,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706;C1552654;C1552713;C4086878
1145,interval from onset of symptoms,C1272706;C1552654;C1552713;C4086878
1144,ra ndosii zat ion,C0022023;C1700702;C3538806;C4048756
1143,patients without ra  as  or psa ( n = $nmbr$  $nmbr$ ),C0030705;C3538806;C4048756
1143,patients with ra  as  or psa ( n = $nmbr$ ),C0030705;C3538806;C4048756
1142,ra symptom duration — year,C0439234;C0439508;C0449238;C1457887;C2926735;C3538806;C3854129;C4048756
1142,ra duration ( months ) *,C0439231;C0449238;C2926735;C3538806;C4048756
1142,ra,C3538806;C4048756
1142,duration of ra ( years ),C0439234;C0449238;C2926735;C3538806;C4048756
1142,duration of ra ( time from symptom onset )  years,C0040223;C0449238;C2926735;C3538806;C3541383;C4048756
1142,duration of ra  mean ± sd years,C0439234;C0444504;C0449238;C2347634;C2348143;C2699239;C2926735;C3538806;C4048756
1142,duration of ra,C0449238;C2926735;C3538806;C4048756
1141,ra - beam,C0338248;C2347880;C3538806;C4048756;C4521565
1140,all - baricitinib ra ( n = $nmbr$ ) *,C3538806;C4044947;C4048756
1139,saudi arabia,C0036243
1139,sa acs,C0036243;C0038702;C0742343;C1539696;C1825840;C3539736;C4318612;C4521691
1139,sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
1138,ua ( n = $nmbr$ ),C0041580;C0042014
1138,ua,C0041580;C0042014
1138,serum ua < $nmbr$ mg / dl by month $nmbr$,C0041580;C0042014;C0229671;C0332177;C0439231;C0439269;C1546774;C1550100
1137,ukraine,C0041580
1137,russia / ukraine / belarus,C0006539;C0035970;C0041580
1136,physician ' s ga  $nmbr$ - $nmbr$ mmvas,C0016993;C0031831;C0804815
1136,ga / a,C0016993
1136,a / ga,C0016993
1135,patient ' s ga  $nmbr$ - $nmbr$ mm vas,C0016993;C0030705;C0042815;C3536884;C3827561;C4330985;C4554674
1135,ga,C0016993
1134,modi fied la grade *,C0023031;C0023749;C0230347;C0342276;C0441800;C0919553;C2346906;C3244287;C4553351
1134,la grade a  n ( % ) f,C0023031;C0023749;C0230347;C2346906;C4553351
1134,la diameter,C0023031;C0023749;C0230347;C1301886;C2346906;C4553351
1134,fpg  mmol / la,C0023031;C0023749;C0230347;C0439190;C2346906;C4553351
1134,fev $nmbr$  la,C0023031;C0023749;C0230347;C2346906;C3714541;C4553351
1133,na ( mmol / l ),C0597484;C1272460;C1532563;C1546968;C1879645;C4049872;C4552882
1132,tnfi - na ï ve  n ( % ),C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,tnfi - na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,tnf - na ï ve,C0042469;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,na ï ve,C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
1132,mn - na ï ve population,C0026327;C0026405;C0032659;C0042469;C0597484;C1257890;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
1132,anti ‐ tnf ‐ na ï ve    n   ( % ),C0042469;C0432633;C0597484;C1272460;C1448177;C1546968;C1879645;C3714652;C4049872;C4321495;C4552882
1132,all mn - na ï ve patients,C0026327;C0026405;C0030705;C0042469;C0597484;C1272460;C1546968;C1879645;C3714652;C4049872;C4285072;C4321495;C4552882
1131,rando . in na * *,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
1131,not rando . in na *,C0597484;C1272460;C1518422;C1546968;C1879645;C4049872;C4552882
1131,n . a .,C1272460
1131,ci = confidence interval  na = not applicable or not analyzed .,C0008107;C0009667;C0597484;C1272460;C1546968;C1879645;C3259781;C4049872;C4552882
1130,n / a,C1272460
1130,a / v ( n = $nmbr$ ) v ( n = $nmbr$ ),C0560268;C1272460;C3887614
1130,a / v ( n = $nmbr$ ),C1272460
1130,a $nmbr$ c [ n ( % ) ],C1272460
1130,a $nmbr$ + e $nmbr$ ( n = $nmbr$ ),C1272460
1129,( nyha grade iii or iv ),C0205617;C0450094;C0475271;C0687697;C1275491;C3889290;C4050000;C4283820;C4283821;C4283822
1128,nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline,C1275491
1128,nyha ii  n ( % ),C1275491;C1710602;C4082587
1128,nyha ii,C1275491;C1710602;C4082587
1127,nyha iv  n ( % ),C0022326;C1275491;C4265176
1127,nyha iv  %,C0022326;C1275491;C4265176
1127,nyha,C1275491
1127,dyspnea at rest ( nyha iv )  ( % ),C0022326;C0743330;C1275491;C4265176
1126,psa pain ( vas ),C0042815;C3810537;C3813209
1125,psa ‐ modified mases score ( $nmbr$ – $nmbr$ scale ),C0392747;C3810537;C3813209;C3889737
1125,psa - modified total shs,C3810537;C3813209
1125,psa - modified shs of hands & feet $nmbr$ ( $nmbr$ - $nmbr$ ),C0016504;C0018563;C0347981;C0392747;C1552914;C3810537;C3813209;C3889737
1125,psa - modified shs ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
1125,psa - modified mases score ( $nmbr$ - $nmbr$ ),C0392747;C3810537;C3813209;C3889737
1124,psa subtypes  n ( % ),C0449560;C3810537;C3813209
1124,psa reported  n ( % ),C3810537;C3813209
1124,psa ( n = $nmbr$ ),C3810537;C3813209
1124,no psa ( n = $nmbr$ ),C3810537;C3813209
1124,no psa,C3810537;C3813209
1123,psa ( ng / ml ),C0439275;C3810537;C3813209
1123,psa  ng / ml  mean ( sd ),C0439275;C0444504;C2347634;C2348143;C2699239;C3810537;C3813209
1123,psa,C3810537;C3813209
1122,vdz / pla n = $nmbr$,C0456170
1122,pla « = $nmbr$,C0456170
1122,pla n = $nmbr$,C0456170
1122,pla,C0456170
1122,median blood eosinophil count  cells per pla,C0200638;C0456170;C0549183;C0876920;C2347635;C2348144;C2939193
1122,atio - pla,C0456170
1121,mra ( spironolactone or eplerenone ),C0037982;C0243032;C1609165;C3891069
1120,mra regimen ( n - $nmbr$ ),C0040808;C0243032;C1609165;C2945654;C3891069
1120,mra  ( % ),C0243032;C1609165;C3891069
1120,mra,C0243032;C1609165;C3891069
1119,tocilizumab ( n = $nmbr$ ),C1609165
1119,tocilizumab,C1609165
1118,fair or poor,C2911689
1118,fair / poor,C0032854;C0542537;C2700379;C2911689
1117,poor  tried previous glucocorticoid / non - laba,C0017710;C0032854;C0205156;C0542537;C1518422;C1552607;C2700379
1117,poor  tried previous glucocorticoid + laba,C0017710;C0032854;C0205156;C0542537;C1552607;C2700379
1117,poor,C0032854;C0542537;C2700379
1116,provoked,C1444748
1115,pooled simva,C1709595;C2349200;C4522255
1115,pooled non - canvas studies ( n = $nmbr$ ) : non - cana ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C1518422;C1709595;C2349200;C3281223;C4522255
1115,pooled eze / simva,C1709595;C2349200;C4522255
1115,pooled,C1709595;C2349200;C4522255
1115,* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin  eze = ezetimibe  tc = total cholesterol  tg = triglycerides  hdl - c = high - density lipoprotein - cholesterol  non - hdl - c = non - high - density lipoprotein cholesterol  apo = apolipoprotein,C0003591;C0008377;C0009247;C0023189;C0023821;C0023822;C0036919;C0039411;C0040642;C0041004;C0041405;C0041698;C0062152;C0065055;C0074554;C0178587;C0178602;C0201950;C0337445;C0369773;C0439175;C0439751;C0439810;C0444504;C0444667;C0543421;C0549183;C0599755;C0729627;C0876920;C1142985;C1518422;C1708438;C1709595;C1710181;C1824670;C2347634;C2347635;C2348143;C2348144;C2349200;C2603361;C2939193;C3272447;C3715113;C4522122;C4522255
1114,pooled pah - mctd and pah,C0026272;C0030123;C1709595;C2349200;C3203102;C4284467;C4522255
1114,pooled itt,C1709595;C2349200;C4522255
1113,naproxen,C0027396
1112,ibuprofen,C0020740
1111,low - density lipoprotein choles -,C0023823
1111,low - density lipoprotein ^,C0023823
1111,low - density lipoprotein  mg / dl,C0023823;C0439269
1111,low - density lipoprotein,C0023823
1110,high density lipoprotein ( mg / dl ),C0023821;C0439269
1110,high - density lipoprotein ],C0023821
1110,high - density lipoprotein  mg / dl,C0023821;C0439269
1109,high - density lipoprotein,C0023821
1109,data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl )  p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index  which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .,C0023820;C0023821;C0030705;C0042295;C0205120;C0489786;C1305855;C1511726;C1516606;C1552595;C3245479;C3714741
1108,pulsed blood pressure,C0232108
1107,baseline systolic blood pressure ( mm hg ),C0439475;C4274438
1107,baseline systolic blood pressure  mean ( sd )  mm hg,C0439475;C0444504;C2347634;C2348143;C2699239;C4274438
1107,baseline systolic blood pressure,C4274438
1106,blood pressure lowering medication use,C0005823;C0240320;C0441994;C1271104;C1272641;C2003888
1106,blood pressure ( % ),C0005823;C1271104;C1272641
1106,any blood pressure medications ( % ),C0005823;C0013227;C0033095;C0460139;C0802604;C0849164;C1271104;C1272641;C1306345;C2598133;C4284008;C4284232
1105,blood pressure eontrolt,C0005823;C1271104;C1272641
1105,blood pressure control *,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1105,blood pressure control,C0005823;C0243148;C1271104;C1272641;C1550141;C1882979;C2587213;C3274648;C4553389
1104,bmi = body mass index  bnp = brain natriuretic peptide  dbp = diastolic blood pressure  gfr = glomerular filtration rate  hr = heart rate  iqr = interquartile range  kccq = kansas city cardiomyopathy questionnaire  n = number  nt = n - terminal  nyha = new york heart association  sbp = systolic blood pressure,C0004083;C0005767;C0005768;C0005823;C0017654;C0018787;C0018810;C0027976;C0033095;C0039155;C0054015;C0085805;C0205088;C0229664;C0237753;C0332126;C0439849;C0449788;C0460139;C0536221;C0596306;C0699792;C1095989;C1271104;C1272641;C1275491;C1305855;C1306345;C1417808;C1424601;C1449832;C1561549;C1705314;C1705315;C1711350;C2982014;C3476086;C3476798;C3813197;C3889152;C4050156;C4281799;C4283901;C4284008;C4284038
1104,blood pressure  mm,C0005823;C1271104;C1272641;C4330985;C4554674
1104,blood pressure,C0005823;C1271104;C1272641
1103,body mass index blood pressure — mmhg,C0005823;C0005893;C0439475;C0578022;C1271104;C1272641;C1305855
1103,blood pressure — mmhg,C0005823;C0439475;C1271104;C1272641
1103,blood pressure — mm hg,C0005823;C0439475;C1271104;C1272641
1103,blood pressure while seated — mm hg,C0005823;C1271104;C1272641
1102,weight  kg blood pressure  mm hg,C0005823;C0005910;C0022718;C0043100;C0439209;C0439475;C1271104;C1272641;C1305866;C1705104;C4054209
1102,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823;C0030705;C0439475;C0445204;C1271104;C1272641
1102,heart rate ( sd )  bpm blood pressure  mm hg,C0005823;C0018810;C0439475;C1271104;C1272641;C2699239
1102,blood pressure systolic  mm hg,C0005823;C0039155;C0439475;C1271104;C1272641
1102,blood pressure at entry ( mm   hg ),C0005823;C0439475;C1271104;C1272641;C1705654
1102,blood pressure > $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1102,blood pressure < $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
1102,blood pressure < $nmbr$ / $nmbr$ mmhg  n ( % ),C0005823;C0439475;C1271104;C1272641
1102,blood pressure ( mmhg ),C0005823;C0439475;C1271104;C1272641
1102,blood pressure ( mm hg ) systolic,C0005823;C0439475;C1271104;C1272641
1102,blood pressure ( mm hg ) *,C0005823;C0439475;C1271104;C1272641
1102,blood pressure ( mm hg ),C0005823;C0439475;C1271104;C1272641
1102,blood pressure  mmhg systolic,C0005823;C0439475;C1271104;C1272641
1102,blood pressure  mmhg,C0005823;C0439475;C1271104;C1272641
1102,blood pressure  mm hg,C0005823;C0439475;C1271104;C1272641
1102,arterial blood pressure  mm hg,C0439475;C1272641
1101,blood bilirubin increased,C0005437;C0005767;C0005768;C0229664
1100,systolic blood pressurea  mm hg,C0005767;C0005768;C0039155;C0229664;C0439475
1100,diastolic blood pressurea  mmhg,C0005767;C0005768;C0012000;C0229664;C0439475
1099,blood pressure at baseline :,C0005767;C0005768;C0005823;C0168634;C0229664;C0443150;C1271104;C1272641;C1442488
1099,baseline diastolic blood,C0005767;C0005768;C0012000;C0168634;C0229664;C1442488
1099,any blood,C0005767;C0005768;C0229664
1098,troponin t ( pg / ml ),C0077404;C0439297;C1420827
1098,troponin t,C0077404;C1420827
1098,elevated troponin t ( > $nmbr$ . $nmbr$ / xg / l ),C0017209;C0077404;C0205250;C1292284;C1420827;C1421532;C3163633
1097,thrombolysis,C0520997
1097,pci / thrombolysis at randomization,C0034656;C0520997;C4049621
1096,original dabigatran protocol,C0205313;C0442711;C1507394;C1522729;C2347409;C2348066;C2348563;C2599718;C3715209;C4282383
1096,amended dabigatran protocol,C0442711;C1507394;C1522729;C1691222;C2348066;C2348563;C2599718;C3715209;C4282383
1095,study protocol,C1507394;C2348563;C2599718
1095,atv $nmbr$ mg study protocol,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1507394;C1960952;C2346927;C2348563;C2599718;C4321396;C4521761
1094,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710;C0168634;C1442488;C1527415
1094,oral glucocorticoid use,C0017710;C1527415
1093,oral glucocorticoid dose  mg ( prednisone equivalent ),C0017710;C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0442027;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761;C4521986
1093,glucocorticoid,C0017710
1092,no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778
1092,glucocorticoids only,C0017710;C0205171;C1720467;C3540777;C3540778
1092,glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778
1092,glucocorticoids *,C0017710;C3540777;C3540778
1092,glucocorticoids,C0017710;C3540777;C3540778
1092,any glucocorticoid *,C0017710
1091,use of oral glucocorticoids,C0017710;C0442027;C1524063;C3540777;C3540778;C4521986
1091,use of inhaled glucocorticoids at screening — no . ( % ),C0004048;C0017710;C1524063;C3540777;C3540778
1091,use of inhaled glucocorticoids at baseline,C0004048;C0017710;C1524063;C3540777;C3540778
1090,neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778
1090,glucocorticoids plus immunosuppressive agents,C0017710;C0021081;C3540777;C3540778
1090,glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778
1089,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710;C0032790;C0034656;C0042153;C0457083;C0687676;C1521970;C1704687;C1947944;C3469826
1089,postoperative glucocorticoid use,C0017710;C0032790;C0042153;C0457083;C1947944
1089,glucocorticoid ],C0017710
1088,mh + crpnorr,C0026514;C2930980
1087,all non - mn,C0026327;C0026405;C1518422;C4285072
1086,egfr  ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$,C0026327;C0026405;C0369637;C0439526;C0441923;C1705224;C1739039;C3811844;C3812682;C3887665;C4285072
1086,cardiac index  l • mn ' • m $nmbr$,C0026327;C0026405;C0369637;C0428776;C0441923;C4285072
1085,mn population  n,C0026327;C0026405;C0032659;C1257890;C4285072
1085,mn population,C0026327;C0026405;C0032659;C1257890;C4285072
1084,atenolol use at $nmbr$ month,C0004147;C0042153;C0332177;C0439231;C0457083;C1947944
1083,ccsc at $nmbr$ month before enrollment,C0332177;C0439231;C1516705
1082,pci > $nmbr$ month ago,C0332177;C0439231;C4049621
1082,cabg > $nmbr$ month ago,C0010055;C0332177;C0439231
1081,> $nmbr$ month n = $nmbr$,C0332177;C0439231
1081,< $nmbr$ month n = $nmbr$,C0332177;C0439231
1081,$nmbr$ week to $nmbr$ month,C0332174;C0332177;C0439230;C0439231
1080,fpg month $nmbr$ ( mg / dl ),C0332177;C0439231;C0439269
1080,$nmbr$ month l,C0332177;C0439231
1079,smoking ( during the previous month ),C0332177;C0439231;C2114448
1078,number ( % ) reporting migraine on $nmbr$ - month questionnaire,C0034394;C0149931;C0237753;C0332177;C0439231;C0449788;C0700287
1078,month $nmbr$,C0332177;C0439231
1078,$nmbr$ - $nmbr$ / month,C0332177;C0439231
1077,monthly,C0332177
1077,evolocumab $nmbr$ mg monthly ( n = $nmbr$ ),C0024671;C0026410;C0332177;C0439269;C1960952;C2346927;C3529352;C4321396;C4521761
1076,fall in last $nmbr$ mo,C0026544;C0085639;C0238715;C0332177;C4553726
1076,at least $nmbr$ / mo,C0026544;C0332177
1075,unstable angina > $nmbr$ mo ago,C0002965;C0026544;C0332177
1075,> $nmbr$ mo,C0026544;C0332177
1074,left ventricular ejection fraction within previous $nmbr$ mo |,C0026544;C0205156;C0332177;C0428772;C0488728;C1552607
1074,antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177
1073,duration of initial anticoagulation  mean ( sd )  mo,C0003281;C0026544;C0205265;C0332177;C0444504;C0449238;C1279901;C1555582;C1705685;C2347634;C2348143;C2699239;C2917212;C2919015;C2926735;C3537050
1073,< $nmbr$ mo  n ( % ),C0026544;C0332177
1073,< $nmbr$ mo,C0026544;C0332177
1073,$nmbr$ to < $nmbr$ mo,C0026544;C0332177
1073,$nmbr$ mo - $nmbr$ y,C0026544;C0332177
1073,$nmbr$ mo  mean ( sd ) x,C0026544;C0332177;C0444504;C2347634;C2348143;C2699239
1073,$nmbr$ mo,C0026544;C0332177
1073,$nmbr$ - < $nmbr$ mo  n ( % ),C0026544;C0332177
1073,$nmbr$ - $nmbr$ mo,C0026544;C0332177
1072,duration of disease — mo,C0026544;C0332177;C0872146
1071,median duration of chf — mo,C0018802;C0026544;C0332177;C0449238;C0549183;C0876920;C2347635;C2348144;C2926735;C2939193
1071,duration of macular edema  mo,C0024440;C0026544;C0271051;C0332177;C0449238;C2926735
1070,methotrexate dose | |  mg,C0024671;C0025677;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1070,methotrexate dose at baseline,C0025677;C0168634;C0178602;C0869039;C1114758;C1442488
1070,methotrexate alone ^,C0025677
1070,methotrexate,C0025677
1069,nonbiologic disease - modifying drug other than methotrexate : :,C0025677;C0392747;C4036059
1069,methotrexate plus other csdmardfl,C0025677
1069,csdmard otherthan methotrexate,C0025677
1068,mtx plus infliximab,C0025677;C0332287;C0666743;C1417487
1067,rituximab ( $nmbr$ x $nmbr$ mg ) + mtx,C0024671;C0025677;C0026410;C0393022;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1067,$nmbr$ tcz + mtx mtx,C0025677;C1417487
1067,$nmbr$ tcz + mtx,C0025677;C1417487
1067,$nmbr$ mg + mtx,C0024671;C0025677;C0026410;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1066,mtx ≤ $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1066,mtx sio mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1039355;C1417487;C1960952;C2346927;C4321396;C4521761
1066,mtx > $nmbr$ mg / week,C0024671;C0025677;C0026410;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1066,mtx > $nmbr$ and £ $nmbr$ mg / week,C0025677;C1417487
1066,mtx > $nmbr$ and si $nmbr$ mg / week,C0025677;C1417487
1065,mtx only,C0025677;C0205171;C1417487;C1720467
1065,mtx naive or free,C0025677;C1417487
1064,non - mtx csdmards,C0025677;C1417487;C1518422
1064,mtx + non - mtx,C0025677;C1417487;C1518422
1064,mtx,C0025677;C1417487
1063,mtx at baseline  n ( % ),C0025677;C0168634;C1417487;C1442488
1063,mtx ( n ),C0025677;C1417487
1062,ssz + mtx ( n = $nmbr$ ),C0025677;C1417487
1062,mtx n = $nmbr$,C0025677;C1417487
1062,mtx ( n = $nmbr$ ),C0025677;C1417487
1062,lef + mtx ( n = $nmbr$ ),C0025677;C1417487
1062,hcq + mtx ( n = $nmbr$ ),C0020336;C0025677;C1417487
1062,etn + mtx ( n = $nmbr$ ),C0014758;C0025677;C0717758;C1417487
1062,etn $nmbr$ mg + mtx n = $nmbr$,C0014758;C0024671;C0025677;C0026410;C0439269;C0717758;C1417487;C1960952;C2346927;C4321396;C4521761
1062,csdmards + mtx ( n = $nmbr$ ),C0025677;C1417487
1061,placebo + mtx ( n = $nmbr$ ),C0025677;C0032042;C1417487;C1696465;C1706408
1061,placebo + mtx,C0025677;C0032042;C1417487;C1696465;C1706408
1061,mtx + othetcsdmards,C0025677;C1417487
1061,mtx + other csomards,C0025677;C1417487
1061,mtx + other csdmards,C0025677;C1417487
1060,white tcz + mtx ( n ),C0007457;C0025677;C0043157;C0220938;C1417487
1060,tcz + mtx ( n ),C0025677;C1417487
1059,$nmbr$ baricitinib $nmbr$ mg ■ baricitinib $nmbr$ mg,C1319635;C4044947
1058,sfc $nmbr$ mg / $nmbr$ mg,C1319635;C4521536
1057,feno $nmbr$ mg / eze $nmbr$ mg ( n = $nmbr$ ),C1319635
1057,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ) ',C1319635;C1333964;C1707618
1057,eze / simva  $nmbr$ / $nmbr$ mg + feno  $nmbr$ mg dn = $nmbr$ ),C1319635;C1333964;C1707618
1056,tiotropium $nmbr$ m g,C0213771;C0456715
1055,olodaterol $nmbr$ m g,C0456715;C2934193
1055,alvmi ( per g / m $nmbr$ ),C0456715
1054,mca,C0149566
1053,hscrp > $nmbr$ . $nmbr$ mga .,C0065879
1053,hscrp < $nmbr$ . $nmbr$ mga . $nmbr$ ( $nmbr$ . $nmbr$ x $nmbr$ ( $nmbr$ . $nmbr$ ),C0065879
1053,$nmbr$ / $nmbr$ mga ( n = $nmbr$ ),C0065879
1052,meddra smq,C1140263
1051,azl - ma,C0024443;C3887485
1051,> = $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1051,< $nmbr$ kg / ma $nmbr$,C0022718;C0024443;C0439209;C3887485;C4054209
1050,≥ $nmbr$ to < $nmbr$ mg / dl,C0439269
1050,ppg  mg / dl,C0439269;C1418888
1050,$nmbr$ to < $nmbr$ mg / dl,C0439269
1050,$nmbr$ nd tertile ( > $nmbr$ to < = $nmbr$ mg / dl [ > $nmbr$ . $nmbr$ to < = $nmbr$ . $nmbr$ mmol / l ] ) c,C0439269
1049,serum cholesterol  mg / dl,C0439269;C0587184
1049,serum cholesterol  mean ( sd ) mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
1049,serum cholesterol  mean ( sd )  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143;C2699239
1049,mean serum cholesterol  mg / dl,C0439269;C0444504;C0587184;C2347634;C2348143
1048,toial cholcsierol ( mg / dl ),C0439269
1048,plasma lipids ( mg / dl ) $nmbr$ total cholesterol mean,C0023779;C0439269;C0444504;C0858034;C2347634;C2348143
1048,plasma cholesterol — mg / dl,C0439269;C0858034
1047,tc  mg / dl  mean + sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
1047,serum creatinine level  mean ( sd )  mg / dl,C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1047,serum creatinine  mg / dl  mean ( sd ),C0201976;C0439269;C0444504;C0600061;C2347634;C2348143;C2699239
1047,mean — mg / dl,C0439269;C0444504;C2347634;C2348143
1047,mean serum potassium  mg / dl,C0302353;C0439269;C0444504;C0543465;C2347634;C2348143
1047,mean serum glucose  mg / dl  mean = sd,C0202041;C0439269;C0444504;C2347634;C2348143;C2699239;C3534430
1047,mean serum creatinine  mg / dl,C0201976;C0439269;C0444504;C0600061;C2347634;C2348143
1047,mean sd ldl - c  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1047,mean sd fpg  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1047,mean  mg / dl,C0439269;C0444504;C2347634;C2348143
1047,ldl - c level  mean ( sd )  mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261
1047,ldl - c $nmbr$ - $nmbr$ mg / dl,C0439269
1047,ldl - c  mg / dl  mean ± sd,C0439269;C0444504;C2347634;C2348143;C2699239
1047,ldl - c  mg / dl  mean + sd,C0439269;C0444504;C2347634;C2348143;C2699239
1047,ldl - c  mg / dl,C0439269
1047,ldl - c  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1047,glucose  mg / dl  mean,C0017725;C0439269;C0444504;C2347634;C2348143
1047,fpg  mg / dl,C0439269
1047,fpg  mean ( sd )  mg / dlt,C0024671;C0026410;C0439269;C0444504;C1413248;C1960952;C2346927;C2347634;C2348143;C2699239;C3273706;C4321396;C4521761
1047,fpg  mean ( sd )  mg / dlf,C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1047,fpg  mean ( sd )  mg / dl [ mmol / l ],C0439269;C0444504;C1532563;C2347634;C2348143;C2699239
1047,fpg  mean ( sd )  mg / dl,C0439269;C0444504;C2347634;C2348143;C2699239
1047,crp ( normal range : $nmbr$ - $nmbr$ . $nmbr$ )  mg / dl  mean ( sd ),C0086715;C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1047,crp  mg / dl  mean ( sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1047,beam values ( mg / dl )  mean ( sd ),C0042295;C0338248;C0439269;C0444504;C2347634;C2347880;C2348143;C2699239;C4521565
1047,$nmbr$ - $nmbr$ mg / dl,C0439269
1046,non - hdl - c  mg / dl  mean ( sd ),C0439269;C0444504;C1518422;C2347634;C2348143;C2699239;C3715113
1046,middle tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C0444598;C0549183;C1514721;C1552826;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
1046,ldl - c ( mg / dl ),C0439269
1046,ldl - c ( bq ) ( mg / dl ) - mean ± sd,C0439269;C0444504;C0560038;C2346983;C2347634;C2348143;C2699239;C3541236;C3642216
1046,fsg ( mg / dl ),C0439269
1046,fsg  mg / dl ( mean ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239
1046,( sd )  mg / dl,C0439269;C2699239
1046,( mg / dl ± sd ),C0439269;C2699239
1045,ldl - c ( mg / dl ) * *,C0439269
1045,hscrp  mg / dl,C0439269
1045,crp mean ( mg / dl ± sd ),C0439269;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
1045,crp level  mean ± sd mg / dl,C0439269;C0441889;C0444504;C0456079;C1547707;C2347634;C2348143;C2699239;C2946261;C3890735;C4048285
1045,crp ( mg / dl ) * *,C0439269;C3890735;C4048285
1045,crp ( mg / dl ),C0439269;C3890735;C4048285
1045,crp  mg / dl,C0439269;C3890735;C4048285
1044,crp > $nmbr$ . $nmbr$ mg / dl  n ( % ),C0439269;C3890735;C4048285
1044,crp ( normal < $nmbr$ . $nmbr$ mg / dl ),C0205307;C0231683;C0439166;C0439269;C2347086;C3890735;C4048285;C4553972
1044,crp ( mg / dl ) < $nmbr$ . $nmbr$,C0439269;C3890735;C4048285
1044,> $nmbr$ . $nmbr$ mg / dl,C0439269
1044,< $nmbr$ . $nmbr$ mg / dl,C0439269
1043,ldl - c > $nmbr$ mg / dl,C0439269
1043,baseline triglycerides > $nmbr$ mg / dl and,C0041004;C0168634;C0439269;C1442488
1043,baseline triglycerides < $nmbr$ mg / dl,C0041004;C0168634;C0439269;C1442488
1043,baseline ldl ‐ c  mg / dl,C0168634;C0439269;C1442488
1043,baseline ldl - c > $nmbr$ mg / dl,C0168634;C0439269;C1442488
1043,baseline ldl - c  mg / dl,C0168634;C0439269;C1442488
1043,baseline hdl ‐ c  mg / dl,C0168634;C0439269;C1442488;C3715113
1043,baseline hdl - c level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1043,baseline hdl - c  mg / dl,C0168634;C0439269;C1442488;C3715113
1042,baseline sua  mean ± sd mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1042,baseline mean ( mg / dl ],C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
1042,baseline mean  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143
1042,baseline fpg  mg / dl,C0168634;C0439269;C1442488
1042,baseline . mean _ sd  mg / dl,C0168634;C0439269;C0444504;C1442488;C2347634;C2348143;C2699239
1041,tgs ( mg / dl ),C0439269;C1156212;C1537574
1041,mg / dl,C0439269
1041,fpg ( mg / dl ) x,C0439269
1041,baseline fasting tgs  mg / dl,C0015663;C0168634;C0439269;C1156212;C1442488;C1537574
1040,on maximum tolerated medications ( % ) median ( $nmbr$ th to $nmbr$ th quartile ) sua ( mg / dl ),C0013227;C0039725;C0039738;C0439269;C0549183;C0802604;C0806909;C0876920;C1420718;C1552615;C2347635;C2348144;C2598133;C2826546;C2828255;C2939193;C4282123;C4284232;C4285344
1040,median  mg / dl,C0439269;C0549183;C0876920;C2347635;C2348144;C2939193
1040,baseline tg  ( mg / dl )  median ( iqr ),C0168634;C0337445;C0439269;C0549183;C0876920;C1442488;C2347635;C2348144;C2939193
1040,$nmbr$ $nmbr$ mg / dl,C0439269
1039,elevated serum creatinine ( > $nmbr$ . $nmbr$ mg / dl_ ),C0439269;C0700225
1039,elevated serum creatinine  > $nmbr$ . $nmbr$ mg / dl,C0439269;C0700225
1038,tg > $nmbr$ mg / dl  n ( ° / o ),C0337445;C0439269
1038,tg > $nmbr$ . hdl < $nmbr$ ( mg / dl ) ( / ? = $nmbr$ ),C0337445;C0439269;C3715113
1038,> $nmbr$ to < $nmbr$ mg dl,C0439269
1038,> $nmbr$ to < $nmbr$ mg / dl,C0439269
1038,> $nmbr$ mg dl,C0439269
1038,> $nmbr$ & < $nmbr$ mg / dl,C0439269
1038,> $nmbr$  < $nmbr$ mg / dl,C0439269
1037,tg mg / dl  median ( sd ),C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
1037,tg ( mg / dl )  median ± sd,C0337445;C0439269;C0549183;C0876920;C2347635;C2348144;C2699239;C2939193
1037,tg ( mg / dl ),C0337445;C0439269
1036,blood urea nitrogen ( mg / dl ),C0005845;C0439269;C0600137
1036,blood urea nitrogen  mg / dl,C0005845;C0439269;C0600137
1035,serum uric acid ( mg / dl ),C0439269;C0455272;C0700634
1035,serum uric acid  mg / dl,C0439269;C0455272;C0700634
1035,( mg / dl ),C0439269
1034,serum urate ( mg / dl )  n ( % ),C0439269;C0455272
1034,serum urate ( mg / dl ),C0439269;C0455272
1034,baseline serum urate ( mg / dl ) a,C0168634;C0439269;C0455272;C1442488
1033,£ $nmbr$ mg / dl,C0439269
1033,present ( £ $nmbr$ mg / dl ),C0150312;C0439269;C0449450
1033,present ( > $nmbr$ mg / dl ),C0150312;C0439269;C0449450
1032,final ( mg / dl ),C0205088;C0439269;C1546485;C3853528
1032,apoal ( mg / dl ) *,C0439269
1031,hemoglobin  mg / dl,C0019046;C0439269
1031,haemoglobin ( mg / dl ),C0019046;C0439269
1031,haemoglobin  mg / dl,C0019046;C0439269
1030,women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),C0043210;C0439269;C1532563
1030,fpg  mg / dl ( mmol / l ),C0439269;C1532563
1030,fpg  ( mg / dl ),C0439269
1029,uric acid tertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
1029,uric acid tertile $nmbr$ ( < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
1029,uric acid tertile $nmbr$ ( $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mg / dl ),C0041980;C0439269
1029,uric acid fertile $nmbr$ ( > $nmbr$ . $nmbr$ mg / dl ),C0015895;C0041980;C0439269
1029,uric acid ( mg / dl ) creatinine clearance ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C0024671;C0026410;C0041980;C0151280;C0369637;C0439269;C0441923;C1960952;C2346927;C3642208;C4321396;C4521761
1029,uric acid ( mg / dl ),C0041980;C0439269
1028,bun ( mg / dl ),C0439269
1028,albumin ( mg / dl ),C0001924;C0439269
1027,fpg change ( mg / dl ) *,C0392747;C0439269;C0443172;C1705241;C4319952
1027,fpg ( mg / dl ),C0439269
1027,fbg ( mg / dl ),C0439269
1026,≥ $nmbr$ mg / dl,C0439269
1026,non - hdl - c ( mg / dl ),C0439269;C1518422;C3715113
1026,non - hdl ( mg / dl ) < $nmbr$,C0439269;C1518422;C3715113
1026,high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl ),C0025266;C0205250;C0439269;C1299351;C2700149;C3715113;C3887512;C3889660;C4321237;C4522209
1026,hdl < $nmbr$ mg / dl,C0439269;C3715113
1026,hdl - c < $nmbr$ mg / dl . n ( % ),C0439269;C3715113
1026,hdl - c  $nmbr$ mg / dl  n ( % ),C0439269;C3715113
1026,< $nmbr$ mg / dl,C0439269
1025,metsyn with ldl > $nmbr$ . $nmbr$ mg / dl,C0439269
1025,lpa  mg / dl,C0439269;C1096202;C1439335;C3539666;C4049711;C4553379
1025,baseline lp ( a )  mg / dl,C0065058;C0168634;C0439269;C1439335;C1442488;C4553379
1024,apoal  mg / dl,C0439269
1024,apoa $nmbr$  mg / dl,C0003592;C0439269;C0523508;C4553344;C4553379
1024,apo a $nmbr$ ( mg / dl ),C0003592;C0439269;C0523508;C4553344;C4553379
1024,apo a $nmbr$  mg / dl  mean ( sd ),C0003592;C0439269;C0444504;C0523508;C2347634;C2348143;C2699239;C4553344;C4553379
1023,mean ( s . d . ) apob  mg / dl,C0003593;C0439269;C0444504;C2347634;C2348143;C3252643
1023,bun  mg / dl,C0439269
1023,apolipoprotein b ( mg / dl ),C0003593;C0439269
1023,apolipoprotein b $nmbr$  mg / dl,C0003593;C0439269
1023,apolipoprotein b  mg / dl,C0003593;C0439269
1023,apob ( mg / dl ),C0003593;C0439269;C3252643
1023,apob  mg / dl,C0003593;C0439269;C3252643
1023,apo b ( mg / dl ),C0003593;C0439269;C3252643
1023,apo b  mg / dl,C0003593;C0439269;C3252643
1022,triglycerides — mg / dl ^,C0041004;C0439269
1022,triglycerides — mg / dl,C0041004;C0439269
1022,hdl cholesterol — mg / dl triglycerides — mg / dl,C0023822;C0024671;C0026410;C0041004;C0392885;C0439269;C1960952;C2346927;C3539687;C4321396;C4521761
1022,fasting triglycerides — mg / dl,C0015663;C0041004;C0439269
1021,triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0041004;C0439269;C1532563
1021,triglycerides > $nmbr$ mg / dl,C0041004;C0439269
1021,triglycerides - mg / dl * *,C0041004;C0439269
1021,triglycerides  mg / dl ^,C0041004;C0439269
1021,ldl - c  mg / dl *,C0439269
1021,$nmbr$ . $nmbr$ mg / dl triglycerides ^,C0041004;C0439269
1021,$nmbr$ - $nmbr$ mg / dl *,C0439269
1020,triglycerides — mg / dl | |,C0041004;C0439269
1020,plasma triglyceride — mg / dl,C0032105;C0041004;C0439269;C1550098;C4521445
1019,lipid levels — mg / dlj total cholesterol,C0024671;C0026410;C0201950;C0428460;C0439269;C0543421;C1960952;C2346927;C4321396;C4521761
1019,lipid levels — mg / dl,C0428460;C0439269
1018,fbs > = $nmbr$ mg / dl,C0439269;C3812213
1018,fbs < $nmbr$ mg / dl,C0439269;C3812213
1018,> = $nmbr$ mg / dl,C0439269
1018,> $nmbr$ mg / dl simva ( „ = $nmbr$ ),C0439269
1018,> $nmbr$ mg / dl simva $nmbr$ = $nmbr$ ],C0439269
1018,> $nmbr$ mg / dl eze / simva ( „ = $nmbr$ ),C0439269
1017,low density lipoprotein cholesterol  mg / dl * *,C0023824;C0439269
1017,low - density lipoprotein cholesterol  mg / dl,C0023824;C0439269
1017,low - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023824;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
1016,high density lipoprotein cholesterol  mg / dl ^,C0023822;C0439269
1016,high - density lipoprotein cholesterol — mg / dl,C0023822;C0439269
1016,hdl cholesterol — mg / dl,C0023822;C0392885;C0439269
1016,hdl cholesterol < $nmbr$ mg / dl *,C0023822;C0392885;C0439269
1016,< $nmbr$ mg / dl *,C0439269
1015,high density lipoprotein cholesterol - mg / dl * *,C0023822;C0439269
1015,high - density lipoprotein cholesterol  mg / dl,C0023822;C0439269
1015,baseline high - density lipoprotein cholesterol ( mg / dl ),C0023822;C0168634;C0439269;C1442488
1014,fasting cholesterol — mg / dl,C0008377;C0015663;C0439269
1014,cholesterol — mg / dl,C0008377;C0439269
1013,cholesterol ( mg / dl ),C0008377;C0439269
1013,cholesterol  mg / dl  mean ( sd ) §,C0008377;C0439269;C0444504;C2347634;C2348143;C2699239
1012,h dl cholesterol < $nmbr$ mg / dl,C0008377;C0024671;C0026410;C0033727;C0369286;C0439269;C0441932;C0564385;C1960952;C2346927;C3539687;C4321396;C4521761;C4528284
1012,cholesterol  mg / dl,C0008377;C0439269
1011,total cholesterol level  mg / dl,C0439269;C0878805;C1445957
1010,fasting glucose level  mg / dl,C0202045;C0439269
1009,triglycerides level  mg / dl,C0428475;C0439269
1008,glycemia  mg / dl,C0005802;C0439269
1008,> $nmbr$ mg / dl simva,C0439269
1008,> $nmbr$ mg / dl eze / simva $nmbr$ = $nmbr$ },C0439269
1008,> $nmbr$ mg / dl eze / simva,C0439269
1007,ldl - c < $nmbr$ mg / dl  no . ( % ),C0439269
1007,ldl - c ( mg / dl ) < $nmbr$,C0439269
1007,fc - ldl - c  mg / dl,C0439269;C2983605
1006,ldl - c < $nmbr$ mg / dl,C0439269
1006,< $nmbr$ / $nmbr$ mmhg  ldl - c < $nmbr$ mg / dl,C0439269;C0439475
1005,ldl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261
1005,hdl - c level  mg / dl,C0439269;C0441889;C0456079;C1547707;C2946261;C3715113
1005,baseline tg level { n = $nmbr$  $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1005,baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0337445;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261
1005,baseline ldlc level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1416822;C1442488;C1547707;C2946261
1005,baseline hdl - c level ( n = s $nmbr$  $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1005,baseline hdl - c level ( n = $nmbr$  $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0168634;C0439269;C0441889;C0456079;C1442488;C1547707;C2946261;C3715113
1005,> $nmbr$ mg / dl,C0439269
1005,$nmbr$ mg / dl,C0439269
1004,prednisone - equivalent dose — mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1004,prednisone - equivalent dose  mg,C0024671;C0026410;C0032952;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1004,mtx exposure ( mg / week ),C0024671;C0025677;C0026410;C0274281;C0332157;C0332174;C0439230;C0439269;C1417487;C1960952;C2346927;C4321396;C4521761
1004,mtx average weekly dose  mg / week  mean ( sd ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1510992;C1960952;C2346927;C2347634;C2348143;C2699239;C2825518;C4321396;C4521761
1004,mean dose ( sd ) ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0444504;C0869039;C1114758;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1004,low density lipoprotein cholesterol - mg / dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1004,low - density lipoprotein cholesterol — mg / dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1004,dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1004,crp ( mg / dl  per unit ),C0024671;C0026410;C0439148;C0439269;C0439453;C1509845;C1519795;C1532632;C1638407;C1704753;C1880519;C1960952;C2346927;C3642216;C3853603;C3890735;C4048285;C4321396;C4521761
1004,body mass index ( mg / m $nmbr$ ),C0005893;C0024671;C0026410;C0369637;C0439269;C0441923;C0578022;C1305855;C1960952;C2346927;C4321396;C4521761
1004,average weekly mtx dose ( mg / week ) t,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1004,average weekly mtx dose ( mg / week ),C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1004,average dose ( mg / week ),C0024671;C0026410;C0178602;C0332174;C0439230;C0439269;C0869039;C1114758;C1510992;C1960952;C2346927;C2825518;C4321396;C4521761
1004,$nmbr$ mg / $nmbr$ mgb,C0024671;C0026410;C0373680;C0439269;C1960952;C2346927;C4321396;C4521761
1003,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1003,ratio of urinary albumin ( mg ) to creatinine ( g ),C0024671;C0026410;C0439269;C0456603;C1547037;C1960952;C2346927;C2362049;C4321396;C4521761
1003,baseline sildenafil dose mg,C0024671;C0026410;C0168634;C0178602;C0439269;C0529793;C0869039;C1114758;C1442488;C1960952;C2346927;C4321396;C4521761
1003,baseline ldl ( mg % ),C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
1003,baseline corticosteroid use ( mg ),C0024671;C0026410;C0168634;C0239126;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761
1002,hscrp — mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1002,high - sensitivity crp — mg / liter | |,C0024671;C0026410;C0439269;C0475211;C1441604;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
1002,high - sensitivity c - reactive protein — mg / liter |,C0006560;C0024671;C0026410;C0439269;C0475211;C1413716;C1441604;C1960952;C2346927;C4048285;C4321396;C4521761
1002,crp — mg / liter ^,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
1001,with baseline crp level of > $nmbr$ mg / liter,C0024671;C0026410;C0168634;C0439269;C0441889;C0456079;C0475211;C1442488;C1547707;C1960952;C2346927;C2946261;C3890735;C4048285;C4321396;C4521761
1001,week $nmbr$ czp $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0332174;C0439230;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,vonoprazan $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4080009;C4321396;C4521761
1001,vildagliptin $nmbr$ mg qd n = $nmbr$,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1001,vildagliptin $nmbr$ mg qd,C0024671;C0026410;C0332173;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1001,vildagliptin $nmbr$ mg bid n = $nmbr$,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1001,vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1570906;C1960952;C2346927;C4321396;C4521761
1001,vi $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0205999;C0439269;C1960952;C2346927;C4321396;C4521761
1001,toricoxib $nmbr$ mg n = $nmbr$ ) ( % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
1001,tofacitinib $nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
1001,tofacitinib $nmbr$ mg bid [ n = $nmbr$ |,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
1001,tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
1001,tofacitinib  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2930696;C4321396;C4521761
1001,tiotropium / olodaterol $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
1001,tiotropium / olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
1001,tiotropium / olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
1001,tiotropium + olodaterol $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
1001,tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4032878;C4321396;C4521761
1001,tiotropium $nmbr$ mg respimat ® ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tiotropium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tiotropium $nmbr$ mg ( n = $nmbr$,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tiotropium $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tiotropium $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0213771;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ticagrelor $nmbr$ mg no diabetes n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1001,ticagrelor $nmbr$ mg km %,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1001,ticagrelor $nmbr$ mg diabetes n = $nmbr$,C0011847;C0011849;C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1001,ticagrelor $nmbr$ mg $nmbr$ yr km %,C0024671;C0026410;C0439234;C0439269;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1001,ticagrelor $nmbr$ mg $nmbr$ year km ( % ),C0024671;C0026410;C0439234;C0439269;C0439508;C1960952;C1999375;C2346927;C3887676;C4321396;C4521761
1001,ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1001,ticagrelor  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1001,tcz - sc $nmbr$ mg every other week ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1960952;C2346927;C4321396;C4521761
1001,tanezumab $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1001,tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1001,tadalafil $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1001,tadalafil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1001,tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1001,sita $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
1001,simvastatin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1001,simvastatin $nmbr$ mg ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1001,simvastatin $nmbr$ mg,C0024671;C0026410;C0074554;C0439269;C1960952;C2346927;C4321396;C4521761
1001,silodosin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1870115;C1960952;C2346927;C4321396;C4521761
1001,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
1001,sfc $nmbr$ / $nmbr$ mg twice daily ( n = $nmbr$  $nmbr$ ),C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521536;C4521761
1001,serum triglycerides  mg / dle,C0024138;C0024671;C0026410;C0439269;C0542495;C1960952;C2346927;C3542918;C4321396;C4521761
1001,serum cholesterol  mg / dld,C0024671;C0026410;C0439269;C0587184;C1414063;C1960952;C2346927;C2826331;C4321396;C4521761
1001,secukinumab $nmbr$   mg no load ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab $nmbr$   mg ( n   =   $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab $nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,secukinumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179547;C4321396;C4521761
1001,sc belimumab $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
1001,saxa $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,sal $nmbr$ mg,C0024671;C0026410;C0036140;C0037494;C0206136;C0439269;C1960952;C2346927;C4321396;C4521761
1001,rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C0965129;C1960952;C2346927;C4321396;C4521761
1001,rosuva $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,r $nmbr$ mg + fa ( « = $nmbr$ ),C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
1001,r $nmbr$ mg + fa,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
1001,r $nmbr$ mg,C0024671;C0026410;C0205090;C0439269;C0684010;C1960952;C2346927;C2603358;C4321396;C4521761
1001,placebofigolimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,placebo → golimumab $nmbr$ mg / $nmbr$ mga  b,C0024671;C0026410;C0032042;C0065879;C0439269;C1696465;C1706408;C1960952;C2346927;C2353893;C4321396;C4521761
1001,pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1101838;C1960952;C2346927;C4321396;C4521761
1001,olodaterol $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
1001,olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2934193;C4321396;C4521761
1001,olmesartan medoxomil $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0386393;C0439269;C1960952;C2346927;C4321396;C4521761
1001,mean ( sd ) mtx dose  mg / week,C0024671;C0026410;C0332174;C0366550;C0439230;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C2699239;C4321396;C4521761
1001,lovastatin $nmbr$ mg,C0024027;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,llraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
1001,liraglutide $nmbr$ - $nmbr$ mg mean ( n ),C0024671;C0026410;C0439269;C0444504;C1456408;C1960952;C2346927;C2347634;C2348143;C4321396;C4521761
1001,lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1001,lebrikizumab $nmbr$ - $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2981360;C4321396;C4521761
1001,indacaterol $nmbr$ mg [ n z $nmbr$ ],C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1001,indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1722260;C1960952;C2346927;C4321396;C4521761
1001,golimumab $nmbr$ mg / $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1001,golimumab $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353893;C4321396;C4521761
1001,glycopyrronium $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3814772;C4321396;C4521761
1001,fp $nmbr$ mg,C0016704;C0024671;C0026410;C0439269;C1419068;C1419906;C1960952;C2346927;C3541238;C3541412;C4321396;C4521761
1001,fluvastatin $nmbr$ mg,C0024671;C0026410;C0082608;C0439269;C1960952;C2346927;C4321396;C4521761
1001,feno $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,febuxostat $nmbr$ mg daily n = $nmbr$ n ( % ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1001,febuxostat $nmbr$ mg daily n = $nmbr$ % ( n / n ),C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1001,famotidine $nmbr$ mg ( n = $nmbr$ ),C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,fa $nmbr$ mg ( « = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ezetimibe / simvastatin $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1532737;C1960952;C2346927;C4321396;C4521761
1001,eze / simva $nmbr$ / $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,eze / simva $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,eze / simva  $nmbr$ / $nmbr$ mg dr = $nmbr$ ),C0013014;C0024671;C0026410;C0031831;C0439269;C1707664;C1960952;C2346927;C2348314;C3540849;C4321396;C4521761
1001,eze / simva  $nmbr$ / $nmbr$ mg dn = $nmbr$ c $nmbr$ ),C0024671;C0026410;C0439269;C1333964;C1707618;C1960952;C2346927;C4321396;C4521761
1001,eze $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,empaglifiozin $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,empaglifiozin $nmbr$ . $nmbr$ mg ( w = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,dupiiumab  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,dulaglutide $nmbr$ · $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1001,dose equivalent  mg ( sd ) ),C0024671;C0026410;C0178602;C0205163;C0439185;C0439269;C0869039;C1114758;C1960952;C2346927;C2699239;C4321396;C4521761
1001,dose  mg,C0024671;C0026410;C0178602;C0439269;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
1001,de $nmbr$ mg bid ( n - $nmbr$  $nmbr$ ),C0011198;C0017480;C0024671;C0026410;C0439269;C1960952;C2346927;C3541240;C4321396;C4521761
1001,dapagliflozin $nmbr$ mg group ( n = $nmbr$ ),C0024671;C0026410;C0439269;C0441848;C1960952;C2346927;C2353951;C4321396;C4521761
1001,dapagliflozin $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
1001,dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2353951;C4321396;C4521761
1001,daily dose > $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
1001,daily dose $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
1001,daily dose $nmbr$ - $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C2348070;C4321396;C4521761
1001,dabigatran  $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C2348066;C4321396;C4521761
1001,czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg ( n = lll ),C0024671;C0026410;C0054841;C0439269;C1261077;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg ( n $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg  % ( n / n ),C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,czp $nmbr$ mg,C0024671;C0026410;C0054841;C0439269;C1861828;C1872109;C1960952;C2346927;C4321396;C4521761
1001,crp > $nmbr$ mg / $nmbr$  n [ % ],C0024671;C0026410;C0439269;C1960952;C2346927;C3890735;C4048285;C4321396;C4521761
1001,clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C3714444;C4321396;C4521761
1001,clopidogrel  $nmbr$ mg loading doset,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C4321396;C4521761
1001,clopidogrel  $nmbr$ mg loading dose !,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
1001,clopidogrel  $nmbr$ - mg loading dose,C0024671;C0026410;C0070166;C0439269;C1708715;C1960952;C2346927;C3714444;C4086581;C4321396;C4521761
1001,cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,carisbamate $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
1001,carisbamate $nmbr$  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1871983;C1960952;C2346927;C4321396;C4521761
1001,canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2718773;C4321396;C4521761
1001,cana $nmbr$ mg ( n = $nmbr$ ) *,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
1001,cana $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
1001,cana $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
1001,cana $nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
1001,cana $nmbr$ mg,C0024671;C0026410;C0439269;C1418845;C1960952;C2346927;C4321396;C4521761
1001,benralizumab $nmbr$ mg q $nmbr$ w ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
1001,benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C2982078;C4321396;C4521761
1001,belimumab $nmbr$ mg sc ( n $nmbr$ ),C0024671;C0026410;C0282380;C0439269;C1723401;C1960952;C2346927;C4321396;C4521761
1001,baseline aspirin dose < $nmbr$ mg,C0024671;C0026410;C0168634;C0439269;C1442488;C1960952;C2346927;C4321396;C4521761;C4696290
1001,baricitinib $nmbr$ mg qd ( n = $nmbr$ ),C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
1001,baricitinib $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
1001,baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
1001,baricitinib $nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4044947;C4321396;C4521761
1001,atv $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
1001,atv $nmbr$ mg,C0024671;C0026410;C0210243;C0439269;C0674679;C1145759;C1334862;C1960952;C2346927;C4321396;C4521761
1001,atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ ),C0024671;C0026410;C0286651;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ato $nmbr$ mg and sim $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ato $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,aspirin use ( > $nmbr$ mg ),C0004057;C0024671;C0026410;C0042153;C0439269;C0457083;C1947944;C1960952;C2346927;C4321396;C4521761
1001,aspirin $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,asa > $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
1001,asa < $nmbr$ mg,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C3853627;C4321396;C4521761
1001,apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1001,apixaban  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1001,apixaban  $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1001,anacetrapib $nmbr$ mg ( n - $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1001,anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2604745;C4321396;C4521761
1001,amlodipine / wlsartan i $nmbr$ / $nmbr$ mg,C0021966;C0024671;C0026410;C0051696;C0221138;C0439269;C1960952;C2346927;C4321396;C4521761
1001,amlodipine / valsartan $nmbr$ to $nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1001,amlodipine / valsartan $nmbr$ / $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0439269;C1960952;C1962523;C2346927;C4321396;C4521761
1001,amlodipine $nmbr$ mg / v = $nmbr$,C0024671;C0026410;C0051696;C0439269;C1960952;C2346927;C4321396;C4521761
1001,ami $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
1001,ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4319936;C4321396;C4521761
1001,alogliptin $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
1001,alogliptin $nmbr$ . $nmbr$ mg + pioglitazone ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3535925;C4321396;C4521761
1001,allopurinol $nmbr$ / $nmbr$ mg n = $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,allopurinol $nmbr$ / $nmbr$ mg daily n = $nmbr$,C0002144;C0024671;C0026410;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
1001,alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C3491162;C4321396;C4521761
1001,> $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1001,> $nmbr$ mg / dl — %,C0439269
1001,> $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,> $nmbr$ . $nmbr$ mg / liter antiplatelet agents,C0024671;C0026410;C0085826;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1001,> $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1001,< $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1001,< $nmbr$ mg / dl simva ( n = $nmbr$ ],C0439269
1001,< $nmbr$ mg / dl simva ( n = $nmbr$ ),C0439269
1001,< $nmbr$ mg / dl simva,C0439269
1001,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ },C0439269
1001,< $nmbr$ mg / dl eze / simva ( n = $nmbr$ ),C0439269
1001,< $nmbr$ mg / dl eze / simva,C0439269
1001,< $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,< $nmbr$ . $nmbr$ mg / liter,C0024671;C0026410;C0439269;C0475211;C1960952;C2346927;C4321396;C4521761
1001,* atherosclerotic coronary heart disease  ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg  rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .,C0010054;C0010068;C0012634;C0018787;C0024671;C0026410;C0027361;C0237753;C0333482;C0360714;C0439269;C0449788;C0948008;C1956346;C1960952;C2346927;C4081854;C4321396;C4521761
1001,$nmbr$   mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg twice daily n = $nmbr$,C0024671;C0026410;C0439269;C0585361;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg sirukumab every $nmbr$ weeks ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3254570;C4321396;C4521761
1001,$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg ew n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg eow n = $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg clopidogrel load,C0024671;C0026410;C0070166;C0439269;C1550025;C1704782;C1708715;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg / kgf ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg / $nmbr$ mgc,C0024671;C0026410;C0439269;C1960952;C2346927;C3888239;C4321396;C4521761
1001,$nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ / $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ / $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1001,$nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,week $nmbr$ ertugliflozin $nmbr$   mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,week $nmbr$ ertugliflozin $nmbr$ mg vs . placebo,C0024671;C0026410;C0332174;C0439230;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,ticagrelor $nmbr$ mg vs . placebo hr ( $nmbr$ % ci ),C0024671;C0026410;C0439269;C1960952;C1999375;C2346927;C4321396;C4521761
1000,tanezumab $nmbr$ . $nmbr$ mg + nsaid,C0003211;C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C3536840;C4321396;C4521761
1000,tanezumab $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346819;C2346927;C4321396;C4521761
1000,tamsulosin $nmbr$ . $nmbr$ mg vs . placebo,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1000,tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0257343;C0439269;C1960952;C2346927;C4321396;C4521761
1000,tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1000,tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1000,tadalafil $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1176316;C1960952;C2346927;C4321396;C4521761
1000,saxa $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,p - value d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0439269;C1709380;C1960952;C2346927;C4321396;C4521761
1000,no . of $nmbr$ - mg tablets of acetaminophen,C0024671;C0026410;C0439269;C1243102;C1960952;C2346927;C4321396;C4521761
1000,lowest tertile ( range  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / dl  mean ± sd  $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ mg / dl ),C0024671;C0026410;C0439269;C0444504;C1514721;C1708760;C1960952;C2346927;C2347634;C2348143;C2348147;C2699239;C3539687;C3542016;C4321396;C4521761
1000,liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1000,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1000,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$  $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1000,liraglutide $nmbr$ . $nmbr$ mg  n = $nmbr$,C0024671;C0026410;C0439269;C1456408;C1960952;C2346927;C4321396;C4521761
1000,gly $nmbr$ . $nmbr$ mg b . i . d . n = $nmbr$,C0024671;C0026410;C0152277;C0439269;C1415124;C1960952;C2346927;C4321396;C4521761
1000,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1000,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1000,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1000,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1000,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0024671;C0026410;C0439269;C0972314;C1960952;C2346927;C4321396;C4521761
1000,esrd saxa $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0022661;C0024671;C0026410;C0035078;C0439269;C1960952;C2316810;C2346927;C4321396;C4521761
1000,ertuglrflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,ertugliflozin $nmbr$ mg vs placebo / glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,ertugliflozin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,ertugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,ertugliflozin $nmbr$ mg vs placebo / giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4079805;C4321396;C4521761
1000,ertuglifldzin $nmbr$ mg vs placebo / glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,erlugliflozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,eduglinozin $nmbr$ mg vs placebo / glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,dulaglutide $nmbr$ . $nmbr$ mg *,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1000,dulaglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1000,dulaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3179549;C4321396;C4521761
1000,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . n . . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ )  . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,dabigatran $nmbr$   mg b . i . d .,C0021966;C0024671;C0026410;C0152277;C0221138;C0439269;C0439422;C1960952;C2346927;C2348066;C4321396;C4521761
1000,dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1000,dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1000,dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1000,dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1000,dabigatran  $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2348066;C4321396;C4521761
1000,d $nmbr$ mg vs . warfarin,C0024671;C0026410;C0073187;C0332173;C0439269;C1960952;C2346927;C4321396;C4484261;C4521761
1000,clopidogrel  $nmbr$ mg *,C0024671;C0026410;C0070166;C0439269;C1960952;C2346927;C4321396;C4521761
1000,canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2974540;C4321396;C4521761
1000,aplxaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,apixaban $nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1000,apixaban  $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1000,apixaban  $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1831808;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ mg qw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0043011;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ mg biw $nmbr$ . $nmbr$ pt yrs,C0024671;C0026410;C0032743;C0439269;C0699718;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ mg ( $nmbr$  $nmbr$ . $nmbr$ % ),C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ . $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
1000,$nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
999,urine qmax  ml / s,C0042036;C0042037;C0439390;C2963137
999,qmax  ml / s,C0439390
999,> $nmbr$ ml / s,C0439390
999,< $nmbr$ ml / s,C0439390
998,qmax ( ml / s ),C0439390
998,qmax  ml / s  mean ( sd ),C0439390;C0444504;C2347634;C2348143;C2699239
997,sex m / f,C0009253;C0036864;C0079399;C0804628;C1306057;C1314687;C1522384
997,m / f,C1306057
997,gender ( m / f )  ( % ),C0079399;C1306057;C1522384
996,tr jet velocity ( m / sec ),C0108801;C0336862;C0439493;C0439830;C1539482;C1547053;C1705610;C1872943;C3811249;C3811250;C3814152
995,m $nmbr$ s,C0439493;C1513009
994,mean bmii 士 s . d .  kg / m $nmbr$,C0444504;C1532718;C2347634;C2348143
994,mean bm $nmbr$ ± s . d .  kg / m $nmbr$,C0006416;C0444504;C1532718;C2347634;C2348143
994,kg / m $nmbr$,C1532718
993,> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :,C0020538;C1532718;C1963138
993,> $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
992,bmp kg - m “ $nmbr$,C0053932;C0279266;C1532718;C4281808
991,> $nmbr$ kg / m ’,C1532718
991,> $nmbr$ - s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
991,> $nmbr$ - < s $nmbr$ kg / m ’,C0565930;C1532718;C2603362
991,$nmbr$ - < $nmbr$ kg / m $nmbr$,C1532718
990,≥ $nmbr$ kg / m $nmbr$,C1532718
990,≥ $nmbr$  kg / m $nmbr$,C1532718
990,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection  evaluation  and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women  triglycerides $nmbr$ mg / dl  high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women  mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg  fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren  n $nmbr$  hydrochlorothiazide  n $nmbr$ .,C0001675;C0015663;C0017725;C0020261;C0023822;C0024671;C0025266;C0026410;C0028754;C0039798;C0041004;C0042295;C0087111;C0205437;C0220825;C0231290;C0243161;C0262926;C0332282;C0439070;C0439269;C0439475;C0441833;C0524620;C0600653;C0687744;C0918012;C1257890;C1261322;C1511790;C1519504;C1522326;C1532718;C1533734;C1547282;C1552854;C1637833;C1704706;C1705160;C1705169;C1705428;C1705429;C1706365;C1960952;C1963185;C1999270;C2241628;C2346927;C2986546;C3538994;C3539687;C3887704;C4321396;C4521761
990,body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % ),C0005893;C0022718;C0439209;C0441833;C0441847;C0578022;C0687744;C1257890;C1305855;C1519504;C1532718;C1705428;C1705429;C4054209
990,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
990,$nmbr$ - $nmbr$ kg / m $nmbr$,C1532718
990,$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
989,overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ ),C0497406;C1532718
989,$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
988,body weight index ( kg / m $nmbr$ ),C0005910;C0600653;C0918012;C1305866;C1532718;C1552854;C1637833;C2986546
988,$nmbr$ kg / m $nmbr$ or more,C1532718
987,obese ( > $nmbr$ kg / m ^ $nmbr$ ),C0028754;C1532718
987,> = $nmbr$ kg / m $nmbr$,C1532718
987,> $nmbr$ kg / m ^ ( obesity ),C0028754;C1532718;C1963185
987,> $nmbr$ kg / m ^,C1532718
987,> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
987,> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
986,obesity * ( bm $nmbr$ > $nmbr$ kg / m $nmbr$ ),C0006416;C0028754;C1532718;C1963185
986,bm $nmbr$ ( kg / m $nmbr$ ),C0006416;C1532718
985,£ $nmbr$ kg / m $nmbr$,C1532718
985,obesity ( bmi £ $nmbr$ kg / m $nmbr$ ),C0028754;C0578022;C1532718;C1963185
985,lean ( < $nmbr$ kg / m $nmbr$ ),C1532718
985,bmi £ $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
985,bmi < $nmbr$ kg / m ^ ( n = $nmbr$ / $nmbr$ ),C0578022;C1532718
985,> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
985,< $nmbr$ kg / m ^,C1532718
985,< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),C1532718
985,< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),C1532718
985,< $nmbr$ kg / m $nmbr$,C1532718
984,bmi o $nmbr$ kg / m $nmbr$  n ( % ),C0578022;C1532718
984,bmi category ( kg / m $nmbr$ ),C0578022;C0683312;C1532718;C3889287
984,bmi ( kg / m ’ ),C0578022;C1532718
984,bmi  kg / m $nmbr$  n ( % ),C0578022;C1532718
983,mean ( sd ) bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi ( sd )  kg / m $nmbr$,C0578022;C1532718;C2699239
983,bmi ( kg / m $nmbr$ ) mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi ( kg / m $nmbr$ ) a,C0578022;C1532718
983,bmi ( kg / m $nmbr$ ) ( sd ),C0578022;C1532718;C2699239
983,bmi ( kg / m $nmbr$ )  mean ( sd ) a,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi ( kg / m $nmbr$ )  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi # kg - m “ $nmbr$,C0578022;C1532718
983,bmi  mean ( sd ) ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi  mean ( sd )  kg / m $nmbr$ c,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi  kg / m ’,C0578022;C1532718
983,bmi  kg / m ^  mean ( sd ) ’,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
983,bmi  kg / m $nmbr$ ( sd ),C0578022;C1532718;C2699239
983,bmi  kg / m $nmbr$,C0578022;C1532718
983,a $nmbr$ kg / m $nmbr$,C1532718
983,> $nmbr$ - ^ $nmbr$ kg / m ’,C1532718
983,$nmbr$ kg / m ’,C1532718
983,$nmbr$ kg / m $nmbr$,C1532718
982,mean ± sd bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,mean bmi ± sd ( kg / m $nmbr$ ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,mean bmi ± s . d .  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143
982,mean bmi  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
982,bmi in kg / m $nmbr$  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi : > $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
982,bmi : < $nmbr$ . $nmbr$ kg / m $nmbr$,C0578022;C1532718
982,bmi ( kg / m ),C0578022;C1532718
982,bmi ( kg / m $nmbr$ ) ( mean ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi ( kg / m $nmbr$ )  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi ( kg / m $nmbr$ ),C0578022;C1532718
982,bmi ( kg / ( m ) $nmbr$ ),C0578022;C1532718
982,bmi  x $nmbr$ kg / m $nmbr$,C0578022;C1532718
982,bmi  mean ± sd  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  mean ( sd ) kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  mean ( sd )  kg / m ^,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  mean  kg / m $nmbr$ ( ± sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  mean  kg / m $nmbr$,C0444504;C0578022;C1532718;C2347634;C2348143
982,bmi  kg / m ^  mean ( sd ),C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  kg / m ^,C0578022;C1532718
982,bmi  kg / m $nmbr$  mean ± sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,bmi  kg / m $nmbr$  mean + sd,C0444504;C0578022;C1532718;C2347634;C2348143;C2699239
982,< $nmbr$ . $nmbr$ kg / m $nmbr$,C1532718
981,high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi,C0021966;C0168634;C0205250;C0221138;C0578022;C1299351;C1442488;C1532718;C2700149;C3887512;C3889660;C4321237;C4522209
981,bmi at baseline ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
981,bmi [ kg / m $nmbr$ ],C0578022;C1532718
981,bmi  kg / m $nmbr$  n,C0578022;C1532718
981,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
981,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
981,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
981,baseline bmi > $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
981,baseline bmi > $nmbr$ kg / m $nmbr$,C0168634;C0578022;C1442488;C1532718
981,baseline bmi ( kg / m ^ ),C0168634;C0578022;C1442488;C1532718
981,baseline bmi ( kg / m $nmbr$ ),C0168634;C0578022;C1442488;C1532718
981,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
981,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$ change from baseline to $nmbr$ weeks,C0168634;C0392747;C0443172;C0578022;C1442488;C1532718;C1705241;C4319952
981,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$  $nmbr$,C0168634;C0578022;C1442488;C1532718
981,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$  n = $nmbr$,C0168634;C0578022;C1442488;C1532718
981,[ kg / m ^ ],C1532718
981,< $nmbr$  kg / m $nmbr$,C1532718
981,$nmbr$ to < $nmbr$ kg / m $nmbr$,C1532718
981,$nmbr$ bmi  kg / m,C0578022;C1532718
980,obesity ( body mass index > $nmbr$ kg / m $nmbr$ ),C0005893;C0028754;C0578022;C1305855;C1532718;C1963185
980,median body mass index  kg / m $nmbr$ ( range ),C0005893;C0549183;C0578022;C0876920;C1305855;C1514721;C1532718;C2347635;C2348144;C2348147;C2939193;C3542016
980,mean body mass index ( kg / m $nmbr$ ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143
980,mean ( sd ) body mass index  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,kg / m $nmbr$ ),C1532718
980,bodymass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
980,body mass index > $nmbr$ kg / m $nmbr$ *,C0005893;C0578022;C1305855;C1532718
980,body mass index ( range ) ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1514721;C1532718;C2348147;C3542016
980,body mass index ( kg / m ),C0005893;C0578022;C1305855;C1532718
980,body mass index ( kg / m $nmbr$ ) ∗,C0005893;C0578022;C1305855;C1532718
980,body mass index ( kg / m $nmbr$ ) - mean ± sd,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index ( kg / m $nmbr$ )  mean ( sd ) c,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index ( kg / m $nmbr$ ),C0005893;C0578022;C1305855;C1532718
980,body mass index ( bmi )  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
980,body mass index  mean + sd ( kg / m ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index  mean ( sd ) kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index  mean ( sd )  kg / m $nmbr$,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index  kg / m ’,C0005893;C0578022;C1305855;C1532718
980,body mass index  kg / m $nmbr$   ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
980,body mass index  kg / m $nmbr$ ( sd ),C0005893;C0578022;C1305855;C1532718;C2699239
980,body mass index  kg / m $nmbr$  mean ( sd ) §,C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body mass index  kg / m $nmbr$,C0005893;C0578022;C1305855;C1532718
980,body - mass index ( kg / m $nmbr$ ) ( mean  sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,body - mass index ( kg / m $nmbr$ )  mean ( sd ),C0005893;C0444504;C0578022;C1305855;C1532718;C2347634;C2348143;C2699239
980,> $nmbr$ kg / m $nmbr$,C1532718
979,mab,C0003250;C0369637
978,m o nito ring treatment,C0039798;C0087111;C0369637;C0441923;C0521164;C1260969;C1522326;C1533734;C1705169;C1882954;C3538994;C3887704
978,m being,C0369637;C0441923
977,six - minute walk distance  m,C0012751;C0369637;C0441923;C3900196
977,$nmbr$ mw distance  m,C0012751;C0024548;C0026385;C0369637;C0441923;C0556966
976,baseline $nmbr$ - min walk distance m,C0168634;C0369637;C0429886;C0441923;C0702093;C1442488;C1524029;C3813700
976,$nmbr$ - minute walk distance — m,C0369637;C0429886;C0439232;C0441923;C0700321;C0702093;C1282918;C2347166
976,$nmbr$ - min walk distance m,C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
976,$nmbr$ - min walk distance ( m ),C0369637;C0429886;C0441923;C0702093;C1524029;C3813700
975,stroke / m $nmbr$,C0038454;C0369637;C0441923;C4554100
975,> $nmbr$ to < $nmbr$ iiil / iiim / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0441923
974,≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
974,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$ *,C0369637;C0439445;C0441923;C3811844;C3839656
974,estimated glomerular filtration rate ( mdrd )  ml · min $nmbr$ · $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923;C3811844;C3839656
974,egfr from the mdrd equation ( sd )  ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C0552449;C1739039;C2699239;C3811844;C3812682;C3839656
974,egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C1846718;C3811844;C3812682
974,egfr ( mdrd )  ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682;C3839656
974,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’,C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
974,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C0369637;C0439445;C0441923;C1739039;C3811844;C3812682
974,< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m  $nmbr$,C0369637;C0439445;C0441923
974,$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C0369637;C0439445;C0441923
974,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
974,$nmbr$ to < $nmbr$ ml / min / $nmbr$  $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
974,$nmbr$ to < $nmbr$ m um in,C0369637;C0441923
973,m,C0369637;C0441923
973,glomerular filtration rate  $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1561549
973,gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C1424601
973,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  no . ( % ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
973,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
973,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ )  mean ( sd ),C0017654;C0369637;C0439445;C0441923;C0444504;C0750572;C1424601;C2347634;C2348143;C2699239
973,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C0017654;C0369637;C0439445;C0441923;C0750572;C1424601
973,egfrmdrd  ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa,C0369637;C0439445;C0441923
973,baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$  n ( % ),C0017654;C0168634;C0369637;C0439445;C0441923;C1424601;C1442488
973,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441923
972,mean $nmbr$ mwd *  m ( sd ),C0369637;C0441923;C0444504;C2347634;C2348143;C2699239
972,$nmbr$ mwt ( m ),C0369637;C0441923
972,$nmbr$ mwd  m,C0369637;C0441923
971,hr ( b . p . m . ),C0369637;C0441923
971,heart rate ( b . p . m . ),C0018810;C0369637;C0441923
970,azl - m / cld ( n = $nmbr$ ),C0369637;C0441923
970,azl - m + cldb,C0369637;C0441923
970,azl - m $nmbr$ mg + cld $nmbr$ mg,C0369637;C0441923;C1319635
970,azl - m $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0369637;C0439269;C0441923;C1960952;C2346927;C4321396;C4521761
970,azl - m $nmbr$ mg $nmbr$ - cld $nmbr$ mg ( n = l $nmbr$ ),C0369637;C0441923;C2827881
970,azl - m,C0369637;C0441923
969,> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
969,$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C0369637;C0441923;C1552852;C4086268
968,k - m % n,C0369637;C0441923;C0597277;C1708601
968,k - m %,C0369637;C0441923;C0597277;C1708601
967,years male gender  n ( % ),C0086582;C0439234;C1706180
967,sex ( male  % ),C0086582
967,sex  male  no . ( % ),C0086582
967,sex  male  n ( % ),C0086582
967,sex  male,C0086582
967,sex  % male,C0086582
967,male sex  n [ % ],C0086582
967,male sex  %,C0086582
967,male sex,C0086582
967,male gender,C0086582;C1706180
966,sex : male ( n = $nmbr$ ),C0086582
966,sex : male,C0086582
966,sex ( male ) ethnic origin,C0015031;C0086582
965,sex ( male ) - no . ( % ),C0086582
965,male vs . female,C0086582;C1706180;C1706428;C1706429
965,male sex ^,C0086582
965,male eze / simva,C0086582;C1706180;C1706428;C1706429
965,male acr definition  ^ . g / mg,C0024671;C0026410;C0086582;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1706180;C1706428;C1706429;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
965,male - no . ( % ),C0086582;C1706180;C1706428;C1706429
965,male,C0086582;C1706180;C1706428;C1706429
965,[ cm { female ) / cm { male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
965,[ cm ( female ) / cm ( male ) ],C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
964,males ( n = $nmbr$ ),C0086582
964,males ( itt ) ( n = $nmbr$ ),C0086582
964,males  %,C0086582
964,male subjects ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
964,male simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male simva,C0086582;C1706180;C1706428;C1706429
964,male eze / simva ( „ = $nmbr$ },C0086582;C1706180;C1706428;C1706429
964,male eze / simva ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
964,male *  n ( % ),C0086582;C1706180;C1706428;C1706429
964,male ( n   = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male ( n z $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male ( n = $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male ( n = $nmbr$  $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male ( n - $nmbr$ ),C0086582;C1706180;C1706428;C1706429
964,male    n   ( % ),C0086582;C1706180;C1706428;C1706429
964,male  n / n ( % ),C0086582;C1706180;C1706428;C1706429
964,male  n,C0086582;C1706180;C1706428;C1706429
964,male  %,C0086582;C1706180;C1706428;C1706429
964,genital mycotic infections male $nmbr$,C0086582;C0740330;C1706180;C1706428;C1706429
964,gender - male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
963,sexa male,C0086582;C1706180;C1706428;C1706429
963,sex ( male / female ) ( n ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
963,sex ( male / female ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
963,sex ( male )  n ( % ),C0086582
963,sex ( male )  %,C0086582
963,sex ( male ),C0086582
963,sex  n ( % ) male,C0086582
963,males [ n ( % ) ],C0086582
963,males ( % ),C0086582
963,males  n ( % ),C0086582
963,male sex 一 no . ( % ),C0086582
963,male sex — no . { % ),C0086582
963,male sex — no . of patients ( % ),C0086582
963,male sex — no . / total no . ( % ),C0086582
963,male sex — no . ( % ) weight — no . ( % ),C0086582
963,male sex — no . ( % ) risk factors,C0086582
963,male sex — no . ( % ) race — no . ( % ) ) :,C0086582
963,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582
963,male sex — no . ( % ) f,C0086582
963,male sex — no . ( % ),C0086582
963,male sex — %,C0086582
963,male sex \ no . ( % ),C0086582
963,male sex ( % ),C0086582
963,male sex  no . / total no . ( % ),C0086582
963,male sex  no . ( % ),C0086582
963,male sex  n ( % ),C0086582
963,male sex  ( % ),C0086582
963,male gender ( % ),C0086582;C1706180
963,male gender    n   ( % ),C0086582;C1706180
963,male gender  n ( % ),C0086582;C1706180
963,male ( % ),C0086582;C1706180;C1706428;C1706429
963,male  no ( % ),C0086582;C1706180;C1706428;C1706429
963,male  n ( % ),C0086582;C1706180;C1706428;C1706429
963,male  % ( n ),C0086582;C1706180;C1706428;C1706429
963,hdl — male,C0086582;C1706180;C1706428;C1706429;C3715113
963,gender  n ( % ) male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
962,males  > $nmbr$ . $nmbr$,C0086582
962,males  > $nmbr$,C0086582
962,males  < $nmbr$ . $nmbr$,C0086582
962,males  < $nmbr$,C0086582
962,males,C0086582
962,caleitonin  ng / l  males mean ± sd,C0086582;C0439297;C0444504;C2347634;C2348143;C2699239
961,sex ( female ),C0086287
961,female sex — number ( % ),C0086287;C0237753;C0449788
960,sex  female  n ( % ),C0086287
960,female sex ( % ),C0086287
960,female sex  n ( % ) race  n ( % ),C0034510;C0086287;C1706779;C3853635
959,females  > $nmbr$ . $nmbr$,C0086287
959,females  > $nmbr$,C0086287
959,females  < $nmbr$ . $nmbr$,C0086287
959,females  < $nmbr$,C0086287
959,females,C0086287
959,caleitonin  ng / l  females mean ± sd,C0086287;C0439297;C0444504;C2347634;C2348143;C2699239
958,male / female,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
958,gender ( male / female ) ( number ),C0043210;C0079399;C0086287;C0086582;C0237753;C0449788;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
958,gender ( % ) male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
958,gender  male / female,C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
958,female eze / simva,C0043210;C0086287;C1705497;C1705498
958,female acr definition  ^ g / mg,C0024671;C0026410;C0043210;C0086287;C0439267;C0439269;C1412134;C1515941;C1550452;C1704788;C1705497;C1705498;C1960952;C2346927;C3539107;C3888054;C4321396;C4521761
958,female / male ( % ),C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
958,female,C0043210;C0086287;C1705497;C1705498
957,sex : female,C0086287
957,overall  male : female,C0043210;C0086287;C0086582;C0282416;C1561607;C1705497;C1705498;C1706180;C1706428;C1706429
957,female subgroup,C0043210;C0086287;C1079230;C1515021;C1705497;C1705498
957,female participants who are ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0679646;C1705497;C1705498
957,female : ≥ $nmbr$ years postmenopausal,C0043210;C0086287;C0439234;C1705497;C1705498
957,female : premenopausal,C0043210;C0086287;C1705497;C1705498
957,female : perimenopausal or < $nmbr$ years postmenopausal,C0043210;C0086287;C1705497;C1705498
956,sex  male / female  %,C0043210;C0086287;C0086582;C1705497;C1705498;C1706180;C1706428;C1706429
956,sex  female    n   ( % ),C0086287
956,sex  female  %,C0086287
956,sex  female,C0086287
956,sex  % female,C0086287
956,gender female,C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
956,gender  female  n ( % ),C0043210;C0079399;C0086287;C1522384;C1705497;C1705498
956,females ( n = $nmbr$ ),C0086287
956,females ( itt ) ( n = $nmbr$ ),C0086287
956,females  n ( % ),C0086287
956,females  %,C0086287
956,female subjects ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
956,female simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female simva,C0043210;C0086287;C1705497;C1705498
956,female sex  no . / total ( % ),C0086287
956,female sex  no . ( % ),C0086287
956,female sex  n ( % of patients ),C0009253;C0030705;C0036864;C0043210;C0079399;C0086287;C0150831;C0150905;C0804628;C1314687;C1522384;C1705497;C1705498
956,female sex  n ( % ),C0086287
956,female sex  %,C0086287
956,female sex,C0086287
956,female n ( % ),C0043210;C0086287;C1705497;C1705498
956,female gender n ( % ),C0086287
956,female gender ( % ),C0086287
956,female gender,C0086287
956,female eze / simva ( „ = $nmbr$ },C0043210;C0086287;C1705497;C1705498
956,female eze / simva ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female - n ( % ),C0043210;C0086287;C1705497;C1705498
956,female ( n — $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female ( n   = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female ( n z $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female ( n = lll $nmbr$ ),C0043210;C0086287;C1261077;C1705497;C1705498
956,female ( n = $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female ( n = $nmbr$  $nmbr$ ),C0043210;C0086287;C1705497;C1705498
956,female ( % ),C0043210;C0086287;C1705497;C1705498
956,female $nmbr$,C0043210;C0086287;C1705497;C1705498
956,female  no . ( % ),C0043210;C0086287;C1705497;C1705498
956,female  no ( % ),C0043210;C0086287;C1705497;C1705498
956,female  n ( % ) race  n ( % ),C0034510;C0043210;C0086287;C1705497;C1705498;C1706779;C3853635
956,female  n ( % ),C0043210;C0086287;C1705497;C1705498
956,female  %,C0043210;C0086287;C1705497;C1705498
956,$nmbr$ ( except for female alone ),C0043210;C0086287;C1705497;C1705498
955,hdl — female,C0043210;C0086287;C1705497;C1705498;C3715113
955,female — no . ( % ),C0043210;C0086287;C1705497;C1705498
955,female sex — no . { % ),C0086287
955,female sex — no . ( % ) race — no . ( % ) f,C0086287
955,female sex — no . ( % ),C0086287
955,female sex — %,C0086287
954,hard mace,C0018599;C0349381;C0949745;C1445339
953,mace +,C0349381;C0949745;C1445339
953,expanded mace,C0205229;C0349381;C0949745;C1445339
952,secondary mace endpoint,C0349381;C0949745;C1445339;C4528314
952,primary outcome ( $nmbr$ - point mace ),C0205225;C0349381;C0439612;C0439631;C0949745;C1274040;C1445339;C1552961;C2347617;C3714763
952,adjudicated mace $nmbr$,C0349381;C0949745;C1445339
952,$nmbr$ - polnt mace,C0349381;C0949745;C1445339
951,mace,C0349381;C0949745;C1445339
951,first mace,C0205435;C0349381;C0949745;C1279901;C1445339
951,b mace,C0349381;C0949745;C1445339
950,octi & mate $nmbr$,C0682323;C1260875
950,mate !,C0682323;C1260875
950,mate,C0682323;C1260875
949,partial mayo clinic scored,C0002424;C0442592;C0454788;C0728938;C1077578;C1550516
949,mayo clinic scoreb,C0002424;C0442592;C0454788;C1077578
949,mayo clinic score  mean ± sd,C0002424;C0442592;C0444504;C0449820;C0454788;C1077578;C2347634;C2348143;C2699239;C4050231
949,complete mayo clinic score  median ( min  max },C0002424;C0205197;C0442592;C0449820;C0454788;C0549183;C0702093;C0725685;C0876920;C1077578;C1524029;C2347635;C2348144;C2939193;C3813700;C3853530;C4050231;C4283785
948,mayo clinic score §,C0002424;C0442592;C0449820;C0454788;C1077578;C4050231
948,baseline mayo score,C0168634;C0449820;C0454788;C1077578;C1442488;C4050231
948,baseline composite mayo clinic score,C0002424;C0168634;C0442592;C0454788;C1077578;C1442488;C4055211
947,week $nmbr$ mayo endoscopy subscorea,C0014245;C0332174;C0439230;C0454788;C1077578
947,mayo < $nmbr$  n,C0454788;C1077578
947,mayo $ $nmbr$  n,C0454788;C1077578
946,semaglutide ( n = $nmbr$ ),C3885068
946,semaglutide $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C3885068;C4321396;C4521761
946,semaglutide,C3885068
945,sama $nmbr$,C1075468
945,sama  b   n ( % ),C1075468
945,sama,C1075468
944,updrs  part ii ( adl ),C0001288;C0449719;C1420005;C1709471;C1710602;C3639721;C4082587
943,adl subscale ( range  $nmbr$ - $nmbr$ ) *,C0001288;C1420005;C1514721;C2348147;C3542016
943,adl,C0001288;C1420005
942,ada $nmbr$ / $nmbr$ n [ $nmbr$,C1060325;C3811629
942,ada $nmbr$ / $nmbr$ ( n [ $nmbr$ ),C1060325;C3811629
942,ada  no,C1060325;C3811629
941,locally advanced,C1517927
940,advanced  n ( % ),C0205179
940,advanced,C0205179
939,paci ( n = $nmbr$ ),C1165245
939,paci,C1165245
938,laci ( n = $nmbr$ ),C1420705;C3273314;C4281721
938,laci,C1420705;C3273314;C4281721
937,taci ( n = $nmbr$ ),C0666480;C1425349;C4284230
937,taci,C0666480;C1425349;C4284230
936,urinary protein : creatinine ratioa ( mg / mg ),C0042027;C0369901;C0428627;C1319635;C1524119
935,urinary acr ( mg / mmol ),C0042027;C0567349;C1412134;C1515941;C1524119;C2348885
935,urinary acr,C0042027;C1412134;C1515941;C1524119
934,vorapaxar group ( n = $nmbr$ ),C0441848;C2974521
934,vorapaxar ( n = $nmbr$ . $nmbr$ ),C2974521
934,vorapaxar ( n = $nmbr$ )  n ( % ),C2974521
934,vorapaxar ( n = $nmbr$ ),C2974521
934,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521
934,vorapaxar,C2974521
933,vorapaxar n = $nmbr$,C2974521
933,vorapaxar event rate ( n = $nmbr$ )  %,C0441471;C0871208;C1521828;C2974521;C4019010
933,vorapaxar ( n = $nmbr$  $nmbr$ ),C2974521
932,vorapaxar placebo,C0032042;C1696465;C1706408;C2974521
932,vorapaxar no . ( $nmbr$ - y km % ),C2974521
932,vorapaxar $nmbr$ - y,C2974521
931,varespladib ( n = $nmbr$ ),C2713485
931,varespladib,C2713485
930,monoamine oxidase b inhibitors,C2917290;C3653412
929,oxidative stress,C0242606
928,stratified by,C0205363
927,stage $nmbr$ b : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0441781;C1739039;C3811844;C3812682
927,stage $nmbr$ b : > = $nmbr$ and < $nmbr$,C0441781
926,stage $nmbr$ b : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439445;C0441781;C0441923
926,stage $nmbr$ b,C0441781
925,stage of pda,C0013274;C0205390;C0226047;C1300072;C1306673;C4282128
925,stage > $nmbr$ chronic kidney disease ( % ),C0205390;C1300072;C1306673
925,stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ ),C0205390;C1300072;C1306673
925,stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ ),C0205390;C1300072;C1306673
925,stage $nmbr$ a ckd cohort ( secondary analysis ),C0205390;C1300072;C1306673
925,stage $nmbr$ a ckd cohort ( post hoc analysis excluding metformin users ),C0205390;C1300072;C1306673
925,stage $nmbr$ ( four - variable modification of diet in kidney disease ),C0205390;C1300072;C1306673
925,stage $nmbr$ ( cockcroft - gault ),C0205390;C1300072;C1306673
925,stage $nmbr$,C0205390;C1300072;C1306673
924,hoehn and yahr stage ( range  $nmbr$ - $nmbr$ ),C0205390;C1300072;C1306673;C1514721;C2348147;C3542016
924,hoehn and yahr stage ( baseline )  mean ( sd ),C0168634;C0205390;C0444504;C1300072;C1306673;C1442488;C2347634;C2348143;C2699239
924,hoehn and yahr stage,C0205390;C1300072;C1306673
924,hoehn & yahr stage ( “ on ” )  n ( % ),C0205390;C1300072;C1306673
924,hoehn & yahr stage ( “ off ” )  n ( % ),C0205390;C1300072;C1306673
924,hoehn & yahr stage,C0205390;C1300072;C1306673
923,stage iv,C0205390;C1300072;C1306673
923,stage $nmbr$ a : egfr > = $nmbr$ and < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
923,stage $nmbr$ a : > = $nmbr$ and < $nmbr$,C0205390;C1300072;C1306673
923,stage $nmbr$ a : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0205390;C1300072;C1306673
923,stage $nmbr$ a,C0205390;C1300072;C1306673
923,stage $nmbr$ : > = $nmbr$,C0205390;C1300072;C1306673
923,stage $nmbr$ : < $nmbr$,C0205390;C1300072;C1306673
923,gold stage iv,C0018026;C0022326;C0205390;C1300072;C1304897;C1306673;C4265176
922,ckd stages,C1306673;C1561643
922,ckd stage $nmbr$ ( % ),C0205390;C1300072;C1306673;C1561643
922,ckd stage $nmbr$,C0205390;C1300072;C1306673;C1561643
921,established renal disease *,C0022658;C0443211;C1272684
921,established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease,C0022658;C0205156;C0369637;C0439445;C0441923;C0443211;C1272684;C1300563;C1552607;C1739039;C3811844;C3812682
921,established ( n = $nmbr$ ),C0443211;C1272684
921,established,C0443211;C1272684
920,established maerovaseular disease and albuminuria,C0012634;C0443211;C1272684
920,established disease,C0012634;C0443211;C1272684
920,established atherosclerotic disease — no . { % ),C0012634;C0333482;C0443211;C1272684
920,established atherosclerotic disease,C0012634;C0333482;C0443211;C1272684
919,patients with established cv disease aged > $nmbr$ years .,C0007222;C0030705;C0443211;C1272684;C1510829
919,established cardiovascular disease,C0007222;C0443211;C1272684
918,established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’,C0001779;C0007222;C0443211;C1272684;C1561643;C4553188
918,established cvd ( age > $nmbr$ ),C0001779;C0007222;C0443211;C1272684
917,established atherosclerotic cv disease §,C0007222;C0333482;C0443211;C1272684
917,established atherosclerotic,C0333482;C0443211;C1272684
916,$nmbr$ days until end of study ( landmark analysis ),C0002778;C0444930;C0936012;C1524024;C2746065;C2826182
915,stratified analyses,C0002778;C0205363;C0936012;C1524024
915,sensitivity analyses,C0002778;C0020517;C0036667;C0312418;C0427965;C0936012;C1511883;C1522640;C1524024;C2346484;C2349185
915,prespecified analysis,C0002778;C0936012;C1524024
914,pooled analysis sample,C0002778;C0936012;C1303103;C1524024;C1709595;C2349200;C4522255
914,pooled analysis of sustain $nmbr$ — $nmbr$ trials,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
914,pooled analysis,C0002778;C0936012;C1524024;C1709595;C2349200;C4522255
913,responder analyses ( achieving alc < $nmbr$ . $nmbr$ % ),C0002778;C0936012;C1524024
913,patients ( full analysis sety )  n,C0002778;C0030705;C0443225;C0936012;C1524024
913,overall analysis,C0002778;C0282416;C0936012;C1524024;C1561607
913,integrated analysis set ( n = $nmbr$ ),C0002778;C0936012;C1158478;C1524024;C1705422
913,full analysis set  n,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
913,full analysis set,C0002778;C0036849;C0443225;C0936012;C1442518;C1524024;C1705195
913,crude analysis  n ( % ),C0002778;C0936012;C1524024
913,analysis compared with the pretreatment condition ( baseline )  n  ldl = low - density lipoprotein  csf = cerebrospinal fluid .,C0002778;C0936012;C1524024
913,analysis,C0002778;C0936012;C1524024
912,active pso wi $nmbr$ bsa > $nmbr$ %  n ( . % y,C0043193;C0205177;C1520135;C3853793;C3888249
911,active   versus   placebo,C0205177;C3853793;C3888249
911,active vs placebo,C0205177;C3853793;C3888249
911,active smoking,C0037369;C0205177;C0453996;C1881674;C3853793;C3888249
911,active smokers,C0205177;C0337664;C3853793;C3888249
911,active smoker,C0205177;C0337664;C3853793;C3888249
911,active or previous cancer,C0205177;C3853793;C3888249
911,active,C0205177;C3853793;C3888249
910,active canakinumab ( n   =   $nmbr$  $nmbr$ ),C0205177;C2718773;C3853793;C3888249
910,active ( n = $nmbr$ ),C0205177;C3853793;C3888249
909,no active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
909,active comparatorb,C0205177;C3853793;C3888249
909,active cancer — no . ( % ),C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
909,active cancer at randomization  n ( % ),C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
909,active cancer at randomization,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
909,active cancer at randomisation,C0006826;C0034656;C0205177;C0998265;C1306459;C3853793;C3888249
909,active cancer at baseline,C0006826;C0168634;C0205177;C0998265;C1306459;C1442488;C3853793;C3888249
909,active cancer at any timeb,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
909,active cancer,C0006826;C0205177;C0998265;C1306459;C3853793;C3888249
909,active a,C0205177;C3853793;C3888249
908,ease activity ],C0205177;C0439167;C0441655;C1331418;C1561536;C3668946;C4049938;C4049939
908,activity limitation,C0205177;C0439167;C0441655;C0443288;C0449295;C1561536;C3668946;C4049938;C4049939
908,activity ( range $nmbr$ - $nmbr$ )  mean ± sd,C0205177;C0439167;C0441655;C0444504;C1514721;C1561536;C2347634;C2348143;C2348147;C2699239;C3542016;C3668946;C4049938;C4049939
908,activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
907,short - acting b $nmbr$ - agonists,C0079613;C0243192;C1282927;C1704930;C1806781;C1869853;C2350002;C2987634;C3890007;C4048375
907,short - acting anticholinergics,C0079613;C0242896;C1282927;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
907,short - acting,C0079613;C1282927;C1704930;C1806781;C1869853;C2350002;C3890007;C4048375
907,long - acting b $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
907,baseline short - acting anticholinergics  n ( % ),C0079613;C0168634;C0242896;C1282927;C1442488;C1704930;C1806781;C1869853;C2350002;C3537307;C3540711;C3890007;C4048375
907,act - $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
906,with long - acting j $nmbr$ - agonists,C0079613;C0205166;C0243192;C1704930;C1706317;C1869853;C2987634;C3890007;C4048375
906,long acting nitratef,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
906,long - acting or short - acting nitrates,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
906,long - acting nitrates,C0028125;C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
906,long - acting nitrate agents,C0028125;C0079613;C0205166;C0450442;C0699857;C1254351;C1521826;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
906,long - acting nitrate,C0028125;C0079613;C0205166;C0699857;C1704930;C1706317;C1869853;C3848573;C3890007;C4048375
906,long - acting ^,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
906,long - acting,C0079613;C0205166;C1704930;C1706317;C1869853;C3890007;C4048375
905,act total score ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
905,act total score   ≥   $nmbr$ and / or improvement from baseline   ≥   $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
905,act . $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
904,thoracic cage fractures,C0222762
903,foot fracture,C0272774
902,wrist fracture,C0435630;C4553927
901,clavicle fracture,C0159658
900,ankle fracture,C0159877;C4552974
899,femur fracture,C0015802
898,patella fracture,C0159849
897,tibia fracture,C0040185
896,fibula fracture,C0149699
895,humerus fracture,C0020162
894,radius fracture,C0034628
893,hand fracture,C0435632
892,skull  and facial bone fractures,C0037303;C2951888
891,pelvic fractures,C0149531
891,hip fracture only,C0019557;C0149531;C0205171;C1720467;C4552776
891,hip fracture + > $nmbr$,C0019557;C0149531;C4552776
891,hip fracture,C0019557;C0149531;C4552776
890,trait,C0599883
889,urinary tract infection,C0042029;C0262655;C4554638
888,upper respiratory tract inflammation,C0877266
887,upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ ),C0041912
887,upper respiratory tract infection,C0041912
886,no fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
886,fractures ( site not specified ),C0016658
886,fractures,C0016658
886,fracture history ( predefined )  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
886,fracture history  n ( % ),C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
886,fracture history,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
885,prior nonvertebral fracture at age > $nmbr$ years,C0016658;C0332152;C1510829;C2826257
885,prior nonvertebral fracture,C0016658;C0332152;C2826257
885,nonvertebral fractures,C0016658
885,nonvertebral fracture,C0016658
884,bone fracture due to fall,C0016658;C0085639;C0238715;C0678226;C4553726
884,bone fracture,C0016658
883,fracture during follow - up,C0016658;C0589120;C1522577;C1704685;C3274571
883,fracture,C0016658
882,spinal fractures,C0080179;C0518450
881,vertebral fracture and / or t score s - $nmbr$ . $nmbr$,C0080179
881,vertebral fracture and / or t score - $nmbr$ . $nmbr$,C0080179
881,clinical vertebral fractures,C0080179;C0205210
880,vertebral fracture,C0080179
880,subjects with prevalent vertebral fracture  n ( % ) prevalent vertebral fracture,C0033105;C0080179;C0220900;C0681850;C1550501;C1706203;C2349001;C2697811
880,prevalent vertebral fracture status,C0033105;C0080179;C0220900;C0449438
880,prevalent vertebral fracture  n ( % ),C0033105;C0080179;C0220900
880,prevalent vertebral fracture,C0033105;C0080179;C0220900
880,number of prevalent vertebral fractures,C0033105;C0080179;C0220900;C0237753;C0449788
879,history of peripheral vascular disease,C1881056
878,history of cerebrovascular disease — no . { % ),C0585890
878,history of cerebrovascular disease,C0585890
877,prior history of cardiovascular disease  n ( % ),C0332152;C0455539;C2826257
877,history of cardiovascular disease — no . { % ),C0455539
877,history of cardiovascular disease — no . ( % ) ^ |,C0455539
877,history of cardiovascular disease — no . ( % ),C0455539
877,history of cardiovascular disease,C0455539
876,no history of migraine,C0455512
875,no history of cancer,C0455471
875,history of cancer,C0455471
874,history of hyperlipidemia ( % ),C4695788
873,history of microalbuminuria — no . ( % ),C3532606
872,history of gestational diabetes mellitus — no . ( % of women ),C2183115
871,history of hypercholesterolemia  n ( % ),C1533076
871,history of hypercholesterolemia,C1533076
870,medical history of hypertension,C0020538;C0199168;C0205476;C0262926;C0455527;C1963138
870,history of hypertension for $nmbr$ mo or more,C0455527
870,history of hypertension ^  %,C0455527
869,no history of hypertension ( n = $nmbr$ ),C0455527
869,history of systemic hypertension,C0205373;C0455527
869,history of hypertension ( n = $nmbr$ ),C0455527
868,history of hypertension — no . ( % ),C0455527
868,history of hypertension . no . ( % ),C0455527
868,history of hypertension - n ( % ),C0455527
868,history of hypertension ( % ),C0455527
868,history of hypertension  no . ( % ),C0455527
868,history of hypertension  n ( % ),C0455527
868,history of hypertension,C0455527
868,history of currently treated hypertension  n ( % ),C0455527;C0521116;C1522326
867,history of hypertension *,C0455527
867,history of hypertension ( a ) c,C0455527
867,history of diagnosed hypertension prior to randomization  n ( % ),C0011900;C0455527
867,history of diagnosed hypertension n ( % ),C0011900;C0455527
866,atherectomy,C0162513
865,laser or vitrectomy,C0023089;C0458142;C1023865;C1706315
864,no history of heart failure at baseline,C0455531
864,infarction ( yr ) history of congestive heart failure ( % ),C0021308;C0439234;C0455531;C0742742
864,history of heart failure — no . { % ),C0455531
864,history of heart failure — no . ( % ),C0455531
864,history of heart failure at baseline,C0455531
864,history of heart failure  no . ( % ),C0455531
864,history of heart failure  n ( % ),C0455531
864,history of congestive heart failure,C0455531;C0742742
864,any history of congestive heart failure,C0455531;C0742742
863,medical history duration of heart failure ( years ) primary cause of heart failure,C0015127;C0199168;C0205225;C0205476;C0439234;C0439612;C0439631;C0449238;C0455531;C1524003;C2926735
863,history of heart failure,C0455531
862,history of falls in year before randomization,C1561668;C2919132
862,history of falls,C1561668;C2919132
861,history of a transient ischaemic attack,C0455536
860,history of cardiac arrhythmia,C3494593
859,history of intermittent claudication and abi < $nmbr$ - $nmbr$ or substantial peripheral arterial stenosis > $nmbr$ %,C0205267;C2315493
859,history of claudication,C2315493
858,direction of hr,C0449738
857,history of atrial fibrillation  type 一 no . ( % ),C0332307;C0729790;C1547052
857,history of atrial fibrillation,C0729790
856,history of paroxysmal atrial fibrillation  n ( % ),C0205311;C0729790
856,history of atrial fibrillation  n ( % ),C0729790
855,history of atrial fibrillation or flutter treatment at randomisation,C0729790
855,history of atrial fibrillation or flutter,C0729790
855,history of atrial fibrillation or fl utter,C0729790
855,history of atrial fibrillation and / or flutter,C0729790
855,history of atrial fibrillation / flutter,C0016385;C0232197;C0729790;C1998417;C2242390
854,patient ' s history of :,C0679831;C1369882
854,medical history  n ( % of patients ),C0679831;C1369882;C1609576
853,intermediate risk,C3640764
852,specific risk of bleeding ^,C0205369;C1552740;C3251812
852,risk of bleeding,C3251812
851,rest ofworld,C0035253;C1622890
851,rest ofthe world,C0035253;C1622890;C2700280
851,rest of world n z $nmbr$,C0035253;C1622890;C2700280
851,rest of world,C0035253;C1622890;C2700280
851,rest of the world,C0035253;C1622890;C2700280
851,rest - of - world ( n = $nmbr$ ),C0035253;C1622890;C2700280
850,risk marker and model,C1519104
849,other cardiovascular risk factors,C0850624
849,cardiovascular risk factors — no . { % ),C0850624
849,cardiovascular risk factors — no . / total no . ( % ),C0850624
849,cardiovascular risk factor — no . { % ),C0850624
849,at least two cardiovascular risk factors,C0205448;C0850624
848,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0439475;C0488055;C0850624;C0871470;C1306620
848,nonglycemic cardiovascular risk factors,C0850624
847,cardiovascular risk factors and medical history,C0850624
847,cardiovascular risk factors and history — no . ( % ),C0850624
847,cardiovascular risk factors and history ( % ),C0850624
847,cardiovascular risk factors and history,C0850624
847,cardiovascular risk factors alone ( n = $nmbr$ ),C0205171;C0439044;C0679994;C0850624
847,cardiovascular risk factors  no . ( % ),C0850624
847,cardiovascular risk factors  n ( % ),C0850624
847,cardiovascular risk factors,C0850624
846,risk factors  %,C0035648;C1553898
846,cv risk factors  % of patients,C0030705;C0035648;C1553898;C3538987;C4048877;C4318503
846,ascvdor > $nmbr$ cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
846,any cv history / risk factors  n ( % ),C0019664;C0019665;C0035648;C0262512;C0262926;C1553898;C1705255;C2004062;C3538987;C4048877;C4318503
846,> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
846,> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease,C0035648;C1553898;C3538987;C4048877;C4318503
846,> $nmbr$ additional cv risk factors $nmbr$,C0035648;C1524062;C1553898;C3538987;C4048877;C4318503
845,risk factor,C0035648
845,cv risk factors and history,C0035648;C1553898;C3538987;C4048877;C4318503
845,cv risk factors,C0035648;C1553898;C3538987;C4048877;C4318503
845,cv risk factor - no . ( % ),C0035648;C3538987;C4048877;C4318503
845,cv risk factor,C0035648;C3538987;C4048877;C4318503
844,temporary risk factor,C0035648;C0205374;C1548539;C3245481
843,risk factor ( predefined ) for falling at screening  n ( % ),C0035648
843,qualifying risk factor  n ( % ),C0035648;C1514624
843,qualifying risk factor,C0035648;C1514624
842,risk factors only,C0035648;C0205171;C1553898;C1720467
841,risk factors and immobility level  n ( % ),C0035648;C1553898
841,risk factors,C0035648;C1553898
841,diagnoses / risk factors  n ( % ],C0011900;C0035648;C1553898
841,diagnoses / risk factors  n ( % ),C0011900;C0035648;C1553898
841,chads $nmbr$ risk factors  n ( % ),C0007928;C0035648;C1413373;C1553898
840,risk factors for stroke  no . ( % ),C0035648;C1553898
840,risk factors ( % of group ),C0035648;C0441833;C0687744;C1257890;C1519504;C1553898;C1705428;C1705429
840,risk factors ( % ),C0035648;C1553898
840,risk factors  no . ( % ),C0035648;C1553898
840,no . of risk factors for venous thromboembolism  no . ( % ),C0035648;C1553898
840,no . of risk factors ( % ) | |,C0035648;C1553898
839,risk factors for atherosclerosis,C0003850;C0004153;C0035648;C1553898
838,risk factors for stroke,C0035648;C0038454;C1553898;C4554100
837,risk factors — no . ( % ),C0035648;C1553898
837,risk factors specified as inclusion criteria — no . ( % ) f,C0035648;C1553898
837,risk factors for recurrent vte — no . ( % ) f,C0035648;C0630906;C1455761;C1553898;C2945760
836,three of seven risk factors,C0035648;C0205449;C0205453;C1553898
835,risk factors and diabetes status ( % ),C0035648;C1553898
835,baseline risk factors,C0035648;C0168634;C1442488;C1553898
834,other risk factors,C0035648;C1553898
834,other major risk factors,C0035648;C0205082;C0205164;C1553898;C4318856;C4521762
833,ncep atp iii risk factors,C0035648;C0439070;C1553898;C1705160;C2744579;C4552600
832,risk factors and medical history,C0035648;C1553898
832,psychosocial risk factors,C0033963;C0035647;C0035648;C0542298;C1458132;C1553898;C4552904
832,cvd risk factors ( age > $nmbr$ ) ^ “ ^,C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
832,cvd risk factors ( age > $nmbr$ ),C0001779;C0001783;C0007222;C0035647;C0035648;C1553898;C4552904
831,chd risk factors #,C0035648;C0280604;C1553898;C3542407
831,> $nmbr$ chd risk factors,C0035648;C0280604;C1553898;C3542407
830,unadjusted $nmbr$ - y risk per $nmbr$ population = se ( adjusted rate ),C0036919;C0242444;C0456081;C0871208;C1439367;C1521828;C2987720
830,risk group,C0242444
829,absolute risk reductions,C3179139
829,absolute risk reduction ( $nmbr$ % ci )  % / y,C0008107;C3179139;C3259781
828,lower risk ( n = $nmbr$ ),C3272281;C3538919
828,lower risk,C3272281;C3538919
828,low risk ( ri = $nmbr$ - $nmbr$ ),C0035487;C1826843;C3272281;C3538919
828,low risk ( $nmbr$ - $nmbr$ ),C3272281;C3538919
828,$nmbr$ - $nmbr$ ( low risk ),C3272281;C3538919
827,low risk ( n $nmbr$ $nmbr$ ),C3272281;C3538919
827,group b ( low risk  more symptoms )  n ( % ),C0441848;C0683368;C1457887;C3272281;C3538919
826,low risk and more symptoms ( group b ),C3272281;C3538919
826,low risk and fewer symptoms ( group a ),C3272281;C3538919
826,low risk ( ? ics ),C0815320;C3272281;C3538919;C4551720
826,low risk ( - ics ),C0815320;C3272281;C3538919;C4551720
826,low risk,C3272281;C3538919
825,shock risk indext,C0035647;C0036974;C4552904
824,$nmbr$ - $nmbr$ with cv risk but not disease ( n = $nmbr$ ),C0035647;C3538987;C4048877;C4318503;C4552904
824,$nmbr$ - $nmbr$  risk  not disease ( n = $nmbr$  $nmbr$ ),C0035647;C4552904
823,risk difference,C0035647;C1705241;C1705242;C4552904
823,risk,C0035647;C4552904
823,absolute risk difference ( $nmbr$ % cl ),C0035647;C0596019;C1519101;C1549031;C1705241;C1705242;C4552904
822,risk score category ( points ),C0035647;C0449820;C0683312;C3889287;C4050231;C4552904
822,risk category ( points ),C0035647;C0683312;C3889287;C4552904
822,risk categories,C0035647;C0683312;C4552904
821,risk *,C0035647;C4552904
821,abbreviations : ace  angiotensin - converting enzyme  iqr  interquartile range  ml  myocardial infarction . si conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * data are expressed as no . / total ( % ) unless otherwise specified . festimated using cockroft - gault equation . tthe timi risk score was used to categorize patients at low ( $nmbr$ - $nmbr$ )  intermediate ( $nmbr$ - $nmbr$ )  and high ( $nmbr$ - $nmbr$ ) risk . $nmbr$,C0000723;C0021308;C0022709;C0035647;C0205369;C0439526;C0439836;C1511726;C1514721;C1705224;C1719797;C2348147;C2911648;C3245479;C3542016;C3714741;C3887665;C4552904
820,risk stratum,C0035647;C4552904
820,risk at,C0035647;C4552904
820,ncep risk category at study entry  n ( % ),C0035647;C1705654;C2983287;C2983669;C4552904
819,no increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
819,increased risk for falls,C0000921;C0035647;C0085639;C1849142;C4552904;C4699158
818,daily iglar dose at week $nmbr$ ( u ),C0560588;C2348070
817,daily dose of study medication prescribed,C0013175;C2348070
816,average daily dose ( % of target ) *,C1510992;C1521840;C2348070;C2825518;C2986546
816,average daily dose,C1510992;C2348070;C2825518
815,dose of aspirin,C4696290
815,aspirin dose at randomization,C0034656;C4696290
815,aspirin dose,C4696290
815,aspirin at any dose,C4696290
814,time since last dose of,C0946444
814,time from last dose of p $nmbr$ y $nmbr$ inhibitor  days,C0439228;C0946444;C1999216
813,maintenance dose,C3714445
813,ics dose of stable maintenance treatment ( μ g ) ∗  †,C0039798;C0087111;C0178602;C0205360;C0439267;C0814469;C0815320;C0869039;C1114758;C1522326;C1533734;C1547311;C1705169;C3538994;C3714445;C3887704;C4551720
812,dose of rosuvastatin,C0178602;C0869039;C0965129;C1114758
811,ezetimibe / simvastatin - double dose statin - rosuvastatin,C0178602;C0205173;C0360714;C0869039;C0965129;C1114758;C1532737;C1705764;C1705765
811,doubling statin dose,C0178602;C0205173;C0360714;C0869039;C1114758;C1705764
810,ras % target dose,C0034678;C0178602;C0525678;C0869039;C1114758;C1521840;C2986546
810,beta - blocker % target dose,C0001645;C0178602;C0869039;C1114758;C1521840;C2986546
809,etoricoxib dose,C0178602;C0869039;C0972314;C1114758
809,dose of atorvastatin,C0178602;C0286651;C0869039;C1114758
809,concomitant atorvastatin dose  mg,C0024671;C0026410;C0178602;C0286651;C0439269;C0521115;C0869039;C1114758;C1960952;C2346927;C4321396;C4521761
809,atorvastatin dose,C0178602;C0286651;C0869039;C1114758
808,need for $nmbr$ ng edoxaban dose at,C0017887;C0027552;C0028074;C0178602;C0686904;C0869039;C1114758;C2975435
808,edoxaban dose adjusted at randomisation  n ( % ) *,C0178602;C0869039;C1114758;C2975435
808,dose reduced at randomization *,C0178602;C0869039;C1114758
808,dose adjusted,C0178602;C0869039;C1114758
807,ptrend across doses,C0178602
807,intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0070166;C0178602;C0439269;C0869039;C1114758;C1283828;C1551357;C1960952;C2346927;C4321396;C4521761
807,clopidogrel dose,C0070166;C0178602;C0869039;C1114758
806,rolofylline dose,C0166128;C0178602;C0869039;C1114758
806,dose ( n ),C0178602;C0869039;C1114758
806,baseline ics dose  n ( % ),C0168634;C0178602;C0815320;C0869039;C1114758;C1442488;C4551720
806,all doses ( n = $nmbr$ ),C0178602
806,all doses,C0178602
805,canakinumab dose ( per month ),C0178602;C0332177;C0439231;C0869039;C1114758;C2718773
805,canakinumab dose ( per mo ),C0026544;C0178602;C0332177;C0869039;C1114758;C2718773
805,canakinumab dose,C0178602;C0869039;C1114758;C2718773
804,high - dose arb ( n = $nmbr$ ),C0444956;C3888198
803,non high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956;C1518422
803,high dose statin ( n = $nmbr$  $nmbr$ ),C0360714;C0444956
803,high dose,C0444956
803,high - dose statin pretreatment ( n = $nmbr$ ),C0360714;C0444956;C1550147;C2709094;C3539075;C3539076
802,higher dose,C0444956
802,higher - dose edoxaban vs warfarin,C0444956;C2975435
802,higher - dose,C0444956
802,high - dose edoxaban vs warfarin,C0444956;C2975435
802,high - dose edoxaban ( n = $nmbr$ ),C0444956;C2975435
802,high - dose edoxaban,C0444956;C2975435
802,edoxaban higher dose vs warfarin,C0444956;C2975435
801,low - dose edoxaban vs warfarin,C0445550;C1708745;C2975435
801,low - dose edoxaban ( n = $nmbr$ ),C0445550;C1708745;C2975435
801,low - dose edoxaban,C0445550;C1708745;C2975435
800,lower dose,C0445550;C1708745
800,lower - dose,C0445550;C1708745
800,low - dose corticosteroid user,C0001617;C0445550;C1548600;C1706077;C1708745;C3536709
799,low dose,C0445550;C1708745
799,low - dose statin,C0360714;C0445550;C1708745
799,fenofibric acid - $nmbr$ - low - dose statin,C0060179;C0360714;C0445550;C1708745
799,fenofibric acid + low - dose statin,C0060179;C0360714;C0445550;C1708745
798,other diagnostic procedure *,C0430022;C1546908
797,diagnostic catheterization,C0596429
796,prior diagnosis - no . ( % ),C0332132
796,previous diagnosis,C0332132
796,body - mass index ( kg / mj ) previous diagnosis,C0005893;C0022718;C0332132;C0439209;C0439254;C0578022;C1305855;C4054209;C4284025
795,inclusion diagnosis,C0007637;C0011900;C1512693;C1704338;C1704656
794,diagnosis — yr,C0011900;C0439234;C1704338;C1704656
793,time from ra diagnosis  years  median,C0011900;C0556970;C1704338;C1704656;C3538806;C4048756
793,time from pah diagnosis months,C0011900;C0030123;C0556969;C1704338;C1704656;C3203102;C4284467
793,diagnosed  y,C0011900
792,presenting diagnosis,C0011900;C0449450;C1704338;C1704656
792,diagnosis at presentation — no . ( % ),C0011900;C0449450;C1704338;C1704656
792,diagnosis at presentation,C0011900;C0449450;C1704338;C1704656
791,diagnosis of hefh  n ( % ),C0011900;C1704338;C1704656
791,diagnosis of diabetes  n ( % ),C0011847;C0011849;C0011900;C1704338;C1704656
790,past cardiovascular history  no . ( % ),C0007226;C0332119;C1444637;C1880008;C3887460;C4284302
790,cardiovascular history 一 no . ( % ),C1880008
790,cardiovascular history — no . / total no . ( % ),C1880008
790,cardiovascular history — no . ( % ),C1880008
789,cardiovascular history,C1880008
789,bmi ( kg / m $nmbr$ ) cardiovascular history,C0578022;C1532718;C1880008
788,no . of cardiovascular events ( cardiovascular events / $nmbr$ person - years ),C0027361;C0439234;C1320716;C2347489
788,cardiovascular events,C1320716
787,without cerebrovascular disease,C0007820
787,with cerebrovascular disease,C0007820
787,prior cerebrovascular disease,C0007820;C0332152;C2826257
787,cerebrovascular disease,C0007820
787,cerebral vascular disease,C0007820
786,ischemic cerebrovascular disease  n ( % ),C0007820;C0475224
786,cerebrovascular disorders  n ( % ),C0007820
786,cerebrovascular disease n ( % ),C0007820
786,cerebrovascular disease  n ( % ),C0007820
786,cerebrovascular disease  %,C0007820
785,previous cerebrovascular event,C0205156;C0441471;C1552607;C1880018;C4019010
785,pervious cerebrovascular event,C0205326;C0441471;C1880018;C4019010
785,cerebrovascular or peripheral arterial disease    n   ( % ),C1880018
785,cerebrovascular or peripheral arterial disease  n ( % ),C1880018
785,cerebrovascular or peripheral arterial disease,C1880018
785,cerebrovascular,C1880018
784,microvascular outcome,C0443258;C1274040
783,patients with microvascular complications  n ( % ),C0009566;C0030705;C0443258;C1171258
783,microvascular complicationsb,C0443258
783,microvascular complications  n ( % ) ’,C0009566;C0443258;C1171258
782,concomitant cardiovascular therapy — no . ( % ),C0007226;C0521115;C0587038;C1707479;C3887460
782,concomitant cardiovascular therapy,C0007226;C0521115;C0587038;C1707479;C3887460
782,cardiovascular therapies — no . { % ),C0587038
781,secondary cardiovascular endpoint,C0007226;C3887460;C4528314
780,extended cardiovascular endpoint,C0007226;C0231448;C0231449;C0439792;C2349179;C2826544;C3887460
780,core cardiovascular endpoint,C0007226;C0444669;C1167518;C1706352;C1882467;C2349179;C2826544;C3274653;C3887460
780,cardiovascular,C0007226;C3887460
779,recent cardiovascular eventf,C0007226;C0332185;C3887460
779,previous history of cardiovascular events,C0007226;C2004062;C3887460
778,coronary heart disease  n ( % ) cardiovascular risk ( per protocol )  n ( % ) very high,C0007226;C0442711;C1277690;C1507394;C1522729;C1698058;C2348563;C2599718;C3715209;C3887460;C4282383
778,any cardiovascular diseased,C0007226;C3887460
777,no . of predictors of cardiovascular risk,C0007226;C0035647;C2698872;C3887460;C4552904
777,cardiovascular risk  n ( % ),C0007226;C0035647;C3887460;C4552904
777,cardiovascular risk,C0007226;C0035647;C3887460;C4552904
777,cardiovascular metabolic syndrome risk lactors,C0007226;C0035647;C0524620;C3887460;C4552904
776,exploratory cardiovascular and death outcomes,C0007226;C3887460
776,cardiovascular status,C0007226;C0449438;C3887460
776,cardiovascular and respiratory,C0007226;C3887460
776,all cardiovascular,C0007226;C3887460
775,cardiovascular hospitalization,C0007226;C0019993;C3887460
775,cardiovascular hospitalisation §,C0007226;C0019993;C3887460
774,non - cardiovascular mortality,C0007226;C0026565;C0026566;C1518422;C3887460
774,cardiovascular mortality or mi,C0007226;C0026565;C0026566;C3887460
774,cardiovascular mortality  mi  or revascularization,C0007226;C0026565;C0026566;C3810814;C3887460
774,cardiovascular mortality,C0007226;C0026565;C0026566;C3887460
774,cardiovascular and oral hypoglycemic drugs - no . ( % ),C0007226;C3887460
773,single vessel coronary artery diseasea,C0005847;C0265903
772,restenotic vessel,C0005847;C0333186
772,no culprit vessel identified,C0005847
772,culprit vessel,C0005847
771,multi vessel ( or left main ),C0005847;C0439064;C3266262
771,$nmbr$ vessels or left main,C0005847
770,> $nmbr$ vessels treated,C0005847
770,> $nmbr$ lesions per vessel,C0005847;C0221198
770,> $nmbr$ diseased vessels,C0005847
769,vessel size  mean ( sd )  mm,C0005847;C0444504;C0456389;C2347634;C2348143;C2699239;C4330985;C4554674
769,number of diseased vessels  mean ( sd ),C0005847;C0237753;C0444504;C0449788;C2347634;C2348143;C2699239
769,$nmbr$ vessels,C0005847
769,$nmbr$ vessel,C0005847
768,vessel treated  n,C0005847
768,treated vessel ( s ),C0005847;C1522326
768,treated vessel !,C0005847;C1522326
768,treated vessel,C0005847;C1522326
767,no . of vessels with > $nmbr$ % stenosis,C0005847
767,no . of vessels treated,C0005847
767,no . of vessels,C0005847
767,no . of treated vessels,C0005847;C1522326
766,urgent vascular hospitalization,C0005847;C0019993;C0439609;C1558950;C1801960;C3272275
765,vascular accidents  n ( % ),C0000924;C0005847;C1558950;C1801960
764,vascular disordersb,C0005847;C1558950;C1801960
764,vascular,C0005847;C1558950;C1801960
764,history of atherosclerotic vascular disease — no . ( % ) §,C0005847;C0333482;C0683519;C0730226;C0850708;C0944983;C1558950;C1801960
764,baseline history of vascular disease ( % ),C0005847;C0168634;C0683519;C0730226;C0850708;C0944983;C1442488;C1558950;C1801960
763,vascular territory # $nmbr$,C0005847;C1301808;C1558950;C1801960;C2983136
763,vascular intervention,C0005847;C0184661;C0886296;C1273869;C1558950;C1801960
762,vascular access site †,C0005847;C0205145;C0589360;C0750138;C1515974;C1558950;C1801960;C2825164
761,vascular risk score — no . { % ) ^,C0005847;C0035647;C1558950;C1801960;C4552904
761,vascular risk score |,C0005847;C0035647;C0449820;C1558950;C1801960;C4050231;C4552904
760,any vascular diasease,C0005847;C1558950;C1801960
760,any vascular *   efficacy,C0005847;C1280519;C1558950;C1707887;C1801960
759,other selected aes,C1412268;C1707391;C2699274
759,aes related to,C1412268;C2699274
759,aes leading to dose reduction of study drugb,C1412268;C2699274
759,aes leading to discontinuation of study drugb,C1412268;C2699274
759,aes leading to,C1412268;C2699274
758,volume depletion - related aes,C0439849;C0445223;C0546884;C1412268;C2699274
758,osmotic diuresis - related aes,C0232823;C0439849;C0445223;C1412268;C2699274
758,gallbladder - related aes,C0016976;C0439849;C0445223;C1412268;C2699274
757,tier $nmbr$ aes,C1412268;C2699274
757,serious aes,C0205404;C1412268;C2699274
757,any aes  n ( % ),C1412268;C2699274
757,any aes,C1412268;C2699274
757,> $nmbr$ serious aes,C0205404;C1412268;C2699274
757,> $nmbr$ aes leading to discontinuation,C1412268;C2699274
757,> $nmbr$ aes,C1412268;C2699274
756,most common aes ‡,C0205214;C0205393;C1412268;C1522138;C2699274;C3245511
756,most common aes in any group,C0205214;C0205393;C0441833;C0687744;C1257890;C1412268;C1519504;C1522138;C1705428;C1705429;C2699274;C3245511
756,aes *,C1412268;C2699274
755,number of arterial beds involved,C0003842;C0004916;C0221464;C0237753;C0449788
755,> $nmbr$ beds,C0004916
755,< $nmbr$ beds,C0004916
754,yes *,C1549445;C1705108;C1710701
754,yes ( n  % ),C1549445;C1705108;C1710701
754,yes ( any ),C1549445;C1705108;C1710701
754,yes ( % ),C1549445;C1705108;C1710701
754,yes  yes,C1549445;C1705108;C1710701
754,yes  n ( % ),C1549445;C1705108;C1710701
754,history of oxygen use - yes  n ( % ),C0019664;C0019665;C0030054;C0262512;C0262926;C1524063;C1549445;C1705108;C1705255;C1710701;C2004062
754,ed history  n ( % yes ),C0019664;C0019665;C0262512;C0262926;C1549445;C1705108;C1705255;C1710701;C2004062;C3538926
754,concomitant medications ( yes )  n ( % },C0013227;C0521115;C0802604;C1549445;C1705108;C1710701;C2598133;C4284232
754,caffeine consumption ( yes ) ( n ),C0948365;C1549445;C1705108;C1710701
753,yes ( n = $nmbr$ ),C1549445;C1705108;C1710701
753,diabetics - yes ( n = $nmbr$  $nmbr$ ),C0241863;C1549445;C1705108;C1710701
753,diabetic yes,C0241863;C1549445;C1705108;C1710701
753,diabetic ( yes ),C0241863;C1549445;C1705108;C1710701
752,yes ( stopped for trial ),C1549445;C1705108;C1710701
752,use of cgm ( yes ),C1524063;C1549445;C1705108;C1710701
751,yes  r $nmbr$ y,C1549445;C1705108;C1710701
751,yes  proliferative,C1549445;C1705108;C1710701
751,yes  non - proliferative,C1549445;C1705108;C1710701
751,yes  $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
751,partner  n ( % yes ),C0682323;C1549445;C1705108;C1710701;C3887537
751,no  yes,C1549445;C1705108;C1710701
751,etn  yes,C0014758;C0717758;C1549445;C1705108;C1710701
751,diabetesh yes,C1549445;C1705108;C1710701
751,diabetes mellitus yes ( n  % ) hypertension,C0011849;C0020538;C1549445;C1705108;C1710701;C1963138
751,diabetes mellitus  n ( % ) yes,C0011849;C1549445;C1705108;C1710701
751,ada  yes,C1060325;C1549445;C1705108;C1710701;C3811629
750,yes vs . no,C1549445;C1705108;C1710701
750,yes  z $nmbr$ cm,C1549445;C1705108;C1710701
750,yes  unknown,C1549445;C1705108;C1710701
750,yes  o $nmbr$ cm,C1549445;C1705108;C1710701
750,yes  non - insulin - treated,C1549445;C1705108;C1710701
750,insulin yes,C0021641;C1533581;C1549445;C1579433;C1705108;C1710701;C3714501
750,inflix  yes,C0666743;C1549445;C1705108;C1710701
749,yes,C1549445;C1705108;C1710701
749,prior therapy with omalizumab : yes,C0966225;C1514463;C1549445;C1705108;C1710701
749,prior hypertensiona yes,C0332152;C1549445;C1705108;C1710701;C2826257
749,naive : yes,C1549445;C1705108;C1710701
748,hypertension / yes,C0020538;C1549445;C1705108;C1710701;C1963138
748,[ no / yes ] ( % ),C1549445;C1705108;C1710701
747,yes ',C1549445;C1705108;C1710701
747,p - blocker yes,C0369773;C1549445;C1705108;C1710701;C2603361
746,bpearson ' s chi ‐ square test .,C0008041
745,ama 士 s . e .,C0002461;C0279755;C2825862
744,am △ 士 s . e .,C3813124;C3890196;C4520798
743,sys : ns dia : < $nmbr$ . $nmbr$,C0038944;C1112705;C1425041;C1705982;C1706546
742,ns cardiac cisease,C0018787;C0038944;C1112705;C1522601;C1705982
742,ns,C0038944;C1112705;C1705982
741,s / se  mb or death,C0024853;C0036919;C0565930;C2603362
741,s ( s $nmbr$,C0565930;C2603362
741,s $nmbr$ yrs,C0565930;C2603362
741,s $nmbr$ years,C0439234;C0565930;C2603362
741,s $nmbr$ ( $nmbr$ . s ),C0565930;C2603362
741,$nmbr$ ( $nmbr$ s . s ),C0565930;C2603362
740,| : s blocker,C0565930;C2603362
740,s arm,C0446516;C0565930;C2603362;C3715044;C4553528
739,s . e .,C0565930;C2603362
739,s $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
739,s $nmbr$ exacerbations,C0565930;C2603362;C4086268
739,s $nmbr$ - $nmbr$ vs placebo,C0032042;C0565930;C1696465;C1706408;C2603362
739,$nmbr$ s . $nmbr$ ± s . $nmbr$,C0565930;C2603362
738,« s $nmbr$ - $nmbr$,C0565930;C2603362
738,s fs $nmbr$,C0565930;C1517317;C2603362;C3814419
738,s $nmbr$ months,C0439231;C0565930;C2603362
738,s $nmbr$ ml / min,C0439445;C0565930;C2603362
738,s $nmbr$,C0565930;C2603362
738,= s $nmbr$,C0565930;C2603362
737,s $nmbr$ kg / m ^,C0565930;C1532718;C2603362
737,s $nmbr$ kg / m $nmbr$,C0565930;C1532718;C2603362
737,s,C0565930;C2603362
736,s £ $nmbr$,C0565930;C2603362
736,s $nmbr$ mmhg,C0439475;C0565930;C2603362
736,s $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
736,s $nmbr$ . $nmbr$ mg / mmol,C0565930;C0567349;C2348885;C2603362
736,s $nmbr$ - $nmbr$ - s $nmbr$ . $nmbr$ %,C0565930;C2603362
736,s $nmbr$ %,C0565930;C2603362
735,grs,C1412761;C3539564
734,qrs interval > $nmbr$ msec — no . ( % ),C0439223;C0520880
734,qrs < $nmbr$ msec,C0439223
733,mean ( sd ) das $nmbr$ - $nmbr$ ( esr ) *,C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
733,das $nmbr$ - esr remission  %,C0051767;C0057671;C0544452;C0687702;C3811131
733,das $nmbr$ - esr remission,C0051767;C0057671;C0544452;C0687702;C3811131
733,das $nmbr$ - esr lda,C0051767;C0057671;C3811131;C4553195
733,das $nmbr$ - esr  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3811131
733,das $nmbr$ - esr,C0051767;C0057671;C3811131
733,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ t,C0051767;C0057671;C3811131
733,das $nmbr$ - $nmbr$ ( esr ) < $nmbr$ . $nmbr$ *,C0051767;C0057671;C3811131
733,das $nmbr$ - $nmbr$ ( esr ) $nmbr$,C0051767;C0057671;C3811131
733,das $nmbr$ - $nmbr$ ( esr ),C0051767;C0057671;C3811131
733,das $nmbr$ ( esr ),C0051767;C0057671;C3811131
733,change in das $nmbr$ - esr ( mean ) i physical function outcomes week $nmbr$,C0021966;C0051767;C0057671;C0221138;C0332174;C0392747;C0439230;C0443172;C0444504;C0516981;C1274040;C1705241;C2347634;C2348143;C3811131;C4049916;C4319952
732,mean score on das $nmbr$ - $nmbr$ ( crp ) ^,C0051767;C0057671;C3533236;C3890735;C4048285
732,das - $nmbr$ ( crp ) < $nmbr$ . $nmbr$  n ( % ),C0051767;C0057671;C3890735;C4048285
732,das - $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
732,das $nmbr$ ‐ crp,C0051767;C0057671;C3890735;C4048285
732,das $nmbr$ score,C0051767;C0057671
732,das $nmbr$ - hscrp,C0051767;C0057671
732,das $nmbr$ - crp §,C0051767;C0057671;C3890735;C4048285
732,das $nmbr$ - crp,C0051767;C0057671;C3890735;C4048285
732,das $nmbr$ ( crp )  mean ( sd ),C0051767;C0057671;C0444504;C2347634;C2348143;C2699239;C3890735;C4048285
732,das $nmbr$ ( crp ),C0051767;C0057671;C3890735;C4048285
732,das $nmbr$,C0051767;C0057671
732,c . das $nmbr$ - crp < $nmbr$ . $nmbr$,C0051767;C0057671;C3890735;C4048285
731,intravenous vasoactive drugs  % y,C0683092;C1980011
730,y es,C0013754;C0205944
729,less than $nmbr$ y ears,C0013443;C0439092;C0521421
729,< $nmbr$ y ears,C0013443;C0521421
728,hps,C0242994
727,on - pump time : < l : $nmbr$ hrs : min ( n = $nmbr$ ),C0040223;C0702093;C1524029;C1568891;C3541383;C3813700;C3842462
727,^ $nmbr$ hrs,C1568891
727,> $nmbr$ hrs,C1568891
727,> $nmbr$ : $nmbr$ hrs : min ( n = $nmbr$ ),C0702093;C1524029;C1568891;C3813700
727,< $nmbr$ hrs,C1568891
726,itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
726,itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
726,itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
726,itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
726,itch nrs $nmbr$ ( v = $nmbr$ ),C0033774;C1422257;C2240043;C4050142
726,itch nrs,C0033774;C1422257;C2240043;C4050142
725,russia and georgia,C0035970
725,enrolled in russia or georgia,C0035970;C4684790
724,russia / georgia ( n = $nmbr$ ),C0017452;C0017454;C0035970
724,russia / georgia,C0017452;C0017454;C0035970
724,russia,C0035970
723,rs - cough & sputumc,C0010200;C0035970;C1961131;C3274924;C3714753;C3813325;C4084725;C4084726;C4084727
723,rs - chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
723,rs - breathlessnessb,C0035970;C3714753;C3813325
722,rs - totala,C0035970;C3714753;C3813325
722,e - rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
721,rs $nmbr$ ( cc ) & rs $nmbr$,C0008318;C0035970;C3538933;C3714753;C3813325
721,rs $nmbr$ ( ac ) & rs $nmbr$,C0001246;C0003354;C0035970;C1412573;C2000891;C3539770;C3714753;C3813325
721,rs $nmbr$ ( aa ) & rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C3714753;C3813325;C4554792
721,rs $nmbr$ & rs $nmbr$,C0035970;C3714753;C3813325
721,rs $nmbr$,C0035970;C3714753;C3813325
720,secondary p,C0027627;C0175668;C0205436
720,secondary ip,C0027627;C0175668;C0205436;C1308226;C4049997
720,secondary iii *,C0027627;C0175668;C0205436;C0439070;C1705160
720,secondary *,C0027627;C0175668;C0205436
719,secondary pci,C0027627;C0175668;C0205436;C4049621
719,secondary end points iii,C0027627;C0175668;C0205436;C0439070;C1705160;C2349179
719,secondary end points ii,C0027627;C0175668;C0205436;C1710602;C2349179;C4082587
719,secondary end points $nmbr$,C0027627;C0175668;C0205436;C2349179
719,secondary end points,C0027627;C0175668;C0205436;C2349179
719,secondary # $nmbr$,C0027627;C0175668;C0205436
719,key secondary end points,C0027627;C0175668;C0205436;C2349179
718,secondary outcomes,C0027627;C0175668;C0205436;C1274040
718,secondary outcome,C0027627;C0175668;C0205436;C1274040
718,secondary nonresponse,C0027627;C0175668;C0205436
718,secondary kidney composite outcome,C0022646;C0027627;C0175668;C0205199;C0205436;C0227665;C1274040;C1547335
718,secondary ' outcomes,C0027627;C0175668;C0205436;C1274040
717,second year !,C0205436;C0439234;C0439508;C0457385;C0565930;C1561503;C1705190
717,second serum creatinine,C0201976;C0205436;C0457385;C0565930;C0600061;C1561503;C1705190
717,second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
717,second loading dose,C0205436;C0457385;C0565930;C1561503;C1705190;C3714444
717,second co - primary outcome,C0205225;C0205436;C0439612;C0439631;C0457385;C0565930;C1274040;C1561503;C1705190;C3245499
717,second co - primary,C0205436;C0457385;C0565930;C1561503;C1705190;C3245499
717,second - generation stent,C0038257;C0079411;C0205436;C0457385;C0565930;C1561503;C1705190;C3146294
717,second ( n = $nmbr$ ),C0205436;C0457385;C0565930;C1561503;C1705190
717,no second mi,C0205436;C0457385;C0565930;C1561503;C1705190;C3810814
716,on sulfonylurea,C0038766;C3536898
716,non - sulfonylurea secretagogues,C0038766;C1518422;C3536898;C4704833
715,sulfonylureas,C0038766;C3653359
715,sulfonylurea derivatives,C0038766
714,sulfonylurea based,C0038766;C3536898
714,baseline sulfonylurea yes,C0038766;C0168634;C1442488;C1549445;C1705108;C1710701;C3536898
713,treatment with sulphonylurea + biguanide  n ( % ),C0005382;C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3537187;C3538994;C3887704;C4317165
713,treatment with sulphonylurea  n ( % ),C0038766;C0039798;C0087111;C1522326;C1533734;C1705169;C3536898;C3538994;C3887704
713,sulphonylurea,C0038766;C3536898
713,sulfonylurea — no . ( % ),C0038766;C3536898
713,sulfonylurea,C0038766;C3536898
713,other sulfonylurea 一 no . ( % ),C0038766;C3536898
713,any sulfonylurea,C0038766;C3536898
712,metformin + sulphonylureas,C0025598;C0038766
711,sulphonylureas,C0038766
711,insulin + sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
711,insulin + metformin + sulphonylureas,C0021641;C0025598;C0038766;C1533581;C1579433;C3714501
710,syndrome  n ( % ),C0039082
710,specific syndromes,C0039082;C0205369;C1552740;C1558916
710,nonmetabolic syndrome ( n = $nmbr$ ),C0039082
710,cardiometabolic syndrome  ^ n ( % ),C0039082
709,syncope — no . ( % ),C0039070;C3541349;C4554644
709,syncope,C0039070;C3541349;C4554644
708,edss stratification . no . ( % ),C0451246;C1514983;C3887783
708,edss stratification  no . ( % ),C0451246;C1514983;C3887783
708,edss score,C0451246;C3887783
707,with ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
707,standard therapyy ( n = $nmbr$ ),C1442989;C2828392
707,standard,C1442989;C2828392
707,sd  standard,C1442989;C2699239;C2828392
707,no - ckd standard ( n = $nmbr$ ),C1442989;C1561643;C2828392
707,$nmbr$ standard ( n = $nmbr$ ),C1442989;C2828392
706,standard bp lowering  < $nmbr$ mm hg ( n = $nmbr$ ),C0037623;C0439475;C0441994;C1415692;C1442989;C1708288;C2003888;C2828392;C4318478
706,standard ( n = $nmbr$ ),C1442989;C2828392
705,standard ( $nmbr$ ),C1442989;C2828392
705,size ( cm $nmbr$ ) ( mean ± standard deviation ),C0444504;C0456389;C0871420;C1442989;C1828170;C2347634;C2348143;C2828392
704,standard care n ( % ) / $nmbr$ py,C0030428;C1442989;C1947933;C2828392;C3538810
704,standard care n ( % ),C1442989;C1947933;C2828392
704,standard care ( n = $nmbr$ ),C1442989;C1947933;C2828392
704,standard care,C1442989;C1947933;C2828392
704,number standard care,C0237753;C0449788;C1442989;C1947933;C2828392
703,standard care allocation,C1442989;C1706778;C1947933;C2828392
703,standard allocation,C1442989;C1706778;C2828392
702,gender  % of patients,C0030705;C0079399;C1522384
702,eze / simva gender,C0079399;C1522384
701,gender n ( % ),C0079399;C1522384
701,gender [ n ( % ) ],C0079399;C1522384
701,gender - n ( % ),C0079399;C1522384
701,gender  %,C0079399;C1522384
701,gender,C0079399;C1522384
701,age  y gender  n ( % ),C0001779;C0079399;C1522384
701,age  mean years ( sd ) ’ gender  n ( % ),C0079399;C0444504;C1510829;C1522384;C2347634;C2348143;C2699239
700,gender male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender : male    n   ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender ( male )  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender ( female : male  % ),C0043210;C0079399;C0086287;C0086582;C1522384;C1705497;C1705498;C1706180;C1706428;C1706429
700,gender    n   ( % ),C0079399;C1522384
700,gender  n [ % ] male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender  n ( % ],C0079399;C1522384
700,gender  n ( % ),C0079399;C1522384
700,gender  male ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender  male  n ( % ),C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
700,gender  male,C0079399;C0086582;C1522384;C1706180;C1706428;C1706429
699,sex — no . / total no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex — no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex ( women  n [ % ] ),C0009253;C0036864;C0043210;C0079399;C0804628;C1314687;C1522384
699,sex ( p = $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex ( no . ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex ( interaction : p = $nmbr$ . $nmbr$ ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C1704675
699,sex ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  no . ( % ) male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  no . ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  no  ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  n ( % ) b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  n ( % ) *,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  n ( % ),C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,sex  %,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
699,gender  no . ( % ),C0079399;C1522384
699,age  y sex  no . ( % ),C0001779;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
698,subgroup sex,C0009253;C0036864;C0079399;C0804628;C1079230;C1314687;C1515021;C1522384
698,sexy,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
698,sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
698,age mean age  years sex,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143
698,> $nmbr$ yrs sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
698,> $nmbr$ yr sex,C0009253;C0036864;C0079399;C0439234;C0804628;C1314687;C1522384
697,sex :,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
697,gender :,C0079399;C1522384
697,age  years ( mean _ + sd ) sex  n ( % ) :,C0009253;C0036864;C0079399;C0444504;C0804628;C1314687;C1510829;C1522384;C2347634;C2348143;C2699239
696,effect size ^,C0814843
696,effect size !,C0814843
695,sample size ( n ),C0242618
695,sample size  n ( % ) by treatment,C0037793;C0039798;C0087111;C0242618;C0456389;C1522326;C1533734;C1705169;C3538994;C3887704
695,sample size  n,C0242618
695,sample size,C0242618
694,catheter site — femoral,C0449652
693,catheter access site,C0085590;C0444454;C0449652;C0589360;C1554204
693,access site,C0589360
692,internal carotid artery sites,C0007276;C0205145
691,carotid bulb sites,C0007281;C0205145
690,u . s . sites,C0041703;C0205145
690,u . s . site,C0041703;C0205145;C1515974;C2825164
690,sites,C0205145
689,us site,C0205145;C1515974;C2825164
689,site,C0205145;C1515974;C2825164
689,critical site,C0205145;C1511545;C1515974;C2825164
689,any site,C0205145;C1515974;C2825164
689,angiographic complications  site - reported — no . / total no . ( % ),C0002978;C0009566;C0205145;C1171258;C1515974;C2825164
688,disease site — no . of patients ( % ) |,C0012634;C0205145;C1515974;C2825164
688,disease site — no . ( % ) ^,C0012634;C0205145;C1515974;C2825164
688,disease site  n [ % ],C0012634;C0205145;C1515974;C2825164
687,serious adverse events,C1519255
686,≥ $nmbr$ sae,C1519255;C1622657;C4553214
685,saes,C1519255;C1622657;C4553214
685,due to sae,C1519255;C1622657;C4553214
685,due to drug - relateda sae,C0013227;C1254351;C1519255;C1622657;C4553214
685,drug - related saes,C0013227;C0439849;C0445223;C1254351;C1519255;C1622657;C4553214
685,because of sae,C1519255;C1622657;C4553214
685,because of drug ‐ relateda   sae,C0013227;C1254351;C1519255;C1622657;C4553214
685,any sae,C1519255;C1622657;C4553214
684,congenital heart disease,C0152021
683,heart disease risk factors,C0741920
682,rheumatic heart disease,C0035439
681,diabetic kidney disease,C0011881
680,major diabetic eye disease  n ( % ),C0205082;C0205164;C0342245;C4318856;C4521762
680,diabetic eye disease,C0342245
679,uc disease duration ( y ),C0872146
679,duration of disease since,C0872146
679,duration of disease before baseline,C0872146
679,duration of disease ( y )  median ( min  max },C0549183;C0702093;C0872146;C0876920;C1524029;C2347635;C2348144;C2939193;C3813700
679,duration of disease  y,C0872146
679,duration of disease  n ( % ),C0872146
679,duration of disease  median,C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
679,disease duration ( y )  median ( m / n  max ),C0369637;C0441923;C0549183;C0872146;C0876920;C2347635;C2348144;C2939193
678,mean disease duration  y ( sd ),C0444504;C0872146;C2347634;C2348143;C2699239
678,disease duration  y  mean ± sd,C0444504;C0872146;C2347634;C2348143;C2699239
678,disease duration  y,C0872146
678,disease duration,C0872146
677,study eye characteristics,C0015392;C0700042;C1568011
676,microvascular eye diseased,C0015392;C0443258;C0700042
675,patients with specific disease characteristics  n ( % ),C0030705;C0205369;C0599878;C1552740
675,patients with specific disease characteristics,C0030705;C0205369;C0599878;C1552740
675,disease characteristics *,C0599878
675,disease characteristics  n ( % )  unless otherwise stated,C0599878
675,disease characteristics,C0599878
674,small vessel,C0225988
673,single vessel coronary artery disease †,C0581374
673,single vessel coronary artery disease *,C0581374
673,single vessel coronary artery disease $nmbr$,C0581374
672,two - vessel disease,C0581375
671,multi - vessel coronary artery disease,C1299432
670,one - vessel disease,C3275121
669,three - vessel disease,C3272265
668,disease stage,C0699749
667,polyvascular disease * status,C3176928
667,physician ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4050369
667,patient ' s global assessment of disease status score,C0449820;C3176928;C4050231;C4054229
667,global assessment of disease status score,C0281858;C0449820;C3176928;C4050231
666,severe disease,C1836348
666,$nmbr$ ( severe disease ),C1836348
665,self - reported disease severity  $nmbr$ - $nmbr$ scale *,C0175659;C0349674;C0521117;C0681906;C1947916;C2700446
665,disease severity,C0521117
664,extensive disease other,C0849867
663,peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0205390;C1300072;C1306673;C1306889
663,peripheral artery occlusive disease,C1306889
662,valvular disease ( % ),C3258293
662,valvular disease  mitral,C3258293
662,valvular disease,C3258293
661,valvular heart disease — no . ( % ),C0018824;C1963123
661,valvular heart disease  n ( % ),C0018824;C1963123
661,valvular heart disease,C0018824;C1963123
661,cardiac valvular disease,C0018824
660,previous vascular disease,C0042373;C0205156;C1552607
660,other vascular disease — no . ( % ),C0042373
660,other vascular disease,C0042373
659,vascular disease indicator no ( n = $nmbr$ ),C0021212;C0042373;C1235732;C1522602
659,vascular disease,C0042373
659,any vascular disease,C0042373
658,vessel disease,C0042373
658,double - vessel disease  n ( % ),C0042373;C0205173;C1705764;C1705765
657,thyroid disease,C0040128
656,established atherosclerotic cardiovascular disease — no . { % ),C0004153;C0443211;C1272684
656,established atherosclerotic cardiovascular disease,C0004153;C0443211;C1272684
656,atherosclerotic vascular disease — no .,C0004153
656,atherosclerotic cardiovascular disease,C0004153
655,atherosclerotic vascular disease history  n ( % ) t,C0004153;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
655,atherosclerotic vascular disease  n ( % ) §,C0004153
654,high risk with atherosclerotic vascular disease *,C0004153;C0332167;C3272283;C4050568;C4319571
654,atherosclerotic cardiovascular disease *,C0004153
653,type of reflux disease,C0232483;C0457464;C1882919;C4317146
653,erosive reflux disease,C0012634;C0232483;C0439679;C1882919;C4317146
652,gastrooesophageal reflux disease,C0017168;C4553201
652,gastroesophageal reflux disease,C0017168;C4553201
651,observed case,C0868928;C1441672;C1706255;C1706256
651,observed,C1441672
650,history of crohn ' s disease surgery  n ( % ),C0010346;C0455610
650,crohn ’ s disease related surgery,C0010346
650,crohn ' s disease - related medication at baseline  n ( % ),C0010346
649,crohn ' s disease,C0010346
649,concurrent treatment of crohn ' s disease at study entry — no . of patients ( % ) ff,C0010346;C0039798;C0087111;C0205420;C1522326;C1533734;C1705169;C3538994;C3887704
648,chronic kidney diseased,C2364010
647,previous chronic kidney disease,C0205156;C1552607;C1561643;C4553188
647,chronic kidney disease †,C1561643;C4553188
647,chronic kidney disease ( % ),C1561643;C4553188
647,chronic kidney disease  no . ( % ) t,C1561643;C4553188
647,chronic kidney disease  n ( % ),C1561643;C4553188
647,chronic kidney disease,C1561643;C4553188
646,stable coronary artery disease,C0010054;C0010068;C0205360;C1547311;C1956346
646,prior coronary artery disease yes,C0010054;C0010068;C0332152;C1549445;C1705108;C1710701;C1956346;C2826257
646,only coronary artery disease,C0010054;C0010068;C0205171;C1720467;C1956346
646,multivessel coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
646,multivessel coronary artery disease,C0010054;C0010068;C1956346
646,documented coronary artery disease,C0010054;C0010068;C1301725;C1609436;C1956346
646,coronary disease,C0010068;C1956346
646,coronary artery disease — no . ( % ) : c,C0010054;C0010068;C1956346
646,coronary artery disease — no . ( % ) : ! :,C0010054;C0010068;C1956346
646,coronary artery disease — %,C0010054;C0010068;C1956346
646,coronary artery disease §,C0010054;C0010068;C1956346
646,coronary artery disease ^,C0010054;C0010068;C1956346
646,coronary artery disease *,C0010054;C0010068;C1956346
646,coronary artery disease ( n = $nmbr$ $nmbr$ ),C0010054;C0010068;C1956346
646,coronary artery disease    n   ( % ),C0010054;C0010068;C1956346
646,coronary artery disease  %,C0010054;C0010068;C1956346
646,coronary artery disease,C0010054;C0010068;C1956346
646,any established coronary artery disease,C0010054;C0010068;C0443211;C1272684;C1956346
646,any coronary artery disease,C0010054;C0010068;C1956346
645,previous coronary heart disease,C0010054;C0010068;C0205156;C1552607;C1956346
645,previous coronary artery disease  n ( % ),C0010054;C0010068;C0205156;C1552607;C1956346
645,coronary heart disease — no . ( % ),C0010054;C0010068;C1956346
645,coronary heart disease ( % ),C0010054;C0010068;C1956346
645,coronary heart disease  n ( % ) t,C0010054;C0010068;C1956346
645,coronary heart disease  n ( % ) b,C0010054;C0010068;C1956346
645,coronary artery disease — no . / total no . ( % ),C0010054;C0010068;C1956346
645,coronary artery disease — no . ( % ),C0010054;C0010068;C1956346
645,coronary artery disease ( % ),C0010054;C0010068;C1956346
645,coronary artery disease  n ( % ),C0010054;C0010068;C1956346
644,• death from coronary heart disease,C0010054;C0010068;C0011065;C1306577;C1956346;C4082313;C4552775
644,coronary heart disease,C0010054;C0010068;C1956346
643,mer ’ s disease assessment,C0012634;C0673013;C1261322;C1516048;C3810521;C4281714
642,exlertl ot disease,C0012634;C1318464;C1418208;C1705587
641,underlying disease,C0012634;C4067746
641,peripherai arteriai disease,C0012634
640,disease and quality - of - life scores  mean ( sd ),C0012634
640,disease and quality - of - life scores,C0012634
640,baseline disease and quality - of - life scores,C0012634;C0168634;C1442488
639,major coronary disease event ( fatal / non - fatal mi ),C0010068;C0012634;C0205082;C0205164;C0441471;C0741923;C1302234;C1518422;C1705232;C1956346;C3810814;C4019010;C4318856;C4521762
639,intracranial disease of major artery disease t,C0012634;C0205082;C0205164;C0752138;C4318856;C4521762
639,disease,C0012634
639,coronarv arterv disease,C0012634
638,site of disease — no . ( % ),C0012634;C2945843
638,disorders ( soc ),C0012634
638,disease hare . no . ( % ) i,C0012634
637,previous medication for respiratory disease — no . ( % ),C0012634;C0013227;C0035204;C0035242;C0205156;C0418986;C1552607;C3244316;C4284232
637,previous disease — no . ( % ) f,C0012634;C0205156;C1552607
637,no multivessel disease,C0012634
637,multivessel disease 一 no . ( % ),C0012634
637,multivessel disease — no . ( % ),C0012634
636,uc disease durslion,C0012634
636,priorbone disease,C0012634
636,prior disease - modifying drugs resulting in inadequate response — mean no . / patient,C0012634;C0013227;C0332152;C0392747;C2826257;C3687832
636,prior disease,C0012634;C0332152;C2826257
635,priorvascular disease  %,C0012634
635,polyvascular disease * and type $nmbr$ diabetes status,C0012634
635,microvascular disease *,C0012634;C0443258
635,microvascular disease  n ( % ),C0012634;C0443258
635,macrovascular disease  n ( % ),C0012634
634,multivessel disease  no . ( % ),C0012634
634,multivessel disease  n ( % ),C0012634
634,multivessel disease,C0012634
634,disease location ( % ) *,C0012634;C0450429;C1515974;C4284930;C4284931
633,polyvascular disease and type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
633,polyvascular disease and no type $nmbr$ diabetes ( n = $nmbr$ ),C0012634
633,polyvascular disease * ( n = $nmbr$ ),C0012634
633,polyvascular disease ( n = $nmbr$ ),C0012634
633,no polyvascular disease * ( n = $nmbr$ $nmbr$ ),C0012634
633,no polyvascular disease ( n = $nmbr$ $nmbr$ ),C0012634
633,disease extent  n ( % ),C0012634;C0439792
632,disease localization ' ’  n ( % ),C0012634;C0475264;C1744691
632,disease localization  n ( % ),C0012634;C0475264;C1744691
631,clinical atherosclerotic disease *,C0012634;C0205210;C0333482
631,atherosclerotic disease *,C0012634;C0333482
630,established atherosclerotic disease  n ( % ),C0012634;C0333482;C0443211;C1272684
630,atherosclerotic disease ( % ),C0012634;C0333482
629,cerebrovascuiar disease,C0012634
629,cardiovascular disease history ‡,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
629,cardiovascular disease history  n ( % ) *,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
629,cardiovascular disease history,C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
629,any disease,C0012634
629,any cardiovascular disease history  n ( % ),C0007222;C0007226;C0012634;C0019664;C0019665;C0262512;C0262926;C0683519;C1705255;C1880008;C2004062;C3887460
628,cards,C2930619;C3275277
627,premature cad among family members,C0086282;C0151526;C0205252;C1504769;C2239547;C3813548;C4018905;C4284121
627,family history of cad ( diagnosed at < $nmbr$ yr of age ) — no . ( % ) cigarette smoker — no . ( % ),C0241889;C1504769;C2239547;C3813548;C4284121
627,family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
627,familv historv of cad,C1504769;C2239547;C3813548;C4284121
627,cad and abi < $nmbr$ - $nmbr$ §,C1504769;C2239547;C3813548;C4284121
627,cad *,C1504769;C2239547;C3813548;C4284121
626,prior cad,C0332152;C1504769;C2239547;C2826257;C3813548;C4284121
626,previous cad  n ( % ),C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
626,previous cad,C0205156;C1504769;C1552607;C2239547;C3813548;C4284121
626,multivessel cad ( % ),C1504769;C2239547;C3813548;C4284121
626,multivessel cad  n ( % ),C1504769;C2239547;C3813548;C4284121
626,cad and / or crvd ( % ),C1504769;C2239547;C3813548;C4284121
626,cad,C1504769;C2239547;C3813548;C4284121
625,comparison : cat . $nmbr$ vs . cat . $nmbr$,C0007450;C0325090;C0524517;C1443200;C1707455;C3665481;C4050461;C4284282
625,cat > = $nmbr$ ( n = $nmbr$  $nmbr$ ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
625,cat > = $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
625,cat > $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
625,cat < $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
625,cat . $nmbr$ n / n ( % ),C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
624,copd assessment test ( cat ) score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
624,cat total score $nmbr$,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
624,cat total score,C0007450;C0325090;C0524517;C1443200;C2964552;C3665481;C4050461;C4284282
624,cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
624,cat score category,C0007450;C0325090;C0449820;C0524517;C0683312;C1443200;C3665481;C3889287;C4050231;C4050461;C4284282
624,cat score  mean ( sd ),C0007450;C0325090;C0444504;C0449820;C0524517;C1443200;C2347634;C2348143;C2699239;C3665481;C4050231;C4050461;C4284282
624,cat score,C0007450;C0325090;C0449820;C0524517;C1443200;C3665481;C4050231;C4050461;C4284282
623,prostate cancer,C0376358;C0600139;C2984325;C3541264
622,pancreatic cancer,C0235974;C0346647;C2984259
621,non - colorectal cancer,C0009402;C0346629;C1518422;C1527249;C2984278;C3542412
621,colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
620,concern,C2699424
619,cancer surgery,C0920424
618,no adk / e cancer,C0006826;C0998265;C1306459;C1412243
617,cancer  fatal and nonfatal,C0006826;C0998265;C1306459
617,all cancer,C0006826;C0998265;C1306459
617,ac tve cancer,C0001246;C0003354;C0006826;C0998265;C1306459;C1412573;C2000891;C3539770
616,prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
616,previous cancer — no . ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
616,previous cancer  n ( % ),C0006826;C0205156;C0998265;C1306459;C1552607
616,previous cancer,C0006826;C0205156;C0998265;C1306459;C1552607
616,no prior cancer,C0006826;C0332152;C0998265;C1306459;C2826257
616,cancer — no . ( % ),C0006826;C0998265;C1306459
616,cancer §,C0006826;C0998265;C1306459
616,cancer n ( % ),C0006826;C0998265;C1306459
616,cancer * *,C0006826;C0998265;C1306459
616,cancer *,C0006826;C0998265;C1306459
616,cancer ( n = $nmbr$ ),C0006826;C0998265;C1306459
616,cancer,C0006826;C0998265;C1306459
615,canvas - r,C0205090;C0684010;C2603358;C3281223
615,canvas,C3281223
614,cabg surgery by no . of vessels $nmbr$,C0010055;C0042381;C3714645
613,history of cabg surgery  n ( % ),C0010055;C0455610
613,history of cabg  n ( % ),C0010055;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
613,cabg ( % ),C0010055
613,cabg  n ( % ),C0010055
612,previous pci / cabg  n ( % ),C0010055;C0205156;C1552607;C4049621
612,previous cabg ( % total ),C0010055;C0205156;C0439175;C0439810;C1552607
612,previous cabg  n ( % ),C0010055;C0205156;C1552607
612,cabg,C0010055
611,previous cabg ( before index acs ) *,C0010055;C0205156;C0600653;C0742343;C0918012;C1552607;C1552854;C1637833;C2986546;C4318612
611,previous cabg,C0010055;C0205156;C1552607
610,prior cabg ( before index acs ),C0010055;C0332152;C0600653;C0742343;C0918012;C1552854;C1637833;C2826257;C2986546;C4318612
610,prior cabg  %,C0010055;C0332152;C2826257
610,prior cabg,C0010055;C0332152;C2826257
610,no prior cabg,C0010055;C0332152;C2826257
609,prior coronary artery bypass surgery,C0010055;C0332152;C2826257
609,prior coronary artery bypass grafting,C0010055;C0332152;C2826257
609,prior coronary artery bypass graft surgery,C0010055;C0332152;C2826257
609,prior coronary artery bypass graft,C0010055;C0332152;C1260596;C2826257
609,coronary bypass surgery,C0010055
609,coronary artery bypass surgery,C0010055
609,coronary artery bypass,C0010055
608,treated with cabg — no . / total no . ( % ),C0010055;C0332293
608,cabg — no . { % ),C0010055
608,cabg — no . ( % ),C0010055
607,ptca / cabg,C0010055;C2936173
607,cabg or ptca / pci,C0010055
606,cabg performed during index hospitalization,C0010055
606,cabg during index hospitalization,C0010055;C0019993;C0600653;C0918012;C1552854;C1637833;C2986546
605,timi non - cabg major,C0010055;C1518422
605,safety : non - cabg - related bleeding,C0010055;C0036043;C1518422;C1705187
605,non - cabg related bleeding at $nmbr$ h,C0010055;C1518422
605,non - cabg or combined,C0010055;C1518422
605,cabg or valve,C0010055
605,cabg :,C0010055
604,data are mean ( sd ) or number ( % ) . bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . lvef = left ventricular ejection fraction . hf = heart failure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter de ﬁ brillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ rosuvastatin  $nmbr$ placebo ) .,C0010055;C0011198;C0014442;C0017480;C0018801;C0021122;C0024117;C0032042;C0042508;C0085805;C0155626;C0162589;C0428772;C0428883;C0488055;C0488728;C0521942;C0815017;C0871470;C0965129;C1306620;C1452534;C1511726;C1532338;C1696465;C1706408;C3245479;C3541240;C3714741;C3888198;C4284014;C4521602
604,cabg or ptca ( % ),C0010055
604,cabg or pci,C0010055
604,cabg or angioplasty,C0010055
603,coronary artery bypass grafting n ( % ),C0010055
603,coronary artery bypass grafting,C0010055
603,coronary artery bypass graft — no . ( % ),C0010055;C1260596
602,need for urgent coronary - artery bypass grafting,C0010055;C0027552;C0439609;C0686904;C3272275
602,multivessel coronary - artery bypass grafting,C0010055
602,coronary - artery bypass grafting §,C0010055
602,coronary - artery bypass grafting,C0010055
601,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s  multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation  † at discharge . ace angiotensin - converting enzyme  cabg coronary artery bypass graft  ccsc canadian cardiovascular society classi ﬁ cation  mi myocardial infarction  pci percutaneous coronary intervention .,C0007226;C0007447;C0010055;C0018787;C0022709;C0027051;C0037455;C0184661;C0238884;C0439453;C0439836;C0565930;C0886296;C1273869;C1511726;C1516705;C1719797;C2603362;C2911648;C3245479;C3714741;C3887460;C4049621
601,coronary bypass  n ( % ),C0010055
601,ace = angiotensin - converting enzyme  cabg = coronary artery bypass graft  ccsc = canadian cardiovascular society classification  mi = myocardial infarction  pci = percutaneous coronary,C0010055;C0022709;C0027051;C0189695;C0545743;C3640258
600,oct center point thickness  pm,C0205099;C1280412;C1552961;C2347617;C3714763;C3810851;C3828732
600,centre,C0205099;C3810851
599,center level ttr,C0032923;C0205099;C0441889;C0456079;C1421224;C1547707;C2946261;C3810851
599,center,C0205099;C3810851
598,location of treatment center,C0039798;C0087111;C0205099;C1522326;C1533734;C1705169;C3538994;C3887704
598,center location,C0205099
597,central and eastern europe,C0205099;C1879652
597,central / eastern europe / russia,C0015177;C0035970;C0205099;C0682369;C1707877;C1879652
597,central / eastern,C0205099;C1707877;C1879652
596,south ! central america,C0007674;C0037713;C0205099;C1710133;C1879652
596,central or south america,C0205099;C1879652
596,central and south america and mexico,C0205099;C1879652
596,central and south america,C0205099;C1879652
595,diagnosis at study entry — no . ( % ),C1704656;C1705654;C4068481
594,no inducer at core study entry,C0444669;C0557651;C1167518;C1705654;C1706352;C1882467;C2603343;C3274653;C3898767
594,concurrent treatment at study entry — no . ( % ) * *,C0009247;C0039798;C0087111;C0205420;C0557651;C0679827;C1521826;C1522326;C1533734;C1705169;C1705654;C2603343;C3161471;C3538994;C3887704
594,at entry,C1705654
593,udy entry,C1705654
593,medications at study entry — no . / total no . ( % ),C0013175;C1705654
593,copd medication at study entry,C0013175;C0024117;C1412502;C1705654;C3714496
592,entry hip fracture location  n ( % ),C1705654;C3260017
591,entry category,C0683312;C1705654;C3889287
591,controllertreatment before entry *,C1705654
590,entry criteria ( % ),C0243161;C1705654
590,entry criteria,C0243161;C1705654
590,cv entry criteria,C0243161;C1705654;C3538987;C4048877;C4318503
589,lelt ventricular hypertrophy *,C0340279
588,left ventricular hypertrophy — no . ( % ),C0149721;C3484363
588,left ventricular hypertrophy on echo,C0058928;C0149721;C1655045;C3484363
588,left ventricular hypertrophy * *,C0149721;C3484363
588,left ventricular hypertrophy ( % ),C0149721;C3484363
588,left ventricular hypertrophy  n ( % ),C0149721;C3484363
588,left ventricular hypertrophy,C0149721;C3484363
587,left ventricular ejection,C2733342
586,left ventricular systolic dysfunction  n ( % ),C1277187;C1963159;C4553199
585,left ventricular dysfunction,C0242698
584,immunomodulatory agents,C0005525
584,immunomodulators,C0001551;C0005525;C1527392
583,standard control ( n = $nmbr$ ) no . of patients ( percent ),C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
583,standard control,C0243148;C1442989;C1550141;C1882979;C2587213;C2828392;C3274648;C4553389
583,rhythm - control group ( n = $nmbr$ ),C0243148;C0441848;C0871269;C1523018;C1550141;C1882979;C2587213;C3274648;C3828331;C4553389
583,intensive control ( n = $nmbr$ ) no . of patients ( percent ),C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
583,intensive control,C0162425;C0243148;C0522510;C1283828;C1550141;C1550453;C1882979;C2587213;C3274648;C4553389
583,glycaemic control ( hba $nmbr$ c )  n ( % ),C0005802;C0019016;C0243148;C1550141;C1825777;C1882979;C2587213;C3274648;C3538758;C4553389
583,fair control ( $nmbr$ - $nmbr$ . $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C2911689;C3274648;C4553389
583,controls ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control n = $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control group ( n = $nmbr$ ),C0243148;C0441848;C1550141;C1882979;C2587213;C3274648;C4553389
583,control baseline ( n - $nmbr$ ),C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
583,control = warfarin,C0043031;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control ( nz $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control ( n z $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control ( n = $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control ( n - $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,control $nmbr$ months ( n - $nmbr$ ),C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
583,control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,baseline glycemic control,C0005802;C0168634;C0243148;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
583,asthma control,C0004096;C0243148;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
583,asthma - control status at randomization — no . ( % ),C0004096;C0034656;C0243148;C0449438;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
583,active - control study,C0243148;C0557651;C1550141;C1706449;C1882979;C2347179;C2587213;C2603343;C3274648;C4553389
583,( % ) control ( $nmbr$ ),C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
583,% asthma control days {  #,C0004096;C0243148;C0439228;C1550141;C1882979;C2587213;C2984299;C3274648;C4553389
582,controlled : acq - $nmbr$ < $nmbr$ . $nmbr$,C2587213;C2911690;C2919686
582,controlled $nmbr$ — no . ( % ),C2587213;C2911690
582,controlled,C2587213;C2911690
581,uncontrolled on oad ( s ),C0205318
581,uncontrolled on basal insulin,C0205318;C0650607
580,uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$,C0205318;C2919686
580,uncontrolled,C0205318
579,any acuity bleeding,C0333276
578,acuity minor,C0750509
578,acuity major or,C0750509
578,acuity major,C0750509
578,acuity - defined bleeding,C0750509
578,acuity - bleeding major / minor,C0750509
577,positive for anti - cyclic citrullinated peptide antibody — no . ( % ) f,C0741132;C1320283
576,anti - ccp antibody positive  n ( % ),C0432633;C0741132;C1525410;C1704514
576,anti - ccp antibody positive,C0741132;C4318437
576,anti - ccp antibody - positive  n ( % ),C0432633;C0741132;C1525410;C1704514
575,atm - locus,C1708726;C3711796
575,atm - locm,C3711796
574,other anti - platelet agents,C0005821;C0040616
573,anti - anaemics,C0857322
572,prior biologic therapy ( including anti - tnfs ),C0278947
571,noncomplex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0700276;C1384516
571,complex anatomy ( n - $nmbr$  $nmbr$ ),C0002808;C0439855;C0700276;C1384516;C1704241
571,anatomy,C0002808;C0700276;C1384516
570,south american,C0425359
569,central america and south america,C0007674
569,central / south america and mexico,C0007674;C0037713;C0205099;C1710133;C1879652
568,south asian,C1519427
568,south asia,C0037723;C1519427
567,south america ( n = $nmbr$ ),C0037713
567,south america ( % ),C0037713
567,south america,C0037713
566,south africa,C0037712
566,europe ( plus south africa ),C0015176;C0037712;C0332287
565,southern hemisphere,C0205139;C1710133
565,south  n ( % ),C1710133
564,south or central american,C1710133
564,south or central america,C1710133
564,central / south america,C0007674;C0037713;C0205099;C1710133;C1879652
564,central / south,C0205099;C1710133;C1879652
563,north american,C0425358;C2700615
562,north america / oceania,C0028405;C0282279;C4085681
561,north america hr ( $nmbr$ % cl ),C0028405;C0596019
561,north america ( % ),C0028405
560,north america *,C0028405
560,north america ( plus america and new zealand ),C0028405;C0332287
559,region north america,C0017446;C0028405;C0205147
559,region - north america,C0017446;C0028405;C0205147
559,region  north america,C0017446;C0028405;C0205147
559,north america n z $nmbr$,C0028405
559,north america ( n = $nmbr$ ),C0028405
559,north america,C0028405
559,geographic region - north america,C0017446;C0028405
558,north ameriea,C1709269
558,north,C1709269
557,三 $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
557,≥ $nmbr$ to < $nmbr$ %,C0040363;C0041260;C1883351
557,> - $nmbr$ . $nmbr$ to < - $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
557,> $nmbr$ to s $nmbr$ yrs,C0040363;C0041260;C1883351
557,> $nmbr$ to < $nmbr$ uln,C0040363;C0041260;C1519815;C1883351
557,> $nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
557,> $nmbr$ to $nmbr$,C0040363;C0041260;C1883351
557,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
557,> $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
557,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to < $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
557,> $nmbr$ % to < $nmbr$ % ( > $nmbr$ to $nmbr$ mmol / mol ),C0040363;C0041260;C1883351;C3829066
557,> $nmbr$ % to < $nmbr$ %,C0040363;C0041260;C1883351
557,$nmbr$ to less than $nmbr$,C0040363;C0041260;C1883351
557,$nmbr$ to < $nmbr$ bpm ( n = $nmbr$ ),C0040363;C0041260;C1883351
557,$nmbr$ to < $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
557,$nmbr$ to < $nmbr$ ( % ),C0040363;C0041260;C1883351
557,$nmbr$ to < $nmbr$,C0040363;C0041260;C1883351
557,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ( % ),C0040363;C0041260;C1883351
557,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ %,C0040363;C0041260;C1883351
557,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
557,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to - $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
557,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ - $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
557,$nmbr$ $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) [ $nmbr$ ( $nmbr$ . $nmbr$ ) ] $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) [ $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ to $nmbr$ . $nmbr$ ) ],C0040363;C0041260;C1883351
556,naire can range from $nmbr$ to $nmbr$ for the alternative disability portion and from $nmbr$ to $nmbr$ for the pain portion . scores for the medical outcomes,C0040363;C0041260;C0199168;C0205476;C1274040;C1883351
556,$nmbr$ . $nmbr$ to $nmbr$ . $nmbr$,C0040363;C0041260;C1883351
555,tx $nmbr$,C0041403
555,tx,C0041403
555,lipoprotein ( a ) tx difference vs pbo  ls mean % change from baseline ( se ),C0041403;C0065058;C0125953;C1096202;C1439335;C1705241;C1705242
555,homajr tx difference vs pbo  median change from baseline ( se ) $nmbr$ lipid parameters,C0041403;C1705241;C1705242
555,homa_ir tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0022065;C0022071;C0041403;C1448132;C1705241;C1705242
555,hbalc tx difference vs pbo  median change from baseline ( se ) $nmbr$,C0041403;C1705241;C1705242
554,sou ti africa,C0001737;C0039247;C0040302;C1553045;C1704756
554,- $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$ § ti,C0039247;C0040302;C1553045;C1704756
553,tj ( $nmbr$ - $nmbr$ ),C0039247
553,tj ( $nmbr$ % ),C0039247
552,$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u,C0439148;C2603360
551,t - jj ( $nmbr$ - $nmbr$ ),C2603360
551,$nmbr$ t i,C0021966;C0221138;C2603360
550,t $nmbr$ . $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C2603360;C4321396;C4521761
550,t,C2603360
550,other ( $nmbr$ . $nmbr$ % ) t,C2603360
549,t $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ng / ml ),C0439275;C2603360
549,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t,C2603360
548,t $nmbr$ dm,C0011816;C2603360;C3250443
548,t $nmbr$ d,C2603360
548,of t $nmbr$ dm ( years ),C0011816;C0439234;C2603360;C3250443
548,neither t $nmbr$ dm nor mets,C0011816;C2603360;C3250443
547,weight ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0552346;C0876920;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
547,weight  kg  median ( $nmbr$ th  $nmbr$ th ),C0005910;C0022718;C0039725;C0039738;C0043100;C0439209;C0549183;C0876920;C1305866;C1420718;C1705104;C2347635;C2348144;C2939193;C4054209;C4282123;C4285344
547,th c,C0039725;C0039738;C1420718;C4282123;C4285344
547,th ( $nmbr$ % ),C0039725;C0039738;C1420718;C4282123;C4285344
547,median ( $nmbr$ th  $nmbr$ th percentile ),C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,high - density lipoprotein cholesterol  median  ( $nmbr$ th — $nmbr$ th percentiles )  mg / dl,C0023822;C0039725;C0039738;C0439269;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,euroscore additive  median ( $nmbr$ th  $nmbr$ th % ) §,C0039725;C0039738;C0442796;C0549183;C0876920;C1420718;C1550602;C2347635;C2348144;C2939193;C3164744;C4282123;C4285344
547,body mass index  median  ( $nmbr$ th — $nmbr$ th percentiles )  kg / m $nmbr$,C0005893;C0039725;C0039738;C0549183;C0578022;C0876920;C1264641;C1305855;C1420718;C1532718;C2347635;C2348144;C2939193;C4282123;C4285344
547,bmi ( kg / m $nmbr$ ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C0039725;C0039738;C0549183;C0876920;C1420718;C1532718;C2347635;C2348144;C2923536;C2939193;C4282123;C4285344
547,age ( y )  median ( $nmbr$ th to $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,age  yrs  median ( $nmbr$ th  $nmbr$ th ),C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,age  y ( $nmbr$ th  $nmbr$ th percentiles ),C0001779;C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
547,age  median ( $nmbr$ th — $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,age  median ( $nmbr$ th - $nmbr$ th percentiles )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1264641;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,age  median ( $nmbr$ th  $nmbr$ th )  y,C0001779;C0039725;C0039738;C0549183;C0876920;C1420718;C2347635;C2348144;C2939193;C4282123;C4285344
547,$nmbr$ th — $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
547,$nmbr$ th : $nmbr$ . $nmbr$ - $nmbr$ pmol / l,C0039725;C0039738;C0439284;C1420718;C4282123;C4285344
547,$nmbr$ th - $nmbr$ th percentiles,C0039725;C0039738;C1264641;C1420718;C4282123;C4285344
546,tk,C0041405;C0220928;C4050092
545,tc level  mean ( sd ) mg / dl,C0039411;C0040642;C0041405;C0041698;C0439269;C0441889;C0444504;C0456079;C1547707;C1824670;C2347634;C2348143;C2699239;C2946261;C3272447;C4522122
545,tc : hdlc,C0039411;C0040642;C0041405;C0041698;C1704429;C1824670;C3272447;C4522122
545,tc / hdl - c ratio,C0039411;C0040642;C0041405;C0041698;C0456603;C1547037;C1824670;C3272447;C3715113;C4522122
545,tc / hdl - c,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3715113;C4522122
545,tc ( mmol / l ),C0039411;C0040642;C0041405;C0041698;C1532563;C1824670;C3272447;C4522122
545,tc ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C0439269;C1824670;C3272447;C4522122
545,tc  mmol / l ( mg / dl ),C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C3642216;C3898312;C4522122
545,tc  mg / dl  mean ± sd,C0039411;C0040642;C0041405;C0041698;C0439269;C0444504;C1824670;C2347634;C2348143;C2699239;C3272447;C4522122
545,tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
545,baseline tc  mg / dl,C0039411;C0040642;C0041405;C0041698;C0168634;C0439269;C1442488;C1824670;C3272447;C4522122
545,apo  apolipoprotein  dm  diabetes mellitus  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  tc  total cholesterol  tg  triglycerides . * includes agents acting on the renin - angiotensin system  beta blocking agents  calcium channel blockers  and diuretics . † median values [ standard deviation for medians calculated by ( q $nmbr$ q $nmbr$ ) / $nmbr$ . $nmbr$ ] . § includes cardiac glycosides  antiarrhythmics class i and iii  vasodilators used in cardiac diseases and other cardiac preparations . ‡ expressed as g / l .,C0001645;C0003195;C0003591;C0003594;C0006684;C0008377;C0011849;C0012634;C0017977;C0023821;C0023824;C0039411;C0040642;C0041004;C0041405;C0041698;C0201950;C0202117;C0428473;C0441885;C0543421;C0549183;C0871420;C1319793;C1824670;C2698967;C2757014;C3272447;C3541930;C3715113;C4522122
545,= ezetimibe  tc = triglycerides  hdl - c = lg / dl l > $nmbr$ . $nmbr$ mmol / l ] ) . to qualify as having,C0023128;C0039411;C0040642;C0041405;C0041698;C0062152;C0439190;C0694651;C1142985;C1824670;C3272447;C3642216;C4522122
544,lisinopril / chlorthalidone,C0008294;C0065374
544,lisinopril - chlorthalidone,C0008294;C0065374
544,chlorthalidone - amlodipine - lisinopril,C0008294;C0051696;C0065374
544,chlorthalidone ( n = $nmbr$ ),C0008294
544,chlorthalidone $nmbr$,C0008294
544,amlodipione - chlorthalidone,C0008294
544,$nmbr$ lisinopril - chlorthalidone,C0008294;C0065374
544,$nmbr$ chlorthalidone ( n = $nmbr$ ),C0008294
544,$nmbr$ chlorthalidone,C0008294
543,chlorthalidone vs lisinopril,C0008294
543,chlorthalidone vs doxazosin,C0008294
543,chlorthalidone vs amlodipine,C0008294
543,chlorthalidone group,C0008294;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
543,chlorthalidone,C0008294
542,favors lisinopril favors chlorthalidone,C0008294;C0065374;C0309049
542,favors favors lisinopril chlorthalidone,C0309049
542,favors favors amlodipine chlorthalidone,C0309049
542,favors amlodipine favors chlorthalidone,C0008294;C0051696;C0309049
541,thiazolidinedione 一 no . ( % ),C0289779;C1257987;C3537039
541,thiazolidinedione yes,C0289779;C1257987;C1549445;C1705108;C1710701;C3537039
541,thiazolidinedione no,C0289779;C1257987;C3537039
541,thiazolidinedione ( includes pioglitazone ),C0289779;C1257987;C3537039
541,any thiazolidinedione,C0289779;C1257987;C3537039
540,thiazolidinedione use at baseline,C0042153;C0168634;C0289779;C0457083;C1257987;C1442488;C1947944;C3537039
540,thiazolidinedione based,C0289779;C1257987;C3537039
540,thiazolidinedione,C0289779;C1257987;C3537039
539,thiazolidinediones *,C1257987;C3541957
539,thiazolidinediones,C1257987;C3541957
538,proctosigmoiditis,C0033252
537,seropositivity status  n,C0449438;C0521143
537,seropositivity,C0521143
536,charlson comorbidity index  mean ( sd ),C0444504;C2347634;C2348143;C2699239;C4546361
536,charlson comorbidity index,C4546361
535,mild thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C1856453
534,thrombocytopenia,C0040034;C0392386
534,profound thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0392386;C0439808
534,moderate thrombocytopenia ( < $nmbr$ x $nmbr$ / l ),C0040034;C0205081;C0392386;C1881878;C4049705;C4049706;C4085643;C4321335
533,tofacitinib $nmbr$ mg bid ( n   = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
533,tofacitinib $nmbr$ mg bid ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
533,tofacitinib  $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0439269;C1960952;C2346927;C2930696;C4321396;C4521761
533,tofacitinib,C2930696
532,theophyllines,C0039771
532,theophylline compound,C0039771;C0205198;C1706082
531,rolofylline n,C0166128
531,rolofylline ( n = $nmbr$ ),C0166128
531,rolofylline ( n = $nmbr$  $nmbr$ ),C0166128
531,rolofylline $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0166128;C0439269;C1960952;C2346927;C4321396;C4521761
531,rolofylline,C0166128
530,thromboembolism,C0040038
529,thrombophilia  no . ( % ) e,C0398623
529,thrombophilia,C0398623
529,known thrombophilic condition — no . ( % ),C0012634;C0205309;C0348080;C0398623;C1705253;C3864998
529,known thrombophilia — no . ( % ),C0205309;C0398623
529,known thrombophilia,C0205309;C0398623
528,no hemoconcentration hemoconcentration,C0549409;C0854379
527,immobilization — no . ( % ),C0020944;C4048292
527,immobilization,C0020944;C4048292
526,coexisting conditions,C0679225
525,prespecified medical conditions  n ( % ) f,C0012634;C0016327;C0199168;C0205476;C0348080;C1705253;C3864998
525,presenting condition  n ( % ),C0012634;C0348080;C0449450;C1705253;C3864998
525,medical conditions  no . ( % ),C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
525,history of other medical conditions  n ( % ),C0012634;C0262926;C0348080;C1705253;C3864998
525,currentother ( notpredefined ) medical conditions,C0012634;C0199168;C0205476;C0348080;C1705253;C3864998
525,condition $nmbr$ ( $nmbr$ . $nmbr$ ),C0012634;C0348080;C1705253;C3864998
525,any condition,C0012634;C0348080;C1705253;C3864998
524,spironolactone ( n = $nmbr$ ),C0037982
524,spironolactone  n ( % ),C0037982
524,spironolactone,C0037982
524,outcomes by treatment ( spironolactone vs placebo ),C0037982;C0085415
523,dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0766326
523,dronedarone ( n = $nmbr$ ),C0766326
523,dronedarone,C0766326
522,nordic countries,C0036273
521,nordic,C0331873
520,aortic,C0003483
519,abdominal aortic — no . ( % ),C0003484
518,morning,C0332170
518,duration of morning,C0332170;C0449238;C2926735
517,question $nmbr$ ( morning stiffness since arising ),C0457086;C1522634
517,question $nmbr$ ( length of morning stiffness since arising ),C0457086;C1444754;C1522634;C1706316
516,stroke of atherosclerotic origin,C0038454;C0079946;C0333482;C0439659;C1550512;C4554100
516,origin [ n ( % ) ],C0079946;C0439659;C1550512
515,combined fatal / nonfatal outcomes,C0205195;C0206277
514,combined estimated gfr and albuminuria status,C0205195
514,combined chd,C0205195;C0280604;C3542407
513,combined trials,C0008976;C0205195
512,combined insulin / oral hypoglycaemic agent use,C0205195;C0240016;C0359086
512,combined,C0205195
511,combined infliximab,C0205195;C0666743
510,golimumab combined ( n = $nmbr$ ),C0205195;C2353893
510,combined golimumab groups,C0205195;C2353893
509,czp combined arms ( n = $nmbr$ ),C0054841;C0205195;C0206655;C0446516;C1861828;C1872109;C2681631;C3715044;C4553528
509,combined n = $nmbr$,C0205195
509,combined ( n = $nmbr$ ),C0205195
508,iglarlixi ( fixed - ratio combination ),C0205195;C0443218;C0456603;C1547037;C1947911;C2827483;C3714578;C3811910
508,combination - facilitated pci ( n = $nmbr$ ),C0205195;C1947911;C3811910
508,combination ( n = $nmbr$ ),C0205195;C1947911;C3811910
507,other combination,C0205195;C1947911;C3811910
507,infliximab combination therapy,C0009429;C0205195;C0556895;C0666743;C1947911;C3811910;C4076075
507,combination,C0205195;C1947911;C3811910
506,comorbidity  no . ( % ),C0009488
506,comorbidities ( % ),C0009488
506,comorbidities  no . ( % ),C0009488
506,comorbidities  n ( % ) a,C0009488
506,comorbidities  %,C0009488
506,comorbid illnesses,C0009488;C0221423
506,comorbid diseasesa diabetesb,C0009488
506,comorbid conditionsb,C0009488
505,comorbidities and concomitant medications,C0009488
505,comorbidities / concomitant medications,C0009488;C0013227;C0521115;C0802604;C2598133;C4284232
505,comorbidities,C0009488
505,co - morbidities  n ( % ),C0009488
505,co - morbidities  a n ( % ),C0009488
505,co - morbidities,C0009488
504,karnofsky score 竺 $nmbr$,C0206065
504,karnofsky score < $nmbr$,C0206065
503,health state index score  uk algorithm,C0002045;C0041700;C0449820;C0600653;C0683314;C0918012;C1552854;C1553907;C1637833;C2986546;C4050231
503,algorithm $nmbr$,C0002045;C1553907
502,mean acq - $nmbr$ scores,C0444504;C2347634;C2348143;C2919686
502,mean acq - $nmbr$ score at randomization  !,C0444504;C2347634;C2348143;C2919686
502,acq score  mean,C0444504;C0449820;C2347634;C2348143;C2919686;C4050231
502,acq - $nmbr$ scoret,C2919686
502,acq - $nmbr$ score  mean ( sd ) e,C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
502,acq - $nmbr$ score,C2919686
502,acq $nmbr$ score  mean ( sd ),C0444504;C0449820;C2347634;C2348143;C2699239;C2919686;C4050231
502,acq $nmbr$ score,C2919686
501,baseline acq - $nmbr$ score,C0168634;C1442488;C2919686
501,acq - $nmbr$ score 本,C2919686
501,acq - $nmbr$ score *,C2919686
501,acq - $nmbr$ score ' ! ',C2919686
500,ease - $nmbr$,C1331418
499,$nmbr$ - $nmbr$ . $nmbr$ : obese class i,C3853264
498,$nmbr$ - $nmbr$ . $nmbr$ : obese class ii,C3853263
497,ai $nmbr$,C0003504;C4551710
497,$nmbr$ i - $nmbr$ - $nmbr$ ai,C0003504;C0021966;C0221138;C4551710
496,placebo - famotidine $nmbr$ - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
496,placebo - famotidine $nmbr$,C0015620;C0032042;C1696465;C1706408
496,famotidine $nmbr$ - famotidine $nmbr$,C0015620
495,glucagon - like peptide - $nmbr$ receptor agonist,C0014361;C4543206
495,glucagon - like peptide - $nmbr$ agonist,C0014361;C2987634
494,js $nmbr$ - agonists,C0243192;C1552154;C2987634
494,$nmbr$ [ $nmbr$ - $nmbr$ js,C1552154
493,smokers : qva $nmbr$ - $nmbr$ fc,C0337664;C2983605
493,fc - ldl - c  friedewald - calculated,C2983605
492,positive for hla - b $nmbr$  n ( % ),C0019737;C0439178;C0550853;C1415561;C1446409;C1514241;C2825490;C3812269
492,hla - b $nmbr$,C0019737;C0550853;C1415561
491,qids - sr $nmbr$,C4331197
490,a $nmbr$ s - hydroxy -,C0700307
489,cgi - s  n ( % ) z :,C4526016
488,$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t,C0718146
487,plaque score ( $nmbr$ - $nmbr$ ),C0429153
486,sun - $nmbr$ ( $nmbr$ ),C0038817;C0376223
485,tender joint count ( $nmbr$ - $nmbr$ possible joints ),C0240094;C4554549;C4696258
484,$nmbr$ % clf,C3540486;C4553190
483,^ $nmbr$ - cell function — % §,C0007613
482,triglycerides  mmol / lf,C0041004;C0439190;C1416933;C2986618;C4554443
482,ldl - cholesterol  mmol / lf,C0023824;C0202117;C0439190;C1416933;C2986618;C4554443
482,$nmbr$ . $nmbr$ ± $nmbr$ . lf,C1416933;C2986618;C4554443
481,sf ‐ $nmbr$ health survey,C0018762;C0037712
480,sf - $nmbr$ pcs score,C0037712;C1864389;C1882368
480,sf - $nmbr$ pcs  mean ± sd,C0037712;C0444504;C1864389;C1882368;C2347634;C2348143;C2699239
480,sf - $nmbr$ pcs  ls mean change from baseline   ±   se,C0023668;C0036919;C0037712;C0168634;C0392747;C0443172;C0444504;C1442488;C1705241;C1864389;C1882368;C2347634;C2348143;C4319952
480,sf - $nmbr$ pcs,C0037712;C1864389;C1882368
480,sf - $nmbr$ mcs score,C0037712
480,sf $nmbr$ - pcs,C0037712;C1864389;C1882368
479,sf - $nmbr$ mcs  mean ± sd,C0037712;C0444504;C2347634;C2348143;C2699239
479,sf - $nmbr$ mcs,C0037712
478,sf - $nmbr$ summary scores,C0037712;C1552616;C1706244
477,short form $nmbr$ ( sf - $nmbr$ ),C0037712;C2964478
476,rankin scale ≥ $nmbr$,C0451405
475,glucose in urine    ≥ $nmbr$ +,C0004076
474,$nmbr$ ix,C0015491
473,insulin lispro mix $nmbr$ / lispro mix $nmbr$ - insulin glargine / insulin lispro,C0293359
473,insulin lispro mix $nmbr$,C0205430;C0293359;C1421951;C1720722;C4553942
472,indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .,C0439417;C1722260;C3814772
471,indacaterol n = $nmbr$,C1722260
471,indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C1722260
471,indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211;C1722260
471,indacaterol $nmbr$ ug ( n = $nmbr$ ),C0041573;C0439211;C1722260
470,dactylitis in > $nmbr$ digit,C3863761
469,fg > $nmbr$,C0016703;C0439214;C2348814
468,< $nmbr$ . $nmbr$ tng > cll,C0023434
467,alt  ast  or both > $nmbr$ x uln,C3831581
466,ck > $nmbr$ xuln,C0009212;C0010287;C1872855
466,ck > $nmbr$ x uln $nmbr$,C0009212;C0010287;C1519815;C1872855
465,high titre ( > $nmbr$ times of uln )  n ( % ),C0040223;C0205250;C0475208;C1299351;C1519815;C1632851;C2700149;C3887512;C3889660;C4321237;C4522209
465,cpk > $nmbr$ times uln,C0040223;C1519815;C1632851
465,> $nmbr$ uln,C1519815
464,> $nmbr$ rd quartile,C0694666;C2828255;C4553350
464,$nmbr$ rd > $nmbr$ . $nmbr$,C0694666;C4553350
463,hl 土 $nmbr$ . $nmbr$,C1453952;C4085347
462,> $nmbr$ ^ mol / liter — no . ( % ),C0347982
462,( $nmbr$ - sitosterol ( p . mol / l ),C0037215;C0220914;C0347982
461,white - cell count — x $nmbr$ _ $nmbr$ / liter,C0023508;C0427512;C0475211
460,white blood cell count  cellsx $nmbr$,C0023508;C0427512
460,blood leukocyte count ( $nmbr$ cells per l ),C0023508;C0023516;C0347983;C0427512
459,all with coenzyme q $nmbr$ ( n = $nmbr$  $nmbr$ ),C0041536
459,$nmbr$ coenzyme q $nmbr$ subgroups for time to first hospitalization ( number of patients variable ) .,C0040223;C0041536;C1079230;C3541383
458,coenzyme q $nmbr$ p  g / ml #,C0041536;C1300565
458,coenzyme q $nmbr$  ^ g / ml #,C0041536;C1300565
458,coenzyme q $nmbr$,C0041536
457,salbutamol  %,C0001927
457,post - albuterol % predicted fev $nmbr$ mean ( sd ) e,C0001927;C0687676;C1704687;C3469826
457,fev $nmbr$ reversibilityz ( pre / post salbutamol )  %,C0001927;C0332152;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
457,fev $nmbr$ ( post - albuterol )  l,C0001927;C0687676;C1704687;C3469826;C3714541
457,fev $nmbr$  post - albuterol  l,C0001927;C0687676;C1704687;C3469826;C3714541
456,fev $nmbr$ reversibility  pre - / post - albuterol  %,C0001927;C0332152;C0449261;C0687676;C0740175;C1704687;C2257086;C3469826;C3669034;C3714541
456,albuterol reversibility  %,C0001927;C0449261
455,total cholesterol > $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
455,total cholesterol > $nmbr$ ' $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
455,total cholesterol < $nmbr$ - $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
455,total cholesterol < $nmbr$ $nmbr$ mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
455,total cholesterol  mmol / lt,C0023376;C0201950;C0230426;C0439190;C0543421;C3887647;C4521399
455,ldl cholesterol  mmol / lt,C0023376;C0023824;C0202117;C0230426;C0439190;C3887647;C4521399
455,hdl cholesterol  mmol / lt,C0023376;C0023822;C0230426;C0392885;C0439190;C3887647;C4521399
455,fpg  mmol / lt,C0023376;C0230426;C0439190;C3887647;C4521399
455,$nmbr$ . $nmbr$ ± o . lt,C0023376;C0230426;C0483204;C3887647;C4521399
454,shared epitope  a % positive,C0003316;C0237876;C1522138
453,cyp $nmbr$ a $nmbr$ inhibitors,C0243077;C1418793;C2634343
453,cyp $nmbr$ a $nmbr$,C1418793;C2634343
452,range iga modified $nmbr$ score  n ( % ),C1514721;C2348147;C2825347;C3542016
452,iga $nmbr$ / $nmbr$,C2825347
451,$nmbr$ nil,C0442734
450,target nail napsi score ( $nmbr$ – $nmbr$ scale ),C0027342;C1432728;C1521840;C2986546;C3538766
449,nail involvement  %,C0027342;C1314939;C1432728;C3538766
448,patients with eot data  n,C2707520
448,* patient characterization data are reproduced from morrow et al . ( $nmbr$ ) .,C1880022;C2707520
447,percent change from baseline to week $nmbr$ in auc ( mean  sem ),C3272907
447,percent change from baseline at week $nmbr$,C3272907
446,> $nmbr$ ft,C1881534;C3890579
446,< $nmbr$ ft,C1881534;C3890579
446,$nmbr$ - min walk distance  ft,C0429886;C0702093;C1524029;C1881534;C3813700;C3890579
446,$nmbr$ - $nmbr$ ft,C1881534;C3890579
445,type $nmbr$ diabetes 一 no . ( % ),C1320657
445,type $nmbr$ diabetes — no . { % ) §,C1320657
445,type $nmbr$ diabetes — no . ( % ) §,C1320657
445,type $nmbr$ diabetes — no . ( % ),C1320657
445,type $nmbr$ diabetes history  n ( % ),C0019664;C0019665;C0262512;C0262926;C1320657;C1705255;C2004062
445,type $nmbr$ diabetes . n ( % ),C1320657
445,type $nmbr$ diabetes  no . ( % ),C1320657
445,type $nmbr$ diabetes  n ( % ) d,C1320657
445,type $nmbr$ diabetes  n ( % ),C1320657
445,type $nmbr$ diabetes,C1320657
444,type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
444,no type $nmbr$ diabetes ( n = $nmbr$  $nmbr$ ),C1320657
444,duration of type $nmbr$ diabetes categories  n ( % ),C1320657;C1547660
443,type $nmbr$ diabetes mellitus  n ( % ),C1320657
443,type $nmbr$ diabetes mellitus,C1320657
443,individuals with type $nmbr$ diabetes  n ( % ),C0027361;C0237401;C1320657
443,diabetes mellitus ( type $nmbr$ or $nmbr$ ),C1320657
443,diabetes mellitus ( type $nmbr$ )  n ( % ),C1320657
442,type $nmbr$ diabetes mellitusa,C1320657
442,type $nmbr$ diabetes mellitus ’,C1320657
442,type $nmbr$ diabetes meiiitus,C1320657
442,type $nmbr$ diabetes duration  years,C0439234;C0449238;C1320657;C2926735
442,type $nmbr$ diabetes *,C1320657
442,known duration of type $nmbr$ diabetes ( years ),C0205309;C0439234;C0449238;C1320657;C2926735
442,known duration of type $nmbr$ diabetes,C0205309;C0449238;C1320657;C2926735
442,duration of type $nmbr$ diabetes mellitus ( years ),C0439234;C0449238;C1320657;C2926735
442,duration of type $nmbr$ diabetes mellitus  years,C0439234;C0449238;C1320657;C2926735
442,duration of type $nmbr$ diabetes ( years ),C0439234;C0449238;C1320657;C2926735
442,duration of type $nmbr$ diabetes  years,C0439234;C0449238;C1320657;C2926735
442,duration of type $nmbr$ diabetes,C0449238;C1320657;C2926735
441,type $nmbr$ diabetes mellitus ' $nmbr$ ',C1320657
441,rosuva  rosuvastatin  sd  standard deviation  t $nmbr$ dm  type $nmbr$ diabetes mellitus .,C0011816;C0011849;C0332307;C0871420;C0965129;C1320657;C1547052;C2699239;C3250443
440,dpp ‐ $nmbr$ inhibitors,C0243077;C1414174
440,dpp - $nmbr$ inhibitors,C0243077;C1414174
440,dpp - $nmbr$,C1414174
439,less than $nmbr$ kg / m $nmbr$,C0439092;C1532718
438,less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0369637;C0439092;C0439445;C0441923
438,less than $nmbr$ . $nmbr$ %,C0439092
438,less than $nmbr$ %,C0439092
437,less than $nmbr$ year,C0439092;C0439234;C0439508
437,less than $nmbr$,C0439092
436,more than $nmbr$ vessels stented,C0005847;C0205172
436,more than $nmbr$ lesions per vessel,C0205172
435,mean blood pressure  mmhg ( s . d . j,C0428886;C0488053;C2347155
434,mean arterial pressure  last,C0428886
434,mean arterial pressure  baseline,C0168634;C0428886;C1442488
433,£ $nmbr$ m b ' m in,C1709500
432,dupilumab $nmbr$,C3660996
431,brain volume  cm ',C1113695
431,brain volume  cm $nmbr$,C1113695
430,prevention )  n ( % ) patients on llt ( other than statin )  n ( % ),C0030705;C0199176;C1706420;C2347090;C2700409
430,gissi prevention $nmbr$ / $nmbr$ - $nmbr$ / $nmbr$,C0199176;C1706420;C2700409
429,section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
429,section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
429,section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
428,protein in urine    ≥ $nmbr$ +,C0033687
427,proteinuria ( > $nmbr$ g / $nmbr$ h )  %,C0033687;C0560020;C1962972;C4554346
427,proteinuria $nmbr$ ( g / day ),C0033687;C0439417;C1962972;C4554346
426,alcohol use ( > $nmbr$ drink / wk ),C0001948;C0042153;C0332174;C0439230;C0452428;C0457083;C0556297;C1947944
426,> $nmbr$ drinks / wk,C0452428
426,> $nmbr$ drinks / week,C0452428
426,> $nmbr$ drinks / dav,C0452428
426,> $nmbr$ drinks,C0452428
426,> $nmbr$ ( $nmbr$ ) drinks / day if male ( female ),C0452428
426,$nmbr$ drinks / wk,C0452428
426,$nmbr$ drinks,C0452428
426,$nmbr$ - $nmbr$ drinks / wk,C0452428
426,$nmbr$ - $nmbr$ drinks / dav,C0452428
426,$nmbr$ - $nmbr$ drinks,C0452428
426,$nmbr$ + drinks / wk,C0452428
425,£ l $nmbr$ kg,C1637390
424,$nmbr$ - h ppg ( mmol / l ) *,C1418888;C2827804
424,$nmbr$ - h ppg ( mmol / l ),C1418888;C2827804
423,ppg  mmol / l,C1418888;C1532563
423,$nmbr$ - hour ppg  mmol / l,C0439227;C0564385;C1418888;C1532563
422,$nmbr$ - h pmg ( mmol / l ),C2827804
422,$nmbr$ - h pmg  mmol / l ( mean ± sd ),C0444504;C2347634;C2348143;C2699239;C2827804
421,> l : $nmbr$ hrs : min ( n = $nmbr$ ),C0439393;C1568891
421,> = $nmbr$ l_ / min,C0439393
421,> = $nmbr$ l / min,C0439393
421,< $nmbr$ l / min,C0439393
420,> $nmbr$ / $nmbr$ lung fields,C0225759
419,> $nmbr$ to < $nmbr$ iu / l,C0439457
419,> $nmbr$ iu / l,C0439457
418,platelet  $nmbr$ / l,C0456525
417,tnl ultrapositive > $nmbr$ . $nmbr$ pg / l  $nmbr$ = $nmbr$,C0439278;C1540071
416,total bilirubin  mg / dl,C0005437;C0368753;C0439269
415,total bilirubin > $nmbr$ x uln $nmbr$,C0005437;C0368753;C1519815
414,eda  %,C0162359;C1539327;C3539920;C3887494
413,lda  %,C4553195
412,selena - sledai activity  n ( % ),C0205177;C0439167;C0441655;C0451528;C1561536;C3668946;C4049938;C4049939
412,selena - sledai > $nmbr$  %,C0451528
411,dip involvement  ! n ( % ),C1314939;C3539618
410,organ system involvement  no . ( % ),C0460002;C1314939
409,affected body - surface area > $nmbr$ % — no . { % ),C0005902;C0205148;C0392760;C1314939;C1879646
408,psoriasis affecting > $nmbr$ % of body - surface,C0033860;C0392760;C0489451;C1314939
407,sri ‐ $nmbr$ response rate  %,C0237629;C1420401
406,treated with laba  %,C0332293
405,preferred term  %,C1709637;C2347664
404,diffusion capacity of the lung for carbon monoxide  % predicted !,C0231971
403,reversibility to salbutamol  %,C1271924
402,hematocrit  %,C0018935;C0518014
401,family history of myocardial infarction prior to age $nmbr$  %,C0455406
400,older subjects ( aged > $nmbr$ years ',C0580836
400,older des ( n = $nmbr$ ),C0011702;C0580836;C4551552
399,younger subjects ( aged < $nmbr$ years ),C0332239
399,younger patients ( aged $nmbr$ years ),C0030705;C0332239
398,lei > $nmbr$ ( n = $nmbr$ ),C0023401;C0428209
398,lei $nmbr$,C0023401;C0428209
398,lei  mean ( sd ),C0023401;C0428209;C0444504;C2347634;C2348143;C2699239
397,mean platelet volume  fl,C0200665;C0344388;C1300812;C1708024
397,fl ( $nmbr$ b ),C1300812;C1708024
397,fl ( $nmbr$ . $nmbr$ ),C1300812;C1708024
396,nihss score,C1697238
396,nihss at baseline,C0168634;C1442488;C1697238
396,baseline nihss score ( % ) #,C0168634;C1442488;C1697238
396,baseline nihss score  median ( range ),C0168634;C1442488;C1697238
396,baseline nihss,C0168634;C1442488;C1697238
395,nih stroke scale,C1697238;C3484372
395,baseline nih stroke scale — no . ( % ) ^,C0168634;C1442488;C1697238;C3484372
394,haq pain score,C0102923;C0451208;C0582148
393,haq score,C0102923;C0451208
393,haq alternative disability score,C0102923;C0231170;C0449820;C0451208;C1523987;C4050231
392,haq pain scale  mean,C0102923;C0444504;C0451208;C1504479;C2347634;C2348143
392,haq,C0102923;C0451208
392,baseline haq mean ( s . e . ),C0102923;C0168634;C0444504;C0451208;C1442488;C2347634;C2348143
391,a mini - mental state examination  insulin glargine vs standard care,C0451306;C0907402
390,insulin glargine allocation,C0907402;C1706778
390,glargine allocation,C0907402;C1706778
389,insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
389,air insulin - insulin glargine - air insulin / insulin glargine,C0001861;C0907402;C3536832
389,air insulin - air insulin / insulin glargine,C0001861;C0907402;C3536832
388,treatment glargine,C0039798;C0087111;C0907402;C1522326;C1533734;C1705169;C3538994;C3887704
388,glargine,C0907402
387,insulin glargine n ( % ) / $nmbr$ py,C0030428;C0907402;C3538810
387,glargine n ( n / loopy ),C0907402
386,glargine $nmbr$,C0907402
386,detemir / insulin glargine  %,C0537270;C0907402
385,number insulin glargine,C0237753;C0449788;C0907402
385,insulin glargine vs standard care least - squares mean ( $nmbr$ % cl ),C0907402
384,insulin glargine n ( x ),C0907402
384,insulin glargine + insulin lispro ( award - $nmbr$  n = $nmbr$ ),C0004446;C0293359;C0907402
384,insulin glargine ( n = $nmbr$ ll ),C0907402
384,insulin glargine ( n = $nmbr$ ),C0907402
384,insulin glargine,C0907402
384,all dulaglutide $nmbr$ . $nmbr$ mg + insulin lispro / insulin glargine ( n = $nmbr$ ),C0024671;C0026410;C0293359;C0439269;C0907402;C1960952;C2346927;C3179549;C4321396;C4521761
383,insulin glargine   ±   oad   +   od prandial,C0229089;C0439164;C0907402;C1512019;C3273373;C3665488
382,insulin glargine   ±   oad   +   bd prandial,C0005126;C0907402;C2344255;C4050145
382,insulin glargine   ±   oad   +   > bd prandial,C0005126;C0907402;C2344255;C4050145
382,insulin glargine   ±   oad,C0907402
381,others  classes i and iiic,C0441885;C1319793;C1955473;C2698967;C3539125
381,class i or no symptoms,C0441885;C1319793;C2698967
381,class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967
380,heart failure ( class i — iii ),C0018801;C0018802;C0021966;C0221138;C0439070;C0441885;C0441887;C1319793;C1705160;C2698967;C2698969;C4554158
380,class i,C0441885;C1319793;C2698967
379,nyha class i,C1882084
379,baseline heart failure severity nyha class i,C0018801;C0018802;C0168634;C0439793;C0522510;C1442488;C1882084;C4554158
378,class iv glomerulonephritis,C0017658;C0441888;C2698970
377,class iv only,C0205171;C0441888;C1720467;C2698970
377,class iv,C0441888;C2698970
376,angina class iii or iv — no . ( % ),C0264677
376,angina class iii or iv prior myocardial infarction,C0264677
376,angina class iii or iv prior,C0264677
375,§ classes on the canadian cardiovascular society ( ccs ) scale range from i to iv,C0007226;C0037455;C0175659;C0238884;C0349674;C1514721;C1879987;C1947916;C2348147;C3542016;C3887460
375,ccs class §,C1879987
374,nyha functional class iii ( % ),C0205245;C0542341;C1882086;C2700217
374,nyha functional class iii,C0205245;C0542341;C1882086;C2700217
374,nyha class iii or iv ( n = $nmbr$ ),C1882086
374,nyha class iii or iv  n ( % ),C1882086
374,nyha class iii  % ( n ),C1882086
374,nyha class iii,C1882086
373,nyha class ii ( n = $nmbr$ l $nmbr$ ),C1882085
373,nyha class ii ( n = $nmbr$ ),C1882085
373,nyha class ii,C1882085
373,nyha class > ii,C1882085
373,nyha class  n ( % ) ii,C1882085
372,nyha class iv,C1882087
371,nyha classes iii - iv,C0278962
371,nyha class iii / iv,C0278962
370,class iii,C0441887;C2698969
369,> $nmbr$ : obese class iii,C1319441
368,renal biopsy class,C0194073;C0456387;C1518526;C1705943
367,class $nmbr$ or no symptoms,C0456387;C1518526;C1705943
367,class $nmbr$ antiarrhythmic agents,C0003195;C0301380;C0456387;C1518526;C1705943
366,claudication ( fontaine class > $nmbr$ ),C0021775;C0311395;C0456387;C1456822;C1518526;C1705943
366,class > $nmbr$,C0456387;C1518526;C1705943
365,modified acc / aha lesion class b $nmbr$ or cj,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
365,modified acc / aha lesion class b $nmbr$ / c,C0050451;C0101856;C0221198;C0392747;C0456387;C0772110;C1518526;C1546698;C1705943;C3889737
365,modified acc - aha lesion class b $nmbr$ or c,C0221198;C0392747;C0456387;C1518526;C1546698;C1705943;C3889737;C4072694
365,kilip class,C0456387;C1518526;C1705943
365,class ll - iv,C0456387;C1518526;C1705943
365,class l / ll heart failure,C0456387;C1518526;C1705943
365,class ic,C0020750;C0456387;C1518526;C1705943;C4554818
365,class ib,C0456387;C1518526;C1705943;C2744579;C3890035;C4283819
365,class ia,C0020980;C0456387;C0694634;C1518526;C1705943;C1947960
365,class $nmbr$,C0456387;C1518526;C1705943
365,acc / aha lesion class b $nmbr$ or c  n ( % ),C0221198;C0456387;C1518526;C1546698;C1705943;C4072694
364,with higher classes indicating greater limitations on physical activity owing to,C0205250;C0456387;C1518526;C1705943;C4019422
364,egfr in $nmbr$ classes,C0456387;C1518526;C1705943;C1739039;C3811844;C3812682;C4019422
364,calculated ldl - c in $nmbr$ classes,C0444686;C0456387;C1441506;C1518526;C1705943;C4019422
364,baseline trl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C4019422
364,baseline lp ( a ) in $nmbr$ classes,C0065058;C0168634;C0456387;C1439335;C1442488;C1518526;C1705943;C4019422;C4553379
364,baseline hdl - c in $nmbr$ classes,C0168634;C0456387;C1442488;C1518526;C1705943;C3715113;C4019422
364,baseline hba $nmbr$ c in $nmbr$ classes,C0019016;C0168634;C0456387;C1442488;C1518526;C1705943;C1825777;C3538758;C4019422
364,baseline albumin / creatinine ratio in $nmbr$ classes,C0168634;C0456387;C0486293;C1318293;C1442488;C1518526;C1705943;C4019422
364,age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
363,tass ’,C0559483
362,killip class ( interaction : p = $nmbr$ . $nmbr$ ),C1704675;C1881332
362,killip class $nmbr$ / $nmbr$,C1881332
361,killip class,C1881332
361,baseline killip class,C0168634;C1442488;C1881332
361,< $nmbr$ baseline killip class,C0168634;C1442488;C1881332
360,killip class — no . / total no . ( % ) i,C1881332
360,killip class — no . ( % ) i,C1881332
360,killip class at admission — no . / total no . ( % ),C0184666;C0809949;C1881332
360,killip class > $nmbr$  no . ( % ),C1881332
360,killip class *,C1881332
360,killip class $nmbr$,C1881332
360,killip class  n ( % ) i,C1881332
360,killip class  n ( % ),C1881332
359,nyha_class,C1882083
359,nyha class — no . ( % ) $,C1882083
359,nyha class — no . ( % ),C1882083
359,nyha class within past month — no . / total no . ( % ),C1882083;C4331910
359,nyha class not reported,C1882083
358,nyha class ( when patient was last in stable condition,C1882083
358,male nyha class,C0086582;C1706180;C1706428;C1706429;C1882083
357,nyha class $nmbr$ - $nmbr$ : no { n = llll ),C1882083
357,nyha chf class,C0018802;C1882083
357,new york heart association congestive heart failure class,C0018802;C1882083
357,new york heart association class,C1882083
356,systolic bp  mm hg ( mean ) nyha class,C0039155;C0439475;C0444504;C0488053;C0871470;C1882083;C2347634;C2348143
356,nyha class $nmbr$ or higher,C1882083
356,nyha class,C1882083
355,nyha functional class at screening,C0205245;C0220908;C0220909;C0542341;C1698960;C1710031;C1710032;C1710477;C1882083;C2348164;C2700217
355,nyha functional class at randomization,C0034656;C0205245;C0542341;C1882083;C2700217
355,nyha functional class ( % ),C0205245;C0542341;C1882083;C2700217
355,nyha functional class $nmbr$,C0205245;C0542341;C1882083;C2700217
355,nyha functional class  n ( % ),C0205245;C0542341;C1882083;C2700217
355,nyha functional class,C0205245;C0542341;C1882083;C2700217
355,nyha class ( when patient was last in stable condition before admission )  %,C1882083
355,nyha class  n ( % ) i,C1882083
355,nyha class  n ( % ),C1882083
355,nyha class  ( % ),C1882083
354,prior bypass graft surgery,C0185098;C0455610
354,bypass graft §,C0185098
353,bypass graft,C0185098
353,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty  cabg  coronary artery bypass graft  ace  angiotensin - converting enzyme  bmi  body mass index ( calculated as weight in kilograms divided by square of height in meters )  hdl - c  high - density lipoprotein cholesterol  ldl - c  low - density lipoprotein cholesterol  fpg  fasting plasma glucose  and fpi  fasting plasma insulin . tto convert cholesterol values to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter  multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter  multiply by $nmbr$ . $nmbr$ .,C0005910;C0015663;C0022709;C0023821;C0023824;C0041061;C0043100;C0185098;C0202042;C0205369;C0441074;C0444686;C0455280;C0475211;C0857690;C1305855;C1305866;C1441506;C1511726;C1705104;C1719797;C2911648;C2936173;C3245479;C3714741
352,coronary bypass graft,C1260596
352,coronary artery bypass graft  n ( % ),C0010055;C1260596
352,coronary artery bypass graft,C0010055;C1260596
351,coronar y - artery bypass grafting,C0450140;C0741847
351,arterial graft,C0450140
350,intra - abdominal abscess ( past ),C0243001;C1444637;C4284302
349,past or never,C1444637;C4284302
349,past or current angina pectoris,C1444637;C4284302
349,past or current,C1444637;C4284302
349,past only,C0205171;C1444637;C1720467;C4284302
348,smoking past,C0037369;C0453996;C1444637;C1881674;C4284302
348,smoking in past yr,C0037369;C0439234;C0453996;C1444637;C1881674;C4284302
348,past smoking,C0037369;C0453996;C1444637;C1881674;C4284302
348,past,C1444637;C4284302
347,current / past,C0521116;C1444637;C1705970;C4284302
346,past smoker,C0337664;C1444637;C4284302
346,past or nonsmoker ( n = $nmbr$ ),C1444637;C4284302
346,past or nonsmoker,C1444637;C4284302
346,current / past smoker,C1444637;C3173209;C3241966;C4284302
345,heparin dose regimen,C0019134;C0770546;C2348331
344,heparins and fondaparinux,C0019134
344,heparin  ‘ ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546
344,heparin  fondaparinux or brvalirudin use between - oex event,C0019134;C0770546;C1098510
343,additional heparin,C0019134;C0770546;C1524062
342,heparin pre - randomization,C0019134;C0034656;C0332152;C0740175;C0770546;C2257086;C3669034
342,heparin at randomization,C0019134;C0034656;C0770546
342,heparin,C0019134;C0770546
341,unfractionated heparin — no . ( % ),C0019134;C2825026
341,unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % ),C0019134;C2825026
341,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0019134;C2825026
341,unfractionated heparin before randomisation,C0019134;C0034656;C2825026
341,unfractionated heparin ( n = $nmbr$ ),C0019134;C2825026
341,unfractionated heparin ( n = $nmbr$  $nmbr$ ),C0019134;C2825026
341,unfractionated heparin,C0019134;C2825026
341,neither unfractionated heparin nor low - molecular - weight heparin,C0019134;C2825026
341,both unfractionated heparin and low - molecular - weight heparin,C0019134;C2825026
340,non - pci intravenous unfractionated heparin,C0354566;C1518422;C4049621
340,intravenous heparin,C0354566
339,psoriasis characteristics,C0033860;C1521970
338,characteristics no . of participants,C1521970
338,characteristic_level,C0441889;C0456079;C1521970;C1547707;C2946261
337,metabolic syndrome ( > $nmbr$ of $nmbr$ characteristics ),C0524620;C1521970
337,characteristic ( a ),C1521970
336,characteristic †,C1521970
336,anthropometric characteristics,C0003188;C1521970
335,characteristic  no . ( % ),C1521970
335,angiographic characteristics  no . ( % ),C0002978;C1521970
334,ed characteristics,C1521970;C3538926
333,e ( characteristic n,C1521970
333,characteristic_name,C0027365;C1521970;C1547383;C4522128
332,characteristics of pulmonary embolism at inclusion,C0034065;C1521970
331,infarct characteristics,C0021308;C1521970
331,characteristic ^,C1521970
330,treatment characteristics,C0039798;C0087111;C1521970;C1522326;C1533734;C1705169;C3538994;C3887704
330,characteristics,C1521970
330,characteristic and treatment,C1521970
329,surgical technique post - randomisation characteristic * *,C0034656;C0683469;C0687676;C1521970;C1704687;C3469826
329,characteristics *,C1521970
329,characteristic *,C1521970
329,characteristic,C1521970
328,number ( s ) of features present,C0237753;C0449788;C1521970;C1706388;C2346469;C2348519
328,feature,C1521970;C1706388;C2346469;C2348519
328,baseline feature,C0168634;C1442488;C1521970;C1706388;C2346469;C2348519
328,angiographic features,C0002978;C1521970;C1706388;C2346469;C2348519
327,nicotine pack - years,C0028040;C1277691
326,smoking consumption pack - years,C0425291;C1277691
325,smoking history ( pack - years ) ∗,C1277691;C1519384
325,smoking history ( pack - years ),C1277691;C1519384
325,smoking history  pack - years,C1277691;C1519384
324,smoking pack - years,C0037369;C0453996;C1277691;C1881674
324,smoking * ( > $nmbr$ pack - years ),C0037369;C0453996;C1277691;C1881674
324,pack - years smoked,C1277691
324,mean ( sd ) duration of smoking  pack - years,C0037369;C0444504;C0449238;C0453996;C1277691;C1881674;C2347634;C2348143;C2699239;C2926735
323,pack - years ( iqr ),C1277691
323,history ( pack - years ),C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
323,history  pack - years,C0019664;C0019665;C0262512;C0262926;C1277691;C1705255;C2004062
322,total pack - years mean ( sd ),C0439175;C0439810;C0444504;C1277691;C2347634;C2348143;C2699239
322,pack years,C1277691
321,total pack - yrs,C0439175;C0439810;C1968515;C2825051;C2828395
321,smoking history ( pack - yr ),C0439234;C1519384;C1968515;C2825051;C2828395
321,no . of pack - yr,C0439234;C1968515;C2825051;C2828395
320,bundle branch block,C0006384;C1879286
319,left bundle - branch block,C0023211;C0344420;C2828132
318,black hispanic - n ( % ),C1533017;C1533018
318,black hispanic,C1533017;C1533018
317,worldwide non - black patients,C0005680;C0027567;C0085756;C0439541;C1829939
317,worldwide black patients,C0005680;C0027567;C0030705;C0085756;C0439541
317,non - black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541;C1518422
317,non - black  worldwide,C0005680;C0027567;C0085756;C0439541;C1518422
317,non - black,C0005680;C0027567;C0085756;C0439541;C1518422
317,hispanic black,C0005680;C0027567;C0085756;C0086409;C0439541
317,black non - hispanic - n ( % ),C0005680;C0027567;C0085756;C0439541;C1518422;C1518424;C1533017;C1533018
317,black / non - black,C0005680;C0027567;C0085756;C0439541;C1518422
317,black  worldwide,C0005680;C0027567;C0085756;C0439541
317,a : worldwide black and non - black patients,C0005680;C0027567;C0085756;C0439541
317,* non - black *,C0005680;C0027567;C0085756;C0439541;C1518422
316,non - black  us,C0005680;C0027567;C0085756;C0439541;C1518422
316,black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ) ■ -,C0005680
316,black race  n ( % ),C0005680
316,black *,C0005680;C0027567;C0085756;C0439541
316,black ( n — $nmbr$ ),C0005680;C0027567;C0085756;C0439541
316,black ( n   = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
316,black ( n = $nmbr$ )  adjusted hazard ratio *,C0005680;C0027567;C0085756;C0439541;C0456081;C2985465
316,black ( n = $nmbr$ ),C0005680;C0027567;C0085756;C0439541
316,black  us,C0005680;C0027567;C0085756;C0439541
316,black  no . ( % ),C0005680;C0027567;C0085756;C0439541
316,black  n ( % ),C0005680;C0027567;C0085756;C0439541
316,$nmbr$ fe black *,C0005680;C0027567;C0085756;C0439541;C3848561
315,white : black : other,C0005680;C0007457;C0027567;C0043157;C0085756;C0220938;C0439541
315,u . s . non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541;C1829939
315,u . s . black patients,C0005680;C0027567;C0030705;C0041703;C0085756;C0439541
315,black race — no . / total no . ( % ) f,C0005680;C0027567;C0085756;C0439541
315,black and other,C0005680;C0027567;C0085756;C0439541
315,black /,C0005680;C0027567;C0085756;C0439541
315,black,C0005680;C0027567;C0085756;C0439541
315,b : u . s . black and non - black patients,C0005680;C0027567;C0041703;C0085756;C0439541
314,non - black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
314,non - black race and ss < $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
314,non - black race ( n = $nmbr$ vs $nmbr$ ),C0005680;C1518422
314,black race and ss > $nmbr$ ( n = $nmbr$ vs $nmbr$ ),C0005680
314,black race ( n = $nmbr$ vs $nmbr$ ),C0005680
314,black race,C0005680
313,placebo no . of events / total no . ( % ),C0032042;C1696465;C1706408
313,placebo no . of events / no .,C0032042;C1696465;C1706408
313,placebo no . / total no .,C0032042;C1696465;C1706408
313,placebo no . / total ( % ),C0032042;C1696465;C1706408
313,placebo /,C0032042;C1696465;C1706408
313,no . of patients ( indacaterol / placebo ),C0030705;C0032042;C1696465;C1706408;C1722260
313,dapagliflozin placebo no . of events / no . of patients,C0032042;C1696465;C1706408;C2353951
312,placebo / simvastatin,C0032042;C0074554;C1696465;C1706408
312,placebo / simva,C0032042;C1696465;C1706408
312,placebo / rosu vastatin,C0032042;C1099881;C1696465;C1706408
312,placebo + $nmbr$ mg / d of simvastatin,C0032042;C0074554;C0439422;C1696465;C1706408
311,randomization to placebo or telmisartan,C0032042;C0034656;C1696465;C1706408
311,placebo §,C0032042;C1696465;C1706408
311,placebo arm,C0032042;C0446516;C1696465;C1706408;C3715044;C4553528
311,placebo allocation,C0032042;C1696465;C1706408;C1706778
311,duration from clopidogrel / placebo to pci  min ( median  iqr ),C0032042;C0070166;C0449238;C1696465;C1706408;C2926735
310,with placebo,C0032042;C1696465;C1706408
310,placebo patients with events / total,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo patients with events,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo events / patients (,C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo events / n ( % ),C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo ( events / n ( % ) ),C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo  events / patients ( % ),C0030705;C0032042;C0441471;C1696465;C1706408;C3541888
310,placebo,C0032042;C1696465;C1706408
310,$nmbr$ placebo,C0032042;C1696465;C1706408
309,stent plus placebo,C0032042;C0038257;C0332287;C1696465;C1706408
309,pooled placebo,C0032042;C1696465;C1706408;C1709595;C2349200;C4522255
309,placebo plus aspirin,C0004057;C0032042;C0332287;C1696465;C1706408
309,mtx plus placebo,C0025677;C0032042;C0332287;C1417487;C1696465;C1706408
309,aspirin plus placebo ( n = $nmbr$ ),C0004057;C0032042;C0332287;C1696465;C1706408
308,comparison with placebo ( mean,C0032042;C0444504;C1696465;C1706408;C1707455;C2347634;C2348143
308,comparison with placebo,C0032042;C1696465;C1706408;C1707455
307,placebo * ( add on to basal insulin ),C0032042;C0650607;C1696465;C1706408;C1883712
306,placebo mean change ( sd ),C0032042;C0392747;C0443172;C0444504;C1696465;C1705241;C1706408;C2347634;C2348143;C2699239;C4319952
306,placebo mean,C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
306,placebo estimated mean,C0032042;C1696465;C1706408
305,placebo pts / n ( % ),C0032042;C1419129;C1696465;C1706408;C2698747
305,placebo n / n ( % ),C0032042;C1696465;C1706408
305,placebo n / n,C0032042;C1696465;C1706408
305,placebo n ( % ),C0032042;C1696465;C1706408
305,placebo n,C0032042;C1696465;C1706408
305,placebo mean ( n ),C0032042;C0444504;C1696465;C1706408;C2347634;C2348143
305,placebo ls means ( n ),C0023668;C0032042;C1696465;C1704970;C1706408
305,placebo croup  n / n ( % ),C0010380;C0032042;C1696465;C1706408
305,placebo ( n z $nmbr$ ),C0032042;C1696465;C1706408
305,placebo ( lsm ),C0032042;C1696465;C1706408
305,placebo  n / n ( % ),C0032042;C1696465;C1706408
305,placebo  n ( % ),C0032042;C1696465;C1706408
305,placebo  % > ( n / n ),C0032042;C1696465;C1706408
305,placebo  % ( n / n ),C0032042;C1696465;C1706408
305,n - $nmbr$ fatty acids - placebo lsm ( $nmbr$ % cl ),C0015684;C0032042;C0369718;C0441922;C0596019;C1696465;C1706408
305,feno placebo ( lsm ),C0032042;C1696465;C1706408
305,chf on placebo ( % ),C0018802;C0032042;C1696465;C1706408
304,with placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
304,placebo - adjusted mean difference in % hba $nmbr$ c ( $nmbr$ % ci  [ p value ] ),C0032042;C1696465;C1706408
304,placebo ( n — $nmbr$ ),C0032042;C1696465;C1706408
304,placebo $nmbr$ / $nmbr$,C0032042;C1696465;C1706408
304,placebo $nmbr$  $nmbr$,C0032042;C1696465;C1706408
304,placebo $nmbr$,C0032042;C1696465;C1706408
304,hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l )  % [ mmol / mol ]  la  n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),C0019016;C0023031;C0023749;C0030705;C0032042;C0036919;C0168634;C0230347;C0392747;C0443172;C1442488;C1532563;C1696465;C1705241;C1706408;C1719767;C1825777;C2346906;C2348589;C2699239;C3538758;C3829066;C4319952;C4553351
304,difference from placebo ( $nmbr$ % cl ),C0032042;C0596019;C1696465;C1705241;C1705242;C1706408
304,difference ( tiotropium - placebo ) ml ( $nmbr$ % ci ),C0008107;C0032042;C0213771;C0439526;C1696465;C1705224;C1705241;C1705242;C1706408;C3259781;C3887665
304,difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year ),C0032042;C0036919;C0439234;C0439508;C1696465;C1705241;C1705242;C1706408;C4330985;C4554674
304,- $nmbr$ placebo,C0032042;C1696465;C1706408
303,placebo ( n = $nmbr$ i $nmbr$ ),C0032042;C1696465;C1706408
303,placebo ( n = $nmbr$ ) i -,C0032042;C1696465;C1706408
303,placebo  n = i $nmbr$,C0032042;C1696465;C1706408
303,i placebo ( n = $nmbr$ ),C0021966;C0032042;C0221138;C1696465;C1706408
303,i placebo,C0021966;C0032042;C0221138;C1696465;C1706408
302,placebo + statin ( n = $nmbr$  $nmbr$ ),C0032042;C0360714;C1696465;C1706408
302,placebo + statin,C0032042;C0360714;C1696465;C1706408
302,placebo + glimepiride,C0032042;C0061323;C1696465;C1706408
302,losartan + placebo,C0032042;C0126174;C1696465;C1706408
301,placebo km %,C0032042;C1696465;C1706408;C3887676
301,placebo analysed ( % ),C0032042;C1696465;C1706408
301,placebo ( % ),C0032042;C1696465;C1706408
301,placebo %,C0032042;C1696465;C1706408
301,placebo $nmbr$ year km ( % ),C0032042;C0439234;C0439508;C1696465;C1706408;C3887676
301,macce ( % ) abciximab placebo,C0032042;C0288672;C1696465;C1706408
301,difference from placebo * ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
301,difference from placebo ( $nmbr$ % ci ),C0008107;C0032042;C1696465;C1705241;C1705242;C1706408;C3259781
300,placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ ),C0024671;C0026410;C0032042;C0439269;C1176308;C1696465;C1706408;C1960952;C2346927;C4321396;C4521761
300,placebo mdi,C0032042;C0993596;C1696465;C1706408;C1839839;C4049613
300,placebo ( n : $nmbr$ ),C0032042;C1696465;C1706408
300,placebo ( n $nmbr$ ),C0032042;C1696465;C1706408
300,canvas ( n = $nmbr$ ) : placebo ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ )  cana $nmbr$ mg ( n = $nmbr$ ),C0032042;C1319635;C1418845;C1696465;C1706408;C3281223
299,placebo no . ( $nmbr$ - y km % ),C0032042;C1696465;C1706408
299,placebo ( n - $nmbr$ . $nmbr$ ),C0032042;C1696465;C1706408
299,placebo ( n - $nmbr$ ),C0032042;C1696465;C1706408
299,placebo ( $nmbr$  $nmbr$ . $nmbr$ % ),C0032042;C1696465;C1706408
299,placebo $nmbr$ . $nmbr$ pt yrs,C0032042;C0032743;C0699718;C1696465;C1706408
299,placebo $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
299,copd - placebo ( $nmbr$ pt ) n . ( % ),C0024117;C0032042;C0032743;C0699718;C1412502;C1696465;C1706408;C3714496
298,rerandomization to placebo ( n = $nmbr$ ) f,C0016327;C0032042;C1696465;C1706408
298,placebo |,C0032042;C1696465;C1706408
298,placebo n ( rate ) $nmbr$,C0032042;C0871208;C1521828;C1696465;C1706408
298,placebo group ( n = $nmbr$ ) ’ j ',C0032042;C0441844;C1696465;C1706408
298,placebo every $nmbr$ weeks ( n = $nmbr$ ),C0032042;C1696465;C1706408
298,placebo [ n = $nmbr$ |,C0032042;C1696465;C1706408
298,placebo ( n = $nmbr$ o ),C0032042;C1696465;C1706408
298,placebo ( n = $nmbr$ * ),C0032042;C1696465;C1706408
298,placebo ( n = $nmbr$ ) ',C0032042;C1696465;C1706408
298,placebo ( n $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
298,placebo ( n $nmbr$ $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
298,placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
298,placebo  n *,C0032042;C1696465;C1706408
298,placebo  n ( rate ),C0032042;C0871208;C1521828;C1696465;C1706408
298,placebo  n,C0032042;C1696465;C1706408
298,baseline to eom placebo ( n = $nmbr$ ),C0032042;C0168634;C0241886;C1442488;C1696465;C1706408
297,placebo dr = $nmbr$ ),C0013014;C0031831;C0032042;C1696465;C1706408;C1707664;C2348314;C3540849
297,placebo ( » = $nmbr$ ),C0032042;C1696465;C1706408
297,placebo ( « = $nmbr$ ),C0032042;C1696465;C1706408
297,= placebo  eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .,C0032042;C0076172;C1422793;C1550452;C1696465;C1704788;C1706408;C2983605;C3539107;C3888054;C4554402
296,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0018623;C0018787;C0027976;C0030705;C0032042;C0032615;C0042508;C0201950;C0428772;C0439849;C0488728;C0543421;C0596019;C0596306;C0699792;C1275491;C1696465;C1704610;C1706408
296,statin + placebo ( n = $nmbr$ ),C0032042;C0360714;C1696465;C1706408
296,placebo plus statin ( n = $nmbr$ ),C0032042;C0332287;C0360714;C1696465;C1706408
296,placebo no diabetes n = $nmbr$,C0032042;C1696465;C1706408
296,placebo n = $nmbr$ subjects,C0032042;C1696465;C1706408
296,placebo n = $nmbr$ n ( % ),C0032042;C1696465;C1706408
296,placebo n = $nmbr$,C0032042;C1696465;C1706408
296,placebo monthly ( n = $nmbr$ ),C0032042;C0332177;C1696465;C1706408
296,placebo group ( n = $nmbr$ ) f,C0016327;C0032042;C0441848;C1696465;C1706408
296,placebo group ( n = $nmbr$ ),C0032042;C0441848;C1696465;C1706408
296,placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0027361;C0032042;C0439234;C0441848;C1696465;C1706408;C2347489
296,placebo dn = $nmbr$ ),C0032042;C1333964;C1696465;C1706408;C1707618
296,placebo diabetes n = $nmbr$,C0011847;C0011849;C0032042;C1696465;C1706408
296,placebo + insulin glargine ( award - $nmbr$  n = $nmbr$ ),C0004446;C0032042;C0907402;C1696465;C1706408
296,placebo + insulin ( n   = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
296,placebo + insulin ( n = $nmbr$ ),C0021641;C0032042;C1533581;C1579433;C1696465;C1706408;C3714501
296,placebo ( w = $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n   =   $nmbr$ ) b,C0032042;C1696465;C1706408
296,placebo ( n   =   $nmbr$ ) a,C0032042;C1696465;C1706408
296,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n   =   $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n   =   $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n   = $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n   = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n = l $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ l ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ ) †,C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ ) n ( % ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ )  n ( % ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$  $nmbr$ ),C0032042;C1696465;C1706408
296,placebo ( n = $nmbr$,C0032042;C1696465;C1706408
296,placebo ( $nmbr$ = $nmbr$ ),C0032042;C1696465;C1706408
296,placebo  n   =   $nmbr$,C0032042;C1696465;C1706408
296,placebo  n = l $nmbr$,C0032042;C1696465;C1706408
296,placebo  n = $nmbr$,C0032042;C1696465;C1706408
296,placebo  ( n = $nmbr$ ),C0032042;C1696465;C1706408
296,placebo  $nmbr$ . $nmbr$ ml ( n = $nmbr$ ),C0032042;C0439526;C1696465;C1705224;C1706408;C3887665
296,$nmbr$ placebo n = $nmbr$,C0032042;C1696465;C1706408
295,tiotropium + placebo ( n [ $nmbr$ ),C0032042;C0213771;C1696465;C1706408
295,placebo n [ $nmbr$,C0032042;C1696465;C1706408
295,placebo [ n z $nmbr$ ],C0032042;C1696465;C1706408
295,placebo [ n = $nmbr$ ],C0032042;C1696465;C1706408
295,placebo ( n [ $nmbr$ ),C0032042;C1696465;C1706408
295,laba plus ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C0332287;C0815320;C1696465;C1706408;C4551720
295,laba ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),C0032042;C0213771;C1696465;C1706408
295,( tiotropium n = $nmbr$  placebo n =,C0032042;C0213771;C1696465;C1706408
295,( tiotropium n = $nmbr$  placebo n,C0032042;C0213771;C1696465;C1706408
295,$nmbr$ placebo ( n = $nmbr$ $nmbr$ ),C0032042;C1696465;C1706408
294,placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
294,placebo - vonoprazan $nmbr$,C0032042;C1696465;C1706408;C4080009
294,placebo - dexlansoprazole,C0032042;C1696465;C1706408;C2348248
294,placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg,C0032042;C1319635;C1696465;C1706408;C1871983
293,placebo - ezetimibe $nmbr$ / simvastatin $nmbr$ - fenofibrate $nmbr$ - ezetimibe $nmbr$ / simvastatin $nmbr$ / ezetimibe $nmbr$,C0032042;C0033228;C1532737;C1696465;C1706408
293,placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$,C0032042;C1619966;C1696465;C1706408
292,placebo mortality rate  events per $nmbr$ person - y,C0026565;C0027361;C0032042;C0205848;C0441471;C1696465;C1706408;C2347489;C3541888
292,placebo - linagliptin,C0032042;C1696465;C1706408;C2746078
292,any placebo,C0032042;C1696465;C1706408
292,$nmbr$ - year rates in placebo groups,C0032042;C0439234;C0439508;C0441833;C0687744;C0871208;C1257890;C1519504;C1521828;C1552839;C1696465;C1705428;C1705429;C1706408
291,abatacept ‡,C1619966
291,abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ ),C0439272;C1619966
291,abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ ),C1619966
290,abatacept plus mtx ( n = $nmbr$ ),C0025677;C1417487;C1619966
290,abatacept monotherapy ( n = $nmbr$ ),C1619966
290,abatacept ( n = $nmbr$ * ),C1619966
290,abatacept,C1619966
289,placebo / open - label abatacept,C0032042;C1619966;C1696465;C1706408;C1709323
289,abatacept / open - label abatacept,C1619966;C1709323
288,beta blocker users,C0001645;C1706077
288,beta blocker  n ( % ),C0001645
288,beta blocker  %,C0001645
287,use of beta - blockers,C0001645;C1524063
287,use of beta - blocker,C0001645;C1524063
286,beta - blockers through hospital discharge or day $nmbr$ — %,C0001645;C0586003
286,beta - blocker  %,C0001645
286,beta - blocker,C0001645
285,no beta - blocker,C0001645
285,beta - blocker — no . / total no . ( % ),C0001645
285,beta - blocker — no . ( % ),C0001645
285,beta - blocker n ( % ),C0001645
285,beta - blocker !,C0001645
285,beta - adrenergic blocker,C0001645;C2757061;C3536830
284,peri - op beta - blockers : no ( n = $nmbr$ ),C0001645;C0347985
284,beta blockers,C0001645
284,beta - blockers ( all )  n ( % ),C0001645
284,beta - blockers  n ( % ),C0001645
284,beta - blockers  ( % ),C0001645
284,beta - blockers,C0001645
283,without beta blocker,C0001645
283,with beta blocker,C0001645
283,no betablocker use,C0001645;C0042153;C0457083;C1947944
283,no beta - blocker use,C0001645;C0042153;C0457083;C1947944
283,betablocker use,C0001645;C0042153;C0457083;C1947944
283,betablocker,C0001645
283,beta blocker use ( % ),C0001645;C0042153;C0457083;C1947944
283,beta blocker use,C0001645;C0042153;C0457083;C1947944
283,beta blocker,C0001645
283,beta - blocker use at randomization,C0001645;C0034656;C0042153;C0457083;C1947944
283,beta - blocker use at baseline,C0001645;C0042153;C0168634;C0457083;C1442488;C1947944
283,beta - blocker use,C0001645;C0042153;C0457083;C1947944
282,chronic inflammatory disease,C1290886
281,inflammatory disease,C1290884
280,inflammatory bowel disease,C0021390
280,active inflammatory bowel disease,C0021390;C0205177;C3853793;C3888249
279,previous anti - inflammatory / antirheumatic products n ( % ),C0003191;C0205156;C0333348;C0432633;C1514468;C1552607
279,inflammatory,C0333348
278,inflammation,C0021368
278,baseline inflammation markers,C0005516;C0021368;C0168634;C1442488
277,impacts,C1825598;C4049986
276,implanted pacemaker,C0848753
275,implantable cardioverter - defibrillator n ( % ),C0162589;C2825184
275,implantable cardioverter - defibrillator,C0162589;C2825184
275,data are mean ( sd ) or number ( % ) . pufa = polyunsaturated fatty acids  bmi = body - mass index . sbp = systolic blood pressure . dbp = diastolic blood pressure . nyha = newyork heart association . lvef = left ventricular ejection fraction . hf = heartfailure . ami = acute myocardial infarction . cabg = coronary artery bypass graft . pci = percutaneous coronary intervention . icd = implantable cardioverter defibrillator . copd = chronic obstructive pulmonary disease . ace = angiotensin - converting enzyme . arbs = angiotensin receptor blockers . * available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa  $nmbr$ placebo ) .,C0004083;C0005823;C0010055;C0018787;C0018801;C0021122;C0022709;C0024117;C0085805;C0155626;C0162589;C0185098;C0205042;C0428772;C0439849;C0488055;C0488728;C0521942;C0536221;C0596306;C0699792;C0815017;C0871470;C1264633;C1271104;C1272641;C1275491;C1305855;C1306620;C1511726;C1532338;C1554103;C2733342;C2825184;C3245479;C3714741;C3813197;C3888198;C4281799
274,implanted cardioverter defibrillator,C0021102;C0810516;C2828363
274,implanted cardioverter - defibrillator,C0021102;C0810516;C2828363
273,parameter statistics,C0681933
272,glycaemic parameters,C0005802;C0449381
271,biometric parameters,C0005544;C0449381;C2718322
270,smoking ( % ) laboratory parameters,C0022877;C0037369;C0449381;C0453996;C1881674;C3244292;C4283904
270,parameters,C0449381
269,efficacy parameter,C0549193;C1280519;C1704769;C1707887;C2350001
268,parameter at baseline,C0168634;C0549193;C1442488;C1704769;C2350001
268,baseline parameter,C0168634;C0549193;C1442488;C1704769;C2350001
267,parameter / variable,C0439828;C0549193;C1704769;C2350001;C4553760
267,parameter ( mg / dl ),C0439269;C0549193;C1704769;C2350001
266,parameter  n ( % ),C0549193;C1704769;C2350001
266,parameter  % ( $nmbr$ % ci ),C0008107;C0549193;C1704769;C2350001;C3259781
266,parameter,C0549193;C1704769;C2350001
266,$nmbr$ parameter,C0549193;C1704769;C2350001
265,previous pneumonia,C0032285;C0205156;C1552607
264,previous treatment failure — no . ( % ) § * *,C0162643;C0205156;C0235828;C0521983;C1547544;C1552607
263,previous vte — no . ( % ),C0205156;C0630906;C1552607
263,previous vte n ( % ),C0205156;C0630906;C1552607
263,previous vte  n ( % ),C0205156;C0630906;C1552607
263,previous vte,C0205156;C0630906;C1552607
262,previous venous thromboembolism — no . ( % ),C0205156;C1552607;C1861172
262,no . of previous venous thromboembolic events,C0205156;C1552607;C1861172;C1997614;C3160733
261,> $nmbr$ previous venous thromboembolisms ( % ),C0205156;C1552607;C1997614
261,> $nmbr$ in previous,C0205156;C1552607
260,previous treatment with a laba and / or lama  n ( % ) c,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
260,previous treatment ?,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
260,previous treatment,C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
260,previous antihypertensive treatment — no . ( % ),C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
260,previous antihypertensive treatment,C0003364;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3538994;C3887704
260,previous antiarrhythmic treatment — no . ( % ),C0003195;C0039798;C0087111;C0205156;C1522326;C1533734;C1552607;C1705169;C3537142;C3538994;C3887704
260,previous,C0205156;C1552607
259,previous systemic treatment  n ( % ),C0205156;C0678812;C1552607
259,previous oad ( % ),C0205156;C1552607
259,previous dmards use  n ( % ),C0205156;C0242708;C1552607
259,previous angioplasty  n ( % ),C0162577;C0205156;C1548817;C1552607
259,no . of previous csdmards  n ( % ),C0205156;C1552607
258,previous tnf antagonist exposure  n ( % ),C0205156;C0231491;C0274281;C0332157;C1448177;C1552607
258,previous tnf - antagonist use  n ( % ),C0042153;C0205156;C0231491;C0457083;C1448177;C1552607;C1947944
258,previous analgesic products n ( % ),C0002771;C0205156;C1552607
257,smoking status ( previous ) ( n ),C0205156;C1519386;C1552607
256,previous stroke 一 no . ( % ),C0205156;C1552607
256,previous stroke — no . ( % ) concomitant treatment — no . ( % ),C0205156;C1552607
256,previous stroke — no . ( % ),C0205156;C1552607
256,previous exposure to a vitamin k antagonist — no . ( % ) current or former never,C0042839;C0087161;C0205156;C0231491;C0332157;C0597277;C1552607;C1708601;C2825076;C3714656
256,no . of previous biologic dmards — no . ( % ),C0205156;C1552607;C4055380
255,previous hypersensitivity reaction — no . ( % ),C0020517;C0205156;C1552607
255,previous bowel resection performed — no . of patients ( % ),C0205156;C0741614;C1552607
255,previous antiparkinson medication  no . ( % ),C0003405;C0205156;C1552607
254,previous hypertension,C0020538;C0205156;C1552607;C1963138
254,previous bdmard received,C0205156;C1552607
253,previous segments resection ( s ) *,C0205156;C1552607;C2987624
253,previous segmental resection — no . ( % ),C0205156;C1552607;C2987624
252,previous cardiovascular events,C0205156;C1320716;C1552607
252,previous cardiovascular event — no . ( % ),C0205156;C1320716;C1552607
252,previous cardiovascular event at randomization,C0034656;C0205156;C1320716;C1552607
252,previous cardiovascular event ( % ),C0205156;C1320716;C1552607
251,previous limb or foot amputation,C0015385;C0205156;C1552607
250,yes previous revascularization,C0205156;C0581603;C1549445;C1552607;C1705108;C1710701
250,previous revascularization,C0205156;C0581603;C1552607
249,previous mi and t $nmbr$ dm,C0205156;C1552607;C3810814
248,previous myocardiaunfarction,C0205156;C1552607
248,previous myocardial infarction — no . ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
248,previous myocardial infarction ( % ),C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
248,previous myocardial infarction,C0027051;C0205156;C0428953;C1552607;C2926063;C3810814;C4552959
248,previous mi — no . ( % ),C0205156;C1552607;C3810814
248,previous mi ( % ),C0205156;C1552607;C3810814
248,previous mi  n ( % ),C0205156;C1552607;C3810814
248,previous mi  %,C0205156;C1552607;C3810814
248,previous mi,C0205156;C1552607;C3810814
247,cardioversion in previous $nmbr$ wk,C0013778;C0205156;C0332174;C0439230;C1552607
246,previous cvd ^,C0007222;C0205156;C1552607
246,previous cardiovascular disease !,C0007222;C0205156;C1552607
245,good  tried previous glucocorticoid + laba,C0017710;C0205156;C0205170;C1552607
245,good  tried previous glucocorticoid,C0017710;C0205156;C0205170;C1552607
244,previous anti - tnf therapy  n [ % ],C0205156;C0279936;C0432633;C1552607
243,previous or current use of im or cs : no,C0205156;C1552607
243,previous or current use of im and cs : no,C0205156;C1552607
243,previous or current im use : no,C0205156;C1552607
243,previous or current cs use : no,C0205156;C1552607
243,previous disease and drug use,C0012634;C0205156;C1552607
243,previous disease :,C0012634;C0205156;C1552607
242,previous af,C0205156;C0344434;C1552607;C4049859
242,previous a - blocker use,C0205156;C1552607
242,previous a - blocker,C0205156;C1552607
241,previous oral glucose - lowering agents  % of patients,C0205156;C0441994;C0600419;C1552607;C1955477;C2003888
240,previous ptca,C0205156;C1552607;C2936173
240,previous cancerc,C0205156;C1552607
240,previous aorta - femoral or lower extremity bypass surgery  pta of iliac  or infrainguinal artery,C0003483;C0205156;C1552607
239,previous $nmbr$ ari use,C0205156;C1412533;C1552607;C4521376
239,previous $nmbr$ - ari use ( % ),C0205156;C1412533;C1552607;C4521376
238,previous ami  n ( % ),C0205156;C1552607;C4319936
238,previous ami,C0205156;C1552607;C4319936
237,previous infliximab therapy — no . of patients ( % ) * *,C0205156;C1552607;C4076075
237,previous infliximab therapy | |,C0205156;C1552607;C4076075
236,previous lev only,C0023556;C0205156;C0205171;C1552607;C1720467
236,previous labd only,C0205156;C0205171;C0396059;C1552607;C1720467
235,participated in a previous febuxostat studyb  n ( % ),C0205156;C0249529;C1552607
235,completed previous febuxostat study,C0205156;C0249529;C1552607;C2348557
234,previous number of ciu / csu medications,C0205156;C0578870;C1552607;C1718138
233,no previous copd medication,C0013227;C0024117;C0205156;C1412502;C1552607;C3244316;C3714496;C4284232
233,no . of previous ciu / csu medications  mean ( median ),C0013227;C0205156;C0444504;C0549183;C0578870;C0802604;C0876920;C1552607;C2347634;C2347635;C2348143;C2348144;C2598133;C2939193;C4284232
233,no . of previous ciu / csu medications,C0013227;C0205156;C0578870;C0802604;C1552607;C2598133;C4284232
232,previous transient ischemic attack,C0007787;C0205156;C0917805;C1552607
232,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0007787;C0038454;C0042153;C0043031;C0205156;C0457083;C0917805;C1552607;C1947944;C4554100
232,previous tia or stroke,C0007787;C0205156;C0917805;C1054154;C1552607
232,previous tia,C0007787;C0205156;C0917805;C1054154;C1552607
232,previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
232,no previous stroke / tia,C0007787;C0038454;C0205156;C0917805;C1054154;C1552607;C4554100
232,no previous ischemic stroke / tia ( n = $nmbr$ $nmbr$  $nmbr$ . $nmbr$ % ),C0007787;C0205156;C0917805;C0948008;C1054154;C1552607
231,former smoking,C0037369;C0205156;C0453996;C0750523;C1881674
231,former or never diabetes,C0205156;C0750523
231,former or never,C0205156;C0750523
231,former or current smokers ( % ),C0205156;C0750523
231,former,C0205156;C0750523
230,former n z $nmbr$,C0205156;C0750523
230,former / current smoker  n ( % ),C0205156;C0337671;C0521116;C0750523;C1705970;C3173209;C3241966
230,former ( n   = $nmbr$  $nmbr$ ),C0205156;C0750523
230,former  n ( % ),C0205156;C0750523
229,prior oad :,C0332152;C2826257
229,prior myocardial intarction,C0027061;C0332152;C1522564;C2826257
229,prior infarction,C0021308;C0332152;C2826257
228,prior migraine *,C0149931;C0332152;C2826257
228,prior migraine,C0149931;C0332152;C2826257
227,prior congestive heart failure yes,C0018802;C0332152;C1549445;C1705108;C1710701;C2826257
227,prior congestive heart failure,C0018802;C0332152;C2826257
227,prior chf  %,C0018802;C0332152;C2826257
227,prior chf,C0018802;C0332152;C2826257
226,prior upper gi clinical event,C0203057;C0205210;C0332152;C0441471;C2826257;C4019010
226,prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
226,prior stroke ( before index event ),C0332152;C0441471;C0456712;C2826257;C4019010
226,prior lower gi clinical event,C0205210;C0332152;C0441471;C0441994;C1548802;C1708130;C2003888;C2826257;C3539617;C4019010;C4050121
226,prior lgi event,C0332152;C0441471;C2826257;C4019010
226,no prior ugi event,C0332152;C0441471;C0560042;C2826257;C4019010
226,no prior lgi event,C0332152;C0441471;C2826257;C4019010
225,prior om,C0028971;C0332152;C1705272;C2826257
225,prior acbi or arb use,C0332152;C2826257
224,prior llt,C0332152;C2347090;C2826257
224,no prior llt,C0332152;C2347090;C2826257
223,prior failure of anti - tnf therapy — no . ( % ),C0231174;C0281481;C0332152;C0680095;C2826257
223,prior brachytherapy,C0006098;C0332152;C2826257
223,prior anti - tnf therapy — no . ( % ),C0281481;C0332152;C2826257
223,prior anti - tnf therapy,C0281481;C0332152;C2826257
222,prior non - haemorrhagic stroke,C0332152;C0553692;C1518422;C2826257
222,prior non - cns se,C0036919;C0332152;C1518422;C2826257;C3714787
222,prior admb,C0332152;C2826257
222,prior,C0332152;C2826257
222,no prior admc,C0332152;C2826257
222,# of prior tnfi among non - tnfi naive,C0332152;C1518422;C2826257
222,# of prior non - tnfi bdmards *,C0332152;C1518422;C2826257
222,# of prior bdmards,C0332152;C2826257
221,prior nsaid  n ( % ) a,C0003211;C0332152;C2826257;C3536840
221,prior aeds  ≥ $nmbr$  n ( % ),C0180309;C0332152;C2826257
221,no . of prior tnfi,C0332152;C2826257
221,no . of prior bdmards,C0332152;C2826257
221,no . of prior aedsd,C0332152;C2826257
221,no . of prior aeds  n ( % ) $nmbr$ - $nmbr$,C0180309;C0332152;C2826257
221,no . of prior aeds  n ( % ),C0180309;C0332152;C2826257
221,no . of prior aeds  c n ( % ),C0180309;C0332152;C2826257
220,prior use of conventional dmards only ( biologic - nai ' ve )  n ( % ),C0042469;C0205171;C0332152;C0439858;C1524063;C1720467;C2826257;C3537218;C3714652;C4055380;C4321495
220,prior tnfi  n ( % ),C0332152;C2826257
220,prior medication use  n ( % ),C0240320;C0332152;C2826257
219,prior peripheralarterialdisease,C0332152;C2826257
219,prior implantable cardiodefibrillator  n ( % ),C0021102;C0332152;C2826257
219,prior antiinflammatory / antirheumatic products  n ( % ),C0003191;C0003209;C0332152;C1514468;C1515999;C2826257
218,prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
218,no prior htn ( n = $nmbr$  $nmbr$ ),C0020538;C0332152;C2826257
217,prior transient ischaemic,C0040704;C0205374;C0332152;C0475224;C2826257
216,prior cardiovascular history,C0332152;C1880008;C2826257
216,prior cardiovascular event — no . ( % ) - j -,C0332152;C1320716;C2826257
216,prior cardiovascular event — no . ( % ),C0332152;C1320716;C2826257
216,prior cardiovascular event  ',C0332152;C1320716;C2826257
216,prior cardiovascular event,C0332152;C1320716;C2826257
215,prior ptca / pci,C0332152;C2826257;C2936173;C4049621
215,prior pci  %,C0332152;C2826257;C4049621
215,no prior pci,C0332152;C2826257;C4049621
214,prior pci or cabg surgery,C0332152;C2826257;C4049621
214,prior pci or cabg,C0332152;C2826257;C4049621
214,prior pci,C0332152;C2826257;C4049621
214,prior coronary revascularization ( pci or cabg ),C0332152;C0877341;C2826257;C4049621
213,prior stroke — no . ( % ),C0332152;C2826257
213,prior stroke ( % ),C0038454;C0332152;C2826257;C4554100
213,prior stroke,C0038454;C0332152;C2826257;C4554100
213,prior ml / stroke,C0038454;C0332152;C0439526;C1705224;C2826257;C3887665;C4554100
213,prior mi / stroke,C0038454;C0332152;C2826257;C3810814;C4554100
213,no prior stroke / tia,C0007787;C0038454;C0332152;C0917805;C1054154;C2826257;C4554100
213,no prior stroke,C0038454;C0332152;C2826257;C4554100
212,completed prior febuxostat studya,C0205197;C0249529;C0332152;C2826257;C3854010
211,prior or new diabetes,C0332152;C2826257
211,prior gestational diabetes,C0085207;C0332152;C2826257
211,prior diabetes,C0011847;C0011849;C0332152;C2826257
210,prior bisphosphonate usage,C0012544;C0332152;C0457083;C2267018;C2826257
209,prior bp use,C0037623;C0042153;C0332152;C0457083;C1415692;C1708288;C1947944;C2826257;C4318478
209,prior a - blocker use,C0332152;C2826257
208,prior use of systemic,C0205373;C0332152;C1524063;C2826257
208,prior use of $ $nmbr$ systemic therapies,C0205373;C0332152;C1514463;C1515119;C1524063;C2826257
208,dissatisfied with / stopped $ $nmbr$ prior systemic therapy because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
208,dissatisfied with / stopped $ $nmbr$ prior systemic therapies because of side effects,C0205373;C0332152;C0870433;C1272691;C1514463;C1515119;C2826257;C4085546
207,prior oac,C0332152;C2826257
207,prior history of bleeding on oac,C0019080;C0019664;C0019665;C0262512;C0262926;C0332152;C1705255;C2004062;C2826257
206,leading to study withdrawal,C0332152;C1522538
206,leading to study drug discontinuation,C0332152;C1522538
206,leading to discontinuation,C0332152;C0457454;C1444662;C1522538;C4552847
205,st ‐ str ≥ $nmbr$ % pre ‐ ci,C0008107;C0036056;C0332152;C0740175;C2257086;C3259781;C3272372;C3669034
204,pre svc,C0231957;C0332152;C0740175;C2257086;C3669034
204,pre hospital ticagrelor,C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
204,pre fvc % pred,C0332152;C0740175;C2257086;C3669034;C3714541
204,pre fvc,C0332152;C0740175;C2257086;C3669034;C3714541
204,pre - treatedforhypertension [ n ( % ) ],C0332152;C0740175;C2257086;C3669034
204,pre - mixed insulin,C0205430;C0332152;C0740175;C2257086;C3160715;C3669034
204,pre - hospital ticagrelor ( n = $nmbr$ ),C0019994;C0332152;C0740175;C1510665;C1999375;C2257086;C3669034
204,pre - hospital,C0019994;C0332152;C0740175;C1510665;C2257086;C3669034
204,pre - bd fvc s $nmbr$ % of predicted,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C3714541;C4050145
204,mean ( sd ) change from pre - to post - bronchodilator fevi  ml,C0332152;C0439526;C0444504;C0687676;C0740175;C1704687;C1705224;C2257086;C2347634;C2348143;C2599594;C2599602;C2699239;C3469826;C3481639;C3669034;C3887665
204,change from pre - to,C0332152;C0392747;C0443172;C0740175;C1705241;C2257086;C3669034;C4319952
204,% predicted pre - bd,C0005126;C0332152;C0681842;C0740175;C1882327;C2257086;C2344255;C3669034;C4050145
203,question $nmbr$ ( fatigue / tiredness ),C0015672;C1522634;C3463815;C4050243;C4553152;C4554645
203,fatigue ( range $nmbr$ - $nmbr$ ),C0015672;C1514721;C2348147;C3463815;C3542016;C4050243;C4554645
203,fatigue,C0015672;C3463815;C4050243;C4554645
203,energy / fatigue,C0015672;C0424589;C0542479;C1442080;C3463815;C4050243;C4330907;C4554645
202,fibrinogen ( pmol / l ) c,C0016006;C0439284;C1167394;C2587184;C3540039
202,fibrinogen  g / l,C0016006;C0439294;C0456615;C1167394;C2587184;C3540039
202,fibrinogen,C0016006;C1167394;C2587184;C3540039
201,salmeterol / fluticasone $nmbr$ / $nmbr$   μ g b . i . d .,C0086706;C0939232
200,salmeterol - fluticasone group ( n = $nmbr$ ),C0441848;C0939232
200,fluticasone - salmeterol ( n = $nmbr$ ),C0939232
200,fluticasone - fluticasone / salmeterol,C0939232
199,fibrates,C1449704;C3540783
198,fibrous  mm ’,C0016059;C0439709;C4330985;C4554674
198,fibrous,C0016059;C0439709
197,febuxostat $nmbr$ mg n = $nmbr$,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
197,febuxostat $nmbr$ mg daily n = $nmbr$,C0024671;C0026410;C0249529;C0332173;C0439269;C1960952;C2346927;C4321396;C4521761
197,febuxostat $nmbr$ mg ( n = $nmbr$ ),C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
197,febuxostat $nmbr$ mg,C0024671;C0026410;C0249529;C0439269;C1960952;C2346927;C4321396;C4521761
197,febuxostat,C0249529
196,febuxostat - febuxostat / lesinurad $nmbr$ - febuxostat / lesinurad $nmbr$,C0249529;C3886073
196,febuxostat - febuxostat / lesinurad $nmbr$,C0249529;C3886073
195,mucocutaneous,
195,allopurinolt,
194,normoalbuminuria or microalbuminuria,
194,normoalbuminuria,
194,macroalbuminuriaf,
194,macroalbuminuria  n ( % ),
194,macroalbuminuria,
194,and microalbuminuria or macroalbuminuria,
193,tolal choleslerol,
193,ldl cholesterolt,
193,ldl choleslerol,
193,ldl cholesicrol ( minol / l ),
193,hypercholesterolemiat,
193,hvpercholesterolemia,
193,hdlcholesterol,
192,corticosteroidsa,
192,any ( including corticosteroid ),
191,clopiodogrel,
190,lleocolon,
190,ileocolonic ( both ileum and colon ),
190,ileocolon,
189,psaqol,
189,neohrodathv . and all - cause mortalitv,
189,all teaes *,
189,all teaes,
189,all subjects - n,
189,all subjects,
189,all strokes *,
189,all rosuva,
189,all randomized all - cause mortality or hospitalization for worsening hf ^,
189,all randomized all - cause mortality,
189,all randomized,
189,all itt sutajects,
189,all grafts,
188,endpointc,
188,educ ssy,
188,edo,
187,randomly assigned to diuretic,
187,randomly assigned to calcium channel blocker,
187,randomly assigned to ace,
187,indzgly,
187,all randomly assigned,
186,ldl - c ( measured ) *,
186,ldl - c ( calculated ) *,
186,ldl *,
186,ldl,
185,strokezsee,
185,nkf stage,
185,all strokes  n ( % ),
185,all strokes,
184,nothfref,
184,hfref ( n = $nmbr$ ),
184,hfref,
183,thromboaspiration,
183,reinfarction,
183,pinteraction = $nmbr$ . $nmbr$,
183,pinteraction,
183,continuation ( n = $nmbr$ ),
183,continuation,
183,combinationf,
182,saxagiiptin,
182,allogliptin,
181,z\tonastaiin,
181,noncaucasian,
181,causaslan,
181,atorvastatinb,
181,aiorvasiaiin,
180,ticlopidin,
180,thiazolidinedionesc,
180,thiazolidinedioneb,
180,niacini,
180,aniagonisi,
179,noninducing,
179,insulina  n ( % ),
179,insulina,
178,without antiplatelets,
178,with antiplatelets,
178,antiplateletsa,
178,antiplatelets  any,
178,antiplatelets,
178,antiplatelet — no . / total no . ( % ),
178,antiplatelet — no . ( % ),
178,antiplatelet,
177,myopathyt,
177,idiopathica,
176,ratet n ( % ),
176,ratet,
176,or ( itt ) ( n = $nmbr$ ),
176,itt,
175,moderatez,
175,moderatey,
175,moderatex,
175,gusto moderate or severe,
175,gusto moderate / severe bleeding,
175,gusto moderate / severe bleed,
175,gusto moderate / severe,
175,gusto moderate,
175,gusto - bleeding severe / moderate,
175,covariates,
175,covariate,
174,mafcaiancy at randorrtzaton,
174,immobazaton,
173,or ( $nmbr$ % ci ) a,
173,hr ( $nmbr$ s % a ),
173,hcru ( a ),
173,a a ( $nmbr$ ( % ),
173,a $nmbr$,
173,> $nmbr$ b ( $nmbr$ b to $nmbr$ a ),
173,( a blocker,
173,$nmbr$ b ( $nmbr$ b to > $nmbr$ a ),
173,$nmbr$ b ( $nmbr$ b to $nmbr$ a ),
172,dcct a $nmbr$ c,
172,a vs . c,
172,a / c,
172,a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,
172,a $nmbr$ c > $nmbr$ . $nmbr$ %,
172,a $nmbr$ c < $nmbr$ . $nmbr$ %,
172,a $nmbr$ c ( % ),
172,a $nmbr$ c  %,
172,a $nmbr$ c,
171,texcaps,
171,saaca,
171,rca  n ( % ),
171,rca,
171,laaca,
170,timi minor,
170,timi major or minor bleeding,
170,timi major or,
170,timi major,
170,timi clinically significant,
170,timi - bleeding major / minor,
170,lixi,
169,tio ( n $nmbr$ $nmbr$ ),
169,tio,
169,timi ≥ $nmbr$ and spoke and time ≤ $nmbr$ h,
169,timi ≥ $nmbr$,
168,iiiv,
168,ii or iii,
168,ii . $nmbr$ ( $nmbr$ . $nmbr$ ) $nmbr$,
168,ii ( $nmbr$ ),
168,ii,
168,$nmbr$ ii ( $nmbr$ . $nmbr$ ),
167,idegasp bid,
167,bid,
167,biasp $nmbr$ bid,
166,stratum  n ( % ),
166,still taking alendronate at study entry  n ( % ),
166,simva n = $nmbr$ n ( % ),
166,simva ( % ),
166,sgrq responder ( % ),
166,scd ( % ),
166,saba ( inhaled )  c   n ( % ),
166,rvfac ( % ),
166,poba  n ( % ),
166,other bdmards ( no tnfi taken ) t  n ( % ),
166,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) $nmbr$ . $nmbr$,
166,or : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ )  p = $nmbr$ . $nmbr$,
166,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
166,or ( $nmbr$ % cl ) = $nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ . $nmbr$ ),
166,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ $nmbr$ ),
166,or ( $nmbr$ % cl ) = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ $nmbr$ ),
166,or ( $nmbr$ % cl ),
166,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ — $nmbr$  $nmbr$ ),
166,or  $nmbr$ . $nmbr$ ( $nmbr$ % cl  $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
166,olaemia  n ( % ),
166,oac experienced  bn   ( % ),
166,no ( % ),
166,mmrm estimates  ls mean ( se )  [ $nmbr$ % ci ],
166,ll ( $nmbr$ ),
166,ll $nmbr$ ( $nmbr$ ),
166,ll  n ( % ),
166,laba ( inhaled )  d   n ( % ),
166,jvp  ( % ),
166,icsusers atbaseline  n ( % ),
166,hr vs control ( $nmbr$ % cl ) *,
166,hr vs . warfarin ( $nmbr$ % ci ),
166,hr ( $nmbr$ % c ! ),
166,hbaie ( % ),
166,hbaic ( % ),
166,granulating  n ( % ) a,
166,caucasiana ( % ),
166,catscorecategory  n ( % ),
166,bsa > $nmbr$ %  n ( % ) t,
166,bsa ( % ),
166,both ( % ),
166,arvfac ( per $nmbr$ % ),
166,alvef ( per $nmbr$ % ),
166,alathosterol ( % ),
166,acholesterol ( % ),
166,aab $nmbr$ ( % ),
166,- $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ) * ll,
166,( sem ),
166,( % ) ( $nmbr$ . $nmbr$ ),
166,$nmbr$ rrmnl ),
166,$nmbr$ . $nmbr$ ( ll . $nmbr$ ),
166,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ),
166,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
166,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
166,$nmbr$ . $nmbr$ % ( $nmbr$ ),
166,$nmbr$ ( $nmbr$ . $nmbr$ ),
166,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per pyr $nmbr$ pyr,
166,$nmbr$ ( $nmbr$ . $nmbr$ % ),
166,$nmbr$ % ( oto $nmbr$ ),
166,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),
165,std n ( n / loopy ),
165,priorother ( predefined ) medical conditions,
165,priorother ( not predefined ) medical conditions,
165,or ( unadjusted ),
165,ol / l ),
165,am pef ( sd )  l / min,
165,( ofl ),
164,gentype,
164,feno + eze,
164,feno,
164,enrope + sonth afriea,
163,epa ( n = $nmbr$ ),
163,epa,
163,e / e ' ( septal ),
163,e $nmbr$ ( n = $nmbr$ ),
163,e,
162,mbes / crbesc,
162,bms,
161,b pooled new and worsened vertebral fractures ( mfas ),
161,b,
160,wssng,
160,persisent,
159,csii,
159,cse ] +,
158,without an sfua,
158,with an sfua,
158,tngtycerides a median,
158,tngtycendes a median,
158,any timi bleeding,
158,any teaes,
158,any teae,
158,any other llts ( other than statin ),
158,any bleeding,
158,any,
158,and infusion,
158,and either an ace inhibitor or angiotension receptor blocker,
158,a ) those receiving no inhaled pre - treatment maintenance medication,
158,a,
157,statini,
157,stalin,
157,phakic,
157,pasia,
157,latin and north america,
157,latin ameriea,
157,latin,
157,and physical examination,
156,tnt and ideal ( pooled ),
156,ideg,
155,laba - inhaled glucocorticoid use at screening,
155,inhaledb,
154,since onset,
154,since diagnosis,
154,incidencea,
153,unprovoked,
153,unfractionated,
152,tnfi naive,
152,tnfi exposed,
152,tnfi - naive,
152,tnfi - exposed †,
152,no . of tnfi among non - tnfi naive,
151,totai mortaiity,
151,or morbidity and mortality,
151,octave sustain,
151,attain,
150,unstableangina,
150,postamendment,
149,spiralcomputedtomographyangiography,
148,monotherapy $nmbr$,
148,monotherapy,
148,metforminmonotherapy,
148,glulisine monotherapy,
147,hbalc ( % ),
147,hbalc,
147,hale,
146,hbaic — %,
146,hbai,
145,transradial,
145,transfemoral,
144,vadas score *,
144,basfi *,
143,islander,
143,baselinec,
143,baselineb,
143,aslan,
143,a from baselineb,
142,samac,
142,sabae,
142,sabaa,
142,saba §,
142,saba,
142,no laba  no ics  n ( % ),
142,lamad,
142,labaa,
142,laba or lama ’ versus ind / gly lsm difference ( $nmbr$ % cl ),
142,laba or lama ’,
142,laba or lama,
142,laba alone,
142,laba ',
142,laba  no ics  n ( % ),
142,laba  n ( % ),
142,laba,
142,laa,
141,vka  only reason,
141,reqion,
141,regiont,
141,redon,
141,previously taken tnfi  %,
141,previously taken methotrexate  %,
141,previously taken dmards other than methotrexate  %,
141,previously,
140,veflonzumao,
140,resllzumab,
140,aiirocumab ( n = $nmbr$ ),
140,aiirocumab,
140,acenocoumaroi,
139,ocs reduced / stopped,
139,ocs maintained / increased,
139,and / or discharge,
139,and / or aza at baseline,
139,afcaps /,
139,acei and / or arb,
139,$nmbr$ - up and / or aza at baseline,
138,x / n *,
138,x / n,
137,rosigiitazone ± oad,
137,oascvd,
137,oam,
137,oads  n ( % ),
137,oad,
137,lad,
137,glulisine + oad,
137,giimepiride ± oad,
137,$nmbr$ oam,
137,$nmbr$ oads,
137,$nmbr$ oad,
136,ucr,
136,uacr  n ( % ) †,
136,uacr,
136,quicki,
136,macroalbuminuria ( uacr > $nmbr$ ),
136,lunchb,
135,jvp ( 〉 $nmbr$ cm ),
135,cm,
135,( cm ),
134,without revascularsation,
134,lithe,
134,ith vs . without ),
134,ish,
134,highjj,
133,no ipst ( n = $nmbr$  $nmbr$ ),
133,no ipst,
133,ipst ( n = $nmbr$ ),
133,ipst,
133,icsf,
133,icsa,
132,• j . the body - mass index is the weight in kilograms divided by the square of the,
132,is only,
132,in thirds,
132,in,
132,im on ] y,
131,insuiin giargine ± oad,
131,giargine,
131,diureties,
131,diureticff,
131,diurciic,
131,baseiine diuretic,
130,fibrofatty,
130,fibrinolysist,
130,fibrate or other lipid - lowering agent,
130,fibrate,
129,smmse < $nmbr$,
129,smmse,
129,simva ( „ = $nmbr$ },
129,simva,
129,numbera,
129,eze / simva ( „ = $nmbr$ },
128,nerd,
128,nd,
128,austrafca and new zealand,
128,> $nmbr$ nd and < $nmbr$ rd quartile,
127,paod,
127,and vfx status,
126,umied,
126,rarertd antocagibtcn before andorrtzafon,
126,normalfunction or mild impairment,
126,currentd,
125,univariable or ( $nmbr$ % ci )  p value *,
125,univariable,
125,uncodable,
125,uacr not available,
125,multivariable,
124,nonfatal,
124,disabling or fatal stroke,
124,disabling or fatal,
123,interact !,
123,/ j - valuc ! l,
122,denotes angiotensin - converting enzyme .,
122,controlld,
122,conservative,
121,nonreversible,
121,nonanterior,
120,qveral,
120,overally,
120,overallb,
120,overaii ( n = $nmbr$ ),
120,overaii,
120,oretal,
120,oralb,
119,ptga ⁎ ⁎ ⁎,
118,wegu,
117,igt or ifg,
117,igm,
116,upcr  n ( % ),
116,tnfi and other bdmardst  n ( % ),
116,previously taken any other dmards  n ( % ),
116,or 、 ( $nmbr$ % ci ),
116,or ulcerations  ® n ( % ),
116,or [ $nmbr$ % cl ],
116,or [ $nmbr$ % ci ],
116,or $nmbr$ % ci,
116,ocs  n ( % ),
116,hr and $nmbr$ % ci *,
116,hr $nmbr$ and $nmbr$ % cl,
116,hfpef ( ef n $nmbr$ )  ( % ),
116,erd *  n ( % ),
116,ef b $nmbr$ %,
116,ef > $nmbr$ % n = $nmbr$,
116,ef > $nmbr$ % hfpef ( n = $nmbr$  $nmbr$ % ),
116,ef > $nmbr$ % ( n = $nmbr$  $nmbr$ ),
116,ef > $nmbr$ % ( n $nmbr$ $nmbr$ ),
116,ef > $nmbr$ %,
116,ef $nmbr$ - $nmbr$ . $nmbr$ % ( n $nmbr$ $nmbr$ ),
116,ef $nmbr$ - $nmbr$ %,
116,ef  %,
116,comorbidites  n ( % ),
116,ckdc  n ( % ),
116,cigarettesmoking  %,
116,annt or bnnh ( $nmbr$ % ci ),
116,anesthesiad  n ( % ),
116,acei  n ( % ),
116,> = $nmbr$ ( % ),
116,> $nmbr$ y . n ( % ),
116,> $nmbr$ y  no . ( % ),
116,> $nmbr$ . $nmbr$ ( % ),
116,> $nmbr$ . $nmbr$ %,
116,> $nmbr$ ( % ),
116,> $nmbr$ % and < $nmbr$ % predicted arr ( n = $nmbr$  $nmbr$ ),
116,> $nmbr$ % $nmbr$,
116,> $nmbr$  no . ( % ),
116,% phg,
116,% fhg,
116,%,
116,$nmbr$ to $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
116,$nmbr$ . $nmbr$ %,
116,$nmbr$ ( > $nmbr$ % ),
116,$nmbr$ ( $nmbr$ % ),
116,$nmbr$ % $nmbr$,
115,ure,
115,ucl,
115,uc,
115,other uc - related gi surgical procedure,
115,ocs use,
114,us w = $nmbr$,
114,us,
114,uc [ gemini $nmbr$ ] ‘,
114,uas $nmbr$ {,
114,uas $nmbr$,
113,ustekinu,
113,usteki,
113,uistekinumab,
112,urti,
112,uniti - $nmbr$ and uniti - $nmbr$ im - uniti,
112,uniti - $nmbr$,
112,im - uniti,
111,timi - defined bleeding,
111,tamong those enrolling via bnp stratum . the study - qualifying bnp or,
111,metrex modified intention - to - treat population with an eosinophilic phenotypey,
111,ldl - csmedian,
111,gusto - defined bleeding,
111,getgoal - s,
111,femoralneck t - scorebybaselinevfxstatus,
111,discontinu - ation,
111,- bi -,
110,crude,
110,crt - p + d  n ( % ),
110,crt - p,
110,crt - d,
110,crt,
110,crj,
109,other ^,
109,on or after e ^ andomization,
109,ijb ^,
108,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ - $nmbr$ / $nmbr$ pg,
108,versus olodaterol $nmbr$ pg,
108,fpg,
107,sirius,
107,mellitus,
106,stratum *,
106,stratum,
106,nitratesf,
105,zotarolimust,
105,versus tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
105,versus tiotropium $nmbr$ pg tiotropium + olodaterol $nmbr$ . $nmbr$ / $nmbr$ pg,
105,versus tiotropium $nmbr$ pg,
105,versus tiotropium $nmbr$ . $nmbr$ pg,
105,tiotropiumc,
104,noncardiovascular,
104,cardiovasculardeath,
104,cardiovascuiar mortaiity,
104,cardioembolism,
104,cardioembolic,
103,iglarlixi ( n   =   $nmbr$ ),
103,iglarlixi,
103,iglar ( n   =   $nmbr$ ),
103,iglar,
102,vka naxve,
102,vka naive  n ( % ),
102,vka naive,
102,vka experienced,
102,vka ( n   = $nmbr$ ),
102,vka,
102,ever been on a vka,
101,vhd,
101,no vhd,
101,chda,
101,b  vhd ( n = $nmbr$ ),
101,a  no vhd ( n = $nmbr$ $nmbr$ ),
100,neither uh or lmw heparin,
100,neither,
100,leader,
100,gertder,
100,gendar,
99,tngtycerides < median,
99,tnglycendes < median,
99,metsyn,
99,hbalc < medan,
98,tzd,
98,eze / simva ( n = $nmbr$ ),
98,eze / simva,
98,eze,
97,vldm n = $nmbr$,
97,vdz n = $nmbr$,
97,vdz / vdz [ n = $nmbr$ ],
97,v ( n = $nmbr$ ),
97,uac =,
97,spirono ( n = $nmbr$ ),
97,socalone ( n = $nmbr$ ),
97,simva ( n = $nmbr$ ),
97,normai fasting giucose levei ( n = $nmbr$ ),
97,naive ( n = $nmbr$ ),
97,mfns ( n = $nmbr$ ),
97,mepo ( n = $nmbr$ ),
97,lgm ( n = $nmbr$ ),
97,igelow ( n = $nmbr$  $nmbr$ ),
97,hydochlorothiazide ( n = $nmbr$ ),
97,hhf ( n = $nmbr$ ),
97,hdm n = $nmbr$,
97,hd ( n = $nmbr$ ),
97,atenoioi ( n = $nmbr$ ),
97,all responders  ( n = $nmbr$ ),
97,> $nmbr$ bpm ( n = $nmbr$ l $nmbr$ ),
97,> $nmbr$ bpm ( n = $nmbr$ ),
97,= $nmbr$ ’ ),
97,= $nmbr$,
97,< $nmbr$ and no moderate or severe deformity ( n = $nmbr$ ),
97,$nmbr$ tol ( n = $nmbr$ ),
96,prediabeticb,
96,prediabetese,
96,nondiabetic,
96,nondiabetes,
96,diabeticb,
96,diabetesz,
96,diabetesf,
96,diabetese,
96,diabetesc,
96,dabetes,
96,brandomization was stratified by diabetic status .,
96,all diabetesd,
95,aget  y,
95,ageadj,
95,agea,
94,raee,
94,racey  z,
94,racea,
93,tbp,
93,sesbp,
93,sedbp,
93,nbp,
93,mssbp / msdbp,
93,mssbp,
93,msdbp,
92,lb,
92,> $nmbr$ lb,
91,vs . placebo,
91,ranotazine vs . placebo km failure rate,
91,plaeebo,
91,placeboa,
91,piacebo,
91,nominal p vs placebo,
91,monteiukast vs placebo,
91,hr vs placebo ( $nmbr$ % ci ),
91,absolutedifferenceestimate vs placebo ( $nmbr$ % ci ),
91,a $nmbr$ vs placebo,
90,fpci vs . ppci in women,
90,fpci vs . ppci in men,
90,differencevs . pbof,
90,combo vs . primary,
89,nonvertebral,
89,gusto severe or,
89,gusto severe,
89,gusto moderate or severe bleeding,
89,cerebral,
88,recervng,
88,recervini },
88,noliecervrig,
88,noirecerving,
87,undeterminedc,
87,undergoing major vascular surgery,
87,uncerlain,
86,remodeling,
86,ranozaline,
86,randomize,
86,a excludes two randomized patients with unknown diabetes status at baseline .,
85,wafarin,
85,vs . warfarin,
85,merformin,
84,empagllflozln,
84,empagllflozin,
84,dapagliflozint,
84,dapaglifloz . in  n,
84,dapaglifloiin  n *,
84,canagiiflozin,
83,“ off ”,
83,maf,
82,or taking antihypertensive medication,
82,hypertensiont,
82,hyperlension,
82,hvpertension,
82,extenswe,
81,teaes leading to discontinuation of study drug,
81,teaes,
81,other teaes,
81,nsteacs,
80,sonti amenca,
80,mensa,
80,amputationsa,
79,hr ( adjusteda ),
79,adjustedaor,
79,adjustedahr,
78,symptomaticb,
78,antithrombotic and anticoagulant medications,
78,antithrombotic,
77,statisticd,
77,characteristicsa,
77,characteristica,
76,vdhmtss,
76,mtss at,
76,mtss ( $nmbr$ - $nmbr$ ),
76,mtss,
75,on omt ( n = $nmbr$ ),
75,on omt,
75,off omt ( n = $nmbr$ ),
75,off omt,
75,ocs,
75,no ocs use  no nasal polyps  pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years,
75,no ocs,
74,womens,
74,some walking,
74,some,
73,hordic,
73,homa - p,
73,homa - b,
73,homa,
72,nonuser,
72,noneh,
72,none 一 no . ( % ),
72,none,
72,nonblack race — no . ( % ) f,
72,nonblack race — no . ( % ) - j -,
72,nonblack,
72,monteiukast ( n = $nmbr$ ),
72,monteiukast,
71,killip ciass,
71,ciass ll - iv,
71,charlson,
70,deathsb,
70,breakfastb,
69,napsit,
69,mnapsi,
69,has - bledo,
69,has - bled score ’,
69,has - bled score,
69,has - bled $nmbr$ - $nmbr$,
69,fas,
69,b ) those on inhaled corticosteroids and long - acting bronchodilators as previous treatment use .,
69,as,
68,xanthinesg,
68,whiteb,
68,w hite,
68,nonwhite race — no . ( % ) ejection fraction,
68,nonwhite,
67,while ethnic origin,
67,while,
67,mhi,
66,sack,
66,blaek / afriean - ameriean,
66,blaek,
66,biack non - hispanic,
66,biack,
65,toward,
65,none ( cdmard - naive or past use at baseline ),
65,cdmard,
65,bdmard - naive,
64,yearl,
64,yaa,
64,> is years,
64,> $nmbr$ yearstos is years,
63,nyhaiiioriv,
63,nyhaii,
62,bempedoic,
61,myoclonic,
61,clonic,
60,soc,
60,evomab + soc,
59,tjc  $nmbr$ - $nmbr$,
59,tjc,
59,sjc  $nmbr$ - $nmbr$,
59,sjc,
59,ldu - c,
59,ldl - c ( measured )  mean ( sd ),
59,ldl - c ( calculated )  mg / dl  mean ( sd ),
59,ldl - c ( calculated )  mean ( sd ),
59,ldl - c,
59,ldl $nmbr$ - c,
59,ldl  - c,
59,c,
58,otherz,
58,otherx,
58,othert,
58,othersc,
58,otherf,
58,otherd,
58,otherc,
58,otherb,
58,othera,
58,other †,
58,other vasculars,
58,other bdmard §,
58,other antiplatelet,
58,other * ’,
58,other *,
58,other ',
58,other !,
58,other,
58,itherchdt,
58,any other antihyperglycaemic drugs,
57,otherj ^ :,
57,other : :,
57,ethnieity,
56,ufh,
56,fh $nmbr$,
55,ppci ( n = $nmbr$ ),
55,ppci,
55,poci ( n = $nmbr$ ),
55,poci,
55,pacific,
54,macce ( % ),
54,macce,
54,cancert,
53,w,
53,rvw,
53,ixeq $nmbr$ w  n = $nmbr$,
52,psychoactivesd,
52,arteriai access,
52,aceis  n ( % ),
52,aceis,
51,octi,
51,acei vs . non - acei,
51,acei use,
51,acei,
50,severitya,
50,obesityj,
50,lntensityd,
50,is domain luts severity ( % ),
50,adverse eventy,
49,cabgorptca,
49,both,
49,b includes both ex - smokers and nonsmokers .,
48,apobe,
48,apoal,
48,apo bt,
47,no ?,
47,crpnonr ?,
46,woscops,
46,timi ≥ $nmbr$ and spoke,
46,timi score,
46,timi risk scoret,
46,spoke,
46,sgrq scores  mean ( sd ),
46,mcs score ( $nmbr$ – $nmbr$ scale ),
46,mcs score,
46,ibdq score |,
46,asui score  mean ( sd ),
46,asui score  mean,
45,subtrochanteric,
45,subgroupt,
44,sulfonylureasb,
44,sulfonylureaa,
43,normoalbuminuria §,
43,ccq score § §,
42,useofmedical therapyathospitaldischarge,
42,irofiban,
42,fenofibric,
41,smokingb,
41,dosing,
40,β ‐ blocker,
40,β blockers,
40,β blocker,
40,β - blockers,
40,β - blocker,
40,| ? > - blocker ( n  % ),
40,| ? ) - blocker  %,
40,j $nmbr$ - blocker,
40,blockers,
40,blocker,
40,b - blockers,
40,b - blocker,
40,a - blockers,
40,a - blocker,
40,^ - blockers,
40,^ - blocker,
40,/ $nmbr$ - blockers,
40,/ $nmbr$ - blocker,
40,( e - blocker,
40,( $nmbr$ blocker,
40,( $nmbr$ - blockers,
40,( $nmbr$ - blocker,
40,$nmbr$ blockers,
40,$nmbr$ blocker,
40,$nmbr$ - blockers,
40,$nmbr$ - blocker,
39,prosper,
39,pnorpci,
39,noppi,
39,did not enrol into osler,
38,prosthetic,
38,northamerica,
38,nonischemic,
37,hypoglycemiat,
37,hyperlipidmemia,
37,hyperkalemiab,
37,hvookalemia,
37,hosji fcrhypoglycemia,
37,dyslipidaemiat,
37,dyslipidaemiaj,
36,— no . ( % ),
36,tion — no . ( % ),
36,thromboaspiration — no . ( % ),
36,other — no . ( % ),
36,other  no . ( % ),
36,normoalbuminuria — no . / total no . ( % ),
36,normoalbuminuria — no . ( % ),
36,no ststm,
36,no oam,
36,no immomtedion,
36,no . of panents . total no . $nmbr$ % ),
36,no . of,
36,no . needed to treat ( $nmbr$ % cl ) *,
36,no . evenls,
36,no . a,
36,no . *,
36,no . ( % ) *,
36,no . ( % ) ',
36,no . ( % ),
36,no .,
36,no *,
36,no ( $nmbr$ . $nmbr$ ),
36,no  no,
36,macroalbuminuria — no . / total no . ( % ),
36,macroalbuminuria — no . ( % ) drug therapy — no . ( % ),
36,ization — no . ( % ),
36,coexisting conditions — no . ( % ),
36,acecoumarol  no . ( % ),
35,or no microalbuminuria or macroalbuminuria,
35,no or unknown,
35,no,
34,pnorcabg,
34,numab,
34,evomab ( n = $nmbr$ ),
34,evomab,
33,qmi,
33,pvaluefor any mi versus no mi,
33,bmit,
33,bmij,
33,bmia,
33,apolipoproiein b ( mij / $nmbr$ ),
32,revive ii,
32,revive i,
32,naive ( no treatment for current flare ),
32,naive,
31,≥ $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
31,≤ $nmbr$ . $nmbr$ %,
31,≤ $nmbr$ %,
31,≤ $nmbr$,
31,£ $nmbr$ . $nmbr$ % * *,
31,£ $nmbr$ %,
31,£ $nmbr$,
31,e $nmbr$ + a $nmbr$ -,
31,e $nmbr$ + a $nmbr$,
31,cclear $nmbr$ +,
31,bsa involved  % $nmbr$,
31,bsa affected  mean ± sd  %,
31,bsa affected  %,
31,bsa  % *,
31,> $nmbr$ . $nmbr$ % and ≤ $nmbr$ . $nmbr$ %,
31,$nmbr$ e $nmbr$,
30,subscale  and $nmbr$ to $nmbr$ for the function subscale  normalized scores can range from $nmbr$ to $nmbr$ . scores for the health assessment question -,
30,sk . $nmbr$,
30,previously failed anti - tnf treatment  no . ( % ),
30,associatedproximaldeep - veinthrombosisatdiagnosis  no . ( % ),
30,< - $nmbr$ . $nmbr$ + vfx,
30,- $nmbr$ . $nmbr$ to - $nmbr$ cm,
30,$nmbr$ c . t,
30,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,
30,$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$,
30,$nmbr$ - $nmbr$ — no . ( % ),
30,$nmbr$ - $nmbr$ . $nmbr$,
29,≥ $nmbr$ . $nmbr$ % and < $nmbr$ . $nmbr$ %,
29,£ $nmbr$ . $nmbr$ yrs,
29,sua < $nmbr$ . $nmbr$,
29,rro . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
29,rro $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
29,rr $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ },
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) * *,
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) *,
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ),
29,rr $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$ . $nmbr$,
29,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$ . $nmbr$ . $nmbr$ ) *,
29,rr $nmbr$ . $nmbr$ ( $nmbr$ - $nmbr$  $nmbr$ . $nmbr$ ),
29,rr $nmbr$ . $nmbr$,
29,rr $nmbr$ - $nmbr$ ( $nmbr$ . $nmbr$  $nmbr$  $nmbr$ ) ’,
29,piacebo ( n = $nmbr$ ) no . of participants with events ( % ),
29,or = $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ) < $nmbr$ . $nmbr$,
29,it $nmbr$ . $nmbr$,
29,ii $nmbr$ ± $nmbr$,
29,hr $nmbr$ . $nmbr$,
29,blaic < $nmbr$ . $nmbr$ %,
29,aqe ^ $nmbr$,
29,a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$,
29,^ $nmbr$ - $nmbr$,
29,^ $nmbr$,
29,[ } ifrerence vs . placebo  % ( $nmbr$ % cl ),
29,> - $nmbr$ . $nmbr$ and < - $nmbr$ . $nmbr$,
29,> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
29,> $nmbr$ - < $nmbr$,
29,< = $nmbr$ . $nmbr$ %,
29,< - $nmbr$ . $nmbr$ cm,
29,< - $nmbr$ . $nmbr$ - vfx,
29,< - $nmbr$ . $nmbr$,
29,< $nmbr$ yrs,
29,< $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
29,< $nmbr$ nwrrtn,
29,< $nmbr$ cm,
29,< $nmbr$ . $nmbr$ yrs,
29,< $nmbr$ . $nmbr$ bpm,
29,< $nmbr$ . $nmbr$ %,
29,< $nmbr$ . $nmbr$,
29,< $nmbr$ - $nmbr$,
29,- $nmbr$ . $nmbr$ ± lno ^,
29,$nmbr$ ± ll,
29,$nmbr$ is ( $nmbr$ . $nmbr$ ),
29,$nmbr$ < - $nmbr$,
29,$nmbr$ . $nmbr$ ± ii . $nmbr$,
29,$nmbr$ . $nmbr$ ± b . b,
29,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ } pty = $nmbr$,
29,$nmbr$ . $nmbr$ { $nmbr$ . $nmbr$  $nmbr$ . $nmbr$ ) pty = $nmbr$,
29,$nmbr$ . $nmbr$ yrs,
29,$nmbr$ . $nmbr$ vs $nmbr$ . $nmbr$,
29,$nmbr$ . $nmbr$ per $nmbr$ pyr,
29,$nmbr$ . $nmbr$ per $nmbr$ $nmbr$ . $nmbr$ per $nmbr$ pyr pyr,
29,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %,
29,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,
29,$nmbr$ . $nmbr$ - < $nmbr$,
29,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),
29,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),
29,$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ ),
29,$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %,
29,$nmbr$ - < $nmbr$ mvmin,
29,$nmbr$ - < $nmbr$ . $nmbr$,
29,$nmbr$ - < $nmbr$ %,
29,$nmbr$ - < $nmbr$,
29,$nmbr$ - $nmbr$ fo - $nmbr$ $nmbr$ - $nmbr$ ^,
29,$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e,
29,$nmbr$ ( $nmbr$ . $nmbr$ ) / $nmbr$ z ( $nmbr$ ze ),
29,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ pyr,
29,$nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ ( $nmbr$ . $nmbr$ % )  $nmbr$ . $nmbr$ per $nmbr$ . $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
29,$nmbr$  $nmbr$ - < $nmbr$ . $nmbr$,
29,$ $nmbr$ and  $nmbr$ years,
29,$ $nmbr$,
28,spga > $nmbr$,
28,sita $nmbr$,
28,jvp > $nmbr$ cm,
28,hbalc a $nmbr$ mmol / mol ( > $nmbr$ . $nmbr$ % ) ( n = $nmbr$ / $nmbr$ ),
28,crci > $nmbr$ - < $nmbr$,
28,crci > $nmbr$,
28,chajdsj - vasc > $nmbr$,
28,chadsj > $nmbr$,
28,blaic > $nmbr$ . $nmbr$ %,
28,a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %,
28,> = $nmbr$ . $nmbr$,
28,> - $nmbr$ cm,
28,> - $nmbr$ . $nmbr$ - vfx,
28,> - $nmbr$ . $nmbr$ + vfx,
28,> - $nmbr$ . $nmbr$,
28,> $nmbr$   vs .   ≤   $nmbr$,
28,> $nmbr$ yrs,
28,> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$,
28,> $nmbr$ oads,
28,> $nmbr$ mlymin,
28,> $nmbr$ microg / l,
28,> $nmbr$ ky / nr,
28,> $nmbr$ hr,
28,> $nmbr$ enroll,
28,> $nmbr$ cm,
28,> $nmbr$ beats / min,
28,> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$,
28,> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$,
28,> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$,
28,> $nmbr$ . $nmbr$   vs . $nmbr$ . $nmbr$ to   ≤   $nmbr$ . $nmbr$,
28,> $nmbr$ . $nmbr$ yrs,
28,> $nmbr$ . $nmbr$ bpm,
28,> $nmbr$ . $nmbr$,
28,> $nmbr$ - $nmbr$ cm,
28,> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
28,> $nmbr$ - $nmbr$ - $nmbr$,
28,> $nmbr$ - $nmbr$,
28,> $nmbr$  < $nmbr$,
28,$nmbr$ nd > $nmbr$ . $nmbr$ / < $nmbr$ . $nmbr$,
27,uncover - $nmbr$,
27,uacr ( mgg - $nmbr$ ),
27,ptga  $nmbr$ - $nmbr$,
27,nct $nmbr$,
27,napsi score ( $nmbr$ - $nmbr$ ) of target fingernail,
27,j $nmbr$ - blocker  % ( n ),
27,hbalc > = $nmbr$ % ( n - $nmbr$ ),
27,golden - $nmbr$ and - $nmbr$,
27,golden - $nmbr$,
27,enact - $nmbr$ trial rerandomization to natalizumab ( n = $nmbr$ ),
27,enact - $nmbr$ trial,
27,ef $nmbr$ - $nmbr$ % hfmref ( n = $nmbr$  $nmbr$ % ),
27,chajdsrvasc $nmbr$ - $nmbr$,
27,chajdsj - vasc $nmbr$ - $nmbr$,
27,chajdsa - vasc $nmbr$ - $nmbr$,
27,barc $nmbr$ - $nmbr$,
27,b - blockers  n ( % ),
27,- ° - $nmbr$  wom -,
27,- $nmbr$ - $nmbr$ ( - $nmbr$ - $nmbr$ too $nmbr$ ),
27,( % ) ( $nmbr$ - $nmbr$ ),
27,( % ) $nmbr$ - $nmbr$,
27,% $nmbr$ - $nmbr$,
27,$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %,
27,$nmbr$ - $nmbr$ y  n ( % ),
27,$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,
27,$nmbr$ - $nmbr$  no . / totalno . ( % ),
27,$nmbr$ - $nmbr$,
27,$nmbr$ ( oo $nmbr$ - o . $nmbr$ ),
27,$nmbr$ % - $nmbr$ %,
27,$nmbr$ $nmbr$ fo $nmbr$ - $nmbr$ $nmbr$ ),
26,« $nmbr$ - $nmbr$,
26,sso - $nmbr$,
26,ssi - $nmbr$,
26,msfc timed $nmbr$ - foot walk test .,
26,msfc timed $nmbr$ - foot walk test  median seconds,
26,has - bled score > $nmbr$,
26,has - bled > $nmbr$,
26,educ $nmbr$ - $nmbr$ y,
26,cclear $nmbr$ - $nmbr$,
26,biolimus a $nmbr$ - eluting stent ¶,
26,$nmbr$ yrs,
26,$nmbr$ or $nmbr$ high - risk categories,
26,$nmbr$ - < $nmbr$ yrs,
26,$nmbr$ - < $nmbr$ y,
26,$nmbr$ - $nmbr$ yrs,
26,$nmbr$ - $nmbr$ hr,
25,≥ $nmbr$ yearsa,
25,≥ $nmbr$ teae,
25,≥ $nmbr$ bpm ( n = $nmbr$ ),
25,≥ $nmbr$ %,
25,≥ $nmbr$,
25,| interactior $nmbr$ p,
25,x ? = l - $nmbr$  p = $nmbr$ - $nmbr$,
25,x ? = $nmbr$ - l  p = $nmbr$ - $nmbr$,
25,x ? = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
25,x $nmbr$ = $nmbr$ - l  p = $nmbr$ - $nmbr$,
25,x $nmbr$ = $nmbr$ - $nmbr$  p = $nmbr$ - $nmbr$,
25,x $nmbr$ = $nmbr$  p = $nmbr$ - $nmbr$,
25,ulpasi $nmbr$,
25,tpasi $nmbr$,
25,teaes reported by ≥ $nmbr$ % patients in the overall brv group    n   ( % ),
25,ppci in - $nmbr$,
25,pdq - $nmbr$,
25,op  vfx,
25,op  no vfx,
25,no op  vfx,
25,no op  no vfx,
25,llpasi $nmbr$,
25,anti - p $nmbr$,
25,$nmbr$ mortis,
25,$nmbr$ montlts,
25,$nmbr$ mentis,
24,tnfi ( no other bdmard taken ) t  n ( % ),
24,tertile $nmbr$ : $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),
24,tertile $nmbr$ ( n = $nmbr$ ),
24,tertile $nmbr$,
24,terlile $nmbr$,
24,q ( q $nmbr$ \,
24,q $nmbr$ w ( n = $nmbr$ ),
24,q $nmbr$ w ( n $nmbr$ $nmbr$ ),
24,q $nmbr$ - q $nmbr$,
24,other $nmbr$,
24,onsetofaf  no . ( % ),
24,normoalbuminuria  no . ( % ),
24,no . ( % ) $nmbr$ ( $nmbr$ ),
24,kellgren and lawrence radiographic reading grade $nmbr$ — no . ( % ),
24,bi ( $nmbr$ . $nmbr$ ),
24,a . beuralizuinab $nmbr$ ing q $nmbr$ w,
24,. $nmbr$,
24,$nmbr$ q $nmbr$ w ( n = $nmbr$ ),
24,$nmbr$ or $nmbr$ — no . / total no . ( % ),
24,$nmbr$ or $nmbr$  no . / total no . ( % ),
24,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),
24,$nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
24,$nmbr$ . $nmbr$,
24,$nmbr$ +  no . ( % ),
24,$nmbr$  $nmbr$ / $nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
24,$nmbr$  $nmbr$ ( $nmbr$ . $nmbr$ ),
24,$nmbr$,
23,randomised to canakinumab $nmbr$ mg,
23,poslmenopausal  no ht,
23,glacial $nmbr$,
23,> $nmbr$ — no . { % ),
23,< $nmbr$ — no . { % ),
23,$nmbr$ — em,
23,$nmbr$ — < $nmbr$,
23,$nmbr$ — $nmbr$ nlmw,
23,$nmbr$ mgrdl,
22,x $nmbr$  n ( % ),
22,or ( $nmbr$ % ci ),
22,on $nmbr$,
22,multivariable or ( $nmbr$ % ci )  p value *,
22,mbesc  n / n ( % ),
22,mbesb  n / n ( % ),
22,mbes / crbesb  n / n ( % ),
22,lvmi ( $nmbr$,
22,ldi $nmbr$,
22,lcz $nmbr$ ( n = $nmbr$ ),
22,lcz $nmbr$,
22,iorii ( n z $nmbr$ ),
22,intensified ( n 二 $nmbr$ ),
22,did not meet atopy and ige $nmbr$ - $nmbr$ ku / lcriteriaa ( n = $nmbr$  $nmbr$ ),
22,bilag a  b or c domain score  n ( % ),
22,apolipoproiein a $nmbr$ ( tng / $nmbr$ ),
22,any other lipid ‐ lowering therapy  n ( % ),
22,$nmbr$ tcz,
22,$nmbr$ or $nmbr$  n ( % ),
22,$nmbr$ or $nmbr$,
22,$nmbr$ / $nmbr$ ( $nmbr$ ),
22,$nmbr$ / $nmbr$,
22,$nmbr$ ( $nmbr$ si,
22,$nmbr$ ( $nmbr$  $nmbr$ ),
21,之 $nmbr$,
21,pollent s $nmbr$,
21,lavolta $nmbr$,
21,inhixanab $nmbr$ mgikg versus piacom,
21,idegasp – biasp $nmbr$,
21,biasp $nmbr$,
21,> = $nmbr$ yea ' s,
21,< $nmbr$ yea ' s,
21,$nmbr$ §,
21,$nmbr$ yrs l,
20,» $nmbr$ y,
20,« = $nmbr$,
20,y $nmbr$,
20,qtc > $nmbr$ n = $nmbr$,
20,ldi - b > $nmbr$ ( n = $nmbr$ ),
20,ii = $nmbr$,
20,educ > $nmbr$ y,
20,^ $nmbr$ y  n ( % ),
20,> = $nmbr$ y,
20,> = $nmbr$ * ( % ),
20,> = $nmbr$,
20,> $nmbr$ y ( n = $nmbr$ ),
20,> $nmbr$ y ( n = $nmbr$  $nmbr$ . $nmbr$ % ),
20,> $nmbr$ y  n ( % ),
20,> $nmbr$ y,
20,> $nmbr$ $nmbr$,
20,< $nmbr$ » < $nmbr$ y,
20,< $nmbr$ y ( n = $nmbr$ ),
20,< $nmbr$ y,
20,* $nmbr$ to < $nmbr$ y,
20,$nmbr$ y,
20,$nmbr$ to $nmbr$ y  n ( % ),
19,zt = $nmbr$,
19,vdz n = \ $nmbr$,
19,v $nmbr$ ( n = $nmbr$,
19,uc ( n   =   $nmbr$ ),
19,saxa + met n = $nmbr$,
19,saxa + dapa + met n = $nmbr$,
19,q $nmbr$ ( n   = $nmbr$ ),
19,ntbnp ( n = $nmbr$ ),
19,nonblack ( n = $nmbr$ ),
19,no laba  no ics ( tiotropium n = $nmbr$  placebo n = $nmbr$ ),
19,no $nmbr$  $nmbr$,
19,lc  n = $nmbr$,
19,handihaler and diskus  n,
19,dapa + met n = $nmbr$,
19,b + a ( n = $nmbr$ ),
19,ampd $nmbr$,
19,a $nmbr$ + ezio a $nmbr$ ( n = $nmbr$ ) ( n = $nmbr$ ),
19,\ $nmbr$,
19,$nmbr$ +,
18,pollent < $nmbr$,
18,hr is < $nmbr$ if pravastatin is better than diet alone,
18,chadsj < $nmbr$,
18,chadsa < $nmbr$,
18,cclear < $nmbr$,
18,aqe < $nmbr$,
18,aqc < $nmbr$,
18,> $nmbr$ but < $nmbr$ mg / dl,
18,> $nmbr$ and < $nmbr$ years,
18,> $nmbr$ and < $nmbr$ mg / dl,
18,> $nmbr$ and < $nmbr$,
18,< $nmbr$ xuln,
18,< $nmbr$ mlymin,
18,< $nmbr$ mlmin ) $nmbr$,
18,< $nmbr$ microg / l,
18,< $nmbr$ lb,
18,< $nmbr$ ky / nr,
18,< $nmbr$ hr,
18,< $nmbr$ enroll,
18,< $nmbr$ beats / min,
18,$nmbr$ to < $nmbr$ mumin,
18,$nmbr$ to < $nmbr$ hr,
17,qtc < $nmbr$ n = $nmbr$,
17,ef < $nmbr$ % n = $nmbr$,
17,ef < $nmbr$ % hfref ( n = $nmbr$  $nmbr$ % ),
17,ef < $nmbr$ % ( n = $nmbr$  $nmbr$ ),
17,> lto < $nmbr$ ( n = $nmbr$ ),
17,> = $nmbr$ mmhq,
17,> $nmbr$ mon ( n = $nmbr$ ),
17,> $nmbr$ and / or > $nmbr$ moderate or severe deformity  or both ( n = $nmbr$ ),
17,> $nmbr$ < $nmbr$,
17,> $nmbr$  < = $nmbr$,
17,> $nmbr$,
17,< = $nmbr$ %,
17,< = $nmbr$,
17,< $nmbr$ mon ( n = $nmbr$ ),
17,< $nmbr$ bpm ( n = $nmbr$ ),
17,< $nmbr$,
16,priorheartfailure  %,
16,hypoglycaemiad  %,
16,hbau  %,
16,hbalc > $nmbr$ %,
16,hbalc < $nmbr$ %,
16,hbalc  %,
16,hbaie  %,
16,ef < $nmbr$ % ( n $nmbr$ $nmbr$ ),
16,ef < $nmbr$ %,
16,antihyperglycemictherapies  %,
16,\ $nmbr$ %,
16,> = $nmbr$ % and < $nmbr$ % ( > = $nmbr$ and < $nmbr$ mmol / mol ),
16,> $nmbr$ and < $nmbr$ %,
16,> $nmbr$ % and < $nmbr$ %,
16,> $nmbr$ %,
16,< $nmbr$ — no . ( % ),
16,< $nmbr$ { % ),
16,< $nmbr$ y  n ( % ),
16,< $nmbr$ no . ( % ),
16,< $nmbr$ . $nmbr$ ( % ),
16,< $nmbr$ ( % ),
16,< $nmbr$ %,
16,$nmbr$ to < $nmbr$ — no . { % ),
16,$nmbr$ e < $nmbr$ %  n ( % ),
16,$nmbr$ e < $nmbr$ %,
16,$nmbr$ - < $nmbr$ ( % ),
16,$nmbr$ ( < $nmbr$ % ),
16,$nmbr$ ( $nmbr$ e < $nmbr$ % ),
16,$nmbr$ $nmbr$,
16,$ $nmbr$ %,
15,hr ‡,
15,hr ( enl vs lcz ) ( $nmbr$ % cl ),
15,hr ( bpm ),
15,hr  bpm,
15,hr,
14,hscrp §,
14,hscrp,
13,lisrs,
13,iqr,
13,idr,
13,( iqr ),
12,tvr,
12,ever smoked ( current / former ),
12,ever,
11,other or missing data,
11,or severe,
11,or esrd,
11,or death,
11,or $nmbr$,
11,or,
11,laba or lamab n = $nmbr$,
11,conieosieroids and / or $nmbr$ - mp,
11,> $nmbr$ or incident vitrectomy or photocoagulation,
11,$nmbr$ yrs or more,
11,$nmbr$ or more,
11,$nmbr$ or greater,
11,$nmbr$ or $nmbr$ step,
11,$nmbr$ or $nmbr$ high cardiovascular risk categories,
11,$nmbr$ or $nmbr$ days,
11,$nmbr$ or $nmbr$ d / wk,
11,$nmbr$ or $nmbr$ d / mo,
11,$nmbr$ . $nmbr$ or more,
11,$nmbr$ . $nmbr$ % or more,
10,rrr,
10,rr *,
10,rr,
10,hr * or rr † ( $nmbr$ % ci ),
10,hr * or rr †,
9,vora,
9,soe or sue,
9,or raloxifene,
9,or primary outcome,
9,or placebo treatment,
9,none or seldom,
9,none or diet,
9,nd not due to swelling or ich,
9,at or above the median,
9,at or above median,
9,antiplatelets or anticoagulants,
9,antiplatelet or anticoagulant therapy,
9,antiplatelet or anticoagulant,
9,antiplatelet or anti - inflammatory drugs,
9,acei or arb pre - randomisation,
9,acei or arb post - randomisation,
9,acei or arb,
8,diff_measure,
7,femalesex,
7,femaleb,
7,femaie,
7,$nmbr$ ( or $nmbr$  if female only ),
6,rvalue,
6,pvalue ∗,
6,pvalue,
6,or_value,
6,or $nmbr$ _value,
5,all patientsb,
5,all participantst ( n = $nmbr$ / $nmbr$ ),
5,all participantsa,
5,all other,
5,all noncompleters,
5,all completers ( n $nmbr$ $nmbr$ ),
5,all completers,
5,all bleeding,
5,all bleed,
5,all,
5,ali,
4,at least $nmbr$ flare,
4,at,
3,am_delta,
3,am_ % delta,
2,> ii,
2,( : > blockers,
1,smi :,
1,naive : no,
1,im use : no,
1,im or cs use : no,
1,im and cs use : no,
